[
  {
    "title": "Johnson & Johnson  ( JNJ )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2204062/johnson-johnson-jnj-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20240101T140012",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default47.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.228807,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.474958",
        "ticker_sentiment_score": "0.13886",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Meet the 2024 Dogs of the Dow",
    "url": "https://www.fool.com/investing/2024/01/01/meet-the-2024-dogs-of-the-dow/",
    "time_published": "20240101T094600",
    "authors": [
      "Dan Caplinger"
    ],
    "summary": "2023 was another tough year for this popular investing strategy, but fans are hoping for better results in the coming year.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F759686%2Fdogs-in-basket-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.156823,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.11983",
        "ticker_sentiment_score": "-0.094691",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.060085",
        "ticker_sentiment_score": "0.013152",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.11983",
        "ticker_sentiment_score": "0.209956",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JPM",
        "relevance_score": "0.11983",
        "ticker_sentiment_score": "0.209956",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.060085",
        "ticker_sentiment_score": "-0.081217",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "10 things turning 100 in 2024, from Band-Aids to Popsicles",
    "url": "https://www.businessinsider.com/inventions-brands-events-100-years-ago-2024-1",
    "time_published": "20240102T212600",
    "authors": [
      "Talia Lakritz"
    ],
    "summary": "Things invented 100 years ago, turning 100 in 2024 - Business Insider ...",
    "banner_image": null,
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "www.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.007075,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KMB",
        "relevance_score": "0.096283",
        "ticker_sentiment_score": "0.04046",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "M",
        "relevance_score": "0.283323",
        "ticker_sentiment_score": "0.138721",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.096283",
        "ticker_sentiment_score": "-0.045114",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Shareholders' Class Action Lawsuit Gets Nod from Federal Judge - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/01/36455727/johnson-johnson-shareholders-class-action-lawsuit-gets-nod-from-federal-judge",
    "time_published": "20240102T190130",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "A federal judge's ruling in Trenton, New Jersey, has paved the way for Johnson & Johnson JNJ shareholders to collectively proceed with a lawsuit alleging the company concealed information about asbestos contamination in its talc products. U.S.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/02/jnjioffice3.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.117439,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.386875",
        "ticker_sentiment_score": "-0.138228",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Travel Updates: Gatwick Hikes Drop-Off Fee",
    "url": "https://www.forbes.com/uk/advisor/travel-insurance/2024/01/02/travel-latest-news/",
    "time_published": "20240102T180148",
    "authors": [
      "Kevin Pratt"
    ],
    "summary": "2 January: Minimum Charge To Rise 20% To \u00a36 For 10 Minutes Gatwick Airport is increasing its minimum drop-off charge by 20% from 5 January, when it will increase from \u00a35 to \u00a36. The minimum charge covers the first 10 minutes and must be paid by midnight the day after the visit.",
    "banner_image": "https://thumbor.forbes.com/thumbor/fit-in/x/https://www.forbes.com/uk/advisor/wp-content/uploads/2022/02/ET-Ski-Resort-Map.jpg",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.007163,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DRTGF",
        "relevance_score": "0.000901",
        "ticker_sentiment_score": "-0.050149",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.000901",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.000901",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAL",
        "relevance_score": "0.001803",
        "ticker_sentiment_score": "0.060776",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.004506",
        "ticker_sentiment_score": "0.034618",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.002704",
        "ticker_sentiment_score": "0.054221",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SHTDF",
        "relevance_score": "0.000901",
        "ticker_sentiment_score": "0.124796",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.000901",
        "ticker_sentiment_score": "0.01804",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.004506",
        "ticker_sentiment_score": "0.034618",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.000901",
        "ticker_sentiment_score": "-0.150718",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "YUGVF",
        "relevance_score": "0.001803",
        "ticker_sentiment_score": "0.049842",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.000901",
        "ticker_sentiment_score": "0.01804",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.004506",
        "ticker_sentiment_score": "0.034618",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RYAOF",
        "relevance_score": "0.003605",
        "ticker_sentiment_score": "-0.032104",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.000901",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "MeiraGTx  ( MGTX )  Stock Surges 35% in a Month: Here's Why",
    "url": "https://www.zacks.com/stock/news/2204585/meiragtx-mgtx-stock-surges-35-in-a-month-heres-why",
    "time_published": "20240102T171700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "MeiraGTx's (MGTX) shares surge on the sale of rights for a rare ocular disease gene therapy for up to $ 415 million. This funding helps MGTX extend its cash runway into mid-2026.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.126725,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MGTX",
        "relevance_score": "0.665629",
        "ticker_sentiment_score": "0.269937",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CTMX",
        "relevance_score": "0.289576",
        "ticker_sentiment_score": "0.07981",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.118064",
        "ticker_sentiment_score": "0.110221",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.344074",
        "ticker_sentiment_score": "0.127683",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's Why You Should Retain Medtronic  ( MDT )  Stock for Now",
    "url": "https://www.zacks.com/stock/news/2204570/heres-why-you-should-retain-medtronic-mdt-stock-for-now",
    "time_published": "20240102T171000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Investors are optimistic about Medtronic's (MDT) expansion in global markets and stable solvency position.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5e/1093.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.995869"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.23334,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SYK",
        "relevance_score": "0.04823",
        "ticker_sentiment_score": "0.097986",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.04823",
        "ticker_sentiment_score": "0.097986",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.04823",
        "ticker_sentiment_score": "0.097986",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PODD",
        "relevance_score": "0.143987",
        "ticker_sentiment_score": "0.055556",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.494156",
        "ticker_sentiment_score": "0.273372",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HAE",
        "relevance_score": "0.237668",
        "ticker_sentiment_score": "0.164475",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DVA",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.106025",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Perspective Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference",
    "url": "https://www.globenewswire.com/news-release/2024/01/02/2802628/0/en/Perspective-Therapeutics-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html",
    "time_published": "20240102T130000",
    "authors": [
      "Inc.",
      "Perspective Therapeutics"
    ],
    "summary": "SEATTLE, Jan. 02, 2024 ( GLOBE NEWSWIRE ) -- Perspective Therapeutics, Inc. ( \"Perspective\" or \"the Company\" ) ( NYSE AMERICAN: CATX ) , today announced that Thijs Spoor, the Company's Chief Executive Officer, will present at the 42nd Annual J.P.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/e8b42463-3d31-441e-8c09-6b88826fe1c6",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.168717,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.038407",
        "ticker_sentiment_score": "0.204125",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.038407",
        "ticker_sentiment_score": "0.204125",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.038407",
        "ticker_sentiment_score": "0.204125",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "XORTX Welcomes New Member to the Board of Directors",
    "url": "https://www.globenewswire.com/news-release/2024/01/02/2802570/0/en/XORTX-Welcomes-New-Member-to-the-Board-of-Directors.html",
    "time_published": "20240102T120000",
    "authors": [
      "XORTX Therapeutics Inc."
    ],
    "summary": "CALGARY, Alberta, Jan. 02, 2024 ( GLOBE NEWSWIRE ) -- XORTX Therapeutics Inc. ( \"XORTX\" or the \"Company\" ) ( NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU ) , a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Mr. ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/9898c4f8-b373-438a-abfa-709c4372a061",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.165514,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PODD",
        "relevance_score": "0.052918",
        "ticker_sentiment_score": "0.052981",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.052918",
        "ticker_sentiment_score": "0.052981",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KALV",
        "relevance_score": "0.052918",
        "ticker_sentiment_score": "0.052981",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.052918",
        "ticker_sentiment_score": "0.052981",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XRTX",
        "relevance_score": "0.157827",
        "ticker_sentiment_score": "0.28239",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( NYSE:JNJ )  Downgraded by StockNews.com to \"Buy\"",
    "url": "https://www.defenseworld.net/2024/01/02/johnson-johnson-nysejnj-downgraded-by-stocknews-com-to-buy.html",
    "time_published": "20240102T072246",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "StockNews.com cut shares of Johnson & Johnson ( NYSE:JNJ - Free Report ) from a strong-buy rating to a buy rating in a report released on Monday morning. Other equities analysts also recently issued research reports about the stock.",
    "banner_image": "https://www.marketbeat.com/logos/johnson--johnson-logo.png?v=20221020135923",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999922"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928769"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.24419,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RBCPF",
        "relevance_score": "0.054607",
        "ticker_sentiment_score": "0.007998",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.054607",
        "ticker_sentiment_score": "0.007998",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.054607",
        "ticker_sentiment_score": "0.007998",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.82927",
        "ticker_sentiment_score": "0.414319",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "PLATINUM EQUITY TO ACQUIRE HORIZON ORGANIC AND WALLABY FROM DANONE",
    "url": "https://www.prnewswire.com/news-releases/platinum-equity-to-acquire-horizon-organic-and-wallaby-from-danone-302024315.html",
    "time_published": "20240102T043500",
    "authors": [
      "Platinum Equity"
    ],
    "summary": "Leading dairy products brands projected to benefit from Platinum Equity's carve-out experience and operational expertise LOS ANGELES, Jan. 1, 2024 /PRNewswire/ -- Platinum Equity today announced the signing of a definitive agreement to acquire Horizon Organic and Wallaby from Danone.",
    "banner_image": "https://mma.prnewswire.com/media/1557720/Platinum_Equity_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99977"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.306214,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MCO",
        "relevance_score": "0.043898",
        "ticker_sentiment_score": "0.172582",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IR",
        "relevance_score": "0.043898",
        "ticker_sentiment_score": "0.037051",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RGBD",
        "relevance_score": "0.043898",
        "ticker_sentiment_score": "0.172582",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EMR",
        "relevance_score": "0.043898",
        "ticker_sentiment_score": "0.037051",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.043898",
        "ticker_sentiment_score": "0.037051",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Rises As Market Takes a Dip: Key Facts",
    "url": "https://www.zacks.com/stock/news/2205270/johnson-johnson-jnj-rises-as-market-takes-a-dip-key-facts",
    "time_published": "20240103T224520",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $160.97, denoting a +0.63% change from the preceding trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default49.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.145177,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.605266",
        "ticker_sentiment_score": "0.126404",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stock Market Trims Losses After Fed Minutes; What The Bad Santa Rally Means For Indexes",
    "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-trims-losses-after-fed-minutes-what-the-bad-santa-rally-means-for-indexes/",
    "time_published": "20240103T201700",
    "authors": [
      "Investor's Business Daily",
      "JUAN CARLOS ARANCIBIA"
    ],
    "summary": "Stock Market Trims Losses After Fed Minutes. What The Bad Santa Rally Means For Indexes Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2022/01/Stock-nyse2-0122-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": -0.128475,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AAPL",
        "relevance_score": "0.179343",
        "ticker_sentiment_score": "-0.1809",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ANET",
        "relevance_score": "0.12013",
        "ticker_sentiment_score": "-0.118997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRWD",
        "relevance_score": "0.12013",
        "ticker_sentiment_score": "-0.118997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "S",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "-0.105001",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.12013",
        "ticker_sentiment_score": "0.112157",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.12013",
        "ticker_sentiment_score": "0.112157",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOW",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "-0.105001",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZS",
        "relevance_score": "0.12013",
        "ticker_sentiment_score": "-0.118997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NET",
        "relevance_score": "0.12013",
        "ticker_sentiment_score": "0.10532",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RYAOF",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.093",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Will 2024 Be The Year Of The Other 493?",
    "url": "https://www.benzinga.com/markets/24/01/36476280/will-2024-be-the-year-of-the-other-493",
    "time_published": "20240103T190842",
    "authors": [
      "Real Investment Advice"
    ],
    "summary": "As we welcome in 2024, one of the most critical questions facing investors is which stocks and sectors will beat the market. Can the Magnificent 7 retain its crown? Or will some subset of the 493 other S&P 500 stocks and their neglected sectors take the throne in 2024? The Magnificent 7 stole the ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/03/nicholas-cappello-wb63zqj5gne-unsplash_12.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999965"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.19366,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.035661",
        "ticker_sentiment_score": "0.247442",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.035661",
        "ticker_sentiment_score": "0.247442",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.245693",
        "ticker_sentiment_score": "0.193291",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.035661",
        "ticker_sentiment_score": "0.247442",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALB",
        "relevance_score": "0.211498",
        "ticker_sentiment_score": "0.04408",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.035661",
        "ticker_sentiment_score": "0.093705",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KHC",
        "relevance_score": "0.035661",
        "ticker_sentiment_score": "0.093705",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.071251",
        "ticker_sentiment_score": "0.034375",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.035661",
        "ticker_sentiment_score": "0.247442",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "This Analyst Downgrades Bristol-Myers Squibb, Cautions Amid Product Launch And Revenue Concerns - Bristol-Myers Squibb  ( NYSE:BMY ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36473452/this-analyst-downgrades-bristol-myers-squibb-cautions-amid-product-launch-and-reven",
    "time_published": "20240103T172930",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "BofA Securities downgraded Bristol-Myers Squibb & Co BMY, noting that initially, the analyst believed that Bristol's loss of exclusivity ( LOEs ) for drugs like Eliquis and Opdivo was widely understood and it was anticipated that new product lineup would compensate for these losses and boost ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/03/bmy.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.241436,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BMY",
        "relevance_score": "0.56415",
        "ticker_sentiment_score": "0.197908",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.303175",
        "ticker_sentiment_score": "0.282842",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.303175",
        "ticker_sentiment_score": "0.282842",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Pharmaceutical Drug Delivery Market Set For Robust Growth: Market Size To Reach $2337 Billion By 2028 As Per The Business Research Company's Pharmaceutical Drug Delivery Global Market Report 2024",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36473207/pharmaceutical-drug-delivery-market-set-for-robust-growth-market-size-to-reach-2337-billion-by-202",
    "time_published": "20240103T163000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LONDON, Jan. 03, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's pharmaceutical drug delivery global market report 2024, the global pharmaceutical drug delivery market has exhibited robust growth, expanding from $1711.47 billion in 2023 to an estimated $1816.05 billion in 2024, ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.332912,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.04882",
        "ticker_sentiment_score": "0.091119",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.04882",
        "ticker_sentiment_score": "0.091119",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.04882",
        "ticker_sentiment_score": "0.091119",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Medytox, Inc. Announces the Formation of Luvantas Subsidiary and Appointment of Key Executives",
    "url": "https://www.prnewswire.com/news-releases/medytox-inc-announces-the-formation-of-luvantas-subsidiary-and-appointment-of-key-executives-302025050.html",
    "time_published": "20240103T134500",
    "authors": [
      "Inc",
      "Luvantas"
    ],
    "summary": "IRVINE, Calif., Jan. 3, 2024 /PRNewswire/ -- Medytox, Inc. is pleased to announce the formation of Luvantas, Inc. ( www.luvantas.com ) as its wholly-owned North American subsidiary.",
    "banner_image": "https://mma.prnewswire.com/media/2309850/Luvantas_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.242939,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.064973",
        "ticker_sentiment_score": "0.092192",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Is TikTok Parent ByteDance Moving Into Biology, Chemistry And Drug Discovery?",
    "url": "https://www.forbes.com/sites/alexandralevine/2024/01/02/tiktok-bytedance-pharmaceuticals-drug-discovery-science-biology-chemistry-ai-china/",
    "time_published": "20240103T113000",
    "authors": [
      "Alexandra S. Levine"
    ],
    "summary": "TikTok's Chinese parent is beginning to recruit across the U.S. for experts in science and healthcare disciplines far afield from social media. Its motives are unclear.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6594bb2c97c00e37e55b0c79/0x0.jpg?format=jpg&crop=1920,1080,x0,y0,safe&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.206995,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.10389",
        "ticker_sentiment_score": "0.158286",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.026042",
        "ticker_sentiment_score": "0.157007",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LTTHF",
        "relevance_score": "0.026042",
        "ticker_sentiment_score": "0.086589",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.026042",
        "ticker_sentiment_score": "0.108238",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 No-Brainer Stocks to Buy With $1,000 Right Now for the New Year",
    "url": "https://www.fool.com/investing/2024/01/03/3-no-brainer-stocks-to-buy-with-1000-right-now/",
    "time_published": "20240103T102100",
    "authors": [
      "Sean Williams"
    ],
    "summary": "A modest amount of money can go a long way when it's put to work in industry-leading, time-tested businesses with well-defined catalysts.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F759756%2Fperson-holding-cash-bills-money-hundred-dollar-fifty-dividend-income-invest-retire-spend-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.997405"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.9545"
      }
    ],
    "overall_sentiment_score": 0.155262,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PYPL",
        "relevance_score": "0.204565",
        "ticker_sentiment_score": "0.140067",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.029545",
        "ticker_sentiment_score": "0.033514",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "V",
        "relevance_score": "0.232996",
        "ticker_sentiment_score": "0.223562",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.146916",
        "ticker_sentiment_score": "-0.051886",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024 - Arcellx  ( NASDAQ:ACLX ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36497306/blood-cancer-player-arcellx-finds-place-on-analyst-conviction-list-potential-room-f",
    "time_published": "20240104T190832",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Needham analyst forecasts a positive outlook for Arcellx Inc ACLX in 2024, citing strong potential stemming from the anticipated pivotal interim readout from the iMMagine-1 study, expected in the second half of 2024. This development is poised to bolster filing prospects for the company in 2025.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.421127,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ACLX",
        "relevance_score": "0.904419",
        "ticker_sentiment_score": "0.647796",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "LEGN",
        "relevance_score": "0.288893",
        "ticker_sentiment_score": "0.629575",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SRPT",
        "relevance_score": "0.288893",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.288893",
        "ticker_sentiment_score": "0.629575",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Check Out What Whales Are Doing With JNJ - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/markets/options/24/01/36494464/check-out-what-whales-are-doing-with-jnj",
    "time_published": "20240104T164549",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "High-rolling investors have positioned themselves bearish on Johnson & Johnson JNJ, and it's important for retail traders to take note. \\This activity came to our attention today through Benzinga's tracking of publicly available options data.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.180222,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.072217",
        "ticker_sentiment_score": "0.140024",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.072217",
        "ticker_sentiment_score": "-0.111749",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.681225",
        "ticker_sentiment_score": "0.347717",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Pharmaceutical First: Eli Lilly Website Will Prescribe Weight Loss Drugs Through Service",
    "url": "https://www.forbes.com/sites/maryroeloffs/2024/01/04/pharmaceutical-first-eli-lilly-website-will-prescribe-weight-loss-drugs-through-service/",
    "time_published": "20240104T145112",
    "authors": [
      "Mary Whitfill Roeloffs"
    ],
    "summary": "Drugmaker Eli Lilly has launched a new website specifically for prescribing weight loss drugs through a telehealth service less than a month after the company's new injectable, Zepbound, became available in U.S. pharmacies for overweight or obese adults.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6596c53428b1282c33d2fb8f/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.009702,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVO",
        "relevance_score": "0.131284",
        "ticker_sentiment_score": "-0.022636",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.065866",
        "ticker_sentiment_score": "0.15594",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Accord BioPharma, Inc. Announces U.S. FDA Acceptance of Biologics License Application for Proposed STELARA\u00ae Biosimilar DMB-3115",
    "url": "https://www.prnewswire.com/news-releases/accord-biopharma-inc-announces-us-fda-acceptance-of-biologics-license-application-for-proposed-stelara-biosimilar-dmb-3115-302025983.html",
    "time_published": "20240104T132200",
    "authors": [
      "Accord BioPharma"
    ],
    "summary": "Accord BioPharma, Inc. Announces U.S. FDA Acceptance of Biologics License Application for Proposed STELARA ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/2310579/BioPharma_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.251433,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.062597",
        "ticker_sentiment_score": "0.090301",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:VND",
        "relevance_score": "0.124809",
        "ticker_sentiment_score": "0.107978",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Antibody Therapeutics Market is Expected to Reach $479.0 Billion | MarketsandMarkets.",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36487416/antibody-therapeutics-market-is-expected-to-reach-479-0-billion-marketsandmarkets",
    "time_published": "20240104T123000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Chicago, Jan. 04, 2024 ( GLOBE NEWSWIRE ) -- Antibody Therapeutics market in terms of revenue was estimated to be worth $247.3 Billion in 2023 and is poised to reach $479.0 billion by 2028, growing at a CAGR of 14.1% from 2023 to 2028 according to a latest report published by MarketsandMarkets\u2122.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.287429,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IMNM",
        "relevance_score": "0.039745",
        "ticker_sentiment_score": "0.095935",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.079392",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.079392",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.079392",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.158",
        "ticker_sentiment_score": "0.04959",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.079392",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.079392",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.079392",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.079392",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.079392",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Sharing COVID therapy secrets is a Trojan horse that would gut U.S. biotech",
    "url": "https://www.marketwatch.com/story/sharing-covid-therapy-secrets-is-a-trojan-horse-that-would-gut-u-s-biotech-734c680c",
    "time_published": "20240104T122000",
    "authors": [
      "James Pooley"
    ],
    "summary": "IP waiver would allow developing countries access to formulas and manufacturing details.",
    "banner_image": "https://images.mktw.net/im-331663/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.081237,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "APNHF",
        "relevance_score": "0.042723",
        "ticker_sentiment_score": "0.02678",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.042723",
        "ticker_sentiment_score": "0.02678",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Delaware Mutual Funds to Build a Strong Portfolio",
    "url": "https://www.zacks.com/stock/news/2205443/3-delaware-mutual-funds-to-build-a-strong-portfolio",
    "time_published": "20240104T114000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Invest in Delaware mutual funds like WLGYX, IDAAX and DDFAX for positive returns.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/a8/346.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999701"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.304026,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MCQEF",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.291503",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.049147",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JPM",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.053163",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "V",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.049147",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HES",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.053163",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.053163",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Advanced Wound Care Market size to grow by USD 4.02 billion from 2022 to 2027, North America to account for 41 ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/advanced-wound-care-market-size-to-grow-by-usd-4-02-billion-from-2022-to-2027--north-america-to-account-for-41-of-market-growth--technavio-302026301.html",
    "time_published": "20240105T190000",
    "authors": [],
    "summary": "Advanced Wound Care Market size to grow by USD 4.02 billion from 2022 to 2027, North America to account for 41 ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.23657,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ETTYF",
        "relevance_score": "0.065327",
        "ticker_sentiment_score": "0.068069",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.065327",
        "ticker_sentiment_score": "0.068069",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.065327",
        "ticker_sentiment_score": "0.068069",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MMM",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.051279",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLPBY",
        "relevance_score": "0.065327",
        "ticker_sentiment_score": "0.068069",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ORGO",
        "relevance_score": "0.065327",
        "ticker_sentiment_score": "0.068069",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CNVVF",
        "relevance_score": "0.065327",
        "ticker_sentiment_score": "0.068069",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANIK",
        "relevance_score": "0.065327",
        "ticker_sentiment_score": "0.068069",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNN",
        "relevance_score": "0.065327",
        "ticker_sentiment_score": "0.068069",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.065327",
        "ticker_sentiment_score": "0.068069",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IART",
        "relevance_score": "0.065327",
        "ticker_sentiment_score": "0.068069",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.065327",
        "ticker_sentiment_score": "0.068069",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VCEL",
        "relevance_score": "0.065327",
        "ticker_sentiment_score": "0.068069",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Illumina's MRD Technology For Cancer Testing Collaborates With Johnson & Johnson Unit - Illumina  ( NASDAQ:ILMN ) , Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/markets/equities/24/01/36513008/illuminas-mrd-technology-for-cancer-testing-collaborates-with-johnson-johnson-unit",
    "time_published": "20240105T170110",
    "authors": [
      "Nabaparna Bhattacharya"
    ],
    "summary": "Illumina, Inc. ILMN announced it has signed an agreement with Janssen Research & Development, a unit of Johnson & Johnson JNJ.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/05/ilmn_co.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.29039,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ILMN",
        "relevance_score": "0.739411",
        "ticker_sentiment_score": "0.299567",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.29234",
        "ticker_sentiment_score": "0.324453",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Dogs Of The Dow 2024: 10 Blue-Chip Dividend Payers",
    "url": "https://www.forbes.com/sites/brettowens/2024/01/07/dogs-of-the-dow-2024-10-blue-chip-dividend-payers/",
    "time_published": "20240107T121500",
    "authors": [
      "Brett Owens"
    ],
    "summary": "The 2024 Dogs of the Dow are particularly homely hounds-which means we're talking big dividends. This year's Dogs yield more than three-times the broader market's paltry payout. So, should we hold our noses and buy? Let's grab some peanut butter treats and investigate.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/5e0e14c60bf81b00072e5836/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.882182"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.917436"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.195231,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CSCO",
        "relevance_score": "0.077156",
        "ticker_sentiment_score": "0.156862",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.115509",
        "ticker_sentiment_score": "0.073793",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.077156",
        "ticker_sentiment_score": "-0.095558",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.096361",
        "ticker_sentiment_score": "0.106898",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IBM",
        "relevance_score": "0.096361",
        "ticker_sentiment_score": "0.003278",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.115509",
        "ticker_sentiment_score": "0.087575",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.057907",
        "ticker_sentiment_score": "0.155125",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.038623",
        "ticker_sentiment_score": "0.1006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPLK",
        "relevance_score": "0.038623",
        "ticker_sentiment_score": "0.25476",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.038623",
        "ticker_sentiment_score": "0.068065",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.096361",
        "ticker_sentiment_score": "0.107227",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DOW",
        "relevance_score": "0.038623",
        "ticker_sentiment_score": "0.106423",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "5 Top Investing Resolutions for 2024",
    "url": "https://www.fool.com/investing/2024/01/07/5-top-investing-resolutions-for-2024/",
    "time_published": "20240107T100000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "You don't need a fortune to start investing today.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F760281%2Fgettyimages-2024-new-year-resolutions.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999499"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.30664,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KO",
        "relevance_score": "0.09186",
        "ticker_sentiment_score": "0.096983",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.09186",
        "ticker_sentiment_score": "0.064008",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.09186",
        "ticker_sentiment_score": "0.096983",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc.  ( Nasdaq - AMAM ) , Gracell Biotechnologies Inc.  ( Nasdaq - GRCL ) , Axonics, Inc.  ( Nasdaq - AXNX ) , Harpoon Therapeutics, Inc.  ( Nasdaq - HARP ) ",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36547175/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-ambrx-biophar",
    "time_published": "20240108T223137",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "BALA CYNWYD, Pa., Jan. 08, 2024 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.232971,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.233556",
        "ticker_sentiment_score": "0.266779",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.233556",
        "ticker_sentiment_score": "0.068874",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRCL",
        "relevance_score": "0.07887",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMAM",
        "relevance_score": "0.07887",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.233556",
        "ticker_sentiment_score": "0.235274",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HARP",
        "relevance_score": "0.07887",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.15697",
        "ticker_sentiment_score": "0.156505",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AXNX",
        "relevance_score": "0.233556",
        "ticker_sentiment_score": "0.216405",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Tech sector powers stock market higher with the Nasdaq jumping 2%",
    "url": "https://markets.businessinsider.com/news/stocks/stock-market-news-today-tech-sector-nasdaq-surge-ces-conference-2024-1",
    "time_published": "20240108T210500",
    "authors": [
      "Matthew Fox"
    ],
    "summary": "Stock Market News Today: Tech Sector Powers Markets Higher With 2% Gain - Markets Insider ...",
    "banner_image": null,
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": -0.196462,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "-0.097935",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "0.065814",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SCBFF",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "-0.097935",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "0.057295",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JPM",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "0.057295",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "0.057295",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.199037",
        "ticker_sentiment_score": "-0.186779",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.199037",
        "ticker_sentiment_score": "-0.143892",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "ALLENTOWN ANNOUNCES STRATEGIC ACQUISITION OF CLORDISYS - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/allentown-announces-strategic-acquisition-of-clordisys-302028906.html",
    "time_published": "20240108T200400",
    "authors": [],
    "summary": "ALLENTOWN ANNOUNCES STRATEGIC ACQUISITION OF CLORDISYS PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      }
    ],
    "overall_sentiment_score": 0.363979,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.041181",
        "ticker_sentiment_score": "0.125941",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Dow Surges Over 100 Points; Commercial Metals Posts Upbeat Q1 Results - Ambrx Biopharma  ( NASDAQ:AMAM ) , Commercial Metals  ( NYSE:CMC ) ",
    "url": "https://www.benzinga.com/news/earnings/24/01/36542311/dow-surges-over-100-points-commercial-metals-posts-upbeat-q1-results",
    "time_published": "20240108T193300",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.35% to 37,596.43 while the NASDAQ rose 1.89% to 14,799.21. The S&P 500 also rose, gaining, 1.11% to 4,749.41. Information technology shares jumped by 2.1% on ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/08/image42.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.145846,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DTC",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "-0.068927",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DADA",
        "relevance_score": "0.217508",
        "ticker_sentiment_score": "-0.017984",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NKTX",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "0.305231",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMAM",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "0.259181",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HARP",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "0.225398",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LMDX",
        "relevance_score": "0.217508",
        "ticker_sentiment_score": "-0.032527",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.073321",
        "ticker_sentiment_score": "0.209122",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CMC",
        "relevance_score": "0.217508",
        "ticker_sentiment_score": "0.162001",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "How To Buy Hot And Promising - But Uncertain - Biotech Stocks",
    "url": "https://www.investors.com/research/how-to-find-the-best-stocks-to-buy/xbi-etf-how-to-buy-hot-and-promising-but-uncertain-biotech-stocks/",
    "time_published": "20240108T173400",
    "authors": [
      "Investor's Business Daily",
      "MATTHEW GALGANI"
    ],
    "summary": "A mix of choppy or nonexistent earnings alongside the promise of game-changing breakthroughs make biotech stocks a challenge for investors. The SPDR S&P Biotech ETF ( XBI ) , now on the IBD Leaderboard watchlist, offers an alternative to betting on a single biotech name.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/Stock-petridishmolecule-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.268824,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.083541",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARWR",
        "relevance_score": "0.166169",
        "ticker_sentiment_score": "0.070153",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.166169",
        "ticker_sentiment_score": "0.200529",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.166169",
        "ticker_sentiment_score": "0.200529",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KRTX",
        "relevance_score": "0.246999",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.400052",
        "ticker_sentiment_score": "0.433085",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.166169",
        "ticker_sentiment_score": "0.070153",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.246999",
        "ticker_sentiment_score": "0.430266",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.166169",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Crude Oil Falls Sharply; Ambrx Biopharma Shares Spike Higher - Ambrx Biopharma  ( NASDAQ:AMAM ) , Commercial Metals  ( NYSE:CMC ) ",
    "url": "https://www.benzinga.com/news/earnings/24/01/36539499/crude-oil-falls-sharply-ambrx-biopharma-shares-spike-higher",
    "time_published": "20240108T172201",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining more than 1% on Monday. The Dow traded down 0.19% to 37,396.28 while the NASDAQ rose 1.20% to 14,698.88. The S&P 500 also rose, gaining, 0.55% to 4,722.93. Information technology shares jumped by 2% on Monday.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/08/crude_oil_4-_logo.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.143659,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DTC",
        "relevance_score": "0.152018",
        "ticker_sentiment_score": "-0.070681",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DADA",
        "relevance_score": "0.226301",
        "ticker_sentiment_score": "-0.01855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMAM",
        "relevance_score": "0.152018",
        "ticker_sentiment_score": "0.265191",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HARP",
        "relevance_score": "0.152018",
        "ticker_sentiment_score": "0.230693",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LMDX",
        "relevance_score": "0.226301",
        "ticker_sentiment_score": "-0.033548",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.076358",
        "ticker_sentiment_score": "0.209987",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CMC",
        "relevance_score": "0.226301",
        "ticker_sentiment_score": "0.167054",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SPEC",
        "relevance_score": "0.152018",
        "ticker_sentiment_score": "0.485307",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Predicine Announces Collaboration with Janssen to Develop PredicineCARE\u2122 as a Companion Diagnostic Assay in Localized Bladder Cancer",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36538805/predicine-announces-collaboration-with-janssen-to-develop-predicinecare-as-a-companion-diagnostic-",
    "time_published": "20240108T170113",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "HAYWARD, Calif., Jan. 08, 2024 ( GLOBE NEWSWIRE ) -- Predicine, Inc., a leading molecular insights company, today announced a collaboration with Janssen Pharmaceutica NV ( Janssen ) , a Johnson & Johnson company.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.099925,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.095899",
        "ticker_sentiment_score": "0.073478",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "J&J's Tentative $700M Agreement To Resolve Talc Powder-Related Lawsuits Across US States - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/news/large-cap/24/01/36537800/j-js-tentative-700m-agreement-to-resolve-talc-powder-related-lawsuits-across-us-states",
    "time_published": "20240108T161950",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Healthcare giant Johnson & Johnson JNJ has reached a tentative agreement to pay approximately $700 million to settle an investigation involving over 40 US states. The settlement seeks to resolve claims that J&J failed to disclose connections between its talc powder and various cancers.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/08/johnsons-5671315_1920.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.164231,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.375251",
        "ticker_sentiment_score": "0.211091",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Will Pay $700 Million To Resolve Baby Powder Marketing Probe, Report Says",
    "url": "https://www.forbes.com/sites/tylerroush/2024/01/08/johnson--johnson-will-pay-700-million-to-resolve-baby-powder-marketing-probe-report-says/",
    "time_published": "20240108T160256",
    "authors": [
      "Ty Roush"
    ],
    "summary": "Johnson & Johnson will pay an estimated $700 million to resolve an investigation by more than 40 states into the pharmaceutical firm's marketing of its talcum powder, according to Bloomberg, following thousands of lawsuits alleging it failed to warn customers about cancer risks.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/659c1c62514d771e8f6ce544/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.176281,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.769861",
        "ticker_sentiment_score": "-0.286231",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Today Is Cancer-Focused Deals Day: Johnson & Johnson Scoops Up Ambrx Biopharma As Merck Boosts Cancer Portfolio With Harpoon Deal - Ambrx Biopharma  ( NASDAQ:AMAM ) , Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/01/36535176/today-is-cancer-focused-deals-day-johnson-johnson-scoops-up-ambrx-biopharma-as-merck-boosts-cance",
    "time_published": "20240108T151852",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Monday, Johnson & Johnson JNJ has agreed to acquire Ambrx Biopharma Inc AMAM in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.9 billion net of estimated cash acquired. Johnson & Johnson will acquire Ambrx for $28.00/share.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/08/amam.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.070032,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMAM",
        "relevance_score": "0.465901",
        "ticker_sentiment_score": "0.239313",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HARP",
        "relevance_score": "0.244109",
        "ticker_sentiment_score": "0.396085",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.465901",
        "ticker_sentiment_score": "0.368504",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Health Care Company Johnson & Johnson Announces Merger With Ambrx Biopharma - Ambrx Biopharma  ( NASDAQ:AMAM ) , Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/m-a/24/01/36535899/health-care-company-johnson-johnson-announces-merger-with-ambrx-biopharma",
    "time_published": "20240108T151010",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Johnson & Johnson JNJ has announced a merger with Ambrx Biopharma AMAM that is expected to be completed 2024-H1. Under the terms of the agreement, Johnson & Johnson has agreed to give Ambrx Biopharma $2.00 billion in cash in exchange for AMAM stock.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.10668,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMAM",
        "relevance_score": "0.628066",
        "ticker_sentiment_score": "0.295837",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.524949",
        "ticker_sentiment_score": "0.263951",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "US Stocks Mixed; Nasdaq Jumps Over 100 Points - Ambrx Biopharma  ( NASDAQ:AMAM ) , Commercial Metals  ( NYSE:CMC ) ",
    "url": "https://www.benzinga.com/news/earnings/24/01/36535602/us-stocks-mixed-nasdaq-jumps-over-100-points",
    "time_published": "20240108T150054",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around 100 points on Monday. Following the market opening Monday, the Dow traded down 0.45% to 37,296.85 while the NASDAQ rose 0.75% to 14,632.70. The S&P 500 also rose, gaining, 0.26% to 4,709.31.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/08/image33.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.056244,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DTC",
        "relevance_score": "0.150592",
        "ticker_sentiment_score": "-0.07026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DADA",
        "relevance_score": "0.22421",
        "ticker_sentiment_score": "-0.018416",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMAM",
        "relevance_score": "0.150592",
        "ticker_sentiment_score": "0.263746",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HARP",
        "relevance_score": "0.150592",
        "ticker_sentiment_score": "0.229419",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LMDX",
        "relevance_score": "0.22421",
        "ticker_sentiment_score": "-0.033305",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.075635",
        "ticker_sentiment_score": "0.209768",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CMC",
        "relevance_score": "0.22421",
        "ticker_sentiment_score": "0.165853",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SPEC",
        "relevance_score": "0.150592",
        "ticker_sentiment_score": "0.48304",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "AAMI and FDA Co-Sponsor Medtech Conference, 'AAMI and FDA neXus'",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36535042/aami-and-fda-co-sponsor-medtech-conference-aami-and-fda-nexus",
    "time_published": "20240108T143700",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Arlington, VA, Jan. 08, 2024 ( GLOBE NEWSWIRE ) -- The Association for the Advancement of Medical Instrumentation ( AAMI ) is delighted to welcome the U.S. Food and Drug Administration as an official co-sponsor of its upcoming medical device standards conference, AAMI and FDA neXus 2024.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.144866,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ISRG",
        "relevance_score": "0.075397",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STE",
        "relevance_score": "0.075397",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.075397",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Two Biotechs Roughly Double After Snagging Splashy Takeover Deals",
    "url": "https://www.investors.com/news/technology/amam-stock-harp-stock-catapult-after-snagging-jnj-merck-buyouts/",
    "time_published": "20240108T141900",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "AMAM Stock, HARP Stock Catapult After Snagging J&J, Merck Buyouts Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/10/stock-JohnsonANDjohnson-02-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      }
    ],
    "overall_sentiment_score": 0.210915,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BSX",
        "relevance_score": "0.529185",
        "ticker_sentiment_score": "0.18163",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HARP",
        "relevance_score": "0.334762",
        "ticker_sentiment_score": "0.110142",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.114682",
        "ticker_sentiment_score": "-0.131349",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXNX",
        "relevance_score": "0.436009",
        "ticker_sentiment_score": "0.214449",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.114682",
        "ticker_sentiment_score": "0.37702",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.227007",
        "ticker_sentiment_score": "0.160288",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "J&J to acquire cancer drug developer Ambrx Biopharma for $2 billion",
    "url": "https://www.cnbc.com/2024/01/08/jj-to-acquire-ambrx-biopharma-a-cancer-drug-developer.html",
    "time_published": "20240108T140931",
    "authors": [
      "Annika Kim Constantino"
    ],
    "summary": "The deal, which was announced on the first day of the annual JPMorgan Healthcare Conference, makes J&J the latest drugmaker to bet on ADCs.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/106974803-1636726862899-gettyimages-1164570932-AFP_1JU2A3.jpeg?v=1704721945&w=1920&h=1080",
    "source": "CNBC",
    "category_within_source": "Business",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.031525,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.154455",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMAM",
        "relevance_score": "0.154455",
        "ticker_sentiment_score": "-0.076968",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JPM",
        "relevance_score": "0.154455",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.154455",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.154455",
        "ticker_sentiment_score": "-0.076968",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Health In Her HUE Announces $3 Million In Funding",
    "url": "https://www.prnewswire.com/news-releases/health-in-her-hue-announces-3-million-in-funding-302028034.html",
    "time_published": "20240108T140000",
    "authors": [
      "Health In Her HUE Inc"
    ],
    "summary": "Health tech startup connects Black women and women of color with culturally sensitive and responsive healthcare providers and content.",
    "banner_image": "https://mma.prnewswire.com/media/2312698/Health_In_Her_HUE_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.399515,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MS",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "0.137916",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.111747",
        "ticker_sentiment_score": "0.152291",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson to Acquire Cancer-Treatment Developer Ambrx for $2 Billion",
    "url": "https://www.wsj.com/health/pharma/johnson-johnson-to-acquire-cancer-treatment-developer-amrbx-for-2b-f7fbafea",
    "time_published": "20240108T130800",
    "authors": [
      "Ben Glickman"
    ],
    "summary": "Johnson & Johnson will acquire cancer-treatment developer Ambrx Biopharma in a $2 billion cash deal.",
    "banner_image": "https://images.wsj.net/im-894720?width=700&height=466",
    "source": "Wall Street Journal",
    "category_within_source": "Business",
    "source_domain": "www.wsj.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.337143,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.716023",
        "ticker_sentiment_score": "0.562146",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Ambrx Announces Sale to Johnson & Johnson",
    "url": "https://www.globenewswire.com/news-release/2024/01/08/2805344/0/en/Ambrx-Announces-Sale-to-Johnson-Johnson.html",
    "time_published": "20240108T123500",
    "authors": [
      "Ambrx Biopharma Inc."
    ],
    "summary": "SAN DIEGO, Jan. 08, 2024 ( GLOBE NEWSWIRE ) -- Ambrx Biopharma, Inc., or Ambrx ( NASDAQ: AMAM ) , today announced that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire all of the outstanding shares of Ambrx for $28.00 per share in cash, representing an ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/41627844-babb-430c-80e2-7278f3ce733d",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.171581,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMAM",
        "relevance_score": "0.071005",
        "ticker_sentiment_score": "0.079387",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.187827",
        "ticker_sentiment_score": "0.16424",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Ambrx Announces Sale to Johnson & Johnson - Ambrx Biopharma  ( NASDAQ:AMAM ) ",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36531191/ambrx-announces-sale-to-johnson-johnson",
    "time_published": "20240108T123500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "SAN DIEGO, Jan. 08, 2024 ( GLOBE NEWSWIRE ) -- Ambrx Biopharma, Inc., or Ambrx AMAM, today announced that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire all of the outstanding shares of Ambrx for $28.00 per share in cash, representing an approximately ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Mergers",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.166834,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMAM",
        "relevance_score": "0.092837",
        "ticker_sentiment_score": "0.079204",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.184422",
        "ticker_sentiment_score": "0.159037",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Human Microbiome Therapeutics Market size to grow by USD 732.95 million from 2022 to 2027, North America to ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/human-microbiome-therapeutics-market-size-to-grow-by-usd-732-95-million-from-2022-to-2027--north-america-to-account-for-41-of-market-growth---technavio-302027860.html",
    "time_published": "20240108T091500",
    "authors": [],
    "summary": "Human Microbiome Therapeutics Market size to grow by USD 732.95 million from 2022 to 2027, North America to ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.243034,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MCRB",
        "relevance_score": "0.050679",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EVLO",
        "relevance_score": "0.050679",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PRTC",
        "relevance_score": "0.050679",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.050679",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EVGN",
        "relevance_score": "0.050679",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYBX",
        "relevance_score": "0.050679",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FNCH",
        "relevance_score": "0.050679",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.050679",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Ascends While Market Falls: Some Facts to Note",
    "url": "https://www.zacks.com/stock/news/2207775/johnson-johnson-jnj-ascends-while-market-falls-some-facts-to-note",
    "time_published": "20240109T224520",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The latest trading day saw Johnson & Johnson (JNJ) settling at $161.63, representing a +0.06% change from its previous close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default280.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.205225,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.601928",
        "ticker_sentiment_score": "0.258805",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - AMAM, CSTR, PGTI, WAVD",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36567500/shareholder-alert-the-m-a-class-action-firm-continues-investigating-the-merger-amam-cstr-pgti-wavd",
    "time_published": "20240109T222750",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, Jan. 09, 2024 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the \"M&A Class Action Firm\" ) , a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.928769"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.348879,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "WAVD",
        "relevance_score": "0.269776",
        "ticker_sentiment_score": "0.167077",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CSTR",
        "relevance_score": "0.269776",
        "ticker_sentiment_score": "0.312899",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ONB",
        "relevance_score": "0.068698",
        "ticker_sentiment_score": "0.15958",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMAM",
        "relevance_score": "0.269776",
        "ticker_sentiment_score": "0.251887",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.068698",
        "ticker_sentiment_score": "0.127207",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PGTI",
        "relevance_score": "0.269776",
        "ticker_sentiment_score": "0.285704",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DOOR",
        "relevance_score": "0.068698",
        "ticker_sentiment_score": "0.145313",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Ambrx  ( AMAM )  Skyrockets 102% on $2B Buyout Offer From J&J",
    "url": "https://www.zacks.com/stock/news/2207649/ambrx-amam-skyrockets-102-on-2b-buyout-offer-from-jj",
    "time_published": "20240109T180400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "J&J (JNJ) is set to acquire Ambrx Biopharma (AMAM) in an all-cash transaction for $2.0 billion. The transaction will likely close in first-half 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/34/973.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.120661,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SKXJF",
        "relevance_score": "0.059488",
        "ticker_sentiment_score": "-0.019018",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.059488",
        "ticker_sentiment_score": "-0.019018",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMAM",
        "relevance_score": "0.234684",
        "ticker_sentiment_score": "0.29989",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HARP",
        "relevance_score": "0.059488",
        "ticker_sentiment_score": "-0.019018",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.234684",
        "ticker_sentiment_score": "0.122646",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.118647",
        "ticker_sentiment_score": "0.213928",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Breast Biopsy Market Set to Achieve US$ 3.8 Billion in Revenue by 2033, Report by Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36561357/breast-biopsy-market-set-to-achieve-us-3-8-billion-in-revenue-by-2033-report-by-persistence-market",
    "time_published": "20240109T171000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 09, 2024 ( GLOBE NEWSWIRE ) -- Breast biopsy is a medical procedure involving the removal of a sample of breast tissue for diagnostic examination. It is a crucial step in the early detection and diagnosis of breast cancer, enabling healthcare professionals to determine the presence ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.191585,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HOLX",
        "relevance_score": "0.020491",
        "ticker_sentiment_score": "0.205118",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.040969",
        "ticker_sentiment_score": "0.02072",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.020491",
        "ticker_sentiment_score": "0.069883",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Illumina Shares Trading Higher After Confirming Partnership With Johnson & Johnson Unit - Illumina  ( NASDAQ:ILMN ) ",
    "url": "https://www.benzinga.com/news/earnings/24/01/36559887/illumina-shares-trading-higher-after-confirming-partnership-with-johnson-johnson-unit",
    "time_published": "20240109T165059",
    "authors": [
      "Nabaparna Bhattacharya"
    ],
    "summary": "Illumina, Inc. ILMN shares are trading higher after announcing preliminary financial results for the fourth quarter ( Q4 ) and fiscal year 2023. For Q4, the company reported preliminary consolidated revenue of approximately $1.115 billion, up 3% from Q4 2022. The analyst consensus stands at ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/09/bz_pharma_briefs.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.106718,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ILMN",
        "relevance_score": "0.766141",
        "ticker_sentiment_score": "0.294902",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.366061",
        "ticker_sentiment_score": "0.365218",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Biotech ETFs Stage Solid Comeback at the Start of 2024",
    "url": "https://www.zacks.com/stock/news/2207551/biotech-etfs-stage-solid-comeback-at-the-start-of-2024",
    "time_published": "20240109T160500",
    "authors": [
      "Sweta Killa"
    ],
    "summary": "The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-time.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.147642,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVO",
        "relevance_score": "0.133346",
        "ticker_sentiment_score": "0.162037",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.084886",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KRTX",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.058856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.084886",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RYZB",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.058856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.058856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.133346",
        "ticker_sentiment_score": "0.06769",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.058856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRCL",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.058856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HARP",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.084886",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.133346",
        "ticker_sentiment_score": "0.162037",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.133346",
        "ticker_sentiment_score": "0.071668",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OMGA",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.140918",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030 - Ambrx Biopharma  ( NASDAQ:AMAM ) , Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36558906/global-oncology-cancer-drugs-market-revenue-projected-to-surpass-289-billion-by-2030",
    "time_published": "20240109T152500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "PALM BEACH, Fla., Jan. 09, 2024 ( GLOBE NEWSWIRE ) -- FN Media Group News Commentary - According to the report titled \"Aging in the United States,\" published by the Population Reference Bureau, \"the number of Americans aged 65 and older is projected to increase more than double over 95 million ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998947"
      }
    ],
    "overall_sentiment_score": 0.103242,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DNPUF",
        "relevance_score": "0.019474",
        "ticker_sentiment_score": "0.086828",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NKTX",
        "relevance_score": "0.077782",
        "ticker_sentiment_score": "-0.066051",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMAM",
        "relevance_score": "0.077782",
        "ticker_sentiment_score": "-0.065019",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSUMF",
        "relevance_score": "0.019474",
        "ticker_sentiment_score": "0.086828",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.058377",
        "ticker_sentiment_score": "0.166162",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ELEV",
        "relevance_score": "0.097141",
        "ticker_sentiment_score": "0.001107",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INCY",
        "relevance_score": "0.038937",
        "ticker_sentiment_score": "0.095682",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.097141",
        "ticker_sentiment_score": "-0.069713",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GLYC",
        "relevance_score": "0.019474",
        "ticker_sentiment_score": "0.133755",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Dr. Rama Kondru Named Chief Executive Officer of Veridix AI - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/dr-rama-kondru-named-chief-executive-officer-of-veridix-ai-302029873.html",
    "time_published": "20240109T140000",
    "authors": [],
    "summary": "Dr. Rama Kondru Named Chief Executive Officer of Veridix AI PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.301566,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JPM",
        "relevance_score": "0.059488",
        "ticker_sentiment_score": "0.079997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.059488",
        "ticker_sentiment_score": "0.046009",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "NeuroTrauma Sciences Appoints William Fricker, CPA, MBA, as Chief Financial Officer",
    "url": "https://www.prnewswire.com/news-releases/neurotrauma-sciences-appoints-william-fricker-cpa-mba-as-chief-financial-officer-302029049.html",
    "time_published": "20240109T133000",
    "authors": [
      "LLC",
      "NeuroTrauma Sciences"
    ],
    "summary": "David Lawrence Departs as CFO; Appointed to Board of Directors",
    "banner_image": "https://mma.prnewswire.com/media/2073146/Neurotrauma_Sciences_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.08129,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BMY",
        "relevance_score": "0.082677",
        "ticker_sentiment_score": "0.026635",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.082677",
        "ticker_sentiment_score": "0.026635",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Daily: One Of Nike's Most Famous Partnerships Comes To An End",
    "url": "https://www.forbes.com/sites/forbesdaily/2024/01/09/forbes-daily-one-of-nikes-most-famous-partnerships-comes-to-an-end/",
    "time_published": "20240109T130922",
    "authors": [
      "Danielle Chemtob"
    ],
    "summary": "Forbes Daily: Nike and Tiger Woods End Endorsement Deal After 27 Years Forbes ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/659d42ecbc4db0ba654cf37c/0x0.jpg?format=jpg&crop=3600,2025,x0,y158,safe&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.0,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.071428",
        "ticker_sentiment_score": "-0.012243",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NKE",
        "relevance_score": "0.142284",
        "ticker_sentiment_score": "0.06845",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SZIHF",
        "relevance_score": "0.023838",
        "ticker_sentiment_score": "-0.035521",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.023838",
        "ticker_sentiment_score": "0.029355",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.023838",
        "ticker_sentiment_score": "-0.232573",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Want to Win in the Stock Market? Be Average.",
    "url": "https://www.fool.com/investing/2024/01/09/want-to-win-in-the-stock-market-be-average/",
    "time_published": "20240109T103000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Start with companies that have proven themselves.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F760525%2Fgettyimages-1323758599.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999896"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.357023,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LTRCF",
        "relevance_score": "0.061315",
        "ticker_sentiment_score": "0.171433",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVAX",
        "relevance_score": "0.061315",
        "ticker_sentiment_score": "0.104012",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.122269",
        "ticker_sentiment_score": "0.187826",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.061315",
        "ticker_sentiment_score": "0.104012",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.122269",
        "ticker_sentiment_score": "0.187826",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "This Dividend Stock Has a $13 Billion Secret Weapon",
    "url": "https://www.fool.com/investing/2024/01/09/this-dividend-stock-has-a-13-billion-secret-weapon/",
    "time_published": "20240109T100000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Johnson & Johnson made a key decision last year.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F760520%2Finvestor-excited-computer.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.300616,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.119532",
        "ticker_sentiment_score": "0.124738",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.119532",
        "ticker_sentiment_score": "0.320641",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( NYSE:JNJ )  Upgraded at StockNews.com",
    "url": "https://www.defenseworld.net/2024/01/09/johnson-johnson-nysejnj-upgraded-at-stocknews-com.html",
    "time_published": "20240109T061446",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Johnson & Johnson ( NYSE:JNJ - Get Free Report ) was upgraded by stock analysts at StockNews.com from a \"buy\" rating to a \"strong-buy\" rating in a research note issued on Tuesday. Other equities research analysts also recently issued research reports about the stock.",
    "banner_image": "https://www.marketbeat.com/logos/johnson--johnson-logo.png?v=20221020135923",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.658903"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.258919,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BCS",
        "relevance_score": "0.057628",
        "ticker_sentiment_score": "0.056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.057628",
        "ticker_sentiment_score": "0.056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.057628",
        "ticker_sentiment_score": "0.056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.057628",
        "ticker_sentiment_score": "0.078207",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.851762",
        "ticker_sentiment_score": "0.430073",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates HARP, AMAM, AXNX, EAR - Ambrx Biopharma  ( NASDAQ:AMAM ) , Axonics  ( NASDAQ:AXNX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36548462/shareholder-rights-investigation-halper-sadeh-llc-investigates-harp-amam-axnx-ear",
    "time_published": "20240109T012135",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, Jan. 08, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Harpoon Therapeutics, Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.10714,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMAM",
        "relevance_score": "0.141726",
        "ticker_sentiment_score": "0.095681",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.141726",
        "ticker_sentiment_score": "0.095681",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HARP",
        "relevance_score": "0.141726",
        "ticker_sentiment_score": "0.095681",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXNX",
        "relevance_score": "0.279015",
        "ticker_sentiment_score": "0.157051",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EAR",
        "relevance_score": "0.279015",
        "ticker_sentiment_score": "0.294303",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.141726",
        "ticker_sentiment_score": "0.095681",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Top Analyst Reports for Johnson & Johnson, Micron Technology & Southern Company",
    "url": "https://www.zacks.com/research-daily/2208227/top-analyst-reports-for-johnson-johnson-micron-technology-southern-company",
    "time_published": "20240110T221600",
    "authors": [
      "Mark Vickery"
    ],
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Micron Technology, Inc. (MU) and The Southern Company (SO).",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f8/4049.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.340444,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SO",
        "relevance_score": "0.098255",
        "ticker_sentiment_score": "0.047229",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.098255",
        "ticker_sentiment_score": "0.266129",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Mastercard crosses $400 billion market-cap level in a sign of spending resilience",
    "url": "https://www.marketwatch.com/story/mastercard-crosses-400-billion-market-cap-level-in-a-sign-of-spending-resilience-59fe2392",
    "time_published": "20240110T214600",
    "authors": [
      "Emily Bary"
    ],
    "summary": "Mastercard vaulted into $400 billion territory for the first time Wednesday in a testament to confidence about consumer spending.",
    "banner_image": "https://images.mktw.net/im-290935/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.294342,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PYPL",
        "relevance_score": "0.271274",
        "ticker_sentiment_score": "0.294333",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.512093",
        "ticker_sentiment_score": "0.389798",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "V",
        "relevance_score": "0.397098",
        "ticker_sentiment_score": "0.335518",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.271274",
        "ticker_sentiment_score": "0.094822",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.271274",
        "ticker_sentiment_score": "0.094822",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "In An Age Of 'Cancel Culture,' Some Voices Persist-On Smaller Platforms",
    "url": "https://www.forbes.com/sites/cmo/2024/01/10/in-an-age-of-cancel-culture-some-voices-persist-on-smaller-platforms/",
    "time_published": "20240110T191547",
    "authors": [
      "Megan Poinski"
    ],
    "summary": "This is the published version of Forbes' CMO newsletter, which offers the latest news for chief marketing officers and other messaging-focused leaders. Click here to get it delivered to your inbox every Wednesday.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/659ede1077df2ab4adf6607f/0x0.jpg?format=jpg&crop=3094,1739,x0,y13,safe&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.06445,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.019962",
        "ticker_sentiment_score": "0.151052",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WBD",
        "relevance_score": "0.039911",
        "ticker_sentiment_score": "-0.034522",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CCZ",
        "relevance_score": "0.019962",
        "ticker_sentiment_score": "0.021104",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOX",
        "relevance_score": "0.019962",
        "ticker_sentiment_score": "0.021104",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.059835",
        "ticker_sentiment_score": "0.049758",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "A Closer Look at Johnson & Johnson's Options Market Dynamics - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/markets/options/24/01/36579369/a-closer-look-at-johnson-johnsons-options-market-dynamics",
    "time_published": "20240110T161701",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bearish approach towards Johnson & Johnson JNJ, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.180773,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.071357",
        "ticker_sentiment_score": "0.139898",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.071357",
        "ticker_sentiment_score": "-0.180309",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.629492",
        "ticker_sentiment_score": "0.35671",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Will Q4 Earnings Push Dow ETF Higher?",
    "url": "https://www.zacks.com/stock/news/2208372/will-q4-earnings-push-dow-etf-higher",
    "time_published": "20240110T161000",
    "authors": [
      "Sweta Killa"
    ],
    "summary": "Let's delve deeper into the probable fourth-quarter earnings picture that will likely aid Dow ETF in the coming days.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default161.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.115267,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DOW",
        "relevance_score": "0.131164",
        "ticker_sentiment_score": "0.016405",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IBM",
        "relevance_score": "0.174272",
        "ticker_sentiment_score": "0.078148",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.131164",
        "ticker_sentiment_score": "0.055623",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JPM",
        "relevance_score": "0.174272",
        "ticker_sentiment_score": "-0.015449",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.131164",
        "ticker_sentiment_score": "-0.001181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.131164",
        "ticker_sentiment_score": "0.017822",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Mens Grooming Products Market Projected to Reach $139,588.4 Million Globally by 2033, with a CAGR of 7.5%, According to Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36575377/mens-grooming-products-market-projected-to-reach-139-588-4-million-globally-by-2033-with-a-cagr-of",
    "time_published": "20240110T133433",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 10, 2024 ( GLOBE NEWSWIRE ) -- Snapshot of the Men's Grooming Products Market: In 2022, the men's grooming products market raked in a revenue of $63,140.3 million, as reported by Persistence Market Research. The demand for these products is set to rise, with key players ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.400912,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PRBZF",
        "relevance_score": "0.027603",
        "ticker_sentiment_score": "0.056832",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.027603",
        "ticker_sentiment_score": "-0.309225",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.055173",
        "ticker_sentiment_score": "0.244008",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IFF",
        "relevance_score": "0.027603",
        "ticker_sentiment_score": "0.199431",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CL",
        "relevance_score": "0.027603",
        "ticker_sentiment_score": "-0.309225",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "EPC",
        "relevance_score": "0.027603",
        "ticker_sentiment_score": "-0.309225",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "LRLCF",
        "relevance_score": "0.027603",
        "ticker_sentiment_score": "0.056832",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Wall Street Doesn't Expect Eli Lilly Stock to Move Much Higher in 2024. Here's Why Analysts Could Be Wrong.",
    "url": "https://www.fool.com/investing/2024/01/10/wall-street-doesnt-expect-eli-lilly-stock-to-move/",
    "time_published": "20240110T105100",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Lilly's sizzle might not fizzle in the new year.",
    "banner_image": "https://g.foolcdn.com/editorial/images/760650/stock-charts-on-screen-analysts.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.164182,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.759979",
        "ticker_sentiment_score": "0.161885",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.062434",
        "ticker_sentiment_score": "0.020019",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Johnson & Johnson Stock a Buy Now?",
    "url": "https://www.fool.com/investing/2024/01/10/is-johnson-johnson-stock-a-buy-now/",
    "time_published": "20240110T102500",
    "authors": [
      "David Jagielski"
    ],
    "summary": "The pharmaceutical giant recently announced another acquisition.",
    "banner_image": "https://g.foolcdn.com/editorial/images/760434/pharmacist-helping-a-customer.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.118318,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.054983",
        "ticker_sentiment_score": "0.035885",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.509589",
        "ticker_sentiment_score": "0.197609",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Bone Wax Market to Reach USD 107.8 billion by 2031, Rising at a CAGR of 3.3% | Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36571219/bone-wax-market-to-reach-usd-107-8-billion-by-2031-rising-at-a-cagr-of-3-3-transparency-market-res",
    "time_published": "20240110T075618",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Jan. 10, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global bone wax market is estimated to rise at a CAGR of 3.3% from 2023 to 2031. Transparency Market Research projects that the overall sales revenue for bone wax is estimated to reach ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.303616,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BAX",
        "relevance_score": "0.096932",
        "ticker_sentiment_score": "0.205777",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.032382",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.096932",
        "ticker_sentiment_score": "0.055751",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.096932",
        "ticker_sentiment_score": "0.056001",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.06471",
        "ticker_sentiment_score": "-0.016098",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Johnson & Johnson, Micron Technology, The Southern Company, TotalEnergies and PACCAR",
    "url": "https://www.zacks.com/stock/news/2208844/the-zacks-analyst-blog-highlights-johnson-johnson-micron-technology-the-southern-company-totalenergies-and-paccar",
    "time_published": "20240111T142200",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Johnson & Johnson, Micron Technology, The Southern Company, TotalEnergies and PACCAR are part of the Zacks top Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.275813,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MU",
        "relevance_score": "0.210579",
        "ticker_sentiment_score": "0.049748",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PCAR",
        "relevance_score": "0.14131",
        "ticker_sentiment_score": "0.037825",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SO",
        "relevance_score": "0.210579",
        "ticker_sentiment_score": "0.05539",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TTE",
        "relevance_score": "0.14131",
        "ticker_sentiment_score": "0.037825",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.278222",
        "ticker_sentiment_score": "0.188508",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Walgreens Cut Its Dividend by 48%: Here Are 5 Better Dow Dividend Stocks to Buy in January",
    "url": "https://www.fool.com/investing/2024/01/11/walgreens-cuts-dividend-better-dow-stocks-buy-now/",
    "time_published": "20240111T110800",
    "authors": [
      "Daniel Foelber"
    ],
    "summary": "Businesses with efficient operations and growth potential open the door to dividend raises for years to come.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F760509%2Fgettyimages-1007651732-1200x754-6541a54.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.238805,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TGT",
        "relevance_score": "0.03642",
        "ticker_sentiment_score": "0.175279",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.215894",
        "ticker_sentiment_score": "0.18948",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.28511",
        "ticker_sentiment_score": "0.060705",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.180595",
        "ticker_sentiment_score": "0.107463",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.108958",
        "ticker_sentiment_score": "-0.018214",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "0.011311",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.03642",
        "ticker_sentiment_score": "0.060978",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.384532",
        "ticker_sentiment_score": "0.235928",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Baby Wipes Market Is Estimated to Translate to a Revenue of US$ 9.9 Billion by 2032, According to Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36589950/baby-wipes-market-is-estimated-to-translate-to-a-revenue-of-us-9-9-billion-by-2032-according-to-pe",
    "time_published": "20240111T110000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 11, 2024 ( GLOBE NEWSWIRE ) -- The Wriggling World of Baby Wipes: A Market Deep Dive Baby wipes are moistened, disposable cloths used for cleaning infants during diaper changes and for general hygiene purposes. They are typically formulated to be gentle on a baby's delicate ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.292668,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HEGIF",
        "relevance_score": "0.040484",
        "ticker_sentiment_score": "0.131624",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.040484",
        "ticker_sentiment_score": "0.244139",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.040484",
        "ticker_sentiment_score": "0.244139",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Eli Lilly Stock Skyrocketed 59% in 2023",
    "url": "https://www.fool.com/investing/2024/01/11/why-eli-lilly-stock-skyrocketed-59-in-2023/",
    "time_published": "20240111T104900",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Lilly's pipeline success in 2023 allowed it to to claim the crown as the biggest drugmaker on the planet by market cap.",
    "banner_image": "https://g.foolcdn.com/editorial/images/760865/scientists-smiling-and-shaking-hands.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.857896"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.163735,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.722311",
        "ticker_sentiment_score": "0.243335",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DICE",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.155496",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Dow Stocks to Buy Hand Over Fist in 2024 and 1 to Avoid Like the Plague",
    "url": "https://www.fool.com/investing/2024/01/11/2-dow-stocks-to-buy-2024-and-1-avoid-like-plague/",
    "time_published": "20240111T102100",
    "authors": [
      "Sean Williams"
    ],
    "summary": "Among the Dow Jones Industrial Average's 30 time-tested components, there are two that are historically cheap and ripe for the picking, while another outperformer is riddled with issues.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F760630%2Fnyse-wall-street-trading-new-york-financial-stock-market-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.988787"
      }
    ],
    "overall_sentiment_score": 0.148655,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SPGI",
        "relevance_score": "0.029149",
        "ticker_sentiment_score": "0.09816",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TWOH",
        "relevance_score": "0.029149",
        "ticker_sentiment_score": "0.1698",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.365235",
        "ticker_sentiment_score": "0.060384",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.201884",
        "ticker_sentiment_score": "0.130795",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Traditional Wound Dressings Market Regain Ground in Evolving Healthcare Landscape: Market Projected to Reach US$ 6.93 Billion by 2032, Report by Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36588271/traditional-wound-dressings-market-regain-ground-in-evolving-healthcare-landscape-market-projected",
    "time_published": "20240111T053000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 11, 2024 ( GLOBE NEWSWIRE ) -- Market Overview: The global traditional wound dressing market recorded a valuation of US$ 5.1 Billion in 2022 and is expected to reach US$ 6.93 billion by the end of 2032, expanding at a CAGR of 3.2% from 2022 to 2032.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.12904,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "HLCO",
        "relevance_score": "0.025299",
        "ticker_sentiment_score": "0.074524",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.012651",
        "ticker_sentiment_score": "-0.007008",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.012651",
        "ticker_sentiment_score": "-0.007008",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Gene Therapy Global Market is Projected to Grow at a CAGR of ~19% by 2028, Predicts DelveInsight",
    "url": "https://www.prnewswire.com/news-releases/gene-therapy-global-market-is-projected-to-grow-at-a-cagr-of-19-by-2028-predicts-delveinsight-302033381.html",
    "time_published": "20240112T220100",
    "authors": [
      "LLP",
      "DelveInsight Business Research"
    ],
    "summary": "LAS VEGAS, Jan. 12, 2024 /PRNewswire/ -- DelveInsight's Gene Therapy Market Insights report provides the current and forecast market analysis, individual leading gene therapy companies' market shares, challenges, gene therapy market drivers, barriers, trends, and key market gene therapy ...",
    "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.203913,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "FOLD",
        "relevance_score": "0.060694",
        "ticker_sentiment_score": "-0.036112",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RARE",
        "relevance_score": "0.060694",
        "ticker_sentiment_score": "0.078001",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLUE",
        "relevance_score": "0.030369",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SRPT",
        "relevance_score": "0.030369",
        "ticker_sentiment_score": "0.096229",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.060694",
        "ticker_sentiment_score": "0.055",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.030369",
        "ticker_sentiment_score": "0.096229",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.030369",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.090931",
        "ticker_sentiment_score": "0.00954",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FRLN",
        "relevance_score": "0.060694",
        "ticker_sentiment_score": "-0.036112",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PTCT",
        "relevance_score": "0.030369",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SLDB",
        "relevance_score": "0.030369",
        "ticker_sentiment_score": "0.096229",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LXEO",
        "relevance_score": "0.030369",
        "ticker_sentiment_score": "0.096229",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RGNX",
        "relevance_score": "0.090931",
        "ticker_sentiment_score": "0.00954",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SIOX",
        "relevance_score": "0.030369",
        "ticker_sentiment_score": "-0.05095",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.030369",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cytokinetics  ( CYTK )  Down on Report of Novartis Not Interested",
    "url": "https://www.zacks.com/stock/news/2209728/cytokinetics-cytk-down-on-report-of-novartis-not-interested",
    "time_published": "20240112T194700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Cytokinetics (CYTK) slumps after a report stating Novartis not interested in acquiring the company surface.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ab/2180.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.166093,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CYTK",
        "relevance_score": "0.654522",
        "ticker_sentiment_score": "0.242155",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.149656",
        "ticker_sentiment_score": "0.058089",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.04437",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.04437",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KDNY",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.067603",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Market Rebounds As Nvidia Leads; Bitcoin ETFs, Tesla Fall: Weekly Review",
    "url": "https://www.investors.com/news/stock-market-rally-rebounds-nvidia-tesla-jpmorgan-bitcoin-etfs-in-focus/",
    "time_published": "20240112T191300",
    "authors": [
      "Investor's Business Daily",
      "IBD STAFF"
    ],
    "summary": "Market Rebounds As Nvidia Leads. Bitcoin ETFs, Tesla Fall: Weekly Review Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2019/11/Stock-bounce-05-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.99489"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": -0.007321,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALK",
        "relevance_score": "0.045612",
        "ticker_sentiment_score": "-0.11938",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLK",
        "relevance_score": "0.068371",
        "ticker_sentiment_score": "0.028338",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.045612",
        "ticker_sentiment_score": "-0.11938",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.091075",
        "ticker_sentiment_score": "0.060214",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JPM",
        "relevance_score": "0.136242",
        "ticker_sentiment_score": "0.010052",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CROX",
        "relevance_score": "0.068371",
        "ticker_sentiment_score": "0.189572",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.045612",
        "ticker_sentiment_score": "-0.022883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HPQ",
        "relevance_score": "0.022815",
        "ticker_sentiment_score": "-0.000921",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BK",
        "relevance_score": "0.068371",
        "ticker_sentiment_score": "0.028338",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.045612",
        "ticker_sentiment_score": "0.128458",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.113705",
        "ticker_sentiment_score": "0.011467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "URBN",
        "relevance_score": "0.068371",
        "ticker_sentiment_score": "0.131736",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KBH",
        "relevance_score": "0.068371",
        "ticker_sentiment_score": "-0.140846",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.022815",
        "ticker_sentiment_score": "0.001816",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TGTX",
        "relevance_score": "0.045612",
        "ticker_sentiment_score": "-0.022883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EADSF",
        "relevance_score": "0.022815",
        "ticker_sentiment_score": "-0.111175",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.136242",
        "ticker_sentiment_score": "-0.148914",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPR",
        "relevance_score": "0.045612",
        "ticker_sentiment_score": "-0.11938",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.045612",
        "ticker_sentiment_score": "0.027908",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HARP",
        "relevance_score": "0.045612",
        "ticker_sentiment_score": "-0.022883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.068371",
        "ticker_sentiment_score": "0.002016",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WT",
        "relevance_score": "0.022815",
        "ticker_sentiment_score": "0.120065",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.091075",
        "ticker_sentiment_score": "0.027513",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXNX",
        "relevance_score": "0.045612",
        "ticker_sentiment_score": "-0.022883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MARA",
        "relevance_score": "0.045612",
        "ticker_sentiment_score": "0.128458",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.068371",
        "ticker_sentiment_score": "0.087256",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.136242",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.045612",
        "ticker_sentiment_score": "0.027908",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNPR",
        "relevance_score": "0.068371",
        "ticker_sentiment_score": "-0.001011",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.045612",
        "ticker_sentiment_score": "-0.022883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AEO",
        "relevance_score": "0.045612",
        "ticker_sentiment_score": "0.185014",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SWN",
        "relevance_score": "0.068371",
        "ticker_sentiment_score": "0.150164",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DAL",
        "relevance_score": "0.136242",
        "ticker_sentiment_score": "-0.020069",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LULU",
        "relevance_score": "0.045612",
        "ticker_sentiment_score": "0.185014",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GCO",
        "relevance_score": "0.045612",
        "ticker_sentiment_score": "0.185014",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ANF",
        "relevance_score": "0.068371",
        "ticker_sentiment_score": "0.131736",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXEL",
        "relevance_score": "0.045612",
        "ticker_sentiment_score": "-0.022883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HPE",
        "relevance_score": "0.180967",
        "ticker_sentiment_score": "-0.001504",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.045612",
        "ticker_sentiment_score": "-0.022883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.068371",
        "ticker_sentiment_score": "0.026257",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.091075",
        "ticker_sentiment_score": "-0.023423",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.246923",
        "ticker_sentiment_score": "0.097548",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Lung Cancer Surgery Market Projected to Reach USD 20.2 billion with Registering at a CAGR of 5.6% by 2031| Transparency Market Research Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36613349/lung-cancer-surgery-market-projected-to-reach-usd-20-2-billion-with-registering-at-a-cagr-of-5-6-b",
    "time_published": "20240112T161947",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Jan. 12, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global lung cancer surgery market is estimated to flourish at a CAGR of 5.6% from 2023 to 2031.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.195235,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.034233",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARAY",
        "relevance_score": "0.136306",
        "ticker_sentiment_score": "0.140847",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.034233",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TFX",
        "relevance_score": "0.068404",
        "ticker_sentiment_score": "0.014449",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.068404",
        "ticker_sentiment_score": "0.105458",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OCPNF",
        "relevance_score": "0.102449",
        "ticker_sentiment_score": "0.233034",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.034233",
        "ticker_sentiment_score": "0.178081",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.102449",
        "ticker_sentiment_score": "0.023021",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  is Attracting Investor Attention: Here is What You Should Know",
    "url": "https://www.zacks.com/stock/news/2209423/johnson-johnson-jnj-is-attracting-investor-attention-here-is-what-you-should-know",
    "time_published": "20240112T140011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default70.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.232787,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.473208",
        "ticker_sentiment_score": "0.173211",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "There's A Paradigm Shift In Immunology; And Big Pharma Is Paying Richly For It",
    "url": "https://www.investors.com/news/technology/biotech-stocks-forge-a-paradigm-shift-in-immunology-and-big-pharma-pays-handsomely-for-it/",
    "time_published": "20240112T140000",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "There's A Paradigm Shift In Immunology. And Big Pharma Is Paying Richly For It Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/10/stock-Merck-02-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.130928,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.023838",
        "ticker_sentiment_score": "-0.146266",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.047654",
        "ticker_sentiment_score": "0.208731",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ROIV",
        "relevance_score": "0.047654",
        "ticker_sentiment_score": "-0.00099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RXDX",
        "relevance_score": "0.023838",
        "ticker_sentiment_score": "-0.000896",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.047654",
        "ticker_sentiment_score": "-0.155656",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.118764",
        "ticker_sentiment_score": "-0.008046",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Antibiotic Resistance Market Projected to Hit US$ 17.8 Billion by 2033 with a CAGR of 5.3% | Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36606656/antibiotic-resistance-market-projected-to-hit-us-17-8-billion-by-2033-with-a-cagr-of-5-3-persisten",
    "time_published": "20240112T090835",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 12, 2024 ( GLOBE NEWSWIRE ) -- The growing demand for new antibiotic therapies to combat antibiotic resistance is a prominent driver in the global market. In a July 2023 Science Daily article, the World Health Organization ( WHO ) recognized antibiotic-resistant bacteria as a major ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.014889,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BIO",
        "relevance_score": "0.018187",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.018187",
        "ticker_sentiment_score": "-0.055056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.018187",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.036365",
        "ticker_sentiment_score": "-0.083171",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.018187",
        "ticker_sentiment_score": "-0.131837",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.018187",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Average Stocks That Could Make You Rich",
    "url": "https://www.fool.com/investing/2024/01/13/2-average-stocks-that-could-make-you-rich/",
    "time_published": "20240113T141000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "You don't always have to pick a game-changing company to win in the stock market.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F760974%2Fgettyimages-1272759382.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.904684"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.410321,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.050465",
        "ticker_sentiment_score": "0.048562",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.513698",
        "ticker_sentiment_score": "0.606803",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JPM",
        "relevance_score": "0.050465",
        "ticker_sentiment_score": "0.145883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.100729",
        "ticker_sentiment_score": "0.052034",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - RYZB, FGH, AMAM, CSTR",
    "url": "https://www.prnewswire.com/news-releases/stockholder-alert-the-ma-class-action-firm-continues-investigating-the-merger--ryzb-fgh-amam-cstr-302033994.html",
    "time_published": "20240113T013000",
    "authors": [
      "Monteverde & Associates PC"
    ],
    "summary": "NEW YORK, Jan. 12, 2024 /PRNewswire/ -- , founder and managing partner of the class action firm ( the \"M&A Class Action Firm\" ) , a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, ...",
    "banner_image": "https://mma.prnewswire.com/media/443626/Monteverde_Associates_PC_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.95493"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.385265,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CSTR",
        "relevance_score": "0.22421",
        "ticker_sentiment_score": "0.232225",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ONB",
        "relevance_score": "0.075635",
        "ticker_sentiment_score": "0.137439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FGF",
        "relevance_score": "0.150592",
        "ticker_sentiment_score": "0.175595",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMAM",
        "relevance_score": "0.22421",
        "ticker_sentiment_score": "0.232225",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.075635",
        "ticker_sentiment_score": "0.137439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RYZB",
        "relevance_score": "0.295867",
        "ticker_sentiment_score": "0.287065",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.075635",
        "ticker_sentiment_score": "0.137439",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Biotech and pharma companies are betting on a promising class of cancer drugs to drive growth",
    "url": "https://www.cnbc.com/2024/01/14/cancer-drugs-renewed-interest-in-adcs-will-continue-in-2024.html",
    "time_published": "20240114T131240",
    "authors": [
      "Annika Kim Constantino"
    ],
    "summary": "The JPMorgan Healthcare Conference was likely just the beginning of another year of heightened interest and investments in ADC cancer drugs.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107238280-1683650170075-gettyimages-1238822565-20090101220228-99-316819.jpeg?v=1705225358&w=1920&h=1080",
    "source": "CNBC",
    "category_within_source": "Business",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.099245,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.032691",
        "ticker_sentiment_score": "-0.025298",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMAM",
        "relevance_score": "0.032691",
        "ticker_sentiment_score": "-0.024714",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JPM",
        "relevance_score": "0.032691",
        "ticker_sentiment_score": "0.092444",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.032691",
        "ticker_sentiment_score": "-0.024714",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SKXJF",
        "relevance_score": "0.065327",
        "ticker_sentiment_score": "0.044577",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.065327",
        "ticker_sentiment_score": "0.044577",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.2258",
        "ticker_sentiment_score": "0.05974",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.032691",
        "ticker_sentiment_score": "-0.166405",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Virpax: A Promising Stock In A Sickly Biotech Market",
    "url": "https://www.forbes.com/sites/lawrencelight/2024/01/14/virpax-a-promising-stock-in-a-sickly-biotech-market/",
    "time_published": "20240114T130000",
    "authors": [
      "Larry Light"
    ],
    "summary": "Biotech always is a tough line of work, with a high failure rate because the research folks' ideas don't pan out, or even if they do, the Food and Drug Administration fails to approve their applications. Of the three FDA stages needed to greenlight a drug, the first has a mere 9% approval rate.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65a2ef10da7904ef829d856a/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": -0.073166,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "REGN",
        "relevance_score": "0.061949",
        "ticker_sentiment_score": "0.165124",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRPX",
        "relevance_score": "0.061949",
        "ticker_sentiment_score": "-0.125278",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.061949",
        "ticker_sentiment_score": "-0.145062",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Super-Safe High-Yield Dividend Stocks You Can Buy Right Now",
    "url": "https://www.fool.com/investing/2024/01/14/super-safe-high-yield-dividend-stocks-buy-now/",
    "time_published": "20240114T105000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "You shouldn't lose any sleep worrying about these great dividends.",
    "banner_image": "https://g.foolcdn.com/editorial/images/760991/man-with-arms-behind-head-looking-at-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.239025,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.310843",
        "ticker_sentiment_score": "0.219693",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIPC",
        "relevance_score": "0.251032",
        "ticker_sentiment_score": "0.180186",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.127119",
        "ticker_sentiment_score": "0.042741",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Former Warren Buffett Stocks That Stand Out as Stong Buys in 2024",
    "url": "https://www.fool.com/investing/2024/01/14/2-former-warren-buffett-stocks-that-stand-out-as-s/",
    "time_published": "20240114T103000",
    "authors": [
      "George Budwell"
    ],
    "summary": "Berkshire Hathaway exited its positions in these two blue chip dividend stocks last year, but they are still superb buys for certain types of investors.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F761125%2Ftime-to-buy.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.295593,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.135347",
        "ticker_sentiment_score": "0.146372",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CURN",
        "relevance_score": "0.067919",
        "ticker_sentiment_score": "-0.025615",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.135347",
        "ticker_sentiment_score": "0.2802",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.449219",
        "ticker_sentiment_score": "0.134039",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bioplastics Packaging Market Projected to Hit US$ 8,913.1 Million by 2033 with a CAGR of 12.5% | Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36632333/bioplastics-packaging-market-projected-to-hit-us-8-913-1-million-by-2033-with-a-cagr-of-12-5-persi",
    "time_published": "20240115T183000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 16, 2024 ( GLOBE NEWSWIRE ) -- In this section, we delve into a comprehensive analysis of the Bioplastics Packaging Market, offering insights into its current dynamics and future prospects.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.30023,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EVKIF",
        "relevance_score": "0.017729",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KDSKF",
        "relevance_score": "0.017729",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.03545",
        "ticker_sentiment_score": "0.214402",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.03545",
        "ticker_sentiment_score": "0.265317",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MTLHF",
        "relevance_score": "0.017729",
        "ticker_sentiment_score": "0.246885",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.03545",
        "ticker_sentiment_score": "0.265317",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CSNVF",
        "relevance_score": "0.017729",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSBHF",
        "relevance_score": "0.017729",
        "ticker_sentiment_score": "0.246885",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ADM",
        "relevance_score": "0.03545",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAK",
        "relevance_score": "0.017729",
        "ticker_sentiment_score": "0.08311",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Forget Meme Stocks and Bitcoin. These Investors Are Hunting Quality.",
    "url": "https://www.wsj.com/finance/stocks/forget-meme-stocks-and-bitcoin-these-investors-are-hunting-quality-1576454e",
    "time_published": "20240115T103000",
    "authors": [
      "Brenda Le\u00f3n"
    ],
    "summary": "The targets are shares of companies with some combination of growth, reliable profits and strong balance sheets.",
    "banner_image": "https://images.wsj.net/im-911681/social",
    "source": "Wall Street Journal",
    "category_within_source": "Markets",
    "source_domain": "www.wsj.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.552435,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.535653",
        "ticker_sentiment_score": "0.741737",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.535653",
        "ticker_sentiment_score": "0.741737",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.535653",
        "ticker_sentiment_score": "0.741737",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.535653",
        "ticker_sentiment_score": "0.741737",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Eye Health Products Market: Projected to Attain US$ 4.7 Billion by 2033, Propelled by a Resilient 7.3% CAGR | Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36627196/eye-health-products-market-projected-to-attain-us-4-7-billion-by-2033-propelled-by-a-resilient-7-3",
    "time_published": "20240115T081000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 15, 2024 ( GLOBE NEWSWIRE ) -- Market Overview: The eye health products market is experiencing a surge in demand, fueled by a growing awareness of eye health, rising prevalence of eye diseases, and an aging global population.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.384775,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALC",
        "relevance_score": "0.036954",
        "ticker_sentiment_score": "0.268271",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BLCO",
        "relevance_score": "0.036954",
        "ticker_sentiment_score": "0.133154",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHC",
        "relevance_score": "0.018482",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESLOF",
        "relevance_score": "0.018482",
        "ticker_sentiment_score": "0.108049",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.018482",
        "ticker_sentiment_score": "0.233091",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Top 5 Life Science ETFs",
    "url": "https://investingnews.com/daily/life-science-investing/biotech-investing/top-performing-life-science-etfs/",
    "time_published": "20240116T211500",
    "authors": [
      "Melissa Pistilli"
    ],
    "summary": "Taking a position in a life science exchange-traded fund ( ETF ) provides exposure to a basket of stocks focused on the healthcare sector, while mitigating the risks of holding shares in a single company.",
    "banner_image": "https://investingnews.com/media-library/two-scientists-in-a-lab.jpg?id=27732936&width=1200&height=800&quality=85&coordinates=0%2C0%2C0%2C0",
    "source": "Investing News Network",
    "category_within_source": "n/a",
    "source_domain": "investingnews.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999476"
      }
    ],
    "overall_sentiment_score": 0.182618,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ARWR",
        "relevance_score": "0.060085",
        "ticker_sentiment_score": "0.081",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CYTK",
        "relevance_score": "0.060085",
        "ticker_sentiment_score": "0.081",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXAS",
        "relevance_score": "0.060085",
        "ticker_sentiment_score": "0.052998",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.1789",
        "ticker_sentiment_score": "0.109406",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KRTX",
        "relevance_score": "0.060085",
        "ticker_sentiment_score": "0.081",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RXRX",
        "relevance_score": "0.060085",
        "ticker_sentiment_score": "0.052998",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.060085",
        "ticker_sentiment_score": "0.02205",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.1789",
        "ticker_sentiment_score": "0.109406",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Options Trading: A Deep Dive into Market Sentiment - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/markets/options/24/01/36648551/johnson-johnson-options-trading-a-deep-dive-into-market-sentiment",
    "time_published": "20240116T193052",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson JNJ we detected 11 trades. If we consider the specifics of each trade, it is accurate to state that 18% of the investors opened trades with bullish ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.159589,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.083251",
        "ticker_sentiment_score": "0.142327",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.535653",
        "ticker_sentiment_score": "0.313788",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Molecular Diagnostics Market Hits US$ 39.5 Billion in 2022, Expected to Reach US$ 59.4 Billion by 2033 with a 4.2% CAGR, Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36643857/molecular-diagnostics-market-hits-us-39-5-billion-in-2022-expected-to-reach-us-59-4-billion-by-203",
    "time_published": "20240116T153000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 16, 2024 ( GLOBE NEWSWIRE ) -- The Molecular Diagnostics Market is experiencing robust growth due to technological advancements and increasing demand for personalized medicine. Key applications include oncology, infectious diseases, genetic testing, and cardiovascular diseases.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.263389,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "A",
        "relevance_score": "0.019797",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HOLX",
        "relevance_score": "0.019797",
        "ticker_sentiment_score": "-0.14516",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.019797",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.019797",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.019797",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIO",
        "relevance_score": "0.019797",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRFS",
        "relevance_score": "0.019797",
        "ticker_sentiment_score": "0.089741",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QGEN",
        "relevance_score": "0.019797",
        "ticker_sentiment_score": "0.071657",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DHR",
        "relevance_score": "0.019797",
        "ticker_sentiment_score": "0.132145",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Liquid Soap Market Bubbles Up to USD 35.70 Billion by 2030, Report by Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36642766/liquid-soap-market-bubbles-up-to-usd-35-70-billion-by-2030-report-by-persistence-market-research",
    "time_published": "20240116T144500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 16, 2024 ( GLOBE NEWSWIRE ) -- Market Overview: The global liquid soap market size was valued at USD 21.18 billion in 2022 and is projected to grow from USD 22.46 billion in 2023 to USD 35.70 billion by 2030, exhibiting a CAGR of 6.84% during the forecast period.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.349971,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BDRFF",
        "relevance_score": "0.016383",
        "ticker_sentiment_score": "0.14692",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.032758",
        "ticker_sentiment_score": "0.085756",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.016383",
        "ticker_sentiment_score": "0.084095",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UL",
        "relevance_score": "0.032758",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HENKY",
        "relevance_score": "0.016383",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CL",
        "relevance_score": "0.016383",
        "ticker_sentiment_score": "0.102022",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ECL",
        "relevance_score": "0.032758",
        "ticker_sentiment_score": "0.090551",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RBGPF",
        "relevance_score": "0.032758",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "After-sun Products Market is Anticipated to Reach USD 3.3 billion at a CAGR of 3.7 % CAGR by 2031 - Report by Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36642400/after-sun-products-market-is-anticipated-to-reach-usd-3-3-billion-at-a-cagr-of-3-7-cagr-by-2031-re",
    "time_published": "20240116T143000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Jan. 16, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - After-sun products accounted for a global market value of US$ 2.4 billion in 2022. From 2023 to 2031, it is expected to expand at a CAGR of 3.7%, reaching US$ 3.3 billion by 2031.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.382977,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.038407",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.114865",
        "ticker_sentiment_score": "0.160374",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.038407",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.038407",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc.  ( Nasdaq - AMAM ) , Gracell Biotechnologies Inc.  ( Nasdaq - GRCL ) , Axonics, Inc.  ( Nasdaq - AXNX ) , Harpoon Therapeutics, Inc.  ( Nasdaq - HARP ) ",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36638641/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-ambrx-biophar",
    "time_published": "20240116T130500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "BALA CYNWYD, Pa., Jan. 16, 2024 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.232971,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.233556",
        "ticker_sentiment_score": "0.266779",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.233556",
        "ticker_sentiment_score": "0.068874",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRCL",
        "relevance_score": "0.07887",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMAM",
        "relevance_score": "0.07887",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.233556",
        "ticker_sentiment_score": "0.235274",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HARP",
        "relevance_score": "0.07887",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.15697",
        "ticker_sentiment_score": "0.156505",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AXNX",
        "relevance_score": "0.233556",
        "ticker_sentiment_score": "0.216405",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Ecovyst Names Kara L. Thornton Vice President and Chief Human Resources Officer",
    "url": "https://www.prnewswire.com/news-releases/ecovyst-names-kara-l-thornton-vice-president-and-chief-human-resources-officer-302033970.html",
    "time_published": "20240116T120000",
    "authors": [
      "Ecovyst Inc."
    ],
    "summary": "MALVERN, Pa., Jan. 16, 2024 /PRNewswire/ -- Ecovyst Inc. ( NYSE: ECVT ) ( \"Ecovyst\" or the \"Company\" ) , a leading integrated and innovative global provider of advanced materials,specialty catalysts and services, today announced that Kara L. Thornton has been appointed Vice President and Chief ...",
    "banner_image": "https://mma.prnewswire.com/media/2243202/Ecovyst_hi_res_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.410021,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SKXJF",
        "relevance_score": "0.102013",
        "ticker_sentiment_score": "-0.057567",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STIM",
        "relevance_score": "0.102013",
        "ticker_sentiment_score": "-0.057567",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ECVT",
        "relevance_score": "0.558244",
        "ticker_sentiment_score": "0.673579",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.102013",
        "ticker_sentiment_score": "-0.057567",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Asia Pacific Facial Care Market Projected to Reach USD 88.4 billion, Growing at a CAGR of 6.9% by 2031: Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36634032/asia-pacific-facial-care-market-projected-to-reach-usd-88-4-billion-growing-at-a-cagr-of-6-9-by-20",
    "time_published": "20240116T023000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Jan. 15, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The Asia Pacific facial care market is estimated to flourish at a CAGR of 6.9% from 2021 to 2031.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.480199,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.03448",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KAOCF",
        "relevance_score": "0.103183",
        "ticker_sentiment_score": "0.430142",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SSDOF",
        "relevance_score": "0.068896",
        "ticker_sentiment_score": "0.368024",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "KOSCF",
        "relevance_score": "0.068896",
        "ticker_sentiment_score": "0.426907",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.03448",
        "ticker_sentiment_score": "-0.185059",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.03448",
        "ticker_sentiment_score": "-0.185059",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "LRLCF",
        "relevance_score": "0.068896",
        "ticker_sentiment_score": "0.182255",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.103183",
        "ticker_sentiment_score": "0.155413",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Stock Moves -0.06%: What You Should Know",
    "url": "https://www.zacks.com/stock/news/2211717/johnson-johnson-jnj-stock-moves--006-what-you-should-know",
    "time_published": "20240117T224519",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) concluded the recent trading session at $160.43, signifying a -0.06% move from its prior day's close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default89.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.95493"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.149789,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.556576",
        "ticker_sentiment_score": "0.16099",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Dry Skin Cream, Lotion, And Ointment Market Set to Soar 8.5% to $59.4 Billion by 2030, Insights by Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36662794/dry-skin-cream-lotion-and-ointment-market-set-to-soar-8-5-to-59-4-billion-by-2030-insights-by-pers",
    "time_published": "20240117T160000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 17, 2024 ( GLOBE NEWSWIRE ) -- Dry skin cream, lotion, and ointment form an essential category dedicated to fulfilling the needs of individuals dealing with dry skin conditions. These formulations are intricately designed to provide hydration, nourishment, and relief to dry and ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.411708,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LRLCF",
        "relevance_score": "0.017915",
        "ticker_sentiment_score": "0.274721",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.035821",
        "ticker_sentiment_score": "0.234516",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.017915",
        "ticker_sentiment_score": "-0.097645",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UL",
        "relevance_score": "0.017915",
        "ticker_sentiment_score": "0.274721",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Tr1X, Inc. Announces $75 Million Series A Financing to Develop Best-in-Class Universal Allogeneic Regulatory T  ( Treg )  and CAR-Treg Cell Therapies to Treat and Potentially Cure Autoimmune and Inflammatory Diseases",
    "url": "https://www.prnewswire.com/news-releases/tr1x-inc-announces-75-million-series-a-financing-to-develop-best-in-class-universal-allogeneic-regulatory-t-treg-and-car-treg-cell-therapies-to-treat-and-potentially-cure-autoimmune-and-inflammatory-diseases-302036679.html",
    "time_published": "20240117T133000",
    "authors": [
      "Inc.",
      "Tr1X"
    ],
    "summary": "Tr1X, Inc. Announces $75 Million Series A Financing to Develop Best-in-Class Universal Allogeneic Regulatory T ( Treg ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/2320244/Tr1X_logo_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.15206,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ANAB",
        "relevance_score": "0.022202",
        "ticker_sentiment_score": "0.015893",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRPH",
        "relevance_score": "0.022202",
        "ticker_sentiment_score": "0.061917",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.022202",
        "ticker_sentiment_score": "0.061917",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.044386",
        "ticker_sentiment_score": "0.048031",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HHH",
        "relevance_score": "0.022202",
        "ticker_sentiment_score": "0.015893",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INCY",
        "relevance_score": "0.022202",
        "ticker_sentiment_score": "0.061013",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JSPR",
        "relevance_score": "0.022202",
        "ticker_sentiment_score": "0.028304",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EGRNQ",
        "relevance_score": "0.022202",
        "ticker_sentiment_score": "0.015893",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.044386",
        "ticker_sentiment_score": "0.043125",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:GBP",
        "relevance_score": "0.022202",
        "ticker_sentiment_score": "0.015893",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cell Therapy Market Global Surge to Over USD 26.8 Billion by 2033, Fueled by Growing Demand in United States",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36658512/cell-therapy-market-global-surge-to-over-usd-26-8-billion-by-2033-fueled-by-growing-demand-in-unit",
    "time_published": "20240117T132147",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 17, 2024 ( GLOBE NEWSWIRE ) -- According to Market.us, the global Cell Therapy Market size is forecasted to exceed USD 26.8 Billion by 2033, with a promising CAGR of 16.9% from 2024 to 2033.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.310463,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALLO",
        "relevance_score": "0.018802",
        "ticker_sentiment_score": "0.168923",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BLUE",
        "relevance_score": "0.018802",
        "ticker_sentiment_score": "0.187222",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.018802",
        "ticker_sentiment_score": "-0.142541",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.018802",
        "ticker_sentiment_score": "0.187222",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.056363",
        "ticker_sentiment_score": "0.182015",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ATRA",
        "relevance_score": "0.018802",
        "ticker_sentiment_score": "-0.142541",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSOI",
        "relevance_score": "0.037593",
        "ticker_sentiment_score": "0.167406",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.037593",
        "ticker_sentiment_score": "0.071135",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JCRRF",
        "relevance_score": "0.018802",
        "ticker_sentiment_score": "-0.142541",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.018802",
        "ticker_sentiment_score": "-0.142541",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors - Kymera Therapeutics  ( NASDAQ:KYMR ) , Nanobiotix  ( NASDAQ:NBTX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36657953/invo-bioscience-files-s-4-registration-and-preliminary-joint-proxy-statements-in-connection-with-m",
    "time_published": "20240117T130000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "INVO INVO and NAYA Biosciences expect to close their previously announced merger in the first quarter of 2024 Experienced, entrepreneurial leadership team to help structure merged public company and accelerate growth",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Mergers",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.938238"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      }
    ],
    "overall_sentiment_score": 0.270204,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KYMR",
        "relevance_score": "0.039844",
        "ticker_sentiment_score": "0.062746",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PTCT",
        "relevance_score": "0.019928",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VIRX",
        "relevance_score": "0.039844",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ORTX",
        "relevance_score": "0.039844",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SLN",
        "relevance_score": "0.039844",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.019928",
        "ticker_sentiment_score": "0.03272",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRES",
        "relevance_score": "0.019928",
        "ticker_sentiment_score": "0.069924",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INVO",
        "relevance_score": "0.575903",
        "ticker_sentiment_score": "0.425763",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NBTX",
        "relevance_score": "0.059736",
        "ticker_sentiment_score": "0.037994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.039844",
        "ticker_sentiment_score": "0.149526",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.019928",
        "ticker_sentiment_score": "0.03272",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Vanguard Health Care ETF  ( VHT ) ?",
    "url": "https://www.zacks.com/stock/news/2211196/should-you-invest-in-the-vanguard-health-care-etf-vht",
    "time_published": "20240117T112007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default100.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.232494,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.064698",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.068306",
        "ticker_sentiment_score": "0.125875",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.064698",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.064698",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Skin Toner Market Set to Surge to US$ 2.0 Billion by 2030 Driven by Soaring Worldwide Demand for Full Ingredient Transparency | Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36655653/skin-toner-market-set-to-surge-to-us-2-0-billion-by-2030-driven-by-soaring-worldwide-demand-for-fu",
    "time_published": "20240117T101500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 17, 2024 ( GLOBE NEWSWIRE ) -- Market Size & Overview: The skin toner market is expected to witness a compound annual growth rate ( CAGR ) of 5.3%, leading to an increase from US$1.3 billion in 2023 to US$2.0 billion by the end of 2030.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      }
    ],
    "overall_sentiment_score": 0.364975,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.039966",
        "ticker_sentiment_score": "0.104837",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NAII",
        "relevance_score": "0.02665",
        "ticker_sentiment_score": "0.232565",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Alzheimer's Disease Diagnostics & Treatment Market Revenues to Reach US$11.9 Billion by 2030 - Market Size, Share, Forecasts, & Trends Analysis Report by Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36655498/alzheimers-disease-diagnostics-treatment-market-revenues-to-reach-us-11-9-billion-by-2030-market-s",
    "time_published": "20240117T100000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 17, 2024 ( GLOBE NEWSWIRE ) -- Market Size & Overview: The global market for Alzheimer's disease diagnostics and treatment is projected to experience a compound annual growth rate ( CAGR ) of 8.9%, reaching a value of US$11.9 billion by the end of 2030, up from US$6.5 billion ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.329342,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.01403",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.01403",
        "ticker_sentiment_score": "0.076513",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.028056",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WLDS",
        "relevance_score": "0.01403",
        "ticker_sentiment_score": "0.16322",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.028056",
        "ticker_sentiment_score": "-0.053084",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.042073",
        "ticker_sentiment_score": "0.148051",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.111877",
        "ticker_sentiment_score": "0.14894",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates FGH, AXNX, AMAM, HARP - Ambrx Biopharma  ( NASDAQ:AMAM ) , Axonics  ( NASDAQ:AXNX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36653978/shareholder-rights-investigation-halper-sadeh-llc-investigates-fgh-axnx-amam-harp",
    "time_published": "20240117T050000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, Jan. 17, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: FG Group Holdings Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.092629,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "FGF",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "0.131811",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMAM",
        "relevance_score": "0.12546",
        "ticker_sentiment_score": "0.089947",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.12546",
        "ticker_sentiment_score": "0.089947",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HARP",
        "relevance_score": "0.12546",
        "ticker_sentiment_score": "0.089947",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXNX",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "0.142764",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.12546",
        "ticker_sentiment_score": "0.089947",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "List Price Of Ozempic And Other Drugs Reportedly Rise: Here's What That Means For Consumers",
    "url": "https://www.forbes.com/sites/ariannajohnson/2024/01/18/list-price-of-ozempic-and-other-drugs-reportedly-rise-heres-what-that-means-for-consumers/",
    "time_published": "20240118T194930",
    "authors": [
      "Arianna Johnson"
    ],
    "summary": "Almost 800 medications-including Ozempic and Mounjaro-had a median list price increase of 4.5% this month, according to a Wall Street Journal report, meaning copays may increase for consumers.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/651ed914b753a9b834db1a57/0x0.jpg?format=jpg&crop=3317,1864,x0,y171,safe&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.061908,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.113329",
        "ticker_sentiment_score": "0.068214",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.056808",
        "ticker_sentiment_score": "0.046999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.113329",
        "ticker_sentiment_score": "0.052573",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.056808",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.113329",
        "ticker_sentiment_score": "0.052573",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Wall Street's Insights Into Key Metrics Ahead of Johnson & Johnson  ( JNJ )  Q4 Earnings",
    "url": "https://www.zacks.com/stock/news/2212378/wall-streets-insights-into-key-metrics-ahead-of-johnson-johnson-jnj-q4-earnings",
    "time_published": "20240118T175600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Get a deeper insight into the potential performance of Johnson & Johnson (JNJ) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default175.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.070098,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.345674",
        "ticker_sentiment_score": "0.079971",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nivolumab Market Overview 2024-2028: Global Expansion Driven By Immunotherapy Advancements And Rising Cancer Incidence As Per The Business Research Company's Nivolumab Global Market Report 2024",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36681451/nivolumab-market-overview-2024-2028-global-expansion-driven-by-immunotherapy-advancements-and-risi",
    "time_published": "20240118T163000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LONDON, Jan. 18, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Nivolumab Global Market Report 2024, nivolumab market has experienced remarkable growth in recent years and is set to continue its upward trajectory, with the market size projected to reach $1.69 billion in 2024, ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.26794,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.061315",
        "ticker_sentiment_score": "0.115659",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.061315",
        "ticker_sentiment_score": "0.115659",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.061315",
        "ticker_sentiment_score": "0.115659",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Otic Drugs Market To Surge At A CAGR Of 7.0%: Global Growth Driven By Rising Prevalence Of Ear Infections And Innovations In Drug Formulations As Per The Business Research Company's Otic Drugs Global Market Report 2024",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36681448/otic-drugs-market-to-surge-at-a-cagr-of-7-0-global-growth-driven-by-rising-prevalence-of-ear-infec",
    "time_published": "20240118T163000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LONDON, Jan. 18, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Otic Drugs Global Market Report 2024, the otic drugs market has witnessed robust growth in recent years and is poised to continue its upward trajectory, with the market size projected to reach $1.71 billion in ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.255916,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.057079",
        "ticker_sentiment_score": "0.097064",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.057079",
        "ticker_sentiment_score": "0.097064",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Inactivated Vaccines Market Set to Reach $7.3 Billion in 2028 - Global Growth Driven by Immunization Initiatives and Advancements in Biomanufacturing As Per The Business Research Company's Inactivated Vaccines Global Market Report 2024",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36681454/inactivated-vaccines-market-set-to-reach-7-3-billion-in-2028-global-growth-driven-by-immunization-",
    "time_published": "20240118T163000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LONDON, Jan. 18, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Inactivated Vaccines Global Market Report 2024, the inactivated vaccines market has exhibited consistent growth, with the market size reaching $5.95 billion in 2023 and expected to climb to $6.19 billion in 2024, ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.277902,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SHTDF",
        "relevance_score": "0.056808",
        "ticker_sentiment_score": "0.180983",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GSK",
        "relevance_score": "0.056808",
        "ticker_sentiment_score": "0.180983",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.056808",
        "ticker_sentiment_score": "0.180983",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.056808",
        "ticker_sentiment_score": "0.180983",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Feminine Hygiene Market is poised to reach US$ 56.5 billion by 2033, with a projected CAGR of 6.0%, Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36681181/feminine-hygiene-market-is-poised-to-reach-us-56-5-billion-by-2033-with-a-projected-cagr-of-6-0-pe",
    "time_published": "20240118T161500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 18, 2024 ( GLOBE NEWSWIRE ) -- The global market for feminine hygiene products has experienced notable growth and transformation due to evolving societal attitudes, increased awareness of women's health, and advancements in product innovation.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.272667,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EPC",
        "relevance_score": "0.038499",
        "ticker_sentiment_score": "0.135783",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.019255",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMB",
        "relevance_score": "0.057721",
        "ticker_sentiment_score": "0.085963",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.038499",
        "ticker_sentiment_score": "0.171373",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.038499",
        "ticker_sentiment_score": "0.137755",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cardiac Sutures Market Estimated to Reach USD 2.3 billion, Advancing at a CAGR of 6.8% by 2031: Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36680030/cardiac-sutures-market-estimated-to-reach-usd-2-3-billion-advancing-at-a-cagr-of-6-8-by-2031-trans",
    "time_published": "20240118T153000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Jan. 18, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global cardiac sutures market is estimated to flourish at a CAGR of 6.8% from 2023 to 2031.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.419293,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.036532",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.072987",
        "ticker_sentiment_score": "0.121937",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.109289",
        "ticker_sentiment_score": "0.084521",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.036532",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.109289",
        "ticker_sentiment_score": "0.118142",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TFX",
        "relevance_score": "0.072987",
        "ticker_sentiment_score": "0.328045",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Fibromyalgia Treatment Market Projected to Surpass US$ 2.7 Billion in Revenue by 2033, According to Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36679018/fibromyalgia-treatment-market-projected-to-surpass-us-2-7-billion-in-revenue-by-2033-according-to-",
    "time_published": "20240118T144500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 18, 2024 ( GLOBE NEWSWIRE ) -- Market Overview: The global revenue from the fibromyalgia treatment market stands at US$ 1.3 billion in 2022, with the global market expected to grow at a CAGR of 7.0% to reach a valuation of approximately US$ 2.7 billion by the end of 2033.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.256784,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VIRI",
        "relevance_score": "0.014775",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.014775",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WLDS",
        "relevance_score": "0.014775",
        "ticker_sentiment_score": "0.165509",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TNXP",
        "relevance_score": "0.014775",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSOI",
        "relevance_score": "0.014775",
        "ticker_sentiment_score": "0.191305",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.014775",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2024 Will Be a Good Year for the Pharma Industry: The Kiplinger Letter",
    "url": "https://www.kiplinger.com/business/a-good-year-for-the-pharma-industry-the-kiplinger-letter",
    "time_published": "20240118T133015",
    "authors": [
      "Matthew Housiaux"
    ],
    "summary": "2024: The Pharma Industry's Good Year Kiplinger's Personal Finance ...",
    "banner_image": "https://cdn.mos.cms.futurecdn.net/UjiFXv5gKrsiSW4baf7dkN-415-80.jpg",
    "source": "Kiplinger",
    "category_within_source": "n/a",
    "source_domain": "www.kiplinger.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.237549,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.19661",
        "ticker_sentiment_score": "-0.0803",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.19661",
        "ticker_sentiment_score": "0.059379",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.291182",
        "ticker_sentiment_score": "0.032821",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.099066",
        "ticker_sentiment_score": "0.066677",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.19661",
        "ticker_sentiment_score": "-0.0803",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.099066",
        "ticker_sentiment_score": "0.066677",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Active Wound Care Market Size to be Worth USD 451.9 million by 2031, with Notable CAGR of 7.3%| Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36676060/active-wound-care-market-size-to-be-worth-usd-451-9-million-by-2031-with-notable-cagr-of-7-3-trans",
    "time_published": "20240118T130000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Jan. 18, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global active wound care market was projected to attain US$ 242.2 million in 2022. It is anticipated to garner a 7.3% CAGR from 2023 to 2031 and by 2031.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.176319,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IART",
        "relevance_score": "0.037155",
        "ticker_sentiment_score": "0.385239",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.037155",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.111144",
        "ticker_sentiment_score": "0.070156",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.037155",
        "ticker_sentiment_score": "0.385239",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Oral Hygiene Products Market Size & Share to Surpass US$ 34.1 Billion by 2033 | Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36673864/oral-hygiene-products-market-size-share-to-surpass-us-34-1-billion-by-2033-persistence-market-rese",
    "time_published": "20240118T104500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 18, 2024 ( GLOBE NEWSWIRE ) -- Market Size & Overview: In 2022, the global revenue from oral hygiene products reached US$ 22.3 billion, and it is projected to experience a Compound Annual Growth Rate ( CAGR ) of 3.9%, reaching a valuation of US$ 34.1 billion by 2033.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.342232,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CL",
        "relevance_score": "0.017219",
        "ticker_sentiment_score": "0.316684",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MMM",
        "relevance_score": "0.017219",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.017219",
        "ticker_sentiment_score": "0.388599",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.017219",
        "ticker_sentiment_score": "0.132825",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UL",
        "relevance_score": "0.017219",
        "ticker_sentiment_score": "0.189217",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Catheter Associated Urinary Tract Infections Treatment Market Surges with a Promising CAGR of 4.0% through 2033 | Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36673659/catheter-associated-urinary-tract-infections-treatment-market-surges-with-a-promising-cagr-of-4-0-",
    "time_published": "20240118T101500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 18, 2024 ( GLOBE NEWSWIRE ) -- Market Size & Overview: The global market for treating catheter-associated urinary tract infections ( CAUTIs ) is projected to grow at a compound annual growth rate ( CAGR ) of 4.0%.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.31153,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.044359",
        "ticker_sentiment_score": "0.083244",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.029581",
        "ticker_sentiment_score": "0.12093",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.029581",
        "ticker_sentiment_score": "0.063368",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.059121",
        "ticker_sentiment_score": "0.096069",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSOI",
        "relevance_score": "0.014793",
        "ticker_sentiment_score": "0.096609",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.044359",
        "ticker_sentiment_score": "0.123953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.029581",
        "ticker_sentiment_score": "0.13709",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cramer's week ahead: Earnings from Procter & Gamble, Tesla, Lockheed Martin",
    "url": "https://www.cnbc.com/2024/01/19/cramers-week-ahead-earnings-from-procter-gamble-tesla-lockheed-martin.html",
    "time_published": "20240119T233625",
    "authors": [
      "Julie Coleman"
    ],
    "summary": "CNBC's Jim Cramer guided investors through next week's Wall Street action, telling them to gear up for a slew of earnings reports.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107059904-1652322792218-200222_IMG_0732.jpg?v=1694819187&w=1920&h=1080",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.110729,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.07913",
        "ticker_sentiment_score": "0.195526",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.07913",
        "ticker_sentiment_score": "-0.091502",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.07913",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SHW",
        "relevance_score": "0.07913",
        "ticker_sentiment_score": "-0.05726",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.157483",
        "ticker_sentiment_score": "0.251301",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LOGI",
        "relevance_score": "0.07913",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.07913",
        "ticker_sentiment_score": "0.195526",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LMT",
        "relevance_score": "0.234307",
        "ticker_sentiment_score": "0.235046",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.234307",
        "ticker_sentiment_score": "0.212822",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNP",
        "relevance_score": "0.07913",
        "ticker_sentiment_score": "-0.05726",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOW",
        "relevance_score": "0.07913",
        "ticker_sentiment_score": "0.187334",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.308891",
        "ticker_sentiment_score": "0.38553",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "LRCX",
        "relevance_score": "0.07913",
        "ticker_sentiment_score": "0.187334",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.07913",
        "ticker_sentiment_score": "-0.05726",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.07913",
        "ticker_sentiment_score": "0.195526",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NSC",
        "relevance_score": "0.07913",
        "ticker_sentiment_score": "-0.05726",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Tesla, Netflix, GE Earnings: Investing Action Plan",
    "url": "https://www.investors.com/research/investing-action-plan/tesla-netflix-ge-earnings-investing-action-plan/",
    "time_published": "20240119T220000",
    "authors": [
      "Investor's Business Daily",
      "IBD STAFF"
    ],
    "summary": "The Nasdaq set a hot pace as the market's rally hammered out yet another weekly gain. The S&P 500 turned early-week losses into a 1.5% advance, taking a record high. The Dow rose 0.7% to test resistance just below 38,000. IBD continues to hold its exposure recommendation to between 80% and 100%.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2018/04/stock-GE-12-company.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999998"
      }
    ],
    "overall_sentiment_score": 0.104897,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KLAC",
        "relevance_score": "0.104228",
        "ticker_sentiment_score": "-0.015303",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.206685",
        "ticker_sentiment_score": "0.142639",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.069596",
        "ticker_sentiment_score": "0.145709",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GTLB",
        "relevance_score": "0.138663",
        "ticker_sentiment_score": "0.136532",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTU",
        "relevance_score": "0.138663",
        "ticker_sentiment_score": "0.136532",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LOGI",
        "relevance_score": "0.069596",
        "ticker_sentiment_score": "0.050162",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.069596",
        "ticker_sentiment_score": "0.042131",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TXN",
        "relevance_score": "0.104228",
        "ticker_sentiment_score": "-0.015303",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAL",
        "relevance_score": "0.069596",
        "ticker_sentiment_score": "0.145709",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ASML",
        "relevance_score": "0.104228",
        "ticker_sentiment_score": "-0.015303",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TXT",
        "relevance_score": "0.104228",
        "ticker_sentiment_score": "-0.05994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LMT",
        "relevance_score": "0.069596",
        "ticker_sentiment_score": "-0.054788",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.172836",
        "ticker_sentiment_score": "0.038869",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.172836",
        "ticker_sentiment_score": "0.001425",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LRCX",
        "relevance_score": "0.104228",
        "ticker_sentiment_score": "-0.015303",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.104228",
        "ticker_sentiment_score": "0.154859",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RCL",
        "relevance_score": "0.138663",
        "ticker_sentiment_score": "0.136532",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SAVE",
        "relevance_score": "0.069596",
        "ticker_sentiment_score": "0.145709",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HXL",
        "relevance_score": "0.104228",
        "ticker_sentiment_score": "-0.05994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.069596",
        "ticker_sentiment_score": "0.103426",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AFRM",
        "relevance_score": "0.104228",
        "ticker_sentiment_score": "0.120286",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.138663",
        "ticker_sentiment_score": "0.008798",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Q4 Earnings Results Reflect Stability",
    "url": "https://www.zacks.com/commentary/2213047/q4-earnings-results-reflect-stability",
    "time_published": "20240119T214800",
    "authors": [
      "Sheraz Mian"
    ],
    "summary": "The picture emerging from the Q4 earnings season thus far has been good enough - not great, but definitely not bad either. Next week, we shift into a much higher gear, with 71 S&P 500 members scheduled to report.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/15974.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.014277,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.098862",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.098862",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.098862",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.098862",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "How Is The Market Feeling About Johnson & Johnson? - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/01/36700113/how-is-the-market-feeling-about-johnson-johnson",
    "time_published": "20240119T190026",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Johnson & Johnson's JNJ short percent of float has fallen 18.75% since its last report. The company recently reported that it has 12.47 million shares sold short, which is 0.52% of all regular shares that are available for trading.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.237013,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.221819",
        "ticker_sentiment_score": "0.081322",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Global Transdermal Skin Patches Market Forecast Report, 2024-2030: A $9.9B Projected Industry, Dominated by Teva Pharma, 3M Company, Nitto Denko Corporation, and Johnson & Johnson",
    "url": "https://www.prnewswire.com/news-releases/global-transdermal-skin-patches-market-forecast-report-2024-2030-a-9-9b-projected-industry-dominated-by-teva-pharma-3m-company-nitto-denko-corporation-and-johnson--johnson-302039341.html",
    "time_published": "20240119T171500",
    "authors": [
      "Research and Markets"
    ],
    "summary": "Global Transdermal Skin Patches Market Forecast Report, 2024-2030: A $9.9B Projected Industry, Dominated by Teva ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.292081,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NDEKF",
        "relevance_score": "0.031738",
        "ticker_sentiment_score": "0.121467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDRFF",
        "relevance_score": "0.031738",
        "ticker_sentiment_score": "0.121467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.031738",
        "ticker_sentiment_score": "0.121467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.063425",
        "ticker_sentiment_score": "0.143639",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VTRS",
        "relevance_score": "0.031738",
        "ticker_sentiment_score": "0.121467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LYPHF",
        "relevance_score": "0.031738",
        "ticker_sentiment_score": "0.121467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.031738",
        "ticker_sentiment_score": "0.121467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.031738",
        "ticker_sentiment_score": "0.121467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MMM",
        "relevance_score": "0.063425",
        "ticker_sentiment_score": "0.126538",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Hyaluronic Acid Serums Market Targets US$ 506.4 Million by 2033 at 5.9% CAGR, Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36697064/hyaluronic-acid-serums-market-targets-us-506-4-million-by-2033-at-5-9-cagr-persistence-market-rese",
    "time_published": "20240119T154500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 19, 2024 ( GLOBE NEWSWIRE ) -- Hyaluronic Acid Serums have witnessed significant growth in recent years, driven by increasing consumer awareness of skincare and anti-aging products.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.378706,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.022389",
        "ticker_sentiment_score": "0.296668",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ZBH",
        "relevance_score": "0.022389",
        "ticker_sentiment_score": "-0.0018",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSDOF",
        "relevance_score": "0.022389",
        "ticker_sentiment_score": "-0.0018",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.022389",
        "ticker_sentiment_score": "-0.0018",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LFCR",
        "relevance_score": "0.022389",
        "ticker_sentiment_score": "-0.0018",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.022389",
        "ticker_sentiment_score": "-0.0018",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHC",
        "relevance_score": "0.022389",
        "ticker_sentiment_score": "-0.0018",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LRLCF",
        "relevance_score": "0.022389",
        "ticker_sentiment_score": "-0.0018",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.022389",
        "ticker_sentiment_score": "-0.0018",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "J&J  ( JNJ )  Gears Up to Report Q4 Earnings: What's in Store?",
    "url": "https://www.zacks.com/stock/news/2212628/jj-jnj-gears-up-to-report-q4-earnings-whats-in-store",
    "time_published": "20240119T123900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.99989"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.169178,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.279015",
        "ticker_sentiment_score": "-0.03092",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.093117",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Shampoo Market to Surge with 5.57% CAGR, Anticipated Valuation Exceeds US$ 50.37 Billion by 2034 | Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36691119/shampoo-market-to-surge-with-5-57-cagr-anticipated-valuation-exceeds-us-50-37-billion-by-2034-pers",
    "time_published": "20240119T085000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 19, 2024 ( GLOBE NEWSWIRE ) -- Market Overview: The shampoo market is a vital segment within the broader personal care and grooming industry, catering to the basic hygiene and aesthetic needs of consumers worldwide.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.44268,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KAOCF",
        "relevance_score": "0.02866",
        "ticker_sentiment_score": "0.108676",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LRLCF",
        "relevance_score": "0.057284",
        "ticker_sentiment_score": "0.114999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.02866",
        "ticker_sentiment_score": "0.107706",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.02866",
        "ticker_sentiment_score": "0.09809",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UL",
        "relevance_score": "0.042979",
        "ticker_sentiment_score": "0.127015",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Hepatitis C Virus Testing Market Poised to Expand at a 5.8% CAGR, Surpassing US$1,185.2 Million by 2030 | Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36691001/hepatitis-c-virus-testing-market-poised-to-expand-at-a-5-8-cagr-surpassing-us-1-185-2-million-by-2",
    "time_published": "20240119T083000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 19, 2024 ( GLOBE NEWSWIRE ) -- Market Overview: The Hepatitis C Virus ( HCV ) Testing Market is a dynamic and evolving sector within the healthcare industry, driven by the persistent threat posed by the Hepatitis C Virus.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.33534,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HOLX",
        "relevance_score": "0.025775",
        "ticker_sentiment_score": "0.244618",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.038655",
        "ticker_sentiment_score": "0.080127",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OSUR",
        "relevance_score": "0.012889",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.012889",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.012889",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIO",
        "relevance_score": "0.025775",
        "ticker_sentiment_score": "0.116589",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QGEN",
        "relevance_score": "0.025775",
        "ticker_sentiment_score": "0.151882",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The 4 most important things we're watching in the stock market this coming week",
    "url": "https://www.cnbc.com/2024/01/20/4-most-important-things-were-watching-in-the-stock-market-this-week.html",
    "time_published": "20240120T151348",
    "authors": [
      "Zev Fima"
    ],
    "summary": "On tap: A handful of key economic updates and a ramp up of quarterly earnings reports.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107228796-16820124152023-04-20t170239z_662865409_rc2gi0azj08i_rtrmadp_0_procter-gamble-discounts.jpeg?v=1682077018&w=1920&h=1080",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.98396"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.050355,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SMBK",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LVS",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SASR",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "-0.028099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GSBC",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFC",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RJF",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OLN",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RBB",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.063313",
        "ticker_sentiment_score": "0.109065",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STX",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CZBS",
        "relevance_score": "0.021124",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FIZN",
        "relevance_score": "0.021124",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WDC",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VBTX",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LBRT",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FNLC",
        "relevance_score": "0.021124",
        "ticker_sentiment_score": "0.025984",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NSC",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMB",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.029072",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.021124",
        "ticker_sentiment_score": "0.239932",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FXNC",
        "relevance_score": "0.021124",
        "ticker_sentiment_score": "0.025984",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PEBO",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "-0.028099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BKR",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FRBA",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAL",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AIT",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CASH",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BKU",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TFIN",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVLG",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WSBC",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FCX",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.029072",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PGR",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.029072",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HXL",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CFB",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CNI",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PCAR",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "-0.028099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ONB",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "-0.028099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.021124",
        "ticker_sentiment_score": "0.023582",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AGNC",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TXN",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "URI",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ASML",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.029072",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OFG",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.029072",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TXT",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.029072",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EWBC",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KNX",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IBM",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BX",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "V",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HAFC",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LRCX",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VLO",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CACI",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CNUN",
        "relevance_score": "0.021124",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COF",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LHX",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMI",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KLAC",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.255971",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VLY",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RMD",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CL",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SFNC",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.029072",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NEE",
        "relevance_score": "0.063313",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HAL",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "-0.028099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UCBI",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.029072",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CFFN",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.029072",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ETD",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BOKF",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.029072",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NEP",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRST",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APPF",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAL",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IBTX",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALK",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLFY",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.029072",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DCOM",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LOGI",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "-0.028099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CNXC",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LRN",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GNTX",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALV",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AUB",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "-0.028099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ELV",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.029072",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EFSG",
        "relevance_score": "0.021124",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EDU",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.029072",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HBT",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.029072",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MMYT",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "-0.028099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYF",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "-0.028099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOC",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SHW",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMP",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.021124",
        "ticker_sentiment_score": "-0.106994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZIONL",
        "relevance_score": "0.021124",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MUR",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOK",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MMM",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "-0.028099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PKG",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOW",
        "relevance_score": "0.021124",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BFST",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MNRO",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.029072",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RNST",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRMK",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STLD",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FHB",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SAP",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.029072",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "-0.028099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HBCP",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MBLY",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNB",
        "relevance_score": "0.021124",
        "ticker_sentiment_score": "-0.025109",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FCCO",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.029072",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "-0.028099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.021124",
        "ticker_sentiment_score": "0.239932",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNP",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CBU",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "-0.028099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GD",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.029072",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AGYS",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "-0.028099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.021124",
        "ticker_sentiment_score": "0.239932",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CVRX",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CCI",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TDY",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.029072",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAH",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBS",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "-0.028099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LUV",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QCRH",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMUS",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LMT",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "-0.028099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PB",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.029072",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WTBA",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.063313",
        "ticker_sentiment_score": "-0.020003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APH",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.029072",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEL",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.029072",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CCZ",
        "relevance_score": "0.021124",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COLB",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRO",
        "relevance_score": "0.042234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 High-Flying Stocks That Could Soar Even More in 2024",
    "url": "https://www.fool.com/investing/2024/01/20/3-high-flying-stocks-that-could-soar-even-more-in/",
    "time_published": "20240120T115000",
    "authors": [
      "David Jagielski",
      "Keith Speights",
      "and Prosper Junior Bakiny"
    ],
    "summary": "These big winners could keep the momentum going.",
    "banner_image": "https://g.foolcdn.com/editorial/images/761822/dna-on-monitor-scientists.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.284698,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.260652",
        "ticker_sentiment_score": "0.195213",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.044222",
        "ticker_sentiment_score": "0.26179",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.044222",
        "ticker_sentiment_score": "0.056817",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.30211",
        "ticker_sentiment_score": "0.160317",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.044222",
        "ticker_sentiment_score": "-0.005924",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The 2024 Dogs of the Dow: Which Ones Are Buys Right Now?",
    "url": "https://www.fool.com/investing/2024/01/20/the-2024-dogs-of-the-dow-which-ones-are-buys/",
    "time_published": "20240120T105000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "A few of these Dogs of the Dow can probably hunt in the new year.",
    "banner_image": "https://g.foolcdn.com/editorial/images/761534/dog-laptop-person.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.143805,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KO",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.13459",
        "ticker_sentiment_score": "0.198925",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "-0.114585",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - RYZB, THRX, AMAM, CSTR",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36704959/shareholder-alert-the-m-a-class-action-firm-continues-investigating-the-merger-ryzb-thrx-amam-cstr",
    "time_published": "20240120T010000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, Jan. 19, 2024 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the \"M&A Class Action Firm\" ) , a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.928769"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.348873,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CSTR",
        "relevance_score": "0.269033",
        "ticker_sentiment_score": "0.312256",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ONB",
        "relevance_score": "0.068502",
        "ticker_sentiment_score": "0.15954",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMAM",
        "relevance_score": "0.269033",
        "ticker_sentiment_score": "0.251355",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.068502",
        "ticker_sentiment_score": "0.127176",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RYZB",
        "relevance_score": "0.269033",
        "ticker_sentiment_score": "0.239471",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "THRX",
        "relevance_score": "0.269033",
        "ticker_sentiment_score": "0.22137",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.068502",
        "ticker_sentiment_score": "0.121075",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "I'm Putting My Cash Stockpile to Work on These 3 Stocks",
    "url": "https://www.fool.com/investing/2024/01/21/im-putting-my-cash-stockpile-to-work-on-these-3-st/",
    "time_published": "20240121T174700",
    "authors": [
      "Matthew DiLallo"
    ],
    "summary": "With the market selling off to start the year, this Fool plans to put some of his growing cash pile to work.",
    "banner_image": "https://g.foolcdn.com/editorial/images/761642/dividends-cart-full-of-money-on-hundred-dollar-bills.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.723405"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.268567,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VICI",
        "relevance_score": "0.342262",
        "ticker_sentiment_score": "0.313662",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRBO",
        "relevance_score": "0.050465",
        "ticker_sentiment_score": "0.107322",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.431065",
        "ticker_sentiment_score": "0.294136",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HES",
        "relevance_score": "0.100729",
        "ticker_sentiment_score": "0.075834",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.050465",
        "ticker_sentiment_score": "-0.019973",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.248343",
        "ticker_sentiment_score": "0.371032",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BOWL",
        "relevance_score": "0.050465",
        "ticker_sentiment_score": "0.195335",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Nearing Retirement? These Stocks Are as Safe as They Come",
    "url": "https://www.fool.com/investing/2024/01/21/nearing-retirement-these-stocks-are-as-safe-as-the/",
    "time_published": "20240121T165100",
    "authors": [
      "Keith Speights"
    ],
    "summary": "These stocks should provide solid income with little drama.",
    "banner_image": "https://g.foolcdn.com/editorial/images/761623/retired-couple-looking-at-computer-screen.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      }
    ],
    "overall_sentiment_score": 0.298878,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.401331",
        "ticker_sentiment_score": "0.348195",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.27432",
        "ticker_sentiment_score": "0.180187",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "March Rate Cut Odds Plummet As Magnificent 7 Surge",
    "url": "https://www.forbes.com/sites/bill_stone/2024/01/21/march-rate-cut-odds-plummet-as-magnificent-7-surge/",
    "time_published": "20240121T163956",
    "authors": [
      "Bill Stone"
    ],
    "summary": "The earnings season continued its slow start last week, with only 23 S&P 500 companies reporting. Banks were a large contingent of the reporters, which weighed on earnings again. The S&P 500 rose 1.2% for the week, finally eclipsing its all-time high from 2022. The 10-year Treasury yield rose ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65ad45a1ae514cbbefbb53ce/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.140026,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.11983",
        "ticker_sentiment_score": "0.107429",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.11983",
        "ticker_sentiment_score": "0.066592",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TFC",
        "relevance_score": "0.11983",
        "ticker_sentiment_score": "-0.06199",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.11983",
        "ticker_sentiment_score": "0.107429",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.11983",
        "ticker_sentiment_score": "0.107429",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.11983",
        "ticker_sentiment_score": "0.107429",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.236972",
        "ticker_sentiment_score": "0.156901",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.11983",
        "ticker_sentiment_score": "-0.06199",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.11983",
        "ticker_sentiment_score": "0.066592",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.11983",
        "ticker_sentiment_score": "0.066592",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Prediction: This Will Be the First Trillion-Dollar Healthcare Stock",
    "url": "https://www.fool.com/investing/2024/01/21/prediction-this-will-be-the-first-trillion-dollar/",
    "time_published": "20240121T160200",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "This company is currently firing on all cylinders.",
    "banner_image": "https://g.foolcdn.com/editorial/images/761056/doctor-with-patient-talking.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.267579,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.637818",
        "ticker_sentiment_score": "0.397667",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.220809",
        "ticker_sentiment_score": "0.191225",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.220809",
        "ticker_sentiment_score": "0.213931",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.166551",
        "ticker_sentiment_score": "0.132619",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Walgreens Boots Alliance Just Cut Its Dividend: Here Are 2 Companies That Won't",
    "url": "https://www.fool.com/investing/2024/01/21/walgreens-boots-alliance-just-cut-its-dividend-her/",
    "time_published": "20240121T154500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "Not every dividend stock is created equal, and these two far exceed Walgreens Boots Alliance.",
    "banner_image": "https://g.foolcdn.com/editorial/images/761057/patient-and-doctor-talking.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.23915,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.393241",
        "ticker_sentiment_score": "0.306164",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.340915",
        "ticker_sentiment_score": "0.071285",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.116914",
        "ticker_sentiment_score": "-0.109065",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Markets tried to fight the Fed on rate cuts. It didn't work | Business",
    "url": "https://www.cnn.com/2024/01/21/markets/stocks-week-ahead-markets-fight-the-fed/index.html",
    "time_published": "20240121T123000",
    "authors": [
      "Bryan Mena"
    ],
    "summary": "Markets are trying to fight the Fed on rate cuts. It's not working ...",
    "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/2024-01-17t192225z-1409670814-rc207s9xpy7v-rtrmadp-3-usa-fed-beigebook.JPG?c=16x9&q=w_800,c_fill",
    "source": "CNN",
    "category_within_source": "Markets",
    "source_domain": "www.cnn.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.999937"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      }
    ],
    "overall_sentiment_score": -0.036215,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.029292",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.029292",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.029292",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JPM",
        "relevance_score": "0.029292",
        "ticker_sentiment_score": "0.103343",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.029292",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAH",
        "relevance_score": "0.029292",
        "ticker_sentiment_score": "0.048689",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CL",
        "relevance_score": "0.029292",
        "ticker_sentiment_score": "0.048689",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAL",
        "relevance_score": "0.029292",
        "ticker_sentiment_score": "-0.001895",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LUV",
        "relevance_score": "0.029292",
        "ticker_sentiment_score": "-0.001895",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LMT",
        "relevance_score": "0.029292",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.029292",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMA",
        "relevance_score": "0.029292",
        "ticker_sentiment_score": "-0.015733",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.029292",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBD",
        "relevance_score": "0.087717",
        "ticker_sentiment_score": "-0.036394",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.029292",
        "ticker_sentiment_score": "0.048689",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.029292",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CCZ",
        "relevance_score": "0.029292",
        "ticker_sentiment_score": "-0.001895",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COF",
        "relevance_score": "0.029292",
        "ticker_sentiment_score": "-0.001895",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.029292",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "My 5 Top Dividend Stocks to Buy Hand Over Fist in 2024",
    "url": "https://www.fool.com/investing/2024/01/21/my-5-top-dividend-stocks-to-buy-in-2024/",
    "time_published": "20240121T111700",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "These stocks may help you win in 2024 -- no matter what the market does.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F761894%2Fgettyimages-1172040755.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999365"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.983783"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.344613,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "0.17327",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.078099",
        "ticker_sentiment_score": "0.311035",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.116914",
        "ticker_sentiment_score": "0.107532",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.226339",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.078099",
        "ticker_sentiment_score": "0.188048",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "24 Dividend Growth Stocks to Buy and Hold in 2024",
    "url": "https://www.fool.com/investing/2024/01/21/24-dividend-growth-stocks-to-buy-and-hold-in-2024/",
    "time_published": "20240121T105100",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Dividends are good. Growing dividends are even better.",
    "banner_image": "https://g.foolcdn.com/editorial/images/761751/excited-investor-looks-at-financial-charts-on-computer.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.658903"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.360211,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IIPR",
        "relevance_score": "0.030958",
        "ticker_sentiment_score": "0.140815",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.153863",
        "ticker_sentiment_score": "0.303904",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LMT",
        "relevance_score": "0.061869",
        "ticker_sentiment_score": "0.190566",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.092688",
        "ticker_sentiment_score": "0.175204",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.030958",
        "ticker_sentiment_score": "0.391015",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.030958",
        "ticker_sentiment_score": "0.141351",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.030958",
        "ticker_sentiment_score": "0.225235",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.030958",
        "ticker_sentiment_score": "0.141351",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.061869",
        "ticker_sentiment_score": "0.127185",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.030958",
        "ticker_sentiment_score": "0.391015",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Genmab Announces Decision in Arbitration Appeal under License Agreement with Janssen",
    "url": "https://www.globenewswire.com/news-release/2024/01/22/2813563/0/en/Genmab-Announces-Decision-in-Arbitration-Appeal-under-License-Agreement-with-Janssen.html",
    "time_published": "20240122T234000",
    "authors": [
      "Genmab A/S"
    ],
    "summary": "Company Announcement ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.112587,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GMAB",
        "relevance_score": "0.612343",
        "ticker_sentiment_score": "0.129232",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.062597",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Rehabilitation Equipment Global Market to Showcase Growth at a CAGR of ~5% by 2028, Examines DelveInsight",
    "url": "https://www.prnewswire.com/news-releases/rehabilitation-equipment-global-market-to-showcase-growth-at-a-cagr-of-5-by-2028-examines-delveinsight-302040512.html",
    "time_published": "20240122T223100",
    "authors": [
      "DelveInsight Business Research",
      "LLP"
    ],
    "summary": "The increasing demand for rehabilitation equipment is driven by several factors, including a growing number of accidents, injuries, and falls.",
    "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.218223,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MFCSF",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "0.089754",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVRO",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "0.026075",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZBH",
        "relevance_score": "0.079921",
        "ticker_sentiment_score": "-0.002038",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EKSO",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "0.098104",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OFIX",
        "relevance_score": "0.05333",
        "ticker_sentiment_score": "0.003986",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RWLK",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "0.098104",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GMED",
        "relevance_score": "0.05333",
        "ticker_sentiment_score": "0.003986",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.05333",
        "ticker_sentiment_score": "0.004985",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.079921",
        "ticker_sentiment_score": "-0.002038",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ATEC",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "-0.011827",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SRGAQ",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "-0.011827",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANIK",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "0.020645",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "0.026075",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DNPUF",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "0.098104",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSUMF",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "0.098104",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRUMF",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "0.020645",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IART",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "-0.023117",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVCRQ",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "0.098104",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DYNT",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "0.098104",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MAAL",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "0.098104",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.079921",
        "ticker_sentiment_score": "0.011181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BVS",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "0.020645",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMAX",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "0.098104",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "0.020645",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "From 3M To Intel, A Big Earnings Week For Dow Jones Stocks",
    "url": "https://www.investors.com/news/dow-jones-stocks-from-3m-to-intel-a-big-earnings-week-for-blue-chips/",
    "time_published": "20240122T210200",
    "authors": [
      "Investor's Business Daily",
      "ALAN R. ELLIOTT"
    ],
    "summary": "The biggest reporting week of the season for Dow Jones Industrials stocks begins Tuesday, when Verizon ( VZ ) , Johnson & Johnson ( JNJ ) , Procter & Gamble ( PG ) and 3M ( MMM ) all deliver results. It is one of the season's biggest reporting days for Dow Jones stocks.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/07/Stock-NYSExchange-71-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.082306,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AAPL",
        "relevance_score": "0.223522",
        "ticker_sentiment_score": "0.107842",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LMT",
        "relevance_score": "0.150122",
        "ticker_sentiment_score": "0.181858",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.294977",
        "ticker_sentiment_score": "-0.041106",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.294977",
        "ticker_sentiment_score": "0.02552",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "V",
        "relevance_score": "0.150122",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.223522",
        "ticker_sentiment_score": "-0.070824",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.223522",
        "ticker_sentiment_score": "0.025524",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.294977",
        "ticker_sentiment_score": "0.02552",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.150122",
        "ticker_sentiment_score": "0.081084",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "JNJ: Johnson & Johnson  ( JNJ ) : Analyzing Signals Before Quarterly Earnings",
    "url": "https://stocknews.com/news/jnj-nvs-nvo-snphy-amam-johnson-johnson-jnj-analyzing-signals-before-quarterly-earnings/",
    "time_published": "20240122T181128",
    "authors": [
      "StockNews.com Staff"
    ],
    "summary": "Boasting a market cap of $389.21 billion, leading pharma giant Johnson & Johnson ( JNJ ) is all set to lift the curtains on its fourth-quarter results ( ended December 2023 ) on January 23, 2024. Thus, this article sheds light on the fundamentals of JNJ to determine the stock's worthiness as an ...",
    "banner_image": "https://stocknews.com/wp-content/uploads/2023/06/Anushka-Mukherjee_Headshot-2.jpg",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "stocknews.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.623304"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.240609,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVS",
        "relevance_score": "0.080593",
        "ticker_sentiment_score": "0.113018",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNPHF",
        "relevance_score": "0.040348",
        "ticker_sentiment_score": "0.10791",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMAM",
        "relevance_score": "0.080593",
        "ticker_sentiment_score": "-0.124994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.080593",
        "ticker_sentiment_score": "0.113018",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.55206",
        "ticker_sentiment_score": "0.312855",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Talc lawsuit: J&J sets up 3rd bankruptcy bid by moving unit to Texas",
    "url": "https://www.business-standard.com/world-news/talc-lawsuit-j-j-sets-up-3rd-bankruptcy-bid-by-moving-unit-to-texas-124012201028_1.html",
    "time_published": "20240122T171255",
    "authors": [
      "Bloomberg"
    ],
    "summary": "Johnson & Johnson is seeking to move a unit to Texas as it prepares for a potential third bankruptcy court filing to resolve more than 50,000 lawsuits alleging tainted talc in its baby powder caused cancer.",
    "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-05/02/full/1683045756-614.jpg?im=FeatureCrop,size=(826,465)",
    "source": "Business Standard",
    "category_within_source": "GoogleRSS",
    "source_domain": "www.business-standard.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.122886,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.110209",
        "ticker_sentiment_score": "-0.213977",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Secures Complete FDA Approval For Bladder Cancer Drug Balversa, After Almost Five Years Of Accelerated Approval - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/01/36719728/johnson-johnson-secures-complete-fda-approval-for-bladder-cancer-drug-balversa-after-almost-five-",
    "time_published": "20240122T165959",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Friday afternoon, the FDA approved Johnson & Johnson's JNJ supplemental New Drug Application ( sNDA ) for Balversa ( erdafitinib ) for adult patients with locally advanced or metastatic urothelial carcinoma ( mUC ) with susceptible fibroblast growth factor receptor 3 ( FGFR3 ) genetic ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/JNJ.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.197358,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMAM",
        "relevance_score": "0.262522",
        "ticker_sentiment_score": "0.234595",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.597963",
        "ticker_sentiment_score": "0.363424",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Earnings Season Heats Up This Week Along With Inflation Data",
    "url": "https://www.forbes.com/sites/jjkinahan/2024/01/22/earnings-season-heats-up-this-week-along-with-inflation-data/",
    "time_published": "20240122T153816",
    "authors": [
      "JJ Kinahan"
    ],
    "summary": "\u2022 Netflix And Tesla Among Companies Reporting This Week \u2022 Market Unconcerned With Much Of Anything Equity markets are picking up steam and setting records. Last week, the S&P 500 closed at an all-time high with a gain of 1.17%. Meanwhile, the Nasdaq Composite is coming up on its all-time highs ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65ae8b76560d7db299b844c1/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.955357"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.990678"
      }
    ],
    "overall_sentiment_score": 0.038463,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.129866",
        "ticker_sentiment_score": "-0.03444",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.129866",
        "ticker_sentiment_score": "-0.03444",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "M",
        "relevance_score": "0.193723",
        "ticker_sentiment_score": "0.16306",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.06515",
        "ticker_sentiment_score": "-0.017046",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Tissue Engineering Market is Expected to Reach $8.9 Billion | MarketsandMarkets\u2122",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36713761/tissue-engineering-market-is-expected-to-reach-8-9-billion-marketsandmarkets",
    "time_published": "20240122T123000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Chicago, Jan. 22, 2024 ( GLOBE NEWSWIRE ) -- Tissue Engineering market in terms of revenue was estimated to be worth $4.4 Billion in 2023 and is poised to reach $8.9 Billion by 2028, growing at a CAGR of 15.3% from 2023 to 2028 according to a latest report published by MarketsandMarkets\u2122.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.22176,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ZBH",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "-0.040123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDXG",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "-0.040123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "-0.040123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "-0.040123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TINLF",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "-0.040123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNN",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "-0.040123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DNPUF",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "-0.040123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "-0.040123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SAUHF",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "-0.040123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSUMF",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "-0.040123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRUMF",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "-0.040123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IART",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "-0.040123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "-0.040123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VCEL",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "-0.040123",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Tim Czartoski Appointed as CEO of Genesis Innovation Group",
    "url": "https://www.prnewswire.com/news-releases/tim-czartoski-appointed-as-ceo-of-genesis-innovation-group-302040014.html",
    "time_published": "20240122T114500",
    "authors": [
      "Genesis Innovation Group"
    ],
    "summary": "GRAND RAPIDS, Mich., Jan. 22, 2024 /PRNewswire/ -- Genesis Innovation Group ( GIG ) , a leader in medical device innovation, is excited to announce the appointment of Tim Czartoski as Chief Executive Officer effective April 1, 2024, and serving in an advisory role until that time.",
    "banner_image": "https://mma.prnewswire.com/media/787220/Genesis_Innovation_Group_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.486428,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.066047",
        "ticker_sentiment_score": "0.087133",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Orthopedic Implants Market Size to Worth USD 61 Million by 2030| According to Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36712657/orthopedic-implants-market-size-to-worth-usd-61-million-by-2030-according-to-persistence-market-re",
    "time_published": "20240122T113000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 22, 2024 ( GLOBE NEWSWIRE ) -- The projected rise in the number of patients in need of orthopedic implant surgery is anticipated to propel the global orthopedic implants market in the coming years.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.300831,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TINLF",
        "relevance_score": "0.020197",
        "ticker_sentiment_score": "0.038733",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZBH",
        "relevance_score": "0.040382",
        "ticker_sentiment_score": "0.103875",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNN",
        "relevance_score": "0.020197",
        "ticker_sentiment_score": "0.038733",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GMED",
        "relevance_score": "0.020197",
        "ticker_sentiment_score": "0.038733",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.020197",
        "ticker_sentiment_score": "0.145597",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.020197",
        "ticker_sentiment_score": "0.038733",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.020197",
        "ticker_sentiment_score": "0.145597",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.020197",
        "ticker_sentiment_score": "0.038733",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KYOCF",
        "relevance_score": "0.020197",
        "ticker_sentiment_score": "0.038733",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Legal-Bay Pre-Settlement Funding Reports Johnson & Johnson Talc Powder Settlement of $700MM with 40 States Nationwide",
    "url": "https://www.prnewswire.com/news-releases/legal-bay-pre-settlement-funding-reports-johnson--johnson-talc-powder-settlement-of-700mm-with-40-states-nationwide-302039711.html",
    "time_published": "20240122T113000",
    "authors": [
      "Legal-Bay",
      "LLC"
    ],
    "summary": "Legal-Bay Pre-Settlement Funding Reports Johnson & Johnson Talc Powder Settlement of $700MM with 40 States ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/126845/legal_bay_llc_logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.623304"
      }
    ],
    "overall_sentiment_score": -0.163952,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.145583",
        "ticker_sentiment_score": "-0.157113",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Tesla, Netflix, Intel Take Center Stage In Pivotal Q4 Earnings Week As S&P 500 Eyes Breaking New Highs - SPDR S&P 500  ( ARCA:SPY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/01/36711792/tesla-netflix-intel-take-center-stage-in-pivotal-q4-earnings-week-as-s-p-500-eyes-breaking-new-high",
    "time_published": "20240122T100045",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "The earnings season is gaining momentum as the tech reporting season kicks off this week. With the S&P 500 Index reaching a new high on Friday, investors are keenly watching earnings reports to sustain the market's upward momentum.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/SP-500.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.997335"
      }
    ],
    "overall_sentiment_score": 0.02392,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALK",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.037843",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.049774",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MBLY",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.037843",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.049774",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TXN",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STM",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.037843",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DFS",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "-0.053689",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FITB",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.193511",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.053749",
        "ticker_sentiment_score": "0.021995",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMA",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.193511",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNP",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.037843",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "V",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WDC",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COF",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AGYS",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.049774",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NSC",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XRX",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.037843",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KLAC",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.21258",
        "ticker_sentiment_score": "0.028138",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HUM",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.037843",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOC",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.037843",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "-0.053689",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BKR",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZIONL",
        "relevance_score": "0.053749",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CL",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOK",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.037843",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAL",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.037843",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "-0.053689",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LUV",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.037843",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MMM",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.049774",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DOW",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.037843",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMUS",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HAL",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.049774",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LMT",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.049774",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RF",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.193511",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.160277",
        "ticker_sentiment_score": "0.021545",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.049774",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CCZ",
        "relevance_score": "0.053749",
        "ticker_sentiment_score": "0.034838",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CNI",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STLD",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Chronic Wound Care Market is expected to see an expansion to US$16.7 billion, as per the projections, By the end of 2030 | Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36710946/chronic-wound-care-market-is-expected-to-see-an-expansion-to-us-16-7-billion-as-per-the-projection",
    "time_published": "20240122T061500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 22, 2024 ( GLOBE NEWSWIRE ) -- Chronic Wound Care Market Booms as Advanced Solutions Emerge to Combat Rising Burden Chronic wound care involves the management and treatment of wounds that fail to progress through normal stages of healing within an expected timeframe.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.262494,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IART",
        "relevance_score": "0.014384",
        "ticker_sentiment_score": "0.199415",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BAX",
        "relevance_score": "0.028764",
        "ticker_sentiment_score": "0.225905",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CLPBY",
        "relevance_score": "0.014384",
        "ticker_sentiment_score": "0.215192",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.014384",
        "ticker_sentiment_score": "0.091828",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.014384",
        "ticker_sentiment_score": "0.215192",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Little-Known Biotech Company Shows How Hard It Is To Ride The Ozempic Wave",
    "url": "https://www.forbes.com/sites/johnkang/2024/01/21/little-known-biotech-company-shows-how-hard-it-is-to-ride-the-ozempic-wave/",
    "time_published": "20240122T030041",
    "authors": [
      "John Kang"
    ],
    "summary": "Shares of Korea-listed Caregen surged on hope its diabetes-weight loss supplement could give the little-known biotech company an Ozempic-like boost. But then the stock crashed.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65a8fe6352659d2a5930c678/0x0.jpg?format=jpg&crop=1920,1080,x0,y0,safe&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      }
    ],
    "overall_sentiment_score": 0.085989,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVO",
        "relevance_score": "0.096283",
        "ticker_sentiment_score": "0.080917",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.024126",
        "ticker_sentiment_score": "0.187772",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.024126",
        "ticker_sentiment_score": "0.187772",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Implantable Drug Delivery Devices Global Market to Exhibit Growth at a Considerable CAGR of ~6% by 2028, Assesses DelveInsight",
    "url": "https://www.prnewswire.com/news-releases/implantable-drug-delivery-devices-global-market-to-exhibit-growth-at-a-considerable-cagr-of-6-by-2028-assesses-delveinsight-302041477.html",
    "time_published": "20240123T223100",
    "authors": [
      "DelveInsight Business Research",
      "LLP"
    ],
    "summary": "Implantable Drug Delivery Devices Global Market to Exhibit Growth at a Considerable CAGR of ~6% by 2028 ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.262341,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BAYZF",
        "relevance_score": "0.027103",
        "ticker_sentiment_score": "0.088505",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.027103",
        "ticker_sentiment_score": "0.088505",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HTSUF",
        "relevance_score": "0.027103",
        "ticker_sentiment_score": "0.027657",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.054175",
        "ticker_sentiment_score": "0.028936",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TFX",
        "relevance_score": "0.054175",
        "ticker_sentiment_score": "0.068904",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARUXF",
        "relevance_score": "0.054175",
        "ticker_sentiment_score": "0.074985",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.054175",
        "ticker_sentiment_score": "0.079826",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ENDPQ",
        "relevance_score": "0.027103",
        "ticker_sentiment_score": "0.027657",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MCRPF",
        "relevance_score": "0.027103",
        "ticker_sentiment_score": "-0.01558",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.027103",
        "ticker_sentiment_score": "0.025235",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.027103",
        "ticker_sentiment_score": "0.027657",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRRMF",
        "relevance_score": "0.027103",
        "ticker_sentiment_score": "0.025235",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FSNUF",
        "relevance_score": "0.054175",
        "ticker_sentiment_score": "0.068904",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRUMF",
        "relevance_score": "0.081184",
        "ticker_sentiment_score": "0.063274",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.027103",
        "ticker_sentiment_score": "0.025235",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALC",
        "relevance_score": "0.027103",
        "ticker_sentiment_score": "0.088505",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAX",
        "relevance_score": "0.027103",
        "ticker_sentiment_score": "0.088505",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LYPHF",
        "relevance_score": "0.054175",
        "ticker_sentiment_score": "0.074985",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WST",
        "relevance_score": "0.027103",
        "ticker_sentiment_score": "0.025235",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PODD",
        "relevance_score": "0.027103",
        "ticker_sentiment_score": "-0.01558",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.081184",
        "ticker_sentiment_score": "0.070488",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UCBJF",
        "relevance_score": "0.027103",
        "ticker_sentiment_score": "0.027657",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSOI",
        "relevance_score": "0.027103",
        "ticker_sentiment_score": "0.176605",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Stocks to Consider After Beating Earnings Estimates",
    "url": "https://www.zacks.com/commentary/2214526/3-stocks-to-consider-after-beating-earnings-estimates",
    "time_published": "20240123T201500",
    "authors": [
      "Ethan Feller"
    ],
    "summary": "Q4 earnings results are rolling in, and these stocks showed strong performance ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ce/407.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.995077"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.30199,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GEHC",
        "relevance_score": "0.050465",
        "ticker_sentiment_score": "0.029951",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.431065",
        "ticker_sentiment_score": "0.260533",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.473208",
        "ticker_sentiment_score": "0.413322",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.199859",
        "ticker_sentiment_score": "0.247982",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Q4 2023 Earnings Call Transcript",
    "url": "https://www.fool.com/earnings/call-transcripts/2024/01/23/johnson-johnson-jnj-q4-2023-earnings-call-transcri/",
    "time_published": "20240123T193016",
    "authors": [
      "Motley Fool Transcribing"
    ],
    "summary": "JNJ earnings call for the period ending December 31, 2023.",
    "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.311323,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GVHIB",
        "relevance_score": "0.004629",
        "ticker_sentiment_score": "0.143773",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.004629",
        "ticker_sentiment_score": "0.114142",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.004629",
        "ticker_sentiment_score": "0.091259",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.004629",
        "ticker_sentiment_score": "0.101356",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.004629",
        "ticker_sentiment_score": "0.114142",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.004629",
        "ticker_sentiment_score": "0.114142",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.055503",
        "ticker_sentiment_score": "0.102029",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.013886",
        "ticker_sentiment_score": "0.163014",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NBTX",
        "relevance_score": "0.004629",
        "ticker_sentiment_score": "-0.035545",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.004629",
        "ticker_sentiment_score": "-0.021025",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "US Stocks Pause As Treasury Yields, Dollar Surge On Trimmed Fed Rate Cut Bets: What's Driving Markets Tuesday? - Alibaba Gr Holding  ( NYSE:BABA ) ",
    "url": "https://www.benzinga.com/markets/cryptocurrency/24/01/36744784/us-stocks-pause-as-treasury-yields-dollar-surge-on-trimmed-fed-rate-cut-bets-whats-driving",
    "time_published": "20240123T190743",
    "authors": [
      "Piero Cingari"
    ],
    "summary": "Wall Street took a breather on Tuesday, with the major U.S. stock indices trading near the flatline or showing slight declines during midday trading in New York as investors closely await a series of relevant earnings reports and crucial economic data slated for the remainder of the week.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/New-York-Stock-Exchange.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.997902"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.95493"
      }
    ],
    "overall_sentiment_score": 0.068003,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BABA",
        "relevance_score": "0.151064",
        "ticker_sentiment_score": "0.129937",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.151064",
        "ticker_sentiment_score": "0.273111",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.151064",
        "ticker_sentiment_score": "0.155311",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.151064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIDU",
        "relevance_score": "0.151064",
        "ticker_sentiment_score": "0.129937",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.151064",
        "ticker_sentiment_score": "-0.239315",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "TXN",
        "relevance_score": "0.151064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.075874",
        "ticker_sentiment_score": "0.167522",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MMM",
        "relevance_score": "0.151064",
        "ticker_sentiment_score": "-0.210684",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "LMT",
        "relevance_score": "0.151064",
        "ticker_sentiment_score": "-0.239315",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NIO",
        "relevance_score": "0.151064",
        "ticker_sentiment_score": "0.129937",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.151064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TKO",
        "relevance_score": "0.151064",
        "ticker_sentiment_score": "0.273111",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.151064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.151064",
        "ticker_sentiment_score": "-0.210684",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.075874",
        "ticker_sentiment_score": "0.119312",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.151064",
        "ticker_sentiment_score": "-0.00952",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.151064",
        "ticker_sentiment_score": "0.237911",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson to settle talc baby powder investigation, will reportedly pay $700 million",
    "url": "https://www.cnbc.com/2024/01/23/johnson-johnson-to-settle-talc-baby-powder-probe.html",
    "time_published": "20240123T185918",
    "authors": [
      "Annika Kim Constantino"
    ],
    "summary": "The settlement does not resolve the tens of thousands of lawsuits alleging that J&J's talc-based products caused cancer.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107221356-1680732858785-gettyimages-1480135077-img_0151_sdiba6q3.jpeg?v=1690578445&w=1920&h=1080",
    "source": "CNBC",
    "category_within_source": "Business",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.106787,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.097854",
        "ticker_sentiment_score": "0.105276",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Global Process Mining Market Research Report 2023-2028: Opportunities in Artificial Intelligence and Machine Learning Integration and Rising Demand for Cloud-Based Solutions",
    "url": "https://www.prnewswire.com/news-releases/global-process-mining-market-research-report-2023-2028-opportunities-in-artificial-intelligence-and-machine-learning-integration-and-rising-demand-for-cloud-based-solutions-302042109.html",
    "time_published": "20240123T184500",
    "authors": [
      "Research and Markets"
    ],
    "summary": "Global Process Mining Market Research Report 2023-2028: Opportunities in Artificial Intelligence and Machine ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.429279,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HTHIF",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.158545",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PATH",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.158545",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.158545",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson's Settlement For Talc Cancer Lawsuits Reaches $700M Settlement With US States - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/01/36743981/johnson-johnsons-settlement-for-talc-cancer-lawsuits-reaches-700m-settlement-with-us-states",
    "time_published": "20240123T181825",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Johnson & Johnson JNJ announced on Tuesday a tentative settlement to address investigations by 42 U.S. states and Washington, D.C., regarding alleged misleading information about the safety of its talc products linked to cancer cases.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/johnsons-5671315-1920.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.179505,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.428632",
        "ticker_sentiment_score": "-0.289603",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Why Johnson & Johnson Stock Was Pulling Back Today",
    "url": "https://www.fool.com/investing/2024/01/23/why-johnson-johnson-stock-was-pulling-back-today/",
    "time_published": "20240123T174111",
    "authors": [
      "Jeremy Bowman"
    ],
    "summary": "The healthcare giant matched estimates, but it wasn't enough to please investors.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F762325%2Fsmiling-healthcare-nurse.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.117271,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.122269",
        "ticker_sentiment_score": "0.132548",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.355588",
        "ticker_sentiment_score": "0.067453",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Medtronic Stock a Buy Now?",
    "url": "https://www.fool.com/investing/2024/01/23/is-medtronic-stock-a-buy-now/",
    "time_published": "20240123T164500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "This longtime healthcare leader still has tricks up its sleeve.",
    "banner_image": "https://media.ycharts.com/charts/449df07f857feea40b1d409022b66dee.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      }
    ],
    "overall_sentiment_score": 0.305087,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MDT",
        "relevance_score": "0.753867",
        "ticker_sentiment_score": "0.552984",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.061631",
        "ticker_sentiment_score": "0.173458",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.061631",
        "ticker_sentiment_score": "0.173458",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's the message yet another bullish Wall Street call sends on this Big Tech stock",
    "url": "https://www.cnbc.com/2024/01/23/wall-street-issues-bullish-call-on-this-big-tech-name-heres-our-take.html",
    "time_published": "20240123T164301",
    "authors": [
      "Morgan Chittum"
    ],
    "summary": "The Investing Club holds its \"Morning Meeting\" every weekday at 10:20 a.m. ET.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/106956311-1633692334197-gettyimages-1227666240-GERMANY_HYDROGEN.jpeg?v=1705940216&w=600&h=300&vtcrop=y",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.995973"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.206223,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.226301",
        "ticker_sentiment_score": "0.154142",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SBUX",
        "relevance_score": "0.368227",
        "ticker_sentiment_score": "0.223605",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.076358",
        "ticker_sentiment_score": "0.089127",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.076358",
        "ticker_sentiment_score": "0.089127",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JPM",
        "relevance_score": "0.076358",
        "ticker_sentiment_score": "0.089127",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.152018",
        "ticker_sentiment_score": "0.115714",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.076358",
        "ticker_sentiment_score": "0.089127",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.152018",
        "ticker_sentiment_score": "0.115714",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Lice Treatment Market Analysis 2024-2028: Expected Market Size, Major Drivers And Leading Segments As Per The Business Research Company's Lice Treatment Global Market Report 2024",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36741497/lice-treatment-market-analysis-2024-2028-expected-market-size-major-drivers-and-leading-segments-a",
    "time_published": "20240123T163000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LONDON, Jan. 23, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Lice Treatment Global Market Report 2024, the global lice treatment market has demonstrated robust growth, reaching $1.05 billion in 2024 with an impressive compound annual growth rate ( CAGR ) of 7.7%.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.339723,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.064623",
        "ticker_sentiment_score": "0.175309",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.064623",
        "ticker_sentiment_score": "0.175309",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "J&J's  ( JNJ )  Q4 Earnings Beat, Darzalex, Stelara Drive Sales",
    "url": "https://www.zacks.com/stock/news/2214342/jjs-jnj-q4-earnings-beat-darzalex-stelara-drive-sales",
    "time_published": "20240123T160300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "J&J (JNJ) beats estimates for fourth-quarter earnings and sales. Sales of several key drugs like Darzalex, Stelara and Tremfya beat estimates.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.19171,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.067094",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.099202",
        "ticker_sentiment_score": "0.041704",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.099202",
        "ticker_sentiment_score": "0.059246",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Mixed Q4 Earnings Report",
    "url": "https://www.zacks.com/stock/news/2214340/mixed-q4-earnings-report",
    "time_published": "20240123T160000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Pre-market futures are mixed at this hour, coming off two strong trading days as Q4 earnings season begins to hit its stride. The Dow is -0.55% currently, while the S&P 500 and Nasdaq are +0.21% and +0.36%, respectively.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d9/573.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.9545"
      }
    ],
    "overall_sentiment_score": 0.282992,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GE",
        "relevance_score": "0.33514",
        "ticker_sentiment_score": "0.370016",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.171485",
        "ticker_sentiment_score": "0.084771",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.171485",
        "ticker_sentiment_score": "0.207522",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Q4 Earnings for J&J, Procter, GE & More",
    "url": "https://www.zacks.com/stock/news/2214313/q4-earnings-for-jj-procter-ge-more",
    "time_published": "20240123T152500",
    "authors": [
      "Mark Vickery"
    ],
    "summary": "Pre-market trading fortunes are mixed for this morning's reportees, including JNJ, PG, GE, MMM and DHI.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/60/857.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.990678"
      }
    ],
    "overall_sentiment_score": 0.267274,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GE",
        "relevance_score": "0.31583",
        "ticker_sentiment_score": "0.330327",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.16117",
        "ticker_sentiment_score": "0.081282",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.16117",
        "ticker_sentiment_score": "0.260185",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "US Stocks Mixed; Johnson & Johnson Posts Upbeat Earnings - FaZe Hldgs  ( NASDAQ:FAZE ) , Etao International Co  ( NASDAQ:ETAO ) ",
    "url": "https://www.benzinga.com/news/earnings/24/01/36739183/us-stocks-mixed-johnson-johnson-posts-upbeat-earnings",
    "time_published": "20240123T150438",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "U.S. stocks traded mixed this morning, with the Dow Jones index falling around 90 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.23% to 37,915.41 while the NASDAQ rose 0.12% to 15,378.87. The S&P 500 also rose, gaining, 0.07% to 4,853.64.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/23/image44.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      }
    ],
    "overall_sentiment_score": 0.103893,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRM",
        "relevance_score": "0.162255",
        "ticker_sentiment_score": "0.115889",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVVE",
        "relevance_score": "0.241284",
        "ticker_sentiment_score": "0.610096",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "FAZE",
        "relevance_score": "0.162255",
        "ticker_sentiment_score": "0.014128",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.241284",
        "ticker_sentiment_score": "0.093444",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RVSN",
        "relevance_score": "0.241284",
        "ticker_sentiment_score": "0.302996",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ETAO",
        "relevance_score": "0.162255",
        "ticker_sentiment_score": "-0.248028",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NUTX",
        "relevance_score": "0.241284",
        "ticker_sentiment_score": "0.162908",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson's Clock 12% Q4 Revenue Growth, Cancer and Crohn's Disease Drugs Account as Largest Sellers - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/01/36738885/johnson-johnsons-clock-12-q4-revenue-growth-cancer-and-crohns-disease-drugs-account-as-largest-se",
    "time_published": "20240123T144932",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Tuesday, Johnson & Johnson JNJ reported fourth-quarter 2023 adjusted earnings of $2.29 per share, up 11.7% year-over-year, beating the consensus of $2.28. Sales increased 7.3% Y/Y to $21.4 billion, beating the consensus of $20.99 billion, with operational growth of 7.2% and adjusted ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/jnj-johnson-shutter_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.210646,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.674691",
        "ticker_sentiment_score": "0.299757",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why J&J's Narrow Beat Is A Blessing For Medtech Stocks",
    "url": "https://www.investors.com/news/technology/jnj-stock-johnson-johnson-earnings-q4-2023/",
    "time_published": "20240123T135100",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "JNJ Stock Inches Higher As Medtech Strength Drives Fourth-Quarter Beat Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2021/01/Stock-JohnsonAndJohnson-syringe-shut.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.192258,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.843611",
        "ticker_sentiment_score": "0.454772",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment - Johnson & Johnson  ( NYSE:JNJ ) , Novartis  ( NYSE:NVS ) , Gilead Sciences  ( NASDAQ:GILD ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/01/36736043/focus-on-bristol-myers-gilead-sciences-johnson-johnson-novartis-fda-to-issue-classwide-black-box-",
    "time_published": "20240123T131918",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies. In its January 19 notification letters, the agency stressed that the potential risk applies to all ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/cancer_3.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.069177,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LEGN",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "-0.091337",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "0.31793",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GRCL",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "0.31793",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "0.007437",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "0.007437",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "0.007437",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "0.007437",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Futures Mixed After Earnings Reports",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-big-earnings-reports-magnificent-seven-stock-netflix-to-report-next/",
    "time_published": "20240123T131200",
    "authors": [
      "Investor's Business Daily",
      "SCOTT LEHTONEN"
    ],
    "summary": "Dow Jones Futures Fall On Big Earnings Reports. Magnificent Seven Stock Netflix To Report Next Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/04/stock-wallstreet-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.161722,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DKNG",
        "relevance_score": "0.170576",
        "ticker_sentiment_score": "0.215034",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.170576",
        "ticker_sentiment_score": "0.08804",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.042953",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.085782",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.212301",
        "ticker_sentiment_score": "0.165004",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.128363",
        "ticker_sentiment_score": "0.0644",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.170576",
        "ticker_sentiment_score": "0.224647",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.085782",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.042953",
        "ticker_sentiment_score": "0.044623",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.042953",
        "ticker_sentiment_score": "0.118591",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.170576",
        "ticker_sentiment_score": "0.096618",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MELI",
        "relevance_score": "0.212301",
        "ticker_sentiment_score": "0.251407",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HAL",
        "relevance_score": "0.128363",
        "ticker_sentiment_score": "0.031178",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.042953",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.128363",
        "ticker_sentiment_score": "0.0644",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.170576",
        "ticker_sentiment_score": "0.166315",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.128363",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.170576",
        "ticker_sentiment_score": "0.150137",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.128363",
        "ticker_sentiment_score": "0.031178",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "FDA Demands \"Boxed Warning\" to CAR T-Cell Therapy Labels",
    "url": "https://www.zacks.com/stock/news/2214008/fda-demands-boxed-warning-to-car-t-cell-therapy-labels",
    "time_published": "20240123T130800",
    "authors": [
      "Ekta Bagri"
    ],
    "summary": "The FDA directs companies like NVS, BMY, GILD and others to add \"boxed warning\" to the labels of their CAR T-cell immunotherapies after it identified adverse events.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/13/54831.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.002389,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "TSVT",
        "relevance_score": "0.056143",
        "ticker_sentiment_score": "0.065992",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.034274",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LEGN",
        "relevance_score": "0.112008",
        "ticker_sentiment_score": "0.075902",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.112008",
        "ticker_sentiment_score": "-0.058239",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "US Stocks Prepare For Nervy Start Ahead of Netflix, TI Earnings: Analyst Says Cash Waiting On Sidelines Could Flood Street If This Happens - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/01/36734767/us-stocks-prepare-for-nervy-start-ahead-of-netflix-ti-earnings-analyst-says-cash-waiting-on-sidelin",
    "time_published": "20240123T123203",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "The mood turned circumspect on Tuesday as traders digested a deluge of earnings reports and anticipated market-moving economic data for the week. Earnings releases from 3M Company MMM and General Electric Co. GE led to a pullback in their stocks during premarket trading.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/nyse-shutter_3.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.997902"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      }
    ],
    "overall_sentiment_score": 0.059945,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.158519",
        "ticker_sentiment_score": "-0.040407",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.191116",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.048514",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LOGI",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "-0.27216",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.048514",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BKR",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TXN",
        "relevance_score": "0.158519",
        "ticker_sentiment_score": "-0.040407",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "0.21978",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MMM",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.022026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "-0.217386",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "HAL",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.048514",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LMT",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.048514",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.158519",
        "ticker_sentiment_score": "0.038721",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.158519",
        "ticker_sentiment_score": "0.038721",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CNI",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STLD",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:JPY",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "-0.173706",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "FOREX:EUR",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "-0.173706",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "-0.078403",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "-0.018227",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cough Suppressant Market to Hit US$ 39,216.3 Million by 2030 | Updated Insights Report by Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36734013/cough-suppressant-market-to-hit-us-39-216-3-million-by-2030-updated-insights-report-by-persistence",
    "time_published": "20240123T120000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 23, 2024 ( GLOBE NEWSWIRE ) -- Cough suppressants, also known as antitussives, are pharmaceutical substances engineered to alleviate cough symptoms.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.291889,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HLCO",
        "relevance_score": "0.020848",
        "ticker_sentiment_score": "0.009603",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "0.183297",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.062488",
        "ticker_sentiment_score": "0.179295",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson earnings beat estimates with boost from medtech sales",
    "url": "https://www.marketwatch.com/story/johnson-johnson-q4-earnings-beat-estimates-amid-strength-in-medtech-1803820f",
    "time_published": "20240123T113500",
    "authors": [
      "Ciara Linnane"
    ],
    "summary": "Medtech sales were up more than 13% in the latest quarter.",
    "banner_image": "https://images.mktw.net/im-305622/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.188782,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.252987",
        "ticker_sentiment_score": "0.317354",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.371523",
        "ticker_sentiment_score": "0.206173",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Genmab Announces Net Sales of DARZALEX\u00ae  ( daratumumab )  for 2023",
    "url": "https://www.globenewswire.com/news-release/2024/01/23/2813898/0/en/Genmab-Announces-Net-Sales-of-DARZALEX-daratumumab-for-2023.html",
    "time_published": "20240123T112400",
    "authors": [
      "Genmab A/S"
    ],
    "summary": "Company Announcement ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.064714,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GMAB",
        "relevance_score": "0.646056",
        "ticker_sentiment_score": "0.099378",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.011832",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson narrowly tops quarterly estimates as pharmaceutical, medtech sales jump",
    "url": "https://www.cnbc.com/2024/01/23/johnson-johnson-jnj-earnings-q4-2023.html",
    "time_published": "20240123T112237",
    "authors": [
      "Annika Kim Constantino"
    ],
    "summary": "The results come six months after J&J completed its spinoff of consumer health unit Kenvue, the company's biggest shake-up in its nearly 140-year history.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/106974800-1636726117188-gettyimages-1234001052-RAFAPRESS_15072021-9655.jpeg?v=1705948573&w=1920&h=1080",
    "source": "CNBC",
    "category_within_source": "Earnings",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.988787"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.021707,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.173333",
        "ticker_sentiment_score": "-0.0242",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.087185",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares U.S. Healthcare ETF  ( IYH ) ?",
    "url": "https://www.zacks.com/stock/news/2213920/should-you-invest-in-the-ishares-us-healthcare-etf-iyh",
    "time_published": "20240123T112006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default46.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.221904,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.066784",
        "ticker_sentiment_score": "0.088171",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.069906",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.069906",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.069906",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Health Care Select Sector SPDR ETF  ( XLV ) ?",
    "url": "https://www.zacks.com/stock/news/2213924/should-you-invest-in-the-health-care-select-sector-spdr-etf-xlv",
    "time_published": "20240123T112005",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default19.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.2573,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.127456",
        "ticker_sentiment_score": "0.063784",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.063933",
        "ticker_sentiment_score": "0.127397",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STT",
        "relevance_score": "0.063933",
        "ticker_sentiment_score": "0.089059",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.127456",
        "ticker_sentiment_score": "0.063784",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.127456",
        "ticker_sentiment_score": "0.063784",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapies",
    "url": "https://www.prnewswire.com/news-releases/accent-therapeutics-announces-75-million-series-c-financing-to-advance-small-molecule-precision-cancer-therapies-302041338.html",
    "time_published": "20240123T110000",
    "authors": [
      "Inc.",
      "Accent Therapeutics"
    ],
    "summary": "Financing led by Mirae Asset Capital Life Science with participation from additional new and existing investors Funds will support advancement of lead programs through early clinical development, including Accent's first-in-class DHX9 inhibitor and newly unveiled, potentially best-in-class KIF18A ...",
    "banner_image": "https://mma.prnewswire.com/media/2048641/Accent_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.072022,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.039418",
        "ticker_sentiment_score": "0.045323",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.039418",
        "ticker_sentiment_score": "0.045323",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.039418",
        "ticker_sentiment_score": "0.045323",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "S&P 500 futures hold at record highs as earnings season ramps up",
    "url": "https://www.marketwatch.com/story/s-p-500-futures-hold-at-record-highs-as-earnings-season-ramps-up-netflix-eyed-after-the-close-de2923e4",
    "time_published": "20240123T103100",
    "authors": [
      "Jamie Chisholm"
    ],
    "summary": "U.S. stock index futures showed benchmarks holding at record levels as bond markets stabilized and traders eyed an accelerating flow of corporate earnings reports.",
    "banner_image": "https://images.mktw.net/im-20251080/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.190016,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BKR",
        "relevance_score": "0.202366",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.202366",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TXN",
        "relevance_score": "0.202366",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.202366",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.202366",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.202366",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Genius Safe Stocks to Buy for 2024 and Beyond",
    "url": "https://www.fool.com/investing/2024/01/23/2-genius-safe-stocks-to-buy-for-2024-and-beyond/",
    "time_published": "20240123T101500",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "These companies have considerable profits and tried-and-true dividends in common.",
    "banner_image": "https://g.foolcdn.com/editorial/images/761857/businesswoman-working-finances-1.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.623304"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.078877,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.041354",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.076708",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.234006",
        "ticker_sentiment_score": "0.072217",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMAM",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "-0.030904",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.279015",
        "ticker_sentiment_score": "0.002106",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Expectorant Drugs Market Poised to Reach US$22.9 Billion by 2030 with a Steady 4.5% CAGR | Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36732382/expectorant-drugs-market-poised-to-reach-us-22-9-billion-by-2030-with-a-steady-4-5-cagr-persistenc",
    "time_published": "20240123T093000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 23, 2024 ( GLOBE NEWSWIRE ) -- Market Size & Overview: The global expectorant drugs market is projected to grow at a robust CAGR of 4.5%, surging from US$16.8 billion in 2023 to reach US$22.9 billion by the conclusion of 2030.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.714479"
      }
    ],
    "overall_sentiment_score": 0.399092,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MFCSF",
        "relevance_score": "0.015226",
        "ticker_sentiment_score": "0.124442",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.015226",
        "ticker_sentiment_score": "0.306033",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.015226",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.015226",
        "ticker_sentiment_score": "0.119248",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.015226",
        "ticker_sentiment_score": "0.066705",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Surgical Staplers Market Soars, Forecasting an 4.7% CAGR Surge to Reach US$5.5 Billion by 2030 | Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36732339/surgical-staplers-market-soars-forecasting-an-4-7-cagr-surge-to-reach-us-5-5-billion-by-2030-persi",
    "time_published": "20240123T091500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 23, 2024 ( GLOBE NEWSWIRE ) -- Market Overview: The Surgical Staplers Market is a vital segment within the broader medical device industry, dedicated to simplifying and enhancing surgical procedures.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.375422,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MDT",
        "relevance_score": "0.014506",
        "ticker_sentiment_score": "0.049119",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CNMD",
        "relevance_score": "0.029008",
        "ticker_sentiment_score": "-0.04468",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.057977",
        "ticker_sentiment_score": "0.147179",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.043499",
        "ticker_sentiment_score": "0.189608",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Surgical Dressing Market Valuation to Reach US$1.9 Billion by 2030, Driven by 6.1% CAGR | Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36732234/surgical-dressing-market-valuation-to-reach-us-1-9-billion-by-2030-driven-by-6-1-cagr-persistence-",
    "time_published": "20240123T085000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 23, 2024 ( GLOBE NEWSWIRE ) -- Market Overview: The surgical dressing market plays a vital role in the healthcare industry, providing essential products that aid in the post-operative care of patients and promote wound healing.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.320894,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HLCO",
        "relevance_score": "0.014757",
        "ticker_sentiment_score": "0.040595",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNN",
        "relevance_score": "0.04425",
        "ticker_sentiment_score": "-0.038999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MCK",
        "relevance_score": "0.014757",
        "ticker_sentiment_score": "0.418091",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.04425",
        "ticker_sentiment_score": "-0.038999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.04425",
        "ticker_sentiment_score": "0.014969",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.04425",
        "ticker_sentiment_score": "0.056789",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLPBY",
        "relevance_score": "0.04425",
        "ticker_sentiment_score": "0.125902",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Fear & Greed Index Remains In 'Greed' Zone; Dow Settles Above 38,000 - Johnson & Johnson  ( NYSE:JNJ ) , Archer-Daniels Midland  ( NYSE:ADM ) ",
    "url": "https://www.benzinga.com/news/earnings/24/01/36731525/fear-greed-index-remains-in-greed-zone-dow-settles-above-38-000",
    "time_published": "20240123T073346",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "The CNN Money Fear and Greed index remained in the \"Greed\" zone on Monday. U.S. stocks closed higher on Monday, with the Dow Jones index settling above the 38,000 mark for the first time.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/23/image38.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": -0.204857,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.263942",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.263942",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.263942",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.263942",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBD",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "-0.489041",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "ADM",
        "relevance_score": "0.263942",
        "ticker_sentiment_score": "0.095791",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "M",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.058844",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Verizon, Netflix And 3 Stocks To Watch Heading Into Tuesday - Netflix  ( NASDAQ:NFLX ) , Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/news/earnings/24/01/36731409/verizon-netflix-and-3-stocks-to-watch-heading-into-tuesday",
    "time_published": "20240123T065300",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "With U.S. stock futures trading mixed this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Verizon Communications Inc. VZ to report quarterly earnings at $1.08 per share on revenue of $34.58 billion before the opening bell.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/23/verizon_communications_-_logo.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.23435,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.504646",
        "ticker_sentiment_score": "0.338779",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.504646",
        "ticker_sentiment_score": "0.333483",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.504646",
        "ticker_sentiment_score": "0.39389",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.504646",
        "ticker_sentiment_score": "0.404618",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.504646",
        "ticker_sentiment_score": "0.39389",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Medical Adhesive Tape Market Is Projected to Reach a Value of US$13.1 Billion by The End 2030, According to Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36731378/medical-adhesive-tape-market-is-projected-to-reach-a-value-of-us-13-1-billion-by-the-end-2030-acco",
    "time_published": "20240123T063000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 23, 2024 ( GLOBE NEWSWIRE ) -- Medical Adhesive Tape Market Booming with Growing Demand and Technological Advancements Medical adhesive tapes are essential in wound care, surgeries, and medical applications.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.381388,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MFCSF",
        "relevance_score": "0.017795",
        "ticker_sentiment_score": "0.128518",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HLCO",
        "relevance_score": "0.017795",
        "ticker_sentiment_score": "0.197876",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NDEKF",
        "relevance_score": "0.035582",
        "ticker_sentiment_score": "0.155746",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NHBAF",
        "relevance_score": "0.017795",
        "ticker_sentiment_score": "0.149182",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNN",
        "relevance_score": "0.017795",
        "ticker_sentiment_score": "0.149182",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVY",
        "relevance_score": "0.035582",
        "ticker_sentiment_score": "0.155746",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.017795",
        "ticker_sentiment_score": "0.149182",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.017795",
        "ticker_sentiment_score": "0.149182",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.035582",
        "ticker_sentiment_score": "0.137674",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "S&P 500 ends with record high for 2nd session in row",
    "url": "https://www.moneycontrol.com/news/business/markets/sp-500-ends-with-record-high-for-2nd-session-in-row-12105241.html",
    "time_published": "20240123T010143",
    "authors": [],
    "summary": "Friday's finish confirmed that the SP 500 has been in a bull market since it closed at its low on Oct. 12, 2022, according to one commonly used measure.",
    "banner_image": "https://images.moneycontrol.com/static-mcnews/2020/08/wall-street-1.jpg?impolicy=website&width=168&height=118",
    "source": "Money Control",
    "category_within_source": "Markets",
    "source_domain": "www.moneycontrol.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.14298,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.11768",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.21237",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.04322",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADM",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.010699",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LPLA",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.063858",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - AMAM, CSTR, RYZB, THRX",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36769662/stockholder-alert-the-m-a-class-action-firm-continues-investigating-the-merger-amam-cstr-ryzb-thrx",
    "time_published": "20240124T221658",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, Jan. 24, 2024 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the \"M&A Class Action Firm\" ) , a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.928769"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.348873,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CSTR",
        "relevance_score": "0.269033",
        "ticker_sentiment_score": "0.312256",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ONB",
        "relevance_score": "0.068502",
        "ticker_sentiment_score": "0.15954",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMAM",
        "relevance_score": "0.269033",
        "ticker_sentiment_score": "0.251355",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.068502",
        "ticker_sentiment_score": "0.127176",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RYZB",
        "relevance_score": "0.269033",
        "ticker_sentiment_score": "0.239471",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "THRX",
        "relevance_score": "0.269033",
        "ticker_sentiment_score": "0.22137",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.068502",
        "ticker_sentiment_score": "0.121075",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Washington state reaches a nearly $150 million settlement with Johnson & Johnson over opioid crisis",
    "url": "https://apnews.com/article/washington-opioids-johnson-johnson-settlement-58038e4877ca7b9bf458c54e110b12d8",
    "time_published": "20240124T210000",
    "authors": [
      "HALLIE GOLDEN",
      "MANUEL VALDES"
    ],
    "summary": "OLYMPIA, Wash. ( AP ) - The Washington state attorney general announced a $149.5 million settlement Wednesday with drugmaker Johnson & Johnson, more than four years after the state sued the company over its role fueling the opioid addiction crisis. \"They knew what the harm was.",
    "banner_image": "https://dims.apnews.com/dims4/default/5ab57e4/2147483647/strip/true/crop/5251x3498+0+2/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2Fe2%2F2c%2F18c43a66a30e9451dfdf08f8f1e7%2F06280d5432514991b45bd245d9114d02",
    "source": "Associated Press",
    "category_within_source": "Business",
    "source_domain": "apnews.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.080233,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.188193",
        "ticker_sentiment_score": "-0.023132",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Gilead's Tecartus Dropped From FDA List Of CAR-T Therapy With Updated Label Warning Of \"Risks Of Secondary Cancer' - Gilead Sciences  ( NASDAQ:GILD ) ",
    "url": "https://www.benzinga.com/general/biotech/24/01/36760938/gileads-tecartus-dropped-from-fda-list-of-car-t-therapy-with-updated-label-warning-of-risks-of-se",
    "time_published": "20240124T153609",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Tuesday, the FDA announced to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Gilead_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.07904,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GILD",
        "relevance_score": "0.353898",
        "ticker_sentiment_score": "-0.336118",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "LEGN",
        "relevance_score": "0.12165",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.240489",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.240489",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stock Market News for Jan 24, 2024",
    "url": "https://www.zacks.com/stock/news/2214906/stock-market-news-for-jan-24-2024",
    "time_published": "20240124T142100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Wall Street closed mixed on Tuesday on strong to mixed quarterly earnings.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/9b/2956.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      }
    ],
    "overall_sentiment_score": 0.040916,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LMT",
        "relevance_score": "0.188928",
        "ticker_sentiment_score": "0.069195",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.188928",
        "ticker_sentiment_score": "0.069195",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What's Going On Johnson & Johnson Stock Today? - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/01/36755938/whats-going-on-johnson-johnson-stock-today",
    "time_published": "20240124T125416",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Tuesday, Johnson & Johnson JNJ released better-than-expected earnings for its fourth quarter of 2023. It reported quarterly adjusted earnings of $2.29 per share, up 11.7% year-over-year, beating the consensus of $2.28. Sales increased 7.3% Y/Y to $21.4 billion, beating the consensus of $20.99 ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Johnson-and-Johnson.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.917436"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.043897,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.219809",
        "ticker_sentiment_score": "0.065799",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.671304",
        "ticker_sentiment_score": "-0.079756",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nasdaq, S&P 500 Futures Jump As Wall Street Eagerly Awaits Tesla's Q4 Earnings: Analyst Says Rally Broadening But Favors These Stocks - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/01/36755805/nasdaq-s-p-500-futures-jump-as-wall-street-eagerly-awaits-teslas-q4-earnings-analyst-says-rally-bro",
    "time_published": "20240124T124145",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "U.S. stock futures indicate a positive opening on Wednesday, buoyed by strong earnings reports from Netflix, Inc. NFLX and semiconductor equipment maker ASML Holding N.V. ASML. Investors are eagerly awaiting Tesla, Inc.'s TSLA fourth-quarter results, which are expected to take center stage.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Wall-Street-US-Stocks.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.967645"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928139"
      }
    ],
    "overall_sentiment_score": 0.181687,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.172919",
        "ticker_sentiment_score": "0.108241",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMB",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "-0.100818",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TXN",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "-0.139714",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.220007",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MMM",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "-0.100818",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ASML",
        "relevance_score": "0.172919",
        "ticker_sentiment_score": "0.185069",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "0.175759",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "T",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BACHY",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.123025",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FCX",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GD",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "-0.139714",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WT",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.206003",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FOREX:EUR",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.175",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Investor Optimism Improves Following Earnings Reports; S&P 500 Reaches Another High - Abbott Laboratories  ( NYSE:ABT ) , IBM  ( NYSE:IBM ) ",
    "url": "https://www.benzinga.com/news/earnings/24/01/36752497/investor-optimism-improves-following-earnings-reports-s-p-500-reaches-another-high",
    "time_published": "20240124T084959",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "The CNN Money Fear and Greed index showed a further increase in overall market sentiment, while the index remained in the \"Greed\" zone on Tuesday. U.S. stocks closed mixed on Tuesday, with the Dow Jones index snapping a three-day winning streak. However, the S&P 500 hit a new all-time closing ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/24/image18.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": -0.053398,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "T",
        "relevance_score": "0.116914",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "0.525561",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "IBM",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "0.525561",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "WBD",
        "relevance_score": "0.116914",
        "ticker_sentiment_score": "-0.206002",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "MMM",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "0.525561",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Virtualware Reports  ( MLVIR.PA )  Record \u20ac4.52 Million Revenue in 2023, a 40% Surge from Previous Year",
    "url": "https://www.globenewswire.com/news-release/2024/01/24/2814776/0/en/Virtualware-Reports-MLVIR-PA-Record-4-52-Million-Revenue-in-2023-a-40-Surge-from-Previous-Year.html",
    "time_published": "20240124T071000",
    "authors": [
      "VIRTUALWARE 2007 SA"
    ],
    "summary": "Bilbao, January 24 - European Virtual Reality company Virtualware ( MLVIR.PA ) ( EPA:MLVIR ) , reported record total revenues of \u20ac4.52 million in 2023, 40% more than in the previous year, just nine months after its IPO on Euronext Access Paris.",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/6aee44c0-62ac-4f66-9be0-b3578d202005",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      }
    ],
    "overall_sentiment_score": 0.210832,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HTHIF",
        "relevance_score": "0.039033",
        "ticker_sentiment_score": "0.074235",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IBDSF",
        "relevance_score": "0.039033",
        "ticker_sentiment_score": "0.074235",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AOMFF",
        "relevance_score": "0.039033",
        "ticker_sentiment_score": "0.074235",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.039033",
        "ticker_sentiment_score": "0.074235",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.039033",
        "ticker_sentiment_score": "0.074235",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "S&P 500 notches third straight record high close",
    "url": "https://www.moneycontrol.com/news/business/markets/sp-500-notches-third-straight-record-high-close-12112521.html",
    "time_published": "20240124T005218",
    "authors": [],
    "summary": "It was the third straight all-time high for the benchmark stock index, and many investors view upcoming quarterly reports from the heavily weighted \"Magnificent 7\" group of megacap companies as key to whether Wall Street's recent rally continues or loses steam.",
    "banner_image": "https://images.moneycontrol.com/static-mcnews/2020/08/wall-street.jpg?impolicy=website&width=168&height=118",
    "source": "Money Control",
    "category_within_source": "Markets",
    "source_domain": "www.moneycontrol.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.904684"
      }
    ],
    "overall_sentiment_score": 0.137646,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.072",
        "ticker_sentiment_score": "0.109706",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.143415",
        "ticker_sentiment_score": "-0.029508",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.072",
        "ticker_sentiment_score": "0.313379",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.072",
        "ticker_sentiment_score": "-0.058136",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.072",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.072",
        "ticker_sentiment_score": "0.313379",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.072",
        "ticker_sentiment_score": "0.079237",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Kuehn Law Encourages CPE, ROVR, AMAM, and JNPR Investors to Contact Law Firm - Ambrx Biopharma  ( NASDAQ:AMAM ) , Callon Petroleum  ( NYSE:CPE ) ",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36789166/kuehn-law-encourages-cpe-rovr-amam-and-jnpr-investors-to-contact-law-firm",
    "time_published": "20240125T202304",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, Jan. 25, 2024 ( GLOBE NEWSWIRE ) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.955357"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.296649,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HPQ",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.266682",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CPE",
        "relevance_score": "0.210274",
        "ticker_sentiment_score": "0.344039",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "APA",
        "relevance_score": "0.210274",
        "ticker_sentiment_score": "0.344039",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMAM",
        "relevance_score": "0.210274",
        "ticker_sentiment_score": "0.478271",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BX",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.051759",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.336739",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates AMAM, HARP, JNPR, TARO - Ambrx Biopharma  ( NASDAQ:AMAM ) , Harpoon Therapeutics  ( NASDAQ:HARP ) ",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36778188/shareholder-notice-halper-sadeh-llc-investigates-amam-harp-jnpr-taro",
    "time_published": "20240125T130347",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, Jan. 25, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Ambrx Biopharma, Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.06938,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "HPQ",
        "relevance_score": "0.140896",
        "ticker_sentiment_score": "0.102747",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNPR",
        "relevance_score": "0.140896",
        "ticker_sentiment_score": "0.102747",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TARO",
        "relevance_score": "0.140896",
        "ticker_sentiment_score": "0.011348",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMAM",
        "relevance_score": "0.140896",
        "ticker_sentiment_score": "0.095371",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HARP",
        "relevance_score": "0.140896",
        "ticker_sentiment_score": "0.095371",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.140896",
        "ticker_sentiment_score": "0.095371",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Better Dividend Stock to Buy Now: Johnson & Johnson vs. Verizon",
    "url": "https://www.fool.com/investing/2024/01/25/better-dividend-stock-to-buy-now-johnson-johnson-v/",
    "time_published": "20240125T121900",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Both recently reported results from the fourth quarter of 2023 and their performances could hardly look more different.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F762457%2Finvestor-dark-room-devices-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999919"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.120029,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VZ",
        "relevance_score": "0.43852",
        "ticker_sentiment_score": "0.385345",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.203643",
        "ticker_sentiment_score": "0.175527",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "UAW endorses Joe Biden; Ohio bans gender-affirming care for minors",
    "url": "https://www.economist.com/in-brief/2024/01/25/uaw-endorses-joe-biden-ohio-bans-gender-affirming-care-for-minors",
    "time_published": "20240125T055405",
    "authors": [
      "The Economist"
    ],
    "summary": "UAW endorses Joe Biden. Ohio bans gender-affirming care for minors The Economist ...",
    "banner_image": "https://www.economist.com/cdn-cgi/image/width=1424,quality=80,format=auto/content-assets/images/20240113_BLP599.jpg",
    "source": "The Economist",
    "category_within_source": "BusinessGoogleRSS",
    "source_domain": "www.economist.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.108222,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BA",
        "relevance_score": "0.068112",
        "ticker_sentiment_score": "0.002027",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.068112",
        "ticker_sentiment_score": "-0.055308",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "UAW endorses Joe Biden; Ohio bans gender-affirming care for minors",
    "url": "https://www.economist.com/news/2024/01/25/uaw-endorses-joe-biden-ohio-bans-gender-affirming-care-for-minors",
    "time_published": "20240125T055405",
    "authors": [
      "The Economist"
    ],
    "summary": "UAW endorses Joe Biden. Ohio bans gender-affirming care for minors The Economist ...",
    "banner_image": "https://www.economist.com/cdn-cgi/image/width=1424,quality=80,format=auto/content-assets/images/20240113_BLP599.jpg",
    "source": "The Economist",
    "category_within_source": "BusinessGoogleRSS",
    "source_domain": "www.economist.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.110579,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BA",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.002025",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "-0.055246",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "UAW endorses Joe Biden; Trump on the attack",
    "url": "https://www.economist.com/in-brief/2024/01/25/uaw-endorses-joe-biden-trump-on-the-attack",
    "time_published": "20240125T055405",
    "authors": [
      "The Economist"
    ],
    "summary": "UAW endorses Joe Biden. Ohio bans gender-affirming care for minors The Economist ...",
    "banner_image": "https://www.economist.com/cdn-cgi/image/width=1424,quality=80,format=auto/content-assets/images/20240113_BLP599.jpg",
    "source": "The Economist",
    "category_within_source": "FinanceGoogleRSS",
    "source_domain": "www.economist.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.100782,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.102332",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "-0.055112",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Global Pompe Disease Drugs Market: USD 294.7 Million Growth Forecasted at a CAGR of 4.16% between 2024 to ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/global-pompe-disease-drugs-market-usd-294-7-million-growth-forecasted-at-a-cagr-of-4-16-between-2024-to-2028--technavio-302045515.html",
    "time_published": "20240126T233100",
    "authors": [],
    "summary": "Global Pompe Disease Drugs Market: USD 294.7 Million Growth Forecasted at a CAGR of 4.16% between 2024 to ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.350011,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "FOLD",
        "relevance_score": "0.051774",
        "ticker_sentiment_score": "0.080886",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.051774",
        "ticker_sentiment_score": "0.080886",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.051774",
        "ticker_sentiment_score": "0.080886",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALPMF",
        "relevance_score": "0.051774",
        "ticker_sentiment_score": "0.080886",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVRO",
        "relevance_score": "0.051774",
        "ticker_sentiment_score": "0.080886",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JCRRF",
        "relevance_score": "0.051774",
        "ticker_sentiment_score": "0.080886",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.051774",
        "ticker_sentiment_score": "0.080886",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Merck, Johnson & Johnson CEOs agree to testify in Senate hearing on high drug prices",
    "url": "https://www.cnbc.com/2024/01/26/merck-jj-ceos-agree-to-testify-in-senate-hearing-on-drug-prices-.html",
    "time_published": "20240126T211709",
    "authors": [
      "Annika Kim Constantino"
    ],
    "summary": "The CEOs of Merck, Johnson & Johnson and Bristol Myers Squibb will testify at the hearing on drug prices, Sen. Bernie Sanders said.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107255764-1686668756779-gettyimages-1235403027-AFP_9NA2ZY.jpeg?v=1686668795&w=1920&h=1080",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.03827,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MRNA",
        "relevance_score": "0.085022",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.085022",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.085022",
        "ticker_sentiment_score": "0.126295",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.085022",
        "ticker_sentiment_score": "0.052216",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.085022",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "S&P 500 Dividend Aristocrats: Who's Out, Who's In",
    "url": "https://www.kiplinger.com/investing/sandp-500-dividend-aristocrats-whos-out-whos-in",
    "time_published": "20240126T195530",
    "authors": [
      "Dan Burrows"
    ],
    "summary": "The S&P 500 Dividend Aristocrats index looks only a little different as we head into the new year. Widely regarded as some of the best dividend stocks for dependable dividend growth, the S&P 500 Dividend Aristocrats is an index of S&P 500 companies that have raised their dividends for at least 25 ...",
    "banner_image": "https://cdn.mos.cms.futurecdn.net/x82x4uLxyhXNtrHX8yMU9R-415-80.jpg",
    "source": "Kiplinger",
    "category_within_source": "n/a",
    "source_domain": "www.kiplinger.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.98396"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.181501,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.178459",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VFC",
        "relevance_score": "0.178459",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FAST",
        "relevance_score": "0.348103",
        "ticker_sentiment_score": "0.165383",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.178459",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.264897",
        "ticker_sentiment_score": "-0.043928",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stocks Rally Amid Big Earnings, Economic Data: Weekly Review",
    "url": "https://www.investors.com/news/stock-market-continues-to-rally-asml-netflix-tesla-intel-are-big-earnings-movers-weekly-review/",
    "time_published": "20240126T172900",
    "authors": [
      "IBD STAFF",
      "Investor's Business Daily"
    ],
    "summary": "Stock Market Continues To Rally. ASML, Netflix, Tesla, Intel Are Big Earnings Movers: Weekly Review Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2023/06/Stock-teslafrontnose-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.928139"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999897"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.08166,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "PCAR",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "0.013004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "-0.067699",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "0.023613",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEX",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "0.143388",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.060287",
        "ticker_sentiment_score": "0.075292",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.020113",
        "ticker_sentiment_score": "0.035033",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TXN",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "-0.107406",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "URI",
        "relevance_score": "0.12023",
        "ticker_sentiment_score": "0.159096",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TXT",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "0.202956",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "0.074287",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.080323",
        "ticker_sentiment_score": "-0.014907",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNP",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "-0.224991",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "V",
        "relevance_score": "0.080323",
        "ticker_sentiment_score": "-0.021101",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LRCX",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "-0.107406",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SAVE",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "-0.13454",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GD",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "0.202956",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "0.035632",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NSC",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "-0.224991",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "KLAC",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "-0.107406",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.12023",
        "ticker_sentiment_score": "0.084831",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HUM",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "0.124534",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOC",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "0.202956",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BAH",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "0.202956",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAL",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "-0.067699",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMUS",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "0.036945",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LMT",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "0.202956",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "-0.038213",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "0.143388",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOW",
        "relevance_score": "0.020113",
        "ticker_sentiment_score": "0.105654",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.060287",
        "ticker_sentiment_score": "0.118296",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "0.036031",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FCX",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "-0.163211",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "BRO",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "0.078443",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAL",
        "relevance_score": "0.060287",
        "ticker_sentiment_score": "0.024078",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "-0.067699",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CNI",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "-0.224991",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "The U.S. has no federal bereavement leave. What to know about options at work when someone you love dies",
    "url": "https://www.cnbc.com/2024/01/26/what-to-know-about-bereavement-leave-at-work-when-someone-you-love-dies.html",
    "time_published": "20240126T144540",
    "authors": [
      "Annie Nova"
    ],
    "summary": "The U.S. has no federal bereavement leave policy, but workers in mourning still have options. Here's what they should know.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107363343-1706043979763-gettyimages-1368009967-cha09884.jpeg?v=1706044002&w=1920&h=1080",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.230792,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.057767",
        "ticker_sentiment_score": "0.092237",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Key Takeaways From JNJ's  ( JNJ )  Q4 Earnings Presentation",
    "url": "https://www.zacks.com/stock/news/2216453/key-takeaways-from-jnjs-jnj-q4-earnings-presentation",
    "time_published": "20240126T143000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "J&J's (JNJ) Innovative Medicines as well as MedTech units outperform expectations in the fourth quarter. Here we discuss some highlights of its performance in the fourth quarter.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.211414,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.114137",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.114137",
        "ticker_sentiment_score": "0.145984",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMAM",
        "relevance_score": "0.114137",
        "ticker_sentiment_score": "0.123283",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.114137",
        "ticker_sentiment_score": "0.060868",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "When You Make A Mistake Take Responsibility",
    "url": "https://www.forbes.com/sites/jerryweissman/2024/01/26/when-you-make-a-mistake-take-responsibility/",
    "time_published": "20240126T140000",
    "authors": [
      "Jerry Weissman"
    ],
    "summary": "Boeing CEO David Calhoun and San Francisco Forty-Niner quarterback Brock Purdy have something in common: each of them took responsibility for their mistakes.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65b041aab8bc7aa159ef55c9/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": -0.074609,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.090816",
        "ticker_sentiment_score": "0.020395",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.090816",
        "ticker_sentiment_score": "0.020395",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.090816",
        "ticker_sentiment_score": "0.020395",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.18046",
        "ticker_sentiment_score": "-0.010155",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.090816",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Men's Skincare Products Market to Acquire a Size of USD 24,824.0 Million By 2030, According to Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36796496/mens-skincare-products-market-to-acquire-a-size-of-usd-24-824-0-million-by-2030-according-to-persi",
    "time_published": "20240126T084404",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 26, 2024 ( GLOBE NEWSWIRE ) -- Men's skincare products industry is a rapidly expanding and continually evolving sector that specializes in creating and distributing personal care products tailored for men's skin.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.30447,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.028456",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.028456",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Better Growth Stock: UnitedHealth Group vs. Johnson & Johnson",
    "url": "https://www.fool.com/investing/2024/01/27/better-growth-stock-unitedhealth-group-vs-johnson/",
    "time_published": "20240127T151500",
    "authors": [
      "David Jagielski"
    ],
    "summary": "These companies have been focusing on growing their operations, but which stock is likely to provide investors with better returns?",
    "banner_image": "https://g.foolcdn.com/editorial/images/762088/a-doctor-looking-at-a-tablet-with-another-person.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.240472,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.063091",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMAM",
        "relevance_score": "0.063091",
        "ticker_sentiment_score": "0.141107",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.473427",
        "ticker_sentiment_score": "0.489705",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.365166",
        "ticker_sentiment_score": "0.24848",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Buy the Dogs of the Dow in 2024?",
    "url": "https://www.fool.com/investing/2024/01/27/should-you-buy-the-dogs-of-the-dow-in-2024/",
    "time_published": "20240127T115900",
    "authors": [
      "Jeremy Bowman"
    ],
    "summary": "The popular dividend-investing strategy has been around for years. Is it right for you?",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F762238%2Fman-holding-cash-dividends.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.989041"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.192136,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.064797",
        "ticker_sentiment_score": "0.134527",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.129168",
        "ticker_sentiment_score": "0.089459",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.064797",
        "ticker_sentiment_score": "0.134527",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.064797",
        "ticker_sentiment_score": "0.134527",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AMBRX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAM",
    "url": "https://www.prnewswire.com/news-releases/ambrx-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick--foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-ambrx-biopharma-inc---amam-302046072.html",
    "time_published": "20240127T041700",
    "authors": [
      "Kahn Swick & Foti",
      "LLC"
    ],
    "summary": "AMBRX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/2170784/Latest_KSF_M_A_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.210541,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMAM",
        "relevance_score": "0.451494",
        "ticker_sentiment_score": "0.195991",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.451494",
        "ticker_sentiment_score": "0.195991",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why It Matters That Consumers Are So Enraged By The Kyte Baby Debacle",
    "url": "https://www.forbes.com/sites/soniathompson/2024/01/28/why-it-matters-that-consumers-are-so-enraged-by-the-kyte-baby-debacle/",
    "time_published": "20240128T164903",
    "authors": [
      "Sonia Thompson"
    ],
    "summary": "Data shows that 71% of consumers want to know the brands they buy from are aligned with their values. And increasingly, real life examples continue to pop up that showcase consumers exercising their credit card activism by refusing to support brands that they feel are either not aligned with ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65b57ab57a268cd588be5e5c/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.331783,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.043342",
        "ticker_sentiment_score": "0.081831",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "20 \"Tech\" Stocks Make Up Over 35% of the S&P 500. Here's What That Means for Your Portfolio.",
    "url": "https://www.fool.com/investing/2024/01/28/20-tech-stocks-sp-500-buy-2024-invest/",
    "time_published": "20240128T152000",
    "authors": [
      "Daniel Foelber"
    ],
    "summary": "The stock market isn't what it used to be.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F762430%2Fgettyimages-1190875206-1201x801-d21b45d.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.133088,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.087027",
        "ticker_sentiment_score": "0.074589",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.087027",
        "ticker_sentiment_score": "0.042305",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.043579",
        "ticker_sentiment_score": "0.1158",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.043579",
        "ticker_sentiment_score": "0.18538",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.043579",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSCO",
        "relevance_score": "0.043579",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.043579",
        "ticker_sentiment_score": "0.1158",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.087027",
        "ticker_sentiment_score": "-0.007225",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "-0.007077",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TXN",
        "relevance_score": "0.043579",
        "ticker_sentiment_score": "0.18538",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.043579",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.043579",
        "ticker_sentiment_score": "-0.003913",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.046066",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.087027",
        "ticker_sentiment_score": "0.042305",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.043579",
        "ticker_sentiment_score": "-0.003913",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QCOM",
        "relevance_score": "0.043579",
        "ticker_sentiment_score": "0.18538",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.043579",
        "ticker_sentiment_score": "-0.011761",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOW",
        "relevance_score": "0.043579",
        "ticker_sentiment_score": "0.18538",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.087027",
        "ticker_sentiment_score": "-0.007225",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "-0.007077",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.043579",
        "ticker_sentiment_score": "0.18538",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.043579",
        "ticker_sentiment_score": "-0.003913",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.043579",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.087027",
        "ticker_sentiment_score": "-0.009277",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.043579",
        "ticker_sentiment_score": "0.050725",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs",
    "url": "https://www.cnbc.com/2024/01/28/big-pharma-merck-bristol-myers-jj-prepare-to-lose-revenue.html",
    "time_published": "20240128T130001",
    "authors": [
      "Annika Kim Constantino"
    ],
    "summary": "Fast-approaching patent expirations will take a bite out of revenues and put the industry's top players in the hot seat over the next few years.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107343469-1701804491567-JJ-OB-Photo-ACJ-PRESS-1.jpg?v=1701804667&w=1920&h=1080",
    "source": "CNBC",
    "category_within_source": "Business",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999993"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.007249,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "HESG",
        "relevance_score": "0.021427",
        "ticker_sentiment_score": "0.115639",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.021427",
        "ticker_sentiment_score": "-0.120651",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KRTX",
        "relevance_score": "0.021427",
        "ticker_sentiment_score": "0.076984",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SKXJF",
        "relevance_score": "0.021427",
        "ticker_sentiment_score": "-0.049995",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.021427",
        "ticker_sentiment_score": "0.054415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.042838",
        "ticker_sentiment_score": "-0.019872",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.021427",
        "ticker_sentiment_score": "-0.049995",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.085553",
        "ticker_sentiment_score": "0.030376",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Want to Invest $1,000 in the \"Magnificent Seven?\" Invest This Amount in an S&P 500 Index Fund",
    "url": "https://www.fool.com/investing/2024/01/28/invest-magnificent-seven-stock-sp-500-fund/",
    "time_published": "20240128T125500",
    "authors": [
      "Daniel Foelber"
    ],
    "summary": "The stock market has become more concentrated than ever before.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F762009%2Fmeeting-business-financial-planning-woman-wheelchair-disability-1200x800-5b2df79.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99986"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.375374,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.050786",
        "ticker_sentiment_score": "0.092402",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.050786",
        "ticker_sentiment_score": "0.038918",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.101367",
        "ticker_sentiment_score": "0.041458",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.050786",
        "ticker_sentiment_score": "0.188381",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.050786",
        "ticker_sentiment_score": "0.038918",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.050786",
        "ticker_sentiment_score": "0.188381",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.050786",
        "ticker_sentiment_score": "0.096735",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.050786",
        "ticker_sentiment_score": "0.096735",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TXN",
        "relevance_score": "0.050786",
        "ticker_sentiment_score": "0.038918",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.050786",
        "ticker_sentiment_score": "0.096735",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.101367",
        "ticker_sentiment_score": "0.041458",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.050786",
        "ticker_sentiment_score": "0.188381",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.050786",
        "ticker_sentiment_score": "0.096735",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QCOM",
        "relevance_score": "0.050786",
        "ticker_sentiment_score": "0.038918",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOW",
        "relevance_score": "0.050786",
        "ticker_sentiment_score": "0.038918",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.050786",
        "ticker_sentiment_score": "0.096735",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.050786",
        "ticker_sentiment_score": "0.096735",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.050786",
        "ticker_sentiment_score": "0.038918",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.050786",
        "ticker_sentiment_score": "0.096735",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Investing Has Its Own Lingo. We'll Help You Understand It.",
    "url": "https://www.fool.com/investing/2024/01/28/investing-has-its-own-lingo-well-help-you-understa/",
    "time_published": "20240128T092500",
    "authors": [
      "Motley Fool Staff"
    ],
    "summary": "We're here to make you smarter, happier, and richer, and today we're focusing on the smarter part.",
    "banner_image": "https://g.foolcdn.com/editorial/images/760956/image.jpeg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "1.0"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.166031,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HMELF",
        "relevance_score": "0.004249",
        "ticker_sentiment_score": "-0.025413",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.004249",
        "ticker_sentiment_score": "0.040853",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.004249",
        "ticker_sentiment_score": "0.040853",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CWH",
        "relevance_score": "0.004249",
        "ticker_sentiment_score": "-0.005172",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.008497",
        "ticker_sentiment_score": "0.14092",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.004249",
        "ticker_sentiment_score": "0.136298",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NYT",
        "relevance_score": "0.004249",
        "ticker_sentiment_score": "0.162933",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study",
    "url": "https://www.globenewswire.com/news-release/2024/01/29/2819438/0/en/Nanobiotix-Announces-Achievement-of-20M-Development-Milestone-Payment-Related-to-Ongoing-Global-Phase-3-Head-and-Neck-Cancer-Study.html",
    "time_published": "20240129T211500",
    "authors": [
      "Nanobiotix S.A."
    ],
    "summary": "PARIS and CAMBRIDGE, Mass., Jan. 29, 2024 ( GLOBE NEWSWIRE ) -- NANOBIOTIX ( Euronext : NANO -- NASDAQ: NBTX - the ''Company'' ) , a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/36fb7b98-27d7-46cb-b989-fa31626657b8",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.071739,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NBTX",
        "relevance_score": "0.534927",
        "ticker_sentiment_score": "0.076567",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.038843",
        "ticker_sentiment_score": "-0.005935",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:NANO",
        "relevance_score": "0.038843",
        "ticker_sentiment_score": "-0.005935",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study - Nanobiotix  ( NASDAQ:NBTX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36833599/nanobiotix-announces-achievement-of-20m-development-milestone-payment-related-to-ongoing-global-ph",
    "time_published": "20240129T211500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "PARIS and CAMBRIDGE, Mass., Jan. 29, 2024 ( GLOBE NEWSWIRE ) -- NANOBIOTIX NBTX, a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced achievement of operational requirements in NANORAY-312, an ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.069285,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NBTX",
        "relevance_score": "0.558976",
        "ticker_sentiment_score": "0.075064",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.038407",
        "ticker_sentiment_score": "-0.00593",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cartilage Degeneration Market Size Is Expected To Reach A Value Of More Than $15 Billion By 2028 As Per The Business Research Company's Cartilage Degeneration Global Market Report 2024",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36828226/cartilage-degeneration-market-size-is-expected-to-reach-a-value-of-more-than-15-billion-by-2028-as",
    "time_published": "20240129T163000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LONDON, Jan. 29, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Cartilage Degeneration Global Market Report 2024, the global cartilage degeneration market has witnessed a substantial upswing, with the market size surging from $11.88 billion in 2023 to $12.63 billion in 2024, ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.130274,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ZBH",
        "relevance_score": "0.116631",
        "ticker_sentiment_score": "0.053561",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.058472",
        "ticker_sentiment_score": "0.047017",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.058472",
        "ticker_sentiment_score": "0.047017",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.058472",
        "ticker_sentiment_score": "0.047017",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson To Pay $149M In Opioid Settlement, Washington State AG Says 'We Are Not Done' - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/markets/cannabis/24/01/36828018/johnson-johnson-to-pay-149m-in-opioid-settlement-washington-state-ag-says-we-are-not-done",
    "time_published": "20240129T161942",
    "authors": [
      "Nina Zdinjak"
    ],
    "summary": "Opioid producer and raw material supplier Johnson & Johnson JNJ reached a settlement last week in an opioid lawsuit with Washington state.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/New-Project-124.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.078188,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.331765",
        "ticker_sentiment_score": "-0.067945",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2216975/johnson-johnson-jnj-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20240129T140009",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default318.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.22202,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.474082",
        "ticker_sentiment_score": "0.150631",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Better Buy in 2024: The \"Magnificent Seven\" or the \"Terrific 10\"?",
    "url": "https://www.fool.com/investing/2024/01/29/better-buy-the-magnificent-seven-or-terrific-ten/",
    "time_published": "20240129T112600",
    "authors": [
      "Daniel Foelber"
    ],
    "summary": "The financial and healthcare sectors make up a massive amount of the market.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F762431%2Fgettyimages-1419726675-1201x633-65d4be6.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999956"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.857896"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.333127,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.068995",
        "ticker_sentiment_score": "0.101721",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.03453",
        "ticker_sentiment_score": "0.122273",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.03453",
        "ticker_sentiment_score": "0.201917",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.068995",
        "ticker_sentiment_score": "0.120472",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.137474",
        "ticker_sentiment_score": "0.163389",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.068995",
        "ticker_sentiment_score": "0.111863",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.204936",
        "ticker_sentiment_score": "0.271149",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.068995",
        "ticker_sentiment_score": "0.101721",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.03453",
        "ticker_sentiment_score": "0.122273",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.171363",
        "ticker_sentiment_score": "0.256013",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.03453",
        "ticker_sentiment_score": "0.103812",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.068995",
        "ticker_sentiment_score": "0.144218",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.137474",
        "ticker_sentiment_score": "0.127343",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.238133",
        "ticker_sentiment_score": "0.303144",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.171363",
        "ticker_sentiment_score": "0.277563",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Dementia and Movement Disorder Treatment Market to Grow by USD 8.55 billion, Market Share, Trends, and Growth ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/dementia-and-movement-disorder-treatment-market-to-grow-by-usd-8-55-billion-market-share-trends-and-growth-analysis----technavio-302045378.html",
    "time_published": "20240129T101500",
    "authors": [],
    "summary": "Dementia and Movement Disorder Treatment Market to Grow by USD 8.55 billion, Market Share, Trends, and Growth ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.263428,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.125702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NBIX",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.125702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SUPN",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.125702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.125702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.125702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KNBWF",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.125702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMRX",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.125702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OGN",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.125702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ACOR",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.125702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.125702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHC",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.125702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UCBJF",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.125702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.125702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.125702",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Healthy Returns: J&J, Merck and Bristol Myers Squibb are in the hot seat",
    "url": "https://www.cnbc.com/2024/01/30/healthy-returns-jj-merck-and-bristol-myers-squibb-in-the-hot-seat.html",
    "time_published": "20240130T185254",
    "authors": [
      "Ashley Capoot",
      "Annika Kim Constantino"
    ],
    "summary": "J&J, Merck and Bristol Myers Squibb face a pivotal few weeks ahead. Meanwhile, Apple will reportedly explore health applications for the Vision Pro headset.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107364710-17062139992021-11-18t014239z_377529114_rc2hwq9kgx1y_rtrmadp_0_merck-co-results.jpeg?v=1706214040&w=1920&h=1080",
    "source": "CNBC",
    "category_within_source": "Business",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.094894,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BMY",
        "relevance_score": "0.15347",
        "ticker_sentiment_score": "-0.00411",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.038592",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Blue Chip Stocks To Watch Ahead Of February 2024",
    "url": "https://stockmarket.com/featured/3-blue-chip-stocks-to-watch-ahead-of-february-2024-2024-01-30",
    "time_published": "20240130T155412",
    "authors": [
      "Joe Samuel"
    ],
    "summary": "Investing in the stock market offers individuals the opportunity to own a share of a company's assets and earnings. It's a way to grow wealth over time, though it comes with varying levels of risk.",
    "banner_image": "https://u3j7m9h7.rocketcdn.me/wp-content/uploads/2023/07/PG-stock.jpg",
    "source": "StockMarket.com",
    "category_within_source": "n/a",
    "source_domain": "stockmarket.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.998663"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.248002,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IBM",
        "relevance_score": "0.411656",
        "ticker_sentiment_score": "0.411834",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.300946",
        "ticker_sentiment_score": "0.227503",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.300946",
        "ticker_sentiment_score": "0.355109",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Drug, Biotech Stocks' Q4 Earnings Due on Jan 31: NVO, NVS & GSK",
    "url": "https://www.zacks.com/stock/news/2217797/drug-biotech-stocks-q4-earnings-due-on-jan-31-nvo-nvs-gsk",
    "time_published": "20240130T140900",
    "authors": [
      "Ahan Chakraborty"
    ],
    "summary": "Let's look at three biotech/drug companies, NVO, NVS and GSK, slated to release quarterly results on Jan 31.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/34/973.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.224479,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVS",
        "relevance_score": "0.219809",
        "ticker_sentiment_score": "0.103918",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GSK",
        "relevance_score": "0.374714",
        "ticker_sentiment_score": "0.159687",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.374714",
        "ticker_sentiment_score": "0.176099",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.110973",
        "ticker_sentiment_score": "0.255206",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "1 Mental Trick You Can Use If You Want to Invest in the S&P 500 but Don't Like the \"Magnificent Seven\"",
    "url": "https://www.fool.com/investing/2024/01/30/mental-trick-buy-market-magnificent-seven-stocks/",
    "time_published": "20240130T140300",
    "authors": [
      "Daniel Foelber"
    ],
    "summary": "These seven companies alone make up more than $12 trillion in value.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F761903%2Fcouple-planning-finances-budget-1200x800-5b2df79.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.244147,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.149192",
        "ticker_sentiment_score": "0.188803",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.112182",
        "ticker_sentiment_score": "0.176975",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.149192",
        "ticker_sentiment_score": "0.193824",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.037504",
        "ticker_sentiment_score": "0.107902",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.037504",
        "ticker_sentiment_score": "0.136778",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.037504",
        "ticker_sentiment_score": "0.136778",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.112182",
        "ticker_sentiment_score": "0.142505",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.149192",
        "ticker_sentiment_score": "0.188803",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.037504",
        "ticker_sentiment_score": "0.136778",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.037504",
        "ticker_sentiment_score": "0.136778",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.037504",
        "ticker_sentiment_score": "0.136778",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.112182",
        "ticker_sentiment_score": "0.169208",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.037504",
        "ticker_sentiment_score": "0.136778",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Will Novo Nordisk Be a $1 Trillion Company by 2030?",
    "url": "https://www.fool.com/investing/2024/01/30/will-novo-nordisk-be-a-1-trillion-company-by-2030/",
    "time_published": "20240130T121500",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Novo Nordisk's market cap has ballooned thanks to the overwhelming success of its Ozempic, Wegovy, and Rybelsus medications.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F762672%2Fdoctor-checking-blood-pressure.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.905476"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.289671,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVO",
        "relevance_score": "0.630923",
        "ticker_sentiment_score": "0.426804",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.047749",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.047749",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.047749",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Wall Street's Greatest Dividend Stock Just Made History Again, and 99% of Investors Probably Don't Realize It Exists",
    "url": "https://www.fool.com/investing/2024/01/30/wall-street-greatest-dividend-stock-made-history/",
    "time_published": "20240130T102100",
    "authors": [
      "Sean Williams"
    ],
    "summary": "This virtually unknown company has been paying a consecutive dividend to its investors for more than 200 years.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F763000%2Fgetting-paid-dividends-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.191543,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "YORW",
        "relevance_score": "0.190267",
        "ticker_sentiment_score": "0.11675",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.114865",
        "ticker_sentiment_score": "0.079162",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWK",
        "relevance_score": "0.114865",
        "ticker_sentiment_score": "0.050688",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWKH",
        "relevance_score": "0.038407",
        "ticker_sentiment_score": "0.065567",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.152741",
        "ticker_sentiment_score": "0.231478",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.190267",
        "ticker_sentiment_score": "0.132779",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.038407",
        "ticker_sentiment_score": "0.151998",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Perfect Stocks for Retirees to Buy Hand Over Fist in the New Bull Market",
    "url": "https://www.fool.com/investing/2024/01/30/3-perfect-stocks-for-retirees-buy-new-bull-market/",
    "time_published": "20240130T100600",
    "authors": [
      "Sean Williams"
    ],
    "summary": "These industry-leading, time-tested companies are ideal for retired investors.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F762966%2Fsenior-reading-financial-newspaper-invest-dividend-retire-money-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999987"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.177882,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SPGI",
        "relevance_score": "0.027731",
        "ticker_sentiment_score": "0.08153",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TWOH",
        "relevance_score": "0.027731",
        "ticker_sentiment_score": "0.028885",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "T",
        "relevance_score": "0.271878",
        "ticker_sentiment_score": "0.071518",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "V",
        "relevance_score": "0.297826",
        "ticker_sentiment_score": "0.129413",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.137987",
        "ticker_sentiment_score": "0.068015",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( NYSE:JNJ )  Downgraded to \"Buy\" at StockNews.com",
    "url": "https://www.defenseworld.net/2024/01/30/johnson-johnson-nysejnj-downgraded-to-buy-at-stocknews-com.html",
    "time_published": "20240130T084445",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "StockNews.com lowered shares of Johnson & Johnson ( NYSE:JNJ - Free Report ) from a strong-buy rating to a buy rating in a research note published on Monday. Other analysts also recently issued research reports about the stock.",
    "banner_image": "https://www.marketbeat.com/logos/johnson--johnson-logo.png?v=20221020135923",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.752319"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.988915"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.243698,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "STT",
        "relevance_score": "0.098255",
        "ticker_sentiment_score": "0.17622",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.049221",
        "ticker_sentiment_score": "0.057808",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.049221",
        "ticker_sentiment_score": "0.057808",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.098255",
        "ticker_sentiment_score": "0.17622",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.75914",
        "ticker_sentiment_score": "0.398076",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Antibody drug conjugates focus draws global pharma giants attention to China, says GlobalData",
    "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/antibody-drug-conjugates-focus-draws-global-pharma-giants-attention-to-china-says-globaldata/3377889/",
    "time_published": "20240130T023000",
    "authors": [
      "Health Desk"
    ],
    "summary": "Antibody-drug conjugates ( ADCs ) represent a significant breakthrough in targeted cancer therapy. By blending the specificity of monoclonal antibodies with the potency of cytotoxic drugs, ADCs offer a targeted approach to cancer treatment, minimizing the damage to healthy cells.",
    "banner_image": "https://www.financialexpress.com/wp-content/uploads/2024/01/syring_b22200.jpg",
    "source": "The Financial Express",
    "category_within_source": "n/a",
    "source_domain": "www.financialexpress.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.169481,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GLDAF",
        "relevance_score": "0.194242",
        "ticker_sentiment_score": "0.047814",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXEL",
        "relevance_score": "0.097854",
        "ticker_sentiment_score": "0.031578",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.097854",
        "ticker_sentiment_score": "0.031578",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADAG",
        "relevance_score": "0.097854",
        "ticker_sentiment_score": "0.031578",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.097854",
        "ticker_sentiment_score": "0.031578",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.097854",
        "ticker_sentiment_score": "0.031578",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why ETF Yields Could Crash, And These 8%+ Payers Will Soar",
    "url": "https://www.forbes.com/sites/brettowens/2024/01/31/why-etf-yields-could-crash-and-these-8-payers-will-soar/",
    "time_published": "20240131T124500",
    "authors": [
      "Brett Owens"
    ],
    "summary": "This market bounce is strangling the payouts on everybody's favorite ETFs. But it's also given us a sweet setup to grab another group of funds kicking out big dividends, to the tune of 9%+ yields. Even better, many of these funds-wallflowers to \"popular-kid\" ETFs-were left off the invite list for ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65b3ebaadd4dc8c7a1cfb90b/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.147792,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.065061",
        "ticker_sentiment_score": "0.149255",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.065061",
        "ticker_sentiment_score": "0.149255",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "V",
        "relevance_score": "0.065061",
        "ticker_sentiment_score": "0.149255",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.065061",
        "ticker_sentiment_score": "0.149255",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Dividend Aristocrat List 2024: 10 Highest-Yielding Stocks",
    "url": "https://www.forbes.com/sites/investor-hub/article/dividend-aristocrats-list/",
    "time_published": "20240201T171128",
    "authors": [
      "Catherine Brock"
    ],
    "summary": "Dividend Aristocrats List 2024: 10 Highest-Yielding Stocks Forbes ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65bbc5ef215138a41b2b7af7/0x0.jpg?format=jpg&crop=3316,1866,x0,y287,safe&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.249969,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.081691",
        "ticker_sentiment_score": "0.146031",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DOV",
        "relevance_score": "0.061315",
        "ticker_sentiment_score": "0.087006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IBM",
        "relevance_score": "0.040899",
        "ticker_sentiment_score": "0.101282",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.102013",
        "ticker_sentiment_score": "0.153193",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.061315",
        "ticker_sentiment_score": "-0.052164",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Biden Administration Starts Negotiations Over Medicare Drug Prices-Here's How Prices May Be Affected",
    "url": "https://www.forbes.com/sites/tylerroush/2024/02/01/biden-administration-starts-negotiations-over-medicare-drug-prices-heres-how-prices-may-be-affected/",
    "time_published": "20240201T155916",
    "authors": [
      "Ty Roush"
    ],
    "summary": "The Biden Administration started negotiations on Thursday with the manufacturers of 10 drugs widely used by older Americans, as part of an effort to cut prescription prices for the costliest medications covered by Medicare, which federal officials estimate could save the health program an ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65bbbf6b3630d3d86b3603b7/0x0.jpg?format=jpg&crop=2510,1410,x0,y0,safe&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": -0.040623,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.068896",
        "ticker_sentiment_score": "-0.025316",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.068896",
        "ticker_sentiment_score": "-0.025316",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.068896",
        "ticker_sentiment_score": "-0.025316",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Q4 Earnings Beat, Raises Sales View for Key Drugs",
    "url": "https://www.zacks.com/stock/news/2220511/abbvie-abbv-q4-earnings-beat-raises-sales-view-for-key-drugs",
    "time_published": "20240202T180400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie???s (ABBV) fourth-quarter earnings and sales beat estimates. Management hikes the 2027 forecast for new immunology drugs to more than $27 billion.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d5/8276.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.998645"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.12283,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CHRS",
        "relevance_score": "0.036926",
        "ticker_sentiment_score": "-0.026577",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.036926",
        "ticker_sentiment_score": "0.126273",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.288893",
        "ticker_sentiment_score": "0.265849",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.146916",
        "ticker_sentiment_score": "0.01294",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GMAB",
        "relevance_score": "0.073773",
        "ticker_sentiment_score": "0.26213",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.073773",
        "ticker_sentiment_score": "0.131161",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "North America Cosmetic Surgery Market is Expected to Reach USD 29.2 billion, Advancing at a CAGR of 6.8% by 2031: Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/02/g36909586/north-america-cosmetic-surgery-market-is-expected-to-reach-usd-29-2-billion-advancing-at-a-cagr-of",
    "time_published": "20240202T140811",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Feb. 02, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The North America cosmetic surgery market is estimated to flourish at a CAGR of 6.8% from 2023 to 2031.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.430043,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MFCSF",
        "relevance_score": "0.035502",
        "ticker_sentiment_score": "0.25434",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.035502",
        "ticker_sentiment_score": "0.05021",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.035502",
        "ticker_sentiment_score": "0.366855",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BHC",
        "relevance_score": "0.070935",
        "ticker_sentiment_score": "0.253102",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.106227",
        "ticker_sentiment_score": "0.079304",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.035502",
        "ticker_sentiment_score": "0.162941",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Hold That Spinoff Stock: Selling Could Cost You Big",
    "url": "https://www.forbes.com/sites/jimosman/2024/02/04/hold-that-spinoff-stock-selling-could-cost-you-big/",
    "time_published": "20240204T160000",
    "authors": [
      "Jim Osman"
    ],
    "summary": "The legendary investor Peter Lynch once said, \"Invest in what you know.\" Lynch emphasized the importance of understanding the companies or investments you're involved in, suggesting that investors will make better decisions if they invest in industries or companies they're familiar with or have ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65beb7ef4281fc77cd49dc20/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999696"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.905476"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.682689"
      }
    ],
    "overall_sentiment_score": 0.338951,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MDLZ",
        "relevance_score": "0.01978",
        "ticker_sentiment_score": "0.069379",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KNF",
        "relevance_score": "0.079",
        "ticker_sentiment_score": "0.02953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MO",
        "relevance_score": "0.01978",
        "ticker_sentiment_score": "0.069379",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNOW",
        "relevance_score": "0.01978",
        "ticker_sentiment_score": "0.021224",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.01978",
        "ticker_sentiment_score": "0.054423",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.01978",
        "ticker_sentiment_score": "0.130559",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BROS",
        "relevance_score": "0.01978",
        "ticker_sentiment_score": "0.021224",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.01978",
        "ticker_sentiment_score": "0.069379",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ENOV",
        "relevance_score": "0.039548",
        "ticker_sentiment_score": "0.167857",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LOVE",
        "relevance_score": "0.01978",
        "ticker_sentiment_score": "0.021224",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZTS",
        "relevance_score": "0.01978",
        "ticker_sentiment_score": "0.069379",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FLEX",
        "relevance_score": "0.01978",
        "ticker_sentiment_score": "0.130559",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TOST",
        "relevance_score": "0.01978",
        "ticker_sentiment_score": "0.021224",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WOR",
        "relevance_score": "0.01978",
        "ticker_sentiment_score": "0.130559",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WS",
        "relevance_score": "0.01978",
        "ticker_sentiment_score": "0.130559",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PM",
        "relevance_score": "0.01978",
        "ticker_sentiment_score": "0.069379",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CXT",
        "relevance_score": "0.079",
        "ticker_sentiment_score": "0.103308",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.039548",
        "ticker_sentiment_score": "0.060121",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDU",
        "relevance_score": "0.098659",
        "ticker_sentiment_score": "0.030886",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NXT(EXP20091224)",
        "relevance_score": "0.01978",
        "ticker_sentiment_score": "0.130559",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:NXT",
        "relevance_score": "0.059292",
        "ticker_sentiment_score": "0.101062",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Healthcare Dividend Kings to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/02/04/2-healthcare-dividend-kings-to-buy-and-hold-foreve/",
    "time_published": "20240204T132000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "It's going to take a lot to interrupt these companies' streaks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/762995/physicians-in-an-operating-room.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.905476"
      }
    ],
    "overall_sentiment_score": 0.189542,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.154455",
        "ticker_sentiment_score": "0.085755",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.254573",
        "ticker_sentiment_score": "-0.096638",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Interim report for the first half of 2023/24 - Correction",
    "url": "https://www.globenewswire.com/news-release/2024/02/05/2823826/0/en/Interim-report-for-the-first-half-of-2023-24-Correction.html",
    "time_published": "20240205T204500",
    "authors": [
      "Chemometec A/S"
    ],
    "summary": "ANNOUNCEMENT NO. ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": -0.100028,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.194242",
        "ticker_sentiment_score": "0.061861",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.194242",
        "ticker_sentiment_score": "0.061861",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.194242",
        "ticker_sentiment_score": "0.061861",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "How Dr. Ted Love Sold His Sickle Cell Company To Pfizer For $5.4B",
    "url": "https://www.forbes.com/sites/shimiteobialo/2024/02/05/how-dr-ted-love-sold-sickle-cell-company-to-pfizer-for-54-billion/",
    "time_published": "20240205T200323",
    "authors": [
      "Shimite Obialo"
    ],
    "summary": "You may not have heard of Dr. Ted Love, a cardiologist turned biotech executive. however, you would have certainly heard of sickle cell disease, an inherited blood disorder that affects more than 100,000 people in the United States and 20 million people worldwide, most of whom are of African ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65c13d74349dd7667055910b/0x0.jpg?format=jpg&crop=2000,1125,x0,y167,safe&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.322661,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABIO",
        "relevance_score": "0.021274",
        "ticker_sentiment_score": "0.202027",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GPCR",
        "relevance_score": "0.021274",
        "ticker_sentiment_score": "0.18657",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RPRX",
        "relevance_score": "0.021274",
        "ticker_sentiment_score": "0.18657",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.127119",
        "ticker_sentiment_score": "0.209891",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.021274",
        "ticker_sentiment_score": "0.116465",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.042534",
        "ticker_sentiment_score": "0.225427",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Interim report 2023/24 - Full-year guidance maintained despite continued challenging market conditions",
    "url": "https://www.globenewswire.com/news-release/2024/02/05/2823798/0/en/Interim-report-2023-24-Full-year-guidance-maintained-despite-continued-challenging-market-conditions.html",
    "time_published": "20240205T190000",
    "authors": [
      "Chemometec A/S"
    ],
    "summary": "ANNOUNCEMENT NO. ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999996"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.10109,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.061003",
        "ticker_sentiment_score": "0.041",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.061003",
        "ticker_sentiment_score": "0.041",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.061003",
        "ticker_sentiment_score": "0.041",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "New Hope For Patients With Chronic Autoimmune Conditions: Johnson & Johnson's Investigational Drug Meets Primary Goal In Two Studies - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/02/36938146/new-hope-for-patients-with-chronic-autoimmune-conditions-johnson-johnsons-investigational-drug-me",
    "time_published": "20240205T181056",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Monday, Johnson & Johnson JNJ announced topline results from the pivotal Phase 3 VIVACITY study of nipocalimab in adults living with generalized myasthenia gravis ( gMG ) as well as the Phase 2 DAHLIAS study of nipocalimab in adults with Sj\u00f6gren's disease ( SjD ) .",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Lab-julia-koblitz-RlOAwXt2fEA-unsplash.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.057062,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ARGX",
        "relevance_score": "0.324495",
        "ticker_sentiment_score": "0.308213",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.324495",
        "ticker_sentiment_score": "0.214796",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson reports positive topline results for nipocalimab from a Phase 3 pivotal study in generalized myasthenia gravis  ( gMG )  and a Phase 2 study in Sj\u00f6gren's Disease  ( SjD ) ",
    "url": "https://www.prnewswire.com/news-releases/johnson--johnson-reports-positive-topline-results-for-nipocalimab-from-a-phase-3-pivotal-study-in-generalized-myasthenia-gravis-gmg-and-a-phase-2-study-in-sjogrens-disease-sjd-302053304.html",
    "time_published": "20240205T130000",
    "authors": [
      "Johnson & Johnson"
    ],
    "summary": "Johnson & Johnson reports positive topline results for nipocalimab from a Phase 3 pivotal study in generalized ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/2333578/Johnson_and_Johnson_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": -0.06027,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.280739",
        "ticker_sentiment_score": "0.088978",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Ophthalmic Equipment Market is Expected to Reach $88.5 Billion | MarketsandMarkets\u2122",
    "url": "https://www.benzinga.com/pressreleases/24/02/g36930112/ophthalmic-equipment-market-is-expected-to-reach-88-5-billion-marketsandmarkets",
    "time_published": "20240205T123000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Chicago, Feb. 05, 2024 ( GLOBE NEWSWIRE ) -- Ophthalmic Equipment market in terms of revenue was estimated to be worth $66.2 billion in 2023 and is poised to reach $88.5 billion by 2029, growing at a CAGR of 4.9% from 2023 to 2029 according to a latest report published by MarketsandMarkets\u2122.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.349313,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CAJFF",
        "relevance_score": "0.027288",
        "ticker_sentiment_score": "0.033467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COO",
        "relevance_score": "0.027288",
        "ticker_sentiment_score": "0.033467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESLOF",
        "relevance_score": "0.027288",
        "ticker_sentiment_score": "0.033467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.027288",
        "ticker_sentiment_score": "0.033467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STAA",
        "relevance_score": "0.027288",
        "ticker_sentiment_score": "0.033467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALC",
        "relevance_score": "0.027288",
        "ticker_sentiment_score": "0.033467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GKOS",
        "relevance_score": "0.027288",
        "ticker_sentiment_score": "0.033467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HOCPF",
        "relevance_score": "0.027288",
        "ticker_sentiment_score": "0.033467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHC",
        "relevance_score": "0.027288",
        "ticker_sentiment_score": "0.033467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TOPCF",
        "relevance_score": "0.027288",
        "ticker_sentiment_score": "0.033467",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Ophthalmology Devices Market to Grow by USD 19.93 billion from 2022 to 2027: North America to contribute 41 ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/ophthalmology-devices-market-to-grow-by-usd-19-93-billion-from-2022-to-2027-north-america-to-contribute-41---technavio-302052731.html",
    "time_published": "20240205T062400",
    "authors": [],
    "summary": "Ophthalmology Devices Market to Grow by USD 19.93 billion from 2022 to 2027: North America to contribute 41 ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.220083,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.074926",
        "ticker_sentiment_score": "0.098933",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Embolization Coil Market to grow by USD 481.9 million from 2022 to 2027, Abbott Laboratories and Achieva Medical ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/embolization-coil-market-to-grow-by-usd-481-9-million-from-2022-to-2027---abbott-laboratories-and-achieva-medical-are-among-the-key-companies--technavio-302053633.html",
    "time_published": "20240206T223600",
    "authors": [],
    "summary": "Embolization Coil Market to grow by USD 481.9 million from 2022 to 2027, Abbott Laboratories and Achieva Medical ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.127694,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MMSI",
        "relevance_score": "0.073321",
        "ticker_sentiment_score": "0.04126",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "0.04477",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.073321",
        "ticker_sentiment_score": "0.04126",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "0.063505",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRUMF",
        "relevance_score": "0.073321",
        "ticker_sentiment_score": "0.04126",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.073321",
        "ticker_sentiment_score": "0.04126",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PEN",
        "relevance_score": "0.073321",
        "ticker_sentiment_score": "0.04126",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.073321",
        "ticker_sentiment_score": "0.04126",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KANKF",
        "relevance_score": "0.073321",
        "ticker_sentiment_score": "0.04126",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.073321",
        "ticker_sentiment_score": "0.04126",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MCRPF",
        "relevance_score": "0.073321",
        "ticker_sentiment_score": "0.04126",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "How Big Tech is Helping Leverage Big Data in Healthcare",
    "url": "https://investingnews.com/big-tech-healthcare/",
    "time_published": "20240206T211500",
    "authors": [
      "Meagen Seatter"
    ],
    "summary": "While experts agree that Big Tech has the potential to improve patient outcomes by revolutionizing the way illnesses are diagnosed and treated, there are also challenges and ethical considerations when implementing AI in healthcare.",
    "banner_image": "https://investingnews.com/media-library/male-doctor-holding-cell-phone.jpg?id=51396674&width=1200&height=800&quality=85&coordinates=0%2C0%2C0%2C0",
    "source": "Investing News Network",
    "category_within_source": "n/a",
    "source_domain": "investingnews.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.251034,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "WLDS",
        "relevance_score": "0.021978",
        "ticker_sentiment_score": "0.131944",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.021978",
        "ticker_sentiment_score": "0.047445",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "icotec Medical Appoints Christoph Eigenmann as New US CEO and Promotes Carter Lonsberry to Executive Chairman ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/icotec-medical-appoints-christoph-eigenmann-as-new-us-ceo-and-promotes-carter-lonsberry-to-executive-chairman-of-the-board-302055071.html",
    "time_published": "20240206T182700",
    "authors": [],
    "summary": "icotec Medical Appoints Christoph Eigenmann as New US CEO and Promotes Carter Lonsberry to Executive Chairman ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.452745,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.072217",
        "ticker_sentiment_score": "0.214925",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Propelling Advances In Adrenal Cancer Diagnostics Market - Projected Market Size Of $180.09 Billion By 2028 As Per The Business Research Company's Adrenal Cancer Diagnostics Global Market Report 2024",
    "url": "https://www.benzinga.com/pressreleases/24/02/g36960048/propelling-advances-in-adrenal-cancer-diagnostics-market-projected-market-size-of-180-09-billion-b",
    "time_published": "20240206T163000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LONDON, Feb. 06, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's research on the adrenal cancer diagnostics market, the adrenal cancer diagnostics market has witnessed robust growth, with the market size increasing from $130.84 billion in 2023 to $140.35 billion in 2024, ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.121979,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.063258",
        "ticker_sentiment_score": "0.102537",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bristol Myers  ( BMY ) , TSVT CAR T-Cell Therapy to Face FDA's ODAC",
    "url": "https://www.zacks.com/stock/news/2221922/bristol-myers-bmy-tsvt-car-t-cell-therapy-to-face-fdas-odac",
    "time_published": "20240206T160300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Bristol Myers (BMY) and its partner TSVT announce that the FDA's ODAC will meet in March to review data supporting the label expansion for CAR T-cell therapy.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b7/2106.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.104,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "TSVT",
        "relevance_score": "0.205807",
        "ticker_sentiment_score": "0.057832",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.051999",
        "ticker_sentiment_score": "-0.073592",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.304428",
        "ticker_sentiment_score": "0.064204",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.051999",
        "ticker_sentiment_score": "-0.073592",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PBYI",
        "relevance_score": "0.205807",
        "ticker_sentiment_score": "0.142187",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Medicare now negotiating price of drug that costs $7,100 in US vs. $900 in Canada | Politics",
    "url": "https://www.cnn.com/2024/02/06/politics/medicare-drug-prices-eliquis-bernie-sanders/index.html",
    "time_published": "20240206T110000",
    "authors": [
      "Tami Luhby"
    ],
    "summary": "Medicare now negotiating price of drug that costs $7,100 in US vs. $900 in Canada ...",
    "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/2024-01-29t162708z-699916914-rc2rr5a8hwzx-rtrmadp-3-health-usa-drugpricing.JPG?c=16x9&q=w_800,c_fill",
    "source": "CNN",
    "category_within_source": "Markets",
    "source_domain": "www.cnn.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.045088,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BMY",
        "relevance_score": "0.081276",
        "ticker_sentiment_score": "0.043728",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.16171",
        "ticker_sentiment_score": "-0.002743",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Big oil's boring quarter was great news for investors",
    "url": "https://www.moneycontrol.com/news/opinion/big-oils-boring-quarter-was-great-news-for-investors-12205171.html",
    "time_published": "20240206T105855",
    "authors": [],
    "summary": "ExxonMobil Corp, Chevron Corp and Shell Plc all did in the fourth quarter what they'd promised: Start new oil and gas projects. cut costs. reward shareholders. Together, the Big Three returned more than $80 billion to shareholders last year, up from $78 billion in 2022 despite lower oil and gas ...",
    "banner_image": "https://images.moneycontrol.com/static-mcnews/2021/10/Zuckerberg-378x213.jpg?impolicy=website&width=168&height=118",
    "source": "Money Control",
    "category_within_source": "Economy",
    "source_domain": "www.moneycontrol.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.074568,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.047654",
        "ticker_sentiment_score": "0.075915",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.047654",
        "ticker_sentiment_score": "-0.026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HES",
        "relevance_score": "0.047654",
        "ticker_sentiment_score": "0.002999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.047654",
        "ticker_sentiment_score": "0.043348",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RTX",
        "relevance_score": "0.047654",
        "ticker_sentiment_score": "0.043348",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.047654",
        "ticker_sentiment_score": "-0.026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PXD",
        "relevance_score": "0.047654",
        "ticker_sentiment_score": "0.002999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RYDAF",
        "relevance_score": "0.047654",
        "ticker_sentiment_score": "-0.026",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( NYSE:JNJ )  Lifted to Strong-Buy at StockNews.com",
    "url": "https://www.defenseworld.net/2024/02/06/johnson-johnson-nysejnj-lifted-to-strong-buy-at-stocknews-com.html",
    "time_published": "20240206T062643",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Johnson & Johnson ( NYSE:JNJ - Get Free Report ) was upgraded by research analysts at StockNews.com from a \"buy\" rating to a \"strong-buy\" rating in a research note issued to investors on Tuesday.",
    "banner_image": "https://www.marketbeat.com/logos/johnson--johnson-logo-1200x675.png?v=20221020135923",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.752319"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.980716"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.253842,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "STT",
        "relevance_score": "0.106541",
        "ticker_sentiment_score": "0.2097",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.05339",
        "ticker_sentiment_score": "0.020972",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.05339",
        "ticker_sentiment_score": "0.020972",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DRVN",
        "relevance_score": "0.05339",
        "ticker_sentiment_score": "0.11403",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.159218",
        "ticker_sentiment_score": "0.150757",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.796741",
        "ticker_sentiment_score": "0.413641",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Looking Into Johnson & Johnson's Recent Short Interest - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/02/36991315/looking-into-johnson-johnsons-recent-short-interest",
    "time_published": "20240207T204525",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Johnson & Johnson's JNJ short percent of float has risen 19.23% since its last report. The company recently reported that it has 15.01 million shares sold short, which is 0.62% of all regular shares that are available for trading.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.265071,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.221819",
        "ticker_sentiment_score": "0.15378",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "As Merck, J&J, Bristol Myers CEOs face drug-pricing questions, real problems remain under the radar, experts say",
    "url": "https://www.marketwatch.com/story/merck-j-j-and-bristol-myers-ceos-face-drug-pricing-grilling-on-capitol-hill-but-experts-cite-deeper-problems-under-the-radar-3bd4055f",
    "time_published": "20240207T190800",
    "authors": [
      "Eleanor Laise"
    ],
    "summary": "Lawmakers have emphasized gaps between U.S. list prices and overseas costs for a handful of drugs made by the three drugmakers.",
    "banner_image": "https://images.mktw.net/im-70733191/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.016523,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DTATF",
        "relevance_score": "0.048523",
        "ticker_sentiment_score": "0.083115",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.144853",
        "ticker_sentiment_score": "0.051055",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.19231",
        "ticker_sentiment_score": "0.061905",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The global hydrogel dressing market size, as forecasted by Straits Research, is poised to hit USD 996.75 million by 2031, experiencing substantial growth at a CAGR of 9.9%",
    "url": "https://www.benzinga.com/pressreleases/24/02/g36983967/the-global-hydrogel-dressing-market-size-as-forecasted-by-straits-research-is-poised-to-hit-usd-99",
    "time_published": "20240207T153000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, United States, Feb. 07, 2024 ( GLOBE NEWSWIRE ) -- Hydrogel is an insoluble polymer chain network crucial in wound care due to its high moisture content, which prevents infections by inhibiting microbes.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.124153,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.03473",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNN",
        "relevance_score": "0.069394",
        "ticker_sentiment_score": "0.059986",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.069394",
        "ticker_sentiment_score": "0.059986",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.069394",
        "ticker_sentiment_score": "0.071166",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IART",
        "relevance_score": "0.069394",
        "ticker_sentiment_score": "0.071166",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NXGL",
        "relevance_score": "0.03473",
        "ticker_sentiment_score": "-0.024704",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MMM",
        "relevance_score": "0.03473",
        "ticker_sentiment_score": "-0.072045",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLPBY",
        "relevance_score": "0.03473",
        "ticker_sentiment_score": "-0.072045",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.03473",
        "ticker_sentiment_score": "0.176515",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CNVVF",
        "relevance_score": "0.069394",
        "ticker_sentiment_score": "0.071166",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Global Dental Floss Market Size is Estimated to Reach USD 955.21 Million by 2031, Growing at a CAGR of 4.96%: Straits Research",
    "url": "https://www.benzinga.com/pressreleases/24/02/g36983131/global-dental-floss-market-size-is-estimated-to-reach-usd-955-21-million-by-2031-growing-at-a-cagr",
    "time_published": "20240207T151000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, United States, Feb. 07, 2024 ( GLOBE NEWSWIRE ) -- Flossing is a fundamental dental hygiene technique because it removes the plaque between teeth, significantly contributing to periodontal diseases.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.198651,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CL",
        "relevance_score": "0.0367",
        "ticker_sentiment_score": "0.046552",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LIOPF",
        "relevance_score": "0.0367",
        "ticker_sentiment_score": "0.046552",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.0367",
        "ticker_sentiment_score": "0.046552",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PBH",
        "relevance_score": "0.0367",
        "ticker_sentiment_score": "0.046552",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.0367",
        "ticker_sentiment_score": "0.046552",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PRGO",
        "relevance_score": "0.0367",
        "ticker_sentiment_score": "0.046552",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Arkuda Therapeutics Announces Option and Asset Purchase Agreement",
    "url": "https://www.prnewswire.com/news-releases/arkuda-therapeutics-announces-option-and-asset-purchase-agreement-302055075.html",
    "time_published": "20240207T120000",
    "authors": [
      "Arkuda Therapeutics"
    ],
    "summary": "- Arkuda to grant Janssen option to acquire Arkuda's portfolio of lysosomal function enhancers in exchange for upfront option payment and opportunity for additional milestone payments",
    "banner_image": "https://mma.prnewswire.com/media/2334811/Arkuda_Therapeutics_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.24302,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.12165",
        "ticker_sentiment_score": "0.021866",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.240489",
        "ticker_sentiment_score": "0.239986",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is Johnson & Johnson Stock a Buy Now?",
    "url": "https://www.fool.com/investing/2024/02/07/is-johnson-johnson-stock-a-buy-now/",
    "time_published": "20240207T102500",
    "authors": [
      "Justin Pope"
    ],
    "summary": "Don't overlook this boring company's stellar reliability.",
    "banner_image": "https://g.foolcdn.com/editorial/images/763633/johnson_and_johnson_employee_with_beaker_and_logo_on_coat_jnj.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.997874"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.253773,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.119235",
        "ticker_sentiment_score": "0.066764",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMAM",
        "relevance_score": "0.059785",
        "ticker_sentiment_score": "0.154009",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.451494",
        "ticker_sentiment_score": "0.243495",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Cementless Total Knee Arthroplasty (TKA) Market is to grow by USD 2.40 billion from 2022 to 2027, Aesculap Implants ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/cementless-total-knee-arthroplasty-tka-market-is-to-grow-by-usd-2-40-billion-from-2022-to-2027--aesculap-implants-systems-llc-and-allegra-orthopaedics-ltd-are-among-the-key-companies--technavio-302055145.html",
    "time_published": "20240207T033600",
    "authors": [],
    "summary": "Cementless Total Knee Arthroplasty ( TKA ) Market is to grow by USD 2.40 billion from 2022 to 2027, Aesculap Implants ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.20276,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ZBH",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNN",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CFMS",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MEDGF",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MCRPF",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "INVESTIGATION ALERT: Halper Sadeh LLC Investigates PGTI, FGH, AMAM - Ambrx Biopharma  ( NASDAQ:AMAM ) , FG Group Holdings  ( AMEX:FGH ) ",
    "url": "https://www.benzinga.com/pressreleases/24/02/g36971411/investigation-alert-halper-sadeh-llc-investigates-pgti-fgh-amam",
    "time_published": "20240207T022653",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, Feb. 06, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: PGT Innovations, Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.083378,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "PGTI",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "0.090541",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FGF",
        "relevance_score": "0.271274",
        "ticker_sentiment_score": "0.141792",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMAM",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "0.094182",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "0.094182",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma CEOs asked to defend high drug prices at Senate hearing - .com",
    "url": "https://www.upi.com/Top_News/US/2024/02/08/drug-prices-Senate-hearing/7771707428395/",
    "time_published": "20240208T220136",
    "authors": [],
    "summary": "Pharma CEOs asked to defend high drug prices at Senate hearing UPI News ...",
    "banner_image": "https://cdnph.upi.com/sv/ph/og/upi/7771707428395/2024/1/857e49d70155a011669b16c949edcc64/v1.5/Pharma-CEOs-asked-to-defend-high-drug-prices-at-Senate-hearing.jpg",
    "source": "UPI Business",
    "category_within_source": "n/a",
    "source_domain": "www.upi.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.088952,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BMY",
        "relevance_score": "0.22595",
        "ticker_sentiment_score": "0.014433",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.114137",
        "ticker_sentiment_score": "0.064201",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stocks: 5 Biggest Companies in 2024",
    "url": "https://investingnews.com/daily/life-science-investing/pharmaceutical-investing/top-10-pharmaceutical-companies/",
    "time_published": "20240208T211500",
    "authors": [
      "Meagen Seatter"
    ],
    "summary": "Companies in this sector are constantly researching and creating innovative treatments for various medical conditions, including immuno-oncology, neurology and rare diseases. In recent years, there has been a particular focus on developing new treatments for diabetes, weight loss and cancer.",
    "banner_image": "https://investingnews.com/media-library/pills-spilling-out-of-a-pill-bottle-on-a-yellow-background.jpg?id=32933343&width=1200&height=800&quality=85&coordinates=65%2C0%2C66%2C0",
    "source": "Investing News Network",
    "category_within_source": "n/a",
    "source_domain": "investingnews.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.129917,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.02118",
        "ticker_sentiment_score": "0.038373",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.02118",
        "ticker_sentiment_score": "0.045406",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.042346",
        "ticker_sentiment_score": "0.083975",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.042346",
        "ticker_sentiment_score": "0.070123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.042346",
        "ticker_sentiment_score": "0.089865",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.02118",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.02118",
        "ticker_sentiment_score": "0.111754",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "J&J, Merck and Bristol Myers CEOs, under fire on Capitol Hill, seek to turn up heat on drug-market middlemen",
    "url": "https://www.marketwatch.com/story/j-j-merck-and-bristol-myers-ceos-under-fire-on-capitol-hill-seek-to-turn-up-heat-on-drug-market-middlemen-abe1fc39",
    "time_published": "20240208T202900",
    "authors": [
      "Eleanor Laise"
    ],
    "summary": "Drugmakers grilled on the cost of prescription drugs on Capitol Hill Thursday sought to deflect the criticism onto drug-market middlemen who they said are pushing list prices for medications higher.",
    "banner_image": "https://images.mktw.net/im-48673845/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.076256,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BMY",
        "relevance_score": "0.100588",
        "ticker_sentiment_score": "0.008637",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.100588",
        "ticker_sentiment_score": "-0.039635",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Kenvue  ( KVUE )  Q4 2023 Earnings Call Transcript",
    "url": "https://www.fool.com/earnings/call-transcripts/2024/02/08/kenvue-kvue-q4-2023-earnings-call-transcript/",
    "time_published": "20240208T164514",
    "authors": [
      "Motley Fool Transcribing"
    ],
    "summary": "KVUE earnings call for the period ending December 31, 2023.",
    "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.682689"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.332108,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.062434",
        "ticker_sentiment_score": "0.164256",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.005208",
        "ticker_sentiment_score": "0.203606",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.005208",
        "ticker_sentiment_score": "0.203606",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CCORF",
        "relevance_score": "0.005208",
        "ticker_sentiment_score": "0.140894",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.015623",
        "ticker_sentiment_score": "0.143136",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "If Bernie Sanders is right about Big Pharma, why are the stocks doing so badly?",
    "url": "https://www.marketwatch.com/story/if-bernie-sanders-is-right-about-big-pharma-why-are-the-stocks-doing-so-badly-d7b07454",
    "time_published": "20240208T164500",
    "authors": [
      "Brett Arends"
    ],
    "summary": "Making money by investing in pharmaceutical companies isn't as easy as you might think.",
    "banner_image": "https://images.mktw.net/im-19753548/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.024123,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BMY",
        "relevance_score": "0.12546",
        "ticker_sentiment_score": "0.013304",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.166743",
        "ticker_sentiment_score": "0.015749",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's Why You Should Invest in Boston Scientific  ( BSX )  Now",
    "url": "https://www.zacks.com/stock/news/2223513/heres-why-you-should-invest-in-boston-scientific-bsx-now",
    "time_published": "20240208T153400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Investors are optimistic about Boston Scientific (BSX) on strength across the target market and upbeat guidance.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999476"
      }
    ],
    "overall_sentiment_score": 0.275819,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "UHS",
        "relevance_score": "0.20279",
        "ticker_sentiment_score": "0.149944",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EW",
        "relevance_score": "0.051221",
        "ticker_sentiment_score": "0.090462",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNN",
        "relevance_score": "0.051221",
        "ticker_sentiment_score": "0.090462",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ITGR",
        "relevance_score": "0.20279",
        "ticker_sentiment_score": "0.073558",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.051221",
        "ticker_sentiment_score": "0.090462",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.251941",
        "ticker_sentiment_score": "0.246126",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.051221",
        "ticker_sentiment_score": "0.090462",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.051221",
        "ticker_sentiment_score": "0.090462",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DVA",
        "relevance_score": "0.102231",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PXXXF",
        "relevance_score": "0.102231",
        "ticker_sentiment_score": "0.119803",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma CEOs Will Testify Today Over Prescription Drug Prices: Here's What To Watch For",
    "url": "https://www.forbes.com/sites/tylerroush/2024/02/08/pharma-ceos-will-testify-today-over-prescription-drug-prices-heres-what-to-watch-for/",
    "time_published": "20240208T152829",
    "authors": [
      "Ty Roush"
    ],
    "summary": "Chief executives from three major pharmaceutical companies will testify before a Senate committee on Thursday, following a back-and-forth with Sen. Bernie Sanders ( I-Vt. ) , who has accused the firms of overcharging Americans for prescription drugs.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65c4f258ec6a6b22d51c0160/0x0.jpg?format=jpg&crop=3696,2078,x0,y378,safe&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.0,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MRNA",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.053732",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.076847",
        "ticker_sentiment_score": "0.042438",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.076847",
        "ticker_sentiment_score": "-0.008213",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.227716",
        "ticker_sentiment_score": "-0.021698",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.076847",
        "ticker_sentiment_score": "0.042438",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Global Acne Treatment Market Revenue is Estimated to Reach USD 9,138.04 million by 2031, Growing at a CAGR of 5.13%: Straits Research",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37010173/global-acne-treatment-market-revenue-is-estimated-to-reach-usd-9-138-04-million-by-2031-growing-at",
    "time_published": "20240208T151000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, United States, Feb. 08, 2024 ( GLOBE NEWSWIRE ) -- Acne is a skin condition that results from clogged skin openings and pores, including hair follicles. Most people who tend to follow this order are teenagers and people in their early 20s.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.165401,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.038655",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VYNE",
        "relevance_score": "0.038655",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CPPSF",
        "relevance_score": "0.038655",
        "ticker_sentiment_score": "0.186339",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SSKN",
        "relevance_score": "0.038655",
        "ticker_sentiment_score": "0.093637",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRXPF",
        "relevance_score": "0.038655",
        "ticker_sentiment_score": "0.139792",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.038655",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.038655",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHC",
        "relevance_score": "0.038655",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LBTSF",
        "relevance_score": "0.038655",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Kenvue's stock slides 2.6% as J & J spinoff's revenue and guidance fall short of expectations",
    "url": "https://www.marketwatch.com/story/j-j-spinoff-kenvue-stock-loses-ground-as-profit-drops-ddbc804d",
    "time_published": "20240208T124100",
    "authors": [
      "Ciara Linnane",
      "Steve Gelsi"
    ],
    "summary": "The company said it will prioritize its U.S. skin-health and beauty business in 2024, and aim to reach more consumers and invest in its brands.",
    "banner_image": "https://images.mktw.net/im-775991/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928769"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.113362,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.362505",
        "ticker_sentiment_score": "0.187614",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.246582",
        "ticker_sentiment_score": "-0.066709",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Senators to question Merck, J&J and Bristol Myers Squibb CEOs over high U.S. drug pricing",
    "url": "https://www.cnbc.com/2024/02/08/jj-merck-bristol-myers-squibb-ceos-senate-drug-price-hearing.html",
    "time_published": "20240208T120001",
    "authors": [
      "Annika Kim Constantino"
    ],
    "summary": "The push to cut drug prices is one of those rare hot-button issues that unites the two major political parties.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107370419-1707331495916-gettyimages-1953244670-sanders_BC_183_012524JPG.jpeg?v=1707350713&w=1920&h=1080",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      }
    ],
    "overall_sentiment_score": 0.065922,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BABA",
        "relevance_score": "0.043658",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.043658",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.415927",
        "ticker_sentiment_score": "0.069353",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.087185",
        "ticker_sentiment_score": "0.120631",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.043658",
        "ticker_sentiment_score": "-0.130701",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Medical Device Technologies Market is Anticipated to Reach USD 662.7 billion by 2028: Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37004095/medical-device-technologies-market-is-anticipated-to-reach-usd-662-7-billion-by-2028-transparency-",
    "time_published": "20240208T120000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Feb. 08, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global medical device technologies market is estimated to flourish at a CAGR of 4.3% from 2021 to 2028.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.423859,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.031612",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.063174",
        "ticker_sentiment_score": "0.107762",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.031612",
        "ticker_sentiment_score": "0.12322",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.063174",
        "ticker_sentiment_score": "0.317822",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "OCPNF",
        "relevance_score": "0.031612",
        "ticker_sentiment_score": "0.148981",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WLDS",
        "relevance_score": "0.031612",
        "ticker_sentiment_score": "0.145032",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.094638",
        "ticker_sentiment_score": "0.1079",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.031612",
        "ticker_sentiment_score": "0.221755",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNN",
        "relevance_score": "0.031612",
        "ticker_sentiment_score": "0.333601",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.063174",
        "ticker_sentiment_score": "0.193004",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.031612",
        "ticker_sentiment_score": "0.333601",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TRUMF",
        "relevance_score": "0.031612",
        "ticker_sentiment_score": "0.148981",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAX",
        "relevance_score": "0.031612",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.063174",
        "ticker_sentiment_score": "0.193004",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Decabillionaire Dynasties: These Are The Richest Families In America",
    "url": "https://www.forbes.com/sites/mattdurot/2024/02/08/americas-richest-families-10-billion-waltons-mars-kochs-rockefeller-decabillionaire-dynasties/",
    "time_published": "20240208T113000",
    "authors": [
      "Matt Durot"
    ],
    "summary": "America's Richest Families 2024 Forbes ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65c3fda2ca7bdc4c0f3f7d05/0x0.jpg?format=jpg&crop=1920,1080,x0,y0,safe&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.998356"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.094113,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DD",
        "relevance_score": "0.007269",
        "ticker_sentiment_score": "0.025415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.014537",
        "ticker_sentiment_score": "0.038755",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SCU",
        "relevance_score": "0.007269",
        "ticker_sentiment_score": "-0.03251",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JOUT",
        "relevance_score": "0.007269",
        "ticker_sentiment_score": "-0.019945",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.007269",
        "ticker_sentiment_score": "0.026525",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "H",
        "relevance_score": "0.029069",
        "ticker_sentiment_score": "0.042992",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPG",
        "relevance_score": "0.007269",
        "ticker_sentiment_score": "0.016838",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "L",
        "relevance_score": "0.021804",
        "ticker_sentiment_score": "0.042007",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ITW",
        "relevance_score": "0.014537",
        "ticker_sentiment_score": "0.035689",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.007269",
        "ticker_sentiment_score": "0.025415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RITM",
        "relevance_score": "0.007269",
        "ticker_sentiment_score": "-0.03251",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WLK",
        "relevance_score": "0.007269",
        "ticker_sentiment_score": "0.022102",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GD",
        "relevance_score": "0.021804",
        "ticker_sentiment_score": "-0.065217",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PSA",
        "relevance_score": "0.014537",
        "ticker_sentiment_score": "-0.040106",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AA",
        "relevance_score": "0.007269",
        "ticker_sentiment_score": "0.114061",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTRS",
        "relevance_score": "0.007269",
        "ticker_sentiment_score": "0.033558",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.007269",
        "ticker_sentiment_score": "0.019167",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.007269",
        "ticker_sentiment_score": "0.07316",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BF-A",
        "relevance_score": "0.007269",
        "ticker_sentiment_score": "0.019945",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.007269",
        "ticker_sentiment_score": "-0.003304",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BEN",
        "relevance_score": "0.007269",
        "ticker_sentiment_score": "-0.010896",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZD",
        "relevance_score": "0.007269",
        "ticker_sentiment_score": "-0.03251",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ICNB",
        "relevance_score": "0.007269",
        "ticker_sentiment_score": "0.002327",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ROL",
        "relevance_score": "0.007269",
        "ticker_sentiment_score": "0.018047",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CPB",
        "relevance_score": "0.007269",
        "ticker_sentiment_score": "0.016164",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.014537",
        "ticker_sentiment_score": "0.035689",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.007269",
        "ticker_sentiment_score": "0.058742",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MANU",
        "relevance_score": "0.007269",
        "ticker_sentiment_score": "0.01934",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTAS",
        "relevance_score": "0.007269",
        "ticker_sentiment_score": "-0.005586",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MAR",
        "relevance_score": "0.007269",
        "ticker_sentiment_score": "-0.035994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.021804",
        "ticker_sentiment_score": "0.103389",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.007269",
        "ticker_sentiment_score": "0.083218",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Johnson & Johnson a Good Dividend Stock to Buy Now?",
    "url": "https://www.fool.com/investing/2024/02/08/is-johnson-johnson-a-good-dividend-stock-to-buy-no/",
    "time_published": "20240208T103700",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "The healthcare conglomerate has been raising its dividend payout since Kennedy was president, but there have been some recent changes.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F762920%2Finvestor-looking-for-stocks-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.967321"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.122127,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.11894",
        "ticker_sentiment_score": "0.0395",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CURN",
        "relevance_score": "0.059636",
        "ticker_sentiment_score": "-0.091999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.11894",
        "ticker_sentiment_score": "0.056503",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.235252",
        "ticker_sentiment_score": "0.219396",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Drug Delivery Systems Market is Set to Increase to USD 71.6 billion, Registering a 6.8 % CAGR from 2023 to 2031 | Report by Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/02/g36997902/drug-delivery-systems-market-is-set-to-increase-to-usd-71-6-billion-registering-a-6-8-cagr-from-20",
    "time_published": "20240208T023000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Feb. 07, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - Drug delivery systems were valued at US$ 40.1 billion in 2022. A CAGR of 6.8% is expected between 2023 and 2031, reaching US$ 71.6 billion by 2031.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.261837,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.033098",
        "ticker_sentiment_score": "0.04966",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.033098",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.033098",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.033098",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.033098",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAX",
        "relevance_score": "0.033098",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.099066",
        "ticker_sentiment_score": "0.10858",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.066139",
        "ticker_sentiment_score": "0.043048",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Energy-Based Aesthetic Devices Market to grow by USD 1.75 billion from 2022 to 2027, Alma Lasers GmbH, Bausch ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/energy-based-aesthetic-devices-market-to-grow-by-usd-1-75-billion-from-2022-to-2027--alma-lasers-gmbh-bausch-health-co-inc-and-candela-corp-are-key-companies--technavio-302056710.html",
    "time_published": "20240208T011200",
    "authors": [],
    "summary": "Energy-Based Aesthetic Devices Market to grow by USD 1.75 billion from 2022 to 2027, Alma Lasers GmbH, Bausch ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.259903,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IRIX",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.044537",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VERO",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.044537",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CUTR",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.044537",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.044537",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - BBAI, PGTI, AMAM, FGH",
    "url": "https://www.benzinga.com/pressreleases/24/02/g36996709/investigation-the-m-a-class-action-firm-continues-investigating-the-merger-bbai-pgti-amam-fgh",
    "time_published": "20240208T003403",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, Feb. 07, 2024 ( GLOBE NEWSWIRE ) -- Monteverde & Associates PC ( the \"M&A Class Action Firm\" ) , has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.239163,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PGTI",
        "relevance_score": "0.366061",
        "ticker_sentiment_score": "0.356052",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "FGF",
        "relevance_score": "0.188193",
        "ticker_sentiment_score": "0.213212",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMAM",
        "relevance_score": "0.366061",
        "ticker_sentiment_score": "0.31508",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DOOR",
        "relevance_score": "0.094762",
        "ticker_sentiment_score": "0.153405",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.094762",
        "ticker_sentiment_score": "0.134411",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Top Research Reports for Johnson & Johnson, Walt Disney & Uber",
    "url": "https://www.zacks.com/research-daily/2223994/top-research-reports-for-johnson-johnson-walt-disney-uber",
    "time_published": "20240209T214200",
    "authors": [
      "Mark Vickery"
    ],
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), The Walt Disney Company (DIS) and Uber Technologies, Inc. (UBER).",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cf/2435.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.319902,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.087185",
        "ticker_sentiment_score": "0.035317",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.257442",
        "ticker_sentiment_score": "0.262544",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.087185",
        "ticker_sentiment_score": "0.011657",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What to think about 'Peak 65'",
    "url": "https://www.marketwatch.com/story/what-to-think-about-peak-65-d23f2413",
    "time_published": "20240209T190600",
    "authors": [
      "Philip van Doorn"
    ],
    "summary": "Also: Strategies to build a retirement nest egg and make it last, and a different way for investors to play the weight-loss-drug craze.",
    "banner_image": "https://images.mktw.net/im-74524387?width=700&height=486",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.992549"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.095345,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VKTX",
        "relevance_score": "0.085936",
        "ticker_sentiment_score": "0.071851",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.04303",
        "ticker_sentiment_score": "0.012989",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.128592",
        "ticker_sentiment_score": "-0.025551",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.085936",
        "ticker_sentiment_score": "-0.062043",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.128592",
        "ticker_sentiment_score": "0.022061",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WEWOW",
        "relevance_score": "0.04303",
        "ticker_sentiment_score": "0.093845",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NYCB",
        "relevance_score": "0.085936",
        "ticker_sentiment_score": "-0.045374",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.085936",
        "ticker_sentiment_score": "-0.062043",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Is Illumina Stock Trading Lower Today? - Illumina  ( NASDAQ:ILMN ) ",
    "url": "https://www.benzinga.com/news/earnings/24/02/37034941/dna-sequencing-kit-provider-illuminas-q4-earnings-edge-above-street-estimates-works-to-resolve-grai",
    "time_published": "20240209T143218",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Thursday, Illumina Inc ILMN reported fourth-quarter 2023 sales of $1.12 billion, up 4% Y/Y, beating the consensus of $1.09 billion. The company reported adjusted EPS of $0.14, surpassing the consensus estimate of $0.02.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/ILMN.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.285694,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ILMN",
        "relevance_score": "0.917585",
        "ticker_sentiment_score": "0.56318",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "0.334873",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Bernie Sanders Blasts Big Pharma's Pricing Of Lifesaving Drugs In US During Senate Hearing On Medicare - Johnson & Johnson  ( NYSE:JNJ ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
    "url": "https://www.benzinga.com/markets/cannabis/24/02/37034215/bernie-sanders-blasts-big-pharmas-pricing-of-lifesaving-drugs-in-us-during-senate-hearing-on-med",
    "time_published": "20240209T141014",
    "authors": [
      "Nina Zdinjak"
    ],
    "summary": "CEOs of Johnson & Johnson JNJ, Merck MRK and Bristol-Myers Squibb BMY defended the high prices of their drugs as they were grilled by the Senate Health Committee, led by Senator Bernie Sanders who submitted a report blasting the extravagant cost of three drugs.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/New-York--Usa---April-14--2016-President.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.105557,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NYT",
        "relevance_score": "0.063258",
        "ticker_sentiment_score": "0.024376",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.063258",
        "ticker_sentiment_score": "0.294697",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.126119",
        "ticker_sentiment_score": "-0.103185",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.126119",
        "ticker_sentiment_score": "-0.103185",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  is Attracting Investor Attention: Here is What You Should Know",
    "url": "https://www.zacks.com/stock/news/2223976/johnson-johnson-jnj-is-attracting-investor-attention-here-is-what-you-should-know",
    "time_published": "20240209T140011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default345.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.230814,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.481177",
        "ticker_sentiment_score": "0.14001",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "5 things to know for Feb. 9: Presidential race, Prescription drugs, Vladimir Putin, Red Sea, Volcano eruption",
    "url": "https://www.cnn.com/2024/02/09/us/5-things-to-know-for-feb-9-presidential-race-prescription-drugs-vladimir-putin-red-sea-volcano-eruption/index.html",
    "time_published": "20240209T115300",
    "authors": [
      "Alexandra Banner"
    ],
    "summary": "Astronomers have discovered a potentially habitable \"super-Earth\" around 137 light-years away. Its estimated size is one and a half times as wide as our planet, and research shows it may be able to hold the right temperature for liquid water to exist on its surface.",
    "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/240209020548-jill-dougherty-vladimir-putin-2.jpg?c=16x9&q=w_850,c_fill",
    "source": "CNN",
    "category_within_source": "Markets",
    "source_domain": "www.cnn.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.012203,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "TSLA",
        "relevance_score": "0.034381",
        "ticker_sentiment_score": "-0.231789",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "FOX",
        "relevance_score": "0.034381",
        "ticker_sentiment_score": "-0.057699",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.034381",
        "ticker_sentiment_score": "0.035347",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.034381",
        "ticker_sentiment_score": "0.035347",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Ophthalmology Surgical Devices Market Size Estimated to Reach USD 12.1 billion, Rising at a CAGR of 4.7% by 2031: Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37028724/ophthalmology-surgical-devices-market-size-estimated-to-reach-usd-12-1-billion-rising-at-a-cagr-of",
    "time_published": "20240209T093000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Feb. 09, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global ophthalmology surgical devices market is estimated to flourish at a CAGR of 4.7% from 2023 to 2031.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.382076,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.03545",
        "ticker_sentiment_score": "0.050198",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.215386",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "STAA",
        "relevance_score": "0.03545",
        "ticker_sentiment_score": "0.420624",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ALC",
        "relevance_score": "0.07083",
        "ticker_sentiment_score": "0.176899",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BLCO",
        "relevance_score": "0.07083",
        "ticker_sentiment_score": "0.176899",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GKOS",
        "relevance_score": "0.03545",
        "ticker_sentiment_score": "0.369733",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "HOCPF",
        "relevance_score": "0.07083",
        "ticker_sentiment_score": "0.144236",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IRIX",
        "relevance_score": "0.03545",
        "ticker_sentiment_score": "0.193516",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TOPCF",
        "relevance_score": "0.03545",
        "ticker_sentiment_score": "0.175472",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.099956",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.03545",
        "ticker_sentiment_score": "0.175472",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Senate panel grills pharmaceutical CEOs on drug prices: 'You bear a measure of responsibility'",
    "url": "https://www.cnn.com/2024/02/08/health/senate-hearing-drug-prices/index.html",
    "time_published": "20240209T001800",
    "authors": [
      "Jacqueline Howard"
    ],
    "summary": "US senators and pharmaceutical CEOs faced off in a hearing Thursday about why prescription drugs have higher price tags in the United States than in other nations.",
    "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/2024-01-29t162708z-699916914-rc2rr5a8hwzx-rtrmadp-3-health-usa-drugpricing.JPG?c=16x9&q=h_144,w_256,c_fill",
    "source": "CNN",
    "category_within_source": "Markets",
    "source_domain": "www.cnn.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.111311,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "WBD",
        "relevance_score": "0.027226",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.108589",
        "ticker_sentiment_score": "0.084372",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.081552",
        "ticker_sentiment_score": "0.050203",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors",
    "url": "https://www.globenewswire.com/news-release/2024/02/12/2827878/0/en/Connect-Biopharma-Appoints-Industry-Veteran-James-Huang-to-Board-of-Directors.html",
    "time_published": "20240212T213000",
    "authors": [
      "Connect Biopharma Holdings Limited"
    ],
    "summary": "SAN DIEGO, CA and TAICANG, China, Feb. 12, 2024 ( GLOBE NEWSWIRE ) -- Connect Biopharma Holdings Limited ( Nasdaq: CNTB ) ( \"Connect Biopharma\" or the \"Company\" ) , a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/6aecdeaf-3bef-4a9b-ba75-921c3ce2b6a5",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.152993,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CNTB",
        "relevance_score": "0.330102",
        "ticker_sentiment_score": "0.111969",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.042496",
        "ticker_sentiment_score": "0.06721",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.042496",
        "ticker_sentiment_score": "0.06721",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors - Connect Biopharma Hldgs  ( NASDAQ:CNTB ) ",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37080173/connect-biopharma-appoints-industry-veteran-james-huang-to-board-of-directors",
    "time_published": "20240212T213000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "James Huang brings over 30 years of biotech experience as a successful entrepreneur, investor and key opinion leader in the healthcare sector",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.145825,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CNTB",
        "relevance_score": "0.323608",
        "ticker_sentiment_score": "0.107821",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.04161",
        "ticker_sentiment_score": "0.064093",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.04161",
        "ticker_sentiment_score": "0.064093",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "A Look at Pharma ETFs After Q4 Earnings",
    "url": "https://www.zacks.com/stock/news/2224986/a-look-at-pharma-etfs-after-q4-earnings",
    "time_published": "20240212T175900",
    "authors": [
      "Sweta Killa"
    ],
    "summary": "The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs reported solid results, with some beating on earnings or revenues or both.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default282.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999996"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.054971,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.082251",
        "ticker_sentiment_score": "0.071368",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.123104",
        "ticker_sentiment_score": "0.058563",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.082251",
        "ticker_sentiment_score": "-0.003144",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.123104",
        "ticker_sentiment_score": "0.110586",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Infinite Reality, the Global Leader in Immersive Experiences, Acquires Spatial Web Pioneer Ethereal Engine - Newbury Street Acq  ( NASDAQ:NBST ) , Greenidge Generation Hldg  ( NASDAQ:GREE ) ",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37068471/infinite-reality-the-global-leader-in-immersive-experiences-acquires-spatial-web-pioneer-ethereal-",
    "time_published": "20240212T140021",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Virtual Experiences Leader Acquires Ethereal Engine in Share-For-Share Transaction Valuing Infinite Reality at $2.5 Billion and Ethereal Engine at $75 million Entire Ethereal Engine Team, Including Top Executives and Innovators, Has Joined Infinite Reality",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Mergers",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.314462,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NBST",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GREEL",
        "relevance_score": "0.045655",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.045655",
        "ticker_sentiment_score": "0.121313",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is It Too Late to Buy These 2 Brilliant Passive Income Stocks?",
    "url": "https://www.fool.com/investing/2024/02/12/is-it-too-late-to-buy-these-2-brilliant-passive-in/",
    "time_published": "20240212T123000",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "These incredible businesses have long histories of successes behind them, and more to come.",
    "banner_image": "https://g.foolcdn.com/editorial/images/764307/getty-couple-happy-in-kitchen.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.210293,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GLDAF",
        "relevance_score": "0.04028",
        "ticker_sentiment_score": "-0.022456",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.04028",
        "ticker_sentiment_score": "0.072597",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.04028",
        "ticker_sentiment_score": "0.041031",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.276313",
        "ticker_sentiment_score": "0.123407",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.313817",
        "ticker_sentiment_score": "0.154311",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Cancer Supportive Care Drugs Market to be Worth USD 16.7 billion by 2031, Advancing at a 1.7% CAGR |Exclusive Report by Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37064317/cancer-supportive-care-drugs-market-to-be-worth-usd-16-7-billion-by-2031-advancing-at-a-1-7-cagr-e",
    "time_published": "20240212T114728",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Feb. 12, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global cancer supportive care drugs market was projected to attain US$ 14.3 billion in 2022.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.076884,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.036926",
        "ticker_sentiment_score": "0.050513",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.110462",
        "ticker_sentiment_score": "0.053449",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HRTX",
        "relevance_score": "0.036926",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IUGNF",
        "relevance_score": "0.036926",
        "ticker_sentiment_score": "0.074185",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.036926",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "How Samuel Alito Became The Second-Richest Supreme Court Justice",
    "url": "https://www.forbes.com/sites/kylemullins/2024/02/12/how-samuel-alito-became-the-second-richest-supreme-court-justice/",
    "time_published": "20240212T113000",
    "authors": [
      "Kyle Mullins"
    ],
    "summary": "How Much Is Supreme Court Justice Samuel Alito Worth? Forbes ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65c682ca302c8646e809935a/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.130333,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "COP",
        "relevance_score": "0.022389",
        "ticker_sentiment_score": "0.083472",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.022389",
        "ticker_sentiment_score": "0.083472",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.022389",
        "ticker_sentiment_score": "0.053838",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Johnson & Johnson, Disney, Uber, Goldman Sachs and Elevance Health",
    "url": "https://www.zacks.com/stock/news/2224450/the-zacks-analyst-blog-highlights-johnson-johnson-disney-uber-goldman-sachs-and-elevance-health",
    "time_published": "20240212T110000",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Johnson & Johnson, Disney, Uber, Goldman Sachs and Elevance Health are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f6/446.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.267274,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.064623",
        "ticker_sentiment_score": "0.0335",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.128822",
        "ticker_sentiment_score": "0.038396",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.373378",
        "ticker_sentiment_score": "0.23186",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ELV",
        "relevance_score": "0.128822",
        "ticker_sentiment_score": "0.038396",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DIS",
        "relevance_score": "0.192183",
        "ticker_sentiment_score": "0.049362",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.254307",
        "ticker_sentiment_score": "0.047748",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Small Cell Lung Cancer Therapeutics Market To Witness Rapid Growth, Surpassing $10 Billion By 2028 As Per The Business Research Company's Small Cell Lung Cancer Therapeutics Global Market Report 2024",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37099046/small-cell-lung-cancer-therapeutics-market-to-witness-rapid-growth-surpassing-10-billion-by-2028-a",
    "time_published": "20240213T163000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LONDON, Feb. 13, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's small cell lung cancer therapeutics global market report 2024, the small cell lung cancer therapeutics market is poised for remarkable growth.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.002457,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "A",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.019125",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GTHX",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.019125",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.019125",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.019125",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Federal judge tosses lobbying group's lawsuit challenging Medicare drug price negotiations",
    "url": "https://www.cnbc.com/2024/02/13/medicare-drug-price-negotiations-judge-tosses-phrma-lawsuit.html",
    "time_published": "20240213T162830",
    "authors": [
      "Annika Kim Constantino"
    ],
    "summary": "The decision is an early win for the Biden administration as it grapples with other legal challenges to the Inflation Reduction Act's Medicare price talks.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107130655-1665090556176-gettyimages-1431082899-_m021740_4b5641b7-17d1-48f7-8db3-6aef2e513b99.jpeg?v=1707837044&w=1920&h=1080",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.143508,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.069495",
        "ticker_sentiment_score": "-0.110869",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.069495",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.069495",
        "ticker_sentiment_score": "-0.110869",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Gene Delivery System Market Size to Touch Around USD 10.0 billion, at a CAGR of 7.2% from 2023 to 2031: Report by Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37096872/gene-delivery-system-market-size-to-touch-around-usd-10-0-billion-at-a-cagr-of-7-2-from-2023-to-20",
    "time_published": "20240213T152500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Feb. 13, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global gene delivery system market is estimated to flourish at a CAGR of 7.2% from 2023 to 2031.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.376665,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SGMO",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "0.267177",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "0.04987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GNNSF",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "0.181458",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.067919",
        "ticker_sentiment_score": "0.30534",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "OXBDF",
        "relevance_score": "0.168726",
        "ticker_sentiment_score": "0.322112",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "0.139717",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.101725",
        "ticker_sentiment_score": "0.078237",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This $674 Million Deal Aims To Turn Your Body's Garbage Disposal Into A Disease Fighter",
    "url": "https://www.forbes.com/sites/alexknapp/2024/02/13/this-674-million-deal-aims-to-turn-your-bodys-garbage-disposal-into-a-disease-fighter/",
    "time_published": "20240213T120000",
    "authors": [
      "Alex Knapp"
    ],
    "summary": "he cellular processes that keep us alive produce a lot of waste. Which is why our cells have evolved a natural garbage disposal system, a group of special chemicals called \"protein degraders\" that break down unneeded junk in your body.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65c657baa5622357b682f2d8/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.167234,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BPMC",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.075969",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WM",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "-0.032024",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.141171",
        "ticker_sentiment_score": "0.08369",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.075969",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors - Cingulate  ( NASDAQ:CING ) , IMAC Hldgs  ( NASDAQ:BACK ) ",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37089299/cingulate-appoints-jay-roberts-bryan-lawrence-and-jeff-ervin-to-its-board-of-directors",
    "time_published": "20240213T114500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "KANSAS CITY, Kan., Feb. 13, 2024 ( GLOBE NEWSWIRE ) -- Cingulate Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.11557,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CING",
        "relevance_score": "0.341342",
        "ticker_sentiment_score": "0.029607",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BACK",
        "relevance_score": "0.095899",
        "ticker_sentiment_score": "0.07664",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VYNT",
        "relevance_score": "0.032035",
        "ticker_sentiment_score": "0.047518",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.064018",
        "ticker_sentiment_score": "0.223442",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors",
    "url": "https://www.globenewswire.com/news-release/2024/02/13/2828084/0/en/Cingulate-Appoints-Jay-Roberts-Bryan-Lawrence-and-Jeff-Ervin-to-its-Board-of-Directors.html",
    "time_published": "20240213T114500",
    "authors": [
      "Cingulate Inc."
    ],
    "summary": "Announcement Follows Recent Public Offering and Successful Capital Raising Activity Announcement Follows Recent Public Offering and Successful Capital Raising Activity ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/61f4cd24-74d3-4103-b8f8-a768ef66e0ec",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.972756"
      }
    ],
    "overall_sentiment_score": 0.134082,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CING",
        "relevance_score": "0.24316",
        "ticker_sentiment_score": "0.037754",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BACK",
        "relevance_score": "0.082204",
        "ticker_sentiment_score": "0.076474",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VYNT",
        "relevance_score": "0.027445",
        "ticker_sentiment_score": "0.048191",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.054857",
        "ticker_sentiment_score": "0.222931",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares U.S. Pharmaceuticals ETF  ( IHE ) ?",
    "url": "https://www.zacks.com/stock/news/2225205/should-you-invest-in-the-ishares-us-pharmaceuticals-etf-ihe",
    "time_published": "20240213T112007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default7.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.215642,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.068306",
        "ticker_sentiment_score": "0.032068",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.064698",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZTS",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.064698",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.044001",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.064698",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Fidelity MSCI Health Care Index ETF  ( FHLC ) ?",
    "url": "https://www.zacks.com/stock/news/2225206/should-you-invest-in-the-fidelity-msci-health-care-index-etf-fhlc",
    "time_published": "20240213T112007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default195.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.331073,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.050334",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.050334",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.050334",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "RTX Stock: Bull vs. Bear",
    "url": "https://www.fool.com/investing/2024/02/13/rtx-stock-bull-vs-bear/",
    "time_published": "20240213T104700",
    "authors": [
      "Scott Levine and Lee Samaha"
    ],
    "summary": "Clouds are on the horizon for RTX, but do they mean the stock's not worth buying?",
    "banner_image": "https://g.foolcdn.com/editorial/images/763703/a-silver-bull-and-bear-on-a-financial-chart.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.20964,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LMT",
        "relevance_score": "0.04912",
        "ticker_sentiment_score": "0.050997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.04912",
        "ticker_sentiment_score": "0.050997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.04912",
        "ticker_sentiment_score": "-0.027013",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Dow Stocks You Can Confidently Buy Now and Hold Forever",
    "url": "https://www.fool.com/investing/2024/02/13/3-dow-stocks-you-can-buy-now-and-hold-forever/",
    "time_published": "20240213T102100",
    "authors": [
      "Sean Williams"
    ],
    "summary": "Three highly profitable, time-tested Dow components have the necessary tools to make their patient shareholders notably richer.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F764927%2Fstock-chart-quote-bear-bull-trading-invest-short-options-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.190704,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AXP",
        "relevance_score": "0.035502",
        "ticker_sentiment_score": "0.032642",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.035502",
        "ticker_sentiment_score": "0.135904",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TWOH",
        "relevance_score": "0.035502",
        "ticker_sentiment_score": "0.18071",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.035502",
        "ticker_sentiment_score": "-0.030169",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "V",
        "relevance_score": "0.343755",
        "ticker_sentiment_score": "0.233522",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.176116",
        "ticker_sentiment_score": "0.058933",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Court dismisses pharmaceutical group's lawsuit over Medicare drug price programme",
    "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/court-dismisses-pharmaceutical-groups-lawsuit-over-medicare-drug-price-programme/3392958/",
    "time_published": "20240213T100238",
    "authors": [
      "Health Desk"
    ],
    "summary": "A federal judge has dismissed a lawsuit by the Pharmaceutical Research and Manufacturers of America ( PhRMA ) challenging a new program that allows Medicare to negotiate prices with drug companies for selected costly drugs. According to a report by news agency Reuters, U.S.",
    "banner_image": "https://www.financialexpress.com/wp-content/uploads/2024/02/painkillers-g0651a5da2_1920.jpg",
    "source": "The Financial Express",
    "category_within_source": "n/a",
    "source_domain": "www.financialexpress.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.218278,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.097457",
        "ticker_sentiment_score": "-0.155529",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.097457",
        "ticker_sentiment_score": "-0.155529",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "David Einhorn's Greenlight Capital adds Kenvue, ETFs and exits Southwestern Energy",
    "url": "https://www.marketwatch.com/story/david-einhorns-greenlight-capital-adds-kenvue-etfs-and-exits-southwestern-energy-47937929",
    "time_published": "20240214T233800",
    "authors": [
      "Joy Wiltermuth"
    ],
    "summary": "Greenlight Capital picks up a new stake in Kenvue Inc, formerly the consumer healthcare division of Johnson & Johnson.",
    "banner_image": "https://images.mktw.net/im-790959/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.007016,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.904419",
        "ticker_sentiment_score": "0.012492",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.733479",
        "ticker_sentiment_score": "-0.22896",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.733479",
        "ticker_sentiment_score": "0.199695",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Genmab Publishes 2023 Annual Report",
    "url": "https://www.globenewswire.com/news-release/2024/02/14/2829266/0/en/Genmab-Publishes-2023-Annual-Report.html",
    "time_published": "20240214T160200",
    "authors": [
      "Genmab A/S"
    ],
    "summary": "Company Announcement ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.134216,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GMAB",
        "relevance_score": "0.417611",
        "ticker_sentiment_score": "0.145663",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.024372",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZLAB",
        "relevance_score": "0.024372",
        "ticker_sentiment_score": "0.02372",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.024372",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.097259",
        "ticker_sentiment_score": "0.077179",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARGX",
        "relevance_score": "0.024372",
        "ticker_sentiment_score": "0.083727",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.024372",
        "ticker_sentiment_score": "0.017036",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.121404",
        "ticker_sentiment_score": "0.088215",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.024372",
        "ticker_sentiment_score": "0.083727",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Drug, Biotech Stock Q4 Earnings Due on Feb 15: ALNY, BPMC & More",
    "url": "https://www.zacks.com/stock/news/2226283/drug-biotech-stock-q4-earnings-due-on-feb-15-alny-bpmc-more",
    "time_published": "20240214T151200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Let's look at five biotech/drug companies, ALNY, BPMC, AGIO, CORT and RARE, slated to release quarterly results on Feb 15.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2297.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.120839,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CORT",
        "relevance_score": "0.159834",
        "ticker_sentiment_score": "0.056556",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AGIO",
        "relevance_score": "0.199037",
        "ticker_sentiment_score": "0.117008",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RARE",
        "relevance_score": "0.159834",
        "ticker_sentiment_score": "-0.078734",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "0.26205",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALNY",
        "relevance_score": "0.159834",
        "ticker_sentiment_score": "0.057876",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BPMC",
        "relevance_score": "0.237745",
        "ticker_sentiment_score": "0.139837",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "-0.237683",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Should iShares Core High Dividend ETF  ( HDV )  Be on Your Investing Radar?",
    "url": "https://www.zacks.com/stock/news/2225919/should-ishares-core-high-dividend-etf-hdv-be-on-your-investing-radar",
    "time_published": "20240214T112003",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Style Box ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default178.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.242251,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.060694",
        "ticker_sentiment_score": "0.117008",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.121037",
        "ticker_sentiment_score": "0.193897",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.121037",
        "ticker_sentiment_score": "0.068013",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.121037",
        "ticker_sentiment_score": "0.068013",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.121037",
        "ticker_sentiment_score": "0.068013",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Global Advanced Drug Delivery Systems Market Report 2024: Review of Patents and Patent Applications Filed on Drug Delivery Release Mechanisms and Novel Applications",
    "url": "https://www.prnewswire.com/news-releases/global-advanced-drug-delivery-systems-market-report-2024-review-of-patents-and-patent-applications-filed-on-drug-delivery-release-mechanisms-and-novel-applications-302063265.html",
    "time_published": "20240215T224500",
    "authors": [
      "Research and Markets"
    ],
    "summary": "Global Advanced Drug Delivery Systems Market Report 2024: Review of Patents and Patent Applications Filed on Drug ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.163653,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVS",
        "relevance_score": "0.042876",
        "ticker_sentiment_score": "0.09682",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.042876",
        "ticker_sentiment_score": "0.09682",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.042876",
        "ticker_sentiment_score": "0.09682",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.042876",
        "ticker_sentiment_score": "0.09682",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Coca-Cola Boosts Its Dividend Again",
    "url": "https://www.barrons.com/amp/articles/coca-cola-dividend-4ced4850",
    "time_published": "20240215T205000",
    "authors": [
      "Andrew Bary"
    ],
    "summary": "Coca-Cola Lifts Dividend by ...",
    "banner_image": "https://images.barrons.com/im-77493230/social",
    "source": "Barrons",
    "category_within_source": "n/a",
    "source_domain": "www.barrons.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.318442,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PEP",
        "relevance_score": "0.31482",
        "ticker_sentiment_score": "0.246831",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.582526",
        "ticker_sentiment_score": "0.688049",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.31482",
        "ticker_sentiment_score": "0.084392",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.31482",
        "ticker_sentiment_score": "0.084392",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024",
    "url": "https://www.prnewswire.com/news-releases/alkermes-plc-reports-financial-results-for-the-fourth-quarter-and-year-ended-dec-31-2023-and-provides-financial-expectations-for-2024-302062983.html",
    "time_published": "20240215T120000",
    "authors": [
      "Alkermes plc"
    ],
    "summary": "Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.905476"
      }
    ],
    "overall_sentiment_score": 0.16266,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MURA",
        "relevance_score": "0.015412",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALKS",
        "relevance_score": "0.343175",
        "ticker_sentiment_score": "0.036906",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.015412",
        "ticker_sentiment_score": "0.006869",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.015412",
        "ticker_sentiment_score": "0.155303",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.015412",
        "ticker_sentiment_score": "-0.02066",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.015412",
        "ticker_sentiment_score": "-0.02066",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara\u00ae  ( ustekinumab ) ",
    "url": "https://www.globenewswire.com/news-release/2024/02/15/2829780/0/en/Alvotech-Announces-Expected-Global-Market-Entry-Dates-for-AVT04-Biosimilar-to-Stelara-ustekinumab.html",
    "time_published": "20240215T113000",
    "authors": [
      "Alvotech"
    ],
    "summary": "Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has reached settlement agreements with Johnson & Johnson in Japan, Canada and in the European Economic Area ( EEA ) for ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.104003,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALVO",
        "relevance_score": "0.536148",
        "ticker_sentiment_score": "0.161299",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.026562",
        "ticker_sentiment_score": "0.059635",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.026562",
        "ticker_sentiment_score": "0.059635",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.026562",
        "ticker_sentiment_score": "0.059635",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.053094",
        "ticker_sentiment_score": "0.105829",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara\u00ae  ( ustekinumab ) ",
    "url": "https://www.globenewswire.com/news-release/2024/02/15/2829779/0/en/Alvotech-Announces-Expected-Global-Market-Entry-Dates-for-AVT04-Biosimilar-to-Stelara-ustekinumab.html",
    "time_published": "20240215T113000",
    "authors": [
      "Alvotech"
    ],
    "summary": "REYKJAVIK, Iceland, Feb. 15, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has reached settlement agreements with Johnson & Johnson in Japan, ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.103994,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALVO",
        "relevance_score": "0.533678",
        "ticker_sentiment_score": "0.160848",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.026415",
        "ticker_sentiment_score": "0.059586",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.026415",
        "ticker_sentiment_score": "0.059586",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.026415",
        "ticker_sentiment_score": "0.059586",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.052801",
        "ticker_sentiment_score": "0.100797",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara\u00ae  ( ustekinumab )  - Alvotech  ( NASDAQ:ALVO ) ",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37152906/alvotech-announces-expected-global-market-entry-dates-for-avt04-biosimilar-to-stelara-ustekinumab",
    "time_published": "20240215T113000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "REYKJAVIK, Iceland, Feb. 15, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ALVO, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has reached settlement agreements with Johnson & Johnson in Japan, Canada and in ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.096748,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALVO",
        "relevance_score": "0.546745",
        "ticker_sentiment_score": "0.153016",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.026013",
        "ticker_sentiment_score": "0.051022",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.026013",
        "ticker_sentiment_score": "0.051022",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.026013",
        "ticker_sentiment_score": "0.051022",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.051999",
        "ticker_sentiment_score": "0.097722",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Evolution Health Group appoints Chris Mycek as Vice President, Enterprise Solutions - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/evolution-health-group-appoints-chris-mycek-as-vice-president-enterprise-solutions-302062372.html",
    "time_published": "20240215T111500",
    "authors": [],
    "summary": "Evolution Health Group appoints Chris Mycek as Vice President, Enterprise Solutions PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.362325,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CTSH",
        "relevance_score": "0.082111",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.082111",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Tips To Negotiate Remote Work  ( At Your Current Job ) ",
    "url": "https://www.forbes.com/sites/shodewan/2024/02/16/3-tips-to-negotiate-remote-work-at-your-current-job/",
    "time_published": "20240216T202450",
    "authors": [
      "Sho Dewan"
    ],
    "summary": "Remote work has become increasingly popular. Initially, it was just a COVID-19 pandemic response, but through the years, it has shown promising outcomes. It offers flexibility in work hours and location, as well as cost-saving opportunities.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65cfc450dc59eb2fde4a265e/0x0.jpg?format=jpg&crop=4729,2659,x0,y0,safe&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.504168,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.242223",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SPLK",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.242223",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.242223",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Inflation Devices Market Anticipated to Surpass USD 851.8 million by 2031, Projected a CAGR of 5.2% - Reports Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37182636/inflation-devices-market-anticipated-to-surpass-usd-851-8-million-by-2031-projected-a-cagr-of-5-2-",
    "time_published": "20240216T164000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Feb. 16, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The inflation devices industry was worth US$ 537.7 million in 2022. The industry is projected to expand at a CAGR of 5.2% from 2023 to 2031, reaching more than US$ 851.8 million by 2031.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.10024,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.035821",
        "ticker_sentiment_score": "0.050279",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MMSI",
        "relevance_score": "0.035821",
        "ticker_sentiment_score": "-0.094617",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.107175",
        "ticker_sentiment_score": "0.139815",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.035821",
        "ticker_sentiment_score": "-0.094617",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.035821",
        "ticker_sentiment_score": "0.039217",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.035821",
        "ticker_sentiment_score": "-0.094617",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What the Options Market Tells Us About Johnson & Johnson - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/options/24/02/37181577/what-the-options-market-tells-us-about-johnson-johnson",
    "time_published": "20240216T154610",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson JNJ we detected 8 trades. If we consider the specifics of each trade, it is accurate to state that 25% of the investors opened trades with bullish ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.127747,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.074692",
        "ticker_sentiment_score": "0.140431",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.074692",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.601191",
        "ticker_sentiment_score": "0.267101",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Wall Street Thinks These 3 Stocks Are Hidden Gems That Could Soar 43% to 59% Over the Next 12 Months",
    "url": "https://www.fool.com/investing/2024/02/16/wall-street-thinks-these-3-stocks-are-hidden-gems/",
    "time_published": "20240216T105000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Analysts are quite bullish about these beaten-down stocks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/765200/oil-rig-workers-talking.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.234969,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BABA",
        "relevance_score": "0.421485",
        "ticker_sentiment_score": "0.231642",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SLB",
        "relevance_score": "0.366061",
        "ticker_sentiment_score": "0.140709",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.063258",
        "ticker_sentiment_score": "0.042253",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RPRX",
        "relevance_score": "0.366061",
        "ticker_sentiment_score": "0.015773",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.063258",
        "ticker_sentiment_score": "0.042253",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.063258",
        "ticker_sentiment_score": "0.042253",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Unstoppable Dividend Stocks That Could Pay You for Life",
    "url": "https://www.fool.com/investing/2024/02/17/3-unstoppable-dividend-stocks-that-could-pay-you-f/",
    "time_published": "20240217T145100",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "There are no certainties in life or on the stock market. These companies' dividends are about as close as we can get.",
    "banner_image": "https://g.foolcdn.com/editorial/images/764583/physician-giving-medicine-to-elderly-patient.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.341848,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AAPL",
        "relevance_score": "0.278486",
        "ticker_sentiment_score": "0.35424",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MPW",
        "relevance_score": "0.047371",
        "ticker_sentiment_score": "0.13966",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "V",
        "relevance_score": "0.365389",
        "ticker_sentiment_score": "0.463746",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.278486",
        "ticker_sentiment_score": "0.244959",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.047371",
        "ticker_sentiment_score": "0.13966",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "If You Invested $10,000 in Johnson & Johnson Stock in 2004, This Is How Much You Would Have Today",
    "url": "https://www.fool.com/investing/2024/02/18/if-you-invested-10000-in-johnson-johnson-stock-in/",
    "time_published": "20240218T135800",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Johnson & Johnson has been a stalwart in the healthcare industry for decades, but has it made for a good investment?",
    "banner_image": "https://g.foolcdn.com/editorial/images/765090/investor-calculating-stock-returns-on-a-calculator.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.246853,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.732373",
        "ticker_sentiment_score": "0.424893",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Respiratory Disease Vaccine Market Overview 2024-2028: Market Size To Reach $76.1 Billion By 2028 As Per The Business Research Company's Respiratory Disease Vaccine Global Market Report 2024",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37202268/respiratory-disease-vaccine-market-overview-2024-2028-market-size-to-reach-76-1-billion-by-2028-as",
    "time_published": "20240219T163000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LONDON, Feb. 19, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Respiratory Disease Vaccine Global Market Report 2024, the respiratory disease vaccine market is poised for robust expansion.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.303034,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.226421",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.057767",
        "ticker_sentiment_score": "0.197384",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "9.18% CAGR growth in Cancer Biologics Market by Product (Monoclonal antibodies, Cell and gene therapy, vaccines ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/9-18-cagr-growth-in-cancer-biologics-market-by-product-monoclonal-antibodies-cell-and-gene-therapy-vaccines-and-others-route-of-administration-and-geography--global-forecast-to-2028--302064076.html",
    "time_published": "20240219T154000",
    "authors": [],
    "summary": "9.18% CAGR growth in Cancer Biologics Market by Product ( Monoclonal antibodies, Cell and gene therapy, vaccines ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.04391,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.058472",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JAZZ",
        "relevance_score": "0.058472",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.058472",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.058472",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VTRS",
        "relevance_score": "0.058472",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.058472",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.058472",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.058472",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.058472",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OPHLF",
        "relevance_score": "0.058472",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Smartest Dividend Stocks to Buy With $400 Right Now",
    "url": "https://www.fool.com/investing/2024/02/19/the-smartest-dividend-stocks-to-buy-with-400-right/",
    "time_published": "20240219T103500",
    "authors": [
      "Justin Pope"
    ],
    "summary": "These companies will build an ever-growing stream of passive income, one share at a time.",
    "banner_image": "https://g.foolcdn.com/editorial/images/765205/group_of_nike_shoes_posed_nke.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999612"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.310115,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NKE",
        "relevance_score": "0.290033",
        "ticker_sentiment_score": "0.305671",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PM",
        "relevance_score": "0.243376",
        "ticker_sentiment_score": "0.226793",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.147516",
        "ticker_sentiment_score": "0.147446",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Oregon Rethinks Groundbreaking Drug Decriminalization Amid Escalating Opioid Crisis",
    "url": "https://www.benzinga.com/news/24/02/37197005/oregon-rethinks-groundbreaking-drug-decriminalization-amid-escalating-opioid-crisis",
    "time_published": "20240219T045232",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "In the wake of the escalating opioid crisis, the state of Oregon is reconsidering its groundbreaking drug decriminalization legislation. This move comes as the state grapples with a surge in drug-related fatalities and a lack of effective implementation of the existing law.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/66th-SFS-carries-opioid-overdose-medicat_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.080168,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.065866",
        "ticker_sentiment_score": "-0.108181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.065866",
        "ticker_sentiment_score": "-0.108181",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "TECVAYLI\u00ae  ( teclistamab-cqyv )  biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma",
    "url": "https://www.prnewswire.com/news-releases/tecvayli-teclistamab-cqyv-biweekly-dosing-approved-by-the-us-fda-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma-302066627.html",
    "time_published": "20240220T212600",
    "authors": [
      "Johnson & Johnson"
    ],
    "summary": "TECVAYLI\u00ae ( teclistamab-cqyv ) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/2343818/Johnson_and_Johnson_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.009673,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.12142",
        "ticker_sentiment_score": "0.097038",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Options Trading: A Deep Dive into Market Sentiment - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/options/24/02/37219687/johnson-johnson-options-trading-a-deep-dive-into-market-sentiment",
    "time_published": "20240220T184544",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bearish approach towards Johnson & Johnson JNJ, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.145523,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.071145",
        "ticker_sentiment_score": "0.139868",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.071145",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.673971",
        "ticker_sentiment_score": "0.344785",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Congenital Diaphragmatic Hernia Drugs Market Size is Expected to Reach $5.8 Billion By 2028 At A CAGR Of More Than 7% As Per The Business Research Company's Congenital Diaphragmatic Hernia Drugs Global Market Report 2024",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37216844/congenital-diaphragmatic-hernia-drugs-market-size-is-expected-to-reach-5-8-billion-by-2028-at-a-ca",
    "time_published": "20240220T163000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LONDON, Feb. 20, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Congenital Diaphragmatic Hernia Drugs Global Market Report 2024, the global congenital diaphragmatic hernia ( CDH ) drugs market has experienced robust expansion in recent years, driven by various factors ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.35108,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVS",
        "relevance_score": "0.061631",
        "ticker_sentiment_score": "0.00901",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.061631",
        "ticker_sentiment_score": "0.00901",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.061631",
        "ticker_sentiment_score": "0.00901",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.061631",
        "ticker_sentiment_score": "0.00901",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Antiparasitic Drugs Industry Poised For Robust Growth: Market To Grow At A Rate Of More Than 6% As Per The Business Research Company's Antiparasitic Drugs Global Market Report 2024",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37216848/antiparasitic-drugs-industry-poised-for-robust-growth-market-to-grow-at-a-rate-of-more-than-6-as-p",
    "time_published": "20240220T163000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LONDON, Feb. 20, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Antiparasitic Drugs Global Market Report 2024, the antiparasitic drugs market is experiencing robust expansion.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.208088,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.059785",
        "ticker_sentiment_score": "0.124002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.059785",
        "ticker_sentiment_score": "0.124002",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Complicated Skin And Skin Structure Infections Drugs Market Anticipates Significant Growth At Rate Of 9.7% Through 2024-2028 As Per TBRC's Complicated Skin And Skin Structure Infections Drugs Global Market Report 2024",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37216846/complicated-skin-and-skin-structure-infections-drugs-market-anticipates-significant-growth-at-rate",
    "time_published": "20240220T163000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LONDON, Feb. 20, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Complicated Skin And Skin Structure Infections Drugs Global Market Report 2024, the complicated skin and skin structure infections drugs market has experienced rapid expansion, driven by a myriad of factors ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.036973,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVS",
        "relevance_score": "0.056407",
        "ticker_sentiment_score": "0.093866",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.056407",
        "ticker_sentiment_score": "0.093866",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.056407",
        "ticker_sentiment_score": "0.093866",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Top 20 global biopharmaceutical companies report 1.6% market capitalization growth to $3.67 trillion in 2023, reveals GlobalData",
    "url": "https://www.investorideas.com/news/2024/biotech/02201Global-Biopharmaceutical.asp",
    "time_published": "20240220T150551",
    "authors": [],
    "summary": "Top 20 global biopharmaceutical companies report 1.6% market capitalization growth to $3.67 trillion in 2023, reveals ... ...",
    "banner_image": null,
    "source": "Investor Ideas",
    "category_within_source": "n/a",
    "source_domain": "www.investorideas.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.152626,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVO",
        "relevance_score": "0.159922",
        "ticker_sentiment_score": "0.108103",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.159922",
        "ticker_sentiment_score": "-0.036799",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GLDAF",
        "relevance_score": "0.159922",
        "ticker_sentiment_score": "0.010941",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.053629",
        "ticker_sentiment_score": "0.260895",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SKXJF",
        "relevance_score": "0.053629",
        "ticker_sentiment_score": "-0.175762",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.053629",
        "ticker_sentiment_score": "-0.175762",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.107016",
        "ticker_sentiment_score": "-0.208134",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.053629",
        "ticker_sentiment_score": "0.260895",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.107016",
        "ticker_sentiment_score": "-0.208134",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.159922",
        "ticker_sentiment_score": "-0.069573",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 American Century Mutual Funds for Excellent Returns",
    "url": "https://www.zacks.com/stock/news/2228248/3-american-century-mutual-funds-for-excellent-returns",
    "time_published": "20240220T110300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Consider investing in American Century mutual funds like AFYDX, AGYWX and ALVDX for consistent performance.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/a8/346.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.270926,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.132004",
        "ticker_sentiment_score": "0.058955",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.132004",
        "ticker_sentiment_score": "0.058955",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.132004",
        "ticker_sentiment_score": "0.058955",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.051063",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.051063",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.051063",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Rises Higher Than Market: Key Facts",
    "url": "https://www.zacks.com/stock/news/2229635/johnson-johnson-jnj-rises-higher-than-market-key-facts",
    "time_published": "20240221T224519",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the most recent trading session, Johnson & Johnson (JNJ) closed at $158.68, indicating a +0.52% shift from the previous trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default62.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.206997,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.548363",
        "ticker_sentiment_score": "0.252117",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Global Ophthalmic Drugs Market Size is Estimated to Reach USD 62.55 billion by 2030, Growing at a CAGR of 7.4%: Straits Research",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37238229/global-ophthalmic-drugs-market-size-is-estimated-to-reach-usd-62-55-billion-by-2030-growing-at-a-c",
    "time_published": "20240221T152000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, United States, Feb. 21, 2024 ( GLOBE NEWSWIRE ) -- Anti-infectives in a product designed specifically to be injected into or applied to the eye or eyes are known as ophthalmic anti-infectives. An example of an anti-infective for the eyes is eyedrops, gels, and ointments.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.211074,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.038655",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.038655",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.038655",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALC",
        "relevance_score": "0.115602",
        "ticker_sentiment_score": "0.137469",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KALA",
        "relevance_score": "0.038655",
        "ticker_sentiment_score": "0.323546",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CHRS",
        "relevance_score": "0.038655",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.038655",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.038655",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.077218",
        "ticker_sentiment_score": "0.043676",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Immix Biopharma 12 Month Review Progress Update",
    "url": "https://www.globenewswire.com/news-release/2024/02/21/2832855/0/en/Immix-Biopharma-12-Month-Review-Progress-Update.html",
    "time_published": "20240221T143100",
    "authors": [
      "Immix Biopharma",
      "Inc."
    ],
    "summary": "LOS ANGELES, Feb. 21, 2024 ( GLOBE NEWSWIRE ) -- Immix Biopharma, Inc. ( Nasdaq: IMMX ) , a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced its 12-month progress update including shareholder letter.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/b46d5687-65de-44df-81d5-e36f2665d8e7",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.139016,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BAC",
        "relevance_score": "0.040795",
        "ticker_sentiment_score": "0.145594",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IMMX",
        "relevance_score": "0.241085",
        "ticker_sentiment_score": "0.133816",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.020404",
        "ticker_sentiment_score": "-0.026128",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.020404",
        "ticker_sentiment_score": "-0.026128",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Investors Heavily Search Johnson & Johnson  ( JNJ ) : Here is What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2229159/investors-heavily-search-johnson-johnson-jnj-here-is-what-you-need-to-know",
    "time_published": "20240221T140023",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default265.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.224281,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.477606",
        "ticker_sentiment_score": "0.142358",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Generative AI Contracting Copilots Drive Icertis Above $250 Million in Annual Recurring Revenue",
    "url": "https://www.prnewswire.com/news-releases/generative-ai-contracting-copilots-drive-icertis-above-250-million-in-annual-recurring-revenue-302066928.html",
    "time_published": "20240221T140000",
    "authors": [
      "Icertis"
    ],
    "summary": "BELLEVUE, Wash., Feb. 21, 2024 /PRNewswire/ -- Icertis, the global leader in AI-powered contract intelligence, today announced that the launch of Icertis Copilots and continued adoption of contract intelligence worldwide have driven the company above $250 million in annual recurring revenue ( ...",
    "banner_image": "https://mma.prnewswire.com/media/371539/Icertis_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.427902,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BBY",
        "relevance_score": "0.059341",
        "ticker_sentiment_score": "0.198024",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.118354",
        "ticker_sentiment_score": "0.221493",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LW",
        "relevance_score": "0.059341",
        "ticker_sentiment_score": "0.198024",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MUR",
        "relevance_score": "0.059341",
        "ticker_sentiment_score": "0.198024",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "G",
        "relevance_score": "0.176717",
        "ticker_sentiment_score": "0.349068",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.059341",
        "ticker_sentiment_score": "0.198024",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Beaten-Down Stocks to Buy and Hold for 10 Years",
    "url": "https://www.fool.com/investing/2024/02/21/2-beaten-down-stocks-to-buy-and-hold-for-10-years/",
    "time_published": "20240221T133000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "One is a longtime healthcare leader, the other a newcomer. both have bright futures despite recent obstacles.",
    "banner_image": "https://media.ycharts.com/charts/cdbbf2d57e6e5084f13bf60b62c503c3.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.35644,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DOCS",
        "relevance_score": "0.380736",
        "ticker_sentiment_score": "0.420511",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.331177",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Topical Antibiotics Market Size Projected to Reach USD 10.0 billion by 2031, With 5.1% CAGR: Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37229711/topical-antibiotics-market-size-projected-to-reach-usd-10-0-billion-by-2031-with-5-1-cagr-transpar",
    "time_published": "20240221T054000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Feb. 21, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global topical antibiotics market is estimated to flourish at a CAGR of 5.1% from 2023 to 2031.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.385265,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.034831",
        "ticker_sentiment_score": "0.050061",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.034831",
        "ticker_sentiment_score": "0.18334",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MAYNF",
        "relevance_score": "0.034831",
        "ticker_sentiment_score": "-0.131195",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.069596",
        "ticker_sentiment_score": "0.196575",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BHC",
        "relevance_score": "0.069596",
        "ticker_sentiment_score": "0.119071",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TARO",
        "relevance_score": "0.069596",
        "ticker_sentiment_score": "0.280263",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.104228",
        "ticker_sentiment_score": "0.079915",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.069596",
        "ticker_sentiment_score": "0.196575",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PRGO",
        "relevance_score": "0.034831",
        "ticker_sentiment_score": "0.195164",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Is Johnson & Johnson  ( JNJ )  Down 0.2% Since Last Earnings Report?",
    "url": "https://www.zacks.com/stock/news/2230334/why-is-johnson-johnson-jnj-down-02-since-last-earnings-report",
    "time_published": "20240222T163020",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default85.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999997"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.237553,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.105026",
        "ticker_sentiment_score": "0.053974",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Surgical Staplers Market Revenue to Reach USD 8.5 billion by 2031 | Says Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37262345/surgical-staplers-market-revenue-to-reach-usd-8-5-billion-by-2031-says-transparency-market-researc",
    "time_published": "20240222T144000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Feb. 22, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global surgical staplers market is estimated to flourish at a CAGR of 6.9% from 2023 to 2031.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.363138,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LEIC",
        "relevance_score": "0.033144",
        "ticker_sentiment_score": "0.148844",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.033144",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.033144",
        "ticker_sentiment_score": "-0.211925",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.099202",
        "ticker_sentiment_score": "0.044504",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.099432",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CNMD",
        "relevance_score": "0.099202",
        "ticker_sentiment_score": "0.223381",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.099202",
        "ticker_sentiment_score": "0.1188",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Students graduating with a Rutgers MBA benefit from robust New Jersey job market - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/students-graduating-with-a-rutgers-mba-benefit-from-robust-new-jersey-job-market-302068310.html",
    "time_published": "20240222T133000",
    "authors": [],
    "summary": "Students graduating with a Rutgers MBA benefit from robust New Jersey job market PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.576289"
      }
    ],
    "overall_sentiment_score": 0.338966,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DELL",
        "relevance_score": "0.043421",
        "ticker_sentiment_score": "0.045803",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.043421",
        "ticker_sentiment_score": "0.117846",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "NOT REAL NEWS: A look at what didn't happen this week",
    "url": "https://apnews.com/article/fact-check-misinformation-c99b70fbd4b0ac0f957305501fb89783",
    "time_published": "20240223T215100",
    "authors": [
      "MELISSA GOLDIN"
    ],
    "summary": "A roundup of some of the most popular but completely untrue stories and visuals of the week. None of these are legit, even though they were shared widely on social media. The Associated Press checked them out. Executive Order 9066 authorized Japanese detention during World War II, not gift cards ...",
    "banner_image": "https://dims.apnews.com/dims4/default/baed137/2147483647/strip/true/crop/3549x2364+26+0/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F4f%2Fc3%2Faababc88cfd92417920ff4d2c1e0%2F29355eddf7a44d6f99ee07e1b7b64905",
    "source": "Associated Press",
    "category_within_source": "Markets",
    "source_domain": "apnews.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.036505,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVAX",
        "relevance_score": "0.024775",
        "ticker_sentiment_score": "0.065689",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.024775",
        "ticker_sentiment_score": "0.065689",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.024775",
        "ticker_sentiment_score": "0.065689",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.024775",
        "ticker_sentiment_score": "0.065689",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.024775",
        "ticker_sentiment_score": "0.065689",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Red Cross did not ban people with COVID-19 vaccinations from donating blood",
    "url": "https://apnews.com/article/fact-check-red-cross-donate-blood-covid-vaccine-372009322832",
    "time_published": "20240223T212900",
    "authors": [
      "MELISSA GOLDIN"
    ],
    "summary": "CLAIM: The American Red Cross banned people who have received a COVID-19 vaccine from donating blood because it is \"tainted.\" AP'S ASSESSMENT: False. No potential donors are deemed ineligible solely due to COVID-19 vaccines, a Red Cross spokesperson told The Associated Press.",
    "banner_image": "https://dims.apnews.com/dims4/default/95127ce/2147483647/strip/true/crop/4033x2686+0+1/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F00%2F0c%2F826dd6e1596af4b2be8aec655449%2F7e930b176591435993293e01aa8402b3",
    "source": "Associated Press",
    "category_within_source": "Markets",
    "source_domain": "apnews.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.074857,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVAX",
        "relevance_score": "0.061159",
        "ticker_sentiment_score": "0.073002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.061159",
        "ticker_sentiment_score": "0.073002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.061159",
        "ticker_sentiment_score": "0.073002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.061159",
        "ticker_sentiment_score": "0.073002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.061159",
        "ticker_sentiment_score": "0.073002",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Extremity Products Market size to grow by USD 1.61 billion from 2022-2027, Acumed LLC, Artificial Limbs ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/extremity-products-market-size-to-grow-by-usd-1-61-billion-from-2022-2027--acumed-llc-artificial-limbs-manufacturing-corp-of-india-aspire-medical-innovation-to-emerge-as-some-of-the-key-companies-technavio-302068993.html",
    "time_published": "20240223T164800",
    "authors": [],
    "summary": "Extremity Products Market size to grow by USD 1.61 billion from 2022-2027, Acumed LLC, Artificial Limbs ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.322161,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ZBH",
        "relevance_score": "0.038468",
        "ticker_sentiment_score": "0.056626",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNN",
        "relevance_score": "0.038468",
        "ticker_sentiment_score": "0.056626",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.038468",
        "ticker_sentiment_score": "0.056626",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.038468",
        "ticker_sentiment_score": "0.056626",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.038468",
        "ticker_sentiment_score": "0.056626",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OMI",
        "relevance_score": "0.038468",
        "ticker_sentiment_score": "0.056626",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CNMD",
        "relevance_score": "0.038468",
        "ticker_sentiment_score": "0.056626",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Evaluating Johnson & Johnson Against Peers In Pharmaceuticals Industry - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/news/24/02/37287246/evaluating-johnson-amp-johnson-against-peers-in-pharmaceuticals-industry",
    "time_published": "20240223T160055",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In today's fast-paced and highly competitive business world, it is crucial for investors and industry followers to conduct comprehensive company evaluations. In this article, we will delve into an extensive industry comparison, evaluating Johnson & Johnson JNJ in relation to its major competitors ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.214057,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.063594",
        "ticker_sentiment_score": "0.139129",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.423504",
        "ticker_sentiment_score": "0.354442",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "2 Top Dividend Stocks To Watch Today",
    "url": "https://stockmarket.com/featured/2-top-dividend-stocks-to-watch-today-2024-02-23",
    "time_published": "20240223T145338",
    "authors": [
      "Josh Dylan"
    ],
    "summary": "Dividends are payments made by a corporation to its shareholders, usually derived from the company's profits. Dividend stocks are those issued by companies that regularly distribute a portion of their earnings to shareholders.",
    "banner_image": "https://u3j7m9h7.rocketcdn.me/wp-content/uploads/2020/08/johnson-and-johnson.jpg",
    "source": "StockMarket.com",
    "category_within_source": "n/a",
    "source_domain": "stockmarket.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.268748,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "UNH",
        "relevance_score": "0.411176",
        "ticker_sentiment_score": "0.253956",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.411176",
        "ticker_sentiment_score": "0.272983",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Spinal implants Market to Expand at a 5.2% CAGR, to Attain a USD 16.7 billion Valuation by 2031 | Exclusive Report by Transparency Market Research Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37280677/spinal-implants-market-to-expand-at-a-5-2-cagr-to-attain-a-usd-16-7-billion-valuation-by-2031-excl",
    "time_published": "20240223T103006",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Feb. 23, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global spinal implant market was projected to attain US$ 10.6 billion in 2022. It is anticipated to garner a 5.2% CAGR from 2023 to 2031, and by 2031, the market is likely to attain ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.093955,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ATCN",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "0.091237",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "0.05115",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.12023",
        "ticker_sentiment_score": "0.051158",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "0.218994",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "These 4 Dividend ETFs Are a Retiree's Best Friend",
    "url": "https://www.fool.com/investing/2024/02/26/these-4-dividend-etfs-are-a-retirees-best-friend/",
    "time_published": "20240226T142400",
    "authors": [
      "Justin Pope"
    ],
    "summary": "Make retirement a breeze with stress-free ETFs.",
    "banner_image": "https://g.foolcdn.com/editorial/images/766555/happy-retirement.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999696"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.39187,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.06211",
        "ticker_sentiment_score": "0.274416",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.06211",
        "ticker_sentiment_score": "0.274416",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.06211",
        "ticker_sentiment_score": "0.274416",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.06211",
        "ticker_sentiment_score": "0.274416",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.06211",
        "ticker_sentiment_score": "0.087135",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.06211",
        "ticker_sentiment_score": "0.207524",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.06211",
        "ticker_sentiment_score": "0.207524",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.06211",
        "ticker_sentiment_score": "0.207524",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.06211",
        "ticker_sentiment_score": "0.274416",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amazon joins 29 other 'blue chip' cos in Dow Jones Industrial Average | World News",
    "url": "https://www.business-standard.com/world-news/amazon-joins-29-other-blue-chip-cos-in-dow-jones-industrial-average-124022600828_1.html",
    "time_published": "20240226T133228",
    "authors": [
      "AP"
    ],
    "summary": "Amazon joins 29 other 'blue chip' cos in Dow Jones Industrial Average Business Standard ...",
    "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2024-02/16/full/1708048506-2242.jpg?im=FeatureCrop,size=(826,465)",
    "source": "Business Standard",
    "category_within_source": "GoogleRSS",
    "source_domain": "www.business-standard.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999998"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.049337,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.043658",
        "ticker_sentiment_score": "0.058522",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.043658",
        "ticker_sentiment_score": "0.058522",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.043658",
        "ticker_sentiment_score": "0.306782",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.043658",
        "ticker_sentiment_score": "-0.05368",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HON",
        "relevance_score": "0.043658",
        "ticker_sentiment_score": "0.038981",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.043658",
        "ticker_sentiment_score": "0.208461",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.173333",
        "ticker_sentiment_score": "-0.032486",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.043658",
        "ticker_sentiment_score": "0.208461",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.043658",
        "ticker_sentiment_score": "0.038981",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.130453",
        "ticker_sentiment_score": "-0.013135",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.173333",
        "ticker_sentiment_score": "0.052535",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.043658",
        "ticker_sentiment_score": "0.058522",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.043658",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.043658",
        "ticker_sentiment_score": "0.038981",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.043658",
        "ticker_sentiment_score": "0.208461",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.043658",
        "ticker_sentiment_score": "0.306782",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.130453",
        "ticker_sentiment_score": "-0.096349",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Global Nanomedicine Market Report 2023-2028: United States Emerges as a Key Player",
    "url": "https://www.prnewswire.com/news-releases/global-nanomedicine-market-report-2023-2028-united-states-emerges-as-a-key-player-302070908.html",
    "time_published": "20240226T114500",
    "authors": [
      "Research and Markets"
    ],
    "summary": "DUBLIN, Feb. 26, 2024 /PRNewswire/ -- The \"Nanomedicine Market - Forecasts from 2023 to 2028\" report has been added to ResearchAndMarkets.com's offering. The medical application of nanotechnology is the focus of the interdisciplinary field of nanomedicine.",
    "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.234378,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.088147",
        "ticker_sentiment_score": "0.109752",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.044141",
        "ticker_sentiment_score": "0.104084",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.044141",
        "ticker_sentiment_score": "0.104084",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.044141",
        "ticker_sentiment_score": "0.104084",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amazon joins 29 other 'blue chip' companies in the Dow Jones Industrial Average",
    "url": "https://apnews.com/article/amazon-walgreens-dow-jones-industrial-average-stock-market-7e7d5e71ee10f7612a45ac1c8bb82c4e",
    "time_published": "20240226T080150",
    "authors": [
      "ALEX VEIGA"
    ],
    "summary": "Amazon.com Inc. is joining the ranks of one of Wall Street's oldest and most exclusive stock indexes: The Dow Jones Industrial Average. The e-commerce pioneer will officially take its position among the 30-company Dow before the open of trading Monday, replacing drugstore operator Walgreens Boots ...",
    "banner_image": "https://dims.apnews.com/dims4/default/8f3f46b/2147483647/strip/true/crop/2070x1379+66+0/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2Fe4%2Fd8%2F3d845bb2445e48452a60b7cf9ff9%2Fd5f048f2446645b3b2987c97b1c501f3",
    "source": "Associated Press",
    "category_within_source": "Markets",
    "source_domain": "apnews.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999998"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.051717,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.045918",
        "ticker_sentiment_score": "0.058718",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.045918",
        "ticker_sentiment_score": "0.058718",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.045918",
        "ticker_sentiment_score": "0.307569",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.045918",
        "ticker_sentiment_score": "-0.058941",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HON",
        "relevance_score": "0.045918",
        "ticker_sentiment_score": "0.039229",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.045918",
        "ticker_sentiment_score": "0.209235",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.182162",
        "ticker_sentiment_score": "-0.036666",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.045918",
        "ticker_sentiment_score": "0.209235",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.045918",
        "ticker_sentiment_score": "0.039229",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.137148",
        "ticker_sentiment_score": "-0.014725",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.182162",
        "ticker_sentiment_score": "0.055967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.045918",
        "ticker_sentiment_score": "0.058718",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.045918",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.045918",
        "ticker_sentiment_score": "0.039229",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.045918",
        "ticker_sentiment_score": "0.209235",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.045918",
        "ticker_sentiment_score": "0.307569",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.137148",
        "ticker_sentiment_score": "-0.098838",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Rises But Trails Market: What Investors Should Know",
    "url": "https://www.zacks.com/stock/news/2232721/johnson-johnson-jnj-rises-but-trails-market-what-investors-should-know",
    "time_published": "20240227T224517",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) concluded the recent trading session at $160.98, signifying a +0.12% move from its prior day's close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default118.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.135816,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.588876",
        "ticker_sentiment_score": "0.066195",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's Why Investors Should Retain STERIS  ( STE )  Stock for Now",
    "url": "https://www.zacks.com/stock/news/2232656/heres-why-investors-should-retain-steris-ste-stock-for-now",
    "time_published": "20240227T172100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Investors are optimistic about STERIS (STE) on continuous recovery of healthcare procedures and upbeat 2024 guidance.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999974"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.1622,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KMB",
        "relevance_score": "0.049322",
        "ticker_sentiment_score": "0.052753",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.24289",
        "ticker_sentiment_score": "0.06054",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STE",
        "relevance_score": "0.542075",
        "ticker_sentiment_score": "0.118015",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.049322",
        "ticker_sentiment_score": "0.052753",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.049322",
        "ticker_sentiment_score": "0.131821",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COR",
        "relevance_score": "0.195419",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.049322",
        "ticker_sentiment_score": "0.052753",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.195419",
        "ticker_sentiment_score": "0.14429",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ECL",
        "relevance_score": "0.049322",
        "ticker_sentiment_score": "0.052753",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Josh Bersin Company Announces New Offerings to Accelerate HR's Transition to AI",
    "url": "https://www.prnewswire.com/news-releases/the-josh-bersin-company-announces-new-offerings-to-accelerate-hrs-transition-to-ai-302072619.html",
    "time_published": "20240227T140000",
    "authors": [
      "The Josh Bersin Company"
    ],
    "summary": "\u2022 New Josh Bersin Academy Certificate Program and in-depth playbooks and case studies \u2022 New AI offering Galileo\u2122 available for HR problem solving and education \u2022 New AI experts to keynote Josh Bersin Company \"Irresistible\" future of work conference",
    "banner_image": "https://mma.prnewswire.com/media/1670975/The_Josh_Bersin_Company.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.339465,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "0.241796",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PCRFF",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "0.241796",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CL",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "0.241796",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ACN",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "0.241796",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "0.241796",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MAR",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "0.241796",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy",
    "url": "https://www.globenewswire.com/news-release/2024/02/27/2835913/0/en/GCANRx-Announces-Completion-of-Preclinical-Study-for-Neuropsychiatric-Cannabinoid-Therapy.html",
    "time_published": "20240227T124500",
    "authors": [
      "The Greater Cannabis Company",
      "Inc."
    ],
    "summary": "BALTIMORE, MD, Feb. 27, 2024 ( GLOBE NEWSWIRE ) -- Greater Cannabis Company, Inc. ( \"GCANRx\" or the \"Company\" ) ( OTC: GCAN ) a biopharmaceutical company pioneering development of next generation cannabinoid therapeutics and consumer products today announced that it has completed the preclinical ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/de9f53cd-e801-432e-9bbe-884b7d855585",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.196737,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GCAN",
        "relevance_score": "0.17618",
        "ticker_sentiment_score": "0.118118",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.044386",
        "ticker_sentiment_score": "0.174742",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.044386",
        "ticker_sentiment_score": "0.174742",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.044386",
        "ticker_sentiment_score": "0.174742",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Pick Johnson & Johnson Stock At $160?",
    "url": "https://www.forbes.com/sites/greatspeculations/2024/02/27/should-you-pick-johnson--johnson-stock-at-160/",
    "time_published": "20240227T120026",
    "authors": [
      "Trefis Team"
    ],
    "summary": "Johnson & Johnson ( NYSE: JNJ ) reported its Q4 results last month, with revenues and earnings marginally above the street estimates. The company reported revenue of $21.4 billion and adjusted earnings of $2.29 per share, compared to the consensus estimates of $21.0 billion and $2.28, ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/648bd40d9a7afc33dd5e44a9/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.996675"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.163924,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.057215",
        "ticker_sentiment_score": "0.106006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.570165",
        "ticker_sentiment_score": "0.230511",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Nested Therapeutics Strengthens Board of Directors with Appointment of New Chair and Directors",
    "url": "https://www.prnewswire.com/news-releases/nested-therapeutics-strengthens-board-of-directors-with-appointment-of-new-chair-and-directors-302071856.html",
    "time_published": "20240227T120000",
    "authors": [
      "Nested Therapeutics Inc."
    ],
    "summary": "CAMBRIDGE, Mass., Feb. 27, 2024 /PRNewswire/ -- Nested Therapeutics, a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers, today announced the appointment of three members to its board of directors: John A.",
    "banner_image": "https://mma.prnewswire.com/media/2348138/Nested_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.135551,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ANAB",
        "relevance_score": "0.050679",
        "ticker_sentiment_score": "0.063497",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HESG",
        "relevance_score": "0.050679",
        "ticker_sentiment_score": "-0.01898",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABUS",
        "relevance_score": "0.050679",
        "ticker_sentiment_score": "0.023867",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TVTX",
        "relevance_score": "0.050679",
        "ticker_sentiment_score": "0.063497",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AFFY",
        "relevance_score": "0.050679",
        "ticker_sentiment_score": "0.063497",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCEL",
        "relevance_score": "0.101154",
        "ticker_sentiment_score": "0.041438",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.101154",
        "ticker_sentiment_score": "0.04591",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KDNY",
        "relevance_score": "0.101154",
        "ticker_sentiment_score": "0.017067",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.101154",
        "ticker_sentiment_score": "-0.020662",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRGX",
        "relevance_score": "0.050679",
        "ticker_sentiment_score": "0.063497",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Boston Partners Mutual Funds for Steady Returns",
    "url": "https://www.zacks.com/stock/news/2232161/2-boston-partners-mutual-funds-for-steady-returns",
    "time_published": "20240227T115500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Invest in Boston Partners mutual funds like BPRRX and BPAVX for consistent returns.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/09/344.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.299022,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.080188",
        "ticker_sentiment_score": "0.066037",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.080188",
        "ticker_sentiment_score": "0.057893",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.080188",
        "ticker_sentiment_score": "0.057893",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.080188",
        "ticker_sentiment_score": "0.066037",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.080188",
        "ticker_sentiment_score": "0.066037",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.080188",
        "ticker_sentiment_score": "0.222574",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Pharmaceutical Industry Research Highlights Sustainability and Growth Opportunities Through 6P Framework Implementation",
    "url": "https://www.prnewswire.com/news-releases/pharmaceutical-industry-research-highlights-sustainability-and-growth-opportunities-through-6p-framework-implementation-302071441.html",
    "time_published": "20240227T011500",
    "authors": [
      "Research and Markets"
    ],
    "summary": "Pharmaceutical Industry Research Highlights Sustainability and Growth Opportunities Through 6P Framework ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.411257,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.062926",
        "ticker_sentiment_score": "0.14035",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.062926",
        "ticker_sentiment_score": "0.14035",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "DRI Healthcare Trust Reports Fourth Quarter and Fiscal 2023 Results",
    "url": "https://www.newswire.ca/news-releases/dri-healthcare-trust-reports-fourth-quarter-and-fiscal-2023-results-808176485.html",
    "time_published": "20240228T220000",
    "authors": [
      "DRI Healthcare Trust"
    ],
    "summary": "- 82% royalty income growth over prior year period underscores transformative year - - Announcing 2024 royalty income guidance of US$153 to US$155 million, excluding milestone income and any new transactions - - Increasing quarterly cash distribution -",
    "banner_image": "https://mma.prnewswire.com/media/2350358/DRI_Healthcare_Trust_DRI_Healthcare_Trust_Reports_Fourth_Quarter.jpg?p=facebook",
    "source": "Canada Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.newswire.ca",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999894"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.312005,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MGNX",
        "relevance_score": "0.008908",
        "ticker_sentiment_score": "0.164782",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DHTRF",
        "relevance_score": "0.017815",
        "ticker_sentiment_score": "0.032198",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.008908",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSBHF",
        "relevance_score": "0.008908",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.008908",
        "ticker_sentiment_score": "0.208694",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "OMER",
        "relevance_score": "0.017815",
        "ticker_sentiment_score": "0.168206",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.008908",
        "ticker_sentiment_score": "0.164782",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Alexander Kalchev and Paul Ducr\u00e9 appointed CEOs of DDB Paris - Omnicom Group  ( NYSE:OMC ) ",
    "url": "https://www.benzinga.com/pressreleases/24/02/n37366456/alexander-kalchev-and-paul-ducr-appointed-ceos-of-ddb-paris",
    "time_published": "20240228T151800",
    "authors": [
      "PRNewswire"
    ],
    "summary": "A story of friendship and a natural transition PARIS, Feb. 28, 2024 /PRNewswire/ -- DDB Paris announces the elevation of globally acclaimed CCO Alexander Kalchev and Paul Ducr\u00e9 as new CEOs, together assuming the role of current CEO Jean-Luc Bravi who will become Chairman, DDB France.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.445592,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NKE",
        "relevance_score": "0.043342",
        "ticker_sentiment_score": "0.147493",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.086556",
        "ticker_sentiment_score": "0.125648",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OMC",
        "relevance_score": "0.086556",
        "ticker_sentiment_score": "0.128753",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REYN",
        "relevance_score": "0.043342",
        "ticker_sentiment_score": "0.122669",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.043342",
        "ticker_sentiment_score": "0.147493",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UL",
        "relevance_score": "0.086556",
        "ticker_sentiment_score": "0.154656",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results",
    "url": "https://www.globenewswire.com/news-release/2024/02/28/2836795/0/en/Mersana-Therapeutics-Provides-Business-Update-and-Announces-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html",
    "time_published": "20240228T120000",
    "authors": [
      "Inc.",
      "Mersana Therapeutics"
    ],
    "summary": "CAMBRIDGE, Mass., Feb. 28, 2024 ( GLOBE NEWSWIRE ) -- Mersana Therapeutics, Inc. ( NASDAQ: MRSN ) , a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates ( ADCs ) targeting cancers in areas of high unmet medical need, today ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/75b0bceb-3927-4f94-9ec8-22925b2a27a4",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.576289"
      }
    ],
    "overall_sentiment_score": 0.139733,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MRSN",
        "relevance_score": "0.093928",
        "ticker_sentiment_score": "0.110136",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GSK",
        "relevance_score": "0.023533",
        "ticker_sentiment_score": "0.0661",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.163592",
        "ticker_sentiment_score": "0.077457",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Stock Has 33% Upside, According to 1 Wall Street Analyst",
    "url": "https://www.fool.com/investing/2024/02/28/johnson-johnson-stock-33-upside-street-analyst/",
    "time_published": "20240228T104900",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Management's thesis regarding the spinoff is now being tested.",
    "banner_image": "https://g.foolcdn.com/editorial/images/767030/three-investors-meet-with-paperwork.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.187113,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.050146",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.463792",
        "ticker_sentiment_score": "0.224755",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Nearing Retirement? These Stocks Are as Cautious as They Come",
    "url": "https://www.fool.com/investing/2024/02/28/nearing-retirement-these-stocks-are-as-cautious-as/",
    "time_published": "20240228T104400",
    "authors": [
      "Justin Pope"
    ],
    "summary": "Healthcare blue chips can provide retirees the consistency they need while growing their nest eggs further.",
    "banner_image": "https://media.ycharts.com/charts/36fce26a2d1d75f1c1bc8adfac20211b.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.307533,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.056943",
        "ticker_sentiment_score": "0.038002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.056943",
        "ticker_sentiment_score": "0.222",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.159604",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.382925",
        "ticker_sentiment_score": "0.361236",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "FOREX:GBP",
        "relevance_score": "0.056943",
        "ticker_sentiment_score": "0.098111",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Intracranial Stents Market Projected to Achieve USD 3.4 billion by 2031, with a 5.2% CAGR Growth: Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37357287/intracranial-stents-market-projected-to-achieve-usd-3-4-billion-by-2031-with-a-5-2-cagr-growth-tra",
    "time_published": "20240228T100234",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Feb. 28, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global intracranial stents market is projected to grow at a CAGR of 5.2% from 2023 to 2031. As per the report published by TMR, a valuation of US$ 3.4 billion is anticipated for the ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.2082,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PEN",
        "relevance_score": "0.040078",
        "ticker_sentiment_score": "0.160178",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.040078",
        "ticker_sentiment_score": "0.051125",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.040078",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.11983",
        "ticker_sentiment_score": "0.036437",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.040078",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.040078",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "We're trimming an embattled portfolio stock facing a binary event that could go either way",
    "url": "https://www.cnbc.com/2024/02/29/were-trimming-an-embattled-portfolio-stock-facing-a-binary-event-that-could-go-either-way.html",
    "time_published": "20240229T171455",
    "authors": [
      "Jim Cramer",
      "Jeff Marks"
    ],
    "summary": "The sale involves roughly one-quarter of our position to manage our downside risk ahead of a key court ruling.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107200471-1677528554272-NUP_200782_00284.jpg?v=1695136854&w=600&h=300&vtcrop=y",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.972756"
      }
    ],
    "overall_sentiment_score": 0.123069,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BHC",
        "relevance_score": "0.509035",
        "ticker_sentiment_score": "0.165216",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BLCO",
        "relevance_score": "0.240489",
        "ticker_sentiment_score": "0.096236",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.061003",
        "ticker_sentiment_score": "0.051257",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pfizer  ( PFE )  Down 0.2% Since Last Earnings Report: Can It Rebound?",
    "url": "https://www.zacks.com/stock/news/2234048/pfizer-pfe-down-02-since-last-earnings-report-can-it-rebound",
    "time_published": "20240229T163036",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default39.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": -0.009646,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.326035",
        "ticker_sentiment_score": "0.132043",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.025817",
        "ticker_sentiment_score": "-0.09522",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.102998",
        "ticker_sentiment_score": "0.038442",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Urinary Tract Cancer Market To Grow At A CAGR Of More Than 19% With The Rising Prevalence Of Urinary Tract Infections As Per The Business Research Company's Urinary Tract Cancer Global Market Report 2024",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37398973/urinary-tract-cancer-market-to-grow-at-a-cagr-of-more-than-19-with-the-rising-prevalence-of-urinar",
    "time_published": "20240229T163000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LONDON, Feb. 29, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's urinary tract cancer global market report 2024, the urinary tract cancer market has experienced remarkable growth in recent years, surging from $2.65 billion in 2023 to $3.21 billion in 2024, representing a ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.030025,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.054983",
        "ticker_sentiment_score": "-0.018085",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.054983",
        "ticker_sentiment_score": "-0.018085",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Global Onychomycosis Treatment Market Size is Estimated to Reach USD 4.51 Billion by 2030, Growing at a CAGR of 5.61%: Straits Research",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37397003/global-onychomycosis-treatment-market-size-is-estimated-to-reach-usd-4-51-billion-by-2030-growing-",
    "time_published": "20240229T153500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, United States, Feb. 29, 2024 ( GLOBE NEWSWIRE ) -- Onychomycosis is a fungal condition that affects the fingernails and toenails and can be painful, ugly, and persistent. Several types of onychomycosis include proximal subungual, white superficial, and distal subungual.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.043083,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.038345",
        "ticker_sentiment_score": "-0.056789",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.038345",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.038345",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.038345",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.038345",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHC",
        "relevance_score": "0.038345",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.038345",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Biocon Biologics signs agreement with Janssen Biotech for psoriasis drug | Company News",
    "url": "https://www.business-standard.com/companies/news/biocon-biologics-signs-agreement-with-janssen-biotech-for-psoriasis-drug-124022901115_1.html",
    "time_published": "20240229T145228",
    "authors": [
      "Aneeka Chatterjee"
    ],
    "summary": "Biocon Biologics signs agreement with Janssen Biotech for psoriasis drug Business Standard ...",
    "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2021-09/17/full/1631878498-1779.jpeg?im=FitAndFill=(826,465)",
    "source": "Business Standard",
    "category_within_source": "GoogleRSS",
    "source_domain": "www.business-standard.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.378675,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.13459",
        "ticker_sentiment_score": "0.126703",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pfizer RSV vaccine maintains protection in older adults over two seasons in trial",
    "url": "https://www.cnbc.com/2024/02/29/pfizer-rsv-vaccine-protects-older-adults-over-two-seasons.html",
    "time_published": "20240229T130001",
    "authors": [
      "Annika Kim Constantino"
    ],
    "summary": "The results come ahead of a meeting of an advisory panel to the CDC, which will consider whether seniors should take RSV shots annually or every other year.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107243426-1684423445438-gettyimages-1265740892-dsc_6883.jpeg?v=1709188517&w=1920&h=1080",
    "source": "CNBC",
    "category_within_source": "Business",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": -0.024393,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.125789",
        "ticker_sentiment_score": "0.218217",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.187705",
        "ticker_sentiment_score": "0.216558",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.125789",
        "ticker_sentiment_score": "0.027768",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.063091",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.063091",
        "ticker_sentiment_score": "0.268528",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Want $1,000 in Ultra-Safe Annual Dividend Income? Invest $19,000 Into the Following 3 Time-Tested Dividend Kings.",
    "url": "https://www.fool.com/investing/2024/02/29/want-1000-safe-annual-dividend-income-invest-19000/",
    "time_published": "20240229T100600",
    "authors": [
      "Sean Williams"
    ],
    "summary": "These rock-solid dividend stocks, which sport an average yield of 5.26%, have raised their base annual payouts for between 54 and 62 consecutive years.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F766963%2Fperson-holding-cash-bills-money-hundred-dollar-fifty-dividend-income-invest-retire-spend-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.986714"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.21729,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SPGI",
        "relevance_score": "0.027667",
        "ticker_sentiment_score": "0.076141",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MO",
        "relevance_score": "0.218571",
        "ticker_sentiment_score": "0.113943",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TWOH",
        "relevance_score": "0.027667",
        "ticker_sentiment_score": "0.216319",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.245065",
        "ticker_sentiment_score": "0.224374",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.027667",
        "ticker_sentiment_score": "-0.046782",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.110335",
        "ticker_sentiment_score": "0.003395",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "RYBREVANT\u00ae  ( amivantamab-vmjw )  in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations",
    "url": "https://www.prnewswire.com/news-releases/rybrevant-amivantamab-vmjw-in-combination-with-chemotherapy-is-the-first-fda-approved-therapy-for-first-line-treatment-of-patients-with-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations-302077581.html",
    "time_published": "20240301T205900",
    "authors": [
      "Johnson & Johnson"
    ],
    "summary": "RYBREVANT\u00ae ( amivantamab-vmjw ) in Combination With Chemotherapy Is the First FDA Approved Therapy for First ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/2303741/JJ_SingleLine_Red_RGB_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": -0.019362,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.174407",
        "ticker_sentiment_score": "0.108791",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "JAMP Pharma Group announces the commercial launch and product availability for PrJamteki\u2122, the first biosimilar of Stelara\u00ae  ( ustekinumab )  in Canada",
    "url": "https://www.newswire.ca/news-releases/jamp-pharma-group-announces-the-commercial-launch-and-product-availability-for-prjamteki-tm-the-first-biosimilar-of-stelara-r-ustekinumab-in-canada-892829386.html",
    "time_published": "20240301T192600",
    "authors": [
      "JAMP Pharma"
    ],
    "summary": "JAMP Pharma Group announces the commercial launch and product availability for PrJamteki\u2122, the first biosimilar of ... Canada ...",
    "banner_image": "https://mma.prnewswire.com/media/2352688/JAMP_Pharma_JAMP_Pharma_Group_announces_the_commercial_launch_an.jpg?p=facebook",
    "source": "Canada Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.newswire.ca",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.322297,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALVO",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.06154",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Judge rejects AstraZeneca's challenge to Medicare drug price negotiations",
    "url": "https://www.cnbc.com/2024/03/01/medicare-drug-price-negotiations-judge-rejects-astrazeneca-challenge.html",
    "time_published": "20240301T190250",
    "authors": [
      "Annika Kim Constantino"
    ],
    "summary": "U.S. District Judge Colm Connolly's decision comes one day before manufacturers have to respond to Medicare's initial price offers for their drugs.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107130655-1665090556176-gettyimages-1431082899-_m021740_4b5641b7-17d1-48f7-8db3-6aef2e513b99.jpeg?v=1709317769&w=1920&h=1080",
    "source": "CNBC",
    "category_within_source": "Business",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.026892,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.306963",
        "ticker_sentiment_score": "0.250416",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "-0.079089",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "-0.079089",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "-0.079089",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This Firm Supplies Clean Power to AI Tech Companies. The CEO Wants More Credit.",
    "url": "https://www.barrons.com/amp/articles/aes-utility-energy-tech-ai-data-centers-feba4636",
    "time_published": "20240301T142700",
    "authors": [
      "Avi Salzman"
    ],
    "summary": "AES Has an AI Edge. The CEO Wants More Credit. ...",
    "banner_image": "https://images.barrons.com/im-27840959/social",
    "source": "Barrons",
    "category_within_source": "n/a",
    "source_domain": "www.barrons.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.904684"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.177295,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.164656",
        "ticker_sentiment_score": "0.169015",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.055236",
        "ticker_sentiment_score": "0.077846",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.055236",
        "ticker_sentiment_score": "0.144049",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.055236",
        "ticker_sentiment_score": "0.144049",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is WisdomTree U.S. Quality Dividend Growth ETF  ( DGRW )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2234343/is-wisdomtree-us-quality-dividend-growth-etf-dgrw-a-strong-etf-right-now",
    "time_published": "20240301T112006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default350.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999981"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.321684,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.111747",
        "ticker_sentiment_score": "0.059292",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.111747",
        "ticker_sentiment_score": "0.059292",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "0.186024",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WT",
        "relevance_score": "0.274628",
        "ticker_sentiment_score": "0.37035",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.111747",
        "ticker_sentiment_score": "0.059292",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Biocon shares gain on licence deal with Janssen, J&J for US markets",
    "url": "https://www.moneycontrol.com/news/business/stocks/biocon-shares-gain-on-licence-deal-with-janssen-jj-for-us-markets-12379491.html",
    "time_published": "20240301T041244",
    "authors": [],
    "summary": "Biocon Share Price | In an another development, the company's subsidiary received observations from US Food and Drug Administration ( USFDA ) .",
    "banner_image": "https://images.moneycontrol.com/static-mcnews/2024/03/WhatsApp-Image-2023-06-05-at-5.44.33-PM.jpeg?impolicy=website&width=168&height=118",
    "source": "Money Control",
    "category_within_source": "Buzzing Stocks",
    "source_domain": "www.moneycontrol.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.197051,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.149656",
        "ticker_sentiment_score": "0.135655",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stocks to watch today, March 01: Paytm, Tata Group, Airtel, Biocon, Suven, Vedanta, L&T | | News on Markets",
    "url": "https://www.business-standard.com/markets/news/stocks-to-watch-paytm-tata-group-airtel-biocon-suven-vedanta-l-t-124030100083_1.html",
    "time_published": "20240301T020847",
    "authors": [
      "Harshita Singh"
    ],
    "summary": "Stocks to watch: Paytm, Tata Group, Airtel, Biocon, Suven, Vedanta, L&T Business Standard ...",
    "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2024-01/16/full/1705389250-0843.jpg?im=FeatureCrop,size=(826,465)",
    "source": "Business Standard",
    "category_within_source": "GoogleRSS",
    "source_domain": "www.business-standard.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.218348,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "WMG",
        "relevance_score": "0.147366",
        "ticker_sentiment_score": "0.02422",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RNECF",
        "relevance_score": "0.147366",
        "ticker_sentiment_score": "0.012852",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FHYDF",
        "relevance_score": "0.074001",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.074001",
        "ticker_sentiment_score": "0.121075",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Berkshire Hathaway Has $168 Billion In Cash: These Stocks Should Be On Buffett's Buy List",
    "url": "https://www.forbes.com/sites/johndobosz/2024/03/02/berkshire-hathaway-has-168-billion-in-cash-these-stocks-should-be-on-buffetts-buy-list/",
    "time_published": "20240302T113000",
    "authors": [
      "John Dobosz"
    ],
    "summary": "Based on what Warren Buffett says and what he owns, it would not be surprising to see Berkshire buy stakes in these 13 stocks.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65e22f56538bd9faeb687c8b/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      }
    ],
    "overall_sentiment_score": 0.31919,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AON",
        "relevance_score": "0.029184",
        "ticker_sentiment_score": "0.120496",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CINF",
        "relevance_score": "0.029184",
        "ticker_sentiment_score": "0.209412",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ULTA",
        "relevance_score": "0.029184",
        "ticker_sentiment_score": "0.175679",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.029184",
        "ticker_sentiment_score": "0.024634",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.05833",
        "ticker_sentiment_score": "0.095983",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.087397",
        "ticker_sentiment_score": "0.078257",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.029184",
        "ticker_sentiment_score": "0.1708",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KHC",
        "relevance_score": "0.029184",
        "ticker_sentiment_score": "0.024634",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.029184",
        "ticker_sentiment_score": "0.1708",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DVA",
        "relevance_score": "0.029184",
        "ticker_sentiment_score": "0.145623",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OXY",
        "relevance_score": "0.029184",
        "ticker_sentiment_score": "0.024634",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.029184",
        "ticker_sentiment_score": "0.145623",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.029184",
        "ticker_sentiment_score": "0.1708",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.05833",
        "ticker_sentiment_score": "0.095983",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.029184",
        "ticker_sentiment_score": "0.1708",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SIGI",
        "relevance_score": "0.029184",
        "ticker_sentiment_score": "0.209412",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WGO",
        "relevance_score": "0.029184",
        "ticker_sentiment_score": "0.117621",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IAUGF",
        "relevance_score": "0.029184",
        "ticker_sentiment_score": "0.120496",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ODFL",
        "relevance_score": "0.029184",
        "ticker_sentiment_score": "0.044952",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRSN",
        "relevance_score": "0.029184",
        "ticker_sentiment_score": "0.145623",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Mezzion Pharmaceuticals Announces Dr. Rahul Rathod of Boston Children's Hospital and Harvard Medical School as ... - PR Newswire",
    "url": "https://www.prnewswire.com/apac/news-releases/mezzion-pharmaceuticals-announces-dr-rahul-rathod-of-boston-childrens-hospital-and-harvard-medical-school-as-the-global-principal-investigator-for-the-confirmatory-pivotal-phase-3-trial-fuel-2-302077704.html",
    "time_published": "20240302T023241",
    "authors": [],
    "summary": "Mezzion Pharmaceuticals Announces Dr. Rahul Rathod of Boston Children's Hospital and Harvard Medical School as ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.210931,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.046363",
        "ticker_sentiment_score": "0.050118",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Dow companies made bigger-than-normal adjustments to profits in Q4",
    "url": "https://www.marketwatch.com/story/companies-in-the-dow-made-bigger-than-normal-adjustments-to-their-profits-in-q4-analysis-shows-08ba9fa9",
    "time_published": "20240303T150100",
    "authors": [
      "Bill Peters"
    ],
    "summary": "The median difference between per-share profit reported based on generally accepted accounting principles and the adjusted kind stood at 31%.",
    "banner_image": "https://images.mktw.net/im-72523698/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999996"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.119097,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JWN",
        "relevance_score": "0.080323",
        "ticker_sentiment_score": "0.11099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TGT",
        "relevance_score": "0.199037",
        "ticker_sentiment_score": "0.036311",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIG",
        "relevance_score": "0.080323",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VSCO",
        "relevance_score": "0.080323",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.080323",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.080323",
        "ticker_sentiment_score": "0.061468",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FL",
        "relevance_score": "0.080323",
        "ticker_sentiment_score": "0.11099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.080323",
        "ticker_sentiment_score": "0.061468",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KR",
        "relevance_score": "0.159834",
        "ticker_sentiment_score": "-0.024337",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NKE",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "0.106114",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AEO",
        "relevance_score": "0.080323",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GPS",
        "relevance_score": "0.080323",
        "ticker_sentiment_score": "0.11099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DOW",
        "relevance_score": "0.080323",
        "ticker_sentiment_score": "0.061468",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BURL",
        "relevance_score": "0.080323",
        "ticker_sentiment_score": "0.11099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.080323",
        "ticker_sentiment_score": "0.049765",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.080323",
        "ticker_sentiment_score": "0.034513",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ROST",
        "relevance_score": "0.080323",
        "ticker_sentiment_score": "0.11099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANF",
        "relevance_score": "0.080323",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DOCU",
        "relevance_score": "0.080323",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRVL",
        "relevance_score": "0.080323",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "0.007873",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:UYU",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "0.05874",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Will Johnson & Johnson Be a Trillion-Dollar Stock by 2030?",
    "url": "https://www.fool.com/investing/2024/03/03/will-johnson-johnson-be-a-trillion-dollar-stock-by/",
    "time_published": "20240303T131400",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Can Johnson & Johnson stock become a hot buy for growth-focused investors, or is this mainly just a dividend play?",
    "banner_image": "https://g.foolcdn.com/editorial/images/766951/surprised-investors-looking-at-their-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.311497,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMAM",
        "relevance_score": "0.0699",
        "ticker_sentiment_score": "-0.022483",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.619618",
        "ticker_sentiment_score": "0.561967",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "3 Nuggets of Investing Wisdom From Warren Buffett's Latest Letter to Berkshire Hathaway Shareholders",
    "url": "https://www.fool.com/investing/2024/03/03/investing-wisdom-warren-buffett-berkshire-letter/",
    "time_published": "20240303T115500",
    "authors": [
      "James Brumley"
    ],
    "summary": "The Oracle of Omaha is still as good at explaining how he picks stocks as he is at actually picking them.",
    "banner_image": "https://g.foolcdn.com/editorial/images/766937/buffett16-tmf.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999897"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.04815,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KO",
        "relevance_score": "0.040348",
        "ticker_sentiment_score": "0.022432",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.040348",
        "ticker_sentiment_score": "0.08631",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.040348",
        "ticker_sentiment_score": "-0.008791",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Dips More Than Broader Market: What You Should Know",
    "url": "https://www.zacks.com/stock/news/2235639/johnson-johnson-jnj-dips-more-than-broader-market-what-you-should-know",
    "time_published": "20240304T224520",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) closed the most recent trading day at $159.84, moving -1.41% from the previous trading session.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default64.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.135784,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.537213",
        "ticker_sentiment_score": "0.128491",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "J&J  ( JNJ )  Secures Full FDA Nod for Rybrevant in Lung Cancer",
    "url": "https://www.zacks.com/stock/news/2235489/jj-jnj-secures-full-fda-nod-for-rybrevant-in-lung-cancer",
    "time_published": "20240304T165100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The approval is based on data from a late-stage study wherein treatment with J&J's (JNJ) Rybrevant plus chemotherapy reduced the disease-progression risk or death by 61% in certain NSCLC patients.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/1612.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.997335"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.18996,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ADMA",
        "relevance_score": "0.382925",
        "ticker_sentiment_score": "0.200211",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ACET",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.052672",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "-0.025716",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PBYI",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.111128",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Global Urinary Incontinence Treatment Devices Market Size is Estimated to Reach USD 6.02 billion by 2030, Growing at a CAGR of 6.58%: Straits Research",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37453577/global-urinary-incontinence-treatment-devices-market-size-is-estimated-to-reach-usd-6-02-billion-b",
    "time_published": "20240304T130500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, United States, March 04, 2024 ( GLOBE NEWSWIRE ) -- A medical disease called urinary incontinence causes uncontrollable urine loss. Medical devices are used to treat chronic urine incontinence and to grow and strengthen the pelvic floor muscles.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.144111,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.03704",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.03704",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.03704",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.03704",
        "ticker_sentiment_score": "0.105774",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.03704",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.03704",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors - Immunome  ( NASDAQ:IMNM ) , Shattuck Labs  ( NASDAQ:STTK ) ",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37450970/shattuck-labs-announces-appointment-of-clay-siegall-ph-d-and-kate-sasser-ph-d-to-its-board-of-dire",
    "time_published": "20240304T120000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "AUSTIN, TX and DURHAM, NC, March 04, 2024 ( GLOBE NEWSWIRE ) -- Shattuck Labs, Inc. ( Shattuck ) STTK, a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.176944,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IMNM",
        "relevance_score": "0.09239",
        "ticker_sentiment_score": "-0.026467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GMAB",
        "relevance_score": "0.046273",
        "ticker_sentiment_score": "0.121464",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.046273",
        "ticker_sentiment_score": "0.121464",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STTK",
        "relevance_score": "0.272282",
        "ticker_sentiment_score": "-0.018778",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Biden's State Of The Union: Grading His Results On Abortion Access, Drug Prices And Opium Epidemic - AstraZeneca  ( NASDAQ:AZN ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
    "url": "https://www.benzinga.com/news/24/03/37495723/bidens-state-of-the-union-grading-his-results-on-abortion-access-drug-prices-and-opium-epidemic",
    "time_published": "20240305T214503",
    "authors": [
      "Natan Ponieman"
    ],
    "summary": "As President Joe Biden prepares for his State of the Union address on Thursday, he's expected to touch on several key issues including Bidenomics, access to healthcare and the U.S.' role in the world.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/joe-biden-shutter4_9.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.140317,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVS",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Smart Money Is Betting Big In JNJ Options - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/options/24/03/37490074/smart-money-is-betting-big-in-jnj-options",
    "time_published": "20240305T181747",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bullish move on Johnson & Johnson. Our analysis of options history for Johnson & Johnson JNJ revealed 12 unusual trades. Delving into the details, we found 75% of traders were bullish, while 25% showed bearish tendencies.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.150829,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.082677",
        "ticker_sentiment_score": "0.142177",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.700759",
        "ticker_sentiment_score": "0.35771",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "BDA Receives Best Place to Work Recognition by The Sports Business Journal",
    "url": "https://www.prnewswire.com/news-releases/bda-receives-best-place-to-work-recognition-by-the-sports-business-journal-302077238.html",
    "time_published": "20240305T140000",
    "authors": [
      "LLC",
      "Bensussen Deutsch & Associates"
    ],
    "summary": "Global Merchandising Agency Earns Medalist Honors for Outstanding Leadership and Commitment to Employee Satisfaction",
    "banner_image": "https://mma.prnewswire.com/media/2142284/BDA_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.520012,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "FDX",
        "relevance_score": "0.06515",
        "ticker_sentiment_score": "0.191432",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.06515",
        "ticker_sentiment_score": "0.191432",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ICNB",
        "relevance_score": "0.129866",
        "ticker_sentiment_score": "0.226214",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.06515",
        "ticker_sentiment_score": "0.191432",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FOREX:EUR",
        "relevance_score": "0.06515",
        "ticker_sentiment_score": "0.118167",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Major shareholder announcement - AIM International Mutual Funds",
    "url": "https://www.globenewswire.com/news-release/2024/03/05/2840228/0/en/Major-shareholder-announcement-AIM-International-Mutual-Funds.html",
    "time_published": "20240305T110100",
    "authors": [
      "Chemometec A/S"
    ],
    "summary": "ANNOUNCEMENT NO. ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.124283,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "IVZ",
        "relevance_score": "0.552443",
        "ticker_sentiment_score": "0.262306",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.295867",
        "ticker_sentiment_score": "0.086705",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.295867",
        "ticker_sentiment_score": "0.086705",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.295867",
        "ticker_sentiment_score": "0.086705",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Major shareholder announcement - Invesco Ltd.",
    "url": "https://www.globenewswire.com/news-release/2024/03/05/2840224/0/en/Major-shareholder-announcement-Invesco-Ltd.html",
    "time_published": "20240305T110000",
    "authors": [
      "Chemometec A/S"
    ],
    "summary": "ANNOUNCEMENT NO. ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.041462,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "IVZ",
        "relevance_score": "0.608634",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.331765",
        "ticker_sentiment_score": "0.094969",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.331765",
        "ticker_sentiment_score": "0.094969",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.331765",
        "ticker_sentiment_score": "0.094969",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Big businesses hit with management idea drought",
    "url": "https://www.moneycontrol.com/news/opinion/big-businesses-hit-with-management-idea-drought-12404311.html",
    "time_published": "20240305T073425",
    "authors": [],
    "summary": "The multibillion-dollar industry has lost the intellectual momentum and edge. There are only so many ideas that you can have about managing people or resources, and many of the best were generated long ago ...",
    "banner_image": "https://images.moneycontrol.com/static-mcnews/2023/12/china-yuan-378x213.jpg?impolicy=website&width=168&height=118",
    "source": "Money Control",
    "category_within_source": "Business",
    "source_domain": "www.moneycontrol.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.09896,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GM",
        "relevance_score": "0.091977",
        "ticker_sentiment_score": "0.041408",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.03072",
        "ticker_sentiment_score": "0.070542",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Sandoz announces nominations to the Board of Directors and leadership change",
    "url": "https://www.globenewswire.com/news-release/2024/03/05/2840074/0/en/Sandoz-announces-nominations-to-the-Board-of-Directors-and-leadership-change.html",
    "time_published": "20240305T060000",
    "authors": [
      "Sandoz International GmbH"
    ],
    "summary": "Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/41ea40f9-fbb7-45d9-9136-33fdb399d0ba",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.181593,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AOMFF",
        "relevance_score": "0.067919",
        "ticker_sentiment_score": "0.002006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TXG",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "0.004778",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "0.004778",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Sandoz announces nominations to the Board of Directors and leadership change",
    "url": "https://markets.businessinsider.com/news/stocks/sandoz-announces-nominations-to-the-board-of-directors-and-leadership-change-1033131130",
    "time_published": "20240305T060000",
    "authors": [
      "markets.businessinsider.com"
    ],
    "summary": "\u2022 Mathai Mammen and Michael Rechsteiner nominated to stand for election to Sandoz Board of Directors at upcoming Annual General Meeting \u2022 Remco Steenbergen appointed as Sandoz CFO and member of Executive Committee as of July 1, 2024, and consequently not standing for re-election to Board of ...",
    "banner_image": "https://ml-eu.globenewswire.com/media/OWJmMGQ2NmMtODAyOS00NWQ3LTgzN2UtNDIxZDUxMWJmMGViLTEwMTQyODI=/tiny/Sandoz-International-GmbH.png",
    "source": "Business Insider",
    "category_within_source": "RSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.181593,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AOMFF",
        "relevance_score": "0.067919",
        "ticker_sentiment_score": "0.002006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TXG",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "0.004778",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "0.004778",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Sandoz announces nominations to the Board of Directors and leadership change - Sandoz Group  ( OTC:SDZNY ) ",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37474269/sandoz-announces-nominations-to-the-board-of-directors-and-leadership-change",
    "time_published": "20240305T060000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Mathai Mammen and Michael Rechsteiner nominated to stand for election to Sandoz Board of Directors at upcoming Annual General Meeting",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.174608,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AOMFF",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.002004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TXG",
        "relevance_score": "0.033144",
        "ticker_sentiment_score": "0.00571",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.033144",
        "ticker_sentiment_score": "0.00571",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cancer-causing chemical can form at 'unacceptably high levels' in certain acne products, independent lab claims",
    "url": "https://www.cnn.com/2024/03/06/health/benzene-acne-products-valisure/index.html",
    "time_published": "20240306T233133",
    "authors": [
      "Jacqueline Howard"
    ],
    "summary": "High levels of benzene, a cancer-causing chemical, can form in acne treatment products containing benzoyl peroxide, according to a new report from Valisure, an independent laboratory.",
    "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/210714221158-johnson-and-johnson-sunscreens.jpg?q=x_0,y_5,h_900,w_1600,c_crop/h_144,w_256",
    "source": "CNN",
    "category_within_source": "Markets",
    "source_domain": "www.cnn.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.061573,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "WBD",
        "relevance_score": "0.081552",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.040829",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "He Got 49 COVID Shots in One Month!",
    "url": "https://www.theatlantic.com/health/archive/2024/03/217-covid-shots-hypervaccination-study/677666/",
    "time_published": "20240306T213600",
    "authors": [
      "Jacob Stern"
    ],
    "summary": "On June 3, 2021, a roughly 60-year-old man in the riverside city of Magdeburg, Germany, received his first COVID vaccine. He opted for Johnson & Johnson's shot, popular at that point because unlike Pfizer's and Moderna's vaccines, it was one-and-done. But that, evidently, was not what he had in ...",
    "banner_image": "https://cdn.theatlantic.com/thumbor/PXP2_01C3dKolU9Hi6bRPrc8L10=/0x0:2000x1125/960x540/media/img/mt/2024/03/217_shots/original.jpg",
    "source": "The Atlantic",
    "category_within_source": "n/a",
    "source_domain": "www.theatlantic.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.026119,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NYT",
        "relevance_score": "0.042346",
        "ticker_sentiment_score": "0.032002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.042346",
        "ticker_sentiment_score": "0.032002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.126561",
        "ticker_sentiment_score": "0.049657",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.126561",
        "ticker_sentiment_score": "0.025729",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.042346",
        "ticker_sentiment_score": "0.032002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.042346",
        "ticker_sentiment_score": "0.032002",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Ambrx Shareholders Approve Acquisition by Johnson & Johnson - Ambrx Biopharma  ( NASDAQ:AMAM ) ",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37517010/ambrx-shareholders-approve-acquisition-by-johnson-johnson",
    "time_published": "20240306T182000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "SAN DIEGO, March 06, 2024 ( GLOBE NEWSWIRE ) -- Ambrx Biopharma, Inc., ( \"Ambrx\" or the \"Company\" ) AMAM, today announced that its shareholders approved a proposal to adopt the merger agreement entered into between the Company and Johnson & Johnson at its Special Meeting of Shareholders.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Mergers",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.184662,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMAM",
        "relevance_score": "0.145437",
        "ticker_sentiment_score": "0.1798",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.097259",
        "ticker_sentiment_score": "0.266488",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Ambrx Shareholders Approve Acquisition by Johnson & Johnson",
    "url": "https://www.globenewswire.com/news-release/2024/03/06/2841709/0/en/Ambrx-Shareholders-Approve-Acquisition-by-Johnson-Johnson.html",
    "time_published": "20240306T182000",
    "authors": [
      "Ambrx Biopharma Inc."
    ],
    "summary": "SAN DIEGO, March 06, 2024 ( GLOBE NEWSWIRE ) -- Ambrx Biopharma, Inc., ( \"Ambrx\" or the \"Company\" ) ( NASDAQ: AMAM ) , today announced that its shareholders approved a proposal to adopt the merger agreement entered into between the Company and Johnson & Johnson at its Special Meeting of ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/4983c39d-12ad-4feb-81fa-fb6d5d6ee6f1",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.191919,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMAM",
        "relevance_score": "0.101797",
        "ticker_sentiment_score": "0.183311",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.101797",
        "ticker_sentiment_score": "0.273097",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Encephalitis Treatment Market Overview 2024-2028: Expected Market Size, Major Growth Factors And Lucrative Segments As Per The Business Research Company's Encephalitis Treatment Global Market Report 2024",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37514086/encephalitis-treatment-market-overview-2024-2028-expected-market-size-major-growth-factors-and-luc",
    "time_published": "20240306T163000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LONDON, March 06, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's encephalitis treatment global market report 2024, the encephalitis treatment market has exhibited robust growth in recent years, with a notable increase in market size.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.3086,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.19606",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.058903",
        "ticker_sentiment_score": "0.174004",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.058903",
        "ticker_sentiment_score": "0.174004",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Chemical linked to cancer found in acne treatment creams including Proactiv | World News",
    "url": "https://www.business-standard.com/world-news/chemical-linked-to-cancer-found-in-acne-treatment-creams-including-proactiv-124030601181_1.html",
    "time_published": "20240306T161543",
    "authors": [
      "Bloomberg"
    ],
    "summary": "Chemical linked to cancer found in acne treatment creams including Proactiv Business Standard ...",
    "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2024-03/06/full/1709741581-9032.png?im=Resize=(640,480)",
    "source": "Business Standard",
    "category_within_source": "GoogleRSS",
    "source_domain": "www.business-standard.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.052076,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "TARO",
        "relevance_score": "0.03798",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.03798",
        "ticker_sentiment_score": "-0.018641",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.03798",
        "ticker_sentiment_score": "-0.018641",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RBGPF",
        "relevance_score": "0.03798",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UL",
        "relevance_score": "0.075874",
        "ticker_sentiment_score": "-0.060062",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2236576/johnson-johnson-jnj-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20240306T140014",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default358.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.233293,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.478494",
        "ticker_sentiment_score": "0.151501",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "A man deliberately got 217 Covid shots. Here's what happened",
    "url": "https://www.cnn.com/2024/03/06/health/covid-217-shots-hypervaccination-lancet/index.html",
    "time_published": "20240306T111100",
    "authors": [
      "Mira Cheng"
    ],
    "summary": "One German man has redefined \"man on a mission.\" A 62-year-old from Magdeburg deliberately got 217 Covid-19 vaccine shots in the span of 29 months, according to a new study, going against national vaccine recommendations. That's an average of one jab every four days.",
    "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/231002112056-04-mrna-vaccine-technology-explainer-shot.jpg?c=16x9&q=h_144,w_256,c_fill",
    "source": "CNN",
    "category_within_source": "Markets",
    "source_domain": "www.cnn.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.083586,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "WBD",
        "relevance_score": "0.069798",
        "ticker_sentiment_score": "-0.018145",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.034933",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.034933",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.034933",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.034933",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.034933",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley - Arcellx  ( NASDAQ:ACLX ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37544416/arcellxs-lead-asset-can-potentially-outperform-bristol-myers-squibb-johnson-johnson",
    "time_published": "20240307T195219",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Morgan Stanley initiates Arcellx Inc ACLX, noting a differentiated CAR-T platform for blood cancer backed by an established CAR-T partner. ddBCMA ( aka anito-cel ) is Arcellx's lead asset, incorporating its patent-protected D-domain as the extracellular binding domain.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Ozempic-weight-loss-pill_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.31082,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ACLX",
        "relevance_score": "0.59972",
        "ticker_sentiment_score": "0.068026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LEGN",
        "relevance_score": "0.220809",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.325924",
        "ticker_sentiment_score": "-0.110687",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.220809",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSVT",
        "relevance_score": "0.220809",
        "ticker_sentiment_score": "0.535033",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.220809",
        "ticker_sentiment_score": "0.308303",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.220809",
        "ticker_sentiment_score": "0.535033",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Noa Therapeutics Secures Pre-Seed Financing to Transform the Treatment of Inflammatory Disease",
    "url": "https://www.newswire.ca/news-releases/noa-therapeutics-secures-pre-seed-financing-to-transform-the-treatment-of-inflammatory-disease-858012411.html",
    "time_published": "20240307T130700",
    "authors": [
      "Noa Therapeutics"
    ],
    "summary": "TORONTO, March 7, 2024 /CNW/ - Noa Therapeutics, a preclinical stage biotech company with a portfolio of novel trimodal therapeutics to address inflammatory barrier diseases, announced that they have secured an oversubscribed pre-seed financing round.",
    "banner_image": "https://mma.prnewswire.com/media/2356568/Noa_Therapeutics_Noa_Therapeutics_Secures_Pre_Seed_Financing_to.jpg?p=facebook",
    "source": "Canada Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.newswire.ca",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.141688,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.089797",
        "ticker_sentiment_score": "0.001097",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Biden Will Tout Lower Drug Prices in State of the Union. Big Pharma Might Be Losing the Fight.",
    "url": "https://www.barrons.com/amp/articles/medicare-drug-prices-pharmaceutical-stocks-0fbfa85e",
    "time_published": "20240307T061500",
    "authors": [
      "Josh Nathan-Kazis"
    ],
    "summary": "Big Pharma Is Running Out of Time to Block Medicare Drug Price Negotiations ...",
    "banner_image": "https://images.barrons.com/im-63785102/social",
    "source": "Barrons",
    "category_within_source": "n/a",
    "source_domain": "www.barrons.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": -0.067061,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.103778",
        "ticker_sentiment_score": "-0.006764",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.03468",
        "ticker_sentiment_score": "-0.086466",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.03468",
        "ticker_sentiment_score": "-0.01659",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "-0.051257",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.03468",
        "ticker_sentiment_score": "-0.086466",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Unusual Options Activity For March 08 - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/options/24/03/37566466/johnson-johnson-unusual-options-activity-for-march-08",
    "time_published": "20240308T190104",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bearish approach towards Johnson & Johnson JNJ, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.171533,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.075635",
        "ticker_sentiment_score": "0.140603",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.552443",
        "ticker_sentiment_score": "0.299646",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Retail Investors Could Make $2,000 on Cummins Exchange Offer. Here's How.",
    "url": "https://www.barrons.com/amp/articles/cummins-exchange-offer-atmus-98ddf4d2",
    "time_published": "20240308T184100",
    "authors": [
      "Andrew Bary"
    ],
    "summary": "An exchange offer by Cummins , the diesel engine maker, for shares in Atmus Filtration Technologies allows small investors to fully participate and potentially make about $2,000 on the trade in the next week or so.",
    "banner_image": "https://images.barrons.com/im-09529025/social",
    "source": "Barrons",
    "category_within_source": "n/a",
    "source_domain": "www.barrons.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.692272"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.237375,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.081552",
        "ticker_sentiment_score": "0.085584",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ATMU",
        "relevance_score": "0.081552",
        "ticker_sentiment_score": "0.063122",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.081552",
        "ticker_sentiment_score": "0.085584",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the VanEck Pharmaceutical ETF  ( PPH ) ?",
    "url": "https://www.zacks.com/stock/news/2237788/should-you-invest-in-the-vaneck-pharmaceutical-etf-pph",
    "time_published": "20240308T112002",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for PPH ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default81.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.152212,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.134968",
        "ticker_sentiment_score": "0.060821",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.134968",
        "ticker_sentiment_score": "0.042552",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.134968",
        "ticker_sentiment_score": "0.060821",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.134968",
        "ticker_sentiment_score": "0.060821",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Legal Challenges To IRA Drug Price Negotiations Face Skeptical Judges",
    "url": "https://www.forbes.com/sites/joshuacohen/2024/03/09/legal-challenges-to-ira-drug-price-negotiations-face-skeptical-judges/",
    "time_published": "20240309T174448",
    "authors": [
      "Joshua Cohen"
    ],
    "summary": "A district court judge in New Jersey heard oral arguments this week with respect to claims brought forth by four pharmaceutical companies that the Inflation Reduction Act's drug price negotiation provision violates certain constitutional rights.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65eb1178e7f08fb8331f00d8/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.009656,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "FGROF",
        "relevance_score": "0.028456",
        "ticker_sentiment_score": "0.013937",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.169477",
        "ticker_sentiment_score": "0.018762",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.056876",
        "ticker_sentiment_score": "-0.035",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.028456",
        "ticker_sentiment_score": "-0.016752",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.028456",
        "ticker_sentiment_score": "-0.016752",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "New data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in moderate-to-severe plaque psoriasis through one year",
    "url": "https://www.prnewswire.com/news-releases/new-data-shows-jnj-2113-the-first-and-only-investigational-targeted-oral-peptide-maintained-skin-clearance-in-moderate-to-severe-plaque-psoriasis-through-one-year-302084693.html",
    "time_published": "20240309T170000",
    "authors": [
      "Johnson & Johnson"
    ],
    "summary": "New data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/2333578/Johnson_and_Johnson_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.090321,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "PTGX",
        "relevance_score": "0.234946",
        "ticker_sentiment_score": "0.160622",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.740019",
        "ticker_sentiment_score": "0.17013",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Samsung Bioepis Presents Two Abstracts for Its Immunology Portfolio at the 2024 American Academy of Dermatology  ( AAD )  Annual Meeting",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37574324/samsung-bioepis-presents-two-abstracts-for-its-immunology-portfolio-at-the-2024-american-academy-o",
    "time_published": "20240309T150500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "INCHEON, Korea, March 09, 2024 ( GLOBE NEWSWIRE ) -- Samsung Bioepis Co., Ltd. presented two new study results for its immunology portfolio - SB5, a biosimilar to Humira1 ( adalimumab ) , and SB17, a proposed biosimilar to Stelara2 ( ustekinumab ) - at the 2024 American Academy of Dermatology ( ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.064972,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SSNLF",
        "relevance_score": "0.162802",
        "ticker_sentiment_score": "0.119639",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.023418",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.023418",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OGN",
        "relevance_score": "0.023418",
        "ticker_sentiment_score": "0.066965",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Increases Despite Market Slip: Here's What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2238883/johnson-johnson-jnj-increases-despite-market-slip-heres-what-you-need-to-know",
    "time_published": "20240311T214519",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The latest trading day saw Johnson & Johnson (JNJ) settling at $161.23, representing a +1.07% change from its previous close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default83.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.169927,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.590482",
        "ticker_sentiment_score": "0.152388",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "U.S. 1st Latino Tech Payroll Startup Trez.co, Announces Advisory Board of Industry Giants and C-Suite Executives As It Opens Its Scaling Seed Round",
    "url": "https://www.prnewswire.com/news-releases/us-1st-latino-tech-payroll-startup-trezco-announces-advisory-board-of-industry-giants-and-c-suite-executives-as-it-opens-its-scaling-seed-round-302085701.html",
    "time_published": "20240311T200000",
    "authors": [
      "Trez Inc"
    ],
    "summary": "U.S. 1st Latino Tech Payroll Startup Trez.co, Announces Advisory Board of Industry Giants and C-Suite Executives As It ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/2359562/Advisory_Board_of_Industry.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.413784,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CSCO",
        "relevance_score": "0.042421",
        "ticker_sentiment_score": "0.100646",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WM",
        "relevance_score": "0.042421",
        "ticker_sentiment_score": "0.098471",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.042421",
        "ticker_sentiment_score": "0.169062",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "K",
        "relevance_score": "0.042421",
        "ticker_sentiment_score": "0.169062",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ICNB",
        "relevance_score": "0.042421",
        "ticker_sentiment_score": "0.169062",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JACK",
        "relevance_score": "0.042421",
        "ticker_sentiment_score": "0.100646",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EC",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "0.315895",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Insights Into Johnson & Johnson's Performance Versus Peers In Pharmaceuticals Sector - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/news/24/03/37592617/insights-into-johnson-amp-johnsons-performance-versus-peers-in-pharmaceuticals-sector",
    "time_published": "20240311T160051",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In the dynamic and fiercely competitive business environment, conducting a thorough analysis of companies is crucial for investors and industry enthusiasts. In this article, we will perform an extensive industry comparison, evaluating Johnson & Johnson JNJ in relation to its major competitors in ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.249941,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.065327",
        "ticker_sentiment_score": "0.139242",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.433877",
        "ticker_sentiment_score": "0.346803",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "UM Named Ad Age A-List 2024 Media Agency of the Year - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/um-named-ad-age-a-list-2024-media-agency-of-the-year-302085369.html",
    "time_published": "20240311T140000",
    "authors": [],
    "summary": "UM Named Ad Age A-List 2024 Media Agency of the Year PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.579266,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SNEJF",
        "relevance_score": "0.098659",
        "ticker_sentiment_score": "0.197768",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MAT",
        "relevance_score": "0.098659",
        "ticker_sentiment_score": "0.197768",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.098659",
        "ticker_sentiment_score": "0.197768",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GPRO",
        "relevance_score": "0.098659",
        "ticker_sentiment_score": "0.197768",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.098659",
        "ticker_sentiment_score": "0.197768",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.098659",
        "ticker_sentiment_score": "0.197768",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.098659",
        "ticker_sentiment_score": "0.197768",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ACN",
        "relevance_score": "0.098659",
        "ticker_sentiment_score": "0.197768",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Neptune Software: 'Environmental Supply Chains - You Don't Need to Sacrifice Profitability to Act Sustainably'",
    "url": "https://www.prnewswire.com/news-releases/neptune-software-environmental-supply-chains---you-dont-need-to-sacrifice-profitability-to-act-sustainably-302083164.html",
    "time_published": "20240311T111500",
    "authors": [
      "Neptune Software"
    ],
    "summary": "OSLO, Norway, March 11, 2024 /PRNewswire/ -- As the urgency to achieve net-zero carbon emissions by 2050 increases, it's more important than ever before that companies do their part to address growing environmental and climate concerns worldwide.",
    "banner_image": "https://mma.prnewswire.com/media/800029/Neptune_Software_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.305623,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.117774",
        "ticker_sentiment_score": "0.033522",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Dividend Kings of Healthcare Stocks to Buy Hand Over Fist in March",
    "url": "https://www.fool.com/investing/2024/03/11/dividend-kings-healthcare-stocks-to-buy-in-march/",
    "time_published": "20240311T093500",
    "authors": [
      "Justin Pope"
    ],
    "summary": "These are some of the best-performing stocks in what's arguably society's most important industry.",
    "banner_image": "https://g.foolcdn.com/editorial/images/767296/jnj.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.319223,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.051886",
        "ticker_sentiment_score": "0.015964",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.103554",
        "ticker_sentiment_score": "0.184254",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.20537",
        "ticker_sentiment_score": "0.211033",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.255106",
        "ticker_sentiment_score": "0.149871",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Major shareholder announcement - BlackRock, Inc.",
    "url": "https://www.globenewswire.com/news-release/2024/03/11/2843540/0/en/Major-shareholder-announcement-BlackRock-Inc.html",
    "time_published": "20240311T093000",
    "authors": [
      "Chemometec A/S"
    ],
    "summary": "ANNOUNCEMENT NO. ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.164459,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.541149",
        "ticker_sentiment_score": "0.344368",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.288893",
        "ticker_sentiment_score": "0.08505",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.288893",
        "ticker_sentiment_score": "0.08505",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.288893",
        "ticker_sentiment_score": "0.08505",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Golden Cross Alert: Johnson & Johnson Shines With Ambrx Deal, Bullish Technical Signal - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/03/37631893/golden-cross-alert-johnson-johnson-shines-with-ambrx-deal-bullish-technical-signal",
    "time_published": "20240312T190501",
    "authors": [
      "Surbhi Jain"
    ],
    "summary": "Johnson & Johnson JNJ stock hasn't displayed much momentum: it is down 1.22% over the past six months, up 5.57% over the past year and up 3% YTD. The stock recently made a Golden Cross on the charts, signaling a reversal in trend. Johnson & Johnson's recent acquisition of Ambrx Biopharma boosted ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/JohnsonampJohnson-Shutterstock.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.217661,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMAM",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "0.104876",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.617765",
        "ticker_sentiment_score": "0.240641",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "CIO Leadership: The Call for Visionary Global Leadership Will Power the Discussion at HMG Strategy's 17th Annual New York CIO Summit of America on April 11",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37627110/cio-leadership-the-call-for-visionary-global-leadership-will-power-the-discussion-at-hmg-strategys",
    "time_published": "20240312T162332",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "WESTPORT, Conn., March 12, 2024 ( GLOBE NEWSWIRE ) -- HMG Strategy, the World's #1 platform for enabling technology executives to reimagine the enterprise and reshape the business world, is thrilled to announce that its signature event - the 17th Annual New York CIO Summit of America - will be ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.214992,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CHH",
        "relevance_score": "0.018257",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.018257",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UPWK",
        "relevance_score": "0.018257",
        "ticker_sentiment_score": "0.044744",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RNG",
        "relevance_score": "0.054732",
        "ticker_sentiment_score": "0.04905",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DRKTF",
        "relevance_score": "0.054732",
        "ticker_sentiment_score": "0.04905",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RMNI",
        "relevance_score": "0.054732",
        "ticker_sentiment_score": "0.04905",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTZ",
        "relevance_score": "0.018257",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBGSF",
        "relevance_score": "0.036504",
        "ticker_sentiment_score": "0.044163",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KFY",
        "relevance_score": "0.018257",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PANW",
        "relevance_score": "0.109206",
        "ticker_sentiment_score": "0.055648",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CL",
        "relevance_score": "0.018257",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PSN",
        "relevance_score": "0.018257",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCO",
        "relevance_score": "0.018257",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMG",
        "relevance_score": "0.018257",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FUTU",
        "relevance_score": "0.018257",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APPN",
        "relevance_score": "0.036504",
        "ticker_sentiment_score": "0.050258",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTNX",
        "relevance_score": "0.054732",
        "ticker_sentiment_score": "0.04905",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BACHY",
        "relevance_score": "0.018257",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FTNT",
        "relevance_score": "0.018257",
        "ticker_sentiment_score": "0.044744",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALC",
        "relevance_score": "0.018257",
        "ticker_sentiment_score": "0.157071",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ZS",
        "relevance_score": "0.054732",
        "ticker_sentiment_score": "0.04905",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FUJIF",
        "relevance_score": "0.018257",
        "ticker_sentiment_score": "0.225042",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UPBD",
        "relevance_score": "0.036504",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IDCBY",
        "relevance_score": "0.018257",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHE",
        "relevance_score": "0.018257",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Global Contraceptive Drugs Market Size is Projected to Reach USD 28.96 billion by 2030, Growing at a CAGR of 7.3%: Straits Research - Agile Therapeutics  ( NASDAQ:AGRX ) , GSK  ( NYSE:GSK ) ",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37621870/global-contraceptive-drugs-market-size-is-projected-to-reach-usd-28-96-billion-by-2030-growing-at-",
    "time_published": "20240312T142000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, United States, March 12, 2024 ( GLOBE NEWSWIRE ) -- Contraception encompasses the use of drugs to prevent pregnancy, the transmission of sexually transmitted diseases ( STDs ) , the transmission of sexually transmitted infections ( STIs ) , family planning, and birth control.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.174997,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AGRX",
        "relevance_score": "0.135347",
        "ticker_sentiment_score": "0.05971",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "0.043225",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "0.043225",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "0.043225",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "0.043225",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GSK",
        "relevance_score": "0.101725",
        "ticker_sentiment_score": "0.085346",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.101725",
        "ticker_sentiment_score": "0.077847",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "0.043225",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's Why You Should Retain Medtronic  ( MDT )  Stock for Now",
    "url": "https://www.zacks.com/stock/news/2239072/heres-why-you-should-retain-medtronic-mdt-stock-for-now",
    "time_published": "20240312T120300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Investors continue to be optimistic about Medtronic (MDT) on the strength of the Neurosurgery and Cardiovascular and Neurosurgery portfolios.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/41/899.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.997845"
      }
    ],
    "overall_sentiment_score": 0.319885,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CAH",
        "relevance_score": "0.158781",
        "ticker_sentiment_score": "0.148603",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.2741",
        "ticker_sentiment_score": "0.335866",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.158781",
        "ticker_sentiment_score": "0.103728",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.039944",
        "ticker_sentiment_score": "0.095015",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DVA",
        "relevance_score": "0.158781",
        "ticker_sentiment_score": "0.090542",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.039944",
        "ticker_sentiment_score": "0.095015",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 High-Yield Dow Jones Dividend Stocks to Buy Now and Hold Forever",
    "url": "https://www.fool.com/investing/2024/03/12/2-high-yield-dow-jones-dividend-stocks-to-buy-now/",
    "time_published": "20240312T105300",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "These industry leaders boast advantages that could expand their bottom lines for decades.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F768701%2Finvesting-screen-analysis-investor-growth-stocks-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.268909,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.060085",
        "ticker_sentiment_score": "0.022017",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.236972",
        "ticker_sentiment_score": "0.049603",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.236972",
        "ticker_sentiment_score": "0.213688",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "J&J  ( JNJ )  Seeks Expanded Use of Tremfya for Ulcerative Colitis",
    "url": "https://www.zacks.com/stock/news/2239023/jj-jnj-seeks-expanded-use-of-tremfya-for-ulcerative-colitis",
    "time_published": "20240312T093900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Tremfya is an important drug in J&J's (JNJ) immunology drugs portfolio and a key driver of top-line growth.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.233709,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.080728",
        "ticker_sentiment_score": "0.140668",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RXDX",
        "relevance_score": "0.080728",
        "ticker_sentiment_score": "0.013242",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.080728",
        "ticker_sentiment_score": "0.140668",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.31482",
        "ticker_sentiment_score": "0.12655",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.238913",
        "ticker_sentiment_score": "0.142881",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "FDA To Review Two Cell Therapies For Multiple Myeloma This Week - Johnson & Johnson And Bristol-Myers - Johnson & Johnson  ( NYSE:JNJ ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/03/37671173/fda-to-review-two-cell-therapies-for-multiple-myeloma-this-week-johnson-johnson-and-bristol-myers",
    "time_published": "20240313T174359",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Friday, 15 March, the FDA's Oncologic Drugs Advisory Committee will meet to discuss Johnson & Johnson JNJ / Legend Biotech Corporation's LEGN supplemental biologics license application for Carvykti ( ciltacabtagene autoleucel ) for relapsed or refractory multiple myeloma, who have received at ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Cancer-Image-by-PDPics-from-Pixabay-_5.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.141877,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BMY",
        "relevance_score": "0.205807",
        "ticker_sentiment_score": "-0.056764",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.304428",
        "ticker_sentiment_score": "0.13617",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LEGN",
        "relevance_score": "0.398148",
        "ticker_sentiment_score": "0.140611",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Chronic Myeloid Leukemia Treatment Market On A Growth Trajectory: Market Size To Reach $12 Billion By 2028 As Per The Business Research Company's Chronic Myeloid Leukemia Treatment Global Market Report 2024",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37665480/chronic-myeloid-leukemia-treatment-market-on-a-growth-trajectory-market-size-to-reach-12-billion-b",
    "time_published": "20240313T153000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LONDON, March 13, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Chronic Myeloid Leukemia Treatment Global Market Report 2024, the chronic myeloid leukemia treatment market has witnessed robust growth in recent years, and projections indicate a continued upward trajectory.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.246224,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PRPO",
        "relevance_score": "0.057079",
        "ticker_sentiment_score": "0.244371",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.113866",
        "ticker_sentiment_score": "0.228771",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.057079",
        "ticker_sentiment_score": "0.157495",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Healthy Returns: What's next in the legal fight over Medicare drug price negotiations",
    "url": "https://www.cnbc.com/2024/03/13/healthy-returns-whats-next-in-medicare-drug-price-negotiations.html",
    "time_published": "20240313T134315",
    "authors": [
      "Annika Kim Constantino",
      "Ashley Capoot"
    ],
    "summary": "The legal battle over Medicare drug price negotiations is so far looking favorable for the Biden administration. Meanwhile, CNBC is on the ground at HIMSS!",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107130655-1665090556176-gettyimages-1431082899-_m021740_4b5641b7-17d1-48f7-8db3-6aef2e513b99.jpeg?v=1710336586&w=1920&h=1080",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.10078,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.068698",
        "ticker_sentiment_score": "0.113653",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.034381",
        "ticker_sentiment_score": "0.033826",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.034381",
        "ticker_sentiment_score": "-0.112074",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.034381",
        "ticker_sentiment_score": "0.083469",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nanotechnology's Promising Role In Fighting Infectious Diseases: Protecting Surfaces With FendX's Nanotechnology - AstraZeneca  ( NASDAQ:AZN ) , FendX Technologies  ( OTC:FDXTF ) ",
    "url": "https://www.benzinga.com/partner/biotech/24/03/37655895/nanotechnologys-promising-role-in-fighting-infectious-diseases-protecting-surfaces-with-fendxs-na",
    "time_published": "20240313T121807",
    "authors": [
      "Meg Flippin"
    ],
    "summary": "From therapeutics to new drug delivery systems, nanotechnology can play an important role in fighting infectious diseases. A prime example is evident in the development of the COVID-19 vaccines. During the pandemic, Pfizer Inc. PFE, Moderna Inc. MRNA, Johnson & Johnson JNJ, AstraZeneca Plc.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Screenshot-2024-03-13-at-5-45-52-PM.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.084406,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SHTDF",
        "relevance_score": "0.04406",
        "ticker_sentiment_score": "0.147254",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.087985",
        "ticker_sentiment_score": "0.155556",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.087985",
        "ticker_sentiment_score": "0.155556",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FDXTF",
        "relevance_score": "0.087985",
        "ticker_sentiment_score": "0.020078",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.087985",
        "ticker_sentiment_score": "0.155556",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.087985",
        "ticker_sentiment_score": "0.155556",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "FOOT LOCKER, INC. NAMES CINDY CARLISLE CHIEF HUMAN RESOURCES OFFICER",
    "url": "https://www.newswire.ca/news-releases/foot-locker-inc-names-cindy-carlisle-chief-human-resources-officer-826430832.html",
    "time_published": "20240313T120000",
    "authors": [
      "Foot Locker",
      "Inc."
    ],
    "summary": "Carlisle brings over 24 years of leadership experience to her role at Foot Locker, Inc. NEW YORK, March 13, 2024 /CNW/ -- Foot Locker, Inc. ( NYSE: FL ) today announced that Cindy Carlisle has assumed the role of Executive Vice President and Chief Human Resources Officer.",
    "banner_image": "https://mma.prnewswire.com/media/2360986/Foot_Locker_Inc_Logo_Black_Logo.jpg?p=facebook",
    "source": "Canada Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.newswire.ca",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.31615,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SYK",
        "relevance_score": "0.114682",
        "ticker_sentiment_score": "-0.123508",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FL",
        "relevance_score": "0.916507",
        "ticker_sentiment_score": "0.523913",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.114682",
        "ticker_sentiment_score": "-0.123508",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 No-Brainer Stocks to Buy With $300 Right Now",
    "url": "https://www.fool.com/investing/2024/03/13/3-no-brainer-stocks-to-buy-with-300-right-now/",
    "time_published": "20240313T092100",
    "authors": [
      "Sean Williams"
    ],
    "summary": "A reasonably modest amount of money can go a long way when it's put to work in historically cheap, industry-leading businesses.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F768988%2Fthree-one-hundred-dollar-bills-cash-money-buried-sand-sunset-beach-summer-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99977"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.179662,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BABA",
        "relevance_score": "0.171485",
        "ticker_sentiment_score": "0.075291",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.028798",
        "ticker_sentiment_score": "0.134087",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.086245",
        "ticker_sentiment_score": "0.290282",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.143244",
        "ticker_sentiment_score": "0.186976",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Appointment of new CEO",
    "url": "https://www.globenewswire.com/news-release/2024/03/13/2845202/0/en/Appointment-of-new-CEO.html",
    "time_published": "20240313T083000",
    "authors": [
      "Chemometec A/S"
    ],
    "summary": "ANNOUNCEMENT NO. 255 ( Changed category - Inside information ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.170644,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.128822",
        "ticker_sentiment_score": "0.047736",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.128822",
        "ticker_sentiment_score": "0.047736",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.128822",
        "ticker_sentiment_score": "0.047736",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Appointment of new CEO",
    "url": "https://www.globenewswire.com/news-release/2024/03/13/2845193/0/en/Appointment-of-new-CEO.html",
    "time_published": "20240313T080200",
    "authors": [
      "Chemometec A/S"
    ],
    "summary": "ANNOUNCEMENT NO. ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.170644,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.128822",
        "ticker_sentiment_score": "0.047736",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.128822",
        "ticker_sentiment_score": "0.047736",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.128822",
        "ticker_sentiment_score": "0.047736",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Faron's Financial Statement Release January 1 to December 31, 2023",
    "url": "https://www.globenewswire.com/news-release/2024/03/13/2845159/0/en/Faron-s-Financial-Statement-Release-January-1-to-December-31-2023.html",
    "time_published": "20240313T070000",
    "authors": [
      "Faron Pharmaceuticals Oy"
    ],
    "summary": "TURKU, Finland and BOSTON, March 13, 2024 ( GLOBE NEWSWIRE ) -- Faron Pharmaceuticals Ltd. ( \"Faron\" or \"the Company\" ) ( AIM: FARN, First North: FARON ) , a clinical-stage biopharmaceutical company focused on tackling cancers via novel myeloid cell targeted immunotherapies, today announced ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/ae344e9a-bc8e-4213-833f-0c0c97b7d047",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.238637,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "OPTGF",
        "relevance_score": "0.006375",
        "ticker_sentiment_score": "0.073925",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.006375",
        "ticker_sentiment_score": "0.052082",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.006375",
        "ticker_sentiment_score": "0.052082",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Congressional Scrutiny Intensifies On Chinese Biotech Firms: WuXi AppTec Faces Biotech Exodus - AstraZeneca  ( NASDAQ:AZN ) , Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/03/37716166/congressional-scrutiny-intensifies-on-chinese-biotech-firms-wuxi-apptec-faces-biotech-exodus",
    "time_published": "20240314T200301",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Amid the ongoing scrutiny from Congress, WuXi AppTec and its affiliates face another setback as the Biotechnology Innovation Organization ( BIO ) , a U.S. industry lobbying group, severs ties with the Chinese biotech.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/US-China-Tatiana-Popova-and-rawf8-by-Shu.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": -0.065123,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.259267",
        "ticker_sentiment_score": "0.106372",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WXXWY",
        "relevance_score": "0.174587",
        "ticker_sentiment_score": "-0.033926",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WUXAY",
        "relevance_score": "0.340915",
        "ticker_sentiment_score": "-0.06817",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.174587",
        "ticker_sentiment_score": "0.069834",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.174587",
        "ticker_sentiment_score": "0.069834",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.174587",
        "ticker_sentiment_score": "0.083857",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "German Conglomerate Bayer Goes Johnson & Johnson Way To Tackle Its Cancer Related Lawsuits - Bayer  ( OTC:BAYRY ) , Bayer  ( OTC:BAYZF ) ",
    "url": "https://www.benzinga.com/general/biotech/24/03/37716027/german-conglomerate-bayer-goes-johnson-johnson-way-to-tackle-its-cancer-related-lawsuits",
    "time_published": "20240314T195901",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Bayer AG BAYRY BAYZF is reportedly considering utilizing the Texas Two-Step bankruptcy approach to tackle the onslaught of lawsuits in the United States implicating its Roundup weedkiller causing cancer.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Bayer-AG-Cross-2005_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.095837,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MMM",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "-0.435121",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights UnitedHealth Johnson & Johnson, Oracle, Wells Fargo & Co and Caterpillar.",
    "url": "https://www.zacks.com/stock/news/2240459/the-zacks-analyst-blog-highlights-unitedhealth-johnson-johnson-oracle-wells-fargo-co-and-caterpillar",
    "time_published": "20240314T120000",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "UnitedHealth, Johnson & Johnson, Oracle, Wells Fargo & Co and Caterpillar are the part of the Zacks top Analyst Blog .",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/79/525.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.297516,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ORCL",
        "relevance_score": "0.263942",
        "ticker_sentiment_score": "0.192808",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.037938",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.263942",
        "ticker_sentiment_score": "0.289426",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.037938",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.199584",
        "ticker_sentiment_score": "0.049258",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update",
    "url": "https://www.globenewswire.com/news-release/2024/03/14/2846139/0/en/AC-Immune-Reports-Full-Year-2023-Financial-Results-and-Provides-a-Corporate-Update.html",
    "time_published": "20240314T110000",
    "authors": [
      "AC Immune SA"
    ],
    "summary": "AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update \u2022 ACI-24.060 ABATE Phase 2 trial to report Abeta-PET imaging results in Q2 and H2 \u2022 ACI-7104.056 VacSYn Phase 2 trial in Parkinson's disease on track for interim data in H2 \u2022 Cash of CHF 103 million at year end, ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/0065cdfd-b9fc-4994-8aca-731c1d031b51",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.130867,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ACIU",
        "relevance_score": "0.265934",
        "ticker_sentiment_score": "0.102851",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.020848",
        "ticker_sentiment_score": "0.03387",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "0.048052",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cellulite Treatment Market Projected to Expand at a CAGR of 10.2%, Elevating to a Valuation of USD 1.7 billion by 2031: Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37689561/cellulite-treatment-market-projected-to-expand-at-a-cagr-of-10-2-elevating-to-a-valuation-of-usd-1",
    "time_published": "20240314T094800",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, March 14, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The cellulite treatment market was worth US$ 710.8 million in 2022. By the end of 2031, it is estimated to reach US$ 1.7 billion, increasing at a CAGR of 10.2% during the forecast period.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.302615,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.036643",
        "ticker_sentiment_score": "0.053336",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.109622",
        "ticker_sentiment_score": "0.105134",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CUTR",
        "relevance_score": "0.073209",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.036643",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Abbott's Formula Selloff Could Be A Buying Opportunity, Says Analyst",
    "url": "https://www.investors.com/news/technology/abbott-stock-infant-formula-similac-lawsuits/",
    "time_published": "20240315T163313",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Abbott Stock Dives As Fellow Formula Maker Fined $60 Million Following Infant Death Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2019/10/stock-Abbott-05-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      }
    ],
    "overall_sentiment_score": -0.096686,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.166169",
        "ticker_sentiment_score": "-0.029786",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.083541",
        "ticker_sentiment_score": "-0.026914",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.166169",
        "ticker_sentiment_score": "-0.06886",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.166169",
        "ticker_sentiment_score": "-0.06886",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RBGPF",
        "relevance_score": "0.246999",
        "ticker_sentiment_score": "-0.305291",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Monoclonal Antibody  ( mABs )  Therapeutics Market Worth $497.5 billion | MarketsandMarkets\u2122",
    "url": "https://www.prnewswire.com/news-releases/monoclonal-antibody-mabs-therapeutics-market-worth-497-5-billion--marketsandmarkets-302090362.html",
    "time_published": "20240315T143000",
    "authors": [
      "MarketsandMarkets"
    ],
    "summary": "CHICAGO, March 15, 2024 /PRNewswire/ -- Monoclonal Antibody ( mABs ) Therapeutics Market in terms of revenue was estimated to be worth $252.6 billion in 2024 and is poised to reach $497.5 billion by 2029, growing at a CAGR of 14.5% from 2024 to 2029 according to a new report by ...",
    "banner_image": "https://mma.prnewswire.com/media/2297424/MarketsandMarkets_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.227469,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.024372",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.078722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.073024",
        "ticker_sentiment_score": "0.08487",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.078722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.078722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.064394",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.078722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GSK",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.078722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.024372",
        "ticker_sentiment_score": "0.081181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.078722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.078722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.078722",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: AZN's New Acquisition, FDA Updates for NVO & LLY and More",
    "url": "https://www.zacks.com/stock/news/2241296/pharma-stock-roundup-azns-new-acquisition-fda-updates-for-nvo-lly-and-more",
    "time_published": "20240315T131900",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "AstraZeneca (AZN) is set to buy a private rare disease drugmaker. FDA delays decision on Lilly's (LLY) donanemab and approves Novo Nordisk's (NVO) Wegovy for reducing cardiovascular risks.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.200599,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.085173",
        "ticker_sentiment_score": "0.06412",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.169378",
        "ticker_sentiment_score": "0.118514",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.127456",
        "ticker_sentiment_score": "0.105455",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.210823",
        "ticker_sentiment_score": "0.128918",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.085173",
        "ticker_sentiment_score": "0.083978",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bristol Myers  ( BMY )  Gets FDA Nod for Breyanzi's Label Expansion",
    "url": "https://www.zacks.com/stock/news/2241446/bristol-myers-bmy-gets-fda-nod-for-breyanzis-label-expansion",
    "time_published": "20240315T131400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Bristol Myers (BMY) obtains FDA approval for the label expansion of CAR T cell therapy, Breyanzi, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/702.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.099238,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ADMA",
        "relevance_score": "0.230454",
        "ticker_sentiment_score": "0.174228",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSVT",
        "relevance_score": "0.046724",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.046724",
        "ticker_sentiment_score": "-0.074888",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GSK",
        "relevance_score": "0.139534",
        "ticker_sentiment_score": "0.063123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.274834",
        "ticker_sentiment_score": "0.186681",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.139534",
        "ticker_sentiment_score": "-0.097325",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Market Cap Game Show: Matt Argersinger vs. Bill Mann",
    "url": "https://www.fool.com/investing/2024/03/16/market-cap-game-show-matt-argersinger-vs-bill-mann/",
    "time_published": "20240316T130000",
    "authors": [
      "Motley Fool Staff"
    ],
    "summary": "Test your knowledge of companies' value on the stock market.",
    "banner_image": "https://g.foolcdn.com/editorial/images/769276/image.jpeg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.682689"
      }
    ],
    "overall_sentiment_score": 0.195314,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.008026",
        "ticker_sentiment_score": "0.05881",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.004013",
        "ticker_sentiment_score": "0.087925",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KLG",
        "relevance_score": "0.024073",
        "ticker_sentiment_score": "0.031939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAH",
        "relevance_score": "0.004013",
        "ticker_sentiment_score": "0.09207",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GLP",
        "relevance_score": "0.004013",
        "ticker_sentiment_score": "-0.076975",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABNB",
        "relevance_score": "0.01605",
        "ticker_sentiment_score": "0.038098",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "K",
        "relevance_score": "0.032094",
        "ticker_sentiment_score": "0.060982",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAL",
        "relevance_score": "0.004013",
        "ticker_sentiment_score": "0.191735",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CCL",
        "relevance_score": "0.01605",
        "ticker_sentiment_score": "0.058104",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.004013",
        "ticker_sentiment_score": "0.191735",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AVD",
        "relevance_score": "0.012038",
        "ticker_sentiment_score": "0.054549",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRC",
        "relevance_score": "0.064136",
        "ticker_sentiment_score": "0.081082",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBUX",
        "relevance_score": "0.004013",
        "ticker_sentiment_score": "0.124721",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EBAY",
        "relevance_score": "0.044119",
        "ticker_sentiment_score": "0.05532",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ETSY",
        "relevance_score": "0.032094",
        "ticker_sentiment_score": "0.022631",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BBW",
        "relevance_score": "0.044119",
        "ticker_sentiment_score": "0.096211",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMX",
        "relevance_score": "0.012038",
        "ticker_sentiment_score": "0.043103",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.008026",
        "ticker_sentiment_score": "0.08488",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MIDD",
        "relevance_score": "0.028084",
        "ticker_sentiment_score": "0.046541",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRNC",
        "relevance_score": "0.036103",
        "ticker_sentiment_score": "0.053749",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.004013",
        "ticker_sentiment_score": "0.191735",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Stock Is Great. Here's Why You Shouldn't Buy It.",
    "url": "https://www.fool.com/investing/2024/03/16/johnson-johnson-great-why-shouldnt-buy-stock/",
    "time_published": "20240316T075500",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Johnson & Johnson's days of being a top healthcare stock could be long gone.",
    "banner_image": "https://g.foolcdn.com/editorial/images/768803/concerned-person-looking-at-a-tablet.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.100506,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.114956",
        "ticker_sentiment_score": "0.018839",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.484697",
        "ticker_sentiment_score": "0.064236",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Investing $10,000 in Each of These 3 Vanguard ETFs Could Generate $1,164 per Year in Passive Income",
    "url": "https://www.fool.com/investing/2024/03/17/investing-vanguard-etf-passive-income/",
    "time_published": "20240317T113000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "These funds provide investors with an easy way to rake in passive income.",
    "banner_image": "https://g.foolcdn.com/editorial/images/769275/man-with-arms-behind-head-looking-at-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.191945,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AVGO",
        "relevance_score": "0.056143",
        "ticker_sentiment_score": "0.135921",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.056143",
        "ticker_sentiment_score": "0.135921",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.056143",
        "ticker_sentiment_score": "0.135921",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.056143",
        "ticker_sentiment_score": "0.135921",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMT",
        "relevance_score": "0.056143",
        "ticker_sentiment_score": "0.102902",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CCI",
        "relevance_score": "0.056143",
        "ticker_sentiment_score": "0.102902",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLD",
        "relevance_score": "0.056143",
        "ticker_sentiment_score": "0.102902",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHP",
        "relevance_score": "0.056143",
        "ticker_sentiment_score": "0.165946",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EQIX",
        "relevance_score": "0.056143",
        "ticker_sentiment_score": "0.102902",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Stock Dips While Market Gains: Key Facts",
    "url": "https://www.zacks.com/stock/news/2242442/johnson-johnson-jnj-stock-dips-while-market-gains-key-facts",
    "time_published": "20240318T214520",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) closed the most recent trading day at $156.76, moving -0.9% from the previous trading session.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default241.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.983783"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.235283,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.56415",
        "ticker_sentiment_score": "0.324595",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Is 2seventy bio Stock Trading Higher On Monday? - Legend Biotech  ( NASDAQ:LEGN ) , Johnson & Johnson  ( NYSE:JNJ ) , 2seventy bio  ( NASDAQ:TSVT ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/03/37785358/fda-adcomm-favors-expanded-use-of-johnson-johnson-bristol-myers-car-t-therapies-for-type-of-blood",
    "time_published": "20240318T141636",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Friday, the FDA's Oncologic Drugs Advisory Committee ( ODAC ) voted positively ( 8-3 ) favoring expanded use of Bristol Myers Squibb & Co BMY 2seventy bio Inc's TSVT Abecma ( idecabtagene vicleucel ) .",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Cancer-Image-by-PDPics-from-Pixabay-_7.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.283561,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TSVT",
        "relevance_score": "0.263942",
        "ticker_sentiment_score": "0.274691",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LEGN",
        "relevance_score": "0.263942",
        "ticker_sentiment_score": "0.131011",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.263942",
        "ticker_sentiment_score": "0.274691",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.263942",
        "ticker_sentiment_score": "0.131011",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bristol Myers'  ( BMY )  Abecma Gets ODAC Votes for Label Expansion",
    "url": "https://www.zacks.com/stock/news/2242244/bristol-myers-bmy-abecma-gets-odac-votes-for-label-expansion",
    "time_published": "20240318T133100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Bristol Myers' (BMY) Abecma gets eight out of 11 votes from the FDA's ODAC for patients with triple-class exposed relapsed or refractory multiple myeloma in earlier lines of therapy.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b7/2106.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.150204,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ADMA",
        "relevance_score": "0.132368",
        "ticker_sentiment_score": "0.142339",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSVT",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "0.058482",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.044304",
        "ticker_sentiment_score": "-0.055744",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.302642",
        "ticker_sentiment_score": "0.11131",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.132368",
        "ticker_sentiment_score": "-0.083335",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  is Attracting Investor Attention: Here is What You Should Know",
    "url": "https://www.zacks.com/stock/news/2241983/johnson-johnson-jnj-is-attracting-investor-attention-here-is-what-you-should-know",
    "time_published": "20240318T130016",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default261.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.215468,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.479385",
        "ticker_sentiment_score": "0.142699",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Major shareholder announcement - BlackRock, Inc.",
    "url": "https://www.globenewswire.com/news-release/2024/03/18/2847710/0/en/Major-shareholder-announcement-BlackRock-Inc.html",
    "time_published": "20240318T113200",
    "authors": [
      "Chemometec A/S"
    ],
    "summary": "ANNOUNCEMENT NO. ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.142267,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.646507",
        "ticker_sentiment_score": "0.295339",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.24289",
        "ticker_sentiment_score": "0.073834",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.24289",
        "ticker_sentiment_score": "0.073834",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.24289",
        "ticker_sentiment_score": "0.073834",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Major shareholder announcement - AIM International Mutual Funds",
    "url": "https://www.globenewswire.com/news-release/2024/03/18/2847693/0/en/Major-shareholder-announcement-AIM-International-Mutual-Funds.html",
    "time_published": "20240318T112800",
    "authors": [
      "Chemometec A/S"
    ],
    "summary": "ANNOUNCEMENT NO. ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.152916,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IVZ",
        "relevance_score": "0.499789",
        "ticker_sentiment_score": "0.294618",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.263942",
        "ticker_sentiment_score": "0.079018",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.263942",
        "ticker_sentiment_score": "0.079018",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.263942",
        "ticker_sentiment_score": "0.079018",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Major shareholder announcement - Invesco Ltd.",
    "url": "https://www.globenewswire.com/news-release/2024/03/18/2847688/0/en/Major-shareholder-announcement-Invesco-Ltd.html",
    "time_published": "20240318T112500",
    "authors": [
      "Chemometec A/S"
    ],
    "summary": "ANNOUNCEMENT NO. ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.088322,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "IVZ",
        "relevance_score": "0.546745",
        "ticker_sentiment_score": "0.155332",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.29234",
        "ticker_sentiment_score": "0.08587",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.29234",
        "ticker_sentiment_score": "0.08587",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.29234",
        "ticker_sentiment_score": "0.08587",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer - Clearside Biomedical  ( NASDAQ:CLSD ) ",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37776311/clearside-biomedical-appoints-victor-chong-m-d-mba-as-chief-medical-officer",
    "time_published": "20240318T110500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "ALPHARETTA, Ga., March 18, 2024 ( GLOBE NEWSWIRE ) -- Clearside Biomedical, Inc. CLSD, a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space ( SCS\u00ae ) , announced today that Victor Chong, M.D., MBA was appointed Chief Medical ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.137807,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CLSD",
        "relevance_score": "0.107335",
        "ticker_sentiment_score": "0.097075",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.035875",
        "ticker_sentiment_score": "0.051615",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "J&J  ( JNJ )  Gets FDA Panel Vote for Carvykti's Expanded Use",
    "url": "https://www.zacks.com/stock/news/2241906/jj-jnj-gets-fda-panel-vote-for-carvyktis-expanded-use",
    "time_published": "20240318T105500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "J&J (JNJ) is looking for expansion of Carvykti's label for the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.9545"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.222324,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ADMA",
        "relevance_score": "0.433523",
        "ticker_sentiment_score": "0.316778",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VNDA",
        "relevance_score": "0.367141",
        "ticker_sentiment_score": "0.103616",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GSK",
        "relevance_score": "0.367141",
        "ticker_sentiment_score": "0.285716",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.297661",
        "ticker_sentiment_score": "0.116829",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "India Baby Care Products Market size to grow by USD 15.69 billion from 2022 to 2027, Market is fragmented due to the ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/india-baby-care-products-market-size-to-grow-by-usd-15-69-billion-from-2022-to-2027--market-is-fragmented-due-to-the-presence-of-prominent-companies-like-abbott-laboratories-artsana-spa-bio-veda-action-research-co-and-many-mor-302090314.html",
    "time_published": "20240318T011200",
    "authors": [],
    "summary": "India Baby Care Products Market size to grow by USD 15.69 billion from 2022 to 2027, Market is fragmented due to the ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.260822,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KMB",
        "relevance_score": "0.033751",
        "ticker_sentiment_score": "0.064873",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MHCRF",
        "relevance_score": "0.033751",
        "ticker_sentiment_score": "0.064873",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.033751",
        "ticker_sentiment_score": "0.064873",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PIGEF",
        "relevance_score": "0.033751",
        "ticker_sentiment_score": "0.064873",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.033751",
        "ticker_sentiment_score": "0.064873",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.033751",
        "ticker_sentiment_score": "0.064873",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UL",
        "relevance_score": "0.033751",
        "ticker_sentiment_score": "0.064873",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PHG",
        "relevance_score": "0.033751",
        "ticker_sentiment_score": "0.064873",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "US Retinal Specialists Highlight the Greatest Opportunity for Gene Therapies",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37829815/us-retinal-specialists-highlight-the-greatest-opportunity-for-gene-therapies",
    "time_published": "20240319T182000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "EXTON, PA, March 19, 2024 ( GLOBE NEWSWIRE ) -- Gene therapies have emerged as a ray of hope, particularly in the realm of eye diseases. The focus on the eye has provided researchers with a promising pathway for delivering genetic material with precision and safety.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.278804,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ADVM",
        "relevance_score": "0.054114",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.054114",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.054114",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cartilage Repair Market Anticipates Rapid Growth, Projected To Reach $2.3 Billion In 2028 As Per The Business Research Company's Cartilage Repair Global Market Report 2024",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37826138/cartilage-repair-market-anticipates-rapid-growth-projected-to-reach-2-3-billion-in-2028-as-per-the",
    "time_published": "20240319T154000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LONDON, March 19, 2024 ( GLOBE NEWSWIRE ) -- The Business Research Company's Cartilage Repair Market Global Report 2024 forecasts significant growth, with the cartilage repair market size expected to rise from $1.24 billion in 2023 to $1.42 billion in 2024, demonstrating a compound annual growth ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.289805,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MDT",
        "relevance_score": "0.056407",
        "ticker_sentiment_score": "0.10634",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.056407",
        "ticker_sentiment_score": "0.10634",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BVS",
        "relevance_score": "0.112532",
        "ticker_sentiment_score": "0.235268",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.056407",
        "ticker_sentiment_score": "0.10634",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ ) , Nvidia Unite to Boost AI for Surgery",
    "url": "https://www.zacks.com/stock/news/2242895/johnson-johnson-jnj-nvidia-unite-to-boost-ai-for-surgery",
    "time_published": "20240319T145100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) collaborates with Nvidia to facilitate the creation of AI-based models and the deployment of applications, offering a route to scale within its digital ecosystem for surgery.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c2/53795.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.2024,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.189175",
        "ticker_sentiment_score": "0.142341",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.250386",
        "ticker_sentiment_score": "0.12185",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DVA",
        "relevance_score": "0.189175",
        "ticker_sentiment_score": "0.139372",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COR",
        "relevance_score": "0.189175",
        "ticker_sentiment_score": "0.100745",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.527295",
        "ticker_sentiment_score": "0.326956",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the Vanguard Health Care ETF  ( VHT ) ?",
    "url": "https://www.zacks.com/stock/news/2242578/should-you-invest-in-the-vanguard-health-care-etf-vht",
    "time_published": "20240319T102005",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default75.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.250395,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.135347",
        "ticker_sentiment_score": "0.064508",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.067919",
        "ticker_sentiment_score": "0.125823",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.135347",
        "ticker_sentiment_score": "0.064508",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.135347",
        "ticker_sentiment_score": "0.064508",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nvidia CEO Jensen Huang unveils successor to its all-conquering AI chip",
    "url": "https://www.business-standard.com/world-news/nvidia-ceo-jensen-huang-unveils-successor-to-its-all-conquering-ai-chip-124031900079_1.html",
    "time_published": "20240319T031146",
    "authors": [
      "Bloomberg"
    ],
    "summary": "A new processor design called Blackwell is multiple times faster at handling the models that underpin AI, the company said at its GTC conference in San Jose, California. That includes the process of developing the technology - a stage known as training - and the running of it, which is called ...",
    "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2024-03/19/full/1710817667-6636.png?im=Resize=(640,480)",
    "source": "Business Standard",
    "category_within_source": "GoogleRSS",
    "source_domain": "www.business-standard.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.20136,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.126339",
        "ticker_sentiment_score": "0.107449",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.084423",
        "ticker_sentiment_score": "0.078232",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.042271",
        "ticker_sentiment_score": "0.120842",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.366661",
        "ticker_sentiment_score": "0.230151",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.042271",
        "ticker_sentiment_score": "0.136212",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMAWF",
        "relevance_score": "0.042271",
        "ticker_sentiment_score": "0.108929",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BYDDF",
        "relevance_score": "0.042271",
        "ticker_sentiment_score": "0.108929",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.042271",
        "ticker_sentiment_score": "0.108929",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ORCL",
        "relevance_score": "0.042271",
        "ticker_sentiment_score": "0.035889",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WSFL",
        "relevance_score": "0.042271",
        "ticker_sentiment_score": "0.108929",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSM",
        "relevance_score": "0.042271",
        "ticker_sentiment_score": "0.033941",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update",
    "url": "https://www.globenewswire.com/news-release/2024/03/20/2849779/0/en/Alvotech-Reports-Financial-Results-for-Full-Year-2023-and-Provides-a-Business-Update.html",
    "time_published": "20240320T201500",
    "authors": [
      "Alvotech"
    ],
    "summary": "Alvotech ( NASDAQ: ALVO, or the \"Company\" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for full year 2023 and provided a summary of recent pipeline and corporate highlights.",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.955357"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.131766,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.011791",
        "ticker_sentiment_score": "0.085539",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.011791",
        "ticker_sentiment_score": "0.085539",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.011791",
        "ticker_sentiment_score": "0.053881",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.023579",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.342487",
        "ticker_sentiment_score": "0.166948",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.011791",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.011791",
        "ticker_sentiment_score": "0.053881",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.011791",
        "ticker_sentiment_score": "0.053881",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.011791",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.011791",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:ISK",
        "relevance_score": "0.035363",
        "ticker_sentiment_score": "0.166852",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FOREX:SEK",
        "relevance_score": "0.023579",
        "ticker_sentiment_score": "0.137997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.035363",
        "ticker_sentiment_score": "0.215495",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update",
    "url": "https://www.globenewswire.com/news-release/2024/03/20/2849778/0/en/Alvotech-Reports-Financial-Results-for-Full-Year-2023-and-Provides-a-Business-Update.html",
    "time_published": "20240320T201500",
    "authors": [
      "Alvotech"
    ],
    "summary": "REYKJAVIK, Iceland, March 20, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO, or the \"Company\" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for full year 2023 and provided a ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.955357"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.129421,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.011762",
        "ticker_sentiment_score": "0.085519",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.011762",
        "ticker_sentiment_score": "0.085519",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.011762",
        "ticker_sentiment_score": "0.053868",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.023521",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.341699",
        "ticker_sentiment_score": "0.166635",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.011762",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.011762",
        "ticker_sentiment_score": "0.053868",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.011762",
        "ticker_sentiment_score": "0.053868",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.011762",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.011762",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:ISK",
        "relevance_score": "0.035276",
        "ticker_sentiment_score": "0.164818",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FOREX:SEK",
        "relevance_score": "0.023521",
        "ticker_sentiment_score": "0.135974",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.035276",
        "ticker_sentiment_score": "0.214421",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy - Johnson & Johnson  ( NYSE:JNJ ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
    "url": "https://www.benzinga.com/24/03/37850854/genscript-losses-shrink-on-strong-growth-for-cancer-cell-therapy",
    "time_published": "20240320T153012",
    "authors": [
      "The Bamboo Works"
    ],
    "summary": "GenScript's cell therapy revenue grew by 143.7% last year as a CAR-T cell therapy developed by its Legend Biotech subsidiary gained traction Legend's Carvykti is expected to hit annual production capacity of 10,000 doses by the end of 2025",
    "banner_image": "https://cdn.benzinga.com/files/genscript_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.138772,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LEGN",
        "relevance_score": "0.384397",
        "ticker_sentiment_score": "0.190643",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WUXAY",
        "relevance_score": "0.033375",
        "ticker_sentiment_score": "0.074487",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.09989",
        "ticker_sentiment_score": "0.03532",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GNNSF",
        "relevance_score": "0.09989",
        "ticker_sentiment_score": "0.077907",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.066691",
        "ticker_sentiment_score": "-0.119272",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Migraine Drugs Market Continues To Surge At A Rate Of More Than 6%, Fueled By Innovation And Demand As Per The Business Research Company's Migraine Drugs Global Market Report 2024",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37850847/migraine-drugs-market-continues-to-surge-at-a-rate-of-more-than-6-fueled-by-innovation-and-demand-",
    "time_published": "20240320T153000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LONDON, March 20, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Migraine Drugs Global Market Report 2024, the migraine drugs market has experienced robust growth in recent years, with promising projections for the future.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.351945,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BAYZF",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "0.256846",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "0.256846",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "0.256846",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Interstitial Cystitis Drugs Market Witnesses Robust Growth, Predicted To Surge At A Rate Of More Than 5% Through 2024-2028 As Per The Business Research Company's Interstitial Cystitis Drugs Global Market Report 2024",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37850849/interstitial-cystitis-drugs-market-witnesses-robust-growth-predicted-to-surge-at-a-rate-of-more-th",
    "time_published": "20240320T153000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LONDON, March 20, 2024 ( GLOBE NEWSWIRE ) -- The Business Research Company's Interstitial Cystitis Drugs Global Market Report 2024, the interstitial cystitis drugs market has experienced significant growth in recent years, with notable projections indicating continued expansion.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.412328,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.05257",
        "ticker_sentiment_score": "0.14497",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.05257",
        "ticker_sentiment_score": "0.14497",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Jim Cramer Reveals Nvidia's Non-Tech Partners That Can Be Potential Market Winner: 'Best Opportunities' - Getty Images Holdings  ( NYSE:GETY ) , GE HealthCare Techs  ( NASDAQ:GEHC ) ",
    "url": "https://www.benzinga.com/markets/equities/24/03/37838206/jim-cramer-reveals-nvidias-non-tech-partners-that-can-be-potential-market-winner-best-opportunit",
    "time_published": "20240320T030350",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "CNBC host Jim Cramer has spotlighted several lesser-known partners of NVIDIA Corp NVDA that could potentially benefit from the company's advanced artificial intelligence ( AI ) technology.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/jim-cramer-nvidia-shutter_6.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.274768,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GEHC",
        "relevance_score": "0.181137",
        "ticker_sentiment_score": "0.218314",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.507932",
        "ticker_sentiment_score": "0.261207",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.181137",
        "ticker_sentiment_score": "0.145654",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GETY",
        "relevance_score": "0.181137",
        "ticker_sentiment_score": "0.145654",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.158334",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.181137",
        "ticker_sentiment_score": "0.218314",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson's Abiomed Unit Recalls Instructions For Some Impella Blood Pumps Due To Cutting Risks - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/news/large-cap/24/03/37878539/johnson-johnsons-abiomed-unit-recalls-instructions-for-some-impella-blood-pumps-due-to-cutting-ris",
    "time_published": "20240321T183138",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Thursday, Johnson & Johnson's JNJ Abiomed said it is recalling its Impella Left Sided Blood Pumps because the pump catheter may perforate ( cut ) the wall of the left ventricle in the heart. During operations, the Impella device could cut through the wall of the left ventricle.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Impella-Pump-Photo-via-JNJ.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.083227,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.350564",
        "ticker_sentiment_score": "0.266168",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "1 Magnificent Growth Stock to Buy and Hold",
    "url": "https://www.fool.com/investing/2024/03/21/1-magnificent-growth-stock-to-buy-and-hold/",
    "time_published": "20240321T124500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "Investing in this company 10 years ago would have produced excellent returns, but it's not too late -- far from it.",
    "banner_image": "https://media.ycharts.com/charts/c61dc5c86256b5d93b6ae8dff7ca618f.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.171972,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MDT",
        "relevance_score": "0.062597",
        "ticker_sentiment_score": "0.036019",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.567746",
        "ticker_sentiment_score": "0.216088",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.124809",
        "ticker_sentiment_score": "0.041961",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bristol Myers  ( BMY )  Gets EC Nod for Abecma's Label Expansion",
    "url": "https://www.zacks.com/stock/news/2243958/bristol-myers-bmy-gets-ec-nod-for-abecmas-label-expansion",
    "time_published": "20240321T115300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Bristol Myers (BMY) wins European Commission's approval for the label expansion of its CAR T cell immunotherapy Abecma in earlier lines for triple-class exposed relapsed and refractory multiple myeloma.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b7/2106.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.917436"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.23117,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ADMA",
        "relevance_score": "0.212674",
        "ticker_sentiment_score": "0.191017",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ANIP",
        "relevance_score": "0.212674",
        "ticker_sentiment_score": "0.202264",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSVT",
        "relevance_score": "0.128592",
        "ticker_sentiment_score": "0.097714",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.04303",
        "ticker_sentiment_score": "-0.062407",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.334008",
        "ticker_sentiment_score": "0.187051",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.04303",
        "ticker_sentiment_score": "-0.062407",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Buy 3M Before April 1?",
    "url": "https://www.fool.com/investing/2024/03/21/should-you-buy-3m-before-april-1st/",
    "time_published": "20240321T090200",
    "authors": [
      "Matt DiLallo"
    ],
    "summary": "A looming stock spinoff should give investors a reason to pause.",
    "banner_image": "https://media.ycharts.com/charts/036e952319cf0965d91f9e1b90f7f6e3.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998356"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.242764,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "0.059169",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.056674",
        "ticker_sentiment_score": "0.004005",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NLOP",
        "relevance_score": "0.056674",
        "ticker_sentiment_score": "0.101109",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "U.S. FDA Approves OPSYNVI\u00ae  ( macitentan and tadalafil )  as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension  ( PAH ) ",
    "url": "https://www.prnewswire.com/news-releases/us-fda-approves-opsynvi-macitentan-and-tadalafil-as-the-first-and-only-once-daily-single-tablet-combination-therapy-for-patients-with-pulmonary-arterial-hypertension-pah-302097530.html",
    "time_published": "20240322T223500",
    "authors": [
      "Johnson & Johnson"
    ],
    "summary": "U.S. FDA Approves OPSYNVI\u00ae ( macitentan and tadalafil ) as the First and Only Once-Daily Single-Tablet Combination ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/2369753/JJ_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.107711,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.307603",
        "ticker_sentiment_score": "0.107039",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/pharmaceuticals-market-in-germany-size-is-set-to-grow-by-usd-21-44-bn-from-2023-2027--abbott-laboratories-abbvie-inc--amgen-inc-and-more-to-emerge-as-some-of-the-key-vendors--technavio-302096253.html",
    "time_published": "20240322T161800",
    "authors": [],
    "summary": "Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.244345,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BAYZF",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLCO",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "-0.020684",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FSNUF",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vaccine Market Insights Revealed in New 2024 Global Industry Report",
    "url": "https://www.prnewswire.com/news-releases/vaccine-market-insights-revealed-in-new-2024-global-industry-report-302095932.html",
    "time_published": "20240322T160000",
    "authors": [
      "Research and Markets"
    ],
    "summary": "DUBLIN, March 22, 2024 /PRNewswire/ -- The \"The World Market for Vaccines, 2024\" report has been added to ResearchAndMarkets.com's offering. The healthcare landscape is ever-evolving, and as infectious diseases continue to be a global concern, the vaccine market remains a critical area of focus ...",
    "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.167321,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MRNA",
        "relevance_score": "0.086556",
        "ticker_sentiment_score": "0.088441",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.086556",
        "ticker_sentiment_score": "0.088441",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.086556",
        "ticker_sentiment_score": "0.088441",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.086556",
        "ticker_sentiment_score": "0.088441",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CIO Leadership: The Call for Cybersecurity Innovation will Power the Discussion at the 13th Annual Washington, D.C. C-Level Technology Leadership Summit on April 18",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37893536/cio-leadership-the-call-for-cybersecurity-innovation-will-power-the-discussion-at-the-13th-annual-",
    "time_published": "20240322T150836",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "WESTPORT, Conn., March 22, 2024 ( GLOBE NEWSWIRE ) -- HMG Strategy, the World's #1 platform for enabling technology executives to reimagine the enterprise and reshape the business world, is thrilled to announce that its 13th Annual Washington, D.C.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.193392,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.01957",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UPWK",
        "relevance_score": "0.039128",
        "ticker_sentiment_score": "0.047481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RNG",
        "relevance_score": "0.058663",
        "ticker_sentiment_score": "0.049171",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DRKTF",
        "relevance_score": "0.058663",
        "ticker_sentiment_score": "0.049171",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DTII",
        "relevance_score": "0.01957",
        "ticker_sentiment_score": "-0.055269",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RMNI",
        "relevance_score": "0.078163",
        "ticker_sentiment_score": "0.049587",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTZ",
        "relevance_score": "0.01957",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBGSF",
        "relevance_score": "0.039128",
        "ticker_sentiment_score": "0.041402",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KFY",
        "relevance_score": "0.01957",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PANW",
        "relevance_score": "0.117009",
        "ticker_sentiment_score": "0.057343",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CL",
        "relevance_score": "0.01957",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OMF",
        "relevance_score": "0.01957",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PSN",
        "relevance_score": "0.01957",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCO",
        "relevance_score": "0.01957",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMG",
        "relevance_score": "0.01957",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FUTU",
        "relevance_score": "0.01957",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APPN",
        "relevance_score": "0.058663",
        "ticker_sentiment_score": "0.049171",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTNX",
        "relevance_score": "0.058663",
        "ticker_sentiment_score": "0.049171",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BACHY",
        "relevance_score": "0.01957",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FTNT",
        "relevance_score": "0.039128",
        "ticker_sentiment_score": "0.047481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALC",
        "relevance_score": "0.01957",
        "ticker_sentiment_score": "0.158266",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ZS",
        "relevance_score": "0.058663",
        "ticker_sentiment_score": "0.049171",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FUJIF",
        "relevance_score": "0.01957",
        "ticker_sentiment_score": "0.2265",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UPBD",
        "relevance_score": "0.039128",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IDCBY",
        "relevance_score": "0.01957",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Gaining An Edge: 5 AI-Powered Strategies For Stock Market Success",
    "url": "https://www.forbes.com/sites/investor/2024/03/22/gaining-an-edge-5-ai-powered-strategies-for-stock-market-success/",
    "time_published": "20240322T150602",
    "authors": [
      "John P. Reese"
    ],
    "summary": "In the fast-paced world of investing, staying ahead of the curve is crucial for success. As artificial intelligence ( AI ) continues to transform various industries, savvy investors are turning to AI-powered tools and strategies to gain a competitive advantage in the stock market.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65fd9dc3088caa9883857ceb/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.43189,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.047185",
        "ticker_sentiment_score": "0.173575",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.047185",
        "ticker_sentiment_score": "0.2056",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.047185",
        "ticker_sentiment_score": "0.101253",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.047185",
        "ticker_sentiment_score": "0.101253",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "GMO Quality Fund Aims To Beat Its Decade-Long Outperformance",
    "url": "https://www.investors.com/etfs-and-funds/mutual-funds/gmo-quality-fund-10-year-performance/",
    "time_published": "20240322T123048",
    "authors": [
      "ROBERT POWELL",
      "Investor's Business Daily"
    ],
    "summary": "Though past performance is not indicative of future results, the decade-long exceptional track record of the GMO Quality Fund - a top winner in Investor's Business Daily's 2024 Best Mutual Funds Awards - deserves some special attention.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/03/w.GMO032524eps-300x127.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.267603,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.111933",
        "ticker_sentiment_score": "0.125738",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.064104",
        "ticker_sentiment_score": "0.053132",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.032078",
        "ticker_sentiment_score": "0.10083",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.032078",
        "ticker_sentiment_score": "0.031324",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.064104",
        "ticker_sentiment_score": "0.146467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.032078",
        "ticker_sentiment_score": "0.10083",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.048101",
        "ticker_sentiment_score": "0.112638",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ACN",
        "relevance_score": "0.032078",
        "ticker_sentiment_score": "0.10083",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SAFRF",
        "relevance_score": "0.016042",
        "ticker_sentiment_score": "0.091909",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.048101",
        "ticker_sentiment_score": "0.001994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NSRGF",
        "relevance_score": "0.016042",
        "ticker_sentiment_score": "0.017574",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.096027",
        "ticker_sentiment_score": "0.083384",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Want Decades of Passive Income? 2 Stocks to Buy Now.",
    "url": "https://www.fool.com/investing/2024/03/22/want-decades-of-passive-income-2-stocks-to-buy-now/",
    "time_published": "20240322T082500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "There aren't many guarantees in the equity market, but the dividend payouts of Johnson & Johnson and Abbott Laboratories may be as close as it gets to a sure thing.",
    "banner_image": "https://media.ycharts.com/charts/f446e49093d77d67a17c38a637be54f2.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.26315,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ISRG",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.188654",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.448316",
        "ticker_sentiment_score": "0.330782",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.448316",
        "ticker_sentiment_score": "0.347852",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Nvidia's AI ambitions in medicine and health care are becoming clear",
    "url": "https://www.cnbc.com/2024/03/24/nvidias-ai-ambitions-in-medicine-and-health-care-are-becoming-clear.html",
    "time_published": "20240324T141834",
    "authors": [
      "Michelle Castillo"
    ],
    "summary": "Applying Nvidia AI chips to health care, whether it's biotechnology, chemicals, or drug discovery is going to be a big business.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107389777-1710888817MM-A-031924-short.jpg?v=1710888817&w=750&h=422&vtcrop=y",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.124784,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MCO",
        "relevance_score": "0.042647",
        "ticker_sentiment_score": "0.082902",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.443626",
        "ticker_sentiment_score": "0.176278",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RXRX",
        "relevance_score": "0.042647",
        "ticker_sentiment_score": "0.048418",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SDGR",
        "relevance_score": "0.042647",
        "ticker_sentiment_score": "0.048202",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WLDS",
        "relevance_score": "0.042647",
        "ticker_sentiment_score": "0.066259",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.042647",
        "ticker_sentiment_score": "0.150241",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Want $1 Million in Retirement? 9 ETFs to Buy Now and Hold for Decades.",
    "url": "https://www.fool.com/investing/2024/03/24/want-million-retirement-etfs-buy-now-hold-decade/",
    "time_published": "20240324T093000",
    "authors": [
      "Selena Maranjian"
    ],
    "summary": "Parking some of your dollars in high-performing sector ETFs may juice your portfolio's returns.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F769398%2Fgetty-closeup-of-happy-smiling-freckled-face.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.183028,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSTR",
        "relevance_score": "0.048133",
        "ticker_sentiment_score": "0.084086",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.048133",
        "ticker_sentiment_score": "0.113901",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.048133",
        "ticker_sentiment_score": "0.113901",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.096091",
        "ticker_sentiment_score": "0.030387",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.048133",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.048133",
        "ticker_sentiment_score": "0.113901",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.048133",
        "ticker_sentiment_score": "0.084086",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.048133",
        "ticker_sentiment_score": "-0.068161",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.048133",
        "ticker_sentiment_score": "0.120877",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.048133",
        "ticker_sentiment_score": "0.120877",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.096091",
        "ticker_sentiment_score": "0.030387",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LEN",
        "relevance_score": "0.048133",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNP",
        "relevance_score": "0.048133",
        "ticker_sentiment_score": "0.10892",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.048133",
        "ticker_sentiment_score": "0.10892",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Assessing Johnson & Johnson's Performance Against Competitors In Pharmaceuticals Industry - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/news/24/03/37917519/assessing-johnson-amp-johnsons-performance-against-competitors-in-pharmaceuticals-industry",
    "time_published": "20240325T160051",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In the fast-paced and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Johnson & Johnson JNJ in comparison to its major competitors within the ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.225598,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.062434",
        "ticker_sentiment_score": "0.139073",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.416516",
        "ticker_sentiment_score": "0.287954",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Nvidia's AI Revolution Is Transforming Healthcare with Johnson & Johnson and GE Healthcare Partnerships - NVIDIA  ( NASDAQ:NVDA ) ",
    "url": "https://www.benzinga.com/news/24/03/37916877/nvidias-ai-revolution-is-transforming-healthcare-with-johnson-johnson-and-ge-healthcare-partnerships",
    "time_published": "20240325T153147",
    "authors": [
      "Anusuya Lahiri"
    ],
    "summary": "Last week, Nvidia Corp NVDA announced significant collaborations with Johnson & Johnson JNJ and General Electric Co GE GE Healthcare to integrate generative AI into surgery and enhance medical imaging.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Artificial-Intelligence-Photo-by-Pixels-_4.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.201614,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMD",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "0.072002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MCO",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "-0.069117",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.421485",
        "ticker_sentiment_score": "0.376016",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "RXRX",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "0.108268",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.261117",
        "ticker_sentiment_score": "0.324991",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "0.243267",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "GE HealthCare  ( GEHC )  Uses AI Solution to Boost Medical Imaging",
    "url": "https://www.zacks.com/stock/news/2245566/ge-healthcare-gehc-uses-ai-solution-to-boost-medical-imaging",
    "time_published": "20240325T142000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "GE HealthCare's (GEHC) SonoSAMTrack demonstrates its pliability and applicability in ultrasound image segmentation by using NVIDIA's technology.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e0/1871.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.327917,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GEHC",
        "relevance_score": "0.104002",
        "ticker_sentiment_score": "0.084829",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.206245",
        "ticker_sentiment_score": "0.156633",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HOLX",
        "relevance_score": "0.206245",
        "ticker_sentiment_score": "0.165448",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.206245",
        "ticker_sentiment_score": "0.172415",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the Health Care Select Sector SPDR ETF  ( XLV ) ?",
    "url": "https://www.zacks.com/stock/news/2245284/should-you-invest-in-the-health-care-select-sector-spdr-etf-xlv",
    "time_published": "20240325T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default168.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.303397,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "0.063944",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.064276",
        "ticker_sentiment_score": "0.127429",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STT",
        "relevance_score": "0.064276",
        "ticker_sentiment_score": "0.089069",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "0.063944",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "0.063944",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why the Market Dipped But Johnson & Johnson  ( JNJ )  Gained Today",
    "url": "https://www.zacks.com/stock/news/2246287/why-the-market-dipped-but-johnson-johnson-jnj-gained-today",
    "time_published": "20240326T214521",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the latest trading session, Johnson & Johnson (JNJ) closed at $155.77, marking a +0.35% move from the previous day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default34.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.122893,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.628699",
        "ticker_sentiment_score": "0.126454",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "FDA approves new drug that may help stop and even reverse a rare, fatal condition that doctors call a 'ticking time bomb'",
    "url": "https://www.cnn.com/2024/03/26/health/winrevair-pah-drug-approval/index.html",
    "time_published": "20240326T210600",
    "authors": [
      "Brenda Goodman"
    ],
    "summary": "When doctors told Katrina Barry that she had a rare and serious condition called pulmonary arterial hypertension or PAH, they warned her not to Google it. Come on, she thought.",
    "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/20240326-merck-drug.jpg?q=w_1110,c_fill",
    "source": "CNN",
    "category_within_source": "Markets",
    "source_domain": "www.cnn.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.092801,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "WBD",
        "relevance_score": "0.017638",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.017638",
        "ticker_sentiment_score": "0.187748",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "What's Going On With Shockwave Medical Stock? - Shockwave Medical  ( NASDAQ:SWAV ) ",
    "url": "https://www.benzinga.com/news/24/03/37945385/whats-going-on-with-shockwave-medical-stock",
    "time_published": "20240326T195358",
    "authors": [
      "Erica Kollmann"
    ],
    "summary": "Shockwave Medical, Inc. SWAV shares are trading higher Tuesday following a report suggesting Johnson & Johnson JNJ is in talks to acquire the company. According to a report from the Wall Street Journal, people familiar with the matter say that a deal to acquire the company could be completed in ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/pulse-cardio.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.240621,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SWAV",
        "relevance_score": "0.841002",
        "ticker_sentiment_score": "0.321853",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.221819",
        "ticker_sentiment_score": "0.174066",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares U.S. Healthcare ETF  ( IYH ) ?",
    "url": "https://www.zacks.com/stock/news/2245797/should-you-invest-in-the-ishares-us-healthcare-etf-iyh",
    "time_published": "20240326T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default11.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.219275,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.066414",
        "ticker_sentiment_score": "0.088153",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.132368",
        "ticker_sentiment_score": "0.069712",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.132368",
        "ticker_sentiment_score": "0.069712",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.132368",
        "ticker_sentiment_score": "0.069712",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bernie Sanders Calls On Novo Nordisk To Lower Cost Of Ozempic And Wegovy",
    "url": "https://www.forbes.com/sites/saradorn/2024/03/27/bernie-sanders-calls-on-novo-nordisk-to-lower-cost-of-ozempic-and-wegovy/",
    "time_published": "20240327T211855",
    "authors": [
      "Sara Dorn"
    ],
    "summary": "Sen. Bernie Sanders, I-Vt., demanded Novo Nordisk, the Danish drug company that manufactures the wildly popular Ozempic and Wegovy weight loss drugs, lower the list price of the drugs, warning the \"outrageously high price has the potential to bankrupt Medicare, the American people and our entire ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/66048cd417ea5d90971467a4/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": -0.055049,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NYT",
        "relevance_score": "0.062271",
        "ticker_sentiment_score": "0.052093",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.245339",
        "ticker_sentiment_score": "-0.071817",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.062271",
        "ticker_sentiment_score": "-0.053135",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.062271",
        "ticker_sentiment_score": "-0.053135",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Strong Strategic Fit For Shockwave Medical, But Medtronic, Boston Scientific Could Be Other Bidder, Says Analyst - Boston Scientific  ( NYSE:BSX ) , Johnson & Johnson  ( NYSE:JNJ ) , Medtronic  ( NYSE:MDT ) , Shockwave Medical  ( NASDAQ:SWAV ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37970454/johnson-johnson-strong-strategic-fit-for-shockwave-medical-but-medtronic-boston-sci",
    "time_published": "20240327T202327",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Tuesday, Shockwave Medical Inc SWAV shares traded higher following a Wall Street Journal report suggesting Johnson & Johnson JNJ is reportedly in talks to acquire the company. Shockwave Medical is a cardiovascular medical device.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Johnson-and-Johnson_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.311393,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MDT",
        "relevance_score": "0.331765",
        "ticker_sentiment_score": "0.448714",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.331765",
        "ticker_sentiment_score": "0.448714",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.883917",
        "ticker_sentiment_score": "0.4855",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.608634",
        "ticker_sentiment_score": "0.494139",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Shockwave Medical Stock Sees Relative Strength Rating Ride Higher",
    "url": "https://www.investors.com/news/shockwave-medical-stock-sees-relative-strength-rating-ride-higher/",
    "time_published": "20240327T190700",
    "authors": [
      "Investor's Business Daily",
      "INVESTOR'S BUSINESS DAILY",
      "JULIE MAK"
    ],
    "summary": "On Wednesday, Shockwave Medical ( SWAV ) stock got a positive adjustment to its Relative Strength ( RS ) Rating, from 90 to 94. The stock has been rallying amid a Wall Street Journal report that Johnson and Johnson ( JNJ ) is in talks to buy Shockwave Medical.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/05/IRU5.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      }
    ],
    "overall_sentiment_score": 0.36848,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BRKR",
        "relevance_score": "0.290607",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.147818",
        "ticker_sentiment_score": "0.221919",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.543935",
        "ticker_sentiment_score": "0.332553",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.290607",
        "ticker_sentiment_score": "0.332694",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Neptune Strengthens Americas Sales Leadership with the Appointment of Jeff Piszczek as Vice President - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/neptune-strengthens-americas-sales-leadership-with-the-appointment-of-jeff-piszczek-as-vice-president-302101233.html",
    "time_published": "20240327T150400",
    "authors": [],
    "summary": "Neptune Strengthens Americas Sales Leadership with the Appointment of Jeff Piszczek as Vice President PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.466435,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.077593",
        "ticker_sentiment_score": "0.20629",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SWDAF",
        "relevance_score": "0.077593",
        "ticker_sentiment_score": "0.204196",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Merck  ( MRK )  Gets FDA Approval for New PAH Drug Winrevair",
    "url": "https://www.zacks.com/stock/news/2246486/merck-mrk-gets-fda-approval-for-new-pah-drug-winrevair",
    "time_published": "20240327T123900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Merck's (MRK) Winrevair becomes the first novel activin signaling inhibitor approved by the FDA to treat PAH.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.261248,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ADMA",
        "relevance_score": "0.38588",
        "ticker_sentiment_score": "0.333986",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.199037",
        "ticker_sentiment_score": "0.271387",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.13347",
        "ticker_sentiment_score": "0.211276",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields - Johnson & Johnson  ( NYSE:JNJ ) , Gilead Sciences  ( NASDAQ:GILD ) ",
    "url": "https://www.benzinga.com/news/24/03/37956052/wall-streets-most-accurate-analysts-views-on-3-health-care-stocks-delivering-high-dividend-yields",
    "time_published": "20240327T121334",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/03/27/image45.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.124976,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GILD",
        "relevance_score": "0.116914",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PDCO",
        "relevance_score": "0.116914",
        "ticker_sentiment_score": "0.225123",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.116914",
        "ticker_sentiment_score": "-0.078277",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "-0.121238",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.116914",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bank Of America Bullish On AI: Spotlights Top Supply Chain Stocks To Watch - NVIDIA  ( NASDAQ:NVDA ) , Alchip Techs  ( OTC:ALCPF ) ",
    "url": "https://www.benzinga.com/markets/equities/24/03/37950500/bank-of-america-bullish-on-ai-spotlights-top-supply-chain-stocks-to-watch",
    "time_published": "20240327T025648",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "Bank of America has identified key global stocks along the AI supply chain, including several NVIDIA Corp NVDA suppliers poised to benefit from the AI boom. What Happened: BofA highlighted the booming AI market and the potential for smaller firms in the global AI supply chain to benefit, reported ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Nvidia-Money-Shutterstock_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.237811,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.504646",
        "ticker_sentiment_score": "0.126314",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PWR",
        "relevance_score": "0.214937",
        "ticker_sentiment_score": "0.280779",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.108466",
        "ticker_sentiment_score": "0.284086",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.108466",
        "ticker_sentiment_score": "0.21569",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.108466",
        "ticker_sentiment_score": "0.21569",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "5 New Advancements In AI And Web3: Base, Meme Coins, Bitcoin Halving",
    "url": "https://www.forbes.com/sites/digital-assets/2024/03/28/5-new-advancements-in-ai-and-web3-meme-coins-base-bitcoin-halving/",
    "time_published": "20240328T171722",
    "authors": [
      "Sandy Carter"
    ],
    "summary": "In Lewis Carroll's classic, \"Alice in Wonderland,\" the Red Queen tells Alice that in her kingdom, \"it takes all the running you can do, to keep in the same place.\" This vivid metaphor is apt for the current pace of technological change, particularly in the realms of artificial intelligence ( AI ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6605a18c9f4dbfe5587f0b07/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.928139"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.354778,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.020722",
        "ticker_sentiment_score": "0.091847",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.020722",
        "ticker_sentiment_score": "0.157557",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.020722",
        "ticker_sentiment_score": "0.141321",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.103331",
        "ticker_sentiment_score": "0.203954",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.020722",
        "ticker_sentiment_score": "0.240372",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.020722",
        "ticker_sentiment_score": "0.157557",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.204936",
        "ticker_sentiment_score": "0.14067",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:ETH",
        "relevance_score": "0.04143",
        "ticker_sentiment_score": "0.199168",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRYPTO:SHIB",
        "relevance_score": "0.020722",
        "ticker_sentiment_score": "0.062256",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:DOGE",
        "relevance_score": "0.06211",
        "ticker_sentiment_score": "0.10225",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Has An Opportunity In Talc-Cancer Lawsuit, Can Challenge Scientific Evidence In Federal Ruling - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/03/37989675/johnson-johnson-has-an-opportunity-in-talc-cancer-lawsuit-can-challenge-scientific-evidence-in-fe",
    "time_published": "20240328T165836",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Johnson & Johnson JNJ reportedly has an opportunity to challenge the scientific evidence linking talc to ovarian cancer, as U.S. District Judge Michael Shipp ruled on Wednesday.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/johnsons-5671315-1920_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.172029,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.464633",
        "ticker_sentiment_score": "-0.172691",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Shockwave Medical  ( SWAV )  Up on Potential Acquisition Rumors",
    "url": "https://www.zacks.com/stock/news/2247467/shockwave-medical-swav-up-on-potential-acquisition-rumors",
    "time_published": "20240328T140200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Shockwave Medical's (SWAV) shares gain as rumors about its potential acquisition by an industry giant get media attention.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/41/899.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      }
    ],
    "overall_sentiment_score": 0.273013,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CAH",
        "relevance_score": "0.215574",
        "ticker_sentiment_score": "0.058873",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.072655",
        "ticker_sentiment_score": "0.187663",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.144708",
        "ticker_sentiment_score": "0.079357",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.072655",
        "ticker_sentiment_score": "0.187663",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.684158",
        "ticker_sentiment_score": "0.438425",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.284696",
        "ticker_sentiment_score": "0.228902",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors - Compass Pathways  ( NASDAQ:CMPS ) ",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37980064/compass-pathways-board-chair-and-co-founder-george-goldsmith-and-co-founder-ekaterina-malievskaia-",
    "time_published": "20240328T120000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LONDON, March 28, 2024 ( GLOBE NEWSWIRE ) -- Compass Pathways plc CMPS ( \"Compass\" ) , a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that Board Chair and co-founder George Goldsmith and fellow co-founder Ekaterina ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.168879,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CMPS",
        "relevance_score": "0.212348",
        "ticker_sentiment_score": "0.273889",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.02686",
        "ticker_sentiment_score": "0.01886",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "4 Best ETF Areas of Q1",
    "url": "https://www.zacks.com/stock/news/2247146/4-best-etf-areas-of-q1",
    "time_published": "20240328T120000",
    "authors": [
      "Sanghamitra Saha"
    ],
    "summary": "Wall Street is poised to conclude the first quarter with robust gains due to a likely dovish Fed and robust economic as well as earnings growth.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/1a/2589.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99246"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.139292,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "IVZ",
        "relevance_score": "0.062271",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.124164",
        "ticker_sentiment_score": "0.073384",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.303926",
        "ticker_sentiment_score": "0.111528",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:ETH",
        "relevance_score": "0.124164",
        "ticker_sentiment_score": "0.075688",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Dividend Stocks That Are Likely to Raise Their Payouts in April",
    "url": "https://www.fool.com/investing/2024/03/28/3-dividend-stocks-that-are-likely-to-raise-their/",
    "time_published": "20240328T101500",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Dividend increases should soon be coming from these stocks, but be careful -- it doesn't mean all of them are great buys.",
    "banner_image": "https://g.foolcdn.com/editorial/images/770398/a-person-smiling-and-reviewing-their-finances.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999922"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      }
    ],
    "overall_sentiment_score": 0.274728,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "COST",
        "relevance_score": "0.2842",
        "ticker_sentiment_score": "0.272521",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.337811",
        "ticker_sentiment_score": "0.175008",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.229149",
        "ticker_sentiment_score": "0.24583",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "J&J can contest evidence linking its talc to ovarian cancer, says US judge",
    "url": "https://www.business-standard.com/world-news/j-j-can-contest-evidence-linking-its-talc-to-ovarian-cancer-says-us-judge-124032800100_1.html",
    "time_published": "20240328T031249",
    "authors": [
      "Reuters"
    ],
    "summary": "Johnson & Johnson will get a new chance to contest the scientific evidence linking talc to ovarian cancer, a federal judge ruled on Wednesday, potentially disrupting more than 53,000 lawsuits the company is now facing over its talc products. In a brief written order, U.S.",
    "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-12/05/full/1701794396-0294.jpg?im=FeatureCrop,size=(826,465)",
    "source": "Business Standard",
    "category_within_source": "GoogleRSS",
    "source_domain": "www.business-standard.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.11087,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.060085",
        "ticker_sentiment_score": "-0.096292",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.060085",
        "ticker_sentiment_score": "-0.101187",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.060085",
        "ticker_sentiment_score": "-0.096292",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Titan Medical Reports Fiscal Year 2023 Results",
    "url": "https://www.globenewswire.com/news-release/2024/03/29/2854853/0/en/Titan-Medical-Reports-Fiscal-Year-2023-Results.html",
    "time_published": "20240329T214100",
    "authors": [
      "Titan Medical Inc."
    ],
    "summary": "TORONTO, Ontario, March 29, 2024 ( GLOBE NEWSWIRE ) -- Titan Medical Inc. ( \"Titan\" or the \"Company\" ) ( TSX: TMD. OTC: TMDIF ) , today reported financial results for the fiscal year ended December 31, 2023.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/e9df9371-cb74-4840-8337-d9d5faea1dce",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.271129,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MDT",
        "relevance_score": "0.107016",
        "ticker_sentiment_score": "0.2279",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "0.157169",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TMDIF",
        "relevance_score": "0.142355",
        "ticker_sentiment_score": "0.211099",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Microsoft, Salesforce woo skeptical CFOs on new generative AI tool spending",
    "url": "https://www.cnbc.com/2024/03/29/microsoft-salesforce-woo-skeptical-cfos-on-new-generative-ai-spending.html",
    "time_published": "20240329T142858",
    "authors": [
      "Ian Thomas"
    ],
    "summary": "Salesforce and Microsoft are among the enterprise software giants trying to convince hesitant CFOs to spend on new finance-focused generative AI tools.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107379577-17091270721709127069-33512186519-1080pnbcnews.jpg?v=1709127071&w=750&h=422&vtcrop=y",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.189886,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "FCN",
        "relevance_score": "0.034282",
        "ticker_sentiment_score": "0.032331",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.068502",
        "ticker_sentiment_score": "0.11942",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.034282",
        "ticker_sentiment_score": "0.117293",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRMNF",
        "relevance_score": "0.034282",
        "ticker_sentiment_score": "0.059182",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.034282",
        "ticker_sentiment_score": "0.117293",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here is What to Know Beyond Why Johnson & Johnson  ( JNJ )  is a Trending Stock",
    "url": "https://www.zacks.com/stock/news/2247838/here-is-what-to-know-beyond-why-johnson-johnson-jnj-is-a-trending-stock",
    "time_published": "20240329T130016",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default338.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.23546,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.47147",
        "ticker_sentiment_score": "0.164529",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Shockwave Medical Stock Rallied as Much as 18% Higher This Week",
    "url": "https://www.fool.com/investing/2024/03/29/why-shockwave-medical-stock-rallied-as-much-as-18/",
    "time_published": "20240329T130000",
    "authors": [
      "Danny Vena"
    ],
    "summary": "Buyout rumors and love from Wall Street propelled the stock to double-digit gains.",
    "banner_image": "https://g.foolcdn.com/editorial/images/771112/a-surgeon-looking-at-a-patient-on-the-operating-table-during-a-robotic-surgical-procedure.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.94762"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.202315,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SPGI",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.044059",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.576289",
        "ticker_sentiment_score": "0.161959",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.406197",
        "ticker_sentiment_score": "0.033564",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Reliable Dividend Growth Stocks With Yields Above 3% That You Can Buy Now and Hold for at Least a Decade",
    "url": "https://www.fool.com/investing/2024/03/30/3-reliable-dividend-growth-stocks-with-yields-abov/",
    "time_published": "20240330T091900",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "These advantaged businesses have what it takes to keep raising their payouts.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F770568%2Fgroup-of-investors-looking-at-charts.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.967321"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      }
    ],
    "overall_sentiment_score": 0.238472,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.146916",
        "ticker_sentiment_score": "-0.045412",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.049221",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.098255",
        "ticker_sentiment_score": "0.049573",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.049221",
        "ticker_sentiment_score": "0.133067",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.098255",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "WM Phoenix Open Delivers Refunds To About 2,800 Fans After Ticket Snafu",
    "url": "https://www.forbes.com/sites/jackmagruder/2024/03/31/wm-phoenix-open-delivers-refunds-to-about-2800-fans-after-ticket-snafu/",
    "time_published": "20240331T214307",
    "authors": [
      "Jack Magruder"
    ],
    "summary": "The \"People's Open\" is attempting to make its people whole. The WM Phoenix Open - which bills itself as the People's Open because of the overwhelming support it receives from the local golf community - has given refunds to about 2,800 ticket holders who were denied entrance to the third round of ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6609d2136f8e76d5f31c49d4/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.007244,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.062434",
        "ticker_sentiment_score": "-0.171128",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "2024 S&P 500 Bull Market: 2 Unstoppable Growth Stocks to Buy Right Now",
    "url": "https://www.fool.com/investing/2024/03/31/2024-sp-500-bull-market-2-unstoppable-growth-stock/",
    "time_published": "20240331T071000",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "The fresh bull market is attracting investors of all trading styles.",
    "banner_image": "https://g.foolcdn.com/editorial/images/770831/getty-listening-learning-headphones-laptop-notes-studying.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999995"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.26699,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.040899",
        "ticker_sentiment_score": "0.069513",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JCI",
        "relevance_score": "0.040899",
        "ticker_sentiment_score": "0.15753",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.461699",
        "ticker_sentiment_score": "0.337535",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.241684",
        "ticker_sentiment_score": "0.260649",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why 3M Stock Was Moving Higher Today",
    "url": "https://www.fool.com/investing/2024/04/01/why-3m-stock-was-moving-higher-today/",
    "time_published": "20240401T210643",
    "authors": [
      "Jeremy Bowman"
    ],
    "summary": "Investors applauded the spin-off of its healthcare business.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F771486%2F3m-st-paul-monument-place001-rgb-1.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.2628,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "0.006257",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KD",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "0.006257",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "0.006257",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Reasons You Can Buy This \"Magnificent Seven\" Stock and Hold It Forever",
    "url": "https://www.fool.com/investing/2024/04/01/3-reasons-you-can-buy-this-magnificent-seven-stock/",
    "time_published": "20240401T150000",
    "authors": [
      "Justin Pope"
    ],
    "summary": "Buy and hold forever is a bold ask. However, Microsoft delivers across the board.",
    "banner_image": "https://g.foolcdn.com/editorial/images/770918/msft-3.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.252095,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.717458",
        "ticker_sentiment_score": "0.370799",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.071357",
        "ticker_sentiment_score": "0.302099",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.071357",
        "ticker_sentiment_score": "0.140933",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Looking Into Johnson & Johnson's Recent Short Interest - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/04/38024239/looking-into-johnson-johnsons-recent-short-interest",
    "time_published": "20240401T143020",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Johnson & Johnson's JNJ short percent of float has risen 6.45% since its last report. The company recently reported that it has 15.84 million shares sold short, which is 0.66% of all regular shares that are available for trading.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.287737,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.147012",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Reasons to Add ShockWave Medical  ( SWAV )  to Your Portfolio Now",
    "url": "https://www.zacks.com/stock/news/2248484/reasons-to-add-shockwave-medical-swav-to-your-portfolio-now",
    "time_published": "20240401T140100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/41/899.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.890401"
      }
    ],
    "overall_sentiment_score": 0.323832,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CAH",
        "relevance_score": "0.166935",
        "ticker_sentiment_score": "0.093567",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ITGR",
        "relevance_score": "0.221313",
        "ticker_sentiment_score": "0.18704",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DVA",
        "relevance_score": "0.111747",
        "ticker_sentiment_score": "0.06145",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.377142",
        "ticker_sentiment_score": "0.514119",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "0.006001",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Spectral AI Appoints Jeremiah Sparks as Chief Commercialization Officer",
    "url": "https://www.globenewswire.com/news-release/2024/04/01/2855212/0/en/Spectral-AI-Appoints-Jeremiah-Sparks-as-Chief-Commercialization-Officer.html",
    "time_published": "20240401T130000",
    "authors": [
      "Spectral AI",
      "Inc."
    ],
    "summary": "Experienced Burn Industry Executive Champions Pivot to Commercialization Experienced Burn Industry Executive Champions Pivot to Commercialization ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/a9a72c47-e800-49a2-a556-205f5f53d330",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.250795,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RCEL",
        "relevance_score": "0.052685",
        "ticker_sentiment_score": "0.09503",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.052685",
        "ticker_sentiment_score": "0.133004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDAI",
        "relevance_score": "0.2589",
        "ticker_sentiment_score": "0.31291",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "United Airlines Names Michelle Freyre to Board of Directors - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/united-airlines-names-michelle-freyre-to-board-of-directors-302104454.html",
    "time_published": "20240401T121400",
    "authors": [],
    "summary": "United Airlines Names Michelle Freyre to Board of Directors PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.477085,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SKYW",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.528475",
        "ticker_sentiment_score": "0.541368",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ERJ",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.059024",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 VALIC Mutual Funds for Consistent Returns",
    "url": "https://www.zacks.com/stock/news/2248136/3-valic-mutual-funds-for-consistent-returns",
    "time_published": "20240401T105200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Invests in VALIC Mutual Funds like VCAAX, VCULX and VBCVX for tax-efficient wealth growth.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/a8/346.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.271059,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.057482",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.057482",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRBG",
        "relevance_score": "0.068306",
        "ticker_sentiment_score": "0.034073",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.068306",
        "ticker_sentiment_score": "0.048112",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.068306",
        "ticker_sentiment_score": "0.048112",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Meet The Billionaire Bond Investor Behind Chelsea F.C., Springsteen's Songbook And The LA Dodgers",
    "url": "https://www.forbes.com/sites/maneetahuja/2024/04/01/meet-the-billionaire-bond-trader-behind-chelsea-fc-springsteens-songbook-and-the-la-dodgers/",
    "time_published": "20240401T103000",
    "authors": [
      "Maneet Ahuja"
    ],
    "summary": "Meet The Billionaire Bond Trader Behind Chelsea F.C., Springsteen's Songbook And The LA Dodgers Forbes ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6606ec6b7bb3d8b0c846fbf2/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.151857,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DKNG",
        "relevance_score": "0.025008",
        "ticker_sentiment_score": "0.043599",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.012506",
        "ticker_sentiment_score": "0.166244",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.012506",
        "ticker_sentiment_score": "0.127766",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.012506",
        "ticker_sentiment_score": "0.050837",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.025008",
        "ticker_sentiment_score": "0.051538",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Stock Moves -0.03%: What You Should Know",
    "url": "https://www.zacks.com/stock/news/2249380/johnson-johnson-jnj-stock-moves--003-what-you-should-know",
    "time_published": "20240402T214521",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The latest trading day saw Johnson & Johnson (JNJ) settling at $157.73, representing a -0.03% change from its previous close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default97.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      }
    ],
    "overall_sentiment_score": 0.122368,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.568651",
        "ticker_sentiment_score": "0.109284",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation",
    "url": "https://www.globenewswire.com/news-release/2024/04/02/2856479/0/en/Nanobiotix-Announces-Completion-of-Phase-1-Dose-Escalation-and-NBTXR3-Recommended-Phase-2-Dose-for-the-Treatment-of-Inoperable-Recurrent-Lung-Cancer-in-Patients-Amenable-to-Re-Irra.html",
    "time_published": "20240402T201500",
    "authors": [
      "Nanobiotix S.A."
    ],
    "summary": "PARIS and CAMBRIDGE, Mass., April 02, 2024 ( GLOBE NEWSWIRE ) -- NANOBIOTIX ( Euronext : NANO -- NASDAQ: NBTX - the ''Company'' ) , a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/36fb7b98-27d7-46cb-b989-fa31626657b8",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.081771,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NBTX",
        "relevance_score": "0.44802",
        "ticker_sentiment_score": "0.030056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.029654",
        "ticker_sentiment_score": "0.045825",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:NANO",
        "relevance_score": "0.029654",
        "ticker_sentiment_score": "-0.049666",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cytokine Market Size is projected to reach USD 148.56 billion by 2031, growing at a CAGR of 8.40%: Straits Research",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38049628/cytokine-market-size-is-projected-to-reach-usd-148-56-billion-by-2031-growing-at-a-cagr-of-8-40-st",
    "time_published": "20240402T144000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, United States, April 02, 2024 ( GLOBE NEWSWIRE ) -- A cytokine is a collection of proteins, peptides, or glycoproteins released by particular cells to regulate the development and function of the immune system and blood cells.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": -0.00724,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.035875",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PTAIF",
        "relevance_score": "0.035875",
        "ticker_sentiment_score": "-0.067573",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.035875",
        "ticker_sentiment_score": "-0.067573",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.035875",
        "ticker_sentiment_score": "-0.067573",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UCBJF",
        "relevance_score": "0.035875",
        "ticker_sentiment_score": "-0.067573",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.035875",
        "ticker_sentiment_score": "-0.067573",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.071677",
        "ticker_sentiment_score": "-0.046635",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AI ETFs: Q1 of 2024 Update",
    "url": "https://www.zacks.com/stock/news/2248900/ai-etfs-q1-of-2024-update",
    "time_published": "20240402T120000",
    "authors": [
      "Sanghamitra Saha"
    ],
    "summary": "The year 2023 was crucial in the Artificial Intelligence (AI) industry. So far this year, we have seen Apple's efforts to join the AI race more prudently, Amazon's billion dollar investment in AI start-up and Nvidia's efforts to foray into various industries with AI initiatives.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d9/21892.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.282198,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.210274",
        "ticker_sentiment_score": "0.295187",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.261117",
        "ticker_sentiment_score": "0.264051",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.359262",
        "ticker_sentiment_score": "0.245994",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.261117",
        "ticker_sentiment_score": "0.2589",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.048514",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Will Johnson & Johnson  ( JNJ )  Beat Estimates Again in Its Next Earnings Report?",
    "url": "https://www.zacks.com/stock/news/2249996/will-johnson-johnson-jnj-beat-estimates-again-in-its-next-earnings-report",
    "time_published": "20240403T161014",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default279.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.99989"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.351386,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.402618",
        "ticker_sentiment_score": "0.498513",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Robust Growth Expected In The Intestinal Pseudo Obstruction Treatment Market: Market To Grow At A Rate Of More Than 5% Through 2024-2028 As Per TBRC's Intestinal Pseudo Obstruction Treatment Global Market Report 2024",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38072443/robust-growth-expected-in-the-intestinal-pseudo-obstruction-treatment-market-market-to-grow-at-a-r",
    "time_published": "20240403T153000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LONDON, April 03, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Intestinal Pseudo Obstruction Treatment Global Market Report 2024, the intestinal pseudo obstruction treatment market has witnessed strong growth in recent years, with the market size projected to increase from ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.130422,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VECT",
        "relevance_score": "0.053271",
        "ticker_sentiment_score": "0.063021",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARDX",
        "relevance_score": "0.053271",
        "ticker_sentiment_score": "0.063021",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IRWD",
        "relevance_score": "0.053271",
        "ticker_sentiment_score": "0.063021",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.053271",
        "ticker_sentiment_score": "0.063021",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.053271",
        "ticker_sentiment_score": "0.063021",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Transformative Growth Expected In The Global Medical Equipment Market: Market Size To Reach $1,077 Billion By 2028 As Per The Business Research Company's Medical Equipment Global Market Report 2024",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38072444/transformative-growth-expected-in-the-global-medical-equipment-market-market-size-to-reach-1-077-b",
    "time_published": "20240403T153000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LONDON, April 03, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Medical Equipment Global Market Report 2024, the medical equipment market has witnessed robust growth in recent years, with the market size expected to reach $775.42 billion in 2024, reflecting a compound annual ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.338179,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GEHC",
        "relevance_score": "0.05133",
        "ticker_sentiment_score": "0.299729",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.05133",
        "ticker_sentiment_score": "0.126428",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.05133",
        "ticker_sentiment_score": "0.126428",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.05133",
        "ticker_sentiment_score": "0.126428",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "5 Things to Know in Investing This Week - Boston Scientific  ( NYSE:BSX ) , Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/news/24/04/38056085/5-things-to-know-in-investing-this-week",
    "time_published": "20240403T142328",
    "authors": [
      "Gary Brode"
    ],
    "summary": "The Personal Consumption Expenditures ( PCE ) Index is the preferred inflation metric for the Federal Reserve. This month's report came out during Good Friday when the markets are closed. Within hours, the hawks who favor higher rates and the doves who favor lower rates all claimed the report ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/02/jason-briscoe-amlfrl8lgls-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999499"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.118043,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SSNLF",
        "relevance_score": "0.046363",
        "ticker_sentiment_score": "0.163746",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.183895",
        "ticker_sentiment_score": "0.131461",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NHNCF",
        "relevance_score": "0.023191",
        "ticker_sentiment_score": "0.135674",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.046363",
        "ticker_sentiment_score": "0.053992",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.046363",
        "ticker_sentiment_score": "-0.074226",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Major shareholder announcement - Swedbank Robur Fonder AB",
    "url": "https://www.globenewswire.com/news-release/2024/04/03/2857099/0/en/Major-shareholder-announcement-Swedbank-Robur-Fonder-AB.html",
    "time_published": "20240403T140500",
    "authors": [
      "Chemometec A/S"
    ],
    "summary": "ANNOUNCEMENT NO. ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.124283,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.303175",
        "ticker_sentiment_score": "0.088424",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.303175",
        "ticker_sentiment_score": "0.088424",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.303175",
        "ticker_sentiment_score": "0.088424",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
    "url": "https://www.zacks.com/stock/news/2249582/these-2-medical-stocks-could-beat-earnings-why-they-should-be-on-your-radar",
    "time_published": "20240403T125011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default249.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999973"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.38715,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.32478",
        "ticker_sentiment_score": "0.367629",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVAX",
        "relevance_score": "0.262522",
        "ticker_sentiment_score": "0.315499",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Great Place To Work unveils Top 10 Best Workplaces in Singapore Healthcare and Biopharma\u2122 2024 - PR Newswire",
    "url": "https://www.prnewswire.com/apac/news-releases/great-place-to-work-unveils-top-10-best-workplaces-in-singapore-healthcare-and-biopharma-2024-302105205.html",
    "time_published": "20240403T040000",
    "authors": [],
    "summary": "Great Place To Work unveils Top 10 Best Workplaces in Singapore Healthcare and Biopharma\u2122 2024 PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.585696,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALC",
        "relevance_score": "0.108958",
        "ticker_sentiment_score": "0.195043",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.054607",
        "ticker_sentiment_score": "0.347092",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.108958",
        "ticker_sentiment_score": "0.200563",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.054607",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.108958",
        "ticker_sentiment_score": "0.152036",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Over 52 Million Myeloma Warriors Reached, Creating Ripples Across the Globe for #MyelomaACTIONMonth",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38089871/over-52-million-myeloma-warriors-reached-creating-ripples-across-the-globe-for-myelomaactionmonth",
    "time_published": "20240404T124500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "STUDIO CITY, Calif., April 04, 2024 ( GLOBE NEWSWIRE ) -- At the conclusion of this year's Myeloma Action Month, the International Myeloma Foundation ( IMF ) was truly grateful and overwhelmed by everyone's support in making the annual campaign a global success -with over 52 million reached in ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.357125,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.060439",
        "ticker_sentiment_score": "0.097145",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.020163",
        "ticker_sentiment_score": "0.178796",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KPTI",
        "relevance_score": "0.020163",
        "ticker_sentiment_score": "0.178796",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MHRE",
        "relevance_score": "0.020163",
        "ticker_sentiment_score": "0.135277",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSVT",
        "relevance_score": "0.020163",
        "ticker_sentiment_score": "0.178796",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MSC",
        "relevance_score": "0.020163",
        "ticker_sentiment_score": "0.236926",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.020163",
        "ticker_sentiment_score": "0.178796",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.020163",
        "ticker_sentiment_score": "0.178796",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.020163",
        "ticker_sentiment_score": "0.178796",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Trinity Biotech Announces Fourth Quarter and Fiscal Year 2023 Financial Results & Business Updates",
    "url": "https://www.globenewswire.com/news-release/2024/04/04/2857682/8624/en/Trinity-Biotech-Announces-Fourth-Quarter-and-Fiscal-Year-2023-Financial-Results-Business-Updates.html",
    "time_published": "20240404T113000",
    "authors": [
      "Trinity Biotech plc"
    ],
    "summary": "DUBLIN, Ireland, April 04, 2024 ( GLOBE NEWSWIRE ) -- Trinity Biotech plc ( Nasdaq: TRIB ) , a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2023 and ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/23a9d0e4-6c22-4509-971e-0c09c45ec985",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.130286,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "TRIB",
        "relevance_score": "0.093087",
        "ticker_sentiment_score": "0.059695",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.010366",
        "ticker_sentiment_score": "0.059081",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:EUR",
        "relevance_score": "0.010366",
        "ticker_sentiment_score": "0.118508",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board - NextCure  ( NASDAQ:NXTC ) ",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38087012/nextcure-appoints-dr-rakesh-dixit-to-scientific-advisory-board",
    "time_published": "20240404T110500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "BELTSVILLE, Md., April 04, 2024 ( GLOBE NEWSWIRE ) -- NextCure, Inc. NXTC, a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to its Scientific ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.326251,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.195025",
        "ticker_sentiment_score": "0.298482",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NXTC",
        "relevance_score": "0.541149",
        "ticker_sentiment_score": "0.331628",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.098255",
        "ticker_sentiment_score": "0.210396",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board",
    "url": "https://www.globenewswire.com/news-release/2024/04/04/2857656/0/en/NextCure-Appoints-Dr-Rakesh-Dixit-to-Scientific-Advisory-Board.html",
    "time_published": "20240404T110500",
    "authors": [
      "NextCure"
    ],
    "summary": "BELTSVILLE, Md., April 04, 2024 ( GLOBE NEWSWIRE ) -- NextCure, Inc. ( Nasdaq: NXTC ) , a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/df24cd65-0f3d-4ede-9e7a-c3f58ce6e9d4",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.162362,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.237163",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NXTC",
        "relevance_score": "0.318074",
        "ticker_sentiment_score": "0.042725",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.065327",
        "ticker_sentiment_score": "0.201503",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Time to Tap Healthcare ETFs on Nvidia's AI Ambition?",
    "url": "https://www.zacks.com/stock/news/2250231/time-to-tap-healthcare-etfs-on-nvidias-ai-ambition",
    "time_published": "20240404T110000",
    "authors": [
      "Sanghamitra Saha"
    ],
    "summary": "At Nvidia's last week's GTC AI conference, the company announced partnerships in the healthcare sector, representing a strategic move toward expanding its revenue streams beyond tech sectors.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/75/44765.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.795202"
      }
    ],
    "overall_sentiment_score": 0.194563,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MCO",
        "relevance_score": "0.084423",
        "ticker_sentiment_score": "-0.048706",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RXRX",
        "relevance_score": "0.167904",
        "ticker_sentiment_score": "0.103476",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SDGR",
        "relevance_score": "0.084423",
        "ticker_sentiment_score": "0.072671",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.249531",
        "ticker_sentiment_score": "0.152713",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Acquisition Watch: Time to Buy Johnson & Johnson  ( JNJ )  or ShockWave Medical's  ( SWAV )  Stock?",
    "url": "https://www.zacks.com/commentary/2251416/acquisition-watch-time-to-buy-johnson-johnson-jnj-or-shockwave-medicals-swav-stock",
    "time_published": "20240405T192700",
    "authors": [
      "Shaun Pruitt"
    ],
    "summary": "News of healthcare behemoth Johnson & Johnson (JNJ) acquiring medical device company ShockWave Medical (SWAV) for $13.1 billion made headlines this morning.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/charts/f7/64441.jpg?v=1798740764",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.287875,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.426824",
        "ticker_sentiment_score": "0.364211",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Stocks Buck Strong Jobs Data; Nvidia Tests This Key Level As Tesla Falls On Stock Market Today",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-tesla-stock-nvidia-stock/",
    "time_published": "20240405T180100",
    "authors": [
      "VIDYA RAMAKRISHNAN",
      "Investor's Business Daily"
    ],
    "summary": "Stocks Buck Strong Jobs Data. Nvidia Tests This Key Level As Tesla Falls Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/02/Stock-Tesla-2024-model3-03-company.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999981"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.130705,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.127119",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARES",
        "relevance_score": "0.127119",
        "ticker_sentiment_score": "0.060216",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CELH",
        "relevance_score": "0.127119",
        "ticker_sentiment_score": "0.32558",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.068215",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.251032",
        "ticker_sentiment_score": "0.021006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.127119",
        "ticker_sentiment_score": "0.118523",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.127119",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "-0.12511",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.127119",
        "ticker_sentiment_score": "-0.145434",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.127119",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AHHLF",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.279698",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.127119",
        "ticker_sentiment_score": "-0.145434",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.18967",
        "ticker_sentiment_score": "-0.111487",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.127119",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.127119",
        "ticker_sentiment_score": "-0.145434",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.127119",
        "ticker_sentiment_score": "-0.145434",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOW",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.052019",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRT",
        "relevance_score": "0.127119",
        "ticker_sentiment_score": "0.32558",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.127119",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MMYT",
        "relevance_score": "0.127119",
        "ticker_sentiment_score": "0.32558",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWAV, KTRA, ABIO - ARCA biopharma  ( NASDAQ:ABIO ) , Kintara Therapeutics  ( NASDAQ:KTRA ) ",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38115003/shareholder-investigation-halper-sadeh-llc-investigates-swav-ktra-abio",
    "time_published": "20240405T174428",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, April 05, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Shockwave Medical, Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.114747,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABIO",
        "relevance_score": "0.118647",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KTRA",
        "relevance_score": "0.118647",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.118647",
        "ticker_sentiment_score": "0.087791",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.118647",
        "ticker_sentiment_score": "0.087791",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CURE Media Group and Oncology Nursing News announce Kristen Dahlgren as keynote speaker for the 2024 Extraordinary Healer\u00ae event",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38113091/cure-media-group-and-oncology-nursing-news-announce-kristen-dahlgren-as-keynote-speaker-for-the-20",
    "time_published": "20240405T160000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "CRANBURY, N.J., April 05, 2024 ( GLOBE NEWSWIRE ) -- CURE\u00ae Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to more than 1 million patients, survivors and caregivers, partners with Oncology Nursing News\u00ae, a multimedia platform dedicated to ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.402117,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.314033",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Uptrend Under Pressure; Tesla, Humana In Focus: Weekly Review",
    "url": "https://www.investors.com/news/market-rally-under-pressure-tesla-humana-in-focus/",
    "time_published": "20240405T154500",
    "authors": [
      "Investor's Business Daily",
      "IBD STAFF"
    ],
    "summary": "Uptrend Under Pressure. Tesla, Humana In Focus: Weekly Review Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/08/WallStreetFinance2-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.858979"
      }
    ],
    "overall_sentiment_score": -0.056248,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "XPEV",
        "relevance_score": "0.074345",
        "ticker_sentiment_score": "-0.040646",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVS",
        "relevance_score": "0.074345",
        "ticker_sentiment_score": "-0.012255",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HUM",
        "relevance_score": "0.148045",
        "ticker_sentiment_score": "0.032097",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ULTA",
        "relevance_score": "0.074345",
        "ticker_sentiment_score": "-0.024013",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GM",
        "relevance_score": "0.111315",
        "ticker_sentiment_score": "-0.125097",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.037213",
        "ticker_sentiment_score": "0.038998",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RIVN",
        "relevance_score": "0.074345",
        "ticker_sentiment_score": "0.057445",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.037213",
        "ticker_sentiment_score": "0.010975",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.148045",
        "ticker_sentiment_score": "0.032097",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.291038",
        "ticker_sentiment_score": "-0.049159",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NIO",
        "relevance_score": "0.074345",
        "ticker_sentiment_score": "-0.040646",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.111315",
        "ticker_sentiment_score": "-0.15039",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "SBH",
        "relevance_score": "0.074345",
        "ticker_sentiment_score": "-0.024013",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TM",
        "relevance_score": "0.074345",
        "ticker_sentiment_score": "-0.113655",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UPS",
        "relevance_score": "0.074345",
        "ticker_sentiment_score": "0.124162",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FDX",
        "relevance_score": "0.074345",
        "ticker_sentiment_score": "0.124162",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LI",
        "relevance_score": "0.074345",
        "ticker_sentiment_score": "-0.040646",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.111315",
        "ticker_sentiment_score": "0.044984",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stock Market Heads Higher After Robust Jobs Data; Tech Rally Led By Amazon, AMD, Netflix",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-nasdaq-sp500-nflx-stock-amazon-stock-amd-stock/",
    "time_published": "20240405T144900",
    "authors": [
      "KEN SHREVE",
      "Investor's Business Daily"
    ],
    "summary": "Stock Market Heads Higher After Robust Jobs Data. Tech Rally Led By Amazon, AMD, Netflix Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2021/02/Stock-MarketBoard-Blue42-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.121495,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DKNG",
        "relevance_score": "0.123844",
        "ticker_sentiment_score": "0.458347",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.123844",
        "ticker_sentiment_score": "-0.018486",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.184834",
        "ticker_sentiment_score": "0.054592",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.06211",
        "ticker_sentiment_score": "0.118094",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.123844",
        "ticker_sentiment_score": "-0.018486",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FTAI",
        "relevance_score": "0.123844",
        "ticker_sentiment_score": "0.458347",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.123844",
        "ticker_sentiment_score": "0.060651",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.184834",
        "ticker_sentiment_score": "0.054592",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRT",
        "relevance_score": "0.123844",
        "ticker_sentiment_score": "0.458347",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.123844",
        "ticker_sentiment_score": "0.364372",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.184834",
        "ticker_sentiment_score": "0.020215",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.123844",
        "ticker_sentiment_score": "0.060651",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stock market today: Wall Street gains ground following surprisingly strong US jobs report",
    "url": "https://apnews.com/article/stock-markets-inflation-cdeea722367b960f1a87b0b3d287fedd",
    "time_published": "20240405T142300",
    "authors": [
      "DAMIAN J. TROISE"
    ],
    "summary": "Stock market today: Wall Street edges higher following surprisingly strong US jobs report The Associated Press ...",
    "banner_image": "https://dims.apnews.com/dims4/default/21218c3/2147483647/strip/true/crop/4604x3067+279+0/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2Fac%2Fa8%2Fea39c40eac6d2050674802e2afce%2Fe22a3195291746b885c2907906788a90",
    "source": "Associated Press",
    "category_within_source": "Markets",
    "source_domain": "apnews.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.9545"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.104508,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.072",
        "ticker_sentiment_score": "0.046611",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.072",
        "ticker_sentiment_score": "0.152117",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Buys Shockwave For $13.1 Billion In Latest Cardio Deal",
    "url": "https://www.forbes.com/sites/tylerroush/2024/04/05/johnson--johnson-buys-shockwave-for-131-billion-in-latest-cardio-deal/",
    "time_published": "20240405T140145",
    "authors": [
      "Ty Roush"
    ],
    "summary": "Johnson & Johnson will acquire Shockwave Medical in a deal valued at $13.1 billion, according to a joint statement Friday, the latest acquisition by the pharmaceutical firm over the last two years as it expands on cardiovascular intervention.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/661003dc039b388009779395/0x0.jpg?format=jpg&crop=4126,2320,x0,y231,safe&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.151974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SWAV",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "0.127301",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.522854",
        "ticker_sentiment_score": "0.298251",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "J&J to pump another $13B into its MedTech business with Shockwave deal",
    "url": "https://apnews.com/article/johnsonshockwavemedtechdeal-fb308f70ee276b007fa759007913ee77",
    "time_published": "20240405T125600",
    "authors": [
      "TOM MURPHY"
    ],
    "summary": "Johnson & Johnson is pumping more money into heart care with a roughly $13 billion deal for Shockwave Medical, which specializes in technology that helps open clogged arteries. The health care giant said Friday that it will spend $335 in cash for each share of Shockwave.",
    "banner_image": "https://dims.apnews.com/dims4/default/d4a7cdd/2147483647/strip/true/crop/8640x5755+0+2/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2Fbf%2Ff6%2Fabd1b09cae88948a1ef55d90b377%2Fb489ad7e1b74464e8247e371365d6597",
    "source": "Associated Press",
    "category_within_source": "Business",
    "source_domain": "apnews.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.234915,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SWAV",
        "relevance_score": "0.21686",
        "ticker_sentiment_score": "0.29379",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.109455",
        "ticker_sentiment_score": "0.282005",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Makes Yet Another Multi-Billion MedTech Deal With Shockwave Medical - Johnson & Johnson  ( NYSE:JNJ ) , Shockwave Medical  ( NASDAQ:SWAV ) ",
    "url": "https://www.benzinga.com/news/large-cap/24/04/38108776/johnson-johnson-makes-yet-another-multi-billion-medtech-deal-with-shockwave-medical",
    "time_published": "20240405T123520",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Friday, Johnson & Johnson JNJ agreed to acquire Shockwave Medical Inc SWAV for $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion, including cash acquired.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Johnson-Johnson-logo-in-front-of-one-of-_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.162565,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SSTK",
        "relevance_score": "0.09186",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.355588",
        "ticker_sentiment_score": "0.382019",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.700945",
        "ticker_sentiment_score": "0.338851",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Futures Bounce Ahead Of Jobs Report",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-jobs-report-meta-stock-nvidia-nvda-tesla-tsla/",
    "time_published": "20240405T120500",
    "authors": [
      "Investor's Business Daily",
      "SCOTT LEHTONEN"
    ],
    "summary": "Stock Market Today: Dow Jones Bounces Ahead Of Jobs Report. Meta, Nvidia, Tesla Rally Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2021/09/Stock-wallstreetflag-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.121747,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DKNG",
        "relevance_score": "0.119235",
        "ticker_sentiment_score": "0.052268",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.079656",
        "ticker_sentiment_score": "-0.06924",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.079656",
        "ticker_sentiment_score": "0.012417",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.197413",
        "ticker_sentiment_score": "0.167288",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ANET",
        "relevance_score": "0.079656",
        "ticker_sentiment_score": "0.013546",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.158519",
        "ticker_sentiment_score": "0.039063",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.158519",
        "ticker_sentiment_score": "0.013825",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.079656",
        "ticker_sentiment_score": "0.165989",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NOW",
        "relevance_score": "0.119235",
        "ticker_sentiment_score": "0.010524",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HUBS",
        "relevance_score": "0.079656",
        "ticker_sentiment_score": "-0.031868",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.039878",
        "ticker_sentiment_score": "0.113657",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.079656",
        "ticker_sentiment_score": "0.165989",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson to Buy Shockwave Medical. It's a Cardio Health Play.",
    "url": "https://www.barrons.com/amp/articles/johnson-johnson-jnj-stock-shockwave-medical-de83a930",
    "time_published": "20240405T111200",
    "authors": [
      "Adam Clark"
    ],
    "summary": "Johnson & Johnson agreed to acquire medical-devices maker Shockwave Medical for a total enterprise value of about $13.1 billion. Johnson & Johnson will pay $335 a share in cash for Shockwave , J&J said in a statement Friday.",
    "banner_image": "https://images.barrons.com/im-459065/social",
    "source": "Barrons",
    "category_within_source": "n/a",
    "source_domain": "www.barrons.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.159966,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SWAV",
        "relevance_score": "0.145145",
        "ticker_sentiment_score": "0.316577",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.727604",
        "ticker_sentiment_score": "0.214185",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson to buy equipment maker Shockwave Medical for $12.5 bn",
    "url": "https://www.business-standard.com/companies/news/johnson-johnson-to-buy-equipment-maker-shockwave-medical-for-12-5-bn-124040500649_1.html",
    "time_published": "20240405T110649",
    "authors": [
      "Reuters"
    ],
    "summary": "Johnson & Johnson on Friday agreed to buy Shockwave Medical for $12.5 billion, in a deal that would help broaden its portfolio of medical devices used in treating heart diseases.",
    "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-12/05/full/1701794396-0294.jpg?im=FeatureCrop,size=(826,465)",
    "source": "Business Standard",
    "category_within_source": "GoogleRSS",
    "source_domain": "www.business-standard.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.333493,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SWAV",
        "relevance_score": "0.327366",
        "ticker_sentiment_score": "0.568925",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.327366",
        "ticker_sentiment_score": "0.568925",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson To Buy Shockwave Medical For $13.1 Billion",
    "url": "https://www.investors.com/news/technology/johnson-johnson-to-buy-shockwave-medical-13-1-billion/",
    "time_published": "20240405T105500",
    "authors": [
      "Investor's Business Daily",
      "ED CARSON"
    ],
    "summary": "Dow Jones giant Johnson & Johnson ( JNJ ) said it would acquire Shockwave Medical ( SWAV ) for $13.1 billion, or $335 a share. Both stocks rose slightly early Friday. SWAV stock had surged 68% to 319.99 as of April 4 in 2024, with takeover speculation among the driving forces.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2022/10/NEWAM_shockwave_101422_BizWire.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.116556,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SWAV",
        "relevance_score": "0.866386",
        "ticker_sentiment_score": "-0.303934",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.739411",
        "ticker_sentiment_score": "-0.023317",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Contineum Therapeutics Announces Pricing of Initial Public Offering",
    "url": "https://www.globenewswire.com/news-release/2024/04/05/2858269/0/en/Contineum-Therapeutics-Announces-Pricing-of-Initial-Public-Offering.html",
    "time_published": "20240405T010200",
    "authors": [
      "Contineum Therapeutics",
      "Inc."
    ],
    "summary": "SAN DIEGO, April 04, 2024 ( GLOBE NEWSWIRE ) -- Contineum Therapeutics, Inc. ( Contineum ) , a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the ...",
    "banner_image": "",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.967645"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.112845,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.107016",
        "ticker_sentiment_score": "0.062762",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.107016",
        "ticker_sentiment_score": "0.062762",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.053629",
        "ticker_sentiment_score": "0.057",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Contineum Therapeutics Announces Pricing of Initial Public Offering",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38103690/contineum-therapeutics-announces-pricing-of-initial-public-offering",
    "time_published": "20240405T010200",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "SAN DIEGO, April 04, 2024 ( GLOBE NEWSWIRE ) -- Contineum Therapeutics, Inc. ( Contineum ) , a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.98396"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.124562,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.102013",
        "ticker_sentiment_score": "0.059706",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.102013",
        "ticker_sentiment_score": "0.059706",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.051111",
        "ticker_sentiment_score": "0.054974",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Can a New CEO Fix Boeing?",
    "url": "https://www.fool.com/investing/2024/04/06/can-a-new-ceo-fix-boeing/",
    "time_published": "20240406T121500",
    "authors": [
      "Motley Fool Staff"
    ],
    "summary": "We also talk with e.l.f. Beauty CEO Tarang Amin about how the company is succeeding.",
    "banner_image": "https://g.foolcdn.com/editorial/images/771264/mfm_29.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999941"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      }
    ],
    "overall_sentiment_score": 0.187821,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.011107",
        "ticker_sentiment_score": "0.062517",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.055492",
        "ticker_sentiment_score": "0.073",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.027763",
        "ticker_sentiment_score": "0.016757",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BK",
        "relevance_score": "0.005554",
        "ticker_sentiment_score": "-0.054697",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DNUT",
        "relevance_score": "0.083155",
        "ticker_sentiment_score": "0.059964",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MASI",
        "relevance_score": "0.044407",
        "ticker_sentiment_score": "0.102612",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.038861",
        "ticker_sentiment_score": "0.010756",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBUX",
        "relevance_score": "0.005554",
        "ticker_sentiment_score": "0.220055",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.01666",
        "ticker_sentiment_score": "-0.033408",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RBLX",
        "relevance_score": "0.011107",
        "ticker_sentiment_score": "0.207778",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.083155",
        "ticker_sentiment_score": "0.05988",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LRLCF",
        "relevance_score": "0.005554",
        "ticker_sentiment_score": "0.076157",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.033313",
        "ticker_sentiment_score": "0.021151",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.01666",
        "ticker_sentiment_score": "0.104468",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.066567",
        "ticker_sentiment_score": "0.024171",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Wall Street indexes rise after strong jobs data",
    "url": "https://www.moneycontrol.com/news/business/markets/wall-street-indexes-rise-after-strong-jobs-data-12586721.html",
    "time_published": "20240406T041428",
    "authors": [],
    "summary": "The Dow Jones Industrial Average rose 307.06 points, or 0.80%, to 38,904.04, the SP 500 gained 57.13 points, or 1.11%, to 5,204.34 and the Nasdaq Composite gained 199.44 points, or 1.24%, to 16,248.52.",
    "banner_image": "https://images.moneycontrol.com/static-mcnews/2020/08/wall-street-1.jpg?impolicy=website&width=168&height=118",
    "source": "Money Control",
    "category_within_source": "Markets",
    "source_domain": "www.moneycontrol.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.106364,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DNUT",
        "relevance_score": "0.09439",
        "ticker_sentiment_score": "0.062564",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.09439",
        "ticker_sentiment_score": "0.175443",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.09439",
        "ticker_sentiment_score": "0.28044",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.09439",
        "ticker_sentiment_score": "0.28044",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ADTH, NVEI, SWAV",
    "url": "https://www.prnewswire.com/news-releases/shareholder-investigation-halper-sadeh-llc-investigates-adth-nvei-swav-302109621.html",
    "time_published": "20240406T013800",
    "authors": [
      "Halper Sadeh LLP"
    ],
    "summary": "NEW YORK, April 5, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: sale to Cadent, LLC for $3.21 per share.",
    "banner_image": "https://mma.prnewswire.com/media/1896150/Firm_Logo_with_Investor_Law_Firm_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.160445,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVEI",
        "relevance_score": "0.166169",
        "ticker_sentiment_score": "0.109574",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADTH",
        "relevance_score": "0.166169",
        "ticker_sentiment_score": "0.117726",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.166169",
        "ticker_sentiment_score": "0.11365",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's the $4.7 Trillion Market Nvidia Has Its Eyes on Now",
    "url": "https://www.fool.com/investing/2024/04/07/heres-the-47-trillion-market-nvidia-has-its-eyes-o/",
    "time_published": "20240407T183000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "The GPU maker hopes to make a bigger splash in a market that accounts for 18% of the U.S. GDP.",
    "banner_image": "https://g.foolcdn.com/editorial/images/771831/health-monitoring-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.206377,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.759979",
        "ticker_sentiment_score": "0.178064",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RXRX",
        "relevance_score": "0.062434",
        "ticker_sentiment_score": "-0.043004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.124486",
        "ticker_sentiment_score": "0.051584",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Examining High Drug Costs In America. What You Need To Know",
    "url": "https://www.forbes.com/sites/omerawan/2024/04/07/examining-high-drug-costs-in-america-what-you-need-to-know/",
    "time_published": "20240407T144611",
    "authors": [
      "Omer Awan"
    ],
    "summary": "Soaring drug prices in America have left many Americans unable to pay for medications and treatments that could otherwise improve their health and well-being. 58 million Americans experience medication insecurity, or the inability to pay for a medication in the last 12 months, according to a ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65ce66449641ba299a647061/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.026363,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.05234",
        "ticker_sentiment_score": "-0.001997",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "More Risks, More Opportunities: What's Next For Employers In Healthcare?",
    "url": "https://www.forbes.com/sites/gebai/2024/04/07/more-risks-more-opportunities-whats-next-for-employers-in-healthcare/",
    "time_published": "20240407T120143",
    "authors": [
      "Ge Bai"
    ],
    "summary": "More Risks, More Opportunities For Employers In Healthcare Forbes ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/66127d7772fcbb3adce2e90e/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.201602,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "COST",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "0.031238",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.056674",
        "ticker_sentiment_score": "0.261002",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.056674",
        "ticker_sentiment_score": "-0.181224",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.056674",
        "ticker_sentiment_score": "0.261002",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Want $200 Per Month in Passive Income? Invest $80,000 in This Vanguard ETF",
    "url": "https://www.fool.com/investing/2024/04/07/want-200-per-month-in-passive-income-invest-80000/",
    "time_published": "20240407T081500",
    "authors": [
      "Demitri Kalogeropoulos"
    ],
    "summary": "Truly passive income is easy to find on the stock market.",
    "banner_image": "https://g.foolcdn.com/editorial/images/771536/businessman-working-on-laptop-with-diagram-graph-on-computer.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.189723,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HD",
        "relevance_score": "0.073546",
        "ticker_sentiment_score": "0.184822",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.073546",
        "ticker_sentiment_score": "0.184822",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.146469",
        "ticker_sentiment_score": "0.235822",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.073546",
        "ticker_sentiment_score": "0.184822",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's Why Johnson & Johnson  ( JNJ )  Fell More Than Broader Market",
    "url": "https://www.zacks.com/stock/news/2252223/heres-why-johnson-johnson-jnj-fell-more-than-broader-market",
    "time_published": "20240408T215021",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the latest trading session, Johnson & Johnson (JNJ) closed at $151.59, marking a -0.52% move from the previous day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default340.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.125033,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.524949",
        "ticker_sentiment_score": "0.127572",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Giant-Cell Arteritis Market to Showcase Positive Growth at a CAGR of 9.3% by 2034 | DelveInsight",
    "url": "https://www.prnewswire.com/news-releases/giant-cell-arteritis-market-to-showcase-positive-growth-at-a-cagr-of-9-3-by-2034--delveinsight-302110122.html",
    "time_published": "20240408T213100",
    "authors": [
      "DelveInsight Business Research",
      "LLP"
    ],
    "summary": "The growth of the giant-cell arteritis market is expected to be mainly driven by the growing geriatric population, the rise in the prevalence of cardiovascular disorders, technological advancements in the healthcare industry, and others.",
    "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.163381,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.10608",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.067284",
        "ticker_sentiment_score": "0.029061",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVBXF",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.024703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MESO",
        "relevance_score": "0.044885",
        "ticker_sentiment_score": "0.028414",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RDHL",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.024703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KNSA",
        "relevance_score": "0.089629",
        "ticker_sentiment_score": "0.069374",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VYNE",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.024703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LABP",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.024703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IMAB",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.024703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MYMD",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.024703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SHJBF",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.024703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.089629",
        "ticker_sentiment_score": "0.069374",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGMF",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.024703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.044885",
        "ticker_sentiment_score": "0.028414",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JAPAF",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.026233",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KYMR",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.024703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MOR",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.10608",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FSNUF",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.024703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.024703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.024703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.044885",
        "ticker_sentiment_score": "0.028414",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAIPY",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.024703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABVX",
        "relevance_score": "0.044885",
        "ticker_sentiment_score": "0.028414",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ACRS",
        "relevance_score": "0.044885",
        "ticker_sentiment_score": "0.028414",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GLPG",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.024703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LBTSF",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.024703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SILO",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.024703",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWAV, AIRC, MODN, ABIO - Apartment Income REIT  ( NYSE:AIRC ) , ARCA biopharma  ( NASDAQ:ABIO ) ",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38148577/shareholder-investigation-halper-sadeh-llc-investigates-swav-airc-modn-abio",
    "time_published": "20240408T182523",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, April 08, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Shockwave Medical, Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.140451,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MODN",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.126562",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABIO",
        "relevance_score": "0.107495",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BX",
        "relevance_score": "0.107495",
        "ticker_sentiment_score": "0.162309",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.107495",
        "ticker_sentiment_score": "0.084635",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AIRC",
        "relevance_score": "0.107495",
        "ticker_sentiment_score": "0.162309",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.107495",
        "ticker_sentiment_score": "0.084635",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider Population - Legend Biotech  ( NASDAQ:LEGN ) , Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38148467/johnson-johnsons-carvykti-stands-ahead-of-bristol-myers-rival-blood-cancer-therapy-",
    "time_published": "20240408T181935",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Friday, the FDA approved Johnson & Johnson JNJ Carvykti ( ciltacabtagene autoleucel; cilta-cel ) for relapsed or refractory multiple myeloma patients who have received at least one prior line of therapy and are refractory to lenalidomide.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/jnj-johnson-shutter_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.294894,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVS",
        "relevance_score": "0.188193",
        "ticker_sentiment_score": "0.156582",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.524949",
        "ticker_sentiment_score": "0.393499",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "LEGN",
        "relevance_score": "0.279015",
        "ticker_sentiment_score": "0.394553",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson's $13B Shockwave Medical Deal Accelerates MedTech Strategy, Analyst Says",
    "url": "https://markets.businessinsider.com/news/stocks/johnson-johnson-s-13b-shockwave-medical-deal-accelerates-medtech-strategy-analyst-says-1033230884",
    "time_published": "20240408T175333",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Johnson & Johnson ( NYSE:JNJ ) agreed on Friday to acquire Shockwave Medical Inc ( NASDAQ:SWAV ) for $335 per share in cash, corresponding to an enterprise value of approximately $13.1 billion, including cash acquired.",
    "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2024/JohnsonampJohnson-Shutterstock_0.jpeg",
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.293229,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NHPEF",
        "relevance_score": "0.120431",
        "ticker_sentiment_score": "-0.107712",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.350564",
        "ticker_sentiment_score": "0.301206",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.350564",
        "ticker_sentiment_score": "0.352331",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.636698",
        "ticker_sentiment_score": "0.41207",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson's $13B Shockwave Medical Deal Accelerates MedTech Strategy, Analyst Says - Johnson & Johnson  ( NYSE:JNJ ) , Shockwave Medical  ( NASDAQ:SWAV ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38147469/johnson-johnsons-13b-shockwave-medical-deal-accelerates-medtech-strategy-analyst-sa",
    "time_published": "20240408T172709",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Johnson & Johnson JNJ agreed on Friday to acquire Shockwave Medical Inc SWAV for $335 per share in cash, corresponding to an enterprise value of approximately $13.1 billion, including cash acquired.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/JohnsonampJohnson-Shutterstock_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.333997,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.342487",
        "ticker_sentiment_score": "0.29619",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.445569",
        "ticker_sentiment_score": "0.4016",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.699089",
        "ticker_sentiment_score": "0.422418",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Bristol Myers  ( BMY )  Gets FDA Nod for Label Expansion of Abecma",
    "url": "https://www.zacks.com/stock/news/2252179/bristol-myers-bmy-gets-fda-nod-for-label-expansion-of-abecma",
    "time_published": "20240408T172700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Bristol Myers (BMY) wins FDA approval for CAR T cell immunotherapy, Abecma, in earlier lines of treatment for patients with relapsed or refractory multiple myeloma.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/604.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.167625,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ADMA",
        "relevance_score": "0.199037",
        "ticker_sentiment_score": "0.177048",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSVT",
        "relevance_score": "0.12023",
        "ticker_sentiment_score": "0.109495",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "-0.069652",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.350014",
        "ticker_sentiment_score": "0.188303",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.080323",
        "ticker_sentiment_score": "0.02769",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Shockwave Medical Stock Rises After Johnson & Johnson Buyout - Johnson & Johnson  ( NYSE:JNJ ) , Shockwave Medical  ( NASDAQ:SWAV ) ",
    "url": "https://www.benzinga.com/news/24/04/38142092/shockwave-medical-stock-rises-after-johnson-johnson-buyout",
    "time_published": "20240408T172325",
    "authors": [
      "MarketBeat"
    ],
    "summary": "Shockwave Medical Inc SWAV is in the spotlight today, after blue-chip pharmaceutical giant Johnson & Johnson JNJ announced it would buy the company for $13.1 billion, boosting its portfolio of cardiovascular disease treatment devices.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/08/jesse-orrico-us3aqvyop-o-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.16747,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SWAV",
        "relevance_score": "0.745397",
        "ticker_sentiment_score": "0.128063",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.552443",
        "ticker_sentiment_score": "0.128192",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Fashion Workwear Brand Argent Helps Women In Every Field Drop-Kick The Glass Ceiling",
    "url": "https://www.forbes.com/sites/simonmainwaring/2024/04/08/fashion-workwear-brand-argent-helps-women-in-every-field-drop-kick-the-glass-ceiling/",
    "time_published": "20240408T171520",
    "authors": [
      "Simon Mainwaring"
    ],
    "summary": "Ninety-nine percent of the partnership opportunities that nine-year-old women's fashion workwear brand Argent considers never get a yes. \"We've been really, really intentional with our collaborations,\" says CEO and founder Sali Christeson.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/661425df9b410a3d553f6957/0x0.jpg?format=jpg&crop=1080,607,x0,y0,safe&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.227684,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SFIX",
        "relevance_score": "0.034087",
        "ticker_sentiment_score": "0.208124",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.034087",
        "ticker_sentiment_score": "0.085167",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Shockwave Medical, Inc.  ( Nasdaq - SWAV ) , Apartment Income REIT Corp.  ( NYSE - AIRC ) , Model N, Inc.  ( NYSE - MODN ) , ARCA biopharma, Inc.  ( Nasdaq - ABIO ) ",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38146844/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-shockwave-med",
    "time_published": "20240408T164806",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "BALA CYNWYD, Pa., April 08, 2024 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.94762"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.184657,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DSSMY",
        "relevance_score": "0.220141",
        "ticker_sentiment_score": "0.065709",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BX",
        "relevance_score": "0.220141",
        "ticker_sentiment_score": "0.172827",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AIRC",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.220141",
        "ticker_sentiment_score": "0.188935",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MODN",
        "relevance_score": "0.290607",
        "ticker_sentiment_score": "0.230376",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABIO",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Dementia Drugs Market Size is projected to reach USD 26,795.69 million by 2030, growing at a CAGR of 7.95%: Straits Research",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38143535/dementia-drugs-market-size-is-projected-to-reach-usd-26-795-69-million-by-2030-growing-at-a-cagr-o",
    "time_published": "20240408T141500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, United States, April 08, 2024 ( GLOBE NEWSWIRE ) -- Dementia is a term used to describe a group of symptoms that significantly impair memory, reasoning, and social abilities. The symptoms include cognitive and behavioral changes that worsen over time, making it difficult to perform even ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.128975,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.0428",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.0428",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.0428",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.0428",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.0428",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "FDA Expands J&J's  ( JNJ )  Carvykti Label in Multiple Myeloma",
    "url": "https://www.zacks.com/stock/news/2252028/fda-expands-jjs-jnj-carvykti-label-in-multiple-myeloma",
    "time_published": "20240408T134000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Following the label expansion, J&J's (JNJ) Carvykti is approved as a second-line treatment for adults with relapsed/refractory myeloma. It was initially approved for use as a fifth- or later-line treatment.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.195249,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TSVT",
        "relevance_score": "0.2256",
        "ticker_sentiment_score": "0.06445",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.297661",
        "ticker_sentiment_score": "0.08288",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LEGN",
        "relevance_score": "0.367141",
        "ticker_sentiment_score": "0.150513",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "J&J's  ( JNJ )  $13.1B Shockwave Deal to Boost MedTech Cardio",
    "url": "https://www.zacks.com/stock/news/2251822/jjs-jnj-131b-shockwave-deal-to-boost-medtech-cardio",
    "time_published": "20240408T131800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "J&J's (JNJ) proposed acquisition of Shockwave Medical (SWAV) is expected to strengthen its Medtech cardiovascular portfolio.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/952.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938238"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.226455,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ADMA",
        "relevance_score": "0.408949",
        "ticker_sentiment_score": "0.324922",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.211806",
        "ticker_sentiment_score": "0.198431",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.279813",
        "ticker_sentiment_score": "0.236789",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson's bone cancer drug gets USFDA nod",
    "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/johnson-johnsons-bone-cancer-drug-gets-usfda-nod/3450386/",
    "time_published": "20240408T123535",
    "authors": [
      "Health Desk"
    ],
    "summary": "Johnson & Johnson on Monday announced that the US Food and Drug Administration ( FDA ) has approved Carvykti for the treatment of adult patients with relapsed or refractory multiple myeloma.",
    "banner_image": "https://www.financialexpress.com/wp-content/uploads/2024/01/2024-01-08T155047Z_3979667_RC22R4A4HVZO_RTRMADP_2_HEALTH-DEALS.jpg",
    "source": "The Financial Express",
    "category_within_source": "n/a",
    "source_domain": "www.financialexpress.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.112501,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.229691",
        "ticker_sentiment_score": "0.276282",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LEGN",
        "relevance_score": "0.058188",
        "ticker_sentiment_score": "0.157999",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is Johnson & Johnson Stock A Better Pick Over AbbVie?",
    "url": "https://www.forbes.com/sites/greatspeculations/2024/04/08/is-johnson--johnson-stock-a-better-pick-over-abbvie/",
    "time_published": "20240408T113050",
    "authors": [
      "Trefis Team"
    ],
    "summary": "We believe that the pharmaceuticals bellwether Johnson & Johnson ( NYSE: JNJ ) is currently a better pick over its peer AbbVie ( NYSE: ABBV ) .",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/66138475c142148b65e3d00a/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.998947"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.238945,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.708596",
        "ticker_sentiment_score": "0.385571",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.479258",
        "ticker_sentiment_score": "0.317916",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AstraZeneca, Daiichi drug gets broad tumor approval in US",
    "url": "https://www.moneycontrol.com/news/business/astrazeneca-daiichi-drug-gets-broad-tumor-approval-in-us-12599311.html",
    "time_published": "20240408T090132",
    "authors": [],
    "summary": "The US Food and Drug Administration cleared the medicine for patients who have HER2-positive solid tumors that have spread or can't be removed with surgery, the company said. These patients have already received prior treatment and don't have any good alternatives.",
    "banner_image": "https://images.moneycontrol.com/static-mcnews/2024/04/Astrazeneca-770x433.jpg",
    "source": "Money Control",
    "category_within_source": "Business",
    "source_domain": "www.moneycontrol.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.29451,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PTAIF",
        "relevance_score": "0.350564",
        "ticker_sentiment_score": "0.336945",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.179788",
        "ticker_sentiment_score": "0.375081",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.179788",
        "ticker_sentiment_score": "0.169819",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.179788",
        "ticker_sentiment_score": "0.169819",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Dividend Stocks to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/04/08/2-dividend-stocks-to-buy-and-hold-forever/",
    "time_published": "20240408T074600",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "These dividends are about as safe as they come.",
    "banner_image": "https://g.foolcdn.com/editorial/images/771565/doctor-in-consultation-with-a-patient.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.30126,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.377142",
        "ticker_sentiment_score": "0.29538",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Healthy Returns: J&J cell therapy gains new edge over Bristol Myers rival",
    "url": "https://www.cnbc.com/2024/04/09/healthy-returns-jj-cell-therapy-gains-edge-over-bristol-myers-rival.html",
    "time_published": "20240409T183754",
    "authors": [
      "Annika Kim Constantino",
      "Ashley Capoot"
    ],
    "summary": "J&J's cell therapy is now approved for an earlier line of treatment than a competing drug from Bristol Myers. Meanwhile, a look at Mount Sinai's approach to AI.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107388182-17105168312024-03-08t160017z_281222543_rc2kh6adpeyy_rtrmadp_0_totw-obesity.jpeg?v=1710516917&w=600&h=300&vtcrop=y",
    "source": "CNBC",
    "category_within_source": "Business",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.243915,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TSVT",
        "relevance_score": "0.031654",
        "ticker_sentiment_score": "0.107366",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LEGN",
        "relevance_score": "0.063258",
        "ticker_sentiment_score": "0.18823",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.031654",
        "ticker_sentiment_score": "0.124731",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.031654",
        "ticker_sentiment_score": "0.124731",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Assessing Johnson & Johnson's Performance Against Competitors In Pharmaceuticals Industry - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/news/24/04/38165932/assessing-johnson-amp-johnsons-performance-against-competitors-in-pharmaceuticals-industry",
    "time_published": "20240409T150055",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Amidst today's fast-paced and highly competitive business environment, it is crucial for investors and industry enthusiasts to conduct comprehensive company evaluations.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.225992,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.059785",
        "ticker_sentiment_score": "0.139004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.451494",
        "ticker_sentiment_score": "0.345624",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Expected to Beat Earnings Estimates: Can the Stock Move Higher?",
    "url": "https://www.zacks.com/stock/news/2252668/johnson-johnson-jnj-expected-to-beat-earnings-estimates-can-the-stock-move-higher",
    "time_published": "20240409T140016",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default222.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.171014,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.297061",
        "ticker_sentiment_score": "0.155908",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "How's AT&T Handling Things?",
    "url": "https://www.fool.com/investing/2024/04/09/hows-att-handling-things/",
    "time_published": "20240409T135106",
    "authors": [
      "Motley Fool Staff"
    ],
    "summary": "We've also got a look at 3M's spinoff, gold prices, and the beef industry.",
    "banner_image": "https://g.foolcdn.com/editorial/images/771772/mfm_01.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.158747,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PATH",
        "relevance_score": "0.015502",
        "ticker_sentiment_score": "0.027454",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PYPL",
        "relevance_score": "0.007751",
        "ticker_sentiment_score": "0.108536",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SOLV",
        "relevance_score": "0.046482",
        "ticker_sentiment_score": "0.143241",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NRHI",
        "relevance_score": "0.015502",
        "ticker_sentiment_score": "-0.006244",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.023251",
        "ticker_sentiment_score": "0.06323",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.023251",
        "ticker_sentiment_score": "0.090219",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.023251",
        "ticker_sentiment_score": "0.090942",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MASI",
        "relevance_score": "0.007751",
        "ticker_sentiment_score": "0.048741",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.007751",
        "ticker_sentiment_score": "0.108536",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "T",
        "relevance_score": "0.054218",
        "ticker_sentiment_score": "0.066001",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EBAY",
        "relevance_score": "0.007751",
        "ticker_sentiment_score": "0.108536",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.030998",
        "ticker_sentiment_score": "0.072383",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.015502",
        "ticker_sentiment_score": "0.048142",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZTS",
        "relevance_score": "0.007751",
        "ticker_sentiment_score": "0.108536",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FDX",
        "relevance_score": "0.007751",
        "ticker_sentiment_score": "0.059386",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.007751",
        "ticker_sentiment_score": "0.073734",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "enGene Announces Hiring of Dr. Raj Pruthi as Senior Vice President, Urologic Oncology and Clinical Development",
    "url": "https://www.newswire.ca/news-releases/engene-announces-hiring-of-dr-raj-pruthi-as-senior-vice-president-urologic-oncology-and-clinical-development-814394436.html",
    "time_published": "20240409T120000",
    "authors": [
      "enGene Inc."
    ],
    "summary": "engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development Canada ...",
    "banner_image": "https://mma.prnewswire.com/media/2380935/enGene_Inc__enGene_Announces_Hiring_of_Dr__Raj_Pruthi_as_Senior.jpg?p=facebook",
    "source": "Canada Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.newswire.ca",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.095171,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ENGN",
        "relevance_score": "0.445419",
        "ticker_sentiment_score": "0.12365",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FRBN",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "-0.0331",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "-0.037253",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade",
    "url": "https://www.fool.com/investing/2024/04/09/3-dividend-growth-stocks-with-yields-above-3-that/",
    "time_published": "20240409T082100",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Income-seeking investors can look forward to steady payout raises from these pharma stocks.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F772112%2Finvestor-stock-charts-laptop-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.207428,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.055751",
        "ticker_sentiment_score": "0.057886",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.166169",
        "ticker_sentiment_score": "0.083778",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.055751",
        "ticker_sentiment_score": "-0.058885",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.055751",
        "ticker_sentiment_score": "0.027025",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.220308",
        "ticker_sentiment_score": "0.217001",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.166169",
        "ticker_sentiment_score": "0.06886",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "InnovationRx: $90 Million To Make Drugs In Space",
    "url": "https://www.forbes.com/sites/katiejennings/2024/04/10/innovationrx-90-million-to-make-drugs-in-space/",
    "time_published": "20240410T225208",
    "authors": [
      "Alex Knapp"
    ],
    "summary": "InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here. ess than a month after the company released the results of its first drug manufacturing experiment, Varda Space announced that it has raised a $90 million series B round, bringing its total investments ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65fadd2b7ba222e36c10e1ca/0x0.png?format=png&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.106833,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.058759",
        "ticker_sentiment_score": "0.05406",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.058759",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMLX",
        "relevance_score": "0.058759",
        "ticker_sentiment_score": "-0.064984",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.058759",
        "ticker_sentiment_score": "0.107994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.058759",
        "ticker_sentiment_score": "0.107994",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What's in Store for Dow ETFs in Q1 Earnings?",
    "url": "https://www.zacks.com/stock/news/2253459/whats-in-store-for-dow-etfs-in-q1-earnings",
    "time_published": "20240410T151000",
    "authors": [
      "Sweta Killa"
    ],
    "summary": "Of the 16 Zacks sectors, eight are expected to post earnings growth in the first quarter, with the strongest gains in the Technology sector (19.4%).",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default53.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999696"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.184339,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DOW",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.043885",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IBM",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.028617",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.023965",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.067716",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.055541",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Major shareholder announcement - BlackRock, Inc.",
    "url": "https://www.globenewswire.com/news-release/2024/04/10/2860909/0/en/Major-shareholder-announcement-BlackRock-Inc.html",
    "time_published": "20240410T145000",
    "authors": [
      "Chemometec A/S"
    ],
    "summary": "ANNOUNCEMENT NO. ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.139893,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.63188",
        "ticker_sentiment_score": "0.281997",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.235823",
        "ticker_sentiment_score": "0.072083",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.235823",
        "ticker_sentiment_score": "0.072083",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.235823",
        "ticker_sentiment_score": "0.072083",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Pharmaceutical Industry Finds Itself At A Historical Crossroads - Bristol-Myers Squibb  ( NYSE:BMY ) ",
    "url": "https://www.benzinga.com/markets/penny-stocks/24/04/38184861/the-pharmaceutical-industry-finds-itself-at-a-historical-crossroads",
    "time_published": "20240410T144751",
    "authors": [
      "Upwallstreet"
    ],
    "summary": "Bristol Myers Squibb BMY, Merck & Co Inc MRK, Pfizer Inc PFE and Johnson & JohnsonJNJ are facing the so-called patent cliffs which imply revenue of tens of billions of dollars between now and and the end of this decade is at risk.",
    "banner_image": "https://cdn.benzinga.com/files/covid-recovery-center-female-doctor-holding-older-patient-s-hands_1.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.110152,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MRNA",
        "relevance_score": "0.18602",
        "ticker_sentiment_score": "-0.114666",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "-0.116901",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.046907",
        "ticker_sentiment_score": "0.15966",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ADAG",
        "relevance_score": "0.046907",
        "ticker_sentiment_score": "-0.072999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "0.087284",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "0.32013",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Boston Scientific  ( BSX )  Faces Rising Costs, Competition",
    "url": "https://www.zacks.com/stock/news/2253274/boston-scientific-bsx-faces-rising-costs-competition",
    "time_published": "20240410T133000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "With Boston Scientific (BSX) recording 40% of its sales from the international market, it remains highly exposed to currency fluctuations.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/0e/879.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.993781"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.076668,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "EW",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.061889",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNN",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.061889",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.274012",
        "ticker_sentiment_score": "0.068335",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.061889",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.42503",
        "ticker_sentiment_score": "0.172827",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "COR",
        "relevance_score": "0.220809",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.061889",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.220809",
        "ticker_sentiment_score": "0.158494",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.061889",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXNX",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.112092",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "SWAV Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Shockwave Medical to Johnson & Johnson - Shockwave Medical  ( NASDAQ:SWAV ) ",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38182933/swav-alert-monsey-firm-of-wohl-fruchter-investigating-fairness-of-the-sale-of-shockwave-medical-to",
    "time_published": "20240410T132500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "MONSEY, N.Y., April 10, 2024 ( GLOBE NEWSWIRE ) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the price of $335.00 per share in cash for which Shockwave Medical, Inc. SWAV ( \"Shockwave\" ) has agreed to be sold to Johnson & Johnson.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.217316,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SWAV",
        "relevance_score": "0.255641",
        "ticker_sentiment_score": "0.1762",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.255641",
        "ticker_sentiment_score": "0.207687",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings",
    "url": "https://www.zacks.com/stock/news/2253135/want-better-returns-dont-ignore-these-2-medical-stocks-set-to-beat-earnings",
    "time_published": "20240410T125011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default93.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999682"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.316925,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TMDX",
        "relevance_score": "0.38588",
        "ticker_sentiment_score": "0.394798",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.137371",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.263231",
        "ticker_sentiment_score": "0.22947",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "What's Next For Johnson & Johnson Stock After A 6% Decline In A Month?",
    "url": "https://www.forbes.com/sites/greatspeculations/2024/04/10/whats-next-for-johnson--johnson-stock-after-a-6-decline-in-a-month/",
    "time_published": "20240410T123012",
    "authors": [
      "Trefis Team"
    ],
    "summary": "Johnson & Johnson ( NYSE: JNJ ) recently announced its plans to acquire Shockwave Medical for $13 billion. Shockwave will help J&J extend its offerings in the cardiovascular intervention market.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65f9344dfbca0625a7100477/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.196042,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SWAV",
        "relevance_score": "0.107016",
        "ticker_sentiment_score": "0.029784",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.540646",
        "ticker_sentiment_score": "0.264582",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Does Johnson & Johnson's Latest Acquisition Make It a No-Brainer Buy?",
    "url": "https://www.fool.com/investing/2024/04/10/jnj-stock-acquisition-make-no-brainer-buy/",
    "time_published": "20240410T085700",
    "authors": [
      "David Jagielski"
    ],
    "summary": "The company is hoping to expand, but is there enough here to attract growth investors?",
    "banner_image": "https://g.foolcdn.com/editorial/images/772084/people-agreeing-on-a-deal.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.258978,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.059488",
        "ticker_sentiment_score": "0.154005",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.290952",
        "ticker_sentiment_score": "0.426888",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.498188",
        "ticker_sentiment_score": "0.27869",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Nasdaq Jumps 250 Points; Crude Oil Down 1% - Aptevo Therapeutics  ( NASDAQ:APVO ) , Eliem Therapeutics  ( NASDAQ:ELYM ) ",
    "url": "https://www.benzinga.com/news/earnings/24/04/38210186/nasdaq-jumps-250-points-crude-oil-down-1",
    "time_published": "20240411T192109",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite surging more than 250 points on Thursday. The Dow traded up 0.18% to 38,532.50 while the NASDAQ rose 1.63% to 16,433.83. The S&P 500 also rose, gaining, 0.83% to 5,203.26. Information technology shares rose by 2.2% on ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/11/crude_oil_6-_logo.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      }
    ],
    "overall_sentiment_score": 0.12088,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ENLV",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.116816",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RLYB",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.005358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APVO",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.164567",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.076847",
        "ticker_sentiment_score": "0.004103",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STZ",
        "relevance_score": "0.227716",
        "ticker_sentiment_score": "0.130105",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ELYM",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.356133",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "RCEL",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "-0.061439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RENT",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.358638",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Dow Dips 100 Points; CarMax Earnings Miss Views - CarMax  ( NYSE:KMX ) ",
    "url": "https://www.benzinga.com/news/24/04/38206191/dow-dips-100-points-carmax-earnings-miss-views",
    "time_published": "20240411T155535",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 100 points on Thursday. The Dow traded down 0.35% to 38,328.18 while the NASDAQ rose 0.50% to 16,251.71. The S&P 500 also rose, gaining, 0.03% to 5,162.19.Check This Out: How To Earn $500 A Month From ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/11/image21.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      }
    ],
    "overall_sentiment_score": 0.058409,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "C",
        "relevance_score": "0.076358",
        "ticker_sentiment_score": "0.069728",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ENLV",
        "relevance_score": "0.152018",
        "ticker_sentiment_score": "0.116367",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RLYB",
        "relevance_score": "0.152018",
        "ticker_sentiment_score": "0.005337",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APVO",
        "relevance_score": "0.152018",
        "ticker_sentiment_score": "0.163939",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.076358",
        "ticker_sentiment_score": "0.004099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMX",
        "relevance_score": "0.226301",
        "ticker_sentiment_score": "-0.295068",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ELYM",
        "relevance_score": "0.152018",
        "ticker_sentiment_score": "0.354878",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "RCEL",
        "relevance_score": "0.152018",
        "ticker_sentiment_score": "-0.061201",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RENT",
        "relevance_score": "0.152018",
        "ticker_sentiment_score": "0.357376",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "How To Get Steady Income: 6 Best Monthly Dividend ETFs",
    "url": "https://www.forbes.com/sites/investor-hub/article/best-monthly-dividend-etfs/",
    "time_published": "20240411T153808",
    "authors": [
      "Catherine Brock"
    ],
    "summary": "Dividend exchange-traded funds are the ultimate in passive income. You do the work upfront to evaluate the fund's strategy, then monitor results and count the money that's flowing in. And since the payout drops to your account monthly, it's almost like earning a paycheck-without the boss, ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6616ee3d54b17857edaf62d9/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.208298,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.089797",
        "ticker_sentiment_score": "0.212579",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRBG",
        "relevance_score": "0.029989",
        "ticker_sentiment_score": "0.121904",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PKG",
        "relevance_score": "0.059935",
        "ticker_sentiment_score": "0.130004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VST",
        "relevance_score": "0.059935",
        "ticker_sentiment_score": "0.130004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.029989",
        "ticker_sentiment_score": "0.262267",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.029989",
        "ticker_sentiment_score": "0.262267",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "5 Things To Know In Investing This Week - The Shockwave Takeover Issue - Johnson & Johnson  ( NYSE:JNJ ) , Shockwave Medical  ( NASDAQ:SWAV ) ",
    "url": "https://www.benzinga.com/economics/24/04/38203421/5-things-to-know-in-investing-this-week-the-shockwave-takeover-issue",
    "time_published": "20240411T140240",
    "authors": [
      "Gary Brode"
    ],
    "summary": "The Shockwave offer that DKI predicted in December happened this week with Johnson & Johnson JNJagreeing to pay $335 per share in cash. DKI subscribers celebrated! The PMI came in hot. Don't want to read the details? The conclusion is \"higher for longer\".",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/11/chris-liverani-dbi_my696rk-unsplash_1.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.972756"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.085151,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BSX",
        "relevance_score": "0.041719",
        "ticker_sentiment_score": "0.089695",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.14527",
        "ticker_sentiment_score": "0.142853",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.104047",
        "ticker_sentiment_score": "0.080569",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.020866",
        "ticker_sentiment_score": "0.071174",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday - Janux Therapeutics  ( NASDAQ:JANX ) , Alpine Immune Sciences  ( NASDAQ:ALPN ) , Enliven Therapeutics  ( NASDAQ:ELVN ) ",
    "url": "https://www.benzinga.com/news/24/04/38203373/enliven-therapeutics-alpine-immune-sciences-janux-therapeutics-and-other-big-stocks-moving-higher-on",
    "time_published": "20240411T140151",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. ELVN rose sharply during Thursday's session. Enliven Therapeutics announced proof of concept data from Phase 1 clinical trial of ELVN-001 in chronic myeloid leukemia.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/11/image24_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.231304,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JANX",
        "relevance_score": "0.249106",
        "ticker_sentiment_score": "0.190782",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GYRE",
        "relevance_score": "0.249106",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RLYB",
        "relevance_score": "0.249106",
        "ticker_sentiment_score": "0.179094",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.126119",
        "ticker_sentiment_score": "0.112302",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NEXN",
        "relevance_score": "0.249106",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STEP",
        "relevance_score": "0.249106",
        "ticker_sentiment_score": "0.449181",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "IAG",
        "relevance_score": "0.249106",
        "ticker_sentiment_score": "0.579639",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ANAB",
        "relevance_score": "0.366061",
        "ticker_sentiment_score": "-0.232562",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "FVRR",
        "relevance_score": "0.249106",
        "ticker_sentiment_score": "0.429586",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.126119",
        "ticker_sentiment_score": "-0.108773",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.249106",
        "ticker_sentiment_score": "0.318887",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NRIX",
        "relevance_score": "0.366061",
        "ticker_sentiment_score": "0.282563",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GCT",
        "relevance_score": "0.249106",
        "ticker_sentiment_score": "0.470845",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ALTI",
        "relevance_score": "0.249106",
        "ticker_sentiment_score": "0.579639",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ELVN",
        "relevance_score": "0.572601",
        "ticker_sentiment_score": "0.038707",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nasdaq Gains Over 50 Points; US Producer Prices Increase In March - Aptevo Therapeutics  ( NASDAQ:APVO ) , ClearOne  ( NASDAQ:CLRO ) ",
    "url": "https://www.benzinga.com/news/earnings/24/04/38202938/nasdaq-gains-over-50-points-us-producer-prices-increase-in-march",
    "time_published": "20240411T134148",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "U.S. stocks traded mostly higher this morning, following the release of PPI data. Following the market opening Thursday, the Dow traded up 0.03% to 38,472.80 while the NASDAQ rose 0.40% to 16,234.94. The S&P 500 also rose, gaining, 0.17% to 5,169.21. Real estate shares rose by 0.6% on Thursday.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/11/image10_0.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.153705,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ENLV",
        "relevance_score": "0.179121",
        "ticker_sentiment_score": "0.129694",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RLYB",
        "relevance_score": "0.179121",
        "ticker_sentiment_score": "0.005968",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APVO",
        "relevance_score": "0.179121",
        "ticker_sentiment_score": "0.182504",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.090134",
        "ticker_sentiment_score": "0.004235",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLRO",
        "relevance_score": "0.179121",
        "ticker_sentiment_score": "-0.26463",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ELYM",
        "relevance_score": "0.179121",
        "ticker_sentiment_score": "0.391318",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "RENT",
        "relevance_score": "0.179121",
        "ticker_sentiment_score": "0.394002",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Rare Disease-Focused Rallybio Inks Development Pact With Johnson & Johnson, Stock Shoots Higher - Rallybio  ( NASDAQ:RLYB ) , Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/04/38202543/rare-disease-focused-rallybio-inks-development-pact-with-johnson-johnson-stock-shoots-higher",
    "time_published": "20240411T132704",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Rallybio Corporation RLYB shares are trading higher after the company announced a collaboration with Johnson & Johnson JNJ to support the development of complementary therapeutic approaches aimed at reducing the risk of fetal and neonatal alloimmune thrombocytopenia ( FNAIT ) .",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Labs_3.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.097815,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "RLYB",
        "relevance_score": "0.850429",
        "ticker_sentiment_score": "0.240684",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.487546",
        "ticker_sentiment_score": "0.278135",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Unlocking Q1 Potential of Johnson & Johnson  ( JNJ ) : Exploring Wall Street Estimates for Key Metrics",
    "url": "https://www.zacks.com/stock/news/2253845/unlocking-q1-potential-of-johnson-johnson-jnj-exploring-wall-street-estimates-for-key-metrics",
    "time_published": "20240411T131516",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Johnson & Johnson (JNJ), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default168.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.967321"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.079488,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.33446",
        "ticker_sentiment_score": "0.078904",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Investors Heavily Search Johnson & Johnson  ( JNJ ) : Here is What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2253803/investors-heavily-search-johnson-johnson-jnj-here-is-what-you-need-to-know",
    "time_published": "20240411T130014",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default264.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.226684,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.477606",
        "ticker_sentiment_score": "0.133274",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nike Stock Jumps On Upgrade As Estimates 'Finally Look Achievable' Ahead Of Paris Olympics",
    "url": "https://www.investors.com/news/nike-stock-upgrade-to-buy-paris-olympics/",
    "time_published": "20240411T124100",
    "authors": [
      "Investor's Business Daily",
      "HARRISON MILLER"
    ],
    "summary": "Nike stock rose early Thursday after the Dow Jones sports apparel behemoth received an upgrade from BofA Securities, citing the Paris Olympics as a catalyst. Rival sports retailers and footwear stocks were mixed Thursday morning.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/11/stock-Nike-06-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.997405"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.95493"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.214378,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NKE",
        "relevance_score": "0.510302",
        "ticker_sentiment_score": "0.147188",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.082138",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.156461",
        "ticker_sentiment_score": "0.260882",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DECK",
        "relevance_score": "0.156461",
        "ticker_sentiment_score": "0.189076",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.156461",
        "ticker_sentiment_score": "0.260882",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.156461",
        "ticker_sentiment_score": "0.260882",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Boston Scientific  ( BSX )  Faces Rising Costs, Competition - Boston Scientific  ( NYSE:BSX ) , Cardinal Health  ( NYSE:CAH ) ",
    "url": "https://www.benzinga.com/news/24/04/38185400/boston-scientific-bsx-faces-rising-costs-competition",
    "time_published": "20240411T104536",
    "authors": [
      "Zacks"
    ],
    "summary": "Boston Scientific Corporation BSX has been struggling due to unfavorable currency movement and macroeconomic woes. Strong competitors in the large medical device market also pose a tough challenge for Boston Scientific. The stock carries a Zacks Rank #4 ( Sell ) currently.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/10/hush-naidoo-jade-photography-yo01z-9hqaw-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.993781"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.091136,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "EW",
        "relevance_score": "0.055364",
        "ticker_sentiment_score": "0.061864",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNN",
        "relevance_score": "0.055364",
        "ticker_sentiment_score": "0.061864",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.271576",
        "ticker_sentiment_score": "0.041982",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.055364",
        "ticker_sentiment_score": "0.061864",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.421485",
        "ticker_sentiment_score": "0.177616",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "COR",
        "relevance_score": "0.218817",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.055364",
        "ticker_sentiment_score": "0.061864",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.218817",
        "ticker_sentiment_score": "0.178814",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.055364",
        "ticker_sentiment_score": "0.061864",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXNX",
        "relevance_score": "0.055364",
        "ticker_sentiment_score": "0.112071",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket - Rallybio  ( NASDAQ:RLYB ) ",
    "url": "https://www.benzinga.com/news/24/04/38197762/why-rallybio-shares-are-trading-higher-by-around-78-here-are-20-stocks-moving-premarket",
    "time_published": "20240411T101441",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Shares of Rallybio Corporation RLYB rose sharply in today's pre-market trading after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant individuals at risk of FNAIT. Rallybio shares jumped rose 77.9% to $2.90 in pre-market trading.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/11/image24.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.882182"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.065994,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "WNW",
        "relevance_score": "0.158",
        "ticker_sentiment_score": "-0.180022",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "RLYB",
        "relevance_score": "0.235062",
        "ticker_sentiment_score": "0.014946",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.079392",
        "ticker_sentiment_score": "-0.062998",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVOS",
        "relevance_score": "0.158",
        "ticker_sentiment_score": "-0.431679",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "SPRC",
        "relevance_score": "0.158",
        "ticker_sentiment_score": "0.257022",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ICCT",
        "relevance_score": "0.158",
        "ticker_sentiment_score": "-0.057887",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALLR",
        "relevance_score": "0.158",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TC",
        "relevance_score": "0.158",
        "ticker_sentiment_score": "0.094216",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APVO",
        "relevance_score": "0.235062",
        "ticker_sentiment_score": "-0.32525",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "CURI",
        "relevance_score": "0.158",
        "ticker_sentiment_score": "0.128399",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VERA",
        "relevance_score": "0.158",
        "ticker_sentiment_score": "0.2322",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.158",
        "ticker_sentiment_score": "0.332081",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VERB",
        "relevance_score": "0.158",
        "ticker_sentiment_score": "0.403075",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ADIL",
        "relevance_score": "0.235062",
        "ticker_sentiment_score": "0.279089",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CLRO",
        "relevance_score": "0.158",
        "ticker_sentiment_score": "-0.219103",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ACOR",
        "relevance_score": "0.235062",
        "ticker_sentiment_score": "-0.336041",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "RCEL",
        "relevance_score": "0.158",
        "ticker_sentiment_score": "-0.145508",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FUFU",
        "relevance_score": "0.158",
        "ticker_sentiment_score": "0.316659",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NYXH",
        "relevance_score": "0.158",
        "ticker_sentiment_score": "-0.356361",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "RENT",
        "relevance_score": "0.158",
        "ticker_sentiment_score": "0.237433",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "INVESTOR CALL: Virtualware's CEO to present Annual Report to shareholders",
    "url": "https://www.globenewswire.com/news-release/2024/04/11/2861246/0/en/INVESTOR-CALL-Virtualware-s-CEO-to-present-Annual-Report-to-shareholders.html",
    "time_published": "20240411T060000",
    "authors": [
      "VIRTUALWARE 2007 SA"
    ],
    "summary": "Bilbao, April 11 - Spanish listed company Virtualware ( EPA:MLVIR ) , European leader in the industrial virtual reality sector, invites its shareholders to a meeting to review the Annual Results and Auditors' Report for the 2023 financial year.",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/6aee44c0-62ac-4f66-9be0-b3578d202005",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.199161,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GEV",
        "relevance_score": "0.062271",
        "ticker_sentiment_score": "0.118042",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IBDSF",
        "relevance_score": "0.062271",
        "ticker_sentiment_score": "0.118042",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AOMFF",
        "relevance_score": "0.062271",
        "ticker_sentiment_score": "0.118042",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.062271",
        "ticker_sentiment_score": "0.118042",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.062271",
        "ticker_sentiment_score": "0.118042",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Netflix, Goldman Sachs And The Bitcoin Halving: Investing Action Plan",
    "url": "https://www.investors.com/research/investing-action-plan/netflix-goldman-sachs-and-the-bitcoin-halving-investing-action-plan/",
    "time_published": "20240412T215400",
    "authors": [
      "ALAN R. ELLIOTT",
      "Investor's Business Daily"
    ],
    "summary": "A seesaw week took a turn for the better, then slammed into a financial-sector sell-off on Friday, following JPMorgan's earnings report. Goldman Sachs ( GS ) , Charles Schwab ( SCHW ) and Bank of America ( BAC ) are next up, with earnings due early in the week.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/07/Stock-NYSExchange-71-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998962"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.128234,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.198764",
        "ticker_sentiment_score": "0.104555",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARES",
        "relevance_score": "0.066877",
        "ticker_sentiment_score": "0.045174",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.066877",
        "ticker_sentiment_score": "0.045174",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.066877",
        "ticker_sentiment_score": "-0.107362",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IBKR",
        "relevance_score": "0.066877",
        "ticker_sentiment_score": "0.104229",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.100168",
        "ticker_sentiment_score": "0.00866",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.066877",
        "ticker_sentiment_score": "0.045174",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.066877",
        "ticker_sentiment_score": "0.187188",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CCJ",
        "relevance_score": "0.066877",
        "ticker_sentiment_score": "0.045174",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.100168",
        "ticker_sentiment_score": "0.108608",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.066877",
        "ticker_sentiment_score": "0.187188",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ASML",
        "relevance_score": "0.066877",
        "ticker_sentiment_score": "0.050077",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SCHW",
        "relevance_score": "0.100168",
        "ticker_sentiment_score": "-0.02919",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.100168",
        "ticker_sentiment_score": "0.188917",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SBNY",
        "relevance_score": "0.066877",
        "ticker_sentiment_score": "0.007049",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.066877",
        "ticker_sentiment_score": "0.1454",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.066877",
        "ticker_sentiment_score": "-0.079528",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Stock Moves -0.85%: What You Should Know",
    "url": "https://www.zacks.com/stock/news/2254838/johnson-johnson-jnj-stock-moves--085-what-you-should-know",
    "time_published": "20240412T214520",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The latest trading day saw Johnson & Johnson (JNJ) settling at $147.52, representing a -0.85% change from its previous close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default119.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.147783,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.517534",
        "ticker_sentiment_score": "0.186145",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The Q1 Earnings Season Kicks off Positively",
    "url": "https://www.zacks.com/commentary/2254820/the-q1-earnings-season-kicks-off-positively",
    "time_published": "20240412T202800",
    "authors": [
      "Sheraz Mian"
    ],
    "summary": "We see the Q1 results from the major banks as good enough. not great, but definitely not bad either. Next week, the cycle picks up notable steam, with 41 S&P 500 companies on the reporting docket. How will the market react?",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/bb/14622.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.173813,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.035035",
        "ticker_sentiment_score": "0.049152",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSX",
        "relevance_score": "0.035035",
        "ticker_sentiment_score": "0.049152",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.207868",
        "ticker_sentiment_score": "0.090744",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.207868",
        "ticker_sentiment_score": "0.073889",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.035035",
        "ticker_sentiment_score": "0.049152",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Quarterly Releases to Watch Next Week",
    "url": "https://www.zacks.com/stock/news/2254814/3-quarterly-releases-to-watch-next-week",
    "time_published": "20240412T190000",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Earnings season is always an exciting time for investors, with companies finally revealing what's transpired behind closed doors. And concerning next week's docket, these three notable companies are scheduled to report.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default93.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.995077"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.159859,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DFS",
        "relevance_score": "0.45825",
        "ticker_sentiment_score": "-0.167759",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.45825",
        "ticker_sentiment_score": "0.258643",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.45825",
        "ticker_sentiment_score": "0.382737",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "'s 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet - Constellation Energy  ( NASDAQ:CEG ) , Chipotle Mexican Grill  ( NYSE:CMG ) ",
    "url": "https://www.benzinga.com/general/biotech/24/04/38223087/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet",
    "time_published": "20240412T152613",
    "authors": [
      "Chris Katje"
    ],
    "summary": "Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks just under the surface and warrant attention. Investors are constantly on the hunt for undervalued, under-followed and emerging stocks.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/12/Stock-Whisper-Index-Logo-6-copy.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.658903"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.997874"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.301317,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CEG",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "0.147369",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PUBM",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "0.10615",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RLYB",
        "relevance_score": "0.168884",
        "ticker_sentiment_score": "0.333783",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.223866",
        "ticker_sentiment_score": "0.403267",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "RBLX",
        "relevance_score": "0.223866",
        "ticker_sentiment_score": "0.29593",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "0.118027",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RENT",
        "relevance_score": "0.168884",
        "ticker_sentiment_score": "0.161577",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "J&J  ( JNJ )  to Begin Pharma Q1 Earnings Season: What's in Store?",
    "url": "https://www.zacks.com/stock/news/2254365/jj-jnj-to-begin-pharma-q1-earnings-season-whats-in-store",
    "time_published": "20240412T130900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/85/906.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.99998"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.154225,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PRTA",
        "relevance_score": "0.214462",
        "ticker_sentiment_score": "-0.073209",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVAX",
        "relevance_score": "0.214462",
        "ticker_sentiment_score": "-0.186846",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "FATE",
        "relevance_score": "0.266246",
        "ticker_sentiment_score": "0.085408",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.214462",
        "ticker_sentiment_score": "0.081496",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Clarification of guidance for revenue and lower than expected operating profit in the 2023/24 financial year",
    "url": "https://www.globenewswire.com/news-release/2024/04/12/2862169/0/en/Clarification-of-guidance-for-revenue-and-lower-than-expected-operating-profit-in-the-2023-24-financial-year.html",
    "time_published": "20240412T125500",
    "authors": [
      "Chemometec A/S"
    ],
    "summary": "ANNOUNCEMENT NO. ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.02788,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.056654",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.056654",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.056654",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "5 Dividend Kings That Yield More Than Vanguard's Top Value ETF",
    "url": "https://www.fool.com/investing/2024/04/12/5-dividend-kings-yield-more-vanguard-value-etf/",
    "time_published": "20240412T120000",
    "authors": [
      "Daniel Foelber"
    ],
    "summary": "Despite a thriving bull market, some Dividend Kings still yield more than the Vanguard Value ETF's 2.4% payout.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F772109%2Fgettyimages-1394287688-1200x800-5b2df79.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      }
    ],
    "overall_sentiment_score": 0.176571,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TGT",
        "relevance_score": "0.233931",
        "ticker_sentiment_score": "0.235464",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.157227",
        "ticker_sentiment_score": "0.215062",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SWK",
        "relevance_score": "0.195814",
        "ticker_sentiment_score": "0.173849",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SWKH",
        "relevance_score": "0.039548",
        "ticker_sentiment_score": "0.165902",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.157227",
        "ticker_sentiment_score": "0.213626",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.079",
        "ticker_sentiment_score": "0.13721",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PEP",
        "relevance_score": "0.157227",
        "ticker_sentiment_score": "0.211238",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why NextPlat Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket - NextPlat  ( NASDAQ:NXPL ) ",
    "url": "https://www.benzinga.com/news/24/04/38216687/why-nextplat-shares-are-trading-higher-by-around-30-here-are-20-stocks-moving-premarket",
    "time_published": "20240412T093249",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Shares of NextPlat Corp NXPL rose sharply in today's pre-market trading after the company reported consolidated 2023 revenues of $37.8 million, up 222% year over year NextPlat shares surged 29.8% to $1.96 in pre-market trading. Here are some other stocks moving in pre-market trading.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/12/image29.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.113426,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "HKD",
        "relevance_score": "0.132733",
        "ticker_sentiment_score": "0.444052",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.066598",
        "ticker_sentiment_score": "0.046686",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NXPL",
        "relevance_score": "0.197951",
        "ticker_sentiment_score": "0.10341",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BENF",
        "relevance_score": "0.132733",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KZIA",
        "relevance_score": "0.132733",
        "ticker_sentiment_score": "-0.171658",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "HYMC",
        "relevance_score": "0.132733",
        "ticker_sentiment_score": "0.321448",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MOTS",
        "relevance_score": "0.132733",
        "ticker_sentiment_score": "-0.039992",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OCX",
        "relevance_score": "0.197951",
        "ticker_sentiment_score": "0.377607",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "RLYB",
        "relevance_score": "0.197951",
        "ticker_sentiment_score": "-0.121288",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IONM",
        "relevance_score": "0.132733",
        "ticker_sentiment_score": "0.045095",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.066598",
        "ticker_sentiment_score": "-0.076626",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DPRO",
        "relevance_score": "0.197951",
        "ticker_sentiment_score": "0.040571",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRIN",
        "relevance_score": "0.197951",
        "ticker_sentiment_score": "-0.189595",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ALLR",
        "relevance_score": "0.197951",
        "ticker_sentiment_score": "0.179383",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.066598",
        "ticker_sentiment_score": "-0.119319",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MGRM",
        "relevance_score": "0.132733",
        "ticker_sentiment_score": "0.0578",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MOGU",
        "relevance_score": "0.132733",
        "ticker_sentiment_score": "-0.37561",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "NRIX",
        "relevance_score": "0.132733",
        "ticker_sentiment_score": "0.060456",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADIL",
        "relevance_score": "0.197951",
        "ticker_sentiment_score": "0.245687",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "APLD",
        "relevance_score": "0.132733",
        "ticker_sentiment_score": "-0.198737",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "PXMD",
        "relevance_score": "0.132733",
        "ticker_sentiment_score": "0.121036",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RENT",
        "relevance_score": "0.197951",
        "ticker_sentiment_score": "0.065641",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Americans are savings less these days. Here's why and what that means | Business",
    "url": "https://www.cnn.com/2024/04/14/economy/stocks-week-ahead-americans-savings-less-economy-spending/index.html",
    "time_published": "20240414T113000",
    "authors": [
      "Bryan Mena"
    ],
    "summary": "Americans are saving less these days. Here's why and what that means ...",
    "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-1387286445.jpg?c=16x9&q=w_800,c_fill",
    "source": "CNN",
    "category_within_source": "Markets",
    "source_domain": "www.cnn.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.079323,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALK",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "-0.034531",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "-0.034531",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "-0.055057",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTRS",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "-0.055057",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "-0.055057",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "-0.055057",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "-0.055057",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BK",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "-0.055057",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "-0.079111",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "-0.055057",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSM",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "-0.034531",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XINXF",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.107016",
        "ticker_sentiment_score": "-0.024274",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BX",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "-0.034531",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EFX",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MCO",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "-0.086648",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBD",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "0.217581",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SCHW",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "-0.079111",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Inflation And Banks Drag Stocks Lower Despite Earnings",
    "url": "https://www.forbes.com/sites/bill_stone/2024/04/14/inflation-and-banks-drag-stocks-lower-despite-earnings/",
    "time_published": "20240414T110000",
    "authors": [
      "Bill Stone"
    ],
    "summary": "The earnings season began slowly last week, with only 10 S&P 500 companies reporting. Banks were a large contingent of the reporters, which boosted the sector's earnings expectations for the quarter as all the banks reported better-than-expected earnings.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/661a9378c4fd1dc394bb4920/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.99489"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.07374,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.092927",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.092927",
        "ticker_sentiment_score": "0.056342",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.092927",
        "ticker_sentiment_score": "0.056342",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.092927",
        "ticker_sentiment_score": "0.056342",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.092927",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.092927",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.092927",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.138997",
        "ticker_sentiment_score": "-0.034032",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.092927",
        "ticker_sentiment_score": "0.056342",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.092927",
        "ticker_sentiment_score": "0.056342",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.092927",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.092927",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SCHW",
        "relevance_score": "0.092927",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "If You Like This High-Yield Vanguard Fund, Then You'll Love These Two Dividend Stocks",
    "url": "https://www.fool.com/investing/2024/04/14/high-yield-vanguard-fund-etf-dividend-stocks-buy/",
    "time_published": "20240414T101500",
    "authors": [
      "and Lee Samaha",
      "Scott Levine",
      "Daniel Foelber"
    ],
    "summary": "Boost your passive income in a way that's right for you.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F772097%2Fgettyimages-1386479297-1200x800-5b2df79.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      }
    ],
    "overall_sentiment_score": 0.250757,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.038906",
        "ticker_sentiment_score": "-0.012684",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PGPGF",
        "relevance_score": "0.038906",
        "ticker_sentiment_score": "0.038022",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.038906",
        "ticker_sentiment_score": "-0.012684",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.038906",
        "ticker_sentiment_score": "-0.012684",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.038906",
        "ticker_sentiment_score": "-0.012684",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.038906",
        "ticker_sentiment_score": "-0.012684",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BKR",
        "relevance_score": "0.230235",
        "ticker_sentiment_score": "0.180019",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.038906",
        "ticker_sentiment_score": "-0.012684",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AEP",
        "relevance_score": "0.408446",
        "ticker_sentiment_score": "0.375101",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.038906",
        "ticker_sentiment_score": "-0.012684",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "J&J Braces For Q1 Earnings With Bearish Charts And Patent Cliffs In Play - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/04/38259481/j-j-braces-for-q1-earnings-with-bearish-charts-and-patent-cliffs-in-play",
    "time_published": "20240415T204740",
    "authors": [
      "Surbhi Jain"
    ],
    "summary": "Johnson & Johnson JNJ, will be reporting its first-quarter earnings on April 16. Wall Street expects $2.64 in EPS and $21.4 billion in revenues as the company reports before market hours. Johnson & Johnson stock is down about 9.54% over the past year, and has dropped 5.88% YTD.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/JohnsonampJohnson-Shutterstock_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.03616,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SWAV",
        "relevance_score": "0.104683",
        "ticker_sentiment_score": "-0.052126",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.489394",
        "ticker_sentiment_score": "-0.220283",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Another Ugly Reversal; Tesla Dives On 'Dark Day'",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-reversal-nvidia-slides-tesla-tumbles/",
    "time_published": "20240415T202300",
    "authors": [
      "Investor's Business Daily",
      "ED CARSON"
    ],
    "summary": "Dow Jones Futures: Another Ugly Market Reversal. Nvidia Skids, Tesla Tumbles On 'Dark Day' Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/07/stock-bear-6-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": -0.112639,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.2258",
        "ticker_sentiment_score": "-0.116442",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.256989",
        "ticker_sentiment_score": "-0.185676",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "INFA",
        "relevance_score": "0.097854",
        "ticker_sentiment_score": "-0.183444",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.256989",
        "ticker_sentiment_score": "-0.117984",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.032691",
        "ticker_sentiment_score": "-0.143753",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.065327",
        "ticker_sentiment_score": "-0.120183",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.065327",
        "ticker_sentiment_score": "-0.217589",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.097854",
        "ticker_sentiment_score": "-0.145035",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Medical Device Manufacture Integer To Gain From Expanding Pulsed Field Ablation Market, Earns Upgrade From BofA Why Is Medical Device Manufacture Integer Stock Gaining Today? - Integer Holdings  ( NYSE:ITGR ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38256857/medical-device-manufacture-integer-to-gain-from-expanding-pulsed-field-ablation-mar",
    "time_published": "20240415T184259",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "BofA Securities upgraded Integer Holdings Corporation ITGR, citing the anticipated growth in pulsed field ablation ( PFA ) for treating atrial fibrillation. Integer is one of the largest medical device outsourcing manufacturers, serving the cardiac rhythm management, neuromodulation, ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/15/Medical-Examination-And-Healthcare-Busin.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.286622,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ITGR",
        "relevance_score": "0.82927",
        "ticker_sentiment_score": "0.458772",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.215894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.215894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.215894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson to Report Earnings as Talc Issues Loom",
    "url": "https://www.barrons.com/amp/articles/johnson-jnj-earnings-stock-price-51a43535",
    "time_published": "20240415T143200",
    "authors": [
      "Josh Nathan-Kazis"
    ],
    "summary": "Johnson & Johnson Reports Earnings Tuesday. What to Expect. ...",
    "banner_image": "https://images.barrons.com/im-17398683/social",
    "source": "Barrons",
    "category_within_source": "n/a",
    "source_domain": "www.barrons.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": -0.026624,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BAC",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "-0.073947",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.68039",
        "ticker_sentiment_score": "-0.179753",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "3 Blue Chip Stocks For Your April 2024 Watchlist",
    "url": "https://stockmarket.com/featured/3-blue-chip-stocks-for-your-april-2024-watchlist-2024-04-15",
    "time_published": "20240415T142340",
    "authors": [
      "Jonathan Phillip"
    ],
    "summary": "The stock market serves as a central hub where investors can buy, sell, and trade shares of publicly traded companies. It is a key component of the global economy, reflecting the financial health and trends of industries and entire countries.",
    "banner_image": "https://u3j7m9h7.rocketcdn.me/wp-content/uploads/2020/08/johnson-and-johnson.jpg",
    "source": "StockMarket.com",
    "category_within_source": "n/a",
    "source_domain": "stockmarket.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.286426,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SWAV",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "0.134913",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.274628",
        "ticker_sentiment_score": "0.210041",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.274628",
        "ticker_sentiment_score": "0.346196",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Buy Johnson & Johnson  ( JNJ )  Ahead of Earnings?",
    "url": "https://www.zacks.com/stock/news/2255431/should-you-buy-johnson-johnson-jnj-ahead-of-earnings",
    "time_published": "20240415T140600",
    "authors": [
      "Kaibalya Pravo Dey"
    ],
    "summary": "Johnson & Johnson (JNJ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.99237"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.461543,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.864226",
        "ticker_sentiment_score": "0.593731",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "JPMorgan, Citigroup and even Wells Fargo are part of Zacks Earnings Preview",
    "url": "https://www.zacks.com/stock/news/2255080/jpmorgan-citigroup-and-even-wells-fargo-are-part-of-zacks-earnings-preview",
    "time_published": "20240415T130200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Chicago, IL - April 15, 2024 - Zacks.com releases the list of companies likely to issue earnings surprises. This week's list includes JPMorgan ( JPM Quick QuoteJPM - ) , Citigroup ( C Quick QuoteC - ) and even Wells Fargo ( WFC Quick QuoteWFC - ) .",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/59/80.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.192295,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.049646",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSX",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.049646",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.221481",
        "ticker_sentiment_score": "0.103355",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.221481",
        "ticker_sentiment_score": "0.085464",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.049646",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWAV, AIRC, ABIO, MODN - ARCA biopharma  ( NASDAQ:ABIO ) , Apartment Income REIT  ( NYSE:AIRC ) ",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38247066/shareholder-investigation-halper-sadeh-llc-investigates-swav-airc-abio-modn",
    "time_published": "20240415T123851",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, April 15, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Shockwave Medical, Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.140451,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MODN",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.126562",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABIO",
        "relevance_score": "0.107495",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BX",
        "relevance_score": "0.107495",
        "ticker_sentiment_score": "0.162309",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.107495",
        "ticker_sentiment_score": "0.084635",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AIRC",
        "relevance_score": "0.107495",
        "ticker_sentiment_score": "0.162309",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.107495",
        "ticker_sentiment_score": "0.084635",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "5 U.S. Bigwigs Likely to Gain on Q1 Earnings Beat This Week",
    "url": "https://www.zacks.com/stock/news/2255174/5-us-bigwigs-likely-to-gain-on-q1-earnings-beat-this-week",
    "time_published": "20240415T121900",
    "authors": [
      "Nalak Das"
    ],
    "summary": "We have narrowed our search to five large-cap stocks that are poised to beat on earnings results this week. These are: BAC, JNJ, UAL, PNC, BK.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/92/476.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.214559,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BK",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.129971",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.243701",
        "ticker_sentiment_score": "-0.013326",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.186633",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PNC",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.17885",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.163909",
        "ticker_sentiment_score": "0.220212",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Shockwave Medical, Inc.  ( Nasdaq - SWAV ) , Apartment Income REIT Corp.  ( NYSE - AIRC ) , Model N, Inc.  ( NYSE - MODN ) , ARCA biopharma, Inc.  ( Nasdaq - ABIO ) ",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38246103/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-shockwave-med",
    "time_published": "20240415T120300",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "BALA CYNWYD, Pa., April 15, 2024 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.94762"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.184657,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DSSMY",
        "relevance_score": "0.220141",
        "ticker_sentiment_score": "0.065709",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BX",
        "relevance_score": "0.220141",
        "ticker_sentiment_score": "0.172827",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AIRC",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.220141",
        "ticker_sentiment_score": "0.188935",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MODN",
        "relevance_score": "0.290607",
        "ticker_sentiment_score": "0.230376",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABIO",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares U.S. Pharmaceuticals ETF  ( IHE ) ?",
    "url": "https://www.zacks.com/stock/news/2254978/should-you-invest-in-the-ishares-us-pharmaceuticals-etf-ihe",
    "time_published": "20240415T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default268.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.14492,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.032045",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.13347",
        "ticker_sentiment_score": "0.064047",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RPRX",
        "relevance_score": "0.13347",
        "ticker_sentiment_score": "0.064047",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.13347",
        "ticker_sentiment_score": "0.043543",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.13347",
        "ticker_sentiment_score": "0.064047",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "DIGITAL THERAPEUTICS STARTUP RESPIREE\u2122 ANNOUNCES INCORPORATION IN US WITH RESIDENCY AT JLABS @ SAN FRANCISCO",
    "url": "https://www.prnewswire.com/news-releases/digital-therapeutics-startup-respiree-announces-incorporation-in-us-with-residency-at-jlabs--san-francisco-302116419.html",
    "time_published": "20240415T061500",
    "authors": [
      "Respiree"
    ],
    "summary": "DIGITAL THERAPEUTICS STARTUP RESPIREE\u2122 ANNOUNCES INCORPORATION IN US WITH RESIDENCY AT ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/2386657/Respiree_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.299621,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HCSG",
        "relevance_score": "0.111488",
        "ticker_sentiment_score": "0.118296",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.111488",
        "ticker_sentiment_score": "0.04384",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Johnson & Johnson Stock Got Tossed by the Market Today",
    "url": "https://www.fool.com/investing/2024/04/16/why-johnson-johnson-stock-got-tossed-by-the-market/",
    "time_published": "20240416T214500",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "A mixed quarter and narrowed guidance didn't really please investors.",
    "banner_image": "https://g.foolcdn.com/editorial/images/773151/medical-professional-holding-dollar-sign-paperweight.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.904684"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.042618,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.454174",
        "ticker_sentiment_score": "0.023935",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech and Teva Announce U.S. FDA Approval of SELARSDI\u2122  ( ustekinumab-aekn ) , biosimilar to Stelara\u00ae  ( ustekinumab ) ",
    "url": "https://www.globenewswire.com/news-release/2024/04/16/2864157/0/en/Alvotech-and-Teva-Announce-U-S-FDA-Approval-of-SELARSDI-ustekinumab-aekn-biosimilar-to-Stelara-ustekinumab.html",
    "time_published": "20240416T213000",
    "authors": [
      "Alvotech"
    ],
    "summary": "REYKJAVIK, ICELAND & PARSIPPANY, NJ - Alvotech ( NASDAQ: ALVO ) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. ( NYSE and TASE: TEVA ) , today announced that the U.S. Food and Drug Administration ( FDA ) has approved SELARSDI ( ustekinumab-aekn ) injection for ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.096007,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALVO",
        "relevance_score": "0.323663",
        "ticker_sentiment_score": "0.185829",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.011485",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.06883",
        "ticker_sentiment_score": "0.090486",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.011485",
        "ticker_sentiment_score": "0.053745",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.011485",
        "ticker_sentiment_score": "0.053745",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.045918",
        "ticker_sentiment_score": "0.105859",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech and Teva Announce U.S. FDA Approval of SELARSDI\u2122  ( ustekinumab-aekn ) , biosimilar to Stelara\u00ae  ( ustekinumab ) ",
    "url": "https://www.globenewswire.com/news-release/2024/04/16/2864156/0/en/Alvotech-and-Teva-Announce-U-S-FDA-Approval-of-SELARSDI-ustekinumab-aekn-biosimilar-to-Stelara-ustekinumab.html",
    "time_published": "20240416T213000",
    "authors": [
      "Alvotech"
    ],
    "summary": "REYKJAVIK, Iceland and PARSIPPANY, N.J., April 16, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO ) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. ( NYSE and TASE: TEVA ) , today announced that the U.S. Food and Drug Administration ( FDA ) has approved ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.096029,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALVO",
        "relevance_score": "0.325282",
        "ticker_sentiment_score": "0.186504",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.011546",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.069194",
        "ticker_sentiment_score": "0.089506",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.011546",
        "ticker_sentiment_score": "0.053772",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.011546",
        "ticker_sentiment_score": "0.053772",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.03463",
        "ticker_sentiment_score": "0.108494",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stock Market Today: Stocks Stabilize After Powell's Rate-Cut Warning",
    "url": "https://www.kiplinger.com/investing/stocks/stock-market-today-stocks-stabilize-after-powells-rate-cut-warning",
    "time_published": "20240416T201101",
    "authors": [
      "Karee Venema"
    ],
    "summary": "Stocks struggled for direction Tuesday as investors took in the latest round of corporate earnings reports and a mid-afternoon speech from Fed Chair Jerome Powell. At the close, the S&P 500 ( -0.2% at 5,051 ) and the Nasdaq Composite ( -0.1% at 15,865 ) had made modest moves.",
    "banner_image": "https://cdn.mos.cms.futurecdn.net/hwgJ7osrMtUWhk5koeVme7-320-80.png",
    "source": "Kiplinger",
    "category_within_source": "n/a",
    "source_domain": "www.kiplinger.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.972756"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999965"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.162996,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BAC",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.020841",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.105293",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.21258",
        "ticker_sentiment_score": "0.1684",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.164149",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LPLA",
        "relevance_score": "0.053749",
        "ticker_sentiment_score": "-0.102043",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.198401",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.21258",
        "ticker_sentiment_score": "0.110758",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Q1 2024 Earnings Call Transcript",
    "url": "https://www.fool.com/earnings/call-transcripts/2024/04/16/johnson-johnson-jnj-q1-2024-earnings-call-transcri/",
    "time_published": "20240416T173011",
    "authors": [
      "Motley Fool Transcribing"
    ],
    "summary": "JNJ earnings call for the period ending March 31, 2024.",
    "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999483"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.322753,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BCS",
        "relevance_score": "0.004814",
        "ticker_sentiment_score": "0.114322",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.004814",
        "ticker_sentiment_score": "0.101521",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.004814",
        "ticker_sentiment_score": "0.107473",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.004814",
        "ticker_sentiment_score": "0.09141",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.038499",
        "ticker_sentiment_score": "0.056988",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.004814",
        "ticker_sentiment_score": "0.107473",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.009628",
        "ticker_sentiment_score": "0.134092",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.004814",
        "ticker_sentiment_score": "0.061469",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Shows Focus On Strengthening Its Business Upon Its Consumer Health Unit Spinoff - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/24/04/38275049/johnson-johnson-shows-focus-on-strengthening-its-business-upon-its-consumer-health-unit-spinoff",
    "time_published": "20240416T154917",
    "authors": [
      "Upwallstreet"
    ],
    "summary": "On Tuesday, Johnson & Johnson JNJ delivered a rather mixed first quarter report. Adjusted earnings surpassed estimates as sales in its medical devices business surged, while revenue was almost in line with estimates.",
    "banner_image": "https://cdn.benzinga.com/files/3d-medical-background-with-virus-cells-dna-strand_0.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.988915"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.0,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MRNA",
        "relevance_score": "0.341587",
        "ticker_sentiment_score": "-0.379351",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "-0.30221",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.199447",
        "ticker_sentiment_score": "0.093713",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.551486",
        "ticker_sentiment_score": "0.245629",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Building Permits Come in Lower Than Expected",
    "url": "https://www.zacks.com/stock/news/2256206/building-permits-come-in-lower-than-expected",
    "time_published": "20240416T150200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "New housing data has hit the tape this morning. Housing Starts for March came in -14.7% to 1.3 million seasonally adjusted, annualized units. The previous month's tally has been downwardly revised to 1.45 million from 1.52 million initially reported.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/92/476.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.188524,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BAC",
        "relevance_score": "0.151539",
        "ticker_sentiment_score": "0.191852",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.151539",
        "ticker_sentiment_score": "0.16955",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "J&J  ( JNJ )  Q1 Earnings Beat Estimates, Sales Miss, MedTech Soft",
    "url": "https://www.zacks.com/stock/news/2256185/jj-jnj-q1-earnings-beat-estimates-sales-miss-medtech-soft",
    "time_published": "20240416T145300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "J&J (JNJ) beats estimates for first-quarter earnings but misses the same for sales. It tightens its sales and earnings growth expectations for 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999998"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.160802,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ADMA",
        "relevance_score": "0.190417",
        "ticker_sentiment_score": "0.18323",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ANIP",
        "relevance_score": "0.159148",
        "ticker_sentiment_score": "0.233241",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.064018",
        "ticker_sentiment_score": "0.053502",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.095899",
        "ticker_sentiment_score": "0.058738",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stocks Mixed With Dow In The Lead Lifted By UnitedHealth",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-unh-stock-bac-earnings/",
    "time_published": "20240416T143700",
    "authors": [
      "Investor's Business Daily",
      "KIMBERLEY KOENIG"
    ],
    "summary": "Stock Market Today: Dow Jones, S&P 500 Rebound, UnitedHealth JumpsInvestor's Business Daily Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/12/stock-UnitedHealthcare-02-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": -0.01441,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.056943",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.169676",
        "ticker_sentiment_score": "0.134546",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.169676",
        "ticker_sentiment_score": "-0.167591",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "0.014767",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.049487",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "-0.024348",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LYV",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "-0.00349",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.056943",
        "ticker_sentiment_score": "0.046055",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.010755",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Housing Numbers Shrink as Q1 Earnings Heat Up: BAC, JNJ, UNH",
    "url": "https://www.zacks.com/stock/news/2256163/housing-numbers-shrink-as-q1-earnings-heat-up-bac-jnj-unh",
    "time_published": "20240416T142600",
    "authors": [
      "Mark Vickery"
    ],
    "summary": "Both Housing Starts and Building Permits missed expectations, while BofA, J&J and UnitedHealth all beat on earnings.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/54/7831.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928139"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.169709,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BAC",
        "relevance_score": "0.145145",
        "ticker_sentiment_score": "0.17976",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.145145",
        "ticker_sentiment_score": "0.17976",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MCBC, SWAV, AIRC, MODN - Macatawa Bank  ( NASDAQ:MCBC ) , Apartment Income REIT  ( NYSE:AIRC ) ",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38271938/shareholder-investigation-halper-sadeh-llc-investigates-mcbc-swav-airc-modn",
    "time_published": "20240416T135934",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, April 16, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.1986,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "WTFC",
        "relevance_score": "0.099066",
        "ticker_sentiment_score": "0.174408",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MCBC",
        "relevance_score": "0.099066",
        "ticker_sentiment_score": "0.174408",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BX",
        "relevance_score": "0.099066",
        "ticker_sentiment_score": "0.158348",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AIRC",
        "relevance_score": "0.099066",
        "ticker_sentiment_score": "0.158348",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.099066",
        "ticker_sentiment_score": "0.082593",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MODN",
        "relevance_score": "0.19661",
        "ticker_sentiment_score": "0.118982",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.099066",
        "ticker_sentiment_score": "0.082593",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Crypto Analyst Signals Bitcoin Correction Amid Stumbling Rally; Intel and Nvidia Unveil China-Focused Products, Adjust AI Chip Strategies Amid US Sanctions - Top Headlines Today While US Slept",
    "url": "https://www.benzinga.com/markets/cryptocurrency/24/04/38271237/crypto-analyst-signals-bitcoin-correction-amid-stumbling-rally-intel-and-nvidia-unveil-chi",
    "time_published": "20240416T134719",
    "authors": [
      "Akanksha Bakshi"
    ],
    "summary": "Crypto Analyst Warns Bitcoin's Impending Correction As Rally Falters: 'We Are Bearish Risk Assets' Peter Schiff Challenges Bitcoin's $100K Prediction As Crypto-Linked Stocks Languish In Bear Zone: 'Sell Your Fool's Gold And Buy The Real Thing' Altcoin Bloodbath Incoming?",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/16/Bitcoin-WULF-MARA-MSTR-COIN-HUT.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      }
    ],
    "overall_sentiment_score": -0.081715,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DFLI",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.266793",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.289883",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LMT",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.051115",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MCBC",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.134651",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.09439",
        "ticker_sentiment_score": "-0.087827",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIDU",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "-0.265789",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "IP",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.111736",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RIVN",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.266793",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LDNXF",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.187463",
        "ticker_sentiment_score": "-0.146538",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Macatawa Bank Corporation  ( Nasdaq - MCBC ) , Shockwave Medical, Inc.  ( Nasdaq - SWAV ) , Apartment Income REIT Corp.  ( NYSE - AIRC ) , Model N, Inc.  ( NYSE - MODN ) ",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38270299/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-macatawa-bank",
    "time_published": "20240416T131321",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "BALA CYNWYD, Pa., April 16, 2024 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998333"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.253232,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "WTFC",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.222469",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MCBC",
        "relevance_score": "0.068306",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.202932",
        "ticker_sentiment_score": "0.061659",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BX",
        "relevance_score": "0.202932",
        "ticker_sentiment_score": "0.162385",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AIRC",
        "relevance_score": "0.068306",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.202932",
        "ticker_sentiment_score": "0.177581",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MODN",
        "relevance_score": "0.268294",
        "ticker_sentiment_score": "0.216617",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.068306",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Health Care Bellwether J&J Misses Sales Views, But Profit Beats",
    "url": "https://www.investors.com/news/technology/johnson-johnson-stock-jnj-earnings-q1-2024/",
    "time_published": "20240416T125700",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Johnson & Johnson Stock Dips On Light Sales, But Earnings Beat Forecasts Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/10/stock-JohnsonANDjohnson-01-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.918141"
      }
    ],
    "overall_sentiment_score": 0.268466,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DXCM",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.382124",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.823417",
        "ticker_sentiment_score": "0.109743",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Futures Rebound Ahead Of Powell Comments",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-tesla-tsla-stock-2/",
    "time_published": "20240416T122500",
    "authors": [
      "SCOTT LEHTONEN",
      "Investor's Business Daily"
    ],
    "summary": "Stock Market Today: Dow Jones Tries To Rebound After Sharp Losses. Tesla Stock Extends Sell-Off Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2021/09/Stock-wallstreetflag-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.130079,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DKNG",
        "relevance_score": "0.106541",
        "ticker_sentiment_score": "0.03092",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.141726",
        "ticker_sentiment_score": "0.201942",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.141726",
        "ticker_sentiment_score": "0.156203",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.176631",
        "ticker_sentiment_score": "-0.105986",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.106541",
        "ticker_sentiment_score": "0.185914",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.106541",
        "ticker_sentiment_score": "0.001132",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.106541",
        "ticker_sentiment_score": "0.185914",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.071145",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOW",
        "relevance_score": "0.106541",
        "ticker_sentiment_score": "0.101247",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.141726",
        "ticker_sentiment_score": "0.177222",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.035608",
        "ticker_sentiment_score": "0.112033",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.106541",
        "ticker_sentiment_score": "0.185914",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "J&J Q1 revenue below expectations at $21.38 bn as Stelara sales disappoint",
    "url": "https://www.business-standard.com/world-news/j-j-q1-revenue-below-expectations-at-21-38-bn-as-stelara-sales-disappoint-124041600788_1.html",
    "time_published": "20240416T115134",
    "authors": [
      "Reuters"
    ],
    "summary": "J&J now expects adjusted operating profit per share between $10.60 and $10.75 for 2024, compared with its previous forecast of $10.55 to $10.75. Photo: Bloomberg",
    "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2024-01/09/full/1704769156-995.jpg?im=FeatureCrop,size=(826,465)",
    "source": "Business Standard",
    "category_within_source": "GoogleRSS",
    "source_domain": "www.business-standard.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.034037,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALVO",
        "relevance_score": "0.122269",
        "ticker_sentiment_score": "0.103826",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.122269",
        "ticker_sentiment_score": "-0.020787",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Q1 Earnings Top Estimates",
    "url": "https://www.zacks.com/stock/news/2255793/johnson-johnson-jnj-q1-earnings-top-estimates",
    "time_published": "20240416T113002",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 2.65% and 0.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default178.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999997"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.153019,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.137278",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.396052",
        "ticker_sentiment_score": "0.121187",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson tops quarterly profit estimates as medical device sales jump",
    "url": "https://www.cnbc.com/2024/04/16/johnson-johnson-jnj-earnings-q1-2024.html",
    "time_published": "20240416T102408",
    "authors": [
      "Annika Kim Constantino"
    ],
    "summary": "The company is benefiting from a rebound in demand for nonurgent surgeries among older adults, who deferred those procedures during the Covid pandemic.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/106974803-1636726862899-gettyimages-1164570932-AFP_1JU2A3.jpeg?v=1713209553&w=1920&h=1080",
    "source": "CNBC",
    "category_within_source": "Business",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.99915"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.104181,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.011721",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HUM",
        "relevance_score": "0.070517",
        "ticker_sentiment_score": "0.022269",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ELV",
        "relevance_score": "0.070517",
        "ticker_sentiment_score": "0.022269",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.070517",
        "ticker_sentiment_score": "0.131716",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.070517",
        "ticker_sentiment_score": "0.022269",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.070517",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Genmab Announces Net Sales of DARZALEX\u00ae  ( daratumumab )  for First Quarter of 2024",
    "url": "https://www.globenewswire.com/news-release/2024/04/16/2863401/0/en/Genmab-Announces-Net-Sales-of-DARZALEX-daratumumab-for-First-Quarter-of-2024.html",
    "time_published": "20240416T102400",
    "authors": [
      "Genmab A/S"
    ],
    "summary": "Company Announcement ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.062246,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GMAB",
        "relevance_score": "0.676015",
        "ticker_sentiment_score": "0.097712",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.130571",
        "ticker_sentiment_score": "0.011687",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Fidelity MSCI Health Care Index ETF  ( FHLC ) ?",
    "url": "https://www.zacks.com/stock/news/2255749/should-you-invest-in-the-fidelity-msci-health-care-index-etf-fhlc",
    "time_published": "20240416T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default293.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.29041,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.128822",
        "ticker_sentiment_score": "0.050073",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.128822",
        "ticker_sentiment_score": "0.050073",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.128822",
        "ticker_sentiment_score": "0.050073",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "UnitedHealth, J&J, Live Nation, DJT, Tesla, Bank of America, Morgan Stanley, and More Stock Market Movers",
    "url": "https://www.barrons.com/amp/articles/stock-market-movers-aa344be0",
    "time_published": "20240416T083500",
    "authors": [
      "Joe Woelfel"
    ],
    "summary": "Live Nation, DJT, Tesla, UnitedHealth, J&J, BofA, Morgan Stanley, and More Market Movers ...",
    "banner_image": "https://images.barrons.com/im-46311364/social",
    "source": "Barrons",
    "category_within_source": "n/a",
    "source_domain": "www.barrons.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.993781"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.053305,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "TSLA",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "0.038086",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.09402",
        "ticker_sentiment_score": "0.025295",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "0.029331",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DJT",
        "relevance_score": "0.09402",
        "ticker_sentiment_score": "0.064478",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.09402",
        "ticker_sentiment_score": "0.118633",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Likely To Report Higher Q1 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts",
    "url": "https://markets.businessinsider.com/news/stocks/johnson-johnson-likely-to-report-higher-q1-earnings-here-are-the-recent-forecast-changes-from-wall-street-s-most-accurate-analysts-1033251805",
    "time_published": "20240416T063409",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Johnson & Johnson Likely To Report Higher Q1 Earnings. Here Are The Recent Forecast Changes From Wall Street's ... - Markets Insider ...",
    "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2024/04/16/johnson__johnson_-_logo.jpg",
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.070521,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "RLYB",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.103984",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "-0.021446",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "-0.021446",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCOV",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.181475",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.488007",
        "ticker_sentiment_score": "0.295459",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Likely To Report Higher Q1 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/news/earnings/24/04/38263545/johnson-johnson-likely-to-report-higher-q1-earnings-here-are-the-recent-forecast-changes-from-wall-",
    "time_published": "20240416T061529",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Johnson & Johnson JNJ is set to release earnings results for its first quarter before the opening bell on April 16, 2024. Analysts expect the New Brunswick, New Jersey-based company to report quarterly earnings at $2.64 per share, up from $2.41 per share in the year-ago period.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/16/johnson__johnson_-_logo.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.101223,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "RLYB",
        "relevance_score": "0.120431",
        "ticker_sentiment_score": "0.09273",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.120431",
        "ticker_sentiment_score": "-0.151123",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.120431",
        "ticker_sentiment_score": "-0.079236",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.551295",
        "ticker_sentiment_score": "0.31029",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Bank of America, Morgan Stanley And 3 Stocks To Watch Heading Into Tuesday - Bank of America  ( NYSE:BAC ) , Morgan Stanley  ( NYSE:MS ) ",
    "url": "https://www.benzinga.com/news/earnings/24/04/38263260/bank-of-america-morgan-stanley-and-3-stocks-to-watch-heading-into-tuesday",
    "time_published": "20240416T061019",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "With U.S. stock futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Bank of America Corporation BAC to report quarterly earnings at 77 cents per share on revenue of $25.46 billion before the opening bell, ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/16/bank_of_america_-_logo.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.990786"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.180207,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BAC",
        "relevance_score": "0.431065",
        "ticker_sentiment_score": "0.224823",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.431065",
        "ticker_sentiment_score": "0.315626",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.431065",
        "ticker_sentiment_score": "0.368966",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MITK",
        "relevance_score": "0.431065",
        "ticker_sentiment_score": "0.073777",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MYSZ",
        "relevance_score": "0.431065",
        "ticker_sentiment_score": "0.029509",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Fear & Greed Index Moves To 'Fear' Zone; S&P 500 Down Over 1% - Bank of America  ( NYSE:BAC ) , Goldman Sachs Gr  ( NYSE:GS ) ",
    "url": "https://www.benzinga.com/news/earnings/24/04/38263377/fear-greed-index-moves-to-fear-zone-s-p-500-down-over-1",
    "time_published": "20240416T060947",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "The CNN Money Fear and Greed index showed a decline in the overall market sentiment, with the index moving to the \"Fear\" zone on Monday. U.S. stocks closed lower on Friday amid concerns over the conflict in the Middle East, with the S&P 500 falling more than 1% during the session.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/16/image44.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": -0.25124,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "WBD",
        "relevance_score": "0.12546",
        "ticker_sentiment_score": "-0.398422",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "0.378848",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "REZI",
        "relevance_score": "0.12546",
        "ticker_sentiment_score": "0.245919",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNPO",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "0.378848",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.364275",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Shares Hold Steady After Q1 Earnings, Analysts Optimistic About Future - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38300896/johnson-johnson-shares-hold-steady-after-q1-earnings-analysts-optimistic-about-futu",
    "time_published": "20240417T193734",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Tuesday, Johnson & Johnson JNJ reported first-quarter adjusted EPS of $2.71, up 12.4% year over year, beating the consensus of $2.64. The pharma giant reported sales of $21.38 billion, up 2.3% year over year, almost in line with the consensus of $21.39 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/17/Johnson-and-Johnson.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.288591,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.350564",
        "ticker_sentiment_score": "0.023023",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.636698",
        "ticker_sentiment_score": "0.416276",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Analysts Cut Their Forecasts After Q1 Results - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/news/earnings/24/04/38299178/johnson-johnson-analysts-cut-their-forecasts-after-q1-results",
    "time_published": "20240417T175123",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Johnson & Johnson JNJ reported better-than-expected first-quarter earnings on Tuesday. The company posted adjusted EPS of $2.71, up 12.4% year over year, beating the consensus of $2.64.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/17/johnson__johnson_-_logo.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.120179,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.914521",
        "ticker_sentiment_score": "0.16504",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "JNJ Beats Q1 Earnings Estimates, Misses on Sales: ETFs in Focus",
    "url": "https://www.zacks.com/stock/news/2256952/jnj-beats-q1-earnings-estimates-misses-on-sales-etfs-in-focus",
    "time_published": "20240417T140000",
    "authors": [
      "Sweta Killa"
    ],
    "summary": "Johnson & Johnson (JNJ) continued with its long streak of earnings beat but lagged revenue estimates.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999855"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.904684"
      }
    ],
    "overall_sentiment_score": 0.195622,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALVO",
        "relevance_score": "0.046816",
        "ticker_sentiment_score": "0.126264",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.402761",
        "ticker_sentiment_score": "0.285071",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Company News for Apr 17, 2024",
    "url": "https://www.zacks.com/stock/news/2256693/company-news-for-apr-17-2024",
    "time_published": "20240417T131700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Companies In The Article ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/1612.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": -0.002451,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMD",
        "relevance_score": "0.601928",
        "ticker_sentiment_score": "0.347218",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LYV",
        "relevance_score": "0.601928",
        "ticker_sentiment_score": "0.073328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PNC",
        "relevance_score": "0.601928",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.601928",
        "ticker_sentiment_score": "-0.351004",
        "ticker_sentiment_label": "Bearish"
      }
    ]
  },
  {
    "title": "TRC Amends Its Tender Offer for Johnson & Johnson",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38291656/trc-amends-its-tender-offer-for-johnson-johnson",
    "time_published": "20240417T130500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "TORONTO, April 17, 2024 ( GLOBE NEWSWIRE ) -- TRC Capital Investment Corporation ( TRC ) announced today that based on current market conditions, TRC has amended the terms of its tender offer for up to 1,000,000 common shares of Johnson & Johnson ( the Company ) and has decreased the offer price ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.285771,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.103778",
        "ticker_sentiment_score": "0.145311",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday - Visa  ( NYSE:V ) ",
    "url": "https://www.benzinga.com/news/24/04/38289868/visa-to-rally-around-18-here-are-10-top-analyst-forecasts-for-wednesday",
    "time_published": "20240417T122144",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC Wainwright & Co. cut the price target for Unity Biotechnology, Inc. UBX from $10 to $8.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/17/visa_-_logo.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.101831,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AR",
        "relevance_score": "0.221481",
        "ticker_sentiment_score": "0.197529",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.148731",
        "ticker_sentiment_score": "0.149203",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "V",
        "relevance_score": "0.221481",
        "ticker_sentiment_score": "0.320782",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.221481",
        "ticker_sentiment_score": "-0.142427",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STRA",
        "relevance_score": "0.221481",
        "ticker_sentiment_score": "0.241633",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BK",
        "relevance_score": "0.221481",
        "ticker_sentiment_score": "-0.067578",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBX",
        "relevance_score": "0.221481",
        "ticker_sentiment_score": "0.098335",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.221481",
        "ticker_sentiment_score": "0.012024",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNS",
        "relevance_score": "0.221481",
        "ticker_sentiment_score": "0.003591",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "URBN",
        "relevance_score": "0.221481",
        "ticker_sentiment_score": "-0.091766",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "TikTok Mishandled The Data Of Hundreds Of Top American Advertisers",
    "url": "https://www.forbes.com/sites/alexandralevine/2024/04/17/tiktok-mishandled-advertisers-data-bytedance-china/",
    "time_published": "20240417T103000",
    "authors": [
      "Alexandra S. Levine"
    ],
    "summary": "Sensitive business information from advertisers like Amazon, Disney and the New York Times was widely available to ByteDance staff across the U.S. and China, Forbes has learned. TikTok, which is fighting a ban over its handling of data, declined to comment.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/661f3d1608af9ae56cafc31e/0x0.jpg?format=jpg&crop=1920,1080,x0,y0,safe&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.066968,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.021199",
        "ticker_sentiment_score": "0.03597",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NYT",
        "relevance_score": "0.063537",
        "ticker_sentiment_score": "0.010165",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.021199",
        "ticker_sentiment_score": "-0.01383",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MMM",
        "relevance_score": "0.250172",
        "ticker_sentiment_score": "0.068582",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.021199",
        "ticker_sentiment_score": "0.034787",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.021199",
        "ticker_sentiment_score": "0.034787",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "IAA and ISA to host 'Retrospect & Prospects' event in Mumbai with industry leaders",
    "url": "https://www.financialexpress.com/business/brandwagon-iaa-and-isa-to-host-retrospect-amp-prospects-event-in-mumbai-with-industry-leaders-3459062/",
    "time_published": "20240417T033809",
    "authors": [
      "BrandWagon Online"
    ],
    "summary": "The India Chapter of the International Advertising Association ( IAA ) and The Indian Society of Advertisers ( ISA ) will host an event titled 'Retrospect & Prospects' featuring Manish Anandani, managing director - India, Kenvue ( formerly Johnson & Johnson ) , on April 24th in Mumbai.",
    "banner_image": "https://www.financialexpress.com/wp-content/uploads/2024/04/Shailja-Tiwari-2024-04-17T090334.891.png",
    "source": "The Financial Express",
    "category_within_source": "n/a",
    "source_domain": "www.financialexpress.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.396207,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.344074",
        "ticker_sentiment_score": "0.408168",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.233556",
        "ticker_sentiment_score": "0.187531",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Top Stock Reports for NVIDIA, Alphabet & Johnson & Johnson",
    "url": "https://www.zacks.com/research-daily/2257574/top-stock-reports-for-nvidia-alphabet-johnson-johnson",
    "time_published": "20240418T162200",
    "authors": [
      "Sheraz Mian"
    ],
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Alphabet Inc. (GOOGL) and Johnson & Johnson (JNJ).",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default206.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.237309,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.12165",
        "ticker_sentiment_score": "0.163365",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.12165",
        "ticker_sentiment_score": "-0.021593",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's Why You Should Retain Medtronic  ( MDT )  Stock for Now",
    "url": "https://www.zacks.com/stock/news/2257854/heres-why-you-should-retain-medtronic-mdt-stock-for-now",
    "time_published": "20240418T150900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Investors continue to be optimistic about Medtronic (MDT) due to the strength of its Neurosurgery and Cardiovascular portfolios.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      }
    ],
    "overall_sentiment_score": 0.299826,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SYK",
        "relevance_score": "0.038906",
        "ticker_sentiment_score": "0.047187",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.038906",
        "ticker_sentiment_score": "0.047187",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.038906",
        "ticker_sentiment_score": "0.047187",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LMAT",
        "relevance_score": "0.116348",
        "ticker_sentiment_score": "0.080369",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.154703",
        "ticker_sentiment_score": "0.08129",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.339356",
        "ticker_sentiment_score": "0.367527",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "DVA",
        "relevance_score": "0.116348",
        "ticker_sentiment_score": "0.103952",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Unpacking the Latest Options Trading Trends in Johnson & Johnson - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/options/24/04/38316280/unpacking-the-latest-options-trading-trends-in-johnson-johnson",
    "time_published": "20240418T143229",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bearish move on Johnson & Johnson. Our analysis of options history for Johnson & Johnson JNJ revealed 9 unusual trades. Delving into the details, we found 44% of traders were bullish, while 55% showed bearish tendencies.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.172541,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.075635",
        "ticker_sentiment_score": "0.140603",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.075635",
        "ticker_sentiment_score": "0.095982",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.703655",
        "ticker_sentiment_score": "0.326391",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Home Depot Primed For Bounce; How To Capitalize With Options",
    "url": "https://www.investors.com/research/options/home-depot-stock-option-trading/",
    "time_published": "20240418T123700",
    "authors": [
      "Investor's Business Daily",
      "GAVIN McMASTER"
    ],
    "summary": "Home Depot Primed For Bounce. How To Capitalize With Options Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/11/Stock-homeDepot-01-company.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.623304"
      }
    ],
    "overall_sentiment_score": -0.064503,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "HD",
        "relevance_score": "0.723894",
        "ticker_sentiment_score": "-0.09988",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.15697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Endoscopy Devices Market size is set to grow by USD 14.24 billion from 2024-2028, advances in endoscopy ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/endoscopy-devices-market-size-is-set-to-grow-by-usd-14-24-billion-from-2024-2028--advances-in-endoscopy-technologies-boost-the-market--technavio-302120829.html",
    "time_published": "20240419T221200",
    "authors": [],
    "summary": "Endoscopy Devices Market size is set to grow by USD 14.24 billion from 2024-2028, advances in endoscopy ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.206034,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SYK",
        "relevance_score": "0.033656",
        "ticker_sentiment_score": "0.036539",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLAR",
        "relevance_score": "0.033656",
        "ticker_sentiment_score": "0.036539",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.033656",
        "ticker_sentiment_score": "0.036539",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.033656",
        "ticker_sentiment_score": "0.036539",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FUJIF",
        "relevance_score": "0.033656",
        "ticker_sentiment_score": "0.036539",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.033656",
        "ticker_sentiment_score": "0.036539",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OCPNF",
        "relevance_score": "0.033656",
        "ticker_sentiment_score": "0.036539",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CNMD",
        "relevance_score": "0.033656",
        "ticker_sentiment_score": "0.036539",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.067252",
        "ticker_sentiment_score": "0.074881",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stock Market Shows Bearish Action: Weekly Review",
    "url": "https://www.investors.com/news/stock-market-taiwan-semiconductor-asml-netflix-united-airlines-weekly-review/",
    "time_published": "20240419T165100",
    "authors": [
      "IBD STAFF",
      "Investor's Business Daily"
    ],
    "summary": "Stock Market Sells Off. Taiwan Semi, ASML, Netflix, Tesla In Focus: Weekly Review Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/10/Stock-NYSEbuilding-09-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.041784,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "-0.148103",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.098862",
        "ticker_sentiment_score": "-0.034689",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IBKR",
        "relevance_score": "0.098862",
        "ticker_sentiment_score": "0.102009",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.108439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.108439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.049526",
        "ticker_sentiment_score": "0.071953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SLB",
        "relevance_score": "0.123399",
        "ticker_sentiment_score": "0.018007",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BK",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.108439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.049526",
        "ticker_sentiment_score": "0.105983",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.108869",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSM",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.004134",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KBH",
        "relevance_score": "0.049526",
        "ticker_sentiment_score": "0.102972",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.049526",
        "ticker_sentiment_score": "0.071953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ITCI",
        "relevance_score": "0.049526",
        "ticker_sentiment_score": "-0.127853",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "-0.076438",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.049526",
        "ticker_sentiment_score": "0.107278",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.101928",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.049526",
        "ticker_sentiment_score": "0.012",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SCHW",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.095435",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.088742",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.0156",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "WHO says wider warning about contaminated J&J cough syrup 'likely'",
    "url": "https://www.business-standard.com/world-news/who-says-wider-warning-about-contaminated-j-j-cough-syrup-likely-124041901148_1.html",
    "time_published": "20240419T145440",
    "authors": [
      "Reuters"
    ],
    "summary": "The World Health Organization is likely to issue a wider warning about contaminated Johnson and Johnson-made children's cough syrup found in Nigeria last week, it said in an email. Nigeria's regulator recalled a batch of Benylin syrup last Wednesday, having found a high level of diethylene glycol ...",
    "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-05/16/full/1684234463-8764.jpg?im=FeatureCrop,size=(826,465)",
    "source": "Business Standard",
    "category_within_source": "GoogleRSS",
    "source_domain": "www.business-standard.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.097247,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.331765",
        "ticker_sentiment_score": "-0.070615",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.085324",
        "ticker_sentiment_score": "-0.243445",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "A creator made 5 figures with a dating podcast and quit her job to focus on her side hustle full-time. She breaks down her income from brand deals, sponsored events, and more.",
    "url": "https://www.businessinsider.com/how-much-creator-earns-tiktok-instagram-events-brand-deals-podcast-2024-4",
    "time_published": "20240419T144000",
    "authors": [
      "Shriya Bhattacharya"
    ],
    "summary": "How Much a Creator Makes in a Year From Events, Brand Deals, TikTok - Business Insider ...",
    "banner_image": null,
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "www.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.149059,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.042953",
        "ticker_sentiment_score": "0.169258",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Children's Cough Syrup Contaminated In Some Batches - WHO Poised to Issue Global Alert - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/04/38335588/johnson-johnson-childrens-cough-syrup-contaminated-in-some-batches-who-poised-to-issue-global-ale",
    "time_published": "20240419T141714",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "The World Health Organization ( WHO ) is poised to issue a broader alert regarding contaminated children's cough syrup produced by Johnson and Johnson JNJ in response to the discovery of tainted batches in Nigeria.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/19/Benylin-Syrup.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.076471,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.414559",
        "ticker_sentiment_score": "0.150091",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.414559",
        "ticker_sentiment_score": "-0.057089",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "White River Bancshares Co. Earns $509,000, or $0.51 Per Diluted Share, in First Quarter 2024; Highlighted by Higher Net Interest Income and Double Digit Loan and Deposit Growth Year-Over-Year",
    "url": "https://www.globenewswire.com/news-release/2024/04/19/2866167/0/en/White-River-Bancshares-Co-Earns-509-000-or-0-51-Per-Diluted-Share-in-First-Quarter-2024-Highlighted-by-Higher-Net-Interest-Income-and-Double-Digit-Loan-and-Deposit-Growth-Year-Over.html",
    "time_published": "20240419T130000",
    "authors": [
      "White River Bancshares"
    ],
    "summary": "FAYETTEVILLE, Ark., April 19, 2024 ( GLOBE NEWSWIRE ) -- White River Bancshares Company ( OTCQX: WRIV ) , ( the \"Company\" ) the holding company for Signature Bank of Arkansas ( the \"Bank\" ) , today reported net income of $509,000, or $0.51 per diluted share, in the first quarter of 2024, ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/59f98c26-e808-41b4-b248-610c5133e898",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999993"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.246729,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KO",
        "relevance_score": "0.017729",
        "ticker_sentiment_score": "0.117576",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBNY",
        "relevance_score": "0.07083",
        "ticker_sentiment_score": "0.090446",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSN",
        "relevance_score": "0.017729",
        "ticker_sentiment_score": "0.117576",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.017729",
        "ticker_sentiment_score": "0.117576",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.017729",
        "ticker_sentiment_score": "0.117576",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.017729",
        "ticker_sentiment_score": "0.117576",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights NVIDIA, Alphabet, Johnson & Johnson, Broadridge Financial and Textron",
    "url": "https://www.zacks.com/stock/news/2258173/the-zacks-analyst-blog-highlights-nvidia-alphabet-johnson-johnson-broadridge-financial-and-textron",
    "time_published": "20240419T100000",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "NVIDIA, Alphabet, Johnson & Johnson, Broadridge Financial and Textron are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/20/444.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.216801,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BR",
        "relevance_score": "0.17715",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.262994",
        "ticker_sentiment_score": "0.158228",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TXT",
        "relevance_score": "0.17715",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.262994",
        "ticker_sentiment_score": "-0.017817",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Court Orders Johnson & Johnson And Kenvue To Pay $45 Million In Talcum Baby Powder Lawsuit",
    "url": "https://www.forbes.com/sites/caileygleeson/2024/04/20/court-orders-johnson--johnson-and-kenvue-to-pay-45-million-in-talcum-baby-powder-lawsuit/",
    "time_published": "20240420T192555",
    "authors": [
      "Cailey Gleeson"
    ],
    "summary": "An Illinois court late Friday ordered pharmaceutical giant Johnson & Johnson and Kenvue to pay $45 million to a family that alleged the companies' talcum-based baby powder led to the death of a relative diagnosed with a fatal cancer linked to asbestos exposure, the company's latest legal issue ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/66241662c228281a35936eab/0x0.jpg?format=jpg&crop=3000,1687,x0,y0,safe&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.196063,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.144708",
        "ticker_sentiment_score": "-0.05911",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.47672",
        "ticker_sentiment_score": "-0.257595",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Don't Let Media-Driven Fears Keep You From These 7%+ Dividends",
    "url": "https://www.forbes.com/sites/michaelfoster/2024/04/20/dont-let-media-driven-fears-keep-you-from-these-7-dividends/",
    "time_published": "20240420T133600",
    "authors": [
      "Michael Foster"
    ],
    "summary": "It's starting again-the media has its hooks into a new story to scare investors, in yet another effort to gain attention. The upshot is that we've now got a very nice opportunity to pick up a special kind of closed-end fund ( CEF ) that yields 7%+ and does something unusual to limit downside.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/661fd70b850da1386d0dd00c/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.041812,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.079788",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.079788",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.079788",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - ALPN, LABP, SWAV, FUSN",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38366584/take-action-the-m-a-class-action-firm-launches-legal-inquiry-for-the-merger-alpn-labp-swav-fusn",
    "time_published": "20240422T213316",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, April 22, 2024 ( GLOBE NEWSWIRE ) -- Monteverde & Associates PC ( the \"M&A Class Action Firm\" ) , has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      }
    ],
    "overall_sentiment_score": 0.270721,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LABP",
        "relevance_score": "0.334008",
        "ticker_sentiment_score": "0.312006",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.334008",
        "ticker_sentiment_score": "0.281733",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.085936",
        "ticker_sentiment_score": "0.124976",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.085936",
        "ticker_sentiment_score": "0.124976",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.085936",
        "ticker_sentiment_score": "0.139374",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FUSN",
        "relevance_score": "0.334008",
        "ticker_sentiment_score": "0.312006",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.334008",
        "ticker_sentiment_score": "0.281733",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Macatawa Bank Corporation  ( Nasdaq - MCBC ) , Shockwave Medical, Inc.  ( Nasdaq - SWAV ) , Apartment Income REIT Corp.  ( NYSE - AIRC ) , Model N, Inc.  ( NYSE - MODN ) ",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38360727/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-macatawa-bank",
    "time_published": "20240422T155334",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "BALA CYNWYD, Pa., April 22, 2024 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998333"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.253232,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "WTFC",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.222469",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MCBC",
        "relevance_score": "0.068306",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.202932",
        "ticker_sentiment_score": "0.058294",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BX",
        "relevance_score": "0.202932",
        "ticker_sentiment_score": "0.162385",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AIRC",
        "relevance_score": "0.068306",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.202932",
        "ticker_sentiment_score": "0.177581",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MODN",
        "relevance_score": "0.268294",
        "ticker_sentiment_score": "0.155883",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.068306",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates WIRE, ABIO, SWAV, MODN - Model N  ( NYSE:MODN ) , ARCA biopharma  ( NASDAQ:ABIO ) ",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38359734/shareholder-investigation-halper-sadeh-llc-investigates-wire-abio-swav-modn",
    "time_published": "20240422T151032",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, April 22, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.128619,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MODN",
        "relevance_score": "0.213988",
        "ticker_sentiment_score": "0.126999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABIO",
        "relevance_score": "0.107978",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WIRE",
        "relevance_score": "0.107978",
        "ticker_sentiment_score": "0.084761",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.107978",
        "ticker_sentiment_score": "0.084761",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.107978",
        "ticker_sentiment_score": "0.084761",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Kuehn Law Encourages WIRE, ABIO, MODN, and SWAV Investors to Contact Law Firm - Model N  ( NYSE:MODN ) , ARCA biopharma  ( NASDAQ:ABIO ) ",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38357464/kuehn-law-encourages-wire-abio-modn-and-swav-investors-to-contact-law-firm",
    "time_published": "20240422T134703",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, April 22, 2024 ( GLOBE NEWSWIRE ) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.295874,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MODN",
        "relevance_score": "0.234684",
        "ticker_sentiment_score": "0.333119",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABIO",
        "relevance_score": "0.118647",
        "ticker_sentiment_score": "0.127461",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WIRE",
        "relevance_score": "0.234684",
        "ticker_sentiment_score": "0.459878",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.118647",
        "ticker_sentiment_score": "0.282229",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.118647",
        "ticker_sentiment_score": "0.282229",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2259015/johnson-johnson-jnj-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20240422T130016",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default47.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.224611,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.473208",
        "ticker_sentiment_score": "0.114889",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stock market today: US futures climb as traders await crucial 'Magnificent 7' earnings reports",
    "url": "https://africa.businessinsider.com/markets/stock-market-today-us-futures-climb-as-traders-await-crucial-magnificent-7-earnings/mk3wwc1",
    "time_published": "20240422T101016",
    "authors": [
      "George Glover"
    ],
    "summary": "Samp;P 500 futures were up 0.5% shortly before 6 a.m. ET, while Nasdaq 100 futures had climbed 0.6%. The Dow Jones Industrial Average was on pace to add 165 points.",
    "banner_image": "https://ocdn.eu/pulscms-transforms/1/_xektkuTURBXy8wN2RmMWYwOC0zN2Q5LTRhZWEtYjEyOS1hYTM0YTViYzRiZTYuanBlZ5GTBc0DFs0Brg",
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "africa.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.219403,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.162802",
        "ticker_sentiment_score": "0.223261",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.162802",
        "ticker_sentiment_score": "0.223261",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.162802",
        "ticker_sentiment_score": "0.223261",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.162802",
        "ticker_sentiment_score": "0.223261",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.162802",
        "ticker_sentiment_score": "0.070605",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stock market today: US futures climb as traders await crucial 'Magnificent 7' earnings reports",
    "url": "https://www.businessinsider.com/stock-market-today-microsoft-alphabet-meta-tesla-magnificent-seven-earnings-2024-4",
    "time_published": "20240422T101000",
    "authors": [
      "George Glover"
    ],
    "summary": "Stock market today: US futures climb ahead of Magnificent 7 earnings - Business Insider ...",
    "banner_image": null,
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "www.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.110583,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.232439",
        "ticker_sentiment_score": "0.138028",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.232439",
        "ticker_sentiment_score": "0.138028",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.121385",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.121385",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.121385",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The No. 1 Biotech Stock Just Launched Higher - Here's Why",
    "url": "https://www.investors.com/news/technology/biotech-stock-neurocrine-stock-depression-treatment-win/",
    "time_published": "20240423T132000",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Biotech Stock Neurocrine Launches Higher On A Depression Treatment Win Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2022/08/Stock-neurocrinebio-01-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.955357"
      }
    ],
    "overall_sentiment_score": 0.184606,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.156461",
        "ticker_sentiment_score": "-0.118245",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.306963",
        "ticker_sentiment_score": "0.288375",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NBIX",
        "relevance_score": "0.306963",
        "ticker_sentiment_score": "0.334376",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.306963",
        "ticker_sentiment_score": "0.334376",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "4 Stocks to Watch on Their Recent Dividend Hikes",
    "url": "https://www.zacks.com/stock/news/2260121/4-stocks-to-watch-on-their-recent-dividend-hikes",
    "time_published": "20240423T124200",
    "authors": [
      "Ritujay Ghosh"
    ],
    "summary": "Stocks like KB Home (KBH), Interactive Brokers Group, Inc. (IBKR), QUALCOMM Incorporated (QCOM) and Johnson & Johnson (JNJ) recently hiked dividends.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f2/1790.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.038911,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KBH",
        "relevance_score": "0.415413",
        "ticker_sentiment_score": "0.247372",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IBKR",
        "relevance_score": "0.267413",
        "ticker_sentiment_score": "0.12852",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QCOM",
        "relevance_score": "0.215415",
        "ticker_sentiment_score": "0.121113",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.415413",
        "ticker_sentiment_score": "0.35555",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Investing in Cardiovascular MedTech Companies",
    "url": "https://investingnews.com/investing-in-cardiovascular-medtech-companies/",
    "time_published": "20240424T224704",
    "authors": [
      "Investing News Network"
    ],
    "summary": "Efforts to address the core risk factors associated with cardiovascular diseases are coinciding with recent innovations in medical technology, which have been critical in not only preventing and managing them but also increasing the survival rate.",
    "banner_image": "https://investingnews.com/media-library/illustration-of-heart-attack.png?id=52093924&width=1200&height=800&quality=85&coordinates=0%2C0%2C0%2C0",
    "source": "Investing News Network",
    "category_within_source": "n/a",
    "source_domain": "investingnews.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.426531,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CDEXF",
        "relevance_score": "0.101725",
        "ticker_sentiment_score": "0.094903",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.101725",
        "ticker_sentiment_score": "0.089634",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WLDS",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "0.205849",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.101725",
        "ticker_sentiment_score": "0.089634",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "0.084292",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results",
    "url": "https://www.globenewswire.com/news-release/2024/04/24/2869144/0/en/NANOBIOTIX-Provides-Business-Update-and-Reports-Full-Year-2023-Financial-Results.html",
    "time_published": "20240424T204000",
    "authors": [
      "Nanobiotix S.A."
    ],
    "summary": "Conference call and webcast scheduled for April 25, 2024 at 8:00 A.M. EDT / 2:00 P.M. CEST ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/36fb7b98-27d7-46cb-b989-fa31626657b8",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.94762"
      }
    ],
    "overall_sentiment_score": 0.116494,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NBTX",
        "relevance_score": "0.298749",
        "ticker_sentiment_score": "0.101264",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LIANY",
        "relevance_score": "0.015304",
        "ticker_sentiment_score": "0.082886",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.030602",
        "ticker_sentiment_score": "0.075618",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:NANO",
        "relevance_score": "0.015304",
        "ticker_sentiment_score": "0.047629",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's a rapid-fire update on all 33 portfolio stocks including our tech giants reporting this week",
    "url": "https://www.cnbc.com/2024/04/24/jim-cramers-rapid-fire-update-on-all-33-investing-club-stocks.html",
    "time_published": "20240424T195309",
    "authors": [
      "Kevin Stankiewicz",
      "Morgan Chittum"
    ],
    "summary": "During the Investing Club's Monthly Meeting on Wednesday, Jim Cramer offered his updated thinking on the stocks in the portfolio.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107381791-1709565572170-gettyimages-2050810312-AFP_34KQ4DT.jpeg?v=1713980195&w=1920&h=1080",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999974"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.147834,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DD",
        "relevance_score": "0.014239",
        "ticker_sentiment_score": "0.054481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VMW",
        "relevance_score": "0.014239",
        "ticker_sentiment_score": "0.054481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INFA",
        "relevance_score": "0.028473",
        "ticker_sentiment_score": "0.058975",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.014239",
        "ticker_sentiment_score": "0.054481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "F",
        "relevance_score": "0.014239",
        "ticker_sentiment_score": "0.054481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FL",
        "relevance_score": "0.042698",
        "ticker_sentiment_score": "0.061498",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.014239",
        "ticker_sentiment_score": "0.054481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WYNN",
        "relevance_score": "0.014239",
        "ticker_sentiment_score": "0.054481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.014239",
        "ticker_sentiment_score": "0.054481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.05691",
        "ticker_sentiment_score": "0.062053",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.042698",
        "ticker_sentiment_score": "0.061498",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.014239",
        "ticker_sentiment_score": "0.054481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.042698",
        "ticker_sentiment_score": "0.061498",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BBY",
        "relevance_score": "0.042698",
        "ticker_sentiment_score": "0.061498",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STZ",
        "relevance_score": "0.014239",
        "ticker_sentiment_score": "0.054481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PANW",
        "relevance_score": "0.014239",
        "ticker_sentiment_score": "0.054481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.042698",
        "ticker_sentiment_score": "0.061498",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.028473",
        "ticker_sentiment_score": "0.058975",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.028473",
        "ticker_sentiment_score": "0.058975",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRWD",
        "relevance_score": "0.014239",
        "ticker_sentiment_score": "0.054481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TJX",
        "relevance_score": "0.028473",
        "ticker_sentiment_score": "0.058975",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GM",
        "relevance_score": "0.042698",
        "ticker_sentiment_score": "0.061498",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HON",
        "relevance_score": "0.014239",
        "ticker_sentiment_score": "0.054481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.028473",
        "ticker_sentiment_score": "0.058975",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWK",
        "relevance_score": "0.014239",
        "ticker_sentiment_score": "0.054481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.014239",
        "ticker_sentiment_score": "0.054481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTRA",
        "relevance_score": "0.014239",
        "ticker_sentiment_score": "0.054481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.014239",
        "ticker_sentiment_score": "0.054481",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vanda  ( VNDA )  to Report Q1 Earnings: What's in the Cards?",
    "url": "https://www.zacks.com/stock/news/2261585/vanda-vnda-to-report-q1-earnings-whats-in-the-cards",
    "time_published": "20240424T175800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "On Vanda's (VNDA) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its marketed drugs and certain pipeline and regulatory updates.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/49/1007.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999992"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.109272,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CTMX",
        "relevance_score": "0.190793",
        "ticker_sentiment_score": "-0.003041",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.048133",
        "ticker_sentiment_score": "-0.071085",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SRPT",
        "relevance_score": "0.1437",
        "ticker_sentiment_score": "0.171113",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VNDA",
        "relevance_score": "0.327366",
        "ticker_sentiment_score": "0.028564",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.1437",
        "ticker_sentiment_score": "0.159788",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?",
    "url": "https://www.zacks.com/stock/news/2261011/whats-in-store-for-these-5-pharma-bigwigs-in-q1-earnings",
    "time_published": "20240424T131900",
    "authors": [
      "Ahan Chakraborty"
    ],
    "summary": "Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ad/58479.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.154863,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.039614",
        "ticker_sentiment_score": "-0.008857",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.039614",
        "ticker_sentiment_score": "-0.080241",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.039614",
        "ticker_sentiment_score": "0.342197",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.234307",
        "ticker_sentiment_score": "0.134722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.196132",
        "ticker_sentiment_score": "-0.010985",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.118452",
        "ticker_sentiment_score": "0.061763",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.196132",
        "ticker_sentiment_score": "0.04485",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights KB Home, Interactive Brokers Group, Qualcomm and Johnson & Johnson",
    "url": "https://www.zacks.com/stock/news/2261200/the-zacks-analyst-blog-highlights-kb-home-interactive-brokers-group-qualcomm-and-johnson-johnson",
    "time_published": "20240424T125000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "KB Home, Interactive Brokers Group, Qualcomm and Johnson & Johnson are part of the Zacks top Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/0d/701.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.055662,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KBH",
        "relevance_score": "0.414559",
        "ticker_sentiment_score": "0.193751",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IBKR",
        "relevance_score": "0.28387",
        "ticker_sentiment_score": "0.098158",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QCOM",
        "relevance_score": "0.28387",
        "ticker_sentiment_score": "0.110411",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.414559",
        "ticker_sentiment_score": "0.269325",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "These Are the 10 High-Profile Stocks U.S. Politicians Have Gravitated to Most Over the Last 3 Years",
    "url": "https://www.fool.com/investing/2024/04/24/these-are-the-10-high-profile-stocks-us-politician/",
    "time_published": "20240424T101000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "These stocks kept members of Congress especially busy.",
    "banner_image": "https://g.foolcdn.com/editorial/images/773947/congress-building-capitol-hill.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.19698,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.201021",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PYPL",
        "relevance_score": "0.201021",
        "ticker_sentiment_score": "0.102999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.081138",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.121445",
        "ticker_sentiment_score": "0.251165",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.201021",
        "ticker_sentiment_score": "0.093886",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "T",
        "relevance_score": "0.16144",
        "ticker_sentiment_score": "0.277091",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.353338",
        "ticker_sentiment_score": "0.193378",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.16144",
        "ticker_sentiment_score": "0.109402",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.16144",
        "ticker_sentiment_score": "0.190746",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Got $5,000? Here Are 3 Undervalued Stocks to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/04/24/got-5000-here-are-3-undervalued-stocks-to-buy-and/",
    "time_published": "20240424T092500",
    "authors": [
      "Justin Pope"
    ],
    "summary": "Buying great stocks when they're on sale is a lucrative long-term strategy.",
    "banner_image": "https://g.foolcdn.com/editorial/images/772025/opportunity.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999987"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.247998,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BUD",
        "relevance_score": "0.050894",
        "ticker_sentiment_score": "0.085012",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MO",
        "relevance_score": "0.298264",
        "ticker_sentiment_score": "0.263966",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.298264",
        "ticker_sentiment_score": "-0.024182",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "O",
        "relevance_score": "0.298264",
        "ticker_sentiment_score": "0.290453",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi\u00ae  ( golimumab ) ",
    "url": "https://www.globenewswire.com/news-release/2024/04/24/2868337/0/en/Alvotech-Announces-Topline-Results-from-a-Confirmatory-Clinical-Study-for-AVT05-a-Proposed-Biosimilar-for-Simponi-golimumab.html",
    "time_published": "20240424T080000",
    "authors": [
      "Alvotech"
    ],
    "summary": "Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive topline results from a confirmatory clinical study for AVT05, Alvotech's proposed biosimilar to Simponi\u00ae and Simponi Aria\u00ae ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.128088,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALVO",
        "relevance_score": "0.529556",
        "ticker_sentiment_score": "0.226967",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.025034",
        "ticker_sentiment_score": "0.059121",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.025034",
        "ticker_sentiment_score": "0.059121",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.025034",
        "ticker_sentiment_score": "0.059121",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.025034",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "BioNJ Announces Lineup for BioPartnering Conference",
    "url": "https://www.prnewswire.com/news-releases/bionj-announces-lineup-for-biopartnering-conference-302127910.html",
    "time_published": "20240425T182700",
    "authors": [
      "BioNJ"
    ],
    "summary": "TRENTON, N.J., April 25, 2024 /PRNewswire/ -- BioNJ is pleased to host its 14th Annual BioPartnering Conference on Tuesday, May 14, at the Liberty Science Center in Jersey City. Sponsored by J.P.",
    "banner_image": "https://mma.prnewswire.com/media/2397912/BioNJ_BioPartnering_Conference_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.380824,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.097854",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.194242",
        "ticker_sentiment_score": "0.073971",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.097854",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Monthly Depth Report: The Blind Leading The Confused - Shockwave Medical  ( NASDAQ:SWAV ) ",
    "url": "https://www.benzinga.com/opinion/24/04/38437069/monthly-depth-report-the-blind-leading-the-confused",
    "time_published": "20240425T155927",
    "authors": [
      "Gary Brode"
    ],
    "summary": "One of the best experiences I've had in my investment career was being partner and co portfolio manager with Raji Khabbaz. He's a fantastic stock-picker and the two of us spent the better part of a decade discussing and debating investment ideas.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/25/nicholas-cappello-wb63zqj5gne-unsplash_1.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999986"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.07264,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SWAV",
        "relevance_score": "0.028338",
        "ticker_sentiment_score": "0.085825",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.028338",
        "ticker_sentiment_score": "0.085825",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here Are My Top 5 Dividend Kings to Buy Right Now",
    "url": "https://www.fool.com/investing/2024/04/25/here-are-my-top-5-dividend-kings-to-buy-right-now/",
    "time_published": "20240425T131500",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Dividend Kings are hard to come by, but these five stocks offer investors some great passive income opportunities.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F773701%2Fcopy-of-dividends-blackboard-sketch-doodle.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999701"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.319823,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.137083",
        "ticker_sentiment_score": "0.13966",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SOLV",
        "relevance_score": "0.03443",
        "ticker_sentiment_score": "0.190962",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MO",
        "relevance_score": "0.237469",
        "ticker_sentiment_score": "0.227408",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.103035",
        "ticker_sentiment_score": "0.270812",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.068797",
        "ticker_sentiment_score": "0.145609",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.237469",
        "ticker_sentiment_score": "0.19416",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "This Small-Cap Stock Is Up 140% This Year and Here's Why It Can Go Even Higher",
    "url": "https://www.fool.com/investing/2024/04/25/this-small-cap-stock-is-up-150-this-year-and-heres/",
    "time_published": "20240425T093700",
    "authors": [
      "David Jagielski"
    ],
    "summary": "For investors with a high level of risk tolerance, Mind Medicine could be an intriguing investment option.",
    "banner_image": "https://media.ycharts.com/charts/887c4d12055417c81c6d752c80b64f41.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.28068,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MNMD",
        "relevance_score": "0.575728",
        "ticker_sentiment_score": "0.317542",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.057907",
        "ticker_sentiment_score": "0.127985",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pre-Investor Call Presentation available to shareholders",
    "url": "https://www.globenewswire.com/news-release/2024/04/25/2869320/0/en/Pre-Investor-Call-Presentation-available-to-shareholders.html",
    "time_published": "20240425T064000",
    "authors": [
      "VIRTUALWARE 2007 SA"
    ],
    "summary": "Investors can access and view today's presentation materials by following this link: Headquartered in Bilbao, Spain, Virtualware is a global pioneer in developing virtual reality solutions for large industrial, educational, and healthcare conglomerates.",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/6aee44c0-62ac-4f66-9be0-b3578d202005",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.20415,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GEV",
        "relevance_score": "0.073773",
        "ticker_sentiment_score": "0.119019",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IBDSF",
        "relevance_score": "0.073773",
        "ticker_sentiment_score": "0.119019",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AOMFF",
        "relevance_score": "0.073773",
        "ticker_sentiment_score": "0.119019",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.073773",
        "ticker_sentiment_score": "0.119019",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.073773",
        "ticker_sentiment_score": "0.119019",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Beats on Q1 Earnings & Sales, Ups '24 EPS View",
    "url": "https://www.zacks.com/stock/news/2263588/abbvie-abbv-beats-on-q1-earnings-sales-ups-24-eps-view",
    "time_published": "20240426T161000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie's (ABBV) first-quarter earnings and sales beat estimates. Management hikes the EPS guidance on the back of encouraging Skyrizi product sales.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/31/1512.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.998311"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.126215,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GMAB",
        "relevance_score": "0.112008",
        "ticker_sentiment_score": "0.281693",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.327366",
        "ticker_sentiment_score": "0.299765",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.074809",
        "ticker_sentiment_score": "0.063534",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Are You Looking for a High-Growth Dividend Stock?",
    "url": "https://www.zacks.com/stock/news/2263489/are-you-looking-for-a-high-growth-dividend-stock",
    "time_published": "20240426T154509",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default175.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938238"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999365"
      }
    ],
    "overall_sentiment_score": 0.421112,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.448316",
        "ticker_sentiment_score": "0.497143",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Stocks Rebound Amid Big-Cap Earnings: Weekly Review",
    "url": "https://www.investors.com/news/stock-market-rebounds-tesla-microsoft-google-meta-chipotle-ge-in-focus-weekly-review/",
    "time_published": "20240426T153400",
    "authors": [
      "Investor's Business Daily",
      "IBD STAFF"
    ],
    "summary": "Stock Market Rebounds. Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2019/02/VIDEO-IBDDIFF-NYSE-020819-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.576289"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999993"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.022015,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MEDP",
        "relevance_score": "0.033075",
        "ticker_sentiment_score": "0.224841",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MXL",
        "relevance_score": "0.033075",
        "ticker_sentiment_score": "-0.103259",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ROKU",
        "relevance_score": "0.033075",
        "ticker_sentiment_score": "-0.001918",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.066093",
        "ticker_sentiment_score": "0.023298",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.098998",
        "ticker_sentiment_score": "-0.03743",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.033075",
        "ticker_sentiment_score": "-0.060313",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NBIX",
        "relevance_score": "0.033075",
        "ticker_sentiment_score": "-0.060313",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TXN",
        "relevance_score": "0.033075",
        "ticker_sentiment_score": "-0.103259",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STM",
        "relevance_score": "0.033075",
        "ticker_sentiment_score": "-0.103259",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "URI",
        "relevance_score": "0.049595",
        "ticker_sentiment_score": "0.079806",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.11539",
        "ticker_sentiment_score": "0.136118",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.14802",
        "ticker_sentiment_score": "-0.032445",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HLX",
        "relevance_score": "0.033075",
        "ticker_sentiment_score": "0.022472",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "V",
        "relevance_score": "0.033075",
        "ticker_sentiment_score": "0.009549",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VLO",
        "relevance_score": "0.033075",
        "ticker_sentiment_score": "0.022472",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRT",
        "relevance_score": "0.033075",
        "ticker_sentiment_score": "0.091842",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.066093",
        "ticker_sentiment_score": "0.103051",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GD",
        "relevance_score": "0.049595",
        "ticker_sentiment_score": "0.115876",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.082563",
        "ticker_sentiment_score": "0.139202",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.131733",
        "ticker_sentiment_score": "-0.001266",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NUE",
        "relevance_score": "0.066093",
        "ticker_sentiment_score": "-0.074412",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.066093",
        "ticker_sentiment_score": "0.040467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.131733",
        "ticker_sentiment_score": "0.004932",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.098998",
        "ticker_sentiment_score": "-0.003314",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOC",
        "relevance_score": "0.033075",
        "ticker_sentiment_score": "0.112318",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.033075",
        "ticker_sentiment_score": "0.159617",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GM",
        "relevance_score": "0.033075",
        "ticker_sentiment_score": "0.164521",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "OII",
        "relevance_score": "0.049595",
        "ticker_sentiment_score": "0.023",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.033075",
        "ticker_sentiment_score": "-0.000998",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMUS",
        "relevance_score": "0.049595",
        "ticker_sentiment_score": "-0.034001",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EW",
        "relevance_score": "0.033075",
        "ticker_sentiment_score": "0.159617",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HAL",
        "relevance_score": "0.049595",
        "ticker_sentiment_score": "0.023",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LMT",
        "relevance_score": "0.033075",
        "ticker_sentiment_score": "0.112318",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.033075",
        "ticker_sentiment_score": "-0.000998",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.033075",
        "ticker_sentiment_score": "-0.103259",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.082563",
        "ticker_sentiment_score": "0.097489",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOW",
        "relevance_score": "0.033075",
        "ticker_sentiment_score": "0.037093",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.033075",
        "ticker_sentiment_score": "0.022472",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CDNS",
        "relevance_score": "0.033075",
        "ticker_sentiment_score": "-0.08357",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GEV",
        "relevance_score": "0.066093",
        "ticker_sentiment_score": "-0.049623",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PI",
        "relevance_score": "0.033075",
        "ticker_sentiment_score": "-0.103259",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FTI",
        "relevance_score": "0.049595",
        "ticker_sentiment_score": "0.023",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLF",
        "relevance_score": "0.049595",
        "ticker_sentiment_score": "-0.073841",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.082563",
        "ticker_sentiment_score": "-0.044057",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.033075",
        "ticker_sentiment_score": "-0.000998",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STLD",
        "relevance_score": "0.049595",
        "ticker_sentiment_score": "-0.073841",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "5 Stocks in Focus on Their Recent Dividend Hike",
    "url": "https://www.zacks.com/stock/news/2263132/5-stocks-in-focus-on-their-recent-dividend-hike",
    "time_published": "20240426T121300",
    "authors": [
      "Nalak Das"
    ],
    "summary": "Five stocks to focus with recent dividend hike are: JNJ, TRV, SON, KBH, SPFI.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1948.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999997"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.195152,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KBH",
        "relevance_score": "0.369319",
        "ticker_sentiment_score": "0.166401",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TRV",
        "relevance_score": "0.369319",
        "ticker_sentiment_score": "0.480674",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SON",
        "relevance_score": "0.299478",
        "ticker_sentiment_score": "0.212312",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CTBK",
        "relevance_score": "0.038345",
        "ticker_sentiment_score": "0.061439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPFI",
        "relevance_score": "0.334762",
        "ticker_sentiment_score": "0.144375",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.299478",
        "ticker_sentiment_score": "0.251639",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024 - Cidara Therapeutics  ( NASDAQ:CDTX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38457396/cidara-therapeutics-announces-presentations-highlighting-phase-1-and-phase-2a-clinical-data-on-cd3",
    "time_published": "20240426T120000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "SAN DIEGO, April 26, 2024 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.155306,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CDTX",
        "relevance_score": "0.212425",
        "ticker_sentiment_score": "0.155088",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.07157",
        "ticker_sentiment_score": "0.073387",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "NAMIWalks Greater LA County Mental Health Festival Taking Place at LA State Historic Park",
    "url": "https://www.benzinga.com/pressreleases/24/04/n38476927/namiwalks-greater-la-county-mental-health-festival-taking-place-at-la-state-historic-park",
    "time_published": "20240427T153000",
    "authors": [
      "PRNewswire"
    ],
    "summary": "LOS ANGELES, April 27, 2024 /PRNewswire/ -- The National Alliance on Mental Illness Greater L.A. County ( NAMI GLAC ) will celebrate its 20th annual NAMIWalks Greater LA County Mental Health Festival during Mental Health Awareness Month on Saturday, May 4, 2024.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.300726,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.064973",
        "ticker_sentiment_score": "0.198444",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Stock: Buy, Sell, or Hold?",
    "url": "https://www.fool.com/investing/2024/04/27/johnson-johnson-stock-buy-sell-or-hold/",
    "time_published": "20240427T114500",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Is this top healthcare stock worth adding to your portfolio today?",
    "banner_image": "https://g.foolcdn.com/editorial/images/773651/a-doctor-using-a-stethoscope.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.210394,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.330876",
        "ticker_sentiment_score": "0.124083",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Unusual Income ETFs That May Be Just What You're Looking For",
    "url": "https://www.fool.com/investing/2024/04/28/3-unusual-income-etfs-that-may-be-just-what-youre/",
    "time_published": "20240428T131500",
    "authors": [
      "James Brumley"
    ],
    "summary": "They may be off the beaten path, but these exchange-traded funds just might meet your unique income need.",
    "banner_image": "https://g.foolcdn.com/editorial/images/774402/one-thousand-dollars-1000-fanned-out.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.218539,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.034039",
        "ticker_sentiment_score": "0.133002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.034039",
        "ticker_sentiment_score": "0.154281",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.034039",
        "ticker_sentiment_score": "0.154281",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.034039",
        "ticker_sentiment_score": "0.154281",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Top Growth Stocks to Buy Right Now and Hold Forever",
    "url": "https://www.fool.com/investing/2024/04/28/2-top-growth-stocks-to-buy-now-and-hold-forever/",
    "time_published": "20240428T124500",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "These healthcare stocks can provide enviable long-term portfolio growth.",
    "banner_image": "https://g.foolcdn.com/editorial/images/773907/getty-couple-happy-in-kitchen.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.989041"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.318166,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.043738",
        "ticker_sentiment_score": "0.142649",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.087344",
        "ticker_sentiment_score": "0.23405",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.043738",
        "ticker_sentiment_score": "0.195492",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.043738",
        "ticker_sentiment_score": "0.184503",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.043738",
        "ticker_sentiment_score": "0.077297",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.216087",
        "ticker_sentiment_score": "0.249471",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Better Dividend Stock: AbbVie or Johnson & Johnson?",
    "url": "https://www.fool.com/investing/2024/04/28/better-dividend-stock-abbvie-or-johnson-johnson/",
    "time_published": "20240428T082000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "One thing is for sure: Dividend seekers can't go wrong with either.",
    "banner_image": "https://media.ycharts.com/charts/606ca6d7bad2ded63e4e23f32d1c43b2.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.918141"
      }
    ],
    "overall_sentiment_score": 0.215112,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.596349",
        "ticker_sentiment_score": "0.286691",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.051221",
        "ticker_sentiment_score": "0.025897",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.479385",
        "ticker_sentiment_score": "0.29997",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Judge rejects J&J, Bristol Myers Squibb challenges to Medicare drug price negotiations",
    "url": "https://www.cnbc.com/2024/04/29/jj-bristol-myers-squibb-lose-medicare-drug-price-talks-challenges.html",
    "time_published": "20240429T222204",
    "authors": [
      "Annika Kim Constantino"
    ],
    "summary": "The decision is another win for the Biden administration in a bitter legal fight with several drugmakers over the constitutionality of the price talks.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107398685-1712674574391-gettyimages-1593997320-raa-johnsonj230812_npA3P.jpeg?v=1714427697&w=1920&h=1080",
    "source": "CNBC",
    "category_within_source": "Business",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.121913,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVO",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "-0.128057",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.174587",
        "ticker_sentiment_score": "-0.106315",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "-0.015857",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cutting Edge Picks: 3 Med Tech Stocks With Room to Run",
    "url": "https://markets.businessinsider.com/news/stocks/cutting-edge-picks-3-med-tech-stocks-with-room-to-run-1033302252",
    "time_published": "20240429T210742",
    "authors": [
      "Joey Frenette"
    ],
    "summary": "Undoubtedly, investors seem to have a new appetite for next-level revenue growth. Generative AI, GLP-1 weight-loss drugs and other breakthrough innovations ( I'm not sure if the metaverse qualifies right now ) seek to expand in some pretty massive markets.",
    "banner_image": "https://investorplace.com/wp-content/uploads/2020/02/isrg-stock-300x169.jpg",
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.623304"
      }
    ],
    "overall_sentiment_score": 0.295971,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALGN",
        "relevance_score": "0.106541",
        "ticker_sentiment_score": "0.117509",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.05339",
        "ticker_sentiment_score": "-0.017",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.159218",
        "ticker_sentiment_score": "0.153099",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Is a King of Dividend Safety",
    "url": "https://www.fool.com/investing/2024/04/29/johnson-johnson-is-a-king-of-dividend-safety/",
    "time_published": "20240429T142300",
    "authors": [
      "Matt DiLallo"
    ],
    "summary": "The healthcare behemoth has fortified its dividend.",
    "banner_image": "https://media.ycharts.com/charts/5c2ee15090c73ff598de146acb419ed6.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.380671,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.062926",
        "ticker_sentiment_score": "0.184192",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.062926",
        "ticker_sentiment_score": "0.173164",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.614836",
        "ticker_sentiment_score": "0.495553",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "ENA Respiratory Announces FDA IND Clearance for its Prophylactic Intranasal INNA-051 - a First-in-Class Antiviral Innate Immunomodulator",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38482503/ena-respiratory-announces-fda-ind-clearance-for-its-prophylactic-intranasal-inna-051-a-first-in-cl",
    "time_published": "20240429T080000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "MELBOURNE, Australia, April 29, 2024 ( GLOBE NEWSWIRE ) -- ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in at-risk populations, announces today that the U.S.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.215658,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.056674",
        "ticker_sentiment_score": "0.133947",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Spotlight on Johnson & Johnson: Analyzing the Surge in Options Activity - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/options/24/04/38531452/spotlight-on-johnson-johnson-analyzing-the-surge-in-options-activity",
    "time_published": "20240430T184629",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bearish stance on Johnson & Johnson JNJ. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.157822,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.068306",
        "ticker_sentiment_score": "0.139515",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.068306",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.654246",
        "ticker_sentiment_score": "0.294472",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "EPA implements toughest restrictions yet on use of highly toxic chemical in paint stripper",
    "url": "https://www.cnn.com/2024/04/30/health/epa-methylene-chloride-paint-strippers/index.html",
    "time_published": "20240430T130028",
    "authors": [
      "Jen Christensen"
    ],
    "summary": "The US Environmental Protection Agency finalized a rule Tuesday that will end many uses of the highly toxic, cancer-causing solvent methylene chloride. The chemical will still be available for certain purposes, but with new guidelines meant to keep workers safe.",
    "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-1392202076.jpg?c=16x9&q=h_144,w_256,c_fill",
    "source": "CNN",
    "category_within_source": "Markets",
    "source_domain": "www.cnn.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.084712,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "HESG",
        "relevance_score": "0.03319",
        "ticker_sentiment_score": "-0.064286",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBD",
        "relevance_score": "0.03319",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.03319",
        "ticker_sentiment_score": "-0.134419",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Trends In Healthcare Guided By AI And The Companies Behind The Innovation - Johnson & Johnson  ( NYSE:JNJ ) , Cardio Diagnostics Hldgs  ( NASDAQ:CDIO ) ",
    "url": "https://www.benzinga.com/partner/health-care/24/04/38517052/3-trends-in-healthcare-guided-by-ai-and-the-companies-behind-the-innovation",
    "time_published": "20240430T120827",
    "authors": [
      "Jeremy Golden"
    ],
    "summary": "Artificial intelligence ( AI ) is on the cusp of transforming nearly every single industry. When it comes to healthcare, several trends have emerged. As doctors and scientists continue to innovate, the market for AI in healthcare is expanding.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/30/Screenshot-2024-04-30-at-5-36-02PM.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.294133,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CDIO",
        "relevance_score": "0.084423",
        "ticker_sentiment_score": "0.168701",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MFCSF",
        "relevance_score": "0.028188",
        "ticker_sentiment_score": "0.024287",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.276179",
        "ticker_sentiment_score": "0.311727",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.140239",
        "ticker_sentiment_score": "0.070633",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AstraZeneca's Covishield causes rare blood clot disorder TTS: What is it?",
    "url": "https://www.business-standard.com/companies/news/astrazeneca-s-covishield-causes-rare-blood-clot-disorder-tts-what-is-it-124043000340_1.html",
    "time_published": "20240430T070303",
    "authors": [
      "Nandini Singh"
    ],
    "summary": "AstraZeneca, the company that makes the Covishield vaccine for Covid-19 pandemic, has admitted the inoculation has potential side effects.",
    "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2024-04/30/full/1714453725-4118.png?im=FeatureCrop,size=(826,465)",
    "source": "Business Standard",
    "category_within_source": "GoogleRSS",
    "source_domain": "www.business-standard.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.156041,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.570165",
        "ticker_sentiment_score": "-0.198773",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.062926",
        "ticker_sentiment_score": "0.013051",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Indian FMCG industry has been a driver contributing to India's economy, said Manish Anandani at IAA & ISA Retrospect and Prospects",
    "url": "https://www.financialexpress.com/business/brandwagon-the-indianfmcgindustryhas-been-a-driver-contributing-toindiaseconomy-said-manish-anandani-at-iaa-isa-retrospect-and-prospects-3472404/",
    "time_published": "20240430T060527",
    "authors": [
      "BrandWagon Online"
    ],
    "summary": "The India Chapter of the International Advertising Association ( IAA ) in collaboration with The Indian Society of Advertisers ( ISA ) hosted the IAA and ISA Retrospect and Prospects with Manish Anandani, managing director - India, Kenvue ( erstwhile Johnson & Johnson Consumer Health ) on April ...",
    "banner_image": "https://www.financialexpress.com/wp-content/uploads/2024/04/My-project-2024-04-30T113426.023.png",
    "source": "The Financial Express",
    "category_within_source": "n/a",
    "source_domain": "www.financialexpress.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.329582,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.330286",
        "ticker_sentiment_score": "0.27535",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.223866",
        "ticker_sentiment_score": "0.203751",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: DecisionPoint Systems, Inc.  ( NYSE American - DPSI ) , AdTheorent Holding Company, Inc.  ( Nasdaq - ADTH ) , Macatawa Bank Corporation  ( Nasdaq - MCBC ) , Shockwave Medical, Inc.  ( Nasdaq - SWAV ) ",
    "url": "https://www.benzinga.com/pressreleases/24/05/g38562905/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-decisionpoint",
    "time_published": "20240501T191453",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "BALA CYNWYD, Pa., May 01, 2024 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.972756"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.94762"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.271165,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "WTFC",
        "relevance_score": "0.138863",
        "ticker_sentiment_score": "0.224873",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MCBC",
        "relevance_score": "0.069697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.20698",
        "ticker_sentiment_score": "0.062609",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.20698",
        "ticker_sentiment_score": "0.180248",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ADTH",
        "relevance_score": "0.20698",
        "ticker_sentiment_score": "0.20418",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DPSIP",
        "relevance_score": "0.069697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.069697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What's Going With Johnson & Johnson Stock On Wednesday? - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/05/38562078/johnson-johnson-wants-to-deal-with-talc-lawsuit-overhang-proposes-6-5b-settlement-package",
    "time_published": "20240501T184219",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Wednesday, Johnson & Johnson JNJ announced its intention to proceed with a $6.475 billion settlement to resolve numerous lawsuits related to ovarian cancer arising from cosmetic talc litigation.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/01/johnsons-5671315-1920.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.108081,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.616447",
        "ticker_sentiment_score": "-0.235221",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Gene Therapies in Degenerative Retinal Disease Hold Potential to Capture Significant Portion of Market",
    "url": "https://www.benzinga.com/pressreleases/24/05/g38561570/gene-therapies-in-degenerative-retinal-disease-hold-potential-to-capture-significant-portion-of-ma",
    "time_published": "20240501T181736",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "EXTON, PA, May 01, 2024 ( GLOBE NEWSWIRE ) -- In the landscape of healthcare innovation, retinal disorders, including both inherited and degenerative diseases, have become a leading focus area for gene therapy investigation.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.286661,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ADVM",
        "relevance_score": "0.050679",
        "ticker_sentiment_score": "0.188362",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RGNX",
        "relevance_score": "0.050679",
        "ticker_sentiment_score": "0.188362",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.050679",
        "ticker_sentiment_score": "0.188362",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "New to the Market - Life Sciences IPOs;  ( Nasdaq: MNDR )   ( NYSE: PACS )   ( Nasdaq: CTNM ) ",
    "url": "https://www.investorideas.com/news/2024/main/05011Stocks.asp",
    "time_published": "20240501T133826",
    "authors": [],
    "summary": "New to the Market - Life Sciences IPOs. ( Nasdaq: MNDR ) ( NYSE: PACS ...",
    "banner_image": null,
    "source": "Investor Ideas",
    "category_within_source": "n/a",
    "source_domain": "www.investorideas.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.967645"
      }
    ],
    "overall_sentiment_score": 0.308232,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MNDR",
        "relevance_score": "0.04794",
        "ticker_sentiment_score": "0.179769",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PACS",
        "relevance_score": "0.095707",
        "ticker_sentiment_score": "0.126221",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MAMO",
        "relevance_score": "0.04794",
        "ticker_sentiment_score": "0.157769",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ULS",
        "relevance_score": "0.143131",
        "ticker_sentiment_score": "0.379904",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CTNM",
        "relevance_score": "0.04794",
        "ticker_sentiment_score": "0.056862",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.04794",
        "ticker_sentiment_score": "0.056862",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "J&J advances $6.475 billion settlement of talc cancer lawsuits | Business",
    "url": "https://www.cnn.com/2024/05/01/business/j-and-j-talc-cancer-lawsuits-settlement/index.html",
    "time_published": "20240501T133600",
    "authors": [],
    "summary": "Johnson & Johnson moves forward with $6.475 billion settlement of talc cancer lawsuits ...",
    "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-1181904237.jpg?c=16x9&q=w_800,c_fill",
    "source": "CNN",
    "category_within_source": "Markets",
    "source_domain": "www.cnn.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.242776,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.149656",
        "ticker_sentiment_score": "-0.1448",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Forgotten Stock Advice That Delivers 170%+ Payout Growth",
    "url": "https://www.forbes.com/sites/brettowens/2024/05/01/the-forgotten-stock-advice-that-delivers-170-payout-growth/",
    "time_published": "20240501T131500",
    "authors": [
      "Brett Owens"
    ],
    "summary": "One of the best ways to grab a dividend payer set to surge is a strategy you never hear about anymore: Pick up shares of a conglomerate. I know, I know. The word brings to mind \"old school\" companies like 3M ( MMM ) -which we discussed a couple weeks ago-and Honeywell International ( HON ) .",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/662ad1e985461e21e502532f/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.157727,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VLTO",
        "relevance_score": "0.074692",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HON",
        "relevance_score": "0.074692",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DHR",
        "relevance_score": "0.457724",
        "ticker_sentiment_score": "0.258552",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.111834",
        "ticker_sentiment_score": "-0.017918",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics",
    "url": "https://www.globenewswire.com/news-release/2024/05/01/2873221/0/en/Samir-R-Patel-M-D-Appointed-Interim-CEO-for-Akari-Therapeutics.html",
    "time_published": "20240501T120100",
    "authors": [
      "Akari Therapeutics Plc"
    ],
    "summary": "BOSTON and LONDON, May 01, 2024 ( GLOBE NEWSWIRE ) -- Akari Therapeutics, Plc ( Nasdaq: AKTX ) , a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced leadership changes, including the appointment of experienced life sciences entrepreneur ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/8d978f50-07a9-40a3-be69-45f51ccd94d9",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.997902"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.165176,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AKTX",
        "relevance_score": "0.105199",
        "ticker_sentiment_score": "0.149012",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CURN",
        "relevance_score": "0.013188",
        "ticker_sentiment_score": "0.034002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RZLT",
        "relevance_score": "0.013188",
        "ticker_sentiment_score": "0.024376",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.026372",
        "ticker_sentiment_score": "0.026929",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics - Akari Therapeutics  ( NASDAQ:AKTX ) , Peak Bio  ( OTC:PKBO ) ",
    "url": "https://www.benzinga.com/pressreleases/24/05/g38547749/samir-r-patel-m-d-appointed-interim-ceo-for-akari-therapeutics",
    "time_published": "20240501T120100",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "BOSTON and LONDON, May 01, 2024 ( GLOBE NEWSWIRE ) -- Akari Therapeutics, Plc AKTX, a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced leadership changes, including the appointment of experienced life sciences entrepreneur Samir R.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.167436,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AKTX",
        "relevance_score": "0.10361",
        "ticker_sentiment_score": "0.147121",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CURN",
        "relevance_score": "0.012987",
        "ticker_sentiment_score": "0.033928",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RZLT",
        "relevance_score": "0.012987",
        "ticker_sentiment_score": "0.024333",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.025971",
        "ticker_sentiment_score": "0.026861",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "J&J subsidiary proposes paying about USD 6.48B over 25 years to settle talc lawsuits",
    "url": "https://www.business-standard.com/world-news/j-j-subsidiary-proposes-paying-about-usd-6-48b-over-25-years-to-settle-talc-lawsuits-124050100615_1.html",
    "time_published": "20240501T115446",
    "authors": [
      "AP"
    ],
    "summary": "J&J subsidiary proposes paying $6.48 bn over 25 yrs to settle talc lawsuits Business Standard ...",
    "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-05/02/full/1683045756-614.jpg?im=FeatureCrop,size=(826,465)",
    "source": "Business Standard",
    "category_within_source": "GoogleRSS",
    "source_domain": "www.business-standard.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.169448,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "-0.262193",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Stack Capital Invests $8 Million USD Into Canva",
    "url": "https://www.globenewswire.com/news-release/2024/05/01/2873118/0/en/Stack-Capital-Invests-8-Million-USD-Into-Canva.html",
    "time_published": "20240501T113000",
    "authors": [
      "Stack Capital Group Inc."
    ],
    "summary": "Stack Capital is pleased to announce that it has invested US$8 million into Canva, a leading global online design platform.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/499cf09e-5b61-4521-bb8e-af6fd2b41157",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.308501,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PYPL",
        "relevance_score": "0.095138",
        "ticker_sentiment_score": "0.186381",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNEJF",
        "relevance_score": "0.095138",
        "ticker_sentiment_score": "0.186381",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RDDT",
        "relevance_score": "0.095138",
        "ticker_sentiment_score": "0.186381",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SBUX",
        "relevance_score": "0.095138",
        "ticker_sentiment_score": "0.186381",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.095138",
        "ticker_sentiment_score": "0.186381",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "STCGF",
        "relevance_score": "0.717937",
        "ticker_sentiment_score": "0.461161",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "FDX",
        "relevance_score": "0.095138",
        "ticker_sentiment_score": "0.186381",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Did you take Covishield? Doctors advise against panic as AstraZeneca admits to rare side-effects",
    "url": "https://www.financialexpress.com/healthcare/covid-19/did-you-take-covishield-doctors-advise-against-panic-as-astrazeneca-admits-to-rare-side-effects/3474067/",
    "time_published": "20240501T110647",
    "authors": [
      "Sushmita Panda"
    ],
    "summary": "British drugmaker AstraZeneca has admitted that its COVID-19 vaccine can cause a rare side effect of blood clotting and low platelet count after immunisation. The announcement caused panic among the people who took the COVID-19 jab.",
    "banner_image": "https://www.financialexpress.com/wp-content/uploads/2024/05/syringe-g7e75114dd_1920.jpg",
    "source": "The Financial Express",
    "category_within_source": "n/a",
    "source_domain": "www.financialexpress.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.083976,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.161928",
        "ticker_sentiment_score": "0.096388",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.032602",
        "ticker_sentiment_score": "-0.052377",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alkermes plc Reports First Quarter 2024 Financial Results",
    "url": "https://www.prnewswire.com/news-releases/alkermes-plc-reports-first-quarter-2024-financial-results-302132399.html",
    "time_published": "20240501T110000",
    "authors": [
      "Alkermes plc"
    ],
    "summary": "- First Quarter Revenues of $350.4 Million - - GAAP Net Income from Continuing Operations of $38.9 Million and Diluted GAAP Earnings per Share from Continuing Operations of $0.23 - - Company Reiterates 2024 Financial Expectations -",
    "banner_image": "https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      }
    ],
    "overall_sentiment_score": 0.057285,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALKS",
        "relevance_score": "0.544869",
        "ticker_sentiment_score": "-0.006722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.024826",
        "ticker_sentiment_score": "-0.023078",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.024826",
        "ticker_sentiment_score": "-0.023078",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson will pay $6.5 billion to resolve nearly all talc ovarian cancer lawsuits in U.S.",
    "url": "https://www.cnbc.com/2024/05/01/johnson-johnson-will-pay-6point5-billion-to-resolve-nearly-all-talc-ovarian-cancer-lawsuits-in-us.html",
    "time_published": "20240501T103153",
    "authors": [
      "Annika Kim Constantino"
    ],
    "summary": "The deal would allow J&J to resolve the lawsuits through a third bankruptcy filing of a subsidiary company, LTL Management.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107363243-1706035367989-gettyimages-1480096596-0j5a5875_rjbkkqvw.jpeg?v=1714559291&w=1920&h=1080",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.303709,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.295867",
        "ticker_sentiment_score": "-0.458434",
        "ticker_sentiment_label": "Bearish"
      }
    ]
  },
  {
    "title": "3 No-Brainer Stocks to Buy With $200 Right Now",
    "url": "https://www.fool.com/investing/2024/05/01/3-no-brainer-stocks-to-buy-with-200-right-now/",
    "time_published": "20240501T092100",
    "authors": [
      "Sean Williams"
    ],
    "summary": "You don't need a mountain of cash to grow your wealth on Wall Street.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F774971%2Ftwo-hundred-dollars-cash-money-invest-retire-stocks-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.95493"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999767"
      }
    ],
    "overall_sentiment_score": 0.258629,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "FVRR",
        "relevance_score": "0.268458",
        "ticker_sentiment_score": "0.222913",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.210405",
        "ticker_sentiment_score": "0.093093",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AstraZeneca responds to Covishield vaccine concerns: Here's what they said",
    "url": "https://www.business-standard.com/health/astrazeneca-responds-to-covishield-vaccine-concerns-here-s-what-they-said-124050100180_1.html",
    "time_published": "20240501T051827",
    "authors": [
      "Vasudha Mukherjee"
    ],
    "summary": "In response to growing concerns surrounding potential side effects linked to the AstraZeneca-Oxford Covid-19 vaccine, the pharmaceutical giant restated its dedication to patient safety.",
    "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2021-09/03/full/1630670072-8609.jpg?im=FeatureCrop,size=(826,465)",
    "source": "Business Standard",
    "category_within_source": "GoogleRSS",
    "source_domain": "www.business-standard.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.01956,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.504646",
        "ticker_sentiment_score": "0.068946",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.108466",
        "ticker_sentiment_score": "-0.07396",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AstraZeneca reaffirms Covid vaccine safety amid rare side effect concerns",
    "url": "https://www.business-standard.com/amp/health/astrazeneca-reaffirms-covid-vaccine-safety-amid-rare-side-effect-concerns-124050100053_1.html",
    "time_published": "20240501T020317",
    "authors": [
      "ANI"
    ],
    "summary": "In light of recent concerns surrounding potential rare side effects of the AstraZeneca-Oxford COVID-19 vaccine, the pharmaceutical giant has reiterated its commitment to patient safety while emphasising the vaccine's overall safety profile.",
    "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2024-04/29/thumb/fitandfill/400X400/1714409459-4744.jpg",
    "source": "Business Standard",
    "category_within_source": "GoogleRSS",
    "source_domain": "www.business-standard.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.012243,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.391311",
        "ticker_sentiment_score": "0.178844",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.081552",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AstraZeneca reaffirms Covid vaccine safety amid rare side effect concerns",
    "url": "https://www.business-standard.com/health/astrazeneca-reaffirms-covid-vaccine-safety-amid-rare-side-effect-concerns-124050100053_1.html",
    "time_published": "20240501T020317",
    "authors": [
      "ANI"
    ],
    "summary": "AstraZeneca has made the admission in court documents in connection with a case that alleges that the vaccine, developed with the University of Oxford, caused death and serious injury in dozens of cases. ( Photo: Wikimedia Commons )",
    "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2024-04/29/full/1714409459-4744.jpg?im=FitAndFill=(826,465)",
    "source": "Business Standard",
    "category_within_source": "GoogleRSS",
    "source_domain": "www.business-standard.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.022023,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.43852",
        "ticker_sentiment_score": "0.057284",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.077094",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Genmab Announces Financial Results for the First Quarter of 2024",
    "url": "https://www.globenewswire.com/news-release/2024/05/02/2874427/0/en/Genmab-Announces-Financial-Results-for-the-First-Quarter-of-2024.html",
    "time_published": "20240502T150100",
    "authors": [
      "Genmab A/S"
    ],
    "summary": "May 2, 2024 Copenhagen, Denmark. Interim Report for the First Quarter Ended March ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.156708,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVS",
        "relevance_score": "0.030524",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.15173",
        "ticker_sentiment_score": "0.110284",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GMAB",
        "relevance_score": "0.407844",
        "ticker_sentiment_score": "0.175143",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.061003",
        "ticker_sentiment_score": "0.209114",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.030524",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "PDS Biotech Appoints Stephan Toutain as Chief Operating Officer",
    "url": "https://www.globenewswire.com/news-release/2024/05/02/2874120/37149/en/PDS-Biotech-Appoints-Stephan-Toutain-as-Chief-Operating-Officer.html",
    "time_published": "20240502T120000",
    "authors": [
      "PDS Biotechnology Corporation"
    ],
    "summary": "Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/e2e7d124-dbd4-4140-9cc5-449d3488a902",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.995973"
      }
    ],
    "overall_sentiment_score": 0.176757,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALNY",
        "relevance_score": "0.027351",
        "ticker_sentiment_score": "0.035637",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SRPT",
        "relevance_score": "0.027351",
        "ticker_sentiment_score": "0.035637",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PDSB",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.061842",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVXL",
        "relevance_score": "0.027351",
        "ticker_sentiment_score": "0.035637",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.027351",
        "ticker_sentiment_score": "0.035637",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "PDS Biotech Appoints Stephan Toutain as Chief Operating Officer - PDS Biotechnology  ( NASDAQ:PDSB ) ",
    "url": "https://www.benzinga.com/pressreleases/24/05/g38579999/pds-biotech-appoints-stephan-toutain-as-chief-operating-officer",
    "time_published": "20240502T120000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "PRINCETON, N.J., May 02, 2024 ( GLOBE NEWSWIRE ) -- PDS Biotechnology Corporation PDSB ( \"PDS Biotech\" or the \"Company\" ) , a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998333"
      }
    ],
    "overall_sentiment_score": 0.176583,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALNY",
        "relevance_score": "0.026127",
        "ticker_sentiment_score": "0.035383",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SRPT",
        "relevance_score": "0.026127",
        "ticker_sentiment_score": "0.035383",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PDSB",
        "relevance_score": "0.155786",
        "ticker_sentiment_score": "0.066955",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVXL",
        "relevance_score": "0.026127",
        "ticker_sentiment_score": "0.035383",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.026127",
        "ticker_sentiment_score": "0.035383",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nasdaq, S&P 500 Futures Rise Ahead Of Apple Earnings: What's Going On With Stock Market? - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/05/38576979/nasdaq-s-p-500-futures-rise-ahead-of-apple-earnings-why-this-analyst-thinks-no-cut-scenario-may-not",
    "time_published": "20240502T105251",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "U.S. stocks look to push ahead on a positive path, now that the Federal Reserve's rate decision is in the rearview mirror. Major index futures point to a positive open on Thursday.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/02/Wall-Street.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.081907,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AAPL",
        "relevance_score": "0.133655",
        "ticker_sentiment_score": "-0.055256",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.097849",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXPE",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOVA",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.020026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UPWK",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.020026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DASH",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.020026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PENN",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTGR",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.020026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "W",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KLIC",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.020026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "X",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZTS",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CYBR",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "Z",
        "relevance_score": "0.033562",
        "ticker_sentiment_score": "0.018657",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FIVN",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BKNG",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ED",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DKNG",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COP",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ILMN",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MNST",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LYV",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ICE",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RGA",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KIM",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OPEN",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FSLR",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.020026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MGM",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.020026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EBAY",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.020026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ETSY",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.020026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REG",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WOLF",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.020026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NET",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QRVO",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.020026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PXD",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.097849",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.029538",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "BioSig Technologies, Inc. Announces New Appointments to its Now Fully Constituted Board of Directors, which is Comprised of 5 Board Members, 3 Independent",
    "url": "https://www.globenewswire.com/news-release/2024/05/03/2875283/22558/en/BioSig-Technologies-Inc-Announces-New-Appointments-to-its-Now-Fully-Constituted-Board-of-Directors-which-is-Comprised-of-5-Board-Members-3-Independent.html",
    "time_published": "20240503T162200",
    "authors": [
      "BioSig Technologies",
      "Inc."
    ],
    "summary": "Westport, CT, May 03, 2024 ( GLOBE NEWSWIRE ) -- BioSig Technologies, Inc. ( NASDAQ: BSGM ) or ( \"BioSig\" or \"the Company\" ) , a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced new appointments to its now fully ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/1dac0368-d181-4bc1-af5d-f95010be6bdc",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.744043"
      }
    ],
    "overall_sentiment_score": 0.167241,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BSGM",
        "relevance_score": "0.070379",
        "ticker_sentiment_score": "0.127668",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.023487",
        "ticker_sentiment_score": "0.043421",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.046953",
        "ticker_sentiment_score": "0.047568",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "BioSig Technologies, Inc. Announces New Appointments to its Now Fully Constituted Board of Directors, which is Comprised of 5 Board Members, 3 Independent - BioSig Technologies  ( NASDAQ:BSGM ) ",
    "url": "https://www.benzinga.com/pressreleases/24/05/g38619231/biosig-technologies-inc-announces-new-appointments-to-its-now-fully-constituted-board-of-directors",
    "time_published": "20240503T162200",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Westport, CT, May 03, 2024 ( GLOBE NEWSWIRE ) -- BioSig Technologies, Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.839681"
      }
    ],
    "overall_sentiment_score": 0.167188,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BSGM",
        "relevance_score": "0.068962",
        "ticker_sentiment_score": "0.117451",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.023013",
        "ticker_sentiment_score": "0.043296",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.046006",
        "ticker_sentiment_score": "0.047485",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates UNIT, SWAV, IP, NX - International Paper  ( NYSE:IP ) , Quanex Building Prods  ( NYSE:NX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/05/g38618931/shareholder-investigation-halper-sadeh-llc-investigates-unit-swav-ip-nx",
    "time_published": "20240503T160954",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, May 03, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Uniti Group Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.090834,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LPUSF",
        "relevance_score": "0.093289",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNIT",
        "relevance_score": "0.274834",
        "ticker_sentiment_score": "-0.075691",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.185306",
        "ticker_sentiment_score": "0.065791",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IP",
        "relevance_score": "0.360752",
        "ticker_sentiment_score": "0.110941",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.093289",
        "ticker_sentiment_score": "0.081384",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NX",
        "relevance_score": "0.093289",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.093289",
        "ticker_sentiment_score": "0.081384",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Kuehn Law Encourages IP, SWAV, NX, and UNIT Investors to Contact Law Firm - International Paper  ( NYSE:IP ) , Quanex Building Prods  ( NYSE:NX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/05/g38616188/kuehn-law-encourages-ip-swav-nx-and-unit-investors-to-contact-law-firm",
    "time_published": "20240503T144756",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, May 03, 2024 ( GLOBE NEWSWIRE ) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.289685,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LPUSF",
        "relevance_score": "0.217834",
        "ticker_sentiment_score": "0.307429",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNIT",
        "relevance_score": "0.217834",
        "ticker_sentiment_score": "0.194579",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.217834",
        "ticker_sentiment_score": "0.303822",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IP",
        "relevance_score": "0.321673",
        "ticker_sentiment_score": "0.402405",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.109956",
        "ticker_sentiment_score": "0.274329",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NX",
        "relevance_score": "0.109956",
        "ticker_sentiment_score": "0.206737",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.109956",
        "ticker_sentiment_score": "0.274329",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks",
    "url": "https://www.zacks.com/stock/news/2267786/how-to-maximize-your-retirement-portfolio-with-these-top-ranked-dividend-stocks",
    "time_published": "20240503T131002",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default257.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.232802,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IBTX",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.080215",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.21258",
        "ticker_sentiment_score": "0.123104",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  is Attracting Investor Attention: Here is What You Should Know",
    "url": "https://www.zacks.com/stock/news/2267759/johnson-johnson-jnj-is-attracting-investor-attention-here-is-what-you-should-know",
    "time_published": "20240503T130012",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default331.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.217815,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.473208",
        "ticker_sentiment_score": "0.102884",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Robotic Surgeon Will See You Now",
    "url": "https://www.investors.com/news/technology/intuitive-surgical-stock-isrg-robotic-surgery-medtronic-jnj/",
    "time_published": "20240503T123000",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Intuitive Surgical Stock Builds On Its Robotic Surgery Prowess, But Challengers Loom Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/05/wRobSurgGrth-050624-300x239.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999897"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.167233,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BAC",
        "relevance_score": "0.013561",
        "ticker_sentiment_score": "0.124188",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PRCT",
        "relevance_score": "0.027118",
        "ticker_sentiment_score": "0.026302",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.08123",
        "ticker_sentiment_score": "-0.005169",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLVT",
        "relevance_score": "0.027118",
        "ticker_sentiment_score": "-0.027055",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GLDAF",
        "relevance_score": "0.027118",
        "ticker_sentiment_score": "0.133624",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.094709",
        "ticker_sentiment_score": "0.061916",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.329112",
        "ticker_sentiment_score": "0.049837",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Dividend Growth Stocks that Just Raised Their Payouts",
    "url": "https://www.fool.com/investing/2024/05/03/3-dividend-growth-stocks-just-raised-their-payouts/",
    "time_published": "20240503T123000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "One of these stocks boosted its payouts by as much as 13%.",
    "banner_image": "https://g.foolcdn.com/editorial/images/774676/a-couple-counting-money.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.347859,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SO",
        "relevance_score": "0.261678",
        "ticker_sentiment_score": "0.196639",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.3115",
        "ticker_sentiment_score": "0.11925",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TJX",
        "relevance_score": "0.3115",
        "ticker_sentiment_score": "0.472642",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Pharma giant adds Israel to list of Middle East markets after omission raises questions",
    "url": "https://www.foxbusiness.com/lifestyle/pharma-giant-adds-israel-list-middle-east-markets-omission-raises-questions",
    "time_published": "20240505T172400",
    "authors": [
      "Stephen Sorace"
    ],
    "summary": "Johnson & Johnson has added Israel to its directory of global markets on the company's order management website after sparking questions over why the list included \"Palestine\" and not the Jewish state.",
    "banner_image": "https://cf-images.us-east-1.prod.boltdns.net/v1/static/854081161001/c85d6142-c7d0-4c9b-a7ea-4d4aea4ea4c5/7c7e4ed8-6b70-42ee-b3af-73aaba2905b0/1280x720/match/image.jpg",
    "source": "Fox Business News",
    "category_within_source": "n/a",
    "source_domain": "www.foxbusiness.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": -0.04289,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "FOX",
        "relevance_score": "0.328455",
        "ticker_sentiment_score": "-0.085045",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.475251",
        "ticker_sentiment_score": "-0.009277",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Advances Its Two Bladder Cancer Studies, Releases Latest Data - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/05/38650661/johnson-johnson-advances-its-two-bladder-cancer-studies-releases-latest-data",
    "time_published": "20240506T181036",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Sunday, Johnson & Johnson JNJ ) released updated results from an open-label, multicenter, multi-cohort Phase 1 study of TAR-210 in patients with non-muscle-invasive bladder cancer ( NMIBC ) with select FGFR alterations.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/06/Johnson-and-Johnson.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.11783,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.402618",
        "ticker_sentiment_score": "-0.424065",
        "ticker_sentiment_label": "Bearish"
      }
    ]
  },
  {
    "title": "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: DecisionPoint Systems, Inc.  ( NYSE American - DPSI ) , AdTheorent Holding Company, Inc.  ( Nasdaq - ADTH ) , Macatawa Bank Corporation  ( Nasdaq - MCBC ) , Shockwave Medical, Inc.  ( Nasdaq - SWAV ) ",
    "url": "https://www.benzinga.com/pressreleases/24/05/g38648423/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-decisionpoint",
    "time_published": "20240506T162139",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "BALA CYNWYD, Pa., May 06, 2024 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.972756"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.94762"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.271165,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "WTFC",
        "relevance_score": "0.138863",
        "ticker_sentiment_score": "0.224873",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MCBC",
        "relevance_score": "0.069697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.20698",
        "ticker_sentiment_score": "0.062609",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.20698",
        "ticker_sentiment_score": "0.180248",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ADTH",
        "relevance_score": "0.20698",
        "ticker_sentiment_score": "0.20418",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DPSIP",
        "relevance_score": "0.069697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.069697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Comparing Johnson & Johnson With Industry Competitors In Pharmaceuticals Industry - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/news/24/05/38646233/comparing-johnson-amp-johnson-with-industry-competitors-in-pharmaceuticals-industry",
    "time_published": "20240506T150034",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In the fast-paced and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Johnson & Johnson JNJ in comparison to its major competitors within the ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.138148,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.06211",
        "ticker_sentiment_score": "0.13906",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.414559",
        "ticker_sentiment_score": "0.271566",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Kenvue  ( KVUE )  Q1 2024 Earnings Call Transcript",
    "url": "https://www.fool.com/earnings/call-transcripts/2024/05/07/kenvue-kvue-q1-2024-earnings-call-transcript/",
    "time_published": "20240507T190014",
    "authors": [
      "Motley Fool Transcribing"
    ],
    "summary": "KVUE earnings call for the period ending March 31, 2024.",
    "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.356644,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.106352",
        "ticker_sentiment_score": "0.199301",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.005333",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.005333",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.005333",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.005333",
        "ticker_sentiment_score": "0.144743",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson's TARIS Platform - Goldman Sachs Outlines Potential For The Bladder Cancer Therapy - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38679466/johnson-johnsons-taris-platform-goldman-sachs-outlines-potential-for-the-bladder-ca",
    "time_published": "20240507T183150",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Over the weekend, Johnson & Johnson JNJ shared data from its TARIS platform assets ( TAR-210 and TAR-200 ) in patients with different types of bladder cancer. Goldman Sachs notes that the company has framed the platform as having a peak revenue potential of over $5 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/07/jnj-johnson-shutter_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.070197,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.151539",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.660632",
        "ticker_sentiment_score": "0.22017",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Q1 Earnings Season Scorecard and Fresh Analyst Reports for Tesla, JNJ & Netflix",
    "url": "https://www.zacks.com/research-daily/2269663/q1-earnings-season-scorecard-and-fresh-analyst-reports-for-tesla-jnj-netflix",
    "time_published": "20240507T161300",
    "authors": [
      "Sheraz Mian"
    ],
    "summary": "Today's Research Daily features the Q1 earnings season scorecard and updated analyst reports on Tesla (TSLA), JNJ (JNJ), Netflix (NFLX) and others.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default131.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.998947"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.267042,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.16073",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.065327",
        "ticker_sentiment_score": "0.010117",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.051419",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "A Look at Pharma ETFs Post Q1 Earnings",
    "url": "https://www.zacks.com/stock/news/2269782/a-look-at-pharma-etfs-post-q1-earnings",
    "time_published": "20240507T153000",
    "authors": [
      "Sweta Killa"
    ],
    "summary": "Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999989"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.05748,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.156207",
        "ticker_sentiment_score": "0.043449",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.032119",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.078482",
        "ticker_sentiment_score": "-0.002079",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.156207",
        "ticker_sentiment_score": "0.035777",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Shockwave Medical  ( SWAV )  Q1 Earnings Beat, Revenues Rise Y/Y",
    "url": "https://www.zacks.com/stock/news/2269735/shockwave-medical-swav-q1-earnings-beat-revenues-rise-yy",
    "time_published": "20240507T142700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Shockwave Medical's (SWAV) first-quarter results reflect robust revenue growth and gross margin expansion amid JNJ entering into a definitive agreement to acquire the company.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/80/66138.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.998663"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.194997,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALGN",
        "relevance_score": "0.24289",
        "ticker_sentiment_score": "0.038896",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.24289",
        "ticker_sentiment_score": "0.033063",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.646507",
        "ticker_sentiment_score": "0.450481",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ECL",
        "relevance_score": "0.18343",
        "ticker_sentiment_score": "0.095586",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.24289",
        "ticker_sentiment_score": "0.326496",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Perrigo Announces Executive Transition for its Consumer Self-Care International  ( CSCI )  Business",
    "url": "https://www.prnewswire.com/news-releases/perrigo-announces-executive-transition-for-its-consumer-self-care-international-csci-business-302138020.html",
    "time_published": "20240507T102800",
    "authors": [
      "Perrigo Company plc"
    ],
    "summary": "DUBLIN, May 7, 2024 /PRNewswire/ -- Perrigo Company plc ( NYSE: PRGO ) , a leading provider of Consumer Self-Care Products, today announced that Svend Andersen, Executive Vice President and President, Consumer Self-Care International ( CSCI ) , intends to retire from the Company in December of ...",
    "banner_image": "https://mma.prnewswire.com/media/2394816/Perrigo_Logo_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.481993,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.106778",
        "ticker_sentiment_score": "0.140826",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LRLCF",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.127964",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.127964",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PRGO",
        "relevance_score": "0.685927",
        "ticker_sentiment_score": "0.732299",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Q3 2023/24 - First sale of the XM30 completed",
    "url": "https://www.globenewswire.com/news-release/2024/05/08/2878075/0/en/Q3-2023-24-First-sale-of-the-XM30-completed.html",
    "time_published": "20240508T162000",
    "authors": [
      "Chemometec A/S"
    ],
    "summary": "ANNOUNCEMENT NO. ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.079925,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.020096",
        "ticker_sentiment_score": "0.035386",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.020096",
        "ticker_sentiment_score": "0.035386",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.020096",
        "ticker_sentiment_score": "0.035386",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Preparations for CIIE 2024 in full swing - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/preparations-for-ciie-2024-in-full-swing-302139776.html",
    "time_published": "20240508T123000",
    "authors": [],
    "summary": "Preparations for CIIE 2024 in full swing PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.251097,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.070935",
        "ticker_sentiment_score": "0.210566",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.070935",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FXNC",
        "relevance_score": "0.14131",
        "ticker_sentiment_score": "0.072158",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HYMLF",
        "relevance_score": "0.070935",
        "ticker_sentiment_score": "0.13076",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.070935",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Got $1,000? 3 Dividend Stocks to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/05/08/got-1000-3-dividend-stocks-to-buy-and-hold-forever/",
    "time_published": "20240508T111600",
    "authors": [
      "Justin Pope"
    ],
    "summary": "Check out these healthcare stocks for some healthy payouts.",
    "banner_image": "https://g.foolcdn.com/editorial/images/773558/johnson_and_johnson_employee_with_beaker_and_logo_on_coat_jnj-2.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.361249,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.046095",
        "ticker_sentiment_score": "0.094413",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.271274",
        "ticker_sentiment_score": "0.238629",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.046095",
        "ticker_sentiment_score": "0.149314",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.271274",
        "ticker_sentiment_score": "0.277996",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Tesla, Johnson & Johnson, Netflix, Abbott and ConocoPhillips",
    "url": "https://www.zacks.com/stock/news/2270202/the-zacks-analyst-blog-highlights-tesla-johnson-johnson-netflix-abbott-and-conocophillips",
    "time_published": "20240508T101800",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Tesla, Johnson & Johnson, Netflix, Abbott and ConocoPhillips are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/04/590.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.285535,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.355588",
        "ticker_sentiment_score": "0.190577",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.146469",
        "ticker_sentiment_score": "0.037354",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.218161",
        "ticker_sentiment_score": "0.049508",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COP",
        "relevance_score": "0.146469",
        "ticker_sentiment_score": "0.037354",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.288044",
        "ticker_sentiment_score": "0.050653",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "A Look at Pharma ETFs Post Q1 Earnings - Bristol-Myers Squibb  ( NYSE:BMY ) , First Trust Nasdaq Pharmaceuticals ETF  ( NASDAQ:FTXH ) ",
    "url": "https://www.benzinga.com/news/earnings/24/05/38676365/a-look-at-pharma-etfs-post-q1-earnings",
    "time_published": "20240509T144107",
    "authors": [
      "Zacks"
    ],
    "summary": "The first-quarter results of the healthcare sector have been unimpressive, with earnings of 78% of the sector participants that have reported so far down 31.2% despite 4.4% revenue growth. The earnings beat ratio of 93.9% and the revenue beat ratio of 75.8% are assuring, though.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/07/kenny-eliason-8fdhgan5zg0-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999992"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.081562,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.161982",
        "ticker_sentiment_score": "0.054951",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.121856",
        "ticker_sentiment_score": "0.038677",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.121856",
        "ticker_sentiment_score": "-0.002404",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.121856",
        "ticker_sentiment_score": "0.060941",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Top Dividend Stocks to Maximize Your Retirement Income",
    "url": "https://www.zacks.com/stock/news/2271312/3-top-dividend-stocks-to-maximize-your-retirement-income",
    "time_published": "20240509T131003",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default169.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.166023,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IBTX",
        "relevance_score": "0.104228",
        "ticker_sentiment_score": "0.079489",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.206685",
        "ticker_sentiment_score": "0.120441",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the VanEck Pharmaceutical ETF  ( PPH ) ?",
    "url": "https://www.zacks.com/stock/news/2271115/should-you-invest-in-the-vaneck-pharmaceutical-etf-pph",
    "time_published": "20240509T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for PPH ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default274.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      }
    ],
    "overall_sentiment_score": 0.1496,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.061272",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.042878",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.061272",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.061272",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What Is the Dividend Payout for Johnson & Johnson Stock?",
    "url": "https://www.fool.com/investing/2024/05/09/what-is-the-dividend-payout-for-johnson-johnson-st/",
    "time_published": "20240509T090700",
    "authors": [
      "Matt DiLallo"
    ],
    "summary": "Here's a closer look at the healthcare behemoth's dividend.",
    "banner_image": "https://media.ycharts.com/charts/a9d174eb732f6964ea6e6eb04c49e839.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.266078,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.795859",
        "ticker_sentiment_score": "0.445272",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AGS, SWAV, HRT - PlayAGS  ( NYSE:AGS ) , HireRight Holdings  ( NYSE:HRT ) ",
    "url": "https://www.benzinga.com/pressreleases/24/05/g38761292/shareholder-investigation-halper-sadeh-llc-investigates-ags-swav-hrt",
    "time_published": "20240510T135119",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, May 10, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.140797,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "HRT",
        "relevance_score": "0.232439",
        "ticker_sentiment_score": "0.102575",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AGS",
        "relevance_score": "0.232439",
        "ticker_sentiment_score": "0.118227",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.08744",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.08744",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "James Brodie of Johnson & Johnson MedTech Appointed Chair of the Medtech Canada Board of Directors - Canada NewsWire",
    "url": "https://www.newswire.ca/news-releases/james-brodie-of-johnson-amp-johnson-medtech-appointed-chair-of-the-medtech-canada-board-of-directors-866765198.html",
    "time_published": "20240510T130000",
    "authors": [],
    "summary": "James Brodie of Johnson & Johnson MedTech Appointed Chair of the Medtech Canada Board of Directors Canada ...",
    "banner_image": null,
    "source": "Canada Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.newswire.ca",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.416029,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SOLV",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.031972",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EW",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.07497",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FSNUF",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.031972",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.07497",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.172919",
        "ticker_sentiment_score": "0.111187",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.031972",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.031972",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLPBY",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.07497",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CNVVF",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.183",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Prediction: 3 Sensational Stocks That'll Be Worth Far More Than Tesla 2 Years From Now",
    "url": "https://www.fool.com/investing/2024/05/10/prediction-3-stocks-worth-more-than-tesla-2-years/",
    "time_published": "20240510T092100",
    "authors": [
      "Sean Williams"
    ],
    "summary": "Three time-tested businesses have the necessary catalysts to blow past electric-vehicle (EV) maker Tesla by 2026.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F776656%2Fstock-chart-quote-bear-bull-trading-invest-short-options-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.223225,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TSLA",
        "relevance_score": "0.30928",
        "ticker_sentiment_score": "0.246034",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TWOH",
        "relevance_score": "0.031738",
        "ticker_sentiment_score": "0.132526",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.249744",
        "ticker_sentiment_score": "0.052856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.188683",
        "ticker_sentiment_score": "0.130399",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.15769",
        "ticker_sentiment_score": "0.119188",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Tale of misleading advertising! From Patanjali, Cadbury, and Nestle to Johnson & Johnson",
    "url": "https://www.financialexpress.com/business/brandwagon-tale-of-misleading-advertising-from-patanjali-cadbury-and-nestle-to-johnson-amp-johnsonnbsp-3482625/",
    "time_published": "20240510T023000",
    "authors": [
      "Shailja Tiwari"
    ],
    "summary": "What is the role of an advertisement? Simply place a brand in the spotlight to be able to gain consumer attention. The advertisement is further built on a narrative where claims are made to project its unique proposition to consumers.",
    "banner_image": "https://www.financialexpress.com/wp-content/uploads/2024/05/Shailja-15.png",
    "source": "The Financial Express",
    "category_within_source": "n/a",
    "source_domain": "www.financialexpress.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.058922,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NDLS",
        "relevance_score": "0.047749",
        "ticker_sentiment_score": "-0.092969",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NSRGF",
        "relevance_score": "0.07157",
        "ticker_sentiment_score": "-0.007185",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.047749",
        "ticker_sentiment_score": "-0.141696",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UL",
        "relevance_score": "0.023885",
        "ticker_sentiment_score": "0.137204",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Mitch McConnell's Cannabis Gambit: How The Farm Bill Unwittingly Fueled A THC Boom",
    "url": "https://www.benzinga.com/markets/cannabis/24/05/35598477/mitch-mcconnells-cannabis-gambit-how-the-farm-bill-unwittingly-fueled-a-thc-boom",
    "time_published": "20240512T165029",
    "authors": [
      "MG Magazine"
    ],
    "summary": "This article was originally published on MG Magazine and appears here with permission. There is no shortage of unintended legislative consequences in the brief history of legal cannabis, but the 2018 Agricultural Improvement Act-popularly known as the Farm Bill-may take the cake.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/03/shelby-ireland-aemwnj1q8jg-unsplash_4.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.09422,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "WYCC",
        "relevance_score": "0.011855",
        "ticker_sentiment_score": "0.11079",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.011855",
        "ticker_sentiment_score": "0.111127",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Forget Johnson & Johnson: Buy This Better Healthcare Stock Instead",
    "url": "https://www.fool.com/investing/2024/05/12/forget-johnson-johnson-buy-this-cheaper-healthcare/",
    "time_published": "20240512T122000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Johnson & Johnson isn't the ultra-safe stock it used to be.",
    "banner_image": "https://g.foolcdn.com/editorial/images/775882/a-doctor-looking-at-a-tablet-with-another-person.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999998"
      }
    ],
    "overall_sentiment_score": 0.070475,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.575055",
        "ticker_sentiment_score": "0.197614",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.700373",
        "ticker_sentiment_score": "0.050536",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "1 Passive Income Vehicle Every Investor Should Own",
    "url": "https://www.fool.com/investing/2024/05/12/1-passive-income-vehicle-every-investor-should-own/",
    "time_published": "20240512T110000",
    "authors": [
      "George Budwell"
    ],
    "summary": "This healthcare giant is a rock-solid passive income play.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F777012%2Fpassive-income.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.41516,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.139265",
        "ticker_sentiment_score": "0.155943",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Local governments struggle to distribute their share of billions from opioid settlements",
    "url": "https://apnews.com/article/opioid-settlement-small-towns-local-governments-5daabce1ac8da004f94df0cc0b288e43",
    "time_published": "20240512T045100",
    "authors": [
      "GEOFF MULVIHILL"
    ],
    "summary": "Settlement money to help stem the decades-long opioid addiction and overdose epidemic is rolling out to small towns and big cities across the U.S., but advocates worry that chunks of it may be used in ways that don't make a dent in the crisis.",
    "banner_image": "https://dims.apnews.com/dims4/default/678b788/2147483647/strip/true/crop/3936x2622+0+1/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F4a%2F81%2F1a93bba23120e8a479c550d6bd53%2Ff3615d2648614ece84ec11c1256f25c6",
    "source": "Associated Press",
    "category_within_source": "Business",
    "source_domain": "apnews.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.106467,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CVS",
        "relevance_score": "0.032825",
        "ticker_sentiment_score": "-0.065384",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.032825",
        "ticker_sentiment_score": "-0.065384",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Could Be a Great Choice",
    "url": "https://www.zacks.com/stock/news/2272999/johnson-johnson-jnj-could-be-a-great-choice",
    "time_published": "20240513T154508",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default73.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.96136"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999365"
      }
    ],
    "overall_sentiment_score": 0.413082,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.436009",
        "ticker_sentiment_score": "0.484927",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "2 Supercharged Dividend Stocks to Buy and Hold for Years",
    "url": "https://www.fool.com/investing/2024/05/13/2-supercharged-dividend-stocks-to-buy-and-hold-for/",
    "time_published": "20240513T113000",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "Consistent passive income is one top goal long-term investors should have for their portfolio.",
    "banner_image": "https://g.foolcdn.com/editorial/images/776589/smiling-investor-throwing-money-in-the-air.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      }
    ],
    "overall_sentiment_score": 0.205767,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.046724",
        "ticker_sentiment_score": "0.074888",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.230454",
        "ticker_sentiment_score": "0.144505",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.185306",
        "ticker_sentiment_score": "0.162214",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Senhwa Biosciences Announces Jason Huang, MD as New Chief Medical Officer",
    "url": "https://www.prnewswire.com/news-releases/senhwa-biosciences-announces-jason-huang-md-as-new-chief-medical-officer-302143219.html",
    "time_published": "20240513T110000",
    "authors": [
      "Inc.",
      "Senhwa Biosciences"
    ],
    "summary": "NEW TAIPEI CITY, May 13, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. ( TPEx: 6492 ) , announced the appointment of Jason Huang, M.D., former Regional Therapeutic Area Expert ( RTAE ) , Janssen, a subsidiary of Johnson and Johnson, as the company's chief medical officer.",
    "banner_image": "https://mma.prnewswire.com/media/1933477/Senhwa_Logo_Logo_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.285702,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.175549",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Get Decades of Passive Income From This High-Dividend-Yield ETF",
    "url": "https://www.fool.com/investing/2024/05/13/get-passive-income-from-high-dividend-etf/",
    "time_published": "20240513T105000",
    "authors": [
      "Demitri Kalogeropoulos"
    ],
    "summary": "This cheap fund offers diversification and passive income.",
    "banner_image": "https://g.foolcdn.com/editorial/images/776781/businessman-working-on-laptop-with-diagram-graph-on-computer.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.9996"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.327614,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PEP",
        "relevance_score": "0.074692",
        "ticker_sentiment_score": "0.225779",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.074692",
        "ticker_sentiment_score": "0.100243",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.074692",
        "ticker_sentiment_score": "0.100243",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.074692",
        "ticker_sentiment_score": "0.151724",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.074692",
        "ticker_sentiment_score": "0.151724",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Pre-Settlement Legal Funding News: New Hampshire Jury Awards $38MM to David Meehan Sex Abuse Victim in Youth Detention Center  ( YDC )  Bellwether Case",
    "url": "https://www.prnewswire.com/news-releases/pre-settlement-legal-funding-news-new-hampshire-jury-awards-38mm-to-david-meehan-sex-abuse-victim-in-youth-detention-center-ydc-bellwether-case-302142994.html",
    "time_published": "20240513T101500",
    "authors": [
      "LLC",
      "Legal-Bay"
    ],
    "summary": "Pre-Settlement Legal Funding News: New Hampshire Jury Awards $38MM to David Meehan Sex Abuse Victim in ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/126845/legal_bay_llc_logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": -0.054008,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.030998",
        "ticker_sentiment_score": "-0.254509",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "MDMA therapy could be legalized by summer. Why are so many advocates sounding the alarm?",
    "url": "https://www.businessinsider.com/mdma-therapy-maps-lykos-rick-doblin-fda-legalization-trials-2024-5",
    "time_published": "20240513T100100",
    "authors": [
      "Anna Silman"
    ],
    "summary": "MDMA Therapy May Be Legal Soon. Some Advocates Are Sounding the Alarm. - Business Insider ...",
    "banner_image": null,
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "www.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.043221,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.010619",
        "ticker_sentiment_score": "0.038361",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMPS",
        "relevance_score": "0.00531",
        "ticker_sentiment_score": "0.020317",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.00531",
        "ticker_sentiment_score": "0.033015",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.00531",
        "ticker_sentiment_score": "0.018027",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EBAY",
        "relevance_score": "0.00531",
        "ticker_sentiment_score": "-0.022615",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.00531",
        "ticker_sentiment_score": "0.018304",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NYT",
        "relevance_score": "0.00531",
        "ticker_sentiment_score": "0.042607",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.00531",
        "ticker_sentiment_score": "0.042607",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNXYF",
        "relevance_score": "0.00531",
        "ticker_sentiment_score": "-0.010438",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Notification of managers' transactions",
    "url": "https://www.globenewswire.com/news-release/2024/05/13/2880171/0/en/Notification-of-managers-transactions.html",
    "time_published": "20240513T090500",
    "authors": [
      "Chemometec A/S"
    ],
    "summary": "ANNOUNCEMENT NO. ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.117406,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.279015",
        "ticker_sentiment_score": "0.082681",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.279015",
        "ticker_sentiment_score": "0.082681",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.279015",
        "ticker_sentiment_score": "0.082681",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Sugar in cereals, pesticides in spices; why we struggle to keep food safeBa",
    "url": "https://www.business-standard.com/india-news/sugar-in-cereals-pesticides-in-spices-why-we-struggle-to-keep-food-safe-124051300074_1.html",
    "time_published": "20240513T022922",
    "authors": [
      "Bloomberg"
    ],
    "summary": "Sugar in cereals, pesticides in spices. why we struggle to keep food safeBa Business Standard ...",
    "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-03/30/full/1680187858-1998.jpg?im=FitAndFill=(826,465)",
    "source": "Business Standard",
    "category_within_source": "GoogleRSS",
    "source_domain": "www.business-standard.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": -0.156549,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "NSRGF",
        "relevance_score": "0.296761",
        "ticker_sentiment_score": "-0.115717",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.03798",
        "ticker_sentiment_score": "-0.043448",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.03798",
        "ticker_sentiment_score": "-0.043448",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UL",
        "relevance_score": "0.03798",
        "ticker_sentiment_score": "0.015677",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer",
    "url": "https://www.globenewswire.com/news-release/2024/05/14/2881909/0/en/NANOBIOTIX-Announces-US-FDA-Protocol-Acceptance-for-New-Randomized-Phase-2-Study-Evaluating-NBTXR3-for-Patients-with-Stage-Three-Lung-Cancer.html",
    "time_published": "20240514T201500",
    "authors": [
      "Nanobiotix S.A."
    ],
    "summary": "PARIS and CAMBRIDGE, Mass., May 14, 2024 ( GLOBE NEWSWIRE ) -- NANOBIOTIX ( Euronext: NANO -- NASDAQ: NBTX - the ''Company'' ) , a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/36fb7b98-27d7-46cb-b989-fa31626657b8",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.083876,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NBTX",
        "relevance_score": "0.511513",
        "ticker_sentiment_score": "0.087696",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.084871",
        "ticker_sentiment_score": "-0.011479",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:NANO",
        "relevance_score": "0.042496",
        "ticker_sentiment_score": "-0.0109",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2273339/johnson-johnson-jnj-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20240514T130015",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default352.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.623304"
      }
    ],
    "overall_sentiment_score": 0.250902,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.47672",
        "ticker_sentiment_score": "0.165672",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Red Lobster closes dozens of restaurants amid bankruptcy reports - .com",
    "url": "https://www.upi.com/Top_News/US/2024/05/13/red-lobster-closes-dozens-locations/7911715650259/",
    "time_published": "20240514T021150",
    "authors": [
      "Sheri Walsh"
    ],
    "summary": "Red Lobster closes dozens of restaurants amid bankruptcy reports UPI News ...",
    "banner_image": "https://cdnph.upi.com/sv/ph/og/upi/7911715650259/2024/1/9c60b921682dfaef8218b39df09fbd01/v1.5/Red-Lobster-closes-dozens-of-restaurants-amid-bankruptcy-reports.jpg",
    "source": "UPI Business",
    "category_within_source": "n/a",
    "source_domain": "www.upi.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.079271,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "-0.397924",
        "ticker_sentiment_label": "Bearish"
      }
    ]
  },
  {
    "title": "Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results",
    "url": "https://www.globenewswire.com/news-release/2024/05/15/2882924/0/en/Cidara-Therapeutics-Provides-Corporate-Update-and-Reports-First-Quarter-2024-Financial-Results.html",
    "time_published": "20240515T202000",
    "authors": [
      "Cidara Therapeutics",
      "Inc."
    ],
    "summary": "SAN DIEGO, May 15, 2024 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( Nasdaq: CDTX ) ( the Company ) , a biotechnology company using its proprietary Cloudbreak\u00ae platform to develop drug-Fc conjugate ( DFC ) immunotherapies designed to save lives and improve the standard of care for patients ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/97036182-e328-4e3f-a1ef-6d4a151e97cb",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.977154"
      }
    ],
    "overall_sentiment_score": 0.113267,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CAN",
        "relevance_score": "0.049322",
        "ticker_sentiment_score": "0.053787",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DVAX",
        "relevance_score": "0.024673",
        "ticker_sentiment_score": "0.049524",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CDTX",
        "relevance_score": "0.098456",
        "ticker_sentiment_score": "0.070762",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.024673",
        "ticker_sentiment_score": "0.039232",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "1 No-Brainer Growth Stock to Buy and Hold for 10 Years",
    "url": "https://www.fool.com/investing/2024/05/15/1-no-brainer-growth-stock-to-buy-and-hold-for-10/",
    "time_published": "20240515T141500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "This company's potential far outweighs its risks.",
    "banner_image": "https://media.ycharts.com/charts/22f04dff8470cf02bd8b3f976eadcfe1.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.174683,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MDT",
        "relevance_score": "0.058615",
        "ticker_sentiment_score": "-0.095012",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.443626",
        "ticker_sentiment_score": "0.214206",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.058615",
        "ticker_sentiment_score": "-0.095012",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks",
    "url": "https://www.zacks.com/stock/news/2274016/improve-your-retirement-income-with-these-3-top-ranked-dividend-stocks",
    "time_published": "20240515T131002",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default144.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.185136,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "UE",
        "relevance_score": "0.212115",
        "ticker_sentiment_score": "0.192237",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.212115",
        "ticker_sentiment_score": "0.119657",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/05/38878697/johnson-johnson-to-acquire-early-stage-eczema-treatment-developer-proteologix-for-850m",
    "time_published": "20240516T163558",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Thursday, Johnson & Johnson JNJ agreed to acquire Proteologix Inc., a privately held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850 million in cash, with the potential for an additional milestone payment.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/16/jnj-johnson-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.034347,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SWAV",
        "relevance_score": "0.215894",
        "ticker_sentiment_score": "0.364392",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.506613",
        "ticker_sentiment_score": "0.376527",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Ex-Dividend Reminder: Nuvei, Walgreens And Johnson & Johnson",
    "url": "https://www.forbes.com/sites/dividendchannel/2024/05/16/ex-dividend-reminder-nuvei-walgreens-and-johnson--johnson/",
    "time_published": "20240516T154251",
    "authors": [
      "Dividend Channel"
    ],
    "summary": "On 5/20/24, Nuvei, Walgreens Boots Alliance, and Johnson & Johnson will all trade ex-dividend for their respective upcoming dividends. Nuvei will pay its quarterly dividend of $0.10 on 6/6/24, Walgreens Boots Alliance will pay its quarterly dividend of $0.25 on 6/12/24, and Johnson & Johnson will ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6646292f709a7b34b5ff9ece/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.217243,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVEI",
        "relevance_score": "0.796885",
        "ticker_sentiment_score": "0.262818",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.724687",
        "ticker_sentiment_score": "0.253237",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.724687",
        "ticker_sentiment_score": "0.253237",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Up 5.5% Since Last Earnings Report: Can It Continue?",
    "url": "https://www.zacks.com/stock/news/2274916/johnson-johnson-jnj-up-55-since-last-earnings-report-can-it-continue",
    "time_published": "20240516T153012",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default282.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.918141"
      }
    ],
    "overall_sentiment_score": 0.173769,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.095899",
        "ticker_sentiment_score": "0.071638",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game - Pfizer  ( NYSE:PFE ) ",
    "url": "https://www.benzinga.com/markets/penny-stocks/24/05/38871754/pfizer-astrazeneca-sanofi-and-mainz-biomed-to-uplevel-europes-pharma-game",
    "time_published": "20240516T125136",
    "authors": [
      "Upwallstreet"
    ],
    "summary": "On Sunday, Pfizer PFE and AstraZeneca Plc AZN were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France, just ahead of this year's \"Choose France\" business summit.",
    "banner_image": "https://cdn.benzinga.com/files/front-view-doctor-holding-tubes.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      }
    ],
    "overall_sentiment_score": 0.082044,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.191929",
        "ticker_sentiment_score": "0.245408",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.048425",
        "ticker_sentiment_score": "0.070186",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.238601",
        "ticker_sentiment_score": "0.063641",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.096671",
        "ticker_sentiment_score": "0.074679",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.096671",
        "ticker_sentiment_score": "0.037248",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVAX",
        "relevance_score": "0.048425",
        "ticker_sentiment_score": "0.205291",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.191929",
        "ticker_sentiment_score": "-0.078925",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GSK",
        "relevance_score": "0.096671",
        "ticker_sentiment_score": "0.074679",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.191929",
        "ticker_sentiment_score": "0.245408",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.28442",
        "ticker_sentiment_score": "0.329343",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "J&J  ( JNJ )  to Boost Dermatology Portfolio With New Acquisition",
    "url": "https://www.zacks.com/stock/news/2275581/jj-jnj-to-boost-dermatology-portfolio-with-new-acquisition",
    "time_published": "20240517T155600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) inks deal to acquire Proteologix, Inc. for $850 million in cash. The transaction is expected to be closed in mid-2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.239797,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ANIP",
        "relevance_score": "0.406526",
        "ticker_sentiment_score": "0.311236",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LGND",
        "relevance_score": "0.330654",
        "ticker_sentiment_score": "0.316766",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ENTX",
        "relevance_score": "0.251247",
        "ticker_sentiment_score": "0.107334",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.406526",
        "ticker_sentiment_score": "0.250096",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Proteologix, Inc. to be Acquired by Johnson & Johnson",
    "url": "https://www.prnewswire.com/news-releases/proteologix-inc-to-be-acquired-by-johnson--johnson-302148671.html",
    "time_published": "20240517T034500",
    "authors": [
      "Proteologix",
      "Inc."
    ],
    "summary": "REDWOOD CITY, Calif., May 16, 2024 /PRNewswire/ -- Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, today announced that it has entered into a definitive agreement to be acquired by Johnson & Johnson for $850 million in ...",
    "banner_image": "https://mma.prnewswire.com/media/2415654/Proteologix_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.196304,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.265859",
        "ticker_sentiment_score": "0.23946",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch",
    "url": "https://markets.businessinsider.com/news/stocks/cannabis-meets-prescription-drugs-steroids-and-ketamine-in-schedule-iii-what-it-means-key-stocks-to-watch-1033400987",
    "time_published": "20240518T141914",
    "authors": [
      "Nicol&#225;s Jose Rodriguez"
    ],
    "summary": "President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act ( CSA ) . This shift could revolutionize the cannabis industry. But what exactly is Schedule III? What other substances are produced and studied in this ...",
    "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2024/05/17/dalle_2024-05-17_18.49.22_-_.jpeg",
    "source": "Business Insider",
    "category_within_source": "RSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.341804,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.068896",
        "ticker_sentiment_score": "0.134749",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.068896",
        "ticker_sentiment_score": "0.134749",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.068896",
        "ticker_sentiment_score": "0.134749",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JAZZ",
        "relevance_score": "0.068896",
        "ticker_sentiment_score": "0.134749",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.068896",
        "ticker_sentiment_score": "0.134749",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.068896",
        "ticker_sentiment_score": "0.134749",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch - AbbVie  ( NYSE:ABBV ) , Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/markets/cannabis/24/05/38905472/cannabis-meets-prescription-drugs-steroids-and-ketamine-in-schedule-iii-what-it-means-key-stocks",
    "time_published": "20240518T141914",
    "authors": [
      "Nicol\u00e1s Jose Rodriguez"
    ],
    "summary": "President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act ( CSA ) . This shift could revolutionize the cannabis industry. But what exactly is Schedule III? What other substances are produced and studied in this ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/17/dalle_2024-05-17_18.49.22_-_.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.327636,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.117774",
        "ticker_sentiment_score": "0.123682",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.117774",
        "ticker_sentiment_score": "0.151999",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "-0.080549",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JAZZ",
        "relevance_score": "0.117774",
        "ticker_sentiment_score": "0.230325",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.117774",
        "ticker_sentiment_score": "0.067245",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.117774",
        "ticker_sentiment_score": "0.19966",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the Vanguard Health Care ETF? - Johnson & Johnson  ( NYSE:JNJ ) , iShares Global Healthcare ETF  ( ARCA:IXJ ) ",
    "url": "https://www.benzinga.com/news/24/05/38915885/should-you-invest-in-the-vanguard-health-care-etf",
    "time_published": "20240520T171816",
    "authors": [
      "Zacks"
    ],
    "summary": "Looking for broad exposure to the Healthcare - Broad segment of the equity market? You should consider the Vanguard Health Care ETF VHT, a passively managed exchange traded fund launched on 01/26/2004.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/20/kenny-eliason-8fdhgan5zg0-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999994"
      }
    ],
    "overall_sentiment_score": 0.295516,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "0.100561",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.069495",
        "ticker_sentiment_score": "0.14638",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "0.100561",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "0.100561",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "JB Pharma aims to grow its revenue by 12-14% in the next two years",
    "url": "https://www.business-standard.com/companies/news/jb-pharma-aims-to-grow-its-revenue-by-12-14-in-the-next-two-years-124052001344_1.html",
    "time_published": "20240520T152224",
    "authors": [
      "Anjali Singh"
    ],
    "summary": "Mumbai-based pharma company JB Pharma is aiming to grow its revenue by 12-14 per cent in the next two years. The company is particularly focused on expanding its presence in the chronic medicines segment and its contract development and manufacturing organisation ( CDMO ) business.",
    "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2024-03/07/full/1709750255-5349.jpg?im=FeatureCrop,size=(826,465)",
    "source": "Business Standard",
    "category_within_source": "GoogleRSS",
    "source_domain": "www.business-standard.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.237948,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.181137",
        "ticker_sentiment_score": "0.223376",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.181137",
        "ticker_sentiment_score": "0.223376",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "What 9 Analyst Ratings Have To Say About Genmab",
    "url": "https://markets.businessinsider.com/news/stocks/what-9-analyst-ratings-have-to-say-about-genmab-1033404016",
    "time_published": "20240520T151722",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Genmab ( NASDAQ:GMAB ) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the ...",
    "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2023/analyst_ratings_image_2.jpeg",
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.174546,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GMAB",
        "relevance_score": "0.479385",
        "ticker_sentiment_score": "0.068535",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.051221",
        "ticker_sentiment_score": "-0.065991",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.102231",
        "ticker_sentiment_score": "-0.072416",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Inquiry Into Johnson & Johnson's Competitor Dynamics In Pharmaceuticals Industry - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/news/24/05/38920727/inquiry-into-johnson-amp-johnsons-competitor-dynamics-in-pharmaceuticals-industry",
    "time_published": "20240520T150053",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In today's fast-paced and competitive business landscape, it is essential for investors and industry enthusiasts to thoroughly analyze companies before making investment decisions.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.198135,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.060694",
        "ticker_sentiment_score": "0.139019",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.405963",
        "ticker_sentiment_score": "0.381456",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "U.S. Food and Drug Administration  ( FDA )  Extends its Memorandum of Understanding  ( MOU )  with MedISAO",
    "url": "https://www.benzinga.com/pressreleases/24/05/n38916445/u-s-food-and-drug-administration-fda-extends-its-memorandum-of-understanding-mou-with-medisao",
    "time_published": "20240520T120000",
    "authors": [
      "PRNewswire"
    ],
    "summary": "Strategic partnership between FDA and MedISAO emphasizes the importance of strengthening medical device security",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.432769,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DXCM",
        "relevance_score": "0.055621",
        "ticker_sentiment_score": "0.154906",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.055621",
        "ticker_sentiment_score": "0.154906",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the Vanguard Health Care ETF  ( VHT ) ?",
    "url": "https://www.zacks.com/stock/news/2275801/should-you-invest-in-the-vanguard-health-care-etf-vht",
    "time_published": "20240520T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default256.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.26824,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.064229",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.067347",
        "ticker_sentiment_score": "0.12575",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.064229",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.064229",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update",
    "url": "https://www.globenewswire.com/news-release/2024/05/21/2886080/0/en/Alvotech-Reports-Financial-Results-for-First-Quarter-of-2024-and-Provides-a-Business-Update.html",
    "time_published": "20240521T211500",
    "authors": [
      "Alvotech"
    ],
    "summary": "REYKJAVIK, Iceland, May 21, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO, or the \"Company\" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first three months of ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999822"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.111129,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.013693",
        "ticker_sentiment_score": "0.086813",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.013693",
        "ticker_sentiment_score": "0.086813",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.013693",
        "ticker_sentiment_score": "0.054711",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.027382",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.405299",
        "ticker_sentiment_score": "0.22023",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.013693",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.013693",
        "ticker_sentiment_score": "0.054711",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.013693",
        "ticker_sentiment_score": "0.054711",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.013693",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.013693",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:ISK",
        "relevance_score": "0.027382",
        "ticker_sentiment_score": "0.00379",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:SEK",
        "relevance_score": "0.027382",
        "ticker_sentiment_score": "0.00379",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.013693",
        "ticker_sentiment_score": "-0.038604",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update",
    "url": "https://www.globenewswire.com/news-release/2024/05/21/2886079/0/en/Alvotech-Reports-Financial-Results-for-First-Quarter-of-2024-and-Provides-a-Business-Update.html",
    "time_published": "20240521T211400",
    "authors": [
      "Alvotech"
    ],
    "summary": "Alvotech ( NASDAQ: ALVO, or the \"Company\" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first three months of 2024 and provided a summary of recent corporate ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999822"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.111134,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.013732",
        "ticker_sentiment_score": "0.086839",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.013732",
        "ticker_sentiment_score": "0.086839",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.013732",
        "ticker_sentiment_score": "0.054728",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.02746",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.406356",
        "ticker_sentiment_score": "0.220633",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.013732",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.013732",
        "ticker_sentiment_score": "0.054728",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.013732",
        "ticker_sentiment_score": "0.054728",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.013732",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.013732",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:ISK",
        "relevance_score": "0.02746",
        "ticker_sentiment_score": "0.003792",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:SEK",
        "relevance_score": "0.02746",
        "ticker_sentiment_score": "0.003792",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.013732",
        "ticker_sentiment_score": "-0.038614",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth - Nanobiotix  ( NASDAQ:NBTX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/05/g38951099/nanobiotix-announces-progress-in-global-nbtxr3-development-collaboration-highlighting-robust-pipel",
    "time_published": "20240521T201500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Updated Nanobiotix corporate strategy designed to enable long-term growth through execution of the global NBTXR3 collaboration and platforms beyond NBTXR3 Alignment of intent to transfer the sponsorship of the ongoing Phase 3 pivotal trial in head and neck cancer to begin preparations for ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.149242,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NBTX",
        "relevance_score": "0.59504",
        "ticker_sentiment_score": "0.280777",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LIANY",
        "relevance_score": "0.030898",
        "ticker_sentiment_score": "0.033234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.030898",
        "ticker_sentiment_score": "0.070316",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Smart Money Is Betting Big In JNJ Options - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/options/24/05/38950084/smart-money-is-betting-big-in-jnj-options",
    "time_published": "20240521T193120",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bullish approach towards Johnson & Johnson JNJ, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.235206,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.073546",
        "ticker_sentiment_score": "0.140234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.539766",
        "ticker_sentiment_score": "0.392668",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Want $1,000 in Dividend Income? Here's How Much You'd Have to Invest in Johnson & Johnson Stock",
    "url": "https://www.fool.com/investing/2024/05/21/want-1000-in-dividend-income-heres-how-much-youd-h/",
    "time_published": "20240521T145724",
    "authors": [
      "Matt DiLallo"
    ],
    "summary": "Johnson & Johnson is a high-quality dividend stock.",
    "banner_image": "https://g.foolcdn.com/editorial/images/778013/a-person-holding-100-bills.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.386954,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.85773",
        "ticker_sentiment_score": "0.612061",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks",
    "url": "https://www.zacks.com/stock/news/2276513/how-to-maximize-your-retirement-portfolio-with-these-top-ranked-dividend-stocks",
    "time_published": "20240521T131002",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default266.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.201946,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AWON",
        "relevance_score": "0.055492",
        "ticker_sentiment_score": "0.044045",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.219312",
        "ticker_sentiment_score": "0.122836",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Engitix Announces Appointment of Matthew Edwards Ph.D., as SVP Discovery and Emma Huang Ph.D., as VP Data Sciences",
    "url": "https://www.benzinga.com/pressreleases/24/05/g38934103/engitix-announces-appointment-of-matthew-edwards-ph-d-as-svp-discovery-and-emma-huang-ph-d-as-vp-d",
    "time_published": "20240521T082509",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LONDON, May 21, 2024 ( GLOBE NEWSWIRE ) -- Engitix Ltd ( 'Engitix' ) , a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary human extracellular matrix ( ECM ) platform, today announces the appointment of Matthew Edwards, Ph.D., ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.236786,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.095138",
        "ticker_sentiment_score": "0.096914",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer",
    "url": "https://www.globenewswire.com/news-release/2024/05/21/2885233/0/en/Valneva-Appoints-Dr-Hanneke-Schuitemaker-Ph-D-as-Chief-Scientific-Officer.html",
    "time_published": "20240521T050000",
    "authors": [
      "VALNEVA"
    ],
    "summary": "Saint-Herblain ( France ) , May 21, 2024 - Valneva SE ( Nasdaq: VALN. Euronext Paris: VLA ) , a specialty vaccine company, today announced the appointment of Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer ( CSO ) and Executive Committee member, effective June 3, 2024.",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/04f398df-96ac-4b7a-8544-2a2ce2495778",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.193734,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VALN",
        "relevance_score": "0.674691",
        "ticker_sentiment_score": "0.275604",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.049019",
        "ticker_sentiment_score": "0.049006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.049019",
        "ticker_sentiment_score": "0.054381",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer",
    "url": "https://www.benzinga.com/pressreleases/24/05/g38931647/valneva-appoints-dr-hanneke-schuitemaker-ph-d-as-chief-scientific-officer",
    "time_published": "20240521T050000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Saint-Herblain ( France ) , May 21, 2024 - Valneva SE VALNVLA, a specialty vaccine company, today announced the appointment of Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer ( CSO ) and Executive Committee member, effective June 3, 2024.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.20295,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VALN",
        "relevance_score": "0.681742",
        "ticker_sentiment_score": "0.300719",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.046816",
        "ticker_sentiment_score": "0.048999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.046816",
        "ticker_sentiment_score": "0.053136",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Idorsia announces changes to Idorsia Executive Committee and Board of Directors",
    "url": "https://www.globenewswire.com/news-release/2024/05/21/2885236/0/en/Idorsia-announces-changes-to-Idorsia-Executive-Committee-and-Board-of-Directors.html",
    "time_published": "20240521T050000",
    "authors": [
      "Idorsia Pharmaceuticals Ltd"
    ],
    "summary": "Ad hoc announcement pursuant to Art. 53 LR ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/bb724119-468d-4b1d-8206-3c2175d07f2b",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.248733,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GLPG",
        "relevance_score": "0.08376",
        "ticker_sentiment_score": "0.026784",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IDRSF",
        "relevance_score": "0.522236",
        "ticker_sentiment_score": "0.451298",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.020976",
        "ticker_sentiment_score": "0.09226",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.041938",
        "ticker_sentiment_score": "-0.065886",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Idorsia announces financial results for the full year of 2023 - Adapting the company to create sustainable value",
    "url": "https://www.globenewswire.com/news-release/2024/05/21/2885231/0/en/Idorsia-announces-financial-results-for-the-full-year-of-2023-Adapting-the-company-to-create-sustainable-value.html",
    "time_published": "20240521T044000",
    "authors": [
      "Idorsia Pharmaceuticals Ltd"
    ],
    "summary": "Ad hoc announcement pursuant to Art. 53 LR ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/bb724119-468d-4b1d-8206-3c2175d07f2b",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.13181,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SOLTF",
        "relevance_score": "0.072655",
        "ticker_sentiment_score": "-0.006043",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IDRSF",
        "relevance_score": "0.456748",
        "ticker_sentiment_score": "0.270498",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.096769",
        "ticker_sentiment_score": "0.093267",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NBIX",
        "relevance_score": "0.024248",
        "ticker_sentiment_score": "0.028348",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Teva and Alvotech Announce SIMLANDI\u00ae  ( adalimumab-ryvk )  Injection Now Available in the U.S.",
    "url": "https://www.globenewswire.com/news-release/2024/05/21/2885215/0/en/Teva-and-Alvotech-Announce-SIMLANDI-adalimumab-ryvk-Injection-Now-Available-in-the-U-S.html",
    "time_published": "20240521T002500",
    "authors": [
      "Alvotech"
    ],
    "summary": "REYKJAVIK, ICELAND & PARSIPPANY, NJ - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. ( NYSE and TASE: TEVA ) and Alvotech ( NASDAQ: ALVO ) , today announced the availability of SIMLANDI ( adalimumab-ryvk ) injection in the U.S., as an interchangeable biosimilar to ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": -0.007299,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALVO",
        "relevance_score": "0.296131",
        "ticker_sentiment_score": "0.152357",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.011232",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.056116",
        "ticker_sentiment_score": "0.079951",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.011232",
        "ticker_sentiment_score": "0.053633",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.011232",
        "ticker_sentiment_score": "0.053633",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.011232",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Teva and Alvotech Announce SIMLANDI\u00ae  ( adalimumab-ryvk )  Injection Now Available in the U.S.",
    "url": "https://www.globenewswire.com/news-release/2024/05/21/2885214/0/en/Teva-and-Alvotech-Announce-SIMLANDI-adalimumab-ryvk-Injection-Now-Available-in-the-U-S.html",
    "time_published": "20240521T002500",
    "authors": [
      "Alvotech"
    ],
    "summary": "REYKJAVIK, Iceland and PARSIPPANY, N.J., May 21, 2024 ( GLOBE NEWSWIRE ) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. ( NYSE and TASE: TEVA ) and Alvotech ( NASDAQ: ALVO ) , today announced the availability of SIMLANDI ( adalimumab-ryvk ) injection in the ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": -0.007299,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALVO",
        "relevance_score": "0.295735",
        "ticker_sentiment_score": "0.15219",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.011216",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.056038",
        "ticker_sentiment_score": "0.078947",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.011216",
        "ticker_sentiment_score": "0.053626",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.011216",
        "ticker_sentiment_score": "0.053626",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.011216",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson sued by cancer victims over 'fraudulent' bankruptcies",
    "url": "https://www.foxbusiness.com/markets/johnson-johnson-sued-cancer-victims-fraudulent-bankruptcies",
    "time_published": "20240522T205700",
    "authors": [],
    "summary": "A group of cancer victims sued Johnson & Johnson on Wednesday, accusing the healthcare company of committing fraud through repeated and continued efforts to use a shell company's bankruptcy to resolve tens of thousands of lawsuits alleging its talc products contained asbestos and caused cancer.",
    "banner_image": "https://cf-images.us-east-1.prod.boltdns.net/v1/static/854081161001/6ebeea73-563b-4cd1-80d4-800d9700fc36/d664b858-5449-476f-bf12-1cab94bbd764/1280x720/match/image.jpg",
    "source": "Fox Business News",
    "category_within_source": "n/a",
    "source_domain": "www.foxbusiness.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.379594,
    "overall_sentiment_label": "Bearish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.076847",
        "ticker_sentiment_score": "-0.356566",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.227716",
        "ticker_sentiment_score": "-0.529054",
        "ticker_sentiment_label": "Bearish"
      }
    ]
  },
  {
    "title": "Why This Top-Rated Medtech Stock Has 20/20 Vision - And 55% Growth",
    "url": "https://www.investors.com/research/the-new-america/rxsight-rxst-stock-cataracts-surgery-light-adjustable-lenses/",
    "time_published": "20240522T120000",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Why RxSight's Vision Is 20/20 As Shares Approach A Record High Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/05/wNArxsight052724.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      }
    ],
    "overall_sentiment_score": 0.216828,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALC",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.221361",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DYN",
        "relevance_score": "0.044634",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RXST",
        "relevance_score": "0.760155",
        "ticker_sentiment_score": "0.387891",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.221361",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Biden Administration Urges Supreme Court Review in Terrorism Funding Lawsuit Against Pharma Companies - AstraZeneca  ( NASDAQ:AZN ) , GE HealthCare Techs  ( NASDAQ:GEHC ) ",
    "url": "https://www.benzinga.com/general/biotech/24/05/38992121/biden-administration-urges-supreme-court-review-in-terrorism-funding-lawsuit-against-pharma-compa",
    "time_published": "20240523T180016",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "The Biden administration has urged the U.S. Supreme Court to reconsider a ruling involving 21 pharmaceutical and medical equipment companies accused of funding terrorism in Iraq, resulting in the deaths and injuries of American service members. The U.S.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/23/over-the-counter-pills.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.044399,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GEHC",
        "relevance_score": "0.215894",
        "ticker_sentiment_score": "0.100493",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.215894",
        "ticker_sentiment_score": "0.100493",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.215894",
        "ticker_sentiment_score": "0.100493",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.215894",
        "ticker_sentiment_score": "0.100493",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "NVIDIA  ( NVDA )  Q1 Earnings Top Estimates, Revenues Rise Y/Y",
    "url": "https://www.zacks.com/stock/news/2278212/nvidia-nvda-q1-earnings-top-estimates-revenues-rise-yy",
    "time_published": "20240523T160900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "NVIDIA's (NVDA) first-quarter fiscal 2025 results benefited from strong demand for its GPUs, along with an expanding partner base.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/93/534.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.13452,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.112182",
        "ticker_sentiment_score": "0.178654",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XPEV",
        "relevance_score": "0.037504",
        "ticker_sentiment_score": "0.104969",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.037504",
        "ticker_sentiment_score": "0.014579",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.841655",
        "ticker_sentiment_score": "0.436637",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GMGT",
        "relevance_score": "0.037504",
        "ticker_sentiment_score": "0.08742",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.037504",
        "ticker_sentiment_score": "0.24356",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNPS",
        "relevance_score": "0.112182",
        "ticker_sentiment_score": "0.178654",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson's Bankruptcy Tactics Are Fraudulent, Plaintiffs Accuse Company Of Defrauding Cancer Victims - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/05/38989073/johnson-johnsons-bankruptcy-tactics-are-fraudulent-plaintiffs-accuse-company-of-defrauding-cancer",
    "time_published": "20240523T152645",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "A group of cancer victims has reportedly filed a lawsuit against Johnson & Johnson JNJ, accusing the healthcare giant of committing fraud through its persistent efforts to use a shell company's bankruptcy to resolve numerous lawsuits.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/23/jnj-johnson-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.309397,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.098659",
        "ticker_sentiment_score": "-0.388706",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.784902",
        "ticker_sentiment_score": "-0.430283",
        "ticker_sentiment_label": "Bearish"
      }
    ]
  },
  {
    "title": "Action Canada announces its 2024-2025 Fellows - Canada NewsWire",
    "url": "https://www.newswire.ca/news-releases/action-canada-announces-its-2024-2025-fellows-844598230.html",
    "time_published": "20240523T123000",
    "authors": [],
    "summary": "Action Canada announces its 2024-2025 Fellows Canada ...",
    "banner_image": null,
    "source": "Canada Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.newswire.ca",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.269231,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HESG",
        "relevance_score": "0.025034",
        "ticker_sentiment_score": "0.021878",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PWCDF",
        "relevance_score": "0.025034",
        "ticker_sentiment_score": "0.263742",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.025034",
        "ticker_sentiment_score": "0.183938",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.025034",
        "ticker_sentiment_score": "0.263742",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FOREX:EUR",
        "relevance_score": "0.025034",
        "ticker_sentiment_score": "0.018637",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Stock Falls Amid Market Uptick: What Investors Need to Know",
    "url": "https://www.zacks.com/stock/news/2278966/johnson-johnson-jnj-stock-falls-amid-market-uptick-what-investors-need-to-know",
    "time_published": "20240524T214512",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $146.97, denoting a -1.82% change from the preceding trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default98.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.222116,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.537213",
        "ticker_sentiment_score": "0.342103",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Artificial Intelligence  ( AI )  Dow Stocks Billionaire Investors Have Been Buying Hand Over Fist Since 2024 Began",
    "url": "https://www.fool.com/investing/2024/05/24/2-ai-dow-stocks-billionaire-investors-buying-2024/",
    "time_published": "20240524T092100",
    "authors": [
      "Sean Williams"
    ],
    "summary": "Prominent billionaire money managers can't stop buying shares of two Dow Jones Industrial Average components whose growth strategies rely on artificial intelligence (AI).",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F778225%2Fartificial-intelligence-ai-robot-big-data-bull-market-stock-chart-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      }
    ],
    "overall_sentiment_score": 0.289791,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.032338",
        "ticker_sentiment_score": "0.099563",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.032338",
        "ticker_sentiment_score": "0.144529",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.401825",
        "ticker_sentiment_score": "0.298503",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.032338",
        "ticker_sentiment_score": "0.144529",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.032338",
        "ticker_sentiment_score": "0.144529",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.032338",
        "ticker_sentiment_score": "0.068955",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.284788",
        "ticker_sentiment_score": "0.249289",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Stem Cell Therapy Market size is set to grow by USD 11.65 billion from 2023-2027, Increasing prevalence of chronic ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/stem-cell-therapy-market-size-is-set-to-grow-by-usd-11-65-billion-from-2023-2027--increasing-prevalence-of-chronic-diseases-boost-the-market-technavio-302155784.html",
    "time_published": "20240527T221500",
    "authors": [],
    "summary": "Stem Cell Therapy Market size is set to grow by USD 11.65 billion from 2023-2027, Increasing prevalence of chronic ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.081887,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BCLI",
        "relevance_score": "0.031322",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CYYNF",
        "relevance_score": "0.031322",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.031322",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STMM",
        "relevance_score": "0.031322",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.031322",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.031322",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.031322",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MESO",
        "relevance_score": "0.031322",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RNUGF",
        "relevance_score": "0.031322",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRSP",
        "relevance_score": "0.031322",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ATHXQ",
        "relevance_score": "0.031322",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.031322",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.031322",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FUJIF",
        "relevance_score": "0.031322",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VCEL",
        "relevance_score": "0.031322",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.031322",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Home Healthcare Market size is set to grow by USD 312.33 million from 2023-2027, Quality of home healthcare ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/home-healthcare-market-size-is-set-to-grow-by-usd-312-33-million-from-2023-2027--quality-of-home-healthcare-increasing-patient-satisfaction-boost-the-market-technavio-302155780.html",
    "time_published": "20240527T210000",
    "authors": [],
    "summary": "Home Healthcare Market size is set to grow by USD 312.33 million from 2023-2027, Quality of home healthcare ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.297595,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "OMRNF",
        "relevance_score": "0.038345",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.038345",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FSNUF",
        "relevance_score": "0.038345",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.038345",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.038345",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.038345",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RMD",
        "relevance_score": "0.038345",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAX",
        "relevance_score": "0.038345",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVCRQ",
        "relevance_score": "0.038345",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.038345",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.114682",
        "ticker_sentiment_score": "0.232694",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Top Dividend Stocks to Maximize Your Retirement Income",
    "url": "https://www.zacks.com/stock/news/2279347/3-top-dividend-stocks-to-maximize-your-retirement-income",
    "time_published": "20240527T131003",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default332.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.288862,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "FNLC",
        "relevance_score": "0.108222",
        "ticker_sentiment_score": "0.080455",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.054236",
        "ticker_sentiment_score": "-0.036003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.214462",
        "ticker_sentiment_score": "0.123956",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "10 Best Vanguard Funds to Buy Right Now",
    "url": "https://www.fool.com/investing/2024/05/27/10-best-vanguard-funds-to-buy-right-now/",
    "time_published": "20240527T123000",
    "authors": [
      "George Budwell"
    ],
    "summary": "These 10 Vanguard stock ETFs can help you build a top-notch portfolio.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F778686%2Fetf.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.391095,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TRGP",
        "relevance_score": "0.022729",
        "ticker_sentiment_score": "0.300559",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.113276",
        "ticker_sentiment_score": "0.092723",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.090731",
        "ticker_sentiment_score": "0.122297",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.045439",
        "ticker_sentiment_score": "0.217094",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CEG",
        "relevance_score": "0.022729",
        "ticker_sentiment_score": "0.036053",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLDR",
        "relevance_score": "0.022729",
        "ticker_sentiment_score": "0.300559",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.022729",
        "ticker_sentiment_score": "0.24951",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.022729",
        "ticker_sentiment_score": "0.246548",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AXON",
        "relevance_score": "0.022729",
        "ticker_sentiment_score": "0.300559",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.022729",
        "ticker_sentiment_score": "0.246548",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.090731",
        "ticker_sentiment_score": "0.122297",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TDG",
        "relevance_score": "0.022729",
        "ticker_sentiment_score": "0.036053",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.068112",
        "ticker_sentiment_score": "0.158611",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "APH",
        "relevance_score": "0.022729",
        "ticker_sentiment_score": "0.036053",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TM",
        "relevance_score": "0.022729",
        "ticker_sentiment_score": "0.180777",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.022729",
        "ticker_sentiment_score": "0.034958",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NSRGF",
        "relevance_score": "0.022729",
        "ticker_sentiment_score": "0.180777",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the Health Care Select Sector SPDR ETF  ( XLV ) ?",
    "url": "https://www.zacks.com/stock/news/2279193/should-you-invest-in-the-health-care-select-sector-spdr-etf-xlv",
    "time_published": "20240527T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default49.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.256999,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.129168",
        "ticker_sentiment_score": "0.06419",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.064797",
        "ticker_sentiment_score": "0.127481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STT",
        "relevance_score": "0.064797",
        "ticker_sentiment_score": "0.089087",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.129168",
        "ticker_sentiment_score": "0.06419",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.129168",
        "ticker_sentiment_score": "0.06419",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "5 Magnificent Stocks Being Bought for Warren Buffett's $646 Million \"Secret\" Portfolio",
    "url": "https://www.fool.com/investing/2024/05/27/5-stocks-bought-warren-buffett-secret-portfolio/",
    "time_published": "20240527T092100",
    "authors": [
      "Sean Williams"
    ],
    "summary": "Warren Buffett's secret portfolio contains 90 securities -- five of which are phenomenal businesses whose shares were purchased in the March-ended quarter.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F778202%2Fbuffett6-tmf.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999956"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.181999,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CVX",
        "relevance_score": "0.216135",
        "ticker_sentiment_score": "0.084314",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "T",
        "relevance_score": "0.216135",
        "ticker_sentiment_score": "0.05113",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.242352",
        "ticker_sentiment_score": "0.055954",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.18967",
        "ticker_sentiment_score": "0.097613",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.109082",
        "ticker_sentiment_score": "0.120198",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.109082",
        "ticker_sentiment_score": "0.085149",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "YouTube is 19 years old. Here's a timeline of how it was founded and grew to become king of video, with some controversies along the way.",
    "url": "https://www.businessinsider.com/history-of-youtube",
    "time_published": "20240528T220500",
    "authors": [
      "Paige Leskin",
      "Ana Altchek"
    ],
    "summary": "YouTube history: How the video-sharing website became so popular - Business Insider ...",
    "banner_image": null,
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "www.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.150028,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MGLUY",
        "relevance_score": "0.031992",
        "ticker_sentiment_score": "0.091199",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NYT",
        "relevance_score": "0.063933",
        "ticker_sentiment_score": "0.002008",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PYPL",
        "relevance_score": "0.063933",
        "ticker_sentiment_score": "0.094065",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.839605",
        "ticker_sentiment_score": "0.255548",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.031992",
        "ticker_sentiment_score": "-0.048354",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What the Options Market Tells Us About Johnson & Johnson - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/options/24/05/39044112/what-the-options-market-tells-us-about-johnson-johnson",
    "time_published": "20240528T171620",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bullish approach towards Johnson & Johnson JNJ, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.160229,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.077343",
        "ticker_sentiment_score": "0.041453",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.617765",
        "ticker_sentiment_score": "0.243854",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "InnovationRx: MedTech Venture Investment Bounced Back  ( A Little ) ",
    "url": "https://www.forbes.com/sites/alexknapp/2024/05/29/innovationrx-medtech-venture-investment-bounced-back-a-little/",
    "time_published": "20240529T213909",
    "authors": [
      "Katie Jennings"
    ],
    "summary": "InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here. The past few quarters have been rough for healthcare startups looking to raise venture capital, but there may be light at the end of the tunnel-at least for medical devices.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6657a001513dcd830a28c179/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.033541,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SWAV",
        "relevance_score": "0.054732",
        "ticker_sentiment_score": "-0.073816",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.054732",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson's Drug Seltorexant Aces Late-Stage Depression Trial - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/05/39069469/johnson-johnsons-drug-seltorexant-aces-late-stage-depression-trial",
    "time_published": "20240529T165512",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Wednesday, Johnson & Johnson JNJ announced topline results from Phase 3 MDD3001 clinical trial evaluating the efficacy and safety of seltorexant as an adjunctive treatment to baseline antidepressants in adult and elderly patients with major depressive disorder ( MDD ) with insomnia symptoms.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/29/jnj-johnson-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.009923,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.459624",
        "ticker_sentiment_score": "-0.024449",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Newsweek and Plant-A Insights Group Announce Second Annual America's Greatest Workplaces for LGBTQ+ Ranking",
    "url": "https://www.benzinga.com/pressreleases/24/05/g39068877/newsweek-and-plant-a-insights-group-announce-second-annual-americas-greatest-workplaces-for-lgbtq-",
    "time_published": "20240529T163000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, May 29, 2024 ( GLOBE NEWSWIRE ) -- Newsweek, the modern global digital news organization, in partnership with Plant-A Insights Group, today announced the release of its America's Greatest Workplaces for LGBTQ+ 2024 Ranking.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.380559,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.125889",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "D",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.125889",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FSS",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.125889",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.125889",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NKE",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.125889",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.125889",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ECL",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.125889",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GIS",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.125889",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KAI",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.125889",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.291498",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.125889",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RANJF",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.125889",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WRBY",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.125889",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Are You Looking for a High-Growth Dividend Stock?",
    "url": "https://www.zacks.com/stock/news/2280781/are-you-looking-for-a-high-growth-dividend-stock",
    "time_published": "20240529T154508",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default157.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938238"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999365"
      }
    ],
    "overall_sentiment_score": 0.392903,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.448316",
        "ticker_sentiment_score": "0.462495",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Are Boomers Crashing The Economy Or Saving It? Why Investors Are Perplexed And What You Can Do To Prepare Are Boomers Saving The US Economy? Pundits Torn Over Fate Of $76 Trillion In Retirement Funds - CVS Health  ( NYSE:CVS ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
    "url": "https://www.benzinga.com/economics/macro-economic-events/24/05/39066076/are-boomers-crashing-the-economy-or-saving-it-why-investors-are-perplexed-and-wha",
    "time_published": "20240529T145120",
    "authors": [
      "Natan Ponieman"
    ],
    "summary": "The mass retirement of the boomer generation has been anticipated as one of the most impactful economic events of the 21st century. Economists are still trying to understand the consequences of the wealthiest generation in human history going into retirement by the millions each year.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/29/Joyful-Seniors-Taking-A-Group-Selfie---O.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999186"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.135787,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CVS",
        "relevance_score": "0.075995",
        "ticker_sentiment_score": "0.100081",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TNL",
        "relevance_score": "0.03804",
        "ticker_sentiment_score": "-0.017676",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.075995",
        "ticker_sentiment_score": "0.061602",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "T",
        "relevance_score": "0.03804",
        "ticker_sentiment_score": "0.087589",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.075995",
        "ticker_sentiment_score": "0.061602",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.075995",
        "ticker_sentiment_score": "0.100081",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.075995",
        "ticker_sentiment_score": "0.100081",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.075995",
        "ticker_sentiment_score": "0.100081",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "O",
        "relevance_score": "0.03804",
        "ticker_sentiment_score": "0.087589",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  is Attracting Investor Attention: Here is What You Should Know",
    "url": "https://www.zacks.com/stock/news/2280453/johnson-johnson-jnj-is-attracting-investor-attention-here-is-what-you-should-know",
    "time_published": "20240529T130018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default347.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.623304"
      }
    ],
    "overall_sentiment_score": 0.246441,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.47147",
        "ticker_sentiment_score": "0.161568",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "J&J  ( JNJ )  to Buy Rights to Novel Atopic Dermatitis Candidate",
    "url": "https://www.zacks.com/stock/news/2280409/jj-jnj-to-buy-rights-to-novel-atopic-dermatitis-candidate",
    "time_published": "20240529T122100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "J&J (JNJ) is set to acquire Yellow Jersey Therapeutics, which holds NM26 rights, from Numab's shareholder, for a purchase price of $1.25 billion in cash.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/1019.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.0,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BVS",
        "relevance_score": "0.421485",
        "ticker_sentiment_score": "0.386488",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.343279",
        "ticker_sentiment_score": "0.095146",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.421485",
        "ticker_sentiment_score": "0.231637",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "With FDA Clearance, Intuitive Surgical Operates On New Breakout",
    "url": "https://www.investors.com/research/breakout-stocks-technical-analysis/intuittive-surgical-isrg-stock-da-vinci-robotic-surgery/",
    "time_published": "20240529T120100",
    "authors": [
      "MATTHEW GALGANI",
      "Investor's Business Daily"
    ],
    "summary": "In March, robotic surgery leader Intuitive Surgical ( ISRG ) received clearance from the U.S. Federal Drug Administration for the da Vinci 5 next-generation multiport robotic system.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/05/Stock-AIdocs-Adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.955357"
      }
    ],
    "overall_sentiment_score": 0.156921,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MDT",
        "relevance_score": "0.123209",
        "ticker_sentiment_score": "-0.045783",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.785139",
        "ticker_sentiment_score": "0.336537",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.183895",
        "ticker_sentiment_score": "0.027727",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Industry That Ate America",
    "url": "https://www.theatlantic.com/magazine/archive/2024/07/wolves-of-k-street-book-review-lobbying/678523/",
    "time_published": "20240529T110000",
    "authors": [
      "Franklin Foer"
    ],
    "summary": "How K Street Runs America The Atlantic ...",
    "banner_image": "https://cdn.theatlantic.com/thumbor/Sunxjsdzk4n5qQ-ejMdUV9QbXhg=/0x0:329x500/79x120/media/img/book_reviews/2024/05/28/41HxwVSlIvL._SL500_/original.jpg",
    "source": "The Atlantic",
    "category_within_source": "n/a",
    "source_domain": "www.theatlantic.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.146789,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LMT",
        "relevance_score": "0.01429",
        "ticker_sentiment_score": "0.105453",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.01429",
        "ticker_sentiment_score": "-0.083434",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PUPOF",
        "relevance_score": "0.01429",
        "ticker_sentiment_score": "0.068019",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.01429",
        "ticker_sentiment_score": "0.093945",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GM",
        "relevance_score": "0.01429",
        "ticker_sentiment_score": "0.19756",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.01429",
        "ticker_sentiment_score": "-0.01974",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Rises As Market Takes a Dip: Key Facts",
    "url": "https://www.zacks.com/stock/news/2281695/johnson-johnson-jnj-rises-as-market-takes-a-dip-key-facts",
    "time_published": "20240530T214514",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) closed the most recent trading day at $145.28, moving +0.58% from the previous trading session.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default304.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.95493"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.172594,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.635085",
        "ticker_sentiment_score": "0.241129",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Healthy Returns: Pfizer, Merck, J&J and more to release cancer drug data at industry conference",
    "url": "https://www.cnbc.com/2024/05/30/healthy-returns-pfizer-merck-jj-to-release-cancer-drug-data.html",
    "time_published": "20240530T184544",
    "authors": [
      "Annika Kim Constantino",
      "Ashley Capoot"
    ],
    "summary": "CNBC will be on the ground at the ASCO annual meeting in Chicago. Meanwhile, Epic released a free tool set to help health systems evaluate AI models.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107417809-1716301294972-gettyimages-94656638-pdir0780PHi_j0158JPG.jpeg?v=1716301378&w=600&h=300&vtcrop=y",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.105112,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MRNA",
        "relevance_score": "0.040691",
        "ticker_sentiment_score": "-0.251254",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.040691",
        "ticker_sentiment_score": "-0.06742",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Sarepta Therapeutics Stock Is Rising Today - Sarepta Therapeutics  ( NASDAQ:SRPT ) ",
    "url": "https://www.benzinga.com/news/24/05/39095135/why-sarepta-therapeutics-stock-is-rising-today",
    "time_published": "20240530T182054",
    "authors": [
      "Dylan Berman"
    ],
    "summary": "Sarepta Therapeutics, Inc. SRPT stock is trading higher on Thursday after it was announced the company will be added to the S&P MidCap 400. What Happened: Effective prior to the opening of trading on June 3, Sarepta Therapeutics will join the S&P MidCap 400, replacing Shockwave Medical SWAV.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/30/Sarepta-Boston-232.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.98396"
      }
    ],
    "overall_sentiment_score": 0.386496,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SRPT",
        "relevance_score": "0.855251",
        "ticker_sentiment_score": "0.648992",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.468029",
        "ticker_sentiment_score": "0.318666",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.468029",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares U.S. Healthcare ETF? - BlackRock  ( NYSE:BLK ) , iShares U.S. Healthcare ETF  ( ARCA:IYH ) ",
    "url": "https://www.benzinga.com/news/24/05/39083266/should-you-invest-in-the-ishares-u-s-healthcare-etf",
    "time_published": "20240530T170357",
    "authors": [
      "Zacks"
    ],
    "summary": "Looking for broad exposure to the Healthcare - Broad segment of the equity market? You should consider the iShares U.S. Healthcare ETF IYH, a passively managed exchange traded fund launched on 06/12/2000.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/30/alexander-mils-lcphgxs7pww-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      }
    ],
    "overall_sentiment_score": 0.240467,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.103121",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.109151",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.109151",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.109151",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "J&J's  ( JNJ )  Oral Pill Improves Depression & Insomnia Symptoms",
    "url": "https://www.zacks.com/stock/news/2281643/jjs-jnj-oral-pill-improves-depression-insomnia-symptoms",
    "time_published": "20240530T162700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Data from a late-stage study shows that treatment with J&J's (JNJ) experimental drug met all study endpoints in depression patients with insomnia symptoms.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.928139"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.024574,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ARQT",
        "relevance_score": "0.25168",
        "ticker_sentiment_score": "0.101244",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNS",
        "relevance_score": "0.25168",
        "ticker_sentiment_score": "0.047798",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HRTX",
        "relevance_score": "0.311631",
        "ticker_sentiment_score": "0.14463",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.25168",
        "ticker_sentiment_score": "-0.175119",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Merck  ( MRK )  to Buy Private Ophthalmology Company EyeBio",
    "url": "https://www.zacks.com/stock/news/2281600/merck-mrk-to-buy-private-ophthalmology-company-eyebio",
    "time_published": "20240530T162400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Merck's (MRK) acquisition of EyeBio is set to add the latter's lead pipeline candidate, Restoret, a novel Wnt agonist antibody being developed for treating retinal diseases.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cc/389.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.198982,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RXDX",
        "relevance_score": "0.049424",
        "ticker_sentiment_score": "0.050964",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BVS",
        "relevance_score": "0.290033",
        "ticker_sentiment_score": "0.261953",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HRTX",
        "relevance_score": "0.290033",
        "ticker_sentiment_score": "0.170677",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.098659",
        "ticker_sentiment_score": "0.039044",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "OSE Immunotherapeutics Provides Business and Corporate Update",
    "url": "https://www.globenewswire.com/news-release/2024/05/30/2890988/0/en/OSE-Immunotherapeutics-Provides-Business-and-Corporate-Update.html",
    "time_published": "20240530T161500",
    "authors": [
      "OSE Immunotherapeutics"
    ],
    "summary": "\u2022 Three pharmaceutical agreements signed during the last three months: \u2022 New strategic partnership with AbbVie for OSE-230, a novel preclinical potential first-in-class program for the treatment of chronic inflammation. \u2022 Major partnership expansion with Boehringer Ingelheim: \u2022 Amendment of the ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.160417,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.094538",
        "ticker_sentiment_score": "0.105039",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SVYSF",
        "relevance_score": "0.01895",
        "ticker_sentiment_score": "0.061439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.01895",
        "ticker_sentiment_score": "0.057893",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.01895",
        "ticker_sentiment_score": "0.012589",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.01895",
        "ticker_sentiment_score": "0.012589",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.01895",
        "ticker_sentiment_score": "0.012589",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Meet 2024's Net Zero Leaders",
    "url": "https://www.forbes.com/sites/hnewman/2024/05/30/meet-2024s-net-zero-leaders/",
    "time_published": "20240530T141008",
    "authors": [
      "Heather Newman"
    ],
    "summary": "Research suggests that while nearly 60% of U.S. consumers say they are considering buying an electric or hybrid vehicle, less than 20% do, partly because green products tend to be more expensive. But even if customers don't actually buy a company's more sustainable products, they see it cares ...",
    "banner_image": "https://specials-images.forbesimg.com/imageserve/64592f3cfea505125d2796dd/960x0.jpg",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.241525,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MCHP",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.027303",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.104988",
        "ticker_sentiment_score": "0.057985",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.027303",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PM",
        "relevance_score": "0.104988",
        "ticker_sentiment_score": "0.078587",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLX",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.027303",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.027303",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Stocks That Could Be Easy Wealth Builders",
    "url": "https://www.fool.com/investing/2024/05/30/3-stocks-that-could-be-easy-wealth-builders/",
    "time_published": "20240530T133100",
    "authors": [
      "Anders Bylund"
    ],
    "summary": "These investment ideas should help you grow your portfolio with minimal effort.",
    "banner_image": "https://g.foolcdn.com/editorial/images/778909/investor-and-hundred-dollar-bills.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.995077"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.769861"
      }
    ],
    "overall_sentiment_score": 0.344833,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.109622",
        "ticker_sentiment_score": "0.156558",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.217184",
        "ticker_sentiment_score": "0.297357",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.073209",
        "ticker_sentiment_score": "0.069472",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "V",
        "relevance_score": "0.449655",
        "ticker_sentiment_score": "0.243197",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.145804",
        "ticker_sentiment_score": "0.149667",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Monte Rosa Therapeutics Announces Leadership Team Promotions - Monte Rosa Therapeutics  ( NASDAQ:GLUE ) ",
    "url": "https://www.benzinga.com/pressreleases/24/05/g39081952/monte-rosa-therapeutics-announces-leadership-team-promotions",
    "time_published": "20240530T110000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "BOSTON, May 30, 2024 ( GLOBE NEWSWIRE ) -- Monte Rosa Therapeutics, Inc. GLUE, a clinical-stage biotechnology company developing novel molecular glue degrader ( MGD ) -based medicines, today announced three leadership team promotions effective immediately: Sharon Townson, Ph.D., to Chief ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.140797,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KYMR",
        "relevance_score": "0.054983",
        "ticker_sentiment_score": "0.019",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GLUE",
        "relevance_score": "0.217346",
        "ticker_sentiment_score": "0.017551",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.054983",
        "ticker_sentiment_score": "0.019",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.054983",
        "ticker_sentiment_score": "0.184895",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares U.S. Healthcare ETF  ( IYH ) ?",
    "url": "https://www.zacks.com/stock/news/2281071/should-you-invest-in-the-ishares-us-healthcare-etf-iyh",
    "time_published": "20240530T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default186.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.21482,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.088144",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.132004",
        "ticker_sentiment_score": "0.069616",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.132004",
        "ticker_sentiment_score": "0.069616",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.132004",
        "ticker_sentiment_score": "0.069616",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What Stock Investors Can Learn From Venture Capitalists",
    "url": "https://www.fool.com/investing/2024/05/31/what-stock-investors-can-learn-from-venture-capita/",
    "time_published": "20240531T234302",
    "authors": [
      "Motley Fool Staff"
    ],
    "summary": "Venture capitalists don't mind strike outs, as long as they get their home runs.",
    "banner_image": "https://g.foolcdn.com/editorial/images/778751/mfm_26.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.208911,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.021124",
        "ticker_sentiment_score": "0.13136",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.007042",
        "ticker_sentiment_score": "0.039444",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NKLA",
        "relevance_score": "0.007042",
        "ticker_sentiment_score": "0.032613",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.014084",
        "ticker_sentiment_score": "0.11563",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.028163",
        "ticker_sentiment_score": "0.129353",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HPQ",
        "relevance_score": "0.007042",
        "ticker_sentiment_score": "0.084387",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DBX",
        "relevance_score": "0.0352",
        "ticker_sentiment_score": "0.123193",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Live updates: Trump to hold news conference after guilty verdict in hush money case",
    "url": "https://apnews.com/live/trump-guilty-verdict-updates",
    "time_published": "20240531T124200",
    "authors": [],
    "summary": "Donald Trump will hold a news conference at 11:00 a.m. ET at Trump Tower after becoming the first former U.S. president to be convicted of felony crimes.",
    "banner_image": "https://dims.apnews.com/dims4/default/3c00ebb/2147483647/strip/true/crop/6000x3375+0+312/resize/1440x810!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F41%2Fca%2F4e82623d4581868db8ab10b0d19b%2Fap24151610017971.jpg",
    "source": "Associated Press",
    "category_within_source": "Markets",
    "source_domain": "apnews.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.09451,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "-0.115138",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "S&P 500 Giants Lead Five Healthy Stocks Near Buy Points",
    "url": "https://www.investors.com/news/sp-500-giants-stocks-near-buy-points/",
    "time_published": "20240601T120000",
    "authors": [
      "Investor's Business Daily",
      "HARRISON MILLER"
    ],
    "summary": "With many leading stocks in need of some repair, investors may want to seek medical attention. Eli Lilly ( LLY ) , Novo Nordisk ( NVO ) , Vertex Pharmaceuticals ( VRTX ) , Intuitive Surgical ( ISRG ) and Universal Health ( UHS ) are all trading in or near buy zones.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2018/05/Stock-HealthCloud-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.94762"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.124906,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CTLT",
        "relevance_score": "0.064018",
        "ticker_sentiment_score": "-0.132137",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.312026",
        "ticker_sentiment_score": "0.139665",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCA",
        "relevance_score": "0.064018",
        "ticker_sentiment_score": "-0.408769",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.064018",
        "ticker_sentiment_score": "0.094068",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.252006",
        "ticker_sentiment_score": "0.092848",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.159148",
        "ticker_sentiment_score": "0.132957",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.064018",
        "ticker_sentiment_score": "0.094068",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.312026",
        "ticker_sentiment_score": "0.136597",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.032035",
        "ticker_sentiment_score": "-0.073241",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Magnificent Dividend Stocks to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/06/01/3-magnificent-dividend-stocks-to-buy-hold-forever/",
    "time_published": "20240601T095000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "These dividend stocks are keepers for income investors.",
    "banner_image": "https://g.foolcdn.com/editorial/images/779032/young-woman-smiling-hands-behind-head.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.419281,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TGT",
        "relevance_score": "0.383905",
        "ticker_sentiment_score": "0.383892",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.441424",
        "ticker_sentiment_score": "0.507716",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.066598",
        "ticker_sentiment_score": "0.149391",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.383905",
        "ticker_sentiment_score": "0.342668",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "NVIDIA Enables Real-Time Healthcare, Industrial and Scientific AI Applications at the Edge With Enterprise Software Support for NVIDIA IGX With Holoscan - NVIDIA  ( NASDAQ:NVDA ) ",
    "url": "https://www.benzinga.com/pressreleases/24/06/g39126902/nvidia-enables-real-time-healthcare-industrial-and-scientific-ai-applications-at-the-edge-with-ent",
    "time_published": "20240602T125650",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "TAIPEI, Taiwan, June 02, 2024 ( GLOBE NEWSWIRE ) -- COMPUTEX -- To address the increasing need for real-time AI computing at the industrial edge, NVIDIA today announced the general software availability of NVIDIA AI Enterprise-IGX with NVIDIA Holoscan on the NVIDIA IGX\u2122 platform.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.311114,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MDT",
        "relevance_score": "0.075318",
        "ticker_sentiment_score": "0.224901",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.911185",
        "ticker_sentiment_score": "0.543285",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.050254",
        "ticker_sentiment_score": "0.160253",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Dividend-Paying Tech Stocks to Buy in June",
    "url": "https://www.fool.com/investing/2024/06/02/3-dividend-paying-tech-stocks-to-buy-in-june/",
    "time_published": "20240602T120000",
    "authors": [
      "Jeremy Bowman"
    ],
    "summary": "Not every tech stock pays a dividend, but these three offer both growth and income.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F778898%2Fchip-connected-to-some-circuits.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.303694,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.425925",
        "ticker_sentiment_score": "0.433835",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "-0.033013",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.221313",
        "ticker_sentiment_score": "0.196277",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "0.099893",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "-0.033013",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "-0.009002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "0.099893",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ORCL",
        "relevance_score": "0.274628",
        "ticker_sentiment_score": "0.23645",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "US Spin-Offs Beat S&P 500  ( Up 34% YTD ) ",
    "url": "https://www.forbes.com/sites/joecornell/2024/06/03/us-spin-offs-beat-sp-500-up-34-ytd/",
    "time_published": "20240603T160340",
    "authors": [
      "Joe Cornell"
    ],
    "summary": "Large diversified conglomerates aim to unlock value by divesting slower-growing units that tend to hold back the stock's overall valuation, saddling them with the 'conglomerate discount'.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/665de6c9a02ba55b97a63fcc/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999981"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.217839,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CARR",
        "relevance_score": "0.082891",
        "ticker_sentiment_score": "0.111307",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CEG",
        "relevance_score": "0.124057",
        "ticker_sentiment_score": "0.148454",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.020758",
        "ticker_sentiment_score": "0.144176",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MT",
        "relevance_score": "0.020758",
        "ticker_sentiment_score": "0.110542",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "K",
        "relevance_score": "0.020758",
        "ticker_sentiment_score": "0.144176",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.062217",
        "ticker_sentiment_score": "0.097083",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CR",
        "relevance_score": "0.041502",
        "ticker_sentiment_score": "0.111497",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXC",
        "relevance_score": "0.041502",
        "ticker_sentiment_score": "0.11913",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GEV",
        "relevance_score": "0.124057",
        "ticker_sentiment_score": "0.055155",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WOR",
        "relevance_score": "0.020758",
        "ticker_sentiment_score": "0.110542",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WS",
        "relevance_score": "0.103509",
        "ticker_sentiment_score": "0.133291",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CXT",
        "relevance_score": "0.020758",
        "ticker_sentiment_score": "0.101836",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.484616",
        "ticker_sentiment_score": "0.199575",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRYPTO:NXT",
        "relevance_score": "0.020758",
        "ticker_sentiment_score": "0.101836",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson At ASCO Highlights Long Term Data From Multiple Myeloma Drug, Shows Sustained Deep, Durable Responses In Pretreated Patients - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/06/39141103/johnson-johnson-at-asco-highlights-long-term-data-from-multiple-myeloma-drug-shows-sustained-deep",
    "time_published": "20240603T160112",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Monday, Johnson & Johnson JNJ announced longer-term data from Phase 1/2 MajesTEC-1 study of Tecvayli ( teclistamab-cqyv ) showing deep and durable responses in patients with relapsed or refractory multiple myeloma ( RRMM ) .",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/03/Johnson-Johnson-logo-in-front-of-one-of-.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.136869,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.330286",
        "ticker_sentiment_score": "0.195197",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Performance Comparison: Johnson & Johnson And Competitors In Pharmaceuticals Industry - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/news/24/06/39139483/performance-comparison-johnson-amp-johnson-and-competitors-in-pharmaceuticals-industry",
    "time_published": "20240603T150042",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In the fast-paced and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Johnson & Johnson JNJ in comparison to its major competitors within the ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.138046,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.068306",
        "ticker_sentiment_score": "0.041092",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.451494",
        "ticker_sentiment_score": "0.179248",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks",
    "url": "https://www.zacks.com/stock/news/2282559/improve-your-retirement-income-with-these-3-top-ranked-dividend-stocks",
    "time_published": "20240603T131004",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default308.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.202029,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "FNLC",
        "relevance_score": "0.107495",
        "ticker_sentiment_score": "0.080274",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.123315",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Travel News: Lloyds Targets Holidaymakers With Free Foreign Spending",
    "url": "https://www.forbes.com/uk/advisor/travel-insurance/2024/06/03/travel-latest-news/",
    "time_published": "20240603T105848",
    "authors": [
      "Kevin Pratt"
    ],
    "summary": "Lloyds Bank is to scrap overseas spending fees for some of its current account customers this summer, writes Bethany Garner. From 1 July, Lloyds' Silver and Platinum current account holders can make debit card purchases and withdraw cash anywhere in the world free of charge.",
    "banner_image": "https://thumbor.forbes.com/thumbor/fit-in/x/https://www.forbes.com/uk/advisor/wp-content/uploads/2022/02/ET-Ski-Resort-Map.jpg",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.004776,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DRTGF",
        "relevance_score": "0.000869",
        "ticker_sentiment_score": "-0.050132",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.000869",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.000869",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAL",
        "relevance_score": "0.001737",
        "ticker_sentiment_score": "0.060739",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.004343",
        "ticker_sentiment_score": "0.034563",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.002606",
        "ticker_sentiment_score": "0.054167",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SHTDF",
        "relevance_score": "0.000869",
        "ticker_sentiment_score": "0.12476",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.000869",
        "ticker_sentiment_score": "0.018034",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.004343",
        "ticker_sentiment_score": "0.034563",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.000869",
        "ticker_sentiment_score": "-0.150677",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "YUGVF",
        "relevance_score": "0.001737",
        "ticker_sentiment_score": "0.049808",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.000869",
        "ticker_sentiment_score": "0.018034",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.004343",
        "ticker_sentiment_score": "0.034563",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RYAOF",
        "relevance_score": "0.003474",
        "ticker_sentiment_score": "-0.03206",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.000869",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNXYF",
        "relevance_score": "0.000869",
        "ticker_sentiment_score": "0.060996",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Want $1 Million in Retirement? 2 ETFs to Buy Now and Hold for Decades",
    "url": "https://www.fool.com/investing/2024/06/03/want-1-million-in-retirement-2-etfs-to-buy-now/",
    "time_published": "20240603T093000",
    "authors": [
      "Ryan Vanzo"
    ],
    "summary": "These ETFs are an easy way to turn small but regular contributions into a $1 million retirement fund.",
    "banner_image": "https://g.foolcdn.com/editorial/images/775837/etf-hands-business-blocks.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999997"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.232737,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SO",
        "relevance_score": "0.068698",
        "ticker_sentiment_score": "0.08527",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.068698",
        "ticker_sentiment_score": "0.021254",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.068698",
        "ticker_sentiment_score": "0.021254",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NEE",
        "relevance_score": "0.068698",
        "ticker_sentiment_score": "0.08527",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Soars 3.2%: Is Further Upside Left in the Stock?",
    "url": "https://www.zacks.com/stock/news/2282406/abbvie-abbv-soars-32-is-further-upside-left-in-the-stock",
    "time_published": "20240603T063300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default323.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.206255,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.514619",
        "ticker_sentiment_score": "0.1352",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.514619",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "US court jury directs J&J to pay $260 million to baby powder user",
    "url": "https://www.business-standard.com/world-news/us-court-jury-directs-j-j-to-pay-260-million-to-baby-powder-user-124060401899_1.html",
    "time_published": "20240604T173313",
    "authors": [
      "Bloomberg"
    ],
    "summary": "J&J officials said they'd appeal the Oregon verdict and are confident it will be thrown out. Photo: Bloomberg Johnson & Johnson was ordered by an Oregon jury to pay $260 million to a woman who blamed her cancer on life-long use of the company's baby powder as the drugmaker strives to wrap-up ...",
    "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-05/02/full/1683045756-614.jpg?im=FeatureCrop,size=(826,465)",
    "source": "Business Standard",
    "category_within_source": "GoogleRSS",
    "source_domain": "www.business-standard.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.061009,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.11123",
        "ticker_sentiment_score": "-0.190905",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Bitcoin Breaches $70K Before Pulling Back, Analysts Optimistic Despite Volatility; NYSE Fixes Glitch That Slashed Berkshire Hathaway Shares - Top Headlines Today While US Slept",
    "url": "https://www.benzinga.com/markets/cryptocurrency/24/06/39162285/bitcoin-breaches-70k-before-pulling-back-analysts-optimistic-despite-volatility-nyse-fixes",
    "time_published": "20240604T141657",
    "authors": [
      "Akanksha Bakshi"
    ],
    "summary": "Bitcoin Spot ETFs On 15-Day Inflow Streak As Wisconsin Starts Buying Bitcoin What The Ethereum ETF Means For Altcoins And Meme Coins NBA NFT Creator Dapper Labs Settles Securities Violation Lawsuit For $4M: 'Pleased With The Results'",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/04/Bitcoin-crypto-Photo-by-Vladimka-product.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": -0.032016,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.171688",
        "ticker_sentiment_score": "-0.227",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "EADSF",
        "relevance_score": "0.057628",
        "ticker_sentiment_score": "-0.117973",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.057628",
        "ticker_sentiment_score": "-0.278034",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "HQY",
        "relevance_score": "0.057628",
        "ticker_sentiment_score": "0.166995",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.227538",
        "ticker_sentiment_score": "-0.080056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.057628",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.114956",
        "ticker_sentiment_score": "-0.021992",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NIO",
        "relevance_score": "0.057628",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.171688",
        "ticker_sentiment_score": "-0.114024",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.057628",
        "ticker_sentiment_score": "-0.148988",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SAVE",
        "relevance_score": "0.057628",
        "ticker_sentiment_score": "-0.050388",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GME",
        "relevance_score": "0.114956",
        "ticker_sentiment_score": "0.033455",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.335519",
        "ticker_sentiment_score": "0.385287",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CRYPTO:ETH",
        "relevance_score": "0.114956",
        "ticker_sentiment_score": "0.266408",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRYPTO:DOGE",
        "relevance_score": "0.057628",
        "ticker_sentiment_score": "0.3271",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Suddenly Whole-Body Deodorants Are Trending In The U.S.",
    "url": "https://www.forbes.com/sites/joshuacohen/2024/06/04/suddenly-whole-body-deodorants-are-trending-in-the-us/",
    "time_published": "20240604T123337",
    "authors": [
      "Joshua Cohen"
    ],
    "summary": "You've probably seen the ads on television or online regarding deodorant that goes beyond armpits and is meant for your whole body, including your groin area, feet and practically anywhere else you fancy.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6651f7512cb8fadd2e2561d6/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.026753,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NYT",
        "relevance_score": "0.043818",
        "ticker_sentiment_score": "0.067803",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRMNF",
        "relevance_score": "0.043818",
        "ticker_sentiment_score": "-0.208521",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.043818",
        "ticker_sentiment_score": "-0.050404",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Ordered To Pay $260M In Latest Talc Trial - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/06/39151770/johnson-johnson-ordered-to-pay-260m-in-latest-talc-trial",
    "time_published": "20240604T055832",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "A jury has ruled that Johnson & Johnson JNJ must pay $260 million to an Oregon woman who claims to have developed mesothelioma from using the company's talc powder. What Happened: The jury's decision, announced on Monday, includes $60 million in compensatory damages and $200 million in punitive ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/04/Johnson-and-Johnson.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.29229,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.25168",
        "ticker_sentiment_score": "-0.094561",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Stock Drops Despite Market Gains: Important Facts to Note",
    "url": "https://www.zacks.com/stock/news/2284311/johnson-johnson-jnj-stock-drops-despite-market-gains-important-facts-to-note",
    "time_published": "20240605T214510",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) closed at $145.97 in the latest trading session, marking a -1.24% move from the prior day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default253.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.983783"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.212594,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.577838",
        "ticker_sentiment_score": "0.337891",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "J&J  ( JNJ )  Seeks Expanded Use of HIV Drug in US and Europe",
    "url": "https://www.zacks.com/stock/news/2283972/jj-jnj-seeks-expanded-use-of-hiv-drug-in-us-and-europe",
    "time_published": "20240605T134700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "J&J (JNJ) seeks expanded use of its HIV-1 therapy, Prezcobix, for younger kids in the United States and Europe.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.131438,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GILD",
        "relevance_score": "0.166743",
        "ticker_sentiment_score": "-0.057057",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BVS",
        "relevance_score": "0.401331",
        "ticker_sentiment_score": "0.374733",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GSK",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "0.091739",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.326283",
        "ticker_sentiment_score": "0.157381",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AI 'healthcare revolution' already under way, Nvidia says",
    "url": "https://www.aljazeera.com/economy/2024/6/5/ai-healthcare-revolution-already-under-way-nvidia-says",
    "time_published": "20240605T074908",
    "authors": [
      "Erin Hale"
    ],
    "summary": "Top executive says AI likely to affect healthcare more than any other area of life. Taipei, Taiwan - Generative artificial intelligence ( AI ) has already brought about a \"healthcare revolution\" and is set to transform everything from pharmaceutical research to patient diagnostics and ...",
    "banner_image": "https://www.aljazeera.com/wp-content/uploads/2024/06/AFP__20211224__631007442__v2__HighRes__LatestConsumerTechnologyProductsOnDisplayAtCe-1-1717570850.jpg?resize=770%2C513&quality=80",
    "source": "Al Jareeza",
    "category_within_source": "n/a",
    "source_domain": "www.aljazeera.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.16778,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.196344",
        "ticker_sentiment_score": "0.07859",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.066047",
        "ticker_sentiment_score": "0.103177",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Starts Late-Stage Study on Multiple Myeloma Drug",
    "url": "https://www.zacks.com/stock/news/2284943/abbvie-abbv-starts-late-stage-study-on-multiple-myeloma-drug",
    "time_published": "20240606T155300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The late-stage study will evaluate AbbVie's (ABBV) experimental antibody to treat patients with relapsed/refractory multiple myeloma who have received at least two lines of prior therapy.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/36/1919.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.205173,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KPTI",
        "relevance_score": "0.061315",
        "ticker_sentiment_score": "0.017057",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARQT",
        "relevance_score": "0.241684",
        "ticker_sentiment_score": "0.109492",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.558244",
        "ticker_sentiment_score": "0.18078",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GMAB",
        "relevance_score": "0.061315",
        "ticker_sentiment_score": "0.050214",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.122269",
        "ticker_sentiment_score": "0.188978",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.122269",
        "ticker_sentiment_score": "0.188978",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Axtria Ignite 2024: A Celebration of Innovation and Leadership in Life Sciences",
    "url": "https://www.prnewswire.com/in/news-releases/axtria-ignite-2024-a-celebration-of-innovation-and-leadership-in-life-sciences-302166125.html",
    "time_published": "20240606T123000",
    "authors": [
      "Axtria",
      "Inc."
    ],
    "summary": "Join us on June 12-13 in Princeton, New Jersey, for an inspiring event featuring life sciences experts, thought leaders, and award winners.",
    "banner_image": "https://mma.prnewswire.com/media/2256316/Axtria_transparent_bg_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.555647,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.066598",
        "ticker_sentiment_score": "0.358072",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.066598",
        "ticker_sentiment_score": "0.358072",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.066598",
        "ticker_sentiment_score": "0.358072",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.066598",
        "ticker_sentiment_score": "0.358072",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.066598",
        "ticker_sentiment_score": "0.358072",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Premium Cosmetics Market size is set to grow by USD 66.99 billion from 2024-2028, Increased demand for premium ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/premium-cosmetics-market-size-is-set-to-grow-by-usd-66-99-billion-from-2024-2028--increased-demand-for-premium-skincare-products-boost-the-market-technavio-302166550.html",
    "time_published": "20240607T215500",
    "authors": [],
    "summary": "Premium Cosmetics Market size is set to grow by USD 66.99 billion from 2024-2028, Increased demand for premium ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.412387,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.33444",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.33444",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BDRFF",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.049856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KAOCF",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.049856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSDOF",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.049856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REVRQ",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.049856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.049856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.070105",
        "ticker_sentiment_score": "0.174413",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UL",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.049856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HENKY",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.049856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LRLCF",
        "relevance_score": "0.104988",
        "ticker_sentiment_score": "0.188556",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "COTY",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.049856",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Antibiotics Market size is set to grow by USD 16.63 billion from 2024-2028, Rising prevalence of infectious diseases ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/antibiotics-market-size-is-set-to-grow-by-usd-16-63-billion-from-2024-2028--rising-prevalence-of-infectious-diseases-boost-the-market-technavio-302166383.html",
    "time_published": "20240607T211500",
    "authors": [],
    "summary": "Antibiotics Market size is set to grow by USD 16.63 billion from 2024-2028, Rising prevalence of infectious diseases ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.069745,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.01328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APNHF",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.01328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.01328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MAYNF",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.01328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.01328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALPMF",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.01328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.01328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.01328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.01328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.01328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.01328",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Up 400% In 3 Years, Eli Lilly Stock Just Keeps Giving",
    "url": "https://www.forbes.com/sites/greatspeculations/2024/06/07/up-400-in-three-years-eli-lilly-stock-just-keeps-giving/",
    "time_published": "20240607T150023",
    "authors": [
      "Trefis Team"
    ],
    "summary": "Eli Lilly stock ( NYSE: LLY ) has seen phenomenal gains of 400% from levels of $170 in early 2021 to around $840 now. This reflects a meaningful outperformance compared to some of its peers, with Pfizer stock ( NYSE: PFE ) seeing a 15% decline and Johnson & Johnson stock ( NYSE: JNJ ) seeing no ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/662b6a87b3af139422324bac/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.213202,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.849174",
        "ticker_sentiment_score": "0.358132",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.067347",
        "ticker_sentiment_score": "0.174885",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.098765",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.200134",
        "ticker_sentiment_score": "0.123411",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Dow Stocks That Are No-Brainer Buys in June",
    "url": "https://www.fool.com/investing/2024/06/07/3-dow-stocks-that-are-no-brainer-buys-in-june/",
    "time_published": "20240607T082100",
    "authors": [
      "Sean Williams"
    ],
    "summary": "The 30-component Dow Jones Industrial Average has three phenomenal deals hiding in plain sight.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F779822%2Fnyse-wall-street-trading-new-york-financial-stock-market-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.995921"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.2337,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMD",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.034305",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.228143",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TWOH",
        "relevance_score": "0.031907",
        "ticker_sentiment_score": "0.237867",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.310843",
        "ticker_sentiment_score": "0.121315",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.158519",
        "ticker_sentiment_score": "0.227424",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Dry Shampoo Market size is set to grow by USD 3.32 billion from 2024-2028, Product innovation leading to product ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/dry-shampoo-market-size-is-set-to-grow-by-usd-3-32-billion-from-2024-2028--product-innovation-leading-to-product-premiumization-to-boost-the-market-growth-technavio-302167735.html",
    "time_published": "20240609T223500",
    "authors": [],
    "summary": "Dry Shampoo Market size is set to grow by USD 3.32 billion from 2024-2028, Product innovation leading to product ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.309493,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KAOCF",
        "relevance_score": "0.032825",
        "ticker_sentiment_score": "0.081435",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSDOF",
        "relevance_score": "0.032825",
        "ticker_sentiment_score": "0.081435",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KOSCF",
        "relevance_score": "0.032825",
        "ticker_sentiment_score": "0.081435",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REVRQ",
        "relevance_score": "0.032825",
        "ticker_sentiment_score": "0.081435",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.032825",
        "ticker_sentiment_score": "0.081435",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.032825",
        "ticker_sentiment_score": "0.081435",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UL",
        "relevance_score": "0.032825",
        "ticker_sentiment_score": "0.081435",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HENKY",
        "relevance_score": "0.032825",
        "ticker_sentiment_score": "0.081435",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EPC",
        "relevance_score": "0.032825",
        "ticker_sentiment_score": "0.081435",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LRLCF",
        "relevance_score": "0.032825",
        "ticker_sentiment_score": "0.081435",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What are dividends?",
    "url": "https://apnews.com/buyline-personal-finance/article/what-are-dividends",
    "time_published": "20240609T125652",
    "authors": [
      "Jess Ullrich"
    ],
    "summary": "AP Buyline's content is created independently of The Associated Press newsroom. Our evaluations and opinions are not influenced by our advertising relationships, but we might earn commissions from our partners' links in this content. Learn more about our policies and terms here .",
    "banner_image": "https://apnews.com/buyline-personal-finance/static/ab39cd4c242fd136dc13c9a81bac71c8/38bbb/dividend-stampforbetteryields.jpg",
    "source": "Associated Press",
    "category_within_source": "Markets",
    "source_domain": "apnews.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.225255,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SCHW",
        "relevance_score": "0.035397",
        "ticker_sentiment_score": "0.17176",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CCZ",
        "relevance_score": "0.035397",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.035397",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.035397",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Earnings Season Update and Analyst Reports for Broadcom, JNJ & Verizon",
    "url": "https://www.zacks.com/research-daily/2286071/earnings-season-update-and-analyst-reports-for-broadcom-jnj-verizon",
    "time_published": "20240610T202200",
    "authors": [
      "Sheraz Mian"
    ],
    "summary": "Today's Research Daily features an earnings season update and new research reports on Broadcom (AVGO), Johnson & Johnson (JNJ) and Verizon (VZ), as well as two micro-cap stocks Taylor Devices, Inc. (TAYD) and Frequency Electronics, Inc. (FEIM).",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default157.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.29606,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VMW",
        "relevance_score": "0.087185",
        "ticker_sentiment_score": "0.189166",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.043658",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.130453",
        "ticker_sentiment_score": "0.166214",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FEIM",
        "relevance_score": "0.043658",
        "ticker_sentiment_score": "0.177487",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.043658",
        "ticker_sentiment_score": "0.219675",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZO",
        "relevance_score": "0.043658",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.043658",
        "ticker_sentiment_score": "0.010968",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAYD",
        "relevance_score": "0.043658",
        "ticker_sentiment_score": "0.12914",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Over 80 Organizations Kick Off Blood Advocacy Week by Urging Congress to Support the Blood Supply as a National Priority",
    "url": "https://www.benzinga.com/pressreleases/24/06/g39257293/over-80-organizations-kick-off-blood-advocacy-week-by-urging-congress-to-support-the-blood-supply-",
    "time_published": "20240610T184725",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Washington, DC, June 10, 2024 ( GLOBE NEWSWIRE ) -- More than 80 prominent organizations from around the country joined together to kick off Blood Advocacy Week by urging Members of Congress to take key actions to support the blood supply as a national priority. The joint letter to Congress is ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.121905,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BOH",
        "relevance_score": "0.043499",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CERS",
        "relevance_score": "0.043499",
        "ticker_sentiment_score": "-0.053208",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRUMF",
        "relevance_score": "0.043499",
        "ticker_sentiment_score": "-0.053208",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.043499",
        "ticker_sentiment_score": "-0.053208",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Roche alleges counterfeit diabetes medical devices were sold on Amazon",
    "url": "https://www.cnbc.com/2024/06/10/roche-counterfeit-diabetes-medical-devices.html",
    "time_published": "20240610T170006",
    "authors": [
      "Scott Zamost"
    ],
    "summary": "Counterfeit diabetes test strips have been sold on Amazon and shipped to patients across the U.S., said biotech company Roche.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107426373-1718021509074-gettyimages-1135806218-INSULIN_DRUG_PRICING.jpeg?v=1718021536&w=1920&h=1080",
    "source": "CNBC",
    "category_within_source": "Business",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": -0.103313,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.042122",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ULTA",
        "relevance_score": "0.042122",
        "ticker_sentiment_score": "-0.190877",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Cala TAPS Therapy is Now Covered by Medicare for Essential Tremor Patients, And Company Appoints CEO and President",
    "url": "https://www.prnewswire.com/news-releases/cala-taps-therapy-is-now-covered-by-medicare-for-essential-tremor-patients-and-company-appoints-ceo-and-president-302167845.html",
    "time_published": "20240610T130000",
    "authors": [
      "Cala Health"
    ],
    "summary": "Cala TAPS Therapy is Now Covered by Medicare for Essential Tremor Patients, And Company Appoints CEO and ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/2256949/CALA_Wordmark_Logo_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.353117,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MDT",
        "relevance_score": "0.04406",
        "ticker_sentiment_score": "0.141754",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.04406",
        "ticker_sentiment_score": "0.141754",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.04406",
        "ticker_sentiment_score": "0.141754",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Stock Dips While Market Gains: Key Facts",
    "url": "https://www.zacks.com/stock/news/2286932/johnson-johnson-jnj-stock-dips-while-market-gains-key-facts",
    "time_published": "20240611T214518",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) closed the most recent trading day at $146.76, moving -0.25% from the previous trading session.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default74.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.20715,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.526455",
        "ticker_sentiment_score": "0.27443",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Expanding its Launch Activities in the US, Odne Appoints Steve Fanning as Member of the Board - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/expanding-its-launch-activities-in-the-us-odne-appoints-steve-fanning-as-member-of-the-board-302168071.html",
    "time_published": "20240611T140000",
    "authors": [],
    "summary": "Expanding its Launch Activities in the US, Odne Appoints Steve Fanning as Member of the Board PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.257431,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HSIC",
        "relevance_score": "0.043738",
        "ticker_sentiment_score": "0.086697",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVST",
        "relevance_score": "0.043738",
        "ticker_sentiment_score": "0.086697",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.043738",
        "ticker_sentiment_score": "0.086697",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "BDA ACQUIRES EUROPE'S LEADING SPORTS MERCHANDISE PROVIDER, THE GREAT BRANDING COMPANY - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/bda-acquires-europes-leading-sports-merchandise-provider-the-great-branding-company-302169132.html",
    "time_published": "20240611T130000",
    "authors": [],
    "summary": "BDA ACQUIRES EUROPE'S LEADING SPORTS MERCHANDISE PROVIDER, THE GREAT BRANDING COMPANY PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.460542,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MANU",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.107756",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BORUF",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.263782",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.161604",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ICNB",
        "relevance_score": "0.141171",
        "ticker_sentiment_score": "0.180543",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.161604",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.161604",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Hits an All-Time High: Is the Soaring Pharma Stock Still a Buy?",
    "url": "https://www.fool.com/investing/2024/06/11/eli-lilly-all-time-high-buy-pharma-stock/",
    "time_published": "20240611T095000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "The world's biggest healthcare company might become even larger.",
    "banner_image": "https://g.foolcdn.com/editorial/images/780172/scientists-smiling-and-shaking-hands.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.287937,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.683932",
        "ticker_sentiment_score": "0.49332",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.061473",
        "ticker_sentiment_score": "0.050001",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.061473",
        "ticker_sentiment_score": "0.050001",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Broadcom, Johnson & Johnson, Verizon, Taylor Devices and Frequency Electronics",
    "url": "https://www.zacks.com/stock/news/2286373/the-zacks-analyst-blog-highlights-broadcom-johnson-johnson-verizon-taylor-devices-and-frequency-electronics",
    "time_published": "20240611T085100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Broadcom, Johnson & Johnson, Verizon, Taylor Devices and Frequency Electronics are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cd/401.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.905476"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.285526,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VMW",
        "relevance_score": "0.090645",
        "ticker_sentiment_score": "0.190635",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.224072",
        "ticker_sentiment_score": "0.104674",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FEIM",
        "relevance_score": "0.180124",
        "ticker_sentiment_score": "0.123036",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.180124",
        "ticker_sentiment_score": "0.13824",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.180124",
        "ticker_sentiment_score": "0.046573",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAYD",
        "relevance_score": "0.180124",
        "ticker_sentiment_score": "0.096702",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Time to Pounce: 2 High-Yielding Dow Stocks That Are Begging to Be Bought Right Now",
    "url": "https://www.fool.com/investing/2024/06/11/time-to-pounce-2-high-yield-dow-stocks-to-buy-now/",
    "time_published": "20240611T084100",
    "authors": [
      "Sean Williams"
    ],
    "summary": "Among the Dow's 30 components are two high-octane income stocks that have increased their respective payouts for 37 and 62 consecutive years.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F780141%2Fcounting-cash-in-hands-money-bills-dividend-invest-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999365"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.183936,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CVX",
        "relevance_score": "0.288893",
        "ticker_sentiment_score": "0.073913",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.204565",
        "ticker_sentiment_score": "0.155893",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Bright Peak Therapeutics Announces $90 Million in Series C Financing to Advance First-in-Class PD1-IL18 Immunoconjugate Program Into Clinical Trials",
    "url": "https://www.benzinga.com/pressreleases/24/06/g39264814/bright-peak-therapeutics-announces-90-million-in-series-c-financing-to-advance-first-in-class-pd1-",
    "time_published": "20240611T080000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "-- Lead Program, BPT567, will be the first PD1-IL18 immunoconjugate to enter the clinic; Phase 1/2a study in solid tumors expected to begin in 2H 2024 - -- Financing led by Johnson & Johnson with participation by new and existing investors--",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.342259,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.167904",
        "ticker_sentiment_score": "0.180077",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( NYSE:JNJ )  Lowered to Buy at StockNews.com",
    "url": "https://www.defenseworld.net/2024/06/11/johnson-johnson-nysejnj-lowered-to-buy-at-stocknews-com.html",
    "time_published": "20240611T072248",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "StockNews.com cut shares of Johnson & Johnson ( NYSE:JNJ - Free Report ) from a strong-buy rating to a buy rating in a research report released on Monday. A number of other research analysts also recently issued reports on the company.",
    "banner_image": "https://www.marketbeat.com/logos/johnson--johnson-logo.png?v=20221020135923",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.993856"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.245796,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RBCPF",
        "relevance_score": "0.046999",
        "ticker_sentiment_score": "0.076165",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.046999",
        "ticker_sentiment_score": "0.076165",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.046999",
        "ticker_sentiment_score": "0.076165",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.711266",
        "ticker_sentiment_score": "0.391503",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Oklahoma Supreme Court dismisses lawsuit of last Tulsa Race Massacre survivors seeking reparations",
    "url": "https://apnews.com/article/1921-race-massacre-tulsa-black-survivors-b7a4c83514ce79640a8490d49efb9006",
    "time_published": "20240612T180100",
    "authors": [
      "SEAN MURPHY"
    ],
    "summary": "OKLAHOMA CITY ( AP ) - The Oklahoma Supreme Court on Wednesday dismissed a lawsuit of the last two survivors of the 1921 Tulsa Race Massacre, dampening the hope of advocates for racial justice that the government would make amends for one of the in U.S. history.",
    "banner_image": "https://dims.apnews.com/dims4/default/7dd1a17/2147483647/strip/true/crop/5043x3359+0+1/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F20%2F5a%2F8490286359db7b3c9f1d7041597c%2Ffbe58b09a88147009f48220e6e97ffc2",
    "source": "Associated Press",
    "category_within_source": "Markets",
    "source_domain": "apnews.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.148285,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "-0.070978",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "US Gastroenterologists Express Anticipation for Approval of AbbVie's Skyrizi in Ulcerative Colitis, Projecting Rapid Adoption Post-Launch",
    "url": "https://www.benzinga.com/pressreleases/24/06/g39295937/us-gastroenterologists-express-anticipation-for-approval-of-abbvies-skyrizi-in-ulcerative-colitis-",
    "time_published": "20240612T161832",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "EXTON, PA, June 12, 2024 ( GLOBE NEWSWIRE ) -- Despite being the second IL-23 inhibitor to enter the market, AbbVie's Skyrizi ( risankizumab ) is expected to have a substantial impact on ulcerative colitis ( UC ) treatment.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.257903,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.199037",
        "ticker_sentiment_score": "0.171753",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.050254",
        "ticker_sentiment_score": "0.127259",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bitcoin, Ethereum, And Dogecoin Drop Ahead Of The Fed's Rate Decision; The Biden Administration Aims To Extend Sanctions On Semiconductor Sales To Russia, Targeting Chinese Sellers - Top Headlines Today While US Slept",
    "url": "https://www.benzinga.com/news/24/06/39292212/bitcoin-ethereum-and-dogecoin-drop-ahead-of-the-feds-rate-decision-the-biden-administration-aims-to",
    "time_published": "20240612T135325",
    "authors": [
      "Akanksha Bakshi"
    ],
    "summary": "Bitcoin Climbs Above $67.5K As Spot ETFs See $200M Outflows On Tuesday European Law Agency Says Bitcoin Mining Vulnerable To Financial Crimes Even As Donald Trump Cosies Up To The Industry Shiba Inu Spot ETF Petition Crosses 10K Signatures: Wishful Thinking Or Inevitable Reality?",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/12/Cryptocurrency-Photo-by-CMP-NZ-on-Shutte.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.94762"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.143775,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BABA",
        "relevance_score": "0.061003",
        "ticker_sentiment_score": "0.105728",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XPEV",
        "relevance_score": "0.061003",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.061003",
        "ticker_sentiment_score": "0.11101",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.061003",
        "ticker_sentiment_score": "-0.149034",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LUV",
        "relevance_score": "0.061003",
        "ticker_sentiment_score": "0.08272",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LI",
        "relevance_score": "0.061003",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ON",
        "relevance_score": "0.061003",
        "ticker_sentiment_score": "0.150034",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.240489",
        "ticker_sentiment_score": "0.298045",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRYPTO:ETH",
        "relevance_score": "0.12165",
        "ticker_sentiment_score": "0.13591",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:SHIB",
        "relevance_score": "0.061003",
        "ticker_sentiment_score": "-0.154038",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "CRYPTO:DOGE",
        "relevance_score": "0.061003",
        "ticker_sentiment_score": "0.136024",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields - Royalty Pharma  ( NASDAQ:RPRX ) ",
    "url": "https://www.benzinga.com/news/24/06/39291315/wall-streets-most-accurate-analysts-spotlight-on-3-health-care-stocks-delivering-high-dividend-yield",
    "time_published": "20240612T131552",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/12/Interest-Rate-And-Dividend-Yield-Concept.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      }
    ],
    "overall_sentiment_score": 0.066874,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "RPRX",
        "relevance_score": "0.199037",
        "ticker_sentiment_score": "-0.157069",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "-0.014167",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "-0.076473",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "With A Similar Revenue Base, Is Johnson & Johnson A Better Pick Despite The 30% Fall In Tesla Stock This Year?",
    "url": "https://www.forbes.com/sites/greatspeculations/2024/06/12/with-a-similar-revenue-base-is-johnson--johnson-a-better-pick-despite-the-30-fall-in-tesla-stock-this-year/",
    "time_published": "20240612T130047",
    "authors": [
      "Trefis Team"
    ],
    "summary": "We believe that the pharmaceuticals bellwether Johnson & Johnson ( NYSE: JNJ ) is currently a better pick over the auto giant Tesla ( NASDAQ: TSLA ) . The decision to invest often comes down to finding the best stocks within the scope of certain characteristics that suit an investment style.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/66692cbf06f9f14db7840fdf/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.998663"
      }
    ],
    "overall_sentiment_score": 0.181883,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "XPEV",
        "relevance_score": "0.038345",
        "ticker_sentiment_score": "-0.011724",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.436009",
        "ticker_sentiment_score": "0.341628",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.68732",
        "ticker_sentiment_score": "0.273047",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson To Pay $700M To Settle Multi-State Talc Investigation - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/news/24/06/39288492/johnson-johnson-to-pay-700m-to-settle-multi-state-talc-investigation",
    "time_published": "20240612T115323",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "In a significant development, Johnson & Johnson JNJ has agreed to pay a hefty sum to resolve a multi-state investigation into its talc-based products. What Happened: The pharmaceutical giant will pay $700 million to settle allegations that its talc products, including baby powder, led to cancer.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/12/jnj-johnson-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.070963,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.70749",
        "ticker_sentiment_score": "-0.253945",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "A Life Expansion Revolution Is Coming: 3 Stocks That Could Lead the Charge",
    "url": "https://www.fool.com/investing/2024/06/12/a-life-expansion-revolution-is-coming-3-stocks-tha/",
    "time_published": "20240612T113000",
    "authors": [
      "George Budwell"
    ],
    "summary": "The integration of AI and healthcare is well underway.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F780297%2Fbiotech.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.325863,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.143415",
        "ticker_sentiment_score": "0.034246",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXAI",
        "relevance_score": "0.072",
        "ticker_sentiment_score": "0.226022",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.143415",
        "ticker_sentiment_score": "0.400754",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.282234",
        "ticker_sentiment_score": "0.204477",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Stocks You Can Safely Hold for the Long Haul",
    "url": "https://www.fool.com/investing/2024/06/12/2-stocks-you-can-safely-hold-for-the-long-haul/",
    "time_published": "20240612T101000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "Some services will always be in high demand.",
    "banner_image": "https://g.foolcdn.com/editorial/images/779911/patient-and-doctor-talking.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      }
    ],
    "overall_sentiment_score": 0.309722,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MFCSF",
        "relevance_score": "0.056143",
        "ticker_sentiment_score": "0.012002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCA",
        "relevance_score": "0.47379",
        "ticker_sentiment_score": "0.376331",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.377958",
        "ticker_sentiment_score": "0.329577",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson to pay $700m to settle claims it misled consumers",
    "url": "https://www.aljazeera.com/economy/2024/6/12/johnson-johnson-to-pay-700m-to-settle-claims-it-misled-consumers",
    "time_published": "20240612T070835",
    "authors": [
      "Al Jazeera"
    ],
    "summary": "Johnson & Johnson has agreed to pay $700m to settle lawsuits in the United States that accused the pharmaceutical giant of deceiving customers about the safety of its talcum-based powder products.",
    "banner_image": "https://www.aljazeera.com/wp-content/uploads/2024/06/AFP__20230405__1480096603__v1__HighRes__JohnsonJohnsonReachesSettlementIn89BillionDo-1718171363.jpg?resize=770%2C513&quality=80",
    "source": "Al Jareeza",
    "category_within_source": "n/a",
    "source_domain": "www.aljazeera.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": -0.176972,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "NYT",
        "relevance_score": "0.107978",
        "ticker_sentiment_score": "-0.083669",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.107978",
        "ticker_sentiment_score": "0.002412",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "How Is The Market Feeling About Johnson & Johnson? - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/06/39316915/how-is-the-market-feeling-about-johnson-johnson",
    "time_published": "20240613T161524",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Johnson & Johnson's JNJ short percent of float has risen 15.28% since its last report. The company recently reported that it has 19.93 million shares sold short, which is 0.83% of all regular shares that are available for trading.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.287737,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.147012",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "MSFT: 3 Blue-Chip Stocks Offering Stability",
    "url": "https://stocknews.com/news/msft-pg-jnj-cndt-3-blue-chip-stocks-offering-stability/",
    "time_published": "20240613T141351",
    "authors": [
      "StockNews.com Staff"
    ],
    "summary": "Blue-chip stocks belong to large companies with a track record of consistent financial performance, global presence, and dominant market positions.",
    "banner_image": "https://stocknews.com/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "stocknews.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.623304"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999864"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.304175,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.300323",
        "ticker_sentiment_score": "0.329918",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CNDT",
        "relevance_score": "0.047324",
        "ticker_sentiment_score": "0.146635",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.023673",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.278222",
        "ticker_sentiment_score": "0.230948",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.233332",
        "ticker_sentiment_score": "0.362848",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  is Attracting Investor Attention: Here is What You Should Know",
    "url": "https://www.zacks.com/stock/news/2287733/johnson-johnson-jnj-is-attracting-investor-attention-here-is-what-you-should-know",
    "time_published": "20240613T130016",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default208.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.246454,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.477606",
        "ticker_sentiment_score": "0.165866",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Tencent-Backed AI Drug Discovery Startup Xtalpi Rises In Hong Kong Debut",
    "url": "https://www.forbes.com/sites/zinnialee/2024/06/13/tencent-backed-ai-drug-discovery-startup-xtalpi-rises-in-hong-kong-debut/",
    "time_published": "20240613T130007",
    "authors": [
      "Zinnia Lee"
    ],
    "summary": "Shares of Xtalpi, a Shenzhen-based AI drug discovery startup, rose in its highly anticipated Hong Kong stock market debut Thursday, boosting its market capitalization to $2.5 billion.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/666a59c8091e26c2ff538c1f/0x0.jpg?format=jpg&crop=1557,876,x0,y20,safe&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.126933,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.052112",
        "ticker_sentiment_score": "0.054831",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CKHUF",
        "relevance_score": "0.052112",
        "ticker_sentiment_score": "0.148545",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.052112",
        "ticker_sentiment_score": "0.148545",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HLDVF",
        "relevance_score": "0.052112",
        "ticker_sentiment_score": "0.02599",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SZIHF",
        "relevance_score": "0.052112",
        "ticker_sentiment_score": "0.154549",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.052112",
        "ticker_sentiment_score": "0.148545",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBMFF",
        "relevance_score": "0.104002",
        "ticker_sentiment_score": "0.10152",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TCTZF",
        "relevance_score": "0.052112",
        "ticker_sentiment_score": "0.054831",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Young Teen Entrepreneurs and Innovators from Junior Achievement Achieve National Recognition at the 2024 Junior Achievement National Student Leadership Summit",
    "url": "https://www.prnewswire.com/news-releases/young-teen-entrepreneurs-and-innovators-from-junior-achievement-achieve-national-recognition-at-the-2024-junior-achievement-national-student-leadership-summit-302171947.html",
    "time_published": "20240613T115200",
    "authors": [
      "Junior Achievement USA"
    ],
    "summary": "Young Teen Entrepreneurs and Innovators from Junior Achievement Achieve National Recognition at the 2024 Junior ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/2437905/Junior_Achievement_USA_FlameGuard.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.571588,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JHG",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.334488",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FDX",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.334488",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.334488",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Idorsia holds its Annual General Meeting of Shareholders",
    "url": "https://www.globenewswire.com/news-release/2024/06/13/2898055/0/en/Idorsia-holds-its-Annual-General-Meeting-of-Shareholders.html",
    "time_published": "20240613T090000",
    "authors": [
      "Idorsia Pharmaceuticals Ltd"
    ],
    "summary": "Allschwil, Switzerland - June 13, 2024At today's Annual General Meeting ( AGM ) of Idorsia Ltd ( SIX: IDIA ) held in Basel, Switzerland, shareholders voted in favor of all proposals by the Board of Directors with very large majorities.",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/bb724119-468d-4b1d-8206-3c2175d07f2b",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.283816,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IDRSF",
        "relevance_score": "0.62159",
        "ticker_sentiment_score": "0.570657",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.041323",
        "ticker_sentiment_score": "0.256566",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Could Be a Great Choice",
    "url": "https://www.zacks.com/stock/news/2288602/johnson-johnson-jnj-could-be-a-great-choice",
    "time_published": "20240614T154509",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default250.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938238"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998356"
      }
    ],
    "overall_sentiment_score": 0.396943,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.436009",
        "ticker_sentiment_score": "0.478139",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Intellia Therapeutics Names Brian Goff to its Board of Directors",
    "url": "https://www.globenewswire.com/news-release/2024/06/14/2898922/0/en/Intellia-Therapeutics-Names-Brian-Goff-to-its-Board-of-Directors.html",
    "time_published": "20240614T113000",
    "authors": [
      "Intellia Therapeutics",
      "Inc."
    ],
    "summary": "CAMBRIDGE, Mass., June 14, 2024 ( GLOBE NEWSWIRE ) -- Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) , a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the appointment of Brian Goff to its board of directors.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/9b6b17bb-c8a4-4009-b5f8-8cadb4d2296a",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.126577,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AGIO",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.027867",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.027867",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.027867",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTLA",
        "relevance_score": "0.149038",
        "ticker_sentiment_score": "0.186591",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Intellia Therapeutics Names Brian Goff to its Board of Directors - Intellia Therapeutics  ( NASDAQ:NTLA ) ",
    "url": "https://www.benzinga.com/pressreleases/24/06/g39329974/intellia-therapeutics-names-brian-goff-to-its-board-of-directors",
    "time_published": "20240614T113000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "CAMBRIDGE, Mass., June 14, 2024 ( GLOBE NEWSWIRE ) -- Intellia Therapeutics, Inc. NTLA, a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the appointment of Brian Goff to its board of directors.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.128956,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AGIO",
        "relevance_score": "0.045569",
        "ticker_sentiment_score": "0.027662",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.045569",
        "ticker_sentiment_score": "0.027662",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.045569",
        "ticker_sentiment_score": "0.027662",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTLA",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.243381",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "How 4 Ordinary People Invested To Reach Financial Goals",
    "url": "https://www.kiplinger.com/investing/how-ordinary-people-used-investing-to-reach-financial-goals",
    "time_published": "20240616T130055",
    "authors": [
      "Kim Clark"
    ],
    "summary": "How 4 Ordinary People Used Investing To Reach Financial Goals Kiplinger's Personal Finance ...",
    "banner_image": "https://cdn.mos.cms.futurecdn.net/hwgJ7osrMtUWhk5koeVme7-320-80.png",
    "source": "Kiplinger",
    "category_within_source": "n/a",
    "source_domain": "www.kiplinger.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.287357,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.022729",
        "ticker_sentiment_score": "0.062131",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NKE",
        "relevance_score": "0.068112",
        "ticker_sentiment_score": "0.101398",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.045439",
        "ticker_sentiment_score": "0.134485",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.045439",
        "ticker_sentiment_score": "0.134485",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Legend Biotech's Cancer Drug, 'The Most Attractive Product,' Set For Growth: Analyst - Legend Biotech  ( NASDAQ:LEGN ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39361513/legend-biotechs-cancer-drug-the-most-attractive-product-set-for-growth-analyst",
    "time_published": "20240617T161505",
    "authors": [
      "Priya Nigam"
    ],
    "summary": "Shares of cell therapy company Legend Biotech Corp LEGN were trading lower on Monday, after being among the top pharma gainers in the first week of June. The company's Carvykti drug is likely to return to growth and revive investor enthusiasm, according to Truist Securities.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/17/biotech-lab-ai2.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.327245,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.288893",
        "ticker_sentiment_score": "0.36736",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "LEGN",
        "relevance_score": "0.861522",
        "ticker_sentiment_score": "0.41964",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Market Analysis: Johnson & Johnson And Competitors In Pharmaceuticals Industry - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/news/24/06/39359852/market-analysis-johnson-amp-johnson-and-competitors-in-pharmaceuticals-industry",
    "time_published": "20240617T150048",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In today's fast-paced and highly competitive business world, it is crucial for investors and industry followers to conduct comprehensive company evaluations. In this article, we will delve into an extensive industry comparison, evaluating Johnson & Johnson JNJ in relation to its major competitors ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.161433,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.041118",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.457274",
        "ticker_sentiment_score": "0.291438",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Dow Jones Dips As Gold Stock Scores Upgrade; Warren Buffett Unloads This Stock  ( Live Coverage ) ",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-nasdaq-sp500-warren-buffett-nvidia-microsoft/",
    "time_published": "20240617T144300",
    "authors": [
      "Investor's Business Daily",
      "MICHAEL LARKIN"
    ],
    "summary": "Dow Jones Dips As Gold Stock Scores Upgrade. Warren Buffett Unloads This Stock ( Live Coverage ) Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/05/Stock-warrenbuffett-2024-06-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      }
    ],
    "overall_sentiment_score": 0.229199,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.045655",
        "ticker_sentiment_score": "-0.118331",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "-0.124827",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "-0.127847",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.136484",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSCO",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "-0.158528",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "-0.158528",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ADSK",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.074506",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "-0.043278",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.506405",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JHG",
        "relevance_score": "0.045655",
        "ticker_sentiment_score": "0.250248",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "-0.158528",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.225321",
        "ticker_sentiment_score": "-0.010839",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.166723",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NEM",
        "relevance_score": "0.181137",
        "ticker_sentiment_score": "0.052675",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ROST",
        "relevance_score": "0.045655",
        "ticker_sentiment_score": "-0.001996",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.136484",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:NEM",
        "relevance_score": "0.045655",
        "ticker_sentiment_score": "-0.120421",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Solid Power Appoints Renewables Industry Veteran Linda Heller as Chief Financial Officer - Solid Power  ( NASDAQ:SLDP ) , Solid Power  ( NASDAQ:SLDPW ) ",
    "url": "https://www.benzinga.com/pressreleases/24/06/g39354391/solid-power-appoints-renewables-industry-veteran-linda-heller-as-chief-financial-officer",
    "time_published": "20240617T120050",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LOUISVILLE, Colo., June 17, 2024 ( GLOBE NEWSWIRE ) -- Solid Power, Inc. SLDP, a leading developer of solid-state battery technology, today announced that the board of directors has appointed Linda Heller as the company's Chief Financial Officer and Treasurer, effective immediately.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.905476"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.233772,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SLDP",
        "relevance_score": "0.461087",
        "ticker_sentiment_score": "0.288343",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.028833",
        "ticker_sentiment_score": "0.042906",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GDYMF",
        "relevance_score": "0.028833",
        "ticker_sentiment_score": "0.042906",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.028833",
        "ticker_sentiment_score": "0.042906",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Solid Power Appoints Renewables Industry Veteran Linda Heller as Chief Financial Officer",
    "url": "https://www.globenewswire.com/news-release/2024/06/17/2899618/0/en/Solid-Power-Appoints-Renewables-Industry-Veteran-Linda-Heller-as-Chief-Financial-Officer.html",
    "time_published": "20240617T120000",
    "authors": [
      "Inc.",
      "Solid Power"
    ],
    "summary": "Company reaffirms 2024 guidance Company reaffirms 2024 guidance ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/b1a2a6ec-a955-48b7-a113-70e783455de2",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.233873,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SLDP",
        "relevance_score": "0.448513",
        "ticker_sentiment_score": "0.289083",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.029691",
        "ticker_sentiment_score": "0.043089",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GDYMF",
        "relevance_score": "0.029691",
        "ticker_sentiment_score": "0.043089",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.029691",
        "ticker_sentiment_score": "0.043089",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer",
    "url": "https://www.prnewswire.com/news-releases/subcutaneous-amivantamab-biologics-license-application-submitted-to-us-fda-for-patients-with-egfr-mutated-non-small-cell-lung-cancer-302173613.html",
    "time_published": "20240617T120000",
    "authors": [
      "Johnson & Johnson"
    ],
    "summary": "Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/2333578/Johnson_and_Johnson_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": -0.024122,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.105183",
        "ticker_sentiment_score": "0.053255",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "STERIS  ( STE )  Gains From New Offerings, Macro Issues Ail",
    "url": "https://www.zacks.com/stock/news/2288940/steris-ste-gains-from-new-offerings-macro-issues-ail",
    "time_published": "20240617T110200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "STERIS' (STE) AST successfully offers a wide range of sterilization modalities through a worldwide network of more than 50 contract sterilization and laboratory facilities.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.994953"
      }
    ],
    "overall_sentiment_score": 0.20354,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MEDP",
        "relevance_score": "0.126339",
        "ticker_sentiment_score": "0.050775",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMB",
        "relevance_score": "0.042271",
        "ticker_sentiment_score": "0.074751",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STE",
        "relevance_score": "0.573417",
        "ticker_sentiment_score": "0.282345",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.042271",
        "ticker_sentiment_score": "0.074751",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.167904",
        "ticker_sentiment_score": "0.064798",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.042271",
        "ticker_sentiment_score": "0.074751",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RMD",
        "relevance_score": "0.126339",
        "ticker_sentiment_score": "0.050775",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ECL",
        "relevance_score": "0.084423",
        "ticker_sentiment_score": "0.056107",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Fidelity MSCI Health Care Index ETF  ( FHLC ) ?",
    "url": "https://www.zacks.com/stock/news/2288894/should-you-invest-in-the-fidelity-msci-health-care-index-etf-fhlc",
    "time_published": "20240617T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default330.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.294722,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.128478",
        "ticker_sentiment_score": "0.050009",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.128478",
        "ticker_sentiment_score": "0.050009",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.128478",
        "ticker_sentiment_score": "0.050009",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Stock Falls Amid Market Uptick: What Investors Need to Know",
    "url": "https://www.zacks.com/stock/news/2290085/johnson-johnson-jnj-stock-falls-amid-market-uptick-what-investors-need-to-know",
    "time_published": "20240618T214519",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the latest trading session, Johnson & Johnson (JNJ) closed at $145.65, marking a -0.21% move from the previous day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default154.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.995921"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.187802,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.521961",
        "ticker_sentiment_score": "0.213637",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The Inner Circle Acknowledges, Willette Murphy Klausner as a Top Pinnacle Professional",
    "url": "https://www.benzinga.com/pressreleases/24/06/n39388202/the-inner-circle-acknowledges-willette-murphy-klausner-as-a-top-pinnacle-professional",
    "time_published": "20240618T193000",
    "authors": [
      "PRNewswire"
    ],
    "summary": "LOS ANGELES, June 18, 2024 /PRNewswire/ -- Willette Murphy Klausner shines brightly in The Inner Circle, celebrated as a Top Pinnacle Professional for her groundbreaking contributions as a Trailblazer in Theater and Film Production.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.405557,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KO",
        "relevance_score": "0.053992",
        "ticker_sentiment_score": "0.054991",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GM",
        "relevance_score": "0.053992",
        "ticker_sentiment_score": "0.054991",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.053992",
        "ticker_sentiment_score": "0.054991",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.053992",
        "ticker_sentiment_score": "0.054991",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Mega Cap Stock Bargains As Markets Hit All-Time Highs: Novo Nordisk, Johnson & Johnson, PDD Holdings - PDD Holdings  ( NASDAQ:PDD ) , Novo Nordisk  ( NYSE:NVO ) , Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/06/39387535/3-mega-cap-stock-bargains-as-markets-hit-all-time-highs",
    "time_published": "20240618T185138",
    "authors": [
      "Surbhi Jain"
    ],
    "summary": "As markets continue to reach new all-time highs, investors are constantly seeking opportunities that offer both stability and growth potential. With the S&P 500 and Nasdaq recently hitting new all-time highs, investors are out bargain hunting.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/18/Southwest-Gas-Holdings-Inc-_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.353517,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.085629",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PDD",
        "relevance_score": "0.332883",
        "ticker_sentiment_score": "0.484093",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.252987",
        "ticker_sentiment_score": "0.222419",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CGCO",
        "relevance_score": "0.085629",
        "ticker_sentiment_score": "0.201002",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.252987",
        "ticker_sentiment_score": "0.145149",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares U.S. Pharmaceuticals ETF  ( IHE ) ?",
    "url": "https://www.zacks.com/stock/news/2289552/should-you-invest-in-the-ishares-us-pharmaceuticals-etf-ihe",
    "time_published": "20240618T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default241.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.186397,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.067158",
        "ticker_sentiment_score": "0.032048",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.064137",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RPRX",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.064137",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.043607",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.064137",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "JJ talc users want cancer checks for women even if it cost billions",
    "url": "https://www.business-standard.com/world-news/jj-talc-users-want-cancer-checks-for-women-even-if-it-cost-billions-124061800068_1.html",
    "time_published": "20240618T021922",
    "authors": [
      "Bloomberg"
    ],
    "summary": "Johnson & Johnson should be on the hook for potentially billions of dollars in medical fees for women who used its talc-based baby powders and want to monitor their future health over cancer fears, according to a lawsuit.",
    "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2024-06/18/full/1718677065-071.jpg?im=FeatureCrop,size=(826,465)",
    "source": "Business Standard",
    "category_within_source": "GoogleRSS",
    "source_domain": "www.business-standard.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.076589,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.159569",
        "ticker_sentiment_score": "-0.175431",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "3 No-Brainer Stocks to Buy With $500 Right Now",
    "url": "https://www.fool.com/investing/2024/06/19/3-no-brainer-stocks-to-buy-with-500-right-now/",
    "time_published": "20240619T092100",
    "authors": [
      "Sean Williams"
    ],
    "summary": "A modest amount of money can go a long when when it's put to work in game-changing businesses with well-defined catalysts.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F780942%2Fcash-money-five-hundred-dollars-invest-retire-stock-market-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99977"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.206978,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IIPR",
        "relevance_score": "0.151922",
        "ticker_sentiment_score": "0.154383",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MJNA",
        "relevance_score": "0.030563",
        "ticker_sentiment_score": "-0.005617",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.298385",
        "ticker_sentiment_score": "0.166102",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.181819",
        "ticker_sentiment_score": "0.15864",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Faces New Lawsuit ( s )  Related To Its Talc Products - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/06/39419157/johnson-johnson-faces-new-lawsuit-s-related-to-its-talc-products",
    "time_published": "20240620T175330",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Johnson & Johnson JNJ is reportedly facing a new proposed class action lawsuit seeking damages and medical monitoring for women who have developed or may develop cancer due to using the company's talc products.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/20/jnj-johnson-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.220888,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.614086",
        "ticker_sentiment_score": "0.120746",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson's Arthritis Drug Shows Potential In Crohn's Disease - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/markets/equities/24/06/39418047/johnson-johnsons-arthritis-drug-shows-potential-in-crohns-disease",
    "time_published": "20240620T170159",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Thursday, Johnson & Johnson JNJ released topline data from the pivotal Phase 3 GRAVITI investigational study of Tremfya ( guselkumab ) subcutaneous ( SC ) induction therapy in adult patients with moderately to severely active Crohn's disease.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/20/Johnson-and-Johnson.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.300192,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.535653",
        "ticker_sentiment_score": "0.205694",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Want $1 Million in Retirement? 9 ETFs to Buy Now and Hold for Decades.",
    "url": "https://www.fool.com/investing/2024/06/20/want-1-million-in-retirement-9-etfs-to-buy-now-and/",
    "time_published": "20240620T135300",
    "authors": [
      "Selena Maranjian"
    ],
    "summary": "You can build solid wealth with broad index funds -- or you might try to juice your returns with some superperformers.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F780870%2Fgetty-workout-at-gym-fitness-exercise-smiling-happy.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999994"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.183885,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.174587",
        "ticker_sentiment_score": "0.08817",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.174587",
        "ticker_sentiment_score": "0.08817",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.058615",
        "ticker_sentiment_score": "0.061049",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LEN",
        "relevance_score": "0.058615",
        "ticker_sentiment_score": "0.061049",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.058615",
        "ticker_sentiment_score": "0.061049",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.058615",
        "ticker_sentiment_score": "0.061049",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's Why Eli Lilly  ( LLY )  is Probably the Best Drug Stock Now",
    "url": "https://www.zacks.com/stock/news/2290782/heres-why-eli-lilly-lly-is-probably-the-best-drug-stock-now",
    "time_published": "20240620T130100",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.233627,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "-0.063648",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.166743",
        "ticker_sentiment_score": "0.240335",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.153717",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.538782",
        "ticker_sentiment_score": "0.273532",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.059562",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "-0.063648",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.12546",
        "ticker_sentiment_score": "0.068567",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "-0.063648",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.",
    "url": "https://www.fool.com/investing/2024/06/20/want-decades-of-passive-income-2-stocks-to-buy-now/",
    "time_published": "20240620T091500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "These healthcare players offer you dividends and a strong earnings picture.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F780947%2Fgettyimages-1188369583.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.917436"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99793"
      }
    ],
    "overall_sentiment_score": 0.380048,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.109206",
        "ticker_sentiment_score": "0.073797",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.109206",
        "ticker_sentiment_score": "0.164285",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Dry Eye Syndrome Drugs Market size is set to grow by USD 2.13 billion from 2024-2028, Growing geriatric population ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/dry-eye-syndrome-drugs-market-size-is-set-to-grow-by-usd-2-13-billion-from-2024-2028--growing-geriatric-population-boost-the-market-technavio-302178705.html",
    "time_published": "20240621T215500",
    "authors": [],
    "summary": "Dry Eye Syndrome Drugs Market size is set to grow by USD 2.13 billion from 2024-2028, Growing geriatric population ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.145318,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.03458",
        "ticker_sentiment_score": "0.021037",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNPHF",
        "relevance_score": "0.03458",
        "ticker_sentiment_score": "0.021037",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.03458",
        "ticker_sentiment_score": "0.021037",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VTRS",
        "relevance_score": "0.03458",
        "ticker_sentiment_score": "0.021037",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.03458",
        "ticker_sentiment_score": "0.021037",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.03458",
        "ticker_sentiment_score": "0.021037",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHC",
        "relevance_score": "0.03458",
        "ticker_sentiment_score": "0.021037",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Hospital Infection Therapeutics Market size is set to grow by USD 3.46 billion from 2024-2028, Increase in incidence ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/hospital-infection-therapeutics-market-size-is-set-to-grow-by-usd-3-46-billion-from-2024-2028--increase-in-incidence-and-prevalence-of-respiratory-disorders-boost-the-market-technavio-302177964.html",
    "time_published": "20240621T210500",
    "authors": [],
    "summary": "Hospital Infection Therapeutics Market size is set to grow by USD 3.46 billion from 2024-2028, Increase in incidence ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.097863,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BAYZF",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VTRS",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ACHL",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPRO",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Pfizer, Johnson & Johnson and Eli Lilly",
    "url": "https://markets.businessinsider.com/news/stocks/the-zacks-analyst-blog-highlights-pfizer-johnson-johnson-and-eli-lilly-1033497156",
    "time_published": "20240621T194801",
    "authors": [],
    "summary": "Chicago, IL - June 21, 2024 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.",
    "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2024/06/21/jason-briscoe-amlfrl8lgls-unsplash.jpg",
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.238116,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.040829",
        "ticker_sentiment_score": "-0.06354",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.081552",
        "ticker_sentiment_score": "0.209402",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.081552",
        "ticker_sentiment_score": "0.121918",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.081552",
        "ticker_sentiment_score": "0.069954",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.040829",
        "ticker_sentiment_score": "-0.06354",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.122062",
        "ticker_sentiment_score": "0.06016",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.040829",
        "ticker_sentiment_score": "-0.06354",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Pfizer, Johnson & Johnson and Eli Lilly - Johnson & Johnson  ( NYSE:JNJ ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/06/39432381/the-zacks-analyst-blog-highlights-pfizer-johnson-johnson-and-eli-lilly",
    "time_published": "20240621T193114",
    "authors": [
      "Zacks"
    ],
    "summary": "Chicago, IL - June 21, 2024 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/21/jason-briscoe-amlfrl8lgls-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.23596,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.040078",
        "ticker_sentiment_score": "-0.063462",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.080055",
        "ticker_sentiment_score": "0.208813",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.11983",
        "ticker_sentiment_score": "0.133763",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.486415",
        "ticker_sentiment_score": "0.240245",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.080055",
        "ticker_sentiment_score": "0.069699",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.040078",
        "ticker_sentiment_score": "-0.063462",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.159305",
        "ticker_sentiment_score": "0.067239",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.040078",
        "ticker_sentiment_score": "-0.063462",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Face Cream Market size is set to grow by USD 12.20 billion from 2024-2028, Rising demand for natural and organic ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/face-cream-market-size-is-set-to-grow-by-usd-12-20-billion-from-2024-2028--rising-demand-for-natural-and-organic-face-creams-boost-the-market-technavio-302177826.html",
    "time_published": "20240621T183000",
    "authors": [],
    "summary": "Face Cream Market size is set to grow by USD 12.20 billion from 2024-2028, Rising demand for natural and organic ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.268329,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BDRFF",
        "relevance_score": "0.037155",
        "ticker_sentiment_score": "0.036781",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KAOCF",
        "relevance_score": "0.037155",
        "ticker_sentiment_score": "0.036781",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSDOF",
        "relevance_score": "0.037155",
        "ticker_sentiment_score": "0.036781",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.018275",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.037155",
        "ticker_sentiment_score": "0.036781",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UL",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.018275",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LRLCF",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.018275",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RBGPF",
        "relevance_score": "0.037155",
        "ticker_sentiment_score": "0.036781",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments - Gilead Sciences  ( NASDAQ:GILD ) ",
    "url": "https://www.benzinga.com/general/biotech/24/06/39435880/gilead-sciences-faces-wall-street-speculation-about-obesity-drugs-despite-focus-on-liver-treatmen",
    "time_published": "20240621T154222",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Gilead Sciences, Inc. GILD witnessed a flurry of Wall Street speculation regarding its potential involvement in the obesity drug market. But, the biotech company, renowned for its cancer and HIV treatments, has not positioned itself as a contender in this lucrative field.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/21/Doctors-And-Nurses-Walking-In-Hospital-H.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.219317,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.180513",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.22521",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.180513",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.089516",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.078099",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.305058",
        "ticker_sentiment_score": "0.206652",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.22521",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Is Nvidia  ( NVDA )  Up 26% Since Last Earnings Report?",
    "url": "https://www.zacks.com/stock/news/2291637/why-is-nvidia-nvda-up-26-since-last-earnings-report",
    "time_published": "20240621T153008",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Nvidia (NVDA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default99.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.99737"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.155578,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.067823",
        "ticker_sentiment_score": "0.196386",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XPEV",
        "relevance_score": "0.033942",
        "ticker_sentiment_score": "0.103567",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.033942",
        "ticker_sentiment_score": "0.014392",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.782813",
        "ticker_sentiment_score": "0.446449",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GMGT",
        "relevance_score": "0.033942",
        "ticker_sentiment_score": "0.086199",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.033942",
        "ticker_sentiment_score": "0.341709",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNPS",
        "relevance_score": "0.067823",
        "ticker_sentiment_score": "0.196386",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "J&J  ( JNJ )  Seeks Expanded Use of Tremfya for Crohn's Disease",
    "url": "https://www.zacks.com/stock/news/2291318/jj-jnj-seeks-expanded-use-of-tremfya-for-crohns-disease",
    "time_published": "20240621T124900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "J&J (JNJ) seeks label expansion for Tremfya for treating moderately to severely active Crohn's disease. This marks the second sBLA filing for Tremfya in three months.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.219753,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALGS",
        "relevance_score": "0.280294",
        "ticker_sentiment_score": "0.029715",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RAPT",
        "relevance_score": "0.22595",
        "ticker_sentiment_score": "0.026913",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.280294",
        "ticker_sentiment_score": "0.063201",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Pfizer, Johnson & Johnson and Eli Lilly",
    "url": "https://www.zacks.com/stock/news/2291339/the-zacks-analyst-blog-highlights-pfizer-johnson-johnson-and-eli-lilly",
    "time_published": "20240621T115900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Pfizer, Johnson & Johnson and Eli Lilly are part of the Zacks top Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/89/447.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.235581,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.039353",
        "ticker_sentiment_score": "-0.06338",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.208275",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.117678",
        "ticker_sentiment_score": "0.120071",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.478768",
        "ticker_sentiment_score": "0.243569",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.069463",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.039353",
        "ticker_sentiment_score": "-0.06338",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.156461",
        "ticker_sentiment_score": "0.062196",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.039353",
        "ticker_sentiment_score": "-0.06338",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 High-Yield Dividend Stocks Near Their 52-Week Lows to Buy and Hold",
    "url": "https://www.fool.com/investing/2024/06/22/3-dividend-paying-stocks-near-52-week-lows-to-buy/",
    "time_published": "20240622T100300",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "The pharmaceutical industry giants offer reliable profit growth and above-average dividend yields.",
    "banner_image": "https://g.foolcdn.com/editorial/images/781093/investor-dark-room-devices-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998356"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928769"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.172635,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.054359",
        "ticker_sentiment_score": "0.119002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.266828",
        "ticker_sentiment_score": "0.049401",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.214937",
        "ticker_sentiment_score": "0.146969",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.214937",
        "ticker_sentiment_score": "0.15783",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Top Stocks to Buy Now for Years of Passive Income",
    "url": "https://www.fool.com/investing/2024/06/22/top-stocks-to-buy-now-for-years-passive-income/",
    "time_published": "20240622T084500",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "These tried-and-true businesses could be wise additions to your portfolio.",
    "banner_image": "https://g.foolcdn.com/editorial/images/781053/woman-finance-calculator-laptop-notebook.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.752319"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.279958,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.153961",
        "ticker_sentiment_score": "0.070967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.302243",
        "ticker_sentiment_score": "0.355881",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.337811",
        "ticker_sentiment_score": "0.18763",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "StockNews.com Lowers Johnson & Johnson  ( NYSE:JNJ )  to Buy",
    "url": "https://www.defenseworld.net/2024/06/22/stocknews-com-lowers-johnson-johnson-nysejnj-to-buy.html",
    "time_published": "20240622T061443",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Johnson & Johnson ( NYSE:JNJ - Get Free Report ) was downgraded by research analysts at StockNews.com from a \"strong-buy\" rating to a \"buy\" rating in a research note issued on Saturday. JNJ has been the subject of a number of other reports.",
    "banner_image": "https://www.marketbeat.com/logos/johnson--johnson-logo-1200x675.png?v=20221020135923",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.184329,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RBCPF",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "0.08289",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "0.08289",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "0.08289",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "0.08289",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.859898",
        "ticker_sentiment_score": "0.314168",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KMX",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "-0.053027",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "How to invest in dividend stocks",
    "url": "https://apnews.com/buyline-personal-finance/article/how-to-invest-in-dividend-stocks",
    "time_published": "20240623T144816",
    "authors": [
      "Mallika Mitra"
    ],
    "summary": "AP Buyline's content is created independently of The Associated Press newsroom. Our evaluations and opinions are not influenced by our advertising relationships, but we might earn commissions from our partners' links in this content. Learn more about our policies and terms here .",
    "banner_image": "https://apnews.com/buyline-personal-finance/static/142f3b8ef44eb6fd0258cfd57e9aa1a1/38bbb/investing-dividend-young-family-baby-laptop.jpg",
    "source": "Associated Press",
    "category_within_source": "Markets",
    "source_domain": "apnews.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.139442,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VZ",
        "relevance_score": "0.023743",
        "ticker_sentiment_score": "0.033426",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SCHW",
        "relevance_score": "0.023743",
        "ticker_sentiment_score": "0.132379",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.023743",
        "ticker_sentiment_score": "0.122839",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Supreme Court Backs Pharmaceutical Giants in Iraq Terrorism Funding Case - AstraZeneca  ( NASDAQ:AZN ) , Johnson & Johnson  ( NYSE:JNJ ) , Pfizer  ( NYSE:PFE ) ",
    "url": "https://www.benzinga.com/general/biotech/24/06/39465287/supreme-court-backs-pharmaceutical-giants-in-iraq-terrorism-funding-case",
    "time_published": "20240624T194737",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "The U.S. Supreme Court has supported 21 pharmaceutical and medical equipment companies, led by AstraZeneca Plc AZN, in a lawsuit accusing them of funding terrorism that harmed American troops and civilians in Iraq.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/24/Legal-Issues.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.124704,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GEHC",
        "relevance_score": "0.203215",
        "ticker_sentiment_score": "-0.181397",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.203215",
        "ticker_sentiment_score": "-0.144116",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.203215",
        "ticker_sentiment_score": "-0.181397",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.203215",
        "ticker_sentiment_score": "-0.181397",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson's Options: A Look at What the Big Money is Thinking - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/options/24/06/39463633/johnson-johnsons-options-a-look-at-what-the-big-money-is-thinking",
    "time_published": "20240624T180126",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson JNJ we detected 9 trades. If we consider the specifics of each trade, it is accurate to state that 44% of the investors opened trades with bullish ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.111221,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.095899",
        "ticker_sentiment_score": "0.04297",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.60098",
        "ticker_sentiment_score": "0.101605",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Do Options Traders Know Something About Johnson & Johnson  ( JNJ )  Stock We Don't?",
    "url": "https://www.zacks.com/stock/news/2292150/do-options-traders-know-something-about-johnson-johnson-jnj-stock-we-dont",
    "time_published": "20240624T123400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Investors need to pay close attention to Johnson & Johnson (JNJ) stock based on the movements in the options market lately.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.104123,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.555911",
        "ticker_sentiment_score": "0.232335",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Stock Declines While Market Improves: Some Information for Investors",
    "url": "https://www.zacks.com/stock/news/2293171/johnson-johnson-jnj-stock-declines-while-market-improves-some-information-for-investors",
    "time_published": "20240625T214519",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) closed the most recent trading day at $147.19, moving -1.29% from the previous trading session.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default198.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.144862,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.514619",
        "ticker_sentiment_score": "0.099602",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Johnson & Johnson the Best Dividend Stock for You?",
    "url": "https://www.fool.com/investing/2024/06/25/is-johnson-johnson-the-best-dividend-stock-for-you/",
    "time_published": "20240625T105400",
    "authors": [
      "Justin Pope"
    ],
    "summary": "J&J is the textbook blue chip stock -- but it's not for everyone.",
    "banner_image": "https://media.ycharts.com/charts/8b4e8ba50eae9553e58a478d135e1805.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999696"
      }
    ],
    "overall_sentiment_score": 0.222411,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.481677",
        "ticker_sentiment_score": "0.422103",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs",
    "url": "https://www.benzinga.com/pressreleases/24/06/g39511828/neurona-therapeutics-appoints-dr-nadia-agopyan-as-senior-vice-president-of-regulatory-affairs",
    "time_published": "20240626T200500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "SAN FRANCISCO, June 26, 2024 ( GLOBE NEWSWIRE ) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for disorders of the nervous system, today announced the appointment of Nadia Agopyan, Ph.D., RAC, as Senior Vice President of Regulatory ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.229651,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MRKR",
        "relevance_score": "0.050254",
        "ticker_sentiment_score": "0.055899",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.050254",
        "ticker_sentiment_score": "0.055899",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.050254",
        "ticker_sentiment_score": "0.055899",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC - Sanofi  ( NASDAQ:SNY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/06/39502197/sanofi-looks-to-sell-20b-icy-hot-division-likely-bidders-include-advent-pai-partners-blackstone-c",
    "time_published": "20240626T131658",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Sanofi SA SNY is calling for initial bids for its $20 billion consumer health division. The French pharmaceutical giant is also considering a potential public listing. Potential suitors must submit first-round bids by mid-July, Bloomberg reports.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/26/Sanofi.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.166933,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BX",
        "relevance_score": "0.252987",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.252987",
        "ticker_sentiment_score": "0.130306",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EQBBF",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "0.016815",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.252987",
        "ticker_sentiment_score": "0.130306",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TPG",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HLN",
        "relevance_score": "0.252987",
        "ticker_sentiment_score": "0.130306",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GSK",
        "relevance_score": "0.252987",
        "ticker_sentiment_score": "0.130306",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.580018",
        "ticker_sentiment_score": "0.328648",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Global Autologous Stem Cell & Non-Stem Cell Therapies Market: $5.5B in 2024 to $22.2B by 2029, CAGR 32.3% | MarketsandMarkets\u2122",
    "url": "https://www.benzinga.com/pressreleases/24/06/g39500308/global-autologous-stem-cell-non-stem-cell-therapies-market-5-5b-in-2024-to-22-2b-by-2029-cagr-32-3",
    "time_published": "20240626T123000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Chicago, June 26, 2024 ( GLOBE NEWSWIRE ) -- The global autologous stem cell & non-stem cell therapies market is experiencing significant growth, with revenue expected to rise from $5.5 billion in 2024 to $22.2 billion by 2029, at a CAGR of 32.3%.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.200433,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVS",
        "relevance_score": "0.12013",
        "ticker_sentiment_score": "0.107598",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.179343",
        "ticker_sentiment_score": "0.170054",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.179343",
        "ticker_sentiment_score": "0.183037",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.120215",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here Are Trump's 10 Biggest Billionaire Donors",
    "url": "https://www.forbes.com/sites/leokamin/2024/06/26/here-are-trumps-10-biggest-billionaire-donors-mcmahon-mellon-uiehlein/",
    "time_published": "20240626T103000",
    "authors": [
      "Leo Kamin"
    ],
    "summary": "Trump's 10 Biggest Billionaire Donors Are Worth More Than $55 Billion Forbes ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6679e9a1bd955ba2487bf283/0x0.jpg?format=jpg&crop=1920,1080,x0,y0,safe&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.207853,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DJT",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "-0.058647",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ET",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "0.147332",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "0.14374",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Arkansas AG sues Temu over alleged 'deceptive tactics' harming consumers: 'Data theft business'",
    "url": "https://www.foxbusiness.com/lifestyle/arkansas-ag-sues-temu-over-alleged-deceptive-tactics-harming-consumers-data-theft-business",
    "time_published": "20240626T000300",
    "authors": [
      "Bradford Betz"
    ],
    "summary": "Arkansas Attorney General Tim Griffin is taking legal action against the Chinese fast fashion retailer Temu over what he alleges are the company's \"deceptive tactics\" that are harming consumers.",
    "banner_image": "https://cf-images.us-east-1.prod.boltdns.net/v1/static/854081161001/ea32a344-8de4-4509-a80a-7b95288e726b/ecbd6b42-b07b-444f-b906-62a03b549506/1280x720/match/image.jpg",
    "source": "Fox Business News",
    "category_within_source": "n/a",
    "source_domain": "www.foxbusiness.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.024109,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "PDD",
        "relevance_score": "0.208464",
        "ticker_sentiment_score": "-0.279149",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.105141",
        "ticker_sentiment_score": "-0.225513",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement - Eliem Therapeutics  ( NASDAQ:ELYM ) ",
    "url": "https://www.benzinga.com/pressreleases/24/06/g39535463/eliem-therapeutics-announces-the-closing-of-its-acquisition-of-tenet-medicines-and-concurrent-120-",
    "time_published": "20240627T200100",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Eliem to focus on advancing TNT119, an anti-CD19 antibody designed to treat a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous nephropathy",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Mergers",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.905476"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.164726,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ELDN",
        "relevance_score": "0.01892",
        "ticker_sentiment_score": "0.070006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.01892",
        "ticker_sentiment_score": "0.070006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JHG",
        "relevance_score": "0.01892",
        "ticker_sentiment_score": "0.048182",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FGEN",
        "relevance_score": "0.01892",
        "ticker_sentiment_score": "0.035446",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XLO",
        "relevance_score": "0.01892",
        "ticker_sentiment_score": "0.035446",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ELYM",
        "relevance_score": "0.131849",
        "ticker_sentiment_score": "0.202285",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SYBX",
        "relevance_score": "0.075575",
        "ticker_sentiment_score": "0.041445",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.01892",
        "ticker_sentiment_score": "0.035446",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.01892",
        "ticker_sentiment_score": "0.070006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.01892",
        "ticker_sentiment_score": "0.070006",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The $7 billion Purdue bankruptcy plan giving the Sacklers immunity from more lawsuits gets nixed by Supreme Court",
    "url": "https://www.businessinsider.com/supreme-court-rejects-bankruptcy-plan-protecting-sacklers-2024-6",
    "time_published": "20240627T154600",
    "authors": [
      "Jack Newsham"
    ],
    "summary": "Supreme Court rejects $7 billion bankruptcy plan protecting Sacklers - Business Insider ...",
    "banner_image": null,
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "www.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.102828,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "-0.026401",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Investors Heavily Search Johnson & Johnson  ( JNJ ) : Here is What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2294165/investors-heavily-search-johnson-johnson-jnj-here-is-what-you-need-to-know",
    "time_published": "20240627T130016",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default278.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.21943,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.470606",
        "ticker_sentiment_score": "0.15251",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Incredible Dividend Growth Stocks to Buy Right Now",
    "url": "https://www.fool.com/investing/2024/06/27/2-incredible-dividend-growth-stocks-to-buy-right-n/",
    "time_published": "20240627T130000",
    "authors": [
      "George Budwell"
    ],
    "summary": "These two dividend growth stocks can level up your portfolio.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F781764%2Fdividend-concept.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.972756"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.514505,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SPGI",
        "relevance_score": "0.073321",
        "ticker_sentiment_score": "0.19187",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FDX",
        "relevance_score": "0.217508",
        "ticker_sentiment_score": "0.380018",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "0.341047",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Treating Geographic Atrophy Remains a Tough Call for Ophthalmologists as They Voice Hesitancy to Prescribe Complement Inhibitors",
    "url": "https://www.benzinga.com/pressreleases/24/06/g39524015/treating-geographic-atrophy-remains-a-tough-call-for-ophthalmologists-as-they-voice-hesitancy-to-p",
    "time_published": "20240627T124955",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Exton, Pennsylvania, June 27, 2024 ( GLOBE NEWSWIRE ) -- Prior to 2023, there was no treatment for GA, a progressive form of dry age-related macular degeneration that results in blindness. That changed in early 2023 when Apellis gained FDA approval for Syfovre, followed by Iveric Bio/Astellas' ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.202544,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLTE",
        "relevance_score": "0.045396",
        "ticker_sentiment_score": "0.21708",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ANNX",
        "relevance_score": "0.045396",
        "ticker_sentiment_score": "0.21708",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.045396",
        "ticker_sentiment_score": "0.21708",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery",
    "url": "https://www.globenewswire.com/news-release/2024/06/27/2905073/0/en/Clearside-Biomedical-to-Host-Virtual-Key-Opinion-Leader-Event-on-the-Use-and-Versatility-of-Suprachoroidal-Drug-Delivery.html",
    "time_published": "20240627T110500",
    "authors": [
      "Inc.",
      "Clearside Biomedical"
    ],
    "summary": "- Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/6eac24f1-af2b-45eb-9777-0ea32dfc73b8",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.089103,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CLSD",
        "relevance_score": "0.147818",
        "ticker_sentiment_score": "0.103602",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.037155",
        "ticker_sentiment_score": "0.044794",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery - Clearside Biomedical  ( NASDAQ:CLSD ) ",
    "url": "https://www.benzinga.com/pressreleases/24/06/g39520812/clearside-biomedical-to-host-virtual-key-opinion-leader-event-on-the-use-and-versatility-of-suprac",
    "time_published": "20240627T110500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "- Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET - - Retina Specialists to Provide Insights and Real-World Experience with Suprachoroidal Drug Delivery - - Target Profile for CLS-AX in Wet AMD Landscape and Potential Opportunities for Clearside Pipeline Expansion -",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.098431,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CLSD",
        "relevance_score": "0.172836",
        "ticker_sentiment_score": "0.106135",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.034831",
        "ticker_sentiment_score": "0.043394",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Johnson & Johnson Stock a Buy?",
    "url": "https://www.fool.com/investing/2024/06/27/is-johnson-johnson-stock-a-buy/",
    "time_published": "20240627T082300",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Johnson & Johnson's business is growing at a decent rate, but there's still a fair bit of risk surrounding the company.",
    "banner_image": "https://g.foolcdn.com/editorial/images/781348/person-reviewing-a-sample-in-a-lab.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99977"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.175439,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.514619",
        "ticker_sentiment_score": "0.202586",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Warren Buffett reveals about $600 million of his wealth isn't in Berkshire Hathaway stock",
    "url": "https://www.businessinsider.com/warren-buffett-personal-portfolio-net-worth-wealth-berkshire-hathaway-stock-2024-6",
    "time_published": "20240628T151500",
    "authors": [
      "Theron Mohamed"
    ],
    "summary": "Warren Buffett says about $600M of his wealth isn't in Berkshire stock - Business Insider ...",
    "banner_image": null,
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "www.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.323148,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "WFC",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "0.153795",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.223866",
        "ticker_sentiment_score": "0.279674",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "0.153795",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "0.153795",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Top Growth Stocks to Buy in June",
    "url": "https://www.fool.com/investing/2024/06/28/2-top-growth-stocks-to-buy-in-june/",
    "time_published": "20240628T134500",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "Veeva Systems and Bill Holdings are demonstrating impressive growth trajectories.",
    "banner_image": "https://g.foolcdn.com/editorial/images/781625/shocked-woman-looking-at-mobile-phone-screen.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.998682"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.352409,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MAT",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "-0.009972",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "-0.009972",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "-0.009972",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UL",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "-0.009972",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BILL",
        "relevance_score": "0.145437",
        "ticker_sentiment_score": "0.337901",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VEEV",
        "relevance_score": "0.145437",
        "ticker_sentiment_score": "-0.014149",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CL",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "-0.009972",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cencora  ( COR )  Stock Nosedives: Here's What Caused the Decline",
    "url": "https://www.zacks.com/stock/news/2294845/cencora-cor-stock-nosedives-heres-what-caused-the-decline",
    "time_published": "20240628T115200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Cencora (COR) shares declined on Jun 27, following an unfavorable ruling from the Supreme Court related to a previously settled litigation. Here we discuss the key factors that likely led to the decline.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/37920.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.068534,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "WBD",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "-0.054372",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.362858",
        "ticker_sentiment_score": "0.118186",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MCK",
        "relevance_score": "0.362858",
        "ticker_sentiment_score": "0.118186",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COR",
        "relevance_score": "0.654522",
        "ticker_sentiment_score": "0.130909",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "-0.01241",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields - Gilead Sciences  ( NASDAQ:GILD ) ",
    "url": "https://www.benzinga.com/news/24/06/39545594/wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-with-over-3-dividend-yie",
    "time_published": "20240628T113058",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/28/Technology-Online-Banking-Money-Transfer.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.09016,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CVS",
        "relevance_score": "0.204936",
        "ticker_sentiment_score": "-0.008139",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.103331",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.103331",
        "ticker_sentiment_score": "0.179791",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "4 Cheap Stocks to Buy in July",
    "url": "https://www.fool.com/investing/2024/06/29/4-cheap-stocks-to-buy-in-july/",
    "time_published": "20240629T122100",
    "authors": [
      "CPA",
      "Mark Roussin"
    ],
    "summary": "All four of these stocks are trading at very intriguing valuations.",
    "banner_image": "https://g.foolcdn.com/editorial/images/782099/gettyimages-1720247749.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.177969,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.546745",
        "ticker_sentiment_score": "-0.087848",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Unstoppable Dividend Stocks to Buy if There's a Stock Market Sell-Off",
    "url": "https://www.fool.com/investing/2024/06/30/unstoppable-dividend-stocks-buy-if-market-sell-off/",
    "time_published": "20240630T094000",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "Income-seeking investors can find plenty of opportunities in any market environment.",
    "banner_image": "https://g.foolcdn.com/editorial/images/782022/working-on-wall-street.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999186"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.292725,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KO",
        "relevance_score": "0.241444",
        "ticker_sentiment_score": "0.294414",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.049019",
        "ticker_sentiment_score": "0.194038",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.194242",
        "ticker_sentiment_score": "0.130028",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( NYSE:JNJ )  Rating Increased to Strong-Buy at StockNews.com",
    "url": "https://www.defenseworld.net/2024/06/30/johnson-johnson-nysejnj-rating-increased-to-strong-buy-at-stocknews-com.html",
    "time_published": "20240630T052249",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Johnson & Johnson ( NYSE:JNJ - Get Free Report ) was upgraded by investment analysts at StockNews.com from a \"buy\" rating to a \"strong-buy\" rating in a research note issued on Sunday. Other equities analysts also recently issued research reports about the stock.",
    "banner_image": "https://www.marketbeat.com/logos/johnson--johnson-logo-1200x675.png?v=20221020135923",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.658903"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.194498,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RBCPF",
        "relevance_score": "0.056808",
        "ticker_sentiment_score": "0.05899",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.056808",
        "ticker_sentiment_score": "0.05899",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.056808",
        "ticker_sentiment_score": "0.05899",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.824238",
        "ticker_sentiment_score": "0.325368",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "\"Rule Breaker Investing\" Mailbag: Talking Stocks and Options",
    "url": "https://www.fool.com/investing/2024/07/01/rule-breaker-investing-mailbag-talking-stocks-and/",
    "time_published": "20240701T222400",
    "authors": [
      "David Gardner",
      "Motley Fool Staff",
      "and Sean Milliken",
      "Bill Barker",
      "CFA",
      "Jim Mueller"
    ],
    "summary": "We also talk with Sean Milliken, managing director of The Motley Fool Foundation's ImpactFool (IF) Fund.",
    "banner_image": "https://g.foolcdn.com/editorial/images/782162/june.jpeg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.201791,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.011651",
        "ticker_sentiment_score": "0.058016",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PYPL",
        "relevance_score": "0.011651",
        "ticker_sentiment_score": "0.124881",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.019418",
        "ticker_sentiment_score": "0.051102",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.003884",
        "ticker_sentiment_score": "0.114034",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TTD",
        "relevance_score": "0.003884",
        "ticker_sentiment_score": "0.021488",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PTON",
        "relevance_score": "0.007768",
        "ticker_sentiment_score": "-0.010118",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.003884",
        "ticker_sentiment_score": "0.061167",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXON",
        "relevance_score": "0.011651",
        "ticker_sentiment_score": "0.02298",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.007768",
        "ticker_sentiment_score": "0.010943",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNBR",
        "relevance_score": "0.085283",
        "ticker_sentiment_score": "0.067386",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.003884",
        "ticker_sentiment_score": "-0.038905",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EBAY",
        "relevance_score": "0.015535",
        "ticker_sentiment_score": "0.128138",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "U",
        "relevance_score": "0.007768",
        "ticker_sentiment_score": "0.022254",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DAVA",
        "relevance_score": "0.034944",
        "ticker_sentiment_score": "0.051208",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "Z",
        "relevance_score": "0.003884",
        "ticker_sentiment_score": "0.021488",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNXYF",
        "relevance_score": "0.003884",
        "ticker_sentiment_score": "0.130152",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer - Y-mAbs Therapeutics  ( NASDAQ:YMAB ) ",
    "url": "https://www.benzinga.com/pressreleases/24/07/g39583428/y-mabs-appoints-seasoned-biopharma-executive-peter-pfreundschuh-as-chief-financial-officer",
    "time_published": "20240701T200500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, July 01, 2024 ( GLOBE NEWSWIRE ) -- Y-mAbs Therapeutics, Inc. ( the \"Company\" or \"Y-mAbs\" ) YMAB, a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.22327,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "FREQ",
        "relevance_score": "0.064104",
        "ticker_sentiment_score": "0.013003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "URGN",
        "relevance_score": "0.064104",
        "ticker_sentiment_score": "0.013003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "YMAB",
        "relevance_score": "0.190667",
        "ticker_sentiment_score": "0.066376",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.064104",
        "ticker_sentiment_score": "0.013003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VYGR",
        "relevance_score": "0.064104",
        "ticker_sentiment_score": "0.013003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.064104",
        "ticker_sentiment_score": "0.013003",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Assessing Johnson & Johnson's Performance Against Competitors In Pharmaceuticals Industry - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/news/24/07/39577471/assessing-johnson-amp-johnsons-performance-against-competitors-in-pharmaceuticals-industry",
    "time_published": "20240701T150039",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess companies. In this article, we will perform a comprehensive industry comparison, evaluating Johnson & Johnson JNJ against its key competitors in the ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.145458,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.069495",
        "ticker_sentiment_score": "0.041124",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.458446",
        "ticker_sentiment_score": "0.325093",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Judge Blocks Cancer Victims' Attempt To Stop Johnson & Johnson Bankruptcy Plan - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/39576600/judge-blocks-cancer-victims-attempt-to-stop-johnson-johnson-bankruptcy-plan",
    "time_published": "20240701T142553",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "A federal judge has denied a group of cancer victims' request to halt Johnson & Johnson JNJ from moving forward with a proposed bankruptcy settlement addressing tens of thousands of lawsuits alleging the company's talc products, including baby powder, contain cancer-causing asbestos.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/01/JohnsonampJohnson-Shutterstock.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.257329,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.532043",
        "ticker_sentiment_score": "-0.429398",
        "ticker_sentiment_label": "Bearish"
      }
    ]
  },
  {
    "title": "3 Magnificent Stocks Retirees Can Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/07/01/3-magnificent-stocks-retirees-can-buy-and-hold-for/",
    "time_published": "20240701T105000",
    "authors": [
      "David Jagielski",
      "Keith Speights",
      "and Prosper Junior Bakiny"
    ],
    "summary": "These stocks could be ideal for investors in their golden years.",
    "banner_image": "https://g.foolcdn.com/editorial/images/781952/hands-behind-head.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99977"
      }
    ],
    "overall_sentiment_score": 0.277972,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.295358",
        "ticker_sentiment_score": "0.16518",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.171485",
        "ticker_sentiment_score": "0.202911",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.254751",
        "ticker_sentiment_score": "0.177268",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Merck  ( MRK )  Gets CHMP Nod for PAH Drug Winrevair in Europe",
    "url": "https://www.zacks.com/stock/news/2295379/merck-mrk-gets-chmp-nod-for-pah-drug-winrevair-in-europe",
    "time_published": "20240701T093000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Merck's (MRK) Winrevair is poised to become the first activin signaling inhibitor therapy for PAH in Europe if approved by the European Commission.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/49/1007.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.247262,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.127456",
        "ticker_sentiment_score": "0.150305",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GMAB",
        "relevance_score": "0.063933",
        "ticker_sentiment_score": "0.129126",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.190167",
        "ticker_sentiment_score": "0.26268",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.127456",
        "ticker_sentiment_score": "0.206629",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "FDA Approves PYZCHIVA\u00ae  ( ustekinumab-ttwe ) , Samsung Bioepis' Biosimilar to Stelara",
    "url": "https://www.benzinga.com/pressreleases/24/07/g39567744/fda-approves-pyzchiva-ustekinumab-ttwe-samsung-bioepis-biosimilar-to-stelara",
    "time_published": "20240701T060341",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "PYZCHIVA becomes Samsung Bioepis' seventh biosimilar and fourth immunology biosimilar approved by the FDA PYZCHIVA's licensing period will begin on February 22, 2025, in the United States, based on the settlement and licensing agreement with Janssen Biotech Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.041266,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SSNLF",
        "relevance_score": "0.307988",
        "ticker_sentiment_score": "0.184439",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.021068",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "FDA approves biosimilar Pyzchiva\u00ae  ( ustekinumab-ttwe ) , to be commercialized by Sandoz in US",
    "url": "https://www.globenewswire.com/news-release/2024/07/01/2906370/0/en/FDA-approves-biosimilar-Pyzchiva-ustekinumab-ttwe-to-be-commercialized-by-Sandoz-in-US.html",
    "time_published": "20240701T050000",
    "authors": [
      "Sandoz International GmbH"
    ],
    "summary": "Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/511761ff-db95-4da3-a6b1-590b54593456",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.073023,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SSNLF",
        "relevance_score": "0.1789",
        "ticker_sentiment_score": "0.180923",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.030064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson's Cell Therapy Carvykti Shows Better Survival Rate In Pretreated Blood Cancer Patients - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/39598597/johnson-johnsons-cell-therapy-carvykti-shows-better-survival-rate-in-pretreated-blood-cancer-pati",
    "time_published": "20240702T150638",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Tuesday, Johnson & Johnson JNJ announced results from a prespecified second interim analysis of Phase 3 CARTITUDE-4 study evaluating Carvykti ( ciltacabtagene autoleucel.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/02/Johnson-Johnson-logo-in-front-of-one-of-.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.292125,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SSTK",
        "relevance_score": "0.097854",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LEGN",
        "relevance_score": "0.194242",
        "ticker_sentiment_score": "0.247362",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.461283",
        "ticker_sentiment_score": "0.299647",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TRGNF",
        "relevance_score": "0.097854",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Court Rules Against Johnson & Johnson In Talcum Powder Cancer Study Case - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/news/24/07/39596645/court-rules-against-johnson-johnson-in-talcum-powder-cancer-study-case",
    "time_published": "20240702T135505",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "A New Jersey federal judge has dismissed a lawsuit brought by a Johnson & Johnson JNJ subsidiary against Dr. Jacqueline Moline, who published a paper linking talc-based consumer products to cancer. The court found that Moline's research was neither fraudulent nor libelous, reaffirming her free ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/02/johnsons-5671315-1920.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.215171,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.395012",
        "ticker_sentiment_score": "-0.313487",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Intuitive Surgical  ( ISRG )  Rises 10% in a Month: What's Next?",
    "url": "https://www.zacks.com/stock/news/2296101/intuitive-surgical-isrg-rises-10-in-a-month-whats-next",
    "time_published": "20240702T130500",
    "authors": [
      "Indrajit Bandyopadhyay"
    ],
    "summary": "Intuitive Surgical (ISRG) is making strides in the robotic-assisted surgery market with its existing and new launches. However, macro challenges are likely to continue to hurt its performance.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/40/1670.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.299852,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MDT",
        "relevance_score": "0.084423",
        "ticker_sentiment_score": "0.282448",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.403913",
        "ticker_sentiment_score": "0.453487",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.084423",
        "ticker_sentiment_score": "0.282448",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "BCG Unresponsive NMIBC Market to Register Sustainable Growth During the Study Period  ( 2020-2034 )  | DelveInsight",
    "url": "https://www.prnewswire.com/news-releases/bcg-unresponsive-nmibc-market-to-register-sustainable-growth-during-the-study-period-20202034--delveinsight-302187784.html",
    "time_published": "20240703T213100",
    "authors": [
      "LLP",
      "DelveInsight Business Research"
    ],
    "summary": "The BCG unresponsive NMIBC market is anticipated to witness a substantial positive shift owing to better uptake of existing drugs, the expected market launch of photodynamic therapy and non-viral gene therapy, and raised awareness.",
    "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": -0.057056,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ENGN",
        "relevance_score": "0.064276",
        "ticker_sentiment_score": "-0.045485",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "URGN",
        "relevance_score": "0.042876",
        "ticker_sentiment_score": "-0.140559",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.042876",
        "ticker_sentiment_score": "-0.140559",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.106921",
        "ticker_sentiment_score": "-0.049993",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TARA",
        "relevance_score": "0.021446",
        "ticker_sentiment_score": "-0.076106",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CGON",
        "relevance_score": "0.021446",
        "ticker_sentiment_score": "-0.076106",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IBRX",
        "relevance_score": "0.042876",
        "ticker_sentiment_score": "-0.140559",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.021446",
        "ticker_sentiment_score": "-0.076106",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGMF",
        "relevance_score": "0.021446",
        "ticker_sentiment_score": "-0.106207",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.021446",
        "ticker_sentiment_score": "-0.076106",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Announces Health Canada NOC For RYBREVANT Combination - Quick Facts",
    "url": "https://markets.businessinsider.com/news/stocks/johnson-johnson-announces-health-canada-noc-for-rybrevant-combination-quick-facts-1033526326",
    "time_published": "20240703T121023",
    "authors": [
      "markets.businessinsider.com"
    ],
    "summary": "( RTTNews ) - Johnson & Johnson ( JNJ ) announced that Health Canada has issued a Notice of Compliance for RYBREVANT in combination with platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating ...",
    "banner_image": "https://markets.businessinsider.com/Images/FacebookIcon.jpg",
    "source": "Business Insider",
    "category_within_source": "RSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.121466,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.608634",
        "ticker_sentiment_score": "0.010718",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Dermatology Devices Market size is set to grow by USD 154.23 billion from 2024-2028, Increasing prevalence of skin ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/dermatology-devices-market-size-is-set-to-grow-by-usd-154-23-billion-from-2024-2028--increasing-prevalence-of-skin-disorders-to-boost-the-market-growth-technavio-302188850.html",
    "time_published": "20240704T213000",
    "authors": [],
    "summary": "Dermatology Devices Market size is set to grow by USD 154.23 billion from 2024-2028, Increasing prevalence of skin ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.130844,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.024053",
        "ticker_sentiment_score": "0.02029",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRKR",
        "relevance_score": "0.024053",
        "ticker_sentiment_score": "0.02504",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SHPHF",
        "relevance_score": "0.024053",
        "ticker_sentiment_score": "0.02504",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.024053",
        "ticker_sentiment_score": "0.02504",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHC",
        "relevance_score": "0.024053",
        "ticker_sentiment_score": "0.02504",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LRLCF",
        "relevance_score": "0.024053",
        "ticker_sentiment_score": "0.02029",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CUTR",
        "relevance_score": "0.024053",
        "ticker_sentiment_score": "0.02504",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Endoscope Reprocessing Market Surges to USD 3.35 Billion by 2031, Propelled by 7.67% CAGR - Verified Market Research\u00ae",
    "url": "https://www.benzinga.com/pressreleases/24/07/g39635495/endoscope-reprocessing-market-surges-to-usd-3-35-billion-by-2031-propelled-by-7-67-cagr-verified-m",
    "time_published": "20240704T141500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Lewes, Delaware, July 04, 2024 ( GLOBE NEWSWIRE ) -- The Global Endoscope Reprocessing Market is projected to grow at a CAGR of 7.67% from 2024 to 2031, according to a new report published by Verified Market Research\u00ae.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.224153,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ECL",
        "relevance_score": "0.031907",
        "ticker_sentiment_score": "0.111339",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.031907",
        "ticker_sentiment_score": "0.111339",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RSSS",
        "relevance_score": "0.031907",
        "ticker_sentiment_score": "0.170484",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "CLARITI STRATEGIC ADVISORS\u2122 ANNOUNCES THE ADDITION OF THREE NEW TEAM MEMBERS",
    "url": "https://www.newswire.ca/news-releases/clariti-strategic-advisors-tm-announces-the-addition-of-three-new-team-members-888734926.html",
    "time_published": "20240704T140000",
    "authors": [
      "Clariti Strategic Advisors Inc."
    ],
    "summary": "TORONTO, July 4, 2024 /CNW/ - Clariti Strategic Advisors\u2122 ( \"Clariti\" ) is excited to announce that our team has expanded: Tommy Lieu has joined us as a Director, Martin Jakubowski has joined us as an Associate and Aaron Veltri has joined us as an Analyst in our investment banking and strategic ...",
    "banner_image": "https://mma.prnewswire.com/media/2453879/Clariti_Strategic_Advisors_Inc__CLARITI_STRATEGIC_ADVISORS__ANNO.jpg?p=facebook",
    "source": "Canada Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.newswire.ca",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.297344,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "C",
        "relevance_score": "0.075397",
        "ticker_sentiment_score": "0.07369",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.075397",
        "ticker_sentiment_score": "0.028232",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 High-Yield Dividend Stocks/ETFs to Buy Hand Over Fist in July",
    "url": "https://www.fool.com/investing/2024/07/04/3-high-yield-dividend-stocks-etfs-buy-july/",
    "time_published": "20240704T100000",
    "authors": [
      "Daniel Foelber",
      "and Lee Samaha",
      "Scott Levine"
    ],
    "summary": "Investing in equal parts of these three investments would produce a forward-dividend yield over 3.9%.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F782245%2Fgettyimages-941740978-1201x801-d21b45d.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.259829,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KO",
        "relevance_score": "0.0378",
        "ticker_sentiment_score": "0.276381",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "0.012528",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.075516",
        "ticker_sentiment_score": "0.265812",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.430454",
        "ticker_sentiment_score": "0.240658",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PEP",
        "relevance_score": "0.0378",
        "ticker_sentiment_score": "0.276381",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AEP",
        "relevance_score": "0.364453",
        "ticker_sentiment_score": "0.231406",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CLX",
        "relevance_score": "0.0378",
        "ticker_sentiment_score": "0.241728",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.0378",
        "ticker_sentiment_score": "0.276381",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "HDV vs. SCHD: Which Is the Better Dividend ETF?",
    "url": "https://markets.businessinsider.com/news/stocks/hdv-vs-schd-which-is-the-better-dividend-etf-%C2%A0-1033527764",
    "time_published": "20240704T015532",
    "authors": [
      "Tipranks"
    ],
    "summary": "The iShares Core High Dividend ETF ( NYSEARCA:HDV ) and the Schwab U.S. Dividend Equity ETF ( NYSEARCA:SCHD ) are two popular dividend ETFs from blue-chip sponsors. Both are cost-effective options with low expense ratios, feature portfolios of well-known dividend stocks, and have dividend yields ...",
    "banner_image": "https://blog.tipranks.com/wp-content/uploads/2024/07/image-62-1024x555.png?utm_source=markets.businessinsider.com&utm_medium=referral",
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99793"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.305428,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SCHW",
        "relevance_score": "0.037681",
        "ticker_sentiment_score": "0.221681",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.037681",
        "ticker_sentiment_score": "0.067089",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.037681",
        "ticker_sentiment_score": "0.067089",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.075279",
        "ticker_sentiment_score": "0.216793",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.037681",
        "ticker_sentiment_score": "0.289786",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.037681",
        "ticker_sentiment_score": "0.289786",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Zika Virus Therapeutics Market size is set to grow by USD 4.17 billion from 2024-2028, Availability of serology kit for ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/zika-virus-therapeutics-market-size-is-set-to-grow-by-usd-4-17-billion-from-2024-2028--availability-of-serology-kit-for-qualitative-diagnosis-of-zika-virus-infection-to-boost-the-market-growth-technavio-302189587.html",
    "time_published": "20240705T203000",
    "authors": [],
    "summary": "Zika Virus Therapeutics Market size is set to grow by USD 4.17 billion from 2024-2028, Availability of serology kit for ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": -0.002463,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VALN",
        "relevance_score": "0.026474",
        "ticker_sentiment_score": "-0.044727",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.026474",
        "ticker_sentiment_score": "-0.044727",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOVX",
        "relevance_score": "0.026474",
        "ticker_sentiment_score": "-0.044727",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INO",
        "relevance_score": "0.026474",
        "ticker_sentiment_score": "-0.044727",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PRGO",
        "relevance_score": "0.026474",
        "ticker_sentiment_score": "-0.044727",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BVAXF",
        "relevance_score": "0.026474",
        "ticker_sentiment_score": "-0.044727",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.026474",
        "ticker_sentiment_score": "-0.304296",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "EBS",
        "relevance_score": "0.026474",
        "ticker_sentiment_score": "-0.044727",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSRLF",
        "relevance_score": "0.026474",
        "ticker_sentiment_score": "-0.304296",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.026474",
        "ticker_sentiment_score": "-0.011718",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.052918",
        "ticker_sentiment_score": "-0.025002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.026474",
        "ticker_sentiment_score": "-0.011718",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.026474",
        "ticker_sentiment_score": "-0.044727",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Car T-Cell Therapy Market size is set to grow by USD 3.02 billion from 2024-2028, Growing awareness regarding car T ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/car-t-cell-therapy-market-size-is-set-to-grow-by-usd-3-02-billion-from-2024-2028--growing-awareness-regarding-car-t-cell-therapy-to-boost-the-market-growth-technavio-302189578.html",
    "time_published": "20240705T192000",
    "authors": [],
    "summary": "Car T-Cell Therapy Market size is set to grow by USD 3.02 billion from 2024-2028, Growing awareness regarding car T ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.167906,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALLO",
        "relevance_score": "0.027699",
        "ticker_sentiment_score": "0.063089",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SGMO",
        "relevance_score": "0.027699",
        "ticker_sentiment_score": "0.063089",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AUTL",
        "relevance_score": "0.027699",
        "ticker_sentiment_score": "0.063089",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FBIO",
        "relevance_score": "0.027699",
        "ticker_sentiment_score": "0.063089",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.027699",
        "ticker_sentiment_score": "0.063089",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CYADY",
        "relevance_score": "0.027699",
        "ticker_sentiment_score": "0.063089",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.027699",
        "ticker_sentiment_score": "0.063089",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.027699",
        "ticker_sentiment_score": "0.063089",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FATE",
        "relevance_score": "0.027699",
        "ticker_sentiment_score": "0.063089",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.027699",
        "ticker_sentiment_score": "0.063089",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.027699",
        "ticker_sentiment_score": "0.063089",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "A Closer Look At Berkshire Hathaway's Chubb Investment",
    "url": "https://www.forbes.com/sites/gurufocus/2024/07/05/a-closer-look-at-berkshire-hathaways-chubb-investment/",
    "time_published": "20240705T182049",
    "authors": [
      "GuruFocus"
    ],
    "summary": "Synergies between the two companies are likely to rock the property and casualty insurance industry \u2022 Berkshire Hathaway revealed its 6.40% stake in Chubb on May 15. \u2022 Warren Buffett has had a long-term affinity for the insurance business because of its \"Collect-Now Pay-Later\" business model. \u2022 ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6688395dab493d10a3d62c0e/0x0.jpg?format=jpg&crop=2108,1185,x0,y216,safe&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.127039,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "PGR",
        "relevance_score": "0.027603",
        "ticker_sentiment_score": "0.03331",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.027603",
        "ticker_sentiment_score": "0.03331",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RLLWF",
        "relevance_score": "0.013804",
        "ticker_sentiment_score": "0.039672",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.137357",
        "ticker_sentiment_score": "0.108695",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CB",
        "relevance_score": "0.431956",
        "ticker_sentiment_score": "0.19281",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.027603",
        "ticker_sentiment_score": "0.021326",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What's Going On With Johnson and Johnson Shares Friday? - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/news/24/07/39647706/whats-going-on-with-johnson-and-johnson-shares-friday",
    "time_published": "20240705T143519",
    "authors": [
      "Dylan Berman"
    ],
    "summary": "Johnson and Johnson JNJ shares are trending on Friday. In the last week, the pharmaceutical company announced positive results from two clinical trials and authorization from Health Canada for RYBREVANT in combination with platinum-based chemotherapy.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/05/jnj-johnson-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.270271,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.606385",
        "ticker_sentiment_score": "0.295223",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Boston Partners Mutual Funds for Maximum Returns",
    "url": "https://www.zacks.com/stock/news/2297115/2-boston-partners-mutual-funds-for-maximum-returns",
    "time_published": "20240705T110900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Invest in Boston Partners mutual funds like BPRRX and BPAVX for a diversified portfolio approach.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ad/591.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.277178,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.081001",
        "ticker_sentiment_score": "0.057967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.081001",
        "ticker_sentiment_score": "0.057967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.081001",
        "ticker_sentiment_score": "0.057967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.081001",
        "ticker_sentiment_score": "0.057967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.081001",
        "ticker_sentiment_score": "0.222892",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Looking At Johnson & Johnson's Recent Unusual Options Activity - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/options/24/07/39670252/looking-at-johnson-johnsons-recent-unusual-options-activity",
    "time_published": "20240708T160054",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bullish stance on Johnson & Johnson JNJ. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      }
    ],
    "overall_sentiment_score": 0.147904,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.08687",
        "ticker_sentiment_score": "0.042109",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.673811",
        "ticker_sentiment_score": "0.323957",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Disney CEO Bob Iger to be Honored at The Ad Council's 70th Annual Public Service Award Dinner",
    "url": "https://www.prnewswire.com/news-releases/disney-ceo-bob-iger-to-be-honored-at-the-ad-councils-70th-annual-public-service-award-dinner-302189097.html",
    "time_published": "20240708T040100",
    "authors": [
      "The Ad Council"
    ],
    "summary": "NEW YORK, July 8, 2024 /PRNewswire/ -- The Ad Council announced today that Walt Disney Company CEO Bob Iger will be receiving the organization's Award for Public Service at its Public Service Award Dinner on December 5, 2024, at the Glasshouse in New York City.",
    "banner_image": "https://mma.prnewswire.com/media/748305/Ad_Council_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.297584,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.109705",
        "ticker_sentiment_score": "0.03677",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.054983",
        "ticker_sentiment_score": "0.18089",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.054983",
        "ticker_sentiment_score": "0.063841",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.054983",
        "ticker_sentiment_score": "0.063841",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PEP",
        "relevance_score": "0.054983",
        "ticker_sentiment_score": "0.063841",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DIS",
        "relevance_score": "0.109705",
        "ticker_sentiment_score": "0.146864",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.054983",
        "ticker_sentiment_score": "0.063841",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Disney CEO Bob Iger to be Honored at The Ad Council's 70th Annual Public Service Award Dinner",
    "url": "https://www.benzinga.com/pressreleases/24/07/n39658425/disney-ceo-bob-iger-to-be-honored-at-the-ad-councils-70th-annual-public-service-award-dinner",
    "time_published": "20240708T040100",
    "authors": [
      "PRNewswire"
    ],
    "summary": "NEW YORK, July 8, 2024 /PRNewswire/ -- The Ad Council announced today that Walt Disney Company CEO Bob Iger will be receiving the organization's Award for Public Service at its Public Service Award Dinner on December 5, 2024, at the Glasshouse in New York City.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.304199,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.104002",
        "ticker_sentiment_score": "0.036077",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.052112",
        "ticker_sentiment_score": "0.18058",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.052112",
        "ticker_sentiment_score": "0.063633",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.052112",
        "ticker_sentiment_score": "0.063633",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PEP",
        "relevance_score": "0.052112",
        "ticker_sentiment_score": "0.063633",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DIS",
        "relevance_score": "0.104002",
        "ticker_sentiment_score": "0.144142",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.052112",
        "ticker_sentiment_score": "0.063633",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Faces MedTech Challenges But Is 'On Track' To Meet 2024 Guidance: Goldman Sachs",
    "url": "https://markets.businessinsider.com/news/stocks/johnson-johnson-faces-medtech-challenges-but-is-on-track-to-meet-2024-guidance-goldman-sachs-1033540847",
    "time_published": "20240709T190738",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "U.S. pharma giant Johnson & Johnson ( NYSE:JNJ ) will report its second-quarter 2024 earnings on Wednesday, July 17. As per data from Benzinga Pro, analysts estimate sales of $22.29 billion and adjusted EPS of $2.71.",
    "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2024/07/09/JohnsonampJohnson-Shutterstock.jpeg",
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.173522,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.25168",
        "ticker_sentiment_score": "0.153769",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EBS",
        "relevance_score": "0.25168",
        "ticker_sentiment_score": "0.103681",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.577527",
        "ticker_sentiment_score": "0.398886",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Faces MedTech Challenges But Is 'On Track' To Meet 2024 Guidance: Goldman Sachs - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39696693/johnson-johnson-faces-medtech-challenges-but-is-on-track-to-meet-2024-guidance-gold",
    "time_published": "20240709T185343",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "U.S. pharma giant Johnson & Johnson JNJ will report its second-quarter 2024 earnings on Wednesday, July 17. As per data from Benzinga Pro, analysts estimate sales of $22.29 billion and adjusted EPS of $2.71.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/09/JohnsonampJohnson-Shutterstock.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.201318,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.22595",
        "ticker_sentiment_score": "0.141057",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EBS",
        "relevance_score": "0.333257",
        "ticker_sentiment_score": "0.126434",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.610896",
        "ticker_sentiment_score": "0.403684",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Emergent BioSolutions And Johnson & Johnson Resolve Claims Over COVID-19 Vaccine Manufacturing - Emergent BioSolutions  ( NYSE:EBS ) , Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/39687792/emergent-biosolutions-and-johnson-johnson-resolve-claims-over-covid-19-vaccine-manufacturing",
    "time_published": "20240709T125805",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Emergent BioSolutions Inc EBS, through its subsidiary Emergent Manufacturing Operations Baltimore, has reached a settlement with Janssen Pharmaceuticals, Inc., a branch of Johnson & Johnson JNJ, resolving disputes related to the manufacturing of Johnson & Johnson's investigational COVID-19 vaccine.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/09/covid-vaccine-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.080234,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "EBS",
        "relevance_score": "0.663719",
        "ticker_sentiment_score": "0.215183",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.558244",
        "ticker_sentiment_score": "0.167209",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Attovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of Directors -  ( ALPN ) , ORIC Pharmaceuticals  ( NASDAQ:ORIC ) ",
    "url": "https://www.benzinga.com/pressreleases/24/07/g39684095/attovia-therapeutics-announces-election-of-mitchell-gold-and-angie-you-to-board-of-directors",
    "time_published": "20240709T113000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "FREMONT, Calif., July 09, 2024 ( GLOBE NEWSWIRE ) -- Attovia Therapeutics today announced the election of Mitchell H. Gold, M.D., and Angie You, Ph.D., as independent members of its Board of Directors. Drs.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.317633,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ORIC",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.061499",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "0.074039",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "0.056736",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "0.056736",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "0.056736",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the VanEck Pharmaceutical ETF  ( PPH ) ?",
    "url": "https://www.zacks.com/stock/news/2298251/should-you-invest-in-the-vaneck-pharmaceutical-etf-pph",
    "time_published": "20240709T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for PPH ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default321.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999998"
      }
    ],
    "overall_sentiment_score": 0.184208,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.139265",
        "ticker_sentiment_score": "0.061839",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.139265",
        "ticker_sentiment_score": "0.043286",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.139265",
        "ticker_sentiment_score": "0.061839",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.139265",
        "ticker_sentiment_score": "0.061839",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Outpaces Stock Market Gains: What You Should Know",
    "url": "https://www.zacks.com/stock/news/2299553/johnson-johnson-jnj-outpaces-stock-market-gains-what-you-should-know",
    "time_published": "20240710T214519",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the most recent trading session, Johnson & Johnson (JNJ) closed at $149.43, indicating a +1.62% shift from the previous trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default195.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.95493"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.19548,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.576289",
        "ticker_sentiment_score": "0.267877",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Concert Golf Partners Acquires TPC Jasna Polana",
    "url": "https://www.benzinga.com/pressreleases/24/07/n39718948/concert-golf-partners-acquires-tpc-jasna-polana",
    "time_published": "20240710T204400",
    "authors": [
      "PRNewswire"
    ],
    "summary": "Historic clubhouse mansion and Gary Player-designed golf club in Princeton, N.J. was once owned by Johnson & Johnson heir J. Seward Johnson PRINCETON, N.J. and ORLANDO, Fla., July 10, 2024 /PRNewswire/ -- Concert Golf Partners has acquired TPC Jasna Polana ( \"Jasna Polana\" or the \"Club\" ) , a ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.366182,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CWK",
        "relevance_score": "0.063091",
        "ticker_sentiment_score": "0.194626",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.063091",
        "ticker_sentiment_score": "0.104325",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:AOA",
        "relevance_score": "0.03157",
        "ticker_sentiment_score": "0.188132",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "JNJ: 3 Blue-Chip Stocks to Buy and Hold Forever",
    "url": "https://stocknews.com/news/jnj-ibm-t-3-blue-chip-stocks-to-buy-and-hold-forever/",
    "time_published": "20240710T185143",
    "authors": [
      "StockNews.com Staff"
    ],
    "summary": "Investing in blue-chip stocks offers stability and reliable returns in today's volatile market. These industry-leading companies have strong reputations and solid track records.",
    "banner_image": "https://stocknews.com/wp-content/uploads/2023/07/ABhuyan.jpg",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "stocknews.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999612"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999975"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.222228,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "T",
        "relevance_score": "0.028937",
        "ticker_sentiment_score": "0.237513",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.028937",
        "ticker_sentiment_score": "0.157009",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IBM",
        "relevance_score": "0.228341",
        "ticker_sentiment_score": "0.219472",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ASTS",
        "relevance_score": "0.028937",
        "ticker_sentiment_score": "0.221672",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.20045",
        "ticker_sentiment_score": "0.133183",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWDAF",
        "relevance_score": "0.028937",
        "ticker_sentiment_score": "0.084201",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Will Q2 Earnings Power Dow ETFs?",
    "url": "https://www.zacks.com/stock/news/2299347/will-q2-earnings-power-dow-etfs",
    "time_published": "20240710T152500",
    "authors": [
      "Sweta Killa"
    ],
    "summary": "The Dow Jones is underperforming the other large-cap indices, such as the S&P 500 and Nasdaq Composite Index. Can the upcoming Q2 earnings help the index to catch up?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default9.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.188617,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DOW",
        "relevance_score": "0.129516",
        "ticker_sentiment_score": "0.008254",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IBM",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.064162",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.129516",
        "ticker_sentiment_score": "0.076496",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.129516",
        "ticker_sentiment_score": "0.023609",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.129516",
        "ticker_sentiment_score": "0.040182",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Molecular Glues Clinical Trial Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight",
    "url": "https://www.prnewswire.com/news-releases/molecular-glues-clinical-trial-pipeline-appears-robust-with-10-key-pharma-companies-actively-working-in-the-therapeutics-segment--delveinsight-302194515.html",
    "time_published": "20240711T213100",
    "authors": [
      "LLP",
      "DelveInsight Business Research"
    ],
    "summary": "The molecular glues pipeline and clinical trial analysis report delivers important insights on ongoing research, clinical strategies, upcoming therapeutics, and commercial analysis.",
    "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.097856,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "0.028471",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SKXJF",
        "relevance_score": "0.049784",
        "ticker_sentiment_score": "-0.052735",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARQT",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "0.02309",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KNBWF",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "0.02309",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.049784",
        "ticker_sentiment_score": "-0.052735",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.049784",
        "ticker_sentiment_score": "0.027682",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CARA",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "0.02309",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APGE",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "0.02309",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CGEM",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "-0.019809",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GLUE",
        "relevance_score": "0.049784",
        "ticker_sentiment_score": "0.104751",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRTHF",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "0.028471",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NRIX",
        "relevance_score": "0.074615",
        "ticker_sentiment_score": "0.106642",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AKESF",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "0.02309",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CCCC",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "0.028471",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "0.02309",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALDX",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "0.02309",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BGNE",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "0.028471",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.049784",
        "ticker_sentiment_score": "0.031644",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRDF",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "-0.102283",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.099373",
        "ticker_sentiment_score": "-0.001064",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ACLX",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "0.028471",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KYMR",
        "relevance_score": "0.049784",
        "ticker_sentiment_score": "0.110774",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BYSI",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "-0.019809",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRVS",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "0.02309",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IOVA",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "-0.019809",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALLK",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "0.02309",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.074615",
        "ticker_sentiment_score": "-0.053652",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TIL",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "-0.019809",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RNAC",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "0.028471",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.074615",
        "ticker_sentiment_score": "-0.001011",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RVMD",
        "relevance_score": "0.074615",
        "ticker_sentiment_score": "0.082227",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KYKOF",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "0.02309",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Model N Named in U.S. News & World Report's 2024-2025 Best Companies to Work For",
    "url": "https://www.globenewswire.com/news-release/2024/07/11/2912058/0/en/Model-N-Named-in-U-S-News-World-Report-s-2024-2025-Best-Companies-to-Work-For.html",
    "time_published": "20240711T173000",
    "authors": [
      "Model N"
    ],
    "summary": "Model N excelled as one of the top companies to meet employee needs. Model N excelled as one of the top companies to meet employee needs.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/032ddb47-8921-4e6e-a146-a0cf7a4a8b55",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.393306,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AVGO",
        "relevance_score": "0.06515",
        "ticker_sentiment_score": "0.241533",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.06515",
        "ticker_sentiment_score": "0.241533",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "STX",
        "relevance_score": "0.06515",
        "ticker_sentiment_score": "0.241533",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.06515",
        "ticker_sentiment_score": "0.241533",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Magnificent Dow Stocks That Are No-Brainer Buys for the Second Half of 2024",
    "url": "https://www.fool.com/investing/2024/07/11/3-dow-stocks-no-brainer-buys-for-second-half-2024/",
    "time_published": "20240711T085100",
    "authors": [
      "Sean Williams"
    ],
    "summary": "Among the Dow Jones Industrial Average's 30 time-tested components, there are three that stand out as phenomenal buys right now.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F783009%2Fnyse-wall-street-trading-new-york-financial-stock-market-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.989041"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.983783"
      }
    ],
    "overall_sentiment_score": 0.199705,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.02922",
        "ticker_sentiment_score": "0.256638",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.02922",
        "ticker_sentiment_score": "0.256638",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.285859",
        "ticker_sentiment_score": "0.140115",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.285859",
        "ticker_sentiment_score": "0.091804",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.173958",
        "ticker_sentiment_score": "0.228727",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Key Earnings Reports to Watch Next Week",
    "url": "https://www.zacks.com/stock/news/2301247/3-key-earnings-reports-to-watch-next-week",
    "time_published": "20240712T231100",
    "authors": [
      "Derek Lewis"
    ],
    "summary": "With the 2024 Q2 earnings season kicking into a much higher gear next week, there are several reports investors should keep on their radars, including these three.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6d/60158.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999162"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.190618,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.312423",
        "ticker_sentiment_score": "0.060714",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.370602",
        "ticker_sentiment_score": "0.087619",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Q2 Earnings Growth Expected to Reach Two-Year High",
    "url": "https://www.zacks.com/commentary/2301203/q2-earnings-growth-expected-to-reach-two-year-high",
    "time_published": "20240712T221500",
    "authors": [
      "Sheraz Mian"
    ],
    "summary": "We see the Q2 results from the major banks as good enough - not great, but definitely not bad either. The stocks' outperformance entering this reporting cycle contributed to the market's tentative initial reaction to the results.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/95/59803.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.10887,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.047749",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.189298",
        "ticker_sentiment_score": "-0.040251",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.189298",
        "ticker_sentiment_score": "-0.040251",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.047749",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.047749",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "6 Most Undervalued Stocks To Buy In August 2024",
    "url": "https://www.forbes.com/sites/investor-hub/article/top-undervalued-stocks-to-buy-august-2024/",
    "time_published": "20240712T133007",
    "authors": [
      "Catherine Brock"
    ],
    "summary": "The P/E ratio of the S&P 500 is almost 29, and on the rise. That's nearly double the index's historic median of 15. This is a sign investors are eager to own stocks, and hopeful that large-caps continue their recent strength. The enthusiasm is not being applied uniformly, however.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6690467df33181ecfdbea9d8/0x0.jpg?format=jpg&crop=3241,1822,x0,y0,safe&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.220718,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BABA",
        "relevance_score": "0.085324",
        "ticker_sentiment_score": "-0.011542",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BUD",
        "relevance_score": "0.056943",
        "ticker_sentiment_score": "0.241001",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PDD",
        "relevance_score": "0.169676",
        "ticker_sentiment_score": "0.073164",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COP",
        "relevance_score": "0.141726",
        "ticker_sentiment_score": "0.110567",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.252114",
        "ticker_sentiment_score": "-0.016312",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CCZ",
        "relevance_score": "0.085324",
        "ticker_sentiment_score": "0.026053",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.056943",
        "ticker_sentiment_score": "-0.018164",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Unlocking Q2 Potential of Johnson & Johnson  ( JNJ ) : Exploring Wall Street Estimates for Key Metrics",
    "url": "https://www.zacks.com/stock/news/2300663/unlocking-q2-potential-of-johnson-johnson-jnj-exploring-wall-street-estimates-for-key-metrics",
    "time_published": "20240712T131524",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default65.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.967321"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.109662,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.335367",
        "ticker_sentiment_score": "0.07813",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "White River Bancshares Co. Earns a Record $1.85 million, or $1.61 Per Diluted Share, in 2Q24; Highlighted by Successful Capital Raise and Net Interest Margin Expansion",
    "url": "https://www.globenewswire.com/news-release/2024/07/12/2912393/0/en/White-River-Bancshares-Co-Earns-a-Record-1-85-million-or-1-61-Per-Diluted-Share-in-2Q24-Highlighted-by-Successful-Capital-Raise-and-Net-Interest-Margin-Expansion.html",
    "time_published": "20240712T130000",
    "authors": [
      "White River Bancshares"
    ],
    "summary": "FAYETTEVILLE, Ark., July 12, 2024 ( GLOBE NEWSWIRE ) -- White River Bancshares Company ( OTCQX: WRIV ) , ( the \"Company\" ) the holding company for Signature Bank of Arkansas ( the \"Bank\" ) , today reported net income increased 137.5% to $1.85 million, or $1.61 per diluted share, in the second ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/59f98c26-e808-41b4-b248-610c5133e898",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.266511,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KO",
        "relevance_score": "0.017808",
        "ticker_sentiment_score": "0.117637",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBNY",
        "relevance_score": "0.05339",
        "ticker_sentiment_score": "0.123689",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSN",
        "relevance_score": "0.017808",
        "ticker_sentiment_score": "0.117637",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.017808",
        "ticker_sentiment_score": "0.117637",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.017808",
        "ticker_sentiment_score": "0.117637",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.017808",
        "ticker_sentiment_score": "0.117637",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Healthcare Stocks to Buy Hand Over Fist This Month",
    "url": "https://www.fool.com/investing/2024/07/14/2-healthcare-stocks-to-buy-hand-over-fist-this-mon/",
    "time_published": "20240714T133100",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "They don't have the most exciting businesses, but they have a lot to offer nonetheless.",
    "banner_image": "https://g.foolcdn.com/editorial/images/782612/doctor-and-patient-in-a-hospital-room.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.343957,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MDT",
        "relevance_score": "0.454714",
        "ticker_sentiment_score": "0.511875",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.04823",
        "ticker_sentiment_score": "0.155387",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.413803",
        "ticker_sentiment_score": "0.452836",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "These kinds of businesses are driving a surge in US corporate bankruptcies | Business",
    "url": "https://www.cnn.com/2024/07/14/business/stocks-week-ahead-businesses-failing-bankruptcies/index.html",
    "time_published": "20240714T113000",
    "authors": [
      "Bryan Mena"
    ],
    "summary": "These kinds of businesses are driving a surge in US corporate bankruptcies ...",
    "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-1360507858-copy.jpg?c=16x9&q=w_800,c_fill",
    "source": "CNN",
    "category_within_source": "Economy",
    "source_domain": "www.cnn.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.972193"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.049798,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "-0.051234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "-0.051234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LVS",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "-0.051234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FITB",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STT",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.066358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BX",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.066358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EFX",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "-0.051234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBD",
        "relevance_score": "0.126784",
        "ticker_sentiment_score": "0.051963",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.063594",
        "ticker_sentiment_score": "-0.115298",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INFY",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.066358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.066358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTRS",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "-0.051234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMI",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "-0.051234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOK",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.066358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAL",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.066358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AN",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SCHW",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MAN",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.066358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTAS",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.066358",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "These kinds of businesses are driving a surge in US corporate bankruptcies | Business",
    "url": "https://amp.cnn.com/cnn/2024/07/14/business/stocks-week-ahead-businesses-failing-bankruptcies",
    "time_published": "20240714T113000",
    "authors": [
      "Bryan Mena"
    ],
    "summary": "These kinds of businesses are driving a surge in US corporate bankruptcies ...",
    "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-1360507858-copy.jpg?c=16x9&q=w_800,c_fill",
    "source": "CNN",
    "category_within_source": "Markets",
    "source_domain": "amp.cnn.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.972193"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.049798,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "-0.051234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "-0.051234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LVS",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "-0.051234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FITB",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STT",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.066358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BX",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.066358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EFX",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "-0.051234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBD",
        "relevance_score": "0.126784",
        "ticker_sentiment_score": "0.051963",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.063594",
        "ticker_sentiment_score": "-0.115298",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INFY",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.066358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.066358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTRS",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "-0.051234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMI",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "-0.051234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOK",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.066358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAL",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.066358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AN",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SCHW",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MAN",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.066358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTAS",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.066358",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Easing Inflation Ignites Fed Expectations And Small-Cap Stocks",
    "url": "https://www.forbes.com/sites/bill_stone/2024/07/14/easing-inflation-ignites-fed-expectations-and-small-cap-stocks/",
    "time_published": "20240714T110000",
    "authors": [
      "Bill Stone"
    ],
    "summary": "After a second quarter dominated by mega-cap technology stocks, as represented by Magnificent 7, last week's better inflation reading and increased expectations of Federal Reserve rate cuts helped broaden participation in the stock rally.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/66930af6ac504529d9f77dad/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.998626"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.022334,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.148731",
        "ticker_sentiment_score": "0.124464",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.148731",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.148731",
        "ticker_sentiment_score": "0.124464",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.148731",
        "ticker_sentiment_score": "0.124464",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.148731",
        "ticker_sentiment_score": "0.124464",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.148731",
        "ticker_sentiment_score": "0.124464",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.148731",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLD",
        "relevance_score": "0.148731",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 High-Yield Dividend Stocks That Still Look Like Bargains",
    "url": "https://www.fool.com/investing/2024/07/14/3-high-yield-dividend-stocks-that-still-look-like/",
    "time_published": "20240714T082700",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "The prices of these reliable dividend payers haven't kept pace with the frothy stock market.",
    "banner_image": "https://g.foolcdn.com/editorial/images/783254/a-person-sitting-at-their-home-office-desk-using-a-laptop-computer-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.989041"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.208126,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ADC",
        "relevance_score": "0.27838",
        "ticker_sentiment_score": "0.266088",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CURN",
        "relevance_score": "0.056808",
        "ticker_sentiment_score": "-0.012004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.382088",
        "ticker_sentiment_score": "0.3892",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.056808",
        "ticker_sentiment_score": "0.098933",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.169279",
        "ticker_sentiment_score": "0.298133",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Dow Closes at New High as Q2 Earnings Season Heats Up",
    "url": "https://www.zacks.com/stock/news/2302138/dow-closes-at-new-high-as-q2-earnings-season-heats-up",
    "time_published": "20240715T223800",
    "authors": [
      "Mark Vickery"
    ],
    "summary": "Earnings season only picks up steam in the weeks to come.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/54381.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.084265,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.181137",
        "ticker_sentiment_score": "0.008697",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.181137",
        "ticker_sentiment_score": "0.008697",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.181137",
        "ticker_sentiment_score": "0.156643",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.181137",
        "ticker_sentiment_score": "0.156643",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.181137",
        "ticker_sentiment_score": "0.156643",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.181137",
        "ticker_sentiment_score": "0.008697",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.181137",
        "ticker_sentiment_score": "0.156643",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Smart Money Is Betting Big In JNJ Options - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/options/24/07/39781510/smart-money-is-betting-big-in-jnj-options",
    "time_published": "20240715T201619",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bullish approach towards Johnson & Johnson JNJ, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.135027,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.07887",
        "ticker_sentiment_score": "0.04154",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.677874",
        "ticker_sentiment_score": "0.359964",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Q2 Earnings Parade Continues",
    "url": "https://www.zacks.com/stock/news/2301800/q2-earnings-parade-continues",
    "time_published": "20240715T151900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Pre-markets are up solidly to start a new week of trading. This will be the first full week of Q2 earnings season, as well as ushering in plenty of economic data like U.S. Retail Sales and New Housing Starts. In any case, the Dow is currently +220 points, the S&P 500 is +18 and the Nasdaq +60 ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/98/601.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.990678"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.08506,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.160099",
        "ticker_sentiment_score": "0.129483",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.160099",
        "ticker_sentiment_score": "-0.026278",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.160099",
        "ticker_sentiment_score": "-0.026278",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.160099",
        "ticker_sentiment_score": "-0.026278",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.160099",
        "ticker_sentiment_score": "0.105606",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.160099",
        "ticker_sentiment_score": "-0.026278",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "J&J  ( JNJ )  Stock Before Q2 Earnings: To Buy or Not to Buy?",
    "url": "https://www.zacks.com/stock/news/2301766/jj-jnj-stock-before-q2-earnings-to-buy-or-not-to-buy",
    "time_published": "20240715T144700",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e3/1178.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.983605"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999365"
      }
    ],
    "overall_sentiment_score": 0.217562,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.084275",
        "ticker_sentiment_score": "0.161176",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.084275",
        "ticker_sentiment_score": "0.059295",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.126119",
        "ticker_sentiment_score": "0.163775",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Pre-Markets Up as 1st Full Week of Q2 Earnings Begins",
    "url": "https://www.zacks.com/stock/news/2301757/pre-markets-up-as-1st-full-week-of-q2-earnings-begins",
    "time_published": "20240715T143900",
    "authors": [
      "Mark Vickery"
    ],
    "summary": "Goldman Sachs (GS) and BlackRock (BLK) both beat on Q2 earnings this morning, and we're just getting started.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ab/505.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.99489"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.084982,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.154951",
        "ticker_sentiment_score": "0.11644",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.154951",
        "ticker_sentiment_score": "-0.025738",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.154951",
        "ticker_sentiment_score": "-0.025738",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.154951",
        "ticker_sentiment_score": "-0.025738",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.154951",
        "ticker_sentiment_score": "0.103444",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.154951",
        "ticker_sentiment_score": "-0.025738",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Legend Biotech  ( LEGN )  Up 12% on Reports of Takeover Bid",
    "url": "https://www.zacks.com/stock/news/2301726/legend-biotech-legn-up-12-on-reports-of-takeover-bid",
    "time_published": "20240715T131700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "A third-party article suggests that Legend Biotech (LEGN) hired investment banking firm Centerview Partners to help its board review the takeover offer.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.059725,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "TSVT",
        "relevance_score": "0.322023",
        "ticker_sentiment_score": "0.139442",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.164468",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LEGN",
        "relevance_score": "0.396261",
        "ticker_sentiment_score": "0.267312",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors",
    "url": "https://www.globenewswire.com/news-release/2024/07/15/2913027/0/en/NKGen-Biotech-Appoints-Dr-Marco-Gottardis-to-its-Board-of-Directors.html",
    "time_published": "20240715T120500",
    "authors": [
      "NKGen Biotech"
    ],
    "summary": "SANTA ANA, Calif., July 15, 2024 ( GLOBE NEWSWIRE ) -- NKGen Biotech, Inc. ( Nasdaq: NKGN ) ( \"NKGen\" or the \"Company\" ) , a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ( \"NK\" ) cell ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/037f203a-20be-4292-8f3f-e4b4fba670ce",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.07172,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NKGN",
        "relevance_score": "0.097062",
        "ticker_sentiment_score": "0.097078",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.097062",
        "ticker_sentiment_score": "-0.033689",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever",
    "url": "https://www.fool.com/investing/2024/07/15/want-decades-of-passive-income-3-stocks-to-buy-now/",
    "time_published": "20240715T103800",
    "authors": [
      "Justin Pope"
    ],
    "summary": "These companies stand out for their pedigrees, robust financials, and future growth prospects.",
    "banner_image": "https://g.foolcdn.com/editorial/images/783101/healthcare-chemist.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.917436"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.316063,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "UNH",
        "relevance_score": "0.411549",
        "ticker_sentiment_score": "0.239918",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.369456",
        "ticker_sentiment_score": "0.364863",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.143131",
        "ticker_sentiment_score": "0.090953",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Modicus Prime Raises $3.5M to prevent Drug Product Quality failures during Commercial Production",
    "url": "https://www.prnewswire.com/news-releases/modicus-prime-raises-3-5m-to-prevent-drug-product-quality-failures-during-commercial-production-302195851.html",
    "time_published": "20240715T100000",
    "authors": [
      "Modicus Prime"
    ],
    "summary": "Modicus Prime, the AI image processing platform for drug manufacturing, is addressing the cost, legal, and waste liabilities caused by quality control issues",
    "banner_image": "https://mma.prnewswire.com/media/2459885/Modicus_Prime_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.141915,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.107495",
        "ticker_sentiment_score": "0.024508",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Netflix, Goldman Sachs, J&J, ASML Lead Q2 Reports This Week As Analysts See Earnings Growth Accelerating To Fastest In Over 2 Years - SPDR S&P 500  ( ARCA:SPY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/07/39766859/netflix-goldman-sachs-j-j-asml-lead-q2-reports-this-week-as-analysts-see-earnings-growth-accelerati",
    "time_published": "20240715T091317",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "The second-quarter reporting season got off to a rocky start with investors reacting to some big bank earnings. Nevertheless, optimism over a healthy earnings season continues to abound. The Week That Was: Shares of high-profile big banks including JPMorgan Chase & Co. JPM, Citigroup Inc.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/15/earnings.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999813"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.22049,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AA",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALK",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.249464",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "-0.210285",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMI",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SLB",
        "relevance_score": "0.061631",
        "ticker_sentiment_score": "-0.192121",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "DAL",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.089961",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ASML",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DPZ",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SLG",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DFS",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DMPZF",
        "relevance_score": "0.061631",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HAL",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "-0.220592",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.18343",
        "ticker_sentiment_score": "-0.265821",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "-0.220592",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "TRV",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "-0.220592",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STLD",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "JPMorgan, Citigroup and Wells Fargo are part of Zacks Earnings Preview",
    "url": "https://www.zacks.com/stock/news/2301305/jpmorgan-citigroup-and-wells-fargo-are-part-of-zacks-earnings-preview",
    "time_published": "20240715T084100",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "JPMorgan, Citigroup and Wells Fargo have been highlighted in this Earnings Preview article.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e1/1010.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.120821,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.187463",
        "ticker_sentiment_score": "-0.046444",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.187463",
        "ticker_sentiment_score": "-0.046444",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer",
    "url": "https://www.globenewswire.com/news-release/2024/07/16/2914185/0/en/ORIC-Pharmaceuticals-Announces-Multiple-Clinical-Collaborations-with-Strategic-Partners-to-Support-Ongoing-Trial-Evaluating-ORIC-944-in-Combination-with-AR-Inhibitors-for-the-Treat.html",
    "time_published": "20240716T205900",
    "authors": [
      "ORIC Pharmaceuticals"
    ],
    "summary": "ORIC-944, a potential best-in-class PRC2 inhibitor, is being evaluated in combination with darolutamide and in combination with apalutamide in patients with ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/1683fb2b-87fe-46c4-9c2a-8277cbbfa567",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.057949,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ORIC",
        "relevance_score": "0.780208",
        "ticker_sentiment_score": "0.108368",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.067441",
        "ticker_sentiment_score": "0.021084",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Q2 Earnings Preview: Can New Drugs Lift Sagging Stock? - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39802572/johnson-johnson-q2-earnings-preview-can-new-drugs-lift-sagging-stock",
    "time_published": "20240716T190710",
    "authors": [
      "Chris Katje"
    ],
    "summary": "Johnson & Johnson JNJ was one of the worst-performing Dow Jones Industrial Average stocks in the first half of 2024. Investors and analysts will be looking for the company to show progress from a mixed first quarter when second-quarter financial results are reported Wednesday, July 17.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/16/Johnson-JohnsonJohnson.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999162"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.177749,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALC",
        "relevance_score": "0.184834",
        "ticker_sentiment_score": "0.199404",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RXST",
        "relevance_score": "0.123844",
        "ticker_sentiment_score": "-0.005997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.123844",
        "ticker_sentiment_score": "0.222497",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.839263",
        "ticker_sentiment_score": "0.179495",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson: Bullish Charts Signal Strong Setup Before Q2 Earnings - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39799990/johnson-johnson-bullish-charts-signal-strong-setup-before-q2-earnings",
    "time_published": "20240716T164616",
    "authors": [
      "Surbhi Jain"
    ],
    "summary": "Johnson & Johnson JNJ is reporting its second-quarter earnings on Wednesday. Wall Street expects $2.7 in EPS and $22.3 billion in revenues as the company reports before market hours. The stock is down 5.56% over the past year, -4.16% YTD.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/16/JohnsonampJohnson-Shutterstock_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.692272"
      }
    ],
    "overall_sentiment_score": 0.167812,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.748842",
        "ticker_sentiment_score": "0.201429",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Stock Market News for Jul 16, 2024",
    "url": "https://www.zacks.com/stock/news/2302388/stock-market-news-for-jul-16-2024",
    "time_published": "20240716T132700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "U.S stocks closed higher on Monday, building on Friday???s rally, as investors increased their bets on the chances of Donald Trump winning the U.S. presidential election in November following a failed assassination attempt on the Republican nominee over the weekend.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f2/1146.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.072454,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MARA",
        "relevance_score": "0.151064",
        "ticker_sentiment_score": "0.206846",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.151064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.151064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.151064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.27246",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.151064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Scorched Earth & The Burning of the American Consumer",
    "url": "https://www.benzinga.com/pressreleases/24/07/n39792528/scorched-earth-the-burning-of-the-american-consumer",
    "time_published": "20240716T130000",
    "authors": [
      "PRNewswire"
    ],
    "summary": "\"Outside Counsel\" Unveils Riveting Season 2 with Esteemed Legal Commentator DALLAS, July 16, 2024 /PRNewswire/ - Renowned trial lawyer, and co-founder of Simon Greenstone Panatier, PC, law school professor, and author of Last Rights, Jeffrey B.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": -0.02248,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NYT",
        "relevance_score": "0.179121",
        "ticker_sentiment_score": "0.102526",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.090134",
        "ticker_sentiment_score": "0.30175",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.090134",
        "ticker_sentiment_score": "0.033012",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q2 Earnings - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/news/earnings/24/07/39790748/how-to-earn-500-a-month-from-johnson-johnson-stock-ahead-of-q2-earnings",
    "time_published": "20240716T120635",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Johnson & Johnson JNJ will release its second-quarter financial results, before the opening bell on Wednesday, July 17. Analysts expect the New Brunswick, New Jersey-based company to report quarterly earnings at $2.70 per share, up from $2.56 per share in the year-ago period.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/16/JohnsonampJohnson-Shutterstock.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.723405"
      }
    ],
    "overall_sentiment_score": 0.153968,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EBS",
        "relevance_score": "0.211191",
        "ticker_sentiment_score": "0.085435",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.716023",
        "ticker_sentiment_score": "0.272465",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Trawick International Launches Commercial and Specialty Division, Appoints Industry Veteran Jack Coleman as President",
    "url": "https://www.benzinga.com/pressreleases/24/07/g39789257/trawick-international-launches-commercial-and-specialty-division-appoints-industry-veteran-jack-co",
    "time_published": "20240716T111000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "MIAMI, July 16, 2024 ( GLOBE NEWSWIRE ) -- Trawick International, a leading international insurance company, today announced the appointment of Jack Coleman as President of the new Commercial and Specialty division, effective immediately.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.276187,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.080458",
        "ticker_sentiment_score": "-0.1454",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings' - Bristol-Myers Squibb  ( NYSE:BMY ) , Biogen  ( NASDAQ:BIIB ) ",
    "url": "https://www.benzinga.com/news/24/07/39784920/bernie-sanders-getting-sick-in-america-should-not-mean-going-bankrupt-losing-your-home-car-or-life-s",
    "time_published": "20240716T013615",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "Sen. Bernie Sanders ( I-Vt. ) recently expressed his concerns about the high cost of medical care in the United States, highlighting the financial burden it places on patients. What Happened: On Monday, Sanders took to X to voice his concerns about the high cost of healthcare in the United ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/15/Bernie-Sanders.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": -0.036649,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SSTK",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.24289",
        "ticker_sentiment_score": "-0.165803",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.24289",
        "ticker_sentiment_score": "-0.165803",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.24289",
        "ticker_sentiment_score": "-0.165803",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.24289",
        "ticker_sentiment_score": "-0.379949",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.24289",
        "ticker_sentiment_score": "-0.379949",
        "ticker_sentiment_label": "Bearish"
      }
    ]
  },
  {
    "title": "Why Johnson & Johnson Stock Was a Winner on Wednesday",
    "url": "https://www.fool.com/investing/2024/07/17/why-johnson-johnson-stock-was-a-winner-on-wednesda/",
    "time_published": "20240717T221400",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "The company did a fine job of boosting sales of numerous drugs.",
    "banner_image": "https://g.foolcdn.com/editorial/images/783734/stethescope-atop-us-currency-and-coins.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.214894,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.724687",
        "ticker_sentiment_score": "0.280981",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Hits Crucial Roadblock - Can It Break Through? - JPMorgan Chase  ( NYSE:JPM ) , Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/trading-ideas/technicals/24/07/39824201/stock-of-the-day-johnson-johnson-hits-crucial-roadblock-can-it-break-through",
    "time_published": "20240717T191212",
    "authors": [
      "Mark Putrino"
    ],
    "summary": "Investors loved the Johnson & Johnson JNJ earnings report. The stock is trading much higher, but it has stalled out around an important resistance level. In financial markets, some price levels have more importance than others.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/17/jnj-johnson-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.088306,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.380012",
        "ticker_sentiment_score": "0.076478",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Q2 2024 Earnings Call Transcript",
    "url": "https://www.fool.com/earnings/call-transcripts/2024/07/17/johnson-johnson-jnj-q2-2024-earnings-call-transcri/",
    "time_published": "20240717T190018",
    "authors": [
      "Motley Fool Transcribing"
    ],
    "summary": "JNJ earnings call for the period ending June 30, 2024.",
    "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.996718"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.324167,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.014845",
        "ticker_sentiment_score": "0.097484",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMRSQ",
        "relevance_score": "0.004949",
        "ticker_sentiment_score": "0.13028",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.004949",
        "ticker_sentiment_score": "0.107597",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.004949",
        "ticker_sentiment_score": "0.114453",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.004949",
        "ticker_sentiment_score": "0.107597",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.049455",
        "ticker_sentiment_score": "0.120733",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:JPY",
        "relevance_score": "0.004949",
        "ticker_sentiment_score": "0.015827",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:CNY",
        "relevance_score": "0.004949",
        "ticker_sentiment_score": "0.015827",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.004949",
        "ticker_sentiment_score": "0.105891",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment - AstraZeneca  ( NASDAQ:AZN ) , Johnson & Johnson  ( NYSE:JNJ ) , Moderna  ( NASDAQ:MRNA ) , GSK  ( NYSE:GSK ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/39823289/european-commission-faces-court-criticism-over-covid-vaccine-contract-transparency-ahead-of-vote-",
    "time_published": "20240717T182405",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "The European Commission faced criticism from Europe's second-highest court regarding transparency issues surrounding COVID-19 vaccine contracts from four years ago. This scrutiny comes on the eve of a crucial vote on Commission head Ursula von der Leyen's reelection bid.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/17/Pfizer-BioNTech-COVID-19-vaccine-2020-G.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.124235,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.194182",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.194182",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.194182",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GSK",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.194182",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.371523",
        "ticker_sentiment_score": "0.054947",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.194182",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.194182",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FOREX:EUR",
        "relevance_score": "0.096283",
        "ticker_sentiment_score": "-0.111517",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson And Johnson Continues To Focus On Medical Innovation - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/news/24/07/39823007/johnson-and-johnson-continues-to-focus-on-medical-innovation",
    "time_published": "20240717T180500",
    "authors": [
      "Upwallstreet"
    ],
    "summary": "On Wednesday, Johnson & Johnson JNJ reported its second quarter results that reflected a strong momentum of its medtech and innovative medicine divisions.",
    "banner_image": "https://cdn.benzinga.com/files/scientific-specialist-research-lab-wearing-vr-goggles-using-high-tech-equipment-wired-sensors-medical-study-healthcare-practitioner-using-virtual-reality-technology-visualize-datasets.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.156019,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.362858",
        "ticker_sentiment_score": "0.226802",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "ORIC Pharmaceuticals  ( ORIC )  Up on Collaboration With Bayer & JNJ",
    "url": "https://www.zacks.com/stock/news/2303774/oric-pharmaceuticals-oric-up-on-collaboration-with-bayer-jnj",
    "time_published": "20240717T152000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "ORIC Pharmaceuticals (ORIC) teams up with Bayer and Johnson & Johnson for a phase I study on ORIC-944 in patients with metastatic prostate cancer. Its shares rise on the news.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/1981.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.057103,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ORIC",
        "relevance_score": "0.965603",
        "ticker_sentiment_score": "0.153173",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TRDA",
        "relevance_score": "0.152499",
        "ticker_sentiment_score": "0.096",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.227007",
        "ticker_sentiment_score": "0.100645",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Housing Starts Increased More Than Expected",
    "url": "https://www.zacks.com/stock/news/2303632/housing-starts-increased-more-than-expected",
    "time_published": "20240717T151600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Pre-market futures are down this morning. This does not appear to be as a result of any releases ahead of the open, but as sort of a mass realization that markets have climbed historically high over the past few weeks - even the Dow hit an all-time closing high yesterday - and another round of ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.905476"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      }
    ],
    "overall_sentiment_score": 0.037843,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AA",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.084593",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.037122",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nasdaq Smacked By Chip Sell-Off; Dow Stock Breaks Out",
    "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-today-nasdaq-sp500-dow-jones-asml-stock-chip-stocks/",
    "time_published": "20240717T144000",
    "authors": [
      "DAVID SAITO-CHUNG",
      "Investor's Business Daily"
    ],
    "summary": "Nasdaq Smacked As Regulation Fears Pound Chip Stocks. Health Care Giant Breaks Out ( Live Coverage ) Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2018/11/stock-bear-wave-02-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999993"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.050411,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DTST",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "-0.073659",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.13459",
        "ticker_sentiment_score": "0.085876",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.13459",
        "ticker_sentiment_score": "0.085876",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.265378",
        "ticker_sentiment_score": "0.054704",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.13459",
        "ticker_sentiment_score": "0.085876",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stock market today: Big tech stocks dive again as their split deepens with the rest of Wall Street",
    "url": "https://apnews.com/article/stock-markets-rates-fed-china-6f9069df533d393c649ae5a171e31ab8",
    "time_published": "20240717T142600",
    "authors": [
      "STAN CHOE"
    ],
    "summary": "Stock market today: Wall Street's split deepens between big tech stocks and the rest of the market The Associated Press ...",
    "banner_image": "https://dims.apnews.com/dims4/default/d27282c/2147483647/strip/true/crop/3878x2583+19+0/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F%5B2%2F9%2C%2F%20-88%2C%2013%2C%20108%2C%2059%2C%209%2C%20-115%2C%20-108%2C%2058%2C%20-62%2C%20-42%2C%2079%2C%20-52%2C%20110%2C%2099%2C%2048%2C%20-102%2C%20108%2C%20125%2C%20-102%2C%20-28%2C%2011%2C%20-16%2C%20-124%2C%2024%2C%20-71%2C%2032%2C%20-104%5D%2Fe3058c3ec3f54b99abdde247946dc7dc",
    "source": "Associated Press",
    "category_within_source": "Markets",
    "source_domain": "apnews.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": -0.026799,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.046633",
        "ticker_sentiment_score": "0.160438",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TOELF",
        "relevance_score": "0.093108",
        "ticker_sentiment_score": "0.036438",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.046633",
        "ticker_sentiment_score": "0.160438",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.093108",
        "ticker_sentiment_score": "0.089621",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.046633",
        "ticker_sentiment_score": "0.160438",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.046633",
        "ticker_sentiment_score": "0.160438",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PLD",
        "relevance_score": "0.046633",
        "ticker_sentiment_score": "0.069704",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SAVE",
        "relevance_score": "0.046633",
        "ticker_sentiment_score": "-0.138485",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSM",
        "relevance_score": "0.046633",
        "ticker_sentiment_score": "-0.095715",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pre-Markets Book Profits; Housing Starts, J&J Q2 Up",
    "url": "https://www.zacks.com/stock/news/2303581/pre-markets-book-profits-housing-starts-jj-q2-up",
    "time_published": "20240717T142100",
    "authors": [
      "Mark Vickery"
    ],
    "summary": "Pre-market futures are down at this hour, but not apparently as a result of any new reports ahead of the bell.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/60/60979.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.905476"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      }
    ],
    "overall_sentiment_score": 0.037813,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AA",
        "relevance_score": "0.148273",
        "ticker_sentiment_score": "0.084279",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.148273",
        "ticker_sentiment_score": "0.033711",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nasdaq Dips 300 Points; Johnson & Johnson Earnings Top Estimates - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/news/earnings/24/07/39816148/nasdaq-dips-300-points-johnson-johnson-earnings-top-estimates",
    "time_published": "20240717T133919",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "U.S. stocks traded mostly lower this morning, with the Nasdaq Composite falling around 300 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.10% to 40,914.80 while the NASDAQ fell 1.63% to 18,208.05. The S&P 500 also fell, dropping, 0.98% to 5,611.77 .",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/17/Image32.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": -0.053738,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NAAS",
        "relevance_score": "0.146469",
        "ticker_sentiment_score": "-0.233314",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "CRWD",
        "relevance_score": "0.073546",
        "ticker_sentiment_score": "-0.144284",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.218161",
        "ticker_sentiment_score": "0.403625",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ADTX",
        "relevance_score": "0.218161",
        "ticker_sentiment_score": "0.491073",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "LCFY",
        "relevance_score": "0.146469",
        "ticker_sentiment_score": "0.25732",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ASLN",
        "relevance_score": "0.146469",
        "ticker_sentiment_score": "0.015674",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SAVA",
        "relevance_score": "0.146469",
        "ticker_sentiment_score": "0.006414",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SHIM",
        "relevance_score": "0.146469",
        "ticker_sentiment_score": "0.209455",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Beats, But Cuts Guidance",
    "url": "https://www.investors.com/news/technology/johnson-johnson-stock-johnson-johnson-earnings-q2-2024/",
    "time_published": "20240717T121700",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Johnson & Johnson Earnings Top, But Dow Stock Lowers Guidance Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/10/stock-JohnsonANDjohnson-02-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      }
    ],
    "overall_sentiment_score": 0.304212,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.782378",
        "ticker_sentiment_score": "0.456377",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVAX",
        "relevance_score": "0.162802",
        "ticker_sentiment_score": "0.177811",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson's Q2 Earnings: Revenue And Profit Beat On Strong Pharma Sales, Annual Profit Outlook Lowered On M&A Costs - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/39813647/johnson-johnsons-q2-earnings-revenue-and-profit-beat-on-strong-pharma-sales-annual-profit-outlook",
    "time_published": "20240717T121427",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Wednesday, Johnson & Johnson JNJ reported a second-quarter adjusted EPS of $2.82, up 10.2% year-over-year, beating the consensus of $2.70. The pharma giant reported sales of $22.45 billion, up 4.3% year-over-year, beating the consensus of $22.31 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/17/Johnson-and-Johnson.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.233822,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.529185",
        "ticker_sentiment_score": "0.2878",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Nasdaq, S&P 500 Futures Plummet: What's Going On - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/07/39812718/nasdaq-s-p-500-futures-plunge-after-trumps-comments-and-asmls-weak-forecast-deepens-tech-sell-off-a",
    "time_published": "20240717T114103",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "Sentiment will likely reverse course, with the index futures trading notably lower early Wednesday. The recent run-up ideally should render the mood cautious, and the caution may intensify as the first AI-levered chip company from across the Atlantic reported second-quarter results that were not ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/17/wall-street-ai11.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.085762,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AA",
        "relevance_score": "0.073209",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.073209",
        "ticker_sentiment_score": "-0.230419",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.073209",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GTLB",
        "relevance_score": "0.073209",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALLY",
        "relevance_score": "0.073209",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMI",
        "relevance_score": "0.073209",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.073209",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SLG",
        "relevance_score": "0.073209",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DFS",
        "relevance_score": "0.073209",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FIVE",
        "relevance_score": "0.073209",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.073209",
        "ticker_sentiment_score": "-0.230419",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "LPLA",
        "relevance_score": "0.036643",
        "ticker_sentiment_score": "-0.095885",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STLD",
        "relevance_score": "0.073209",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.073209",
        "ticker_sentiment_score": "0.078845",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Beats Q2 Earnings and Revenue Estimates",
    "url": "https://www.zacks.com/stock/news/2303130/johnson-johnson-jnj-beats-q2-earnings-and-revenue-estimates",
    "time_published": "20240717T113002",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 4.06% and 0.43%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default19.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999997"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.150804,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.395012",
        "ticker_sentiment_score": "0.1105",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Beats, But Falls On Lowered Guidance",
    "url": "https://www.investors.com/news/technology/johnson-johnson-stock-johnson-johnson-earnings-q2-2024/",
    "time_published": "20240717T104200",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Johnson & Johnson Earnings Top, But Dow Stock Falls On Lowered Guidance Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/10/stock-JohnsonANDjohnson-02-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      }
    ],
    "overall_sentiment_score": 0.261044,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.785534",
        "ticker_sentiment_score": "0.316807",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVAX",
        "relevance_score": "0.163909",
        "ticker_sentiment_score": "0.178593",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Genmab Announces Net Sales of DARZALEX\u00ae  ( daratumumab )  for Second Quarter of 2024",
    "url": "https://www.globenewswire.com/news-release/2024/07/17/2914398/0/en/Genmab-Announces-Net-Sales-of-DARZALEX-daratumumab-for-Second-Quarter-of-2024.html",
    "time_published": "20240717T102500",
    "authors": [
      "Genmab A/S"
    ],
    "summary": "Company Announcement ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.009624,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GMAB",
        "relevance_score": "0.587597",
        "ticker_sentiment_score": "0.049193",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.011672",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Tech Futures Skid On ASML, Tougher China Curbs, Trump",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-asml-earnings-china-curbs-donald-trump/",
    "time_published": "20240717T094800",
    "authors": [
      "Investor's Business Daily",
      "ED CARSON"
    ],
    "summary": "Dow Jones futures declined slightly early Wednesday, while S&P 500 futures and especially Nasdaq futures fell solidly as semiconductor-equipment giant ASML ( ASML ) tumbled on guidance.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2023/02/Stock-Chip-glows-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.170607,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.269776",
        "ticker_sentiment_score": "-0.051303",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IBKR",
        "relevance_score": "0.151922",
        "ticker_sentiment_score": "0.014848",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.091509",
        "ticker_sentiment_score": "0.085884",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WWD",
        "relevance_score": "0.151922",
        "ticker_sentiment_score": "0.112469",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.061081",
        "ticker_sentiment_score": "-0.109011",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SCHW",
        "relevance_score": "0.061081",
        "ticker_sentiment_score": "0.023594",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TOST",
        "relevance_score": "0.211454",
        "ticker_sentiment_score": "0.083483",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FLS",
        "relevance_score": "0.091509",
        "ticker_sentiment_score": "0.115512",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.121804",
        "ticker_sentiment_score": "0.093348",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.151922",
        "ticker_sentiment_score": "0.139454",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "These Stocks Are Moving the Most Today: Nvidia, Super Micro, ASML, TSMC, J&J, GitLab, Five Below, and More",
    "url": "https://www.barrons.com/amp/articles/stock-market-movers-db08271e",
    "time_published": "20240717T090000",
    "authors": [
      "Joe Woelfel"
    ],
    "summary": "Nvidia, Super Micro, ASML, Spirit Airlines, Five Below, J&J, and More Market Movers ...",
    "banner_image": "https://images.barrons.com/im-408192/social",
    "source": "Barrons",
    "category_within_source": "n/a",
    "source_domain": "www.barrons.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.980509"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.002409,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AA",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "0.048897",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GTLB",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "0.180305",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BE",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "-0.111613",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "0.034913",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DDOG",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "0.180305",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "0.150082",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LVS",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MU",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "0.034913",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ASML",
        "relevance_score": "0.261117",
        "ticker_sentiment_score": "-0.140395",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSM",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "0.097464",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FIVE",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "-0.002867",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SAVE",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "-0.093975",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "These Stocks Are Moving the Most Today: Nvidia, AMD, ASML, TSMC, Intel, J&J, GitLab, Five Below, and More",
    "url": "https://www.barrons.com/amp/articles/stock-market-movers-db08271e",
    "time_published": "20240717T090000",
    "authors": [
      "Joe Woelfel"
    ],
    "summary": "Nvidia, Super Micro, ASML, Spirit Airlines, Five Below, J&J, and More Market Movers ...",
    "banner_image": "https://images.barrons.com/im-408192/social",
    "source": "Barrons",
    "category_within_source": "n/a",
    "source_domain": "www.barrons.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.980509"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": -0.016868,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AA",
        "relevance_score": "0.077845",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMAT",
        "relevance_score": "0.077845",
        "ticker_sentiment_score": "-0.140607",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.077845",
        "ticker_sentiment_score": "-0.140607",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.077845",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GTLB",
        "relevance_score": "0.077845",
        "ticker_sentiment_score": "0.186953",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BE",
        "relevance_score": "0.077845",
        "ticker_sentiment_score": "-0.109486",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.077845",
        "ticker_sentiment_score": "-0.140607",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DDOG",
        "relevance_score": "0.154951",
        "ticker_sentiment_score": "0.238514",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.077845",
        "ticker_sentiment_score": "0.163473",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LVS",
        "relevance_score": "0.077845",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MU",
        "relevance_score": "0.077845",
        "ticker_sentiment_score": "-0.140607",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ASML",
        "relevance_score": "0.2306",
        "ticker_sentiment_score": "-0.127129",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSM",
        "relevance_score": "0.077845",
        "ticker_sentiment_score": "0.145074",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FIVE",
        "relevance_score": "0.154951",
        "ticker_sentiment_score": "-0.002632",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.077845",
        "ticker_sentiment_score": "-0.140607",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SAVE",
        "relevance_score": "0.077845",
        "ticker_sentiment_score": "-0.092205",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "ASML, United Airlines And 3 Other Stocks To Watch Heading Into Wednesday - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/news/earnings/24/07/39809435/asml-united-airlines-and-3-other-stocks-to-watch-heading-into-wednesday",
    "time_published": "20240717T071639",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "With U.S. stock futures trading lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Johnson & Johnson JNJ to report quarterly earnings at $2.70 per share on revenue of $22.31 billion before the opening bell, according to data ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/17/Stocks-Photo-by-Phongphan-on-Shutterstoc.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999346"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.235809,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SSTK",
        "relevance_score": "0.141726",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYF",
        "relevance_score": "0.407844",
        "ticker_sentiment_score": "0.115927",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.407844",
        "ticker_sentiment_score": "0.09838",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SAVE",
        "relevance_score": "0.407844",
        "ticker_sentiment_score": "-0.056532",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ASML",
        "relevance_score": "0.407844",
        "ticker_sentiment_score": "0.697556",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.407844",
        "ticker_sentiment_score": "0.530586",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Dow Jones Closes At Record High As Traders Turn Bullish Amid Hopes Of Fed Cutting Rates In September - Bank of America  ( NYSE:BAC ) ",
    "url": "https://www.benzinga.com/news/earnings/earnings-beats/24/07/39809413/dow-jones-closes-at-record-high-as-traders-turn-bullish-amid-hopes-of-fed-cutting-ra",
    "time_published": "20240717T071423",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, with the index remaining in the \"Greed\" zone on Tuesday. U.S. stocks closed higher on Tuesday, with the Dow Jones index surging to an all-time high and settling at a record level.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/17/Images-of-buildings.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": -0.004879,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "WBD",
        "relevance_score": "0.112008",
        "ticker_sentiment_score": "-0.174182",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "SYF",
        "relevance_score": "0.221819",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SAVE",
        "relevance_score": "0.221819",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.221819",
        "ticker_sentiment_score": "0.558",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.221819",
        "ticker_sentiment_score": "0.558",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.221819",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The World's Top Airport Might Surprise You When It Comes to Cargo",
    "url": "https://www.barrons.com/amp/articles/hong-kong-airport-cargo-92827332",
    "time_published": "20240717T050000",
    "authors": [
      "Andy Serwer"
    ],
    "summary": "A business trivia question for you: What's the biggest airport in the world? If you answered Hartsfield-Jackson Atlanta International Airport, you'd be half right. Hartsfield-Jackson is the No. 1 airport globally in terms of passengers, with 104 million travelers flying in and out there last year ...",
    "banner_image": "https://images.barrons.com/im-26541080/social",
    "source": "Barrons",
    "category_within_source": "n/a",
    "source_domain": "www.barrons.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.123934,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "FDX",
        "relevance_score": "0.04794",
        "ticker_sentiment_score": "0.039422",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.04794",
        "ticker_sentiment_score": "0.08501",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RBGPF",
        "relevance_score": "0.04794",
        "ticker_sentiment_score": "0.08501",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39846742/johnson-johnson-prioritizes-sustainable-growth-in-m-a-amid-sector-diversification-s",
    "time_published": "20240718T185135",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Wednesday, Johnson & Johnson JNJ reported a second-quarter adjusted EPS of $2.82, up 10.2% Y/Y, beating the consensus of $2.70. RBC Capital Markets anticipates a favorable second-quarter environment for companies outside of China.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/18/jnj-johnson-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.389788,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.190417",
        "ticker_sentiment_score": "0.102643",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.190417",
        "ticker_sentiment_score": "0.182895",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.60098",
        "ticker_sentiment_score": "0.52974",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "These Analysts Revise Their Forecasts On Johnson & Johnson After Q2 Results - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/news/earnings/24/07/39843593/these-analysts-revise-their-forecasts-on-johnson-johnson-after-q2-results",
    "time_published": "20240718T161240",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Johnson & Johnson JNJ reported better-than-expected second-quarter earnings on Wednesday. The company posted adjusted EPS of $2.82, up 10.2% year-over-year, beating the consensus of $2.70.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/18/JohnsonampJohnson-Shutterstock.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.264137,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MS",
        "relevance_score": "0.135347",
        "ticker_sentiment_score": "0.146372",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.767202",
        "ticker_sentiment_score": "0.623275",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Comparative Study: Johnson & Johnson And Industry Competitors In Pharmaceuticals Industry - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/news/24/07/39841277/comparative-study-johnson-amp-johnson-and-industry-competitors-in-pharmaceuticals-industry",
    "time_published": "20240718T150048",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In the dynamic and fiercely competitive business environment, conducting a thorough analysis of companies is crucial for investors and industry enthusiasts. In this article, we will perform an extensive industry comparison, evaluating Johnson & Johnson JNJ in relation to its major competitors in ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.20935,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.068112",
        "ticker_sentiment_score": "0.041087",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.450354",
        "ticker_sentiment_score": "0.334765",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Company News for Jul 18, 2024",
    "url": "https://www.zacks.com/stock/news/2304326/company-news-for-jul-18-2024",
    "time_published": "20240718T133400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Companies in The News Are: ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.296934,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CFG",
        "relevance_score": "0.56415",
        "ticker_sentiment_score": "0.431502",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "FHN",
        "relevance_score": "0.56415",
        "ticker_sentiment_score": "0.123187",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.56415",
        "ticker_sentiment_score": "0.328536",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Jim Cramer's top 10 things to watch in the stock market Thursday",
    "url": "https://www.cnbc.com/2024/07/18/jim-cramers-top-10-things-to-watch-in-the-stock-market-thursday.html",
    "time_published": "20240718T125252",
    "authors": [],
    "summary": "Nasdaq futures rose Thursday after the tech-heavy Nasdaq Composite posted its worst day since 2022.",
    "banner_image": null,
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980716"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.103421,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "HUBG",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.012021",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.050991",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.028118",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.063992",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "-0.087996",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FIVE",
        "relevance_score": "0.106778",
        "ticker_sentiment_score": "0.057291",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.170743",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WOOF",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.05277",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Microsoft To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Thursday - Microsoft  ( NASDAQ:MSFT ) ",
    "url": "https://www.benzinga.com/news/24/07/39837138/microsoft-to-rally-around-12-here-are-10-top-analyst-forecasts-for-thursday",
    "time_published": "20240718T123646",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Baird boosted the price target for e.l.f. Beauty, Inc. ELF from $210 to $230.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/18/microsoft-shutter5.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.214394,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DKNG",
        "relevance_score": "0.235062",
        "ticker_sentiment_score": "0.073806",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.235062",
        "ticker_sentiment_score": "-0.036363",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LESL",
        "relevance_score": "0.235062",
        "ticker_sentiment_score": "-0.118264",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYF",
        "relevance_score": "0.235062",
        "ticker_sentiment_score": "0.206243",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.158",
        "ticker_sentiment_score": "0.221724",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.309864",
        "ticker_sentiment_score": "0.172768",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.235062",
        "ticker_sentiment_score": "0.211663",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GPS",
        "relevance_score": "0.235062",
        "ticker_sentiment_score": "0.072156",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TOST",
        "relevance_score": "0.235062",
        "ticker_sentiment_score": "0.28489",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PANW",
        "relevance_score": "0.158",
        "ticker_sentiment_score": "-0.082291",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Medical Devices Market to Surpass $756.59 Billion by 2031 | SkyQuest Technology",
    "url": "https://www.benzinga.com/pressreleases/24/07/g39836904/medical-devices-market-to-surpass-756-59-billion-by-2031-skyquest-technology",
    "time_published": "20240718T123000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Westford, USA, July 18, 2024 ( GLOBE NEWSWIRE ) -- SkyQuest projects that the Medical Devices market will attain a value of $756.59 Billion by 2031, with a CAGR of 5.8% over the forecast period ( 2024-2031 ) . Medical devices are essential tools used in the healthcare sector to diagnose and ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.305725,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MFCSF",
        "relevance_score": "0.044885",
        "ticker_sentiment_score": "0.153954",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNN",
        "relevance_score": "0.044885",
        "ticker_sentiment_score": "0.078515",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.044885",
        "ticker_sentiment_score": "0.078515",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.044885",
        "ticker_sentiment_score": "0.078515",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESLOF",
        "relevance_score": "0.044885",
        "ticker_sentiment_score": "0.078515",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRUMF",
        "relevance_score": "0.044885",
        "ticker_sentiment_score": "0.078515",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.044885",
        "ticker_sentiment_score": "0.078515",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.044885",
        "ticker_sentiment_score": "0.078515",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.044885",
        "ticker_sentiment_score": "0.078515",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XRAY",
        "relevance_score": "0.044885",
        "ticker_sentiment_score": "0.078515",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.044885",
        "ticker_sentiment_score": "0.078515",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.044885",
        "ticker_sentiment_score": "0.153954",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "A Top-Tier Dividend Stock Every Passive-Income Investor Should Consider",
    "url": "https://www.fool.com/investing/2024/07/18/a-top-tier-dividend-stock-every-passive-income-inv/",
    "time_published": "20240718T114500",
    "authors": [
      "George Budwell"
    ],
    "summary": "This healthcare behemoth is one of the best dividend stocks on the planet.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F783682%2Fblood-sample.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.546938,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.144708",
        "ticker_sentiment_score": "0.343081",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Nasdaq, S&P 500 Futures Rebound Thursday: What's Going On - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/07/39835373/wall-street-gearing-up-for-tech-led-rebound-ahead-of-netflix-earnings-economist-expects-soft-landin",
    "time_published": "20240718T113456",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "Beaten-down stocks could make a comeback on Thursday, with Taiwan Semiconductor Manufacturing Company Ltd.'s TSM strong quarterly report lifting sentiment toward tech stocks. The major U.S. index futures were mixed ahead of the trading session.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/18/wall-street-artificial-ai.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99676"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.0,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AA",
        "relevance_score": "0.096866",
        "ticker_sentiment_score": "-0.014137",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALK",
        "relevance_score": "0.096866",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.096866",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMI",
        "relevance_score": "0.096866",
        "ticker_sentiment_score": "-0.014137",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.048523",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.096866",
        "ticker_sentiment_score": "0.053672",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.096866",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOK",
        "relevance_score": "0.096866",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.048523",
        "ticker_sentiment_score": "0.153904",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DPZ",
        "relevance_score": "0.096866",
        "ticker_sentiment_score": "-0.39969",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "SLG",
        "relevance_score": "0.096866",
        "ticker_sentiment_score": "-0.014137",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSM",
        "relevance_score": "0.096866",
        "ticker_sentiment_score": "0.097983",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DMPZF",
        "relevance_score": "0.048523",
        "ticker_sentiment_score": "-0.375517",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.096866",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.096866",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.096866",
        "ticker_sentiment_score": "-0.073158",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Johnson & Johnson a Buy Now?",
    "url": "https://www.fool.com/investing/2024/07/18/is-johnson-johnson-a-buy-now/",
    "time_published": "20240718T094000",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Second-quarter results suggest the spinoff of the company's slow-growing consumer goods segment is having the intended effect.",
    "banner_image": "https://g.foolcdn.com/editorial/images/783645/investor-looking-at-charts-on-a-computer-with-light-reflecting-off-their-glasses.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.135461,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.061159",
        "ticker_sentiment_score": "0.154043",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BGNE",
        "relevance_score": "0.061159",
        "ticker_sentiment_score": "0.154043",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.298749",
        "ticker_sentiment_score": "0.208035",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Magnificent S&P 500 Dividend Stocks Down 19% and 41% to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/07/18/2-sp-500-dividend-stocks-down-buy-forever/",
    "time_published": "20240718T082500",
    "authors": [
      "John Ballard"
    ],
    "summary": "The market can be unpredictable in the short run, but over the long term, the best companies will build lasting wealth for their shareholders.",
    "banner_image": "https://g.foolcdn.com/editorial/images/783556/holding-cash.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      }
    ],
    "overall_sentiment_score": 0.206882,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SBUX",
        "relevance_score": "0.327366",
        "ticker_sentiment_score": "0.262659",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.061893",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Mankind Pharma and EQT compete to acquire BSV Group for Rs 14,000 crore",
    "url": "https://www.business-standard.com/companies/news/mankind-pharma-and-eqt-compete-to-acquire-bsv-group-for-rs-14-000-crore-124071800409_1.html",
    "time_published": "20240718T063721",
    "authors": [
      "Vasudha Mukherjee"
    ],
    "summary": "Advent International, the private equity firm currently owning BSV, appointed JP Morgan and Jefferies to facilitate the sale of the biopharma firm ...",
    "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2022-11/22/full/1669136613-2225.jpg?im=FeatureCrop,size=(826,465)",
    "source": "Business Standard",
    "category_within_source": "Companies",
    "source_domain": "www.business-standard.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.184448,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.066414",
        "ticker_sentiment_score": "0.079129",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Sports Medicine Market to Surpass USD 12.04 Billion by 2031, Witnessing 5.6% CAGR Growth | SkyQuest Technology",
    "url": "https://www.benzinga.com/pressreleases/24/07/g39857589/sports-medicine-market-to-surpass-usd-12-04-billion-by-2031-witnessing-5-6-cagr-growth-skyquest-te",
    "time_published": "20240719T120000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Westford, USA, July 19, 2024 ( GLOBE NEWSWIRE ) -- SkyQuest projects that the Sports Medicine Market will attain a value of USD 12.04 billion by 2031, with a CAGR of 5.6% over the forecast period ( 2024-2031 ) . Performance of an athlete is of paramount importance for any sport and sports ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.298948,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.059341",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This Hidden Gem Vanguard ETF Is Chock-Full of Magnificent Stocks. Here's Why It's a Buy Now.",
    "url": "https://www.fool.com/investing/2024/07/21/hidden-gem-vanguard-etf-buy-growth-value-stock/",
    "time_published": "20240721T093000",
    "authors": [
      "Daniel Foelber"
    ],
    "summary": "This fund has a basket of growth, income, and value stocks.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F783887%2Fgettyimages-1157901252-1200x800-5b2df79.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.225556,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.09439",
        "ticker_sentiment_score": "0.153139",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.187463",
        "ticker_sentiment_score": "0.173287",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TJX",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.11446",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.210634",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.11446",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MMM",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.042323",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.210634",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "QCOM",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.109748",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.141171",
        "ticker_sentiment_score": "0.031315",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.210634",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ADBE",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.042323",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LRCX",
        "relevance_score": "0.09439",
        "ticker_sentiment_score": "0.11762",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ROST",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.11446",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.11446",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.042323",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.042323",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Biden's Exit From Presidential Race 'Yet Another Curveball For Equity Investors': Analysts - Johnson & Johnson  ( NYSE:JNJ ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/39891746/bidens-exit-from-presidential-race-yet-another-curveball-for-equity-investors-analysts",
    "time_published": "20240722T185441",
    "authors": [
      "Michael Juliano"
    ],
    "summary": "President Joe Biden's decision on Sunday to drop his bid for a second term in the White House was \"yet another curveball for equity investors,\" according to RBC Capital Markets analyst Lori Calvasina.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/22/Fueling-Up.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.107802,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.159043",
        "ticker_sentiment_score": "-0.311435",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "SNAP",
        "relevance_score": "0.159043",
        "ticker_sentiment_score": "0.22263",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TTD",
        "relevance_score": "0.236588",
        "ticker_sentiment_score": "0.262705",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.159043",
        "ticker_sentiment_score": "0.394509",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.159043",
        "ticker_sentiment_score": "-0.484568",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.079921",
        "ticker_sentiment_score": "0.204802",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Clearside Biomedical Opens Registration for Suprachoroidal Delivery KOL Webinar to Be Held on Wednesday, July 24, 2024 at 8:00 am ET",
    "url": "https://www.globenewswire.com/news-release/2024/07/22/2916705/0/en/Clearside-Biomedical-Opens-Registration-for-Suprachoroidal-Delivery-KOL-Webinar-to-Be-Held-on-Wednesday-July-24-2024-at-8-00-am-ET.html",
    "time_published": "20240722T160000",
    "authors": [
      "Inc.",
      "Clearside Biomedical"
    ],
    "summary": "ALPHARETTA, Ga., July 22, 2024 ( GLOBE NEWSWIRE ) -- Clearside Biomedical, Inc. ( Nasdaq: CLSD ) , a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space ( SCS\u00ae ) , has opened registration for its virtual key opinion leader ( ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/6eac24f1-af2b-45eb-9777-0ea32dfc73b8",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.089144,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CLSD",
        "relevance_score": "0.150827",
        "ticker_sentiment_score": "0.103566",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "0.044933",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Clearside Biomedical Opens Registration for Suprachoroidal Delivery KOL Webinar to Be Held on Wednesday, July 24, 2024 at 8:00 am ET - Clearside Biomedical  ( NASDAQ:CLSD ) ",
    "url": "https://www.benzinga.com/pressreleases/24/07/g39888510/clearside-biomedical-opens-registration-for-suprachoroidal-delivery-kol-webinar-to-be-held-on-wedn",
    "time_published": "20240722T160000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "ALPHARETTA, Ga., July 22, 2024 ( GLOBE NEWSWIRE ) -- Clearside Biomedical, Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.098464,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CLSD",
        "relevance_score": "0.176116",
        "ticker_sentiment_score": "0.107507",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.035502",
        "ticker_sentiment_score": "0.043525",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "After Disappointing Data, Johnson & Johnson Halts Developing Epilepsy Drug Candidate - Addex Therapeutics  ( NASDAQ:ADXN ) , Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/39883955/after-disappointing-data-johnson-johnson-halts-developing-epilepsy-drug-candidate",
    "time_published": "20240722T131549",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Monday, Addex Therapeutics ADXN announced its partner Janssen Pharmaceuticals, Inc, a unit of Johnson & Johnson JNJ, has discontinued the development of ADX71149 ( JNJ-40411813 ) in epilepsy.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/22/JohnsonampJohnson-Shutterstock.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.159366,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ADXN",
        "relevance_score": "0.585687",
        "ticker_sentiment_score": "-0.311679",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.692465",
        "ticker_sentiment_score": "0.015033",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vericel Announces Appointment of Karen Mahoney as Chief Human Resources Officer",
    "url": "https://www.globenewswire.com/news-release/2024/07/22/2916534/34447/en/Vericel-Announces-Appointment-of-Karen-Mahoney-as-Chief-Human-Resources-Officer.html",
    "time_published": "20240722T123000",
    "authors": [
      "Vericel Corporation"
    ],
    "summary": "CAMBRIDGE, Mass., July 22, 2024 ( GLOBE NEWSWIRE ) -- Vericel Corporation ( NASDAQ:VCEL ) , a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Karen Mahoney as Chief Human Resources Officer following the retirement of Heidi ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/6a144258-8523-493f-8a1e-ccceec233208",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.282891,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MDWD",
        "relevance_score": "0.069495",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VCEL",
        "relevance_score": "0.743088",
        "ticker_sentiment_score": "0.457043",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "0.111528",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Seeks FDA Approval For SPRAVATO Nasal Spray For Treatment-Resistant Depression",
    "url": "https://markets.businessinsider.com/news/stocks/johnson-johnson-seeks-fda-approval-for-spravato-nasal-spray-for-treatment-resistant-depression-1033577430",
    "time_published": "20240722T121844",
    "authors": [
      "markets.businessinsider.com"
    ],
    "summary": "( RTTNews ) - Johnson & Johnson ( JNJ ) announced the submission of a supplemental New Drug Application or sNDA to the U.S. Food and Drug Administration seeking approval of SPRAVATO ( esketamine ) CIII nasal spray as a monotherapy for adults living with treatment-resistant depression or TRD.",
    "banner_image": "https://markets.businessinsider.com/Images/FacebookIcon.jpg",
    "source": "Business Insider",
    "category_within_source": "RSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.083901,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.436009",
        "ticker_sentiment_score": "-0.041117",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Faces Legal Hurdle In Talc Lawsuit Battle - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/39881151/johnson-johnson-faces-legal-hurdle-in-talc-lawsuit-battle",
    "time_published": "20240722T120856",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Johnson & Johnson JNJ faced a legal setback on Friday when a New Jersey judge rejected its bid to disqualify the law firm Beasley Allen from representing plaintiffs who claim the company's talc products caused their cancer.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/22/johnsons-5671315-1920.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.087865,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.7887",
        "ticker_sentiment_score": "-0.317254",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Should You Invest in the Vanguard Health Care ETF  ( VHT ) ?",
    "url": "https://www.zacks.com/stock/news/2305775/should-you-invest-in-the-vanguard-health-care-etf-vht",
    "time_published": "20240722T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default46.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      }
    ],
    "overall_sentiment_score": 0.234733,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.064229",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.067347",
        "ticker_sentiment_score": "0.12575",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.064229",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.064229",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Kubecost Tops 10 Million Installs, Onboards Major Enterprise Customers, and Extends Technical Leadership in Kubernetes and Multi-Cloud Cost Optimization",
    "url": "https://www.benzinga.com/pressreleases/24/07/g39914189/kubecost-tops-10-million-installs-onboards-major-enterprise-customers-and-extends-technical-leader",
    "time_published": "20240723T173510",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "SAN FRANCISCO, July 23, 2024 ( GLOBE NEWSWIRE ) -- Kubecost, the comprehensive solution for monitoring, managing, and optimizing Kubernetes spend at scale, today announced it has surpassed 10 million installs across all platforms, including Amazon ECR, Helm charts, and OpenCost.",
    "banner_image": "https://ml.globenewswire.com/media/67776224-155c-4a51-aa8d-d27d761b30ee/small/kubecost-logo-png.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.242646,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GTLB",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.11223",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UA",
        "relevance_score": "0.149038",
        "ticker_sentiment_score": "0.144422",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAR",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.11223",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.11223",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Giant Johnson & Johnson Asks FDA To Approve Esketamine Nasal Spray For Treatment-Resistant Depression - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/markets/cannabis/24/07/39913847/pharma-giant-johnson-johnson-asks-fda-to-approve-esketamine-nasal-spray-for-treatment-resistant-",
    "time_published": "20240723T172019",
    "authors": [
      "Nina Zdinjak"
    ],
    "summary": "Pharma giant Johnson & Johnson JNJ announced Monday it had asked the Food and Drug Administration ( FDA ) to approve its nasal spray as a monotherapy for treatment-resistant depression ( TRD ) in adults.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/23/Johnson-JohnsonJohnson.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.125712,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.160099",
        "ticker_sentiment_score": "-0.064233",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?",
    "url": "https://www.zacks.com/stock/news/2307083/will-these-5-medical-stocks-surpass-q2-earnings-forecasts",
    "time_published": "20240723T151300",
    "authors": [
      "Ahan Chakraborty"
    ],
    "summary": "Let's look at five biotech and drug companies, AZN, ABBV, VKTX, SNY and BMY, slated to release their second-quarter 2024 results this week.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c2/53795.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.151539,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VKTX",
        "relevance_score": "0.196132",
        "ticker_sentiment_score": "-0.00153",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.345139",
        "ticker_sentiment_score": "0.007258",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.039614",
        "ticker_sentiment_score": "0.00992",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.039614",
        "ticker_sentiment_score": "0.362362",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.234307",
        "ticker_sentiment_score": "0.082219",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.118452",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.196132",
        "ticker_sentiment_score": "0.035205",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Time for Healthcare ETFs?",
    "url": "https://www.zacks.com/stock/news/2306667/time-for-healthcare-etfs",
    "time_published": "20240723T125100",
    "authors": [
      "Sanghamitra Saha"
    ],
    "summary": "Compelling valuation, innovation in specific growth areas and an aging population as well as increasing healthcare spending are the tailwinds of the medical sector.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default151.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.890401"
      }
    ],
    "overall_sentiment_score": 0.279458,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.178459",
        "ticker_sentiment_score": "0.068617",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.178459",
        "ticker_sentiment_score": "0.068617",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bladder Cancer Treatment Drug Market to Attain $14.24 billion by 2034, with 14.1% CAGR | Fact.MR Report",
    "url": "https://www.benzinga.com/pressreleases/24/07/g39901319/bladder-cancer-treatment-drug-market-to-attain-14-24-billion-by-2034-with-14-1-cagr-fact-mr-report",
    "time_published": "20240723T103000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Rockville, MD., July 23, 2024 ( GLOBE NEWSWIRE ) -- According to a new report published by Fact.MR, the global Bladder Cancer Treatment Drug Market is estimated to reach a value of US$ 3.79 billion in 2024 and further expand at a CAGR of 14.1% from 2024 to 2034.",
    "banner_image": "https://ml.globenewswire.com/media/f482b854-04d1-4f4e-9237-f7c7c6823e10/small/factmr-logo-png.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.077374,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.033894",
        "ticker_sentiment_score": "-0.109355",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.033894",
        "ticker_sentiment_score": "-0.109355",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SKXJF",
        "relevance_score": "0.033894",
        "ticker_sentiment_score": "-0.109355",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CGON",
        "relevance_score": "0.033894",
        "ticker_sentiment_score": "-0.109355",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.033894",
        "ticker_sentiment_score": "-0.109355",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCAB",
        "relevance_score": "0.033894",
        "ticker_sentiment_score": "-0.109355",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.033894",
        "ticker_sentiment_score": "-0.109355",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.033894",
        "ticker_sentiment_score": "-0.109355",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Check Out What Whales Are Doing With JNJ - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/options/24/07/39936949/check-out-what-whales-are-doing-with-jnj",
    "time_published": "20240724T160123",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bullish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson JNJ we detected 9 trades. If we consider the specifics of each trade, it is accurate to state that 77% of the investors opened trades with bullish ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1721836880_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.108576,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.083541",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.083541",
        "ticker_sentiment_score": "0.041849",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.654859",
        "ticker_sentiment_score": "0.191084",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences",
    "url": "https://www.zacks.com/stock/news/2307978/the-zacks-analyst-blog-highlights-boston-scientific-thermo-fisher-scientific-align-technology-and-edwards-lifesciences",
    "time_published": "20240724T131900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences are part of the Zacks Top Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/1d/1298.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.158332,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VKTX",
        "relevance_score": "0.151778",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.038162",
        "ticker_sentiment_score": "0.361582",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.189076",
        "ticker_sentiment_score": "0.05321",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.298113",
        "ticker_sentiment_score": "0.00645",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.038162",
        "ticker_sentiment_score": "0.009893",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.22595",
        "ticker_sentiment_score": "0.03072",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  is Attracting Investor Attention: Here is What You Should Know",
    "url": "https://www.zacks.com/stock/news/2307613/johnson-johnson-jnj-is-attracting-investor-attention-here-is-what-you-should-know",
    "time_published": "20240724T130017",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default221.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.235301,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.478494",
        "ticker_sentiment_score": "0.130447",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "[Latest] US Biotechnology Market Size/Share Worth USD 1797.8 Billion by 2033 at a 12.3% CAGR: Custom Market Insights  ( Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value ) ",
    "url": "https://www.benzinga.com/pressreleases/24/07/g39966281/latest-us-biotechnology-market-sizeshare-worth-usd-1797-8-billion-by-2033-at-a-12-3-cagr-custom-ma",
    "time_published": "20240725T173000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Austin, TX, USA, July 25, 2024 ( GLOBE NEWSWIRE ) -- Custom Market Insights has published a new research report titled \"US Biotechnology Market Size, Trends and Insights By Technology ( Nanobiotechnology, Tissue Engineering and Regeneration, DNA Sequencing, Cell-based Assays, Fermentation, PCR ...",
    "banner_image": "https://ml.globenewswire.com/media/74609d89-5437-4826-b7b8-31238ea2e65c/small/cmi-logo-png.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.276326,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.015482",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.015482",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SFSVF",
        "relevance_score": "0.015482",
        "ticker_sentiment_score": "0.06074",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRSN",
        "relevance_score": "0.015482",
        "ticker_sentiment_score": "0.087091",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ILMN",
        "relevance_score": "0.015482",
        "ticker_sentiment_score": "0.070334",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.015482",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.015482",
        "ticker_sentiment_score": "0.063349",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.015482",
        "ticker_sentiment_score": "0.162841",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.030958",
        "ticker_sentiment_score": "0.01749",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.015482",
        "ticker_sentiment_score": "0.114919",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.015482",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Beats on Q2 Earnings & Sales, Ups '24 EPS View",
    "url": "https://www.zacks.com/stock/news/2309203/abbvie-abbv-beats-on-q2-earnings-sales-ups-24-eps-view",
    "time_published": "20240725T142100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie's (ABBV) second-quarter earnings and sales beat estimates. Management hikes the EPS guidance on encouraging product sales for immunology drugs.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/36/1919.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.137565,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GMAB",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "0.28265",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.330286",
        "ticker_sentiment_score": "0.219964",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.075516",
        "ticker_sentiment_score": "0.063588",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Looking Into Johnson & Johnson's Recent Short Interest - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/07/39958296/looking-into-johnson-johnsons-recent-short-interest",
    "time_published": "20240725T131525",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Johnson & Johnson's JNJ short percent of float has fallen 14.77% since its last report. The company recently reported that it has 17.99 million shares sold short, which is 0.75% of all regular shares that are available for trading.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1721913322_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.26221,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.077712",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AC Immune's ACI-35.030  ( now \"JNJ-2056\" )  Granted FDA Fast Track Designation for Alzheimer's Disease",
    "url": "https://www.globenewswire.com/news-release/2024/07/25/2918683/0/en/AC-Immune-s-ACI-35-030-now-JNJ-2056-Granted-FDA-Fast-Track-Designation-for-Alzheimer-s-Disease.html",
    "time_published": "20240725T110000",
    "authors": [
      "AC Immune SA"
    ],
    "summary": "\u2022 Treatment of first randomized person with preclinical AD expected this quarter \u2022 Phase 2b ReTain trial is fully funded and conducted by development partner",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/0065cdfd-b9fc-4994-8aca-731c1d031b51",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.143094,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ACIU",
        "relevance_score": "0.296761",
        "ticker_sentiment_score": "0.157983",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.261117",
        "ticker_sentiment_score": "0.005879",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Sandoz launches biosimilar Pyzchiva\u00ae  ( ustekinumab )  across Europe, to treat chronic inflammatory diseases",
    "url": "https://www.globenewswire.com/news-release/2024/07/25/2918495/0/en/Sandoz-launches-biosimilar-Pyzchiva-ustekinumab-across-Europe-to-treat-chronic-inflammatory-diseases.html",
    "time_published": "20240725T050000",
    "authors": [
      "Sandoz International GmbH"
    ],
    "summary": "Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/511761ff-db95-4da3-a6b1-590b54593456",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.175938,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SSNLF",
        "relevance_score": "0.195419",
        "ticker_sentiment_score": "0.192804",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.049322",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Idorsia announces financial results for the first half 2024",
    "url": "https://www.globenewswire.com/news-release/2024/07/25/2918493/0/en/Idorsia-announces-financial-results-for-the-first-half-2024.html",
    "time_published": "20240725T050000",
    "authors": [
      "Idorsia Pharmaceuticals Ltd"
    ],
    "summary": "Ad hoc announcement pursuant to Art. 53 LR ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/991dd53b-30d5-4bba-a05c-acb30afcc570/image1.png",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.918141"
      }
    ],
    "overall_sentiment_score": 0.169323,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SOLTF",
        "relevance_score": "0.010393",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IDRSF",
        "relevance_score": "0.284696",
        "ticker_sentiment_score": "0.183588",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.010393",
        "ticker_sentiment_score": "0.082002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NBIX",
        "relevance_score": "0.010393",
        "ticker_sentiment_score": "0.021884",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VTRS",
        "relevance_score": "0.175258",
        "ticker_sentiment_score": "0.102263",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Better Buy: Abbott Laboratories vs. Intuitive Surgical",
    "url": "https://www.fool.com/investing/2024/07/26/better-buy-abbott-laboratories-vs-intuitive-surgic/",
    "time_published": "20240726T092700",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "The medical technology business has been good for both companies, but which is right for your portfolio?",
    "banner_image": "https://g.foolcdn.com/editorial/images/784235/investor-calculator-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.207029,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.268",
        "ticker_sentiment_score": "0.309649",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.054607",
        "ticker_sentiment_score": "0.049981",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.368383",
        "ticker_sentiment_score": "0.271892",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.054607",
        "ticker_sentiment_score": "0.049981",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Could Johnson & Johnson's Troubles With Talc Lawsuits Finally Be Coming to an End?",
    "url": "https://www.fool.com/investing/2024/07/27/could-johnson-johnsons-troubles-with-talc-lawsuits/",
    "time_published": "20240727T103500",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Is it safe to buy Johnson & Johnson stock now?",
    "banner_image": "https://g.foolcdn.com/editorial/images/784063/a-group-of-business-people-talking-inside-a-building.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.029454,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.677342",
        "ticker_sentiment_score": "-0.057677",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "4 Top Dividend Stocks Yielding Over 4% to Buy Hand Over Fist Right Now for Decades of Passive Income",
    "url": "https://www.fool.com/investing/2024/07/28/4-top-dividend-stocks-yielding-over-4-to-buy-hand/",
    "time_published": "20240728T120000",
    "authors": [
      "Matt DiLallo"
    ],
    "summary": "These companies offer high-yielding dividends that should continue rising.",
    "banner_image": "https://g.foolcdn.com/editorial/images/784836/online-brokerage-mobile-investing-stocks-smartphone-1200x800-5b2df79.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.992549"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.368315,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.255641",
        "ticker_sentiment_score": "0.361139",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BEP",
        "relevance_score": "0.214177",
        "ticker_sentiment_score": "0.296941",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ICNB",
        "relevance_score": "0.043342",
        "ticker_sentiment_score": "0.14304",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MAA",
        "relevance_score": "0.129516",
        "ticker_sentiment_score": "0.218089",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.043342",
        "ticker_sentiment_score": "0.099903",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Unusual Options Activity For July 29 - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/options/24/07/40023558/johnson-johnson-unusual-options-activity-for-july-29",
    "time_published": "20240729T204554",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bearish move on Johnson & Johnson. Our analysis of options history for Johnson & Johnson JNJ revealed 10 unusual trades. Delving into the details, we found 20% of traders were bullish, while 70% showed bearish tendencies.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1722285951_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.095254,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.078354",
        "ticker_sentiment_score": "0.04151",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.078354",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.674691",
        "ticker_sentiment_score": "0.03338",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations - AstraZeneca  ( NASDAQ:AZN ) , Johnson & Johnson  ( NYSE:JNJ ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/40047654/bristol-myers-johnson-johnson-abbvie-astrazeneca-expect-minimal-impact-from-upcoming-medicare-pri",
    "time_published": "20240730T181215",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Four major pharmaceutical companies involved in the first U.S. negotiations over Medicare drug prices expect limited business impact despite anticipated price cuts.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/30/BristolMeyersSquibb-Courtesyof-02-LVL-Ex.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.047931,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.346884",
        "ticker_sentiment_score": "0.130231",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.263942",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.307811",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?",
    "url": "https://www.zacks.com/stock/news/2312313/watch-these-5-biotech-stocks-for-q2-earnings-beat-or-miss",
    "time_published": "20240730T173100",
    "authors": [
      "Ekta Bagri"
    ],
    "summary": "Let's focus on biotech stocks like GSK, VRTX, BIIB, MRNA and REGN, which are scheduled to report this week.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c2/53795.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.148346,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.040416",
        "ticker_sentiment_score": "0.084018",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.200024",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.040416",
        "ticker_sentiment_score": "0.084018",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.238913",
        "ticker_sentiment_score": "0.050762",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.200024",
        "ticker_sentiment_score": "0.027721",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GSK",
        "relevance_score": "0.31482",
        "ticker_sentiment_score": "0.05152",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.200024",
        "ticker_sentiment_score": "0.029263",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD",
    "url": "https://www.globenewswire.com/news-release/2024/07/30/2921052/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Biosciences-Continues-to-Advance-its-Scientific-Advisory-Board-with-the-Appointment-of-Orian-Shirihai-MD-PhD.html",
    "time_published": "20240730T130000",
    "authors": [
      "Elevai Labs Inc."
    ],
    "summary": "Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/54cf5f33-04a3-4013-9a56-65d021e46a21",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.120066,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ELAB",
        "relevance_score": "0.308614",
        "ticker_sentiment_score": "0.283672",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.040139",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.040139",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.040139",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares U.S. Healthcare ETF  ( IYH ) ?",
    "url": "https://www.zacks.com/stock/news/2311499/should-you-invest-in-the-ishares-us-healthcare-etf-iyh",
    "time_published": "20240730T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default322.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.210296,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.088211",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.13459",
        "ticker_sentiment_score": "0.070304",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.13459",
        "ticker_sentiment_score": "0.070304",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.13459",
        "ticker_sentiment_score": "0.070304",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Health Care Select Sector SPDR ETF? - Johnson & Johnson  ( NYSE:JNJ ) , iShares Global Healthcare ETF  ( ARCA:IXJ ) ",
    "url": "https://www.benzinga.com/news/large-cap/24/07/40064785/should-you-invest-in-the-health-care-select-sector-spdr-etf",
    "time_published": "20240731T184825",
    "authors": [
      "Zacks"
    ],
    "summary": "Looking for broad exposure to the Healthcare - Broad segment of the equity market? You should consider the Health Care Select Sector SPDR ETF XLV, a passively managed exchange traded fund launched on 12/16/1998.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/31/clay-banks-cezmop5ftv4-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999994"
      }
    ],
    "overall_sentiment_score": 0.323143,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.131643",
        "ticker_sentiment_score": "0.097968",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.066047",
        "ticker_sentiment_score": "0.147857",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STT",
        "relevance_score": "0.066047",
        "ticker_sentiment_score": "0.089138",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.131643",
        "ticker_sentiment_score": "0.097968",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.131643",
        "ticker_sentiment_score": "0.097968",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Health Care Select Sector SPDR ETF  ( XLV ) ?",
    "url": "https://www.zacks.com/stock/news/2312590/should-you-invest-in-the-health-care-select-sector-spdr-etf-xlv",
    "time_published": "20240731T102008",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default165.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.296331,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "0.063863",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.064104",
        "ticker_sentiment_score": "0.127413",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STT",
        "relevance_score": "0.064104",
        "ticker_sentiment_score": "0.089064",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "0.063863",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "0.063863",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "8 Best-Performing Small Caps In July: Find Out Which Stock Jumped 803% - CommScope Hldg Co  ( NASDAQ:COMM ) , Meta Data  ( NYSE:AIU ) ",
    "url": "https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/08/40116558/8-best-performing-small-caps-in-july-find-out-which-stock-jumped-803",
    "time_published": "20240801T205440",
    "authors": [
      "Hayden Buckfire"
    ],
    "summary": "The United States' macroeconomic environment was favorable to large-cap companies and unfriendly to small-caps through the first half of 2024. That changed in July. Best Performers: These were the 10 best-performing small caps ( defined as a market cap between $500 million and $10 billion ) in ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/01/trader-ai3.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.390017,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HAWEL",
        "relevance_score": "0.129516",
        "ticker_sentiment_score": "0.250711",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SERV",
        "relevance_score": "0.193207",
        "ticker_sentiment_score": "0.283329",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.064973",
        "ticker_sentiment_score": "0.127181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COMM",
        "relevance_score": "0.255641",
        "ticker_sentiment_score": "0.337438",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HUMA",
        "relevance_score": "0.193207",
        "ticker_sentiment_score": "0.290664",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EBS",
        "relevance_score": "0.193207",
        "ticker_sentiment_score": "0.160663",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.064973",
        "ticker_sentiment_score": "0.126004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APH",
        "relevance_score": "0.064973",
        "ticker_sentiment_score": "0.215528",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AIU",
        "relevance_score": "0.193207",
        "ticker_sentiment_score": "0.303399",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HE",
        "relevance_score": "0.064973",
        "ticker_sentiment_score": "0.527442",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.064973",
        "ticker_sentiment_score": "0.127181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SAVA",
        "relevance_score": "0.129516",
        "ticker_sentiment_score": "0.660671",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Comparative Study: Johnson & Johnson And Industry Competitors In Pharmaceuticals Industry - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/news/24/08/40104755/comparative-study-johnson-amp-johnson-and-industry-competitors-in-pharmaceuticals-industry",
    "time_published": "20240801T150050",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In the dynamic and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Johnson & Johnson JNJ and its primary competitors in the Pharmaceuticals ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1722524447_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.119546,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.068896",
        "ticker_sentiment_score": "0.041107",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.454945",
        "ticker_sentiment_score": "0.223367",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Will Genscript Cash Out Of Legend Biotech In The Face Of Fat Profit Temptation? - Legend Biotech  ( NASDAQ:LEGN ) , Genscript Biotech  ( OTC:GNNSF ) ",
    "url": "https://www.benzinga.com/markets/penny-stocks/24/08/40104540/will-genscript-cash-out-of-legend-biotech-in-the-face-of-fat-profit-temptation",
    "time_published": "20240801T145250",
    "authors": [
      "The Bamboo Works"
    ],
    "summary": "Analysts expect annual sales of Carvykti, Legend Biotech's core cancer therapy, to peak at $7.3 billion With about $2 billion in cash reserves, Genscript isn't under pressure to sell its 48% holding in Legend",
    "banner_image": "https://cdn.benzinga.com/files/legend-biotech.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.113655,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LEGN",
        "relevance_score": "0.082677",
        "ticker_sentiment_score": "0.151431",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WUXAY",
        "relevance_score": "0.041394",
        "ticker_sentiment_score": "0.00297",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRCL",
        "relevance_score": "0.041394",
        "ticker_sentiment_score": "0.16767",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GNNSF",
        "relevance_score": "0.082677",
        "ticker_sentiment_score": "0.321875",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.041394",
        "ticker_sentiment_score": "0.030929",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Looking At Johnson & Johnson's Recent Unusual Options Activity - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/options/24/08/40140417/looking-at-johnson-johnsons-recent-unusual-options-activity",
    "time_published": "20240802T193253",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bullish stance on Johnson & Johnson JNJ. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1722627170_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.140556,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.078099",
        "ticker_sentiment_score": "0.041495",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.078099",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.673107",
        "ticker_sentiment_score": "0.309738",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Forget Johnson & Johnson: Another Healthcare Giant Is a Much Better Bet for Growth",
    "url": "https://www.fool.com/investing/2024/08/02/forget-johnson-johnson-this-could-be-a-much-better/",
    "time_published": "20240802T091700",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Abbott Laboratories' growth rate may look comparable to Johnson & Johnson's, but in the long run it could become much higher.",
    "banner_image": "https://g.foolcdn.com/editorial/images/784778/a-group-of-scientists-looking-at-a-report.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.272999,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.626755",
        "ticker_sentiment_score": "0.428021",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.462395",
        "ticker_sentiment_score": "0.301853",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Prediction: 2 Stocks That Will Be Worth More Than Johnson & Johnson 10 Years From Now",
    "url": "https://www.fool.com/investing/2024/08/03/prediction-2-stocks-that-will-be-worth-more-than-j/",
    "time_published": "20240803T103800",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "These two healthcare companies have far more upside potential than Johnson & Johnson.",
    "banner_image": "https://media.ycharts.com/charts/24cfe84aece23f55456568fbd47c715d.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.231837,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.232661",
        "ticker_sentiment_score": "0.127562",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.277433",
        "ticker_sentiment_score": "0.066605",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.364053",
        "ticker_sentiment_score": "0.214227",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The Market's Excessive Recession Fears",
    "url": "https://www.zacks.com/research-daily/2315964/the-markets-excessive-recession-fears",
    "time_published": "20240805T210800",
    "authors": [
      "Sheraz Mian"
    ],
    "summary": "We comment on the ongoing market sell-off, in addition to featuring new research reports on Johnson & Johnson (JNJ), T-Mobile (TMUS) and Marsh & McLennan (MMC) and others.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default331.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.857896"
      }
    ],
    "overall_sentiment_score": 0.175877,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.046006",
        "ticker_sentiment_score": "-0.081001",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMUS",
        "relevance_score": "0.046006",
        "ticker_sentiment_score": "0.222285",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.046006",
        "ticker_sentiment_score": "0.185804",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NHTC",
        "relevance_score": "0.046006",
        "ticker_sentiment_score": "0.249358",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.046006",
        "ticker_sentiment_score": "0.045947",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs",
    "url": "https://www.globenewswire.com/news-release/2024/08/05/2924647/0/en/ORIC-Pharmaceuticals-Expands-Leadership-Team-with-the-Appointment-of-Keith-Lui-as-Senior-Vice-President-of-Commercial-and-Medical-Affairs.html",
    "time_published": "20240805T201500",
    "authors": [
      "ORIC Pharmaceuticals"
    ],
    "summary": "SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 05, 2024 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc. ( Nasdaq: ORIC ) , a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Keith Lui as ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/acbc0ad2-7a44-4ee7-b729-ab92d57ffafb",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.114878,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ORIC",
        "relevance_score": "0.389429",
        "ticker_sentiment_score": "0.09541",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PRTA",
        "relevance_score": "0.036926",
        "ticker_sentiment_score": "0.120394",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DRRX",
        "relevance_score": "0.073773",
        "ticker_sentiment_score": "0.126101",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.036926",
        "ticker_sentiment_score": "0.120394",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs - ORIC Pharmaceuticals  ( NASDAQ:ORIC ) ",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40171358/oric-pharmaceuticals-expands-leadership-team-with-the-appointment-of-keith-lui-as-senior-vice-pres",
    "time_published": "20240805T201500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 05, 2024 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc. ORIC, a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Keith Lui as Senior Vice ...",
    "banner_image": "https://ml.globenewswire.com/media/acbc0ad2-7a44-4ee7-b729-ab92d57ffafb/small/oric-png.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.124265,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ORIC",
        "relevance_score": "0.40348",
        "ticker_sentiment_score": "0.092236",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PRTA",
        "relevance_score": "0.035189",
        "ticker_sentiment_score": "0.119649",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DRRX",
        "relevance_score": "0.07031",
        "ticker_sentiment_score": "0.125645",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.035189",
        "ticker_sentiment_score": "0.119649",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Immunoassay Market Surges to USD 39.66 Billion by 2031, Propelled by 4.67% CAGR - Verified Market Research\u00ae",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40161821/immunoassay-market-surges-to-usd-39-66-billion-by-2031-propelled-by-4-67-cagr-verified-market-rese",
    "time_published": "20240805T141500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Lewes, Delaware, Aug. 05, 2024 ( GLOBE NEWSWIRE ) -- The Global Immunoassay Market Size is projected to grow at a CAGR of 4.67% from 2024 to 2031, according to a new report published by Verified Market Research\u00ae.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/54097ce1-6e07-411d-8cc7-f86096bda0f1/immunoassay-market-size-and-forecast-1024x576.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.274905,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TRIB",
        "relevance_score": "0.027795",
        "ticker_sentiment_score": "0.095953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.027795",
        "ticker_sentiment_score": "0.095953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSMXF",
        "relevance_score": "0.027795",
        "ticker_sentiment_score": "0.095953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.027795",
        "ticker_sentiment_score": "0.095953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.027795",
        "ticker_sentiment_score": "0.095953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RSSS",
        "relevance_score": "0.027795",
        "ticker_sentiment_score": "0.168128",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIO",
        "relevance_score": "0.027795",
        "ticker_sentiment_score": "0.095953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SEMHF",
        "relevance_score": "0.027795",
        "ticker_sentiment_score": "0.095953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DHR",
        "relevance_score": "0.027795",
        "ticker_sentiment_score": "0.095953",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "All It Takes Is $10,000 Invested in Coca-Cola and Each of These 2 Dividend Kings to Generate Over $1,000 in Passive Income per Year",
    "url": "https://www.fool.com/investing/2024/08/05/buy-coca-cola-stock-dividend-king-passive-income/",
    "time_published": "20240805T130700",
    "authors": [
      "Daniel Foelber"
    ],
    "summary": "Constructing a portfolio that is built to last requires investing in quality companies, purposeful allocation, and diversification.",
    "banner_image": "https://g.foolcdn.com/editorial/images/785103/person-studying-investments.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999996"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.998333"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.271793,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.457977",
        "ticker_sentiment_score": "0.259427",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PEP",
        "relevance_score": "0.064797",
        "ticker_sentiment_score": "0.200432",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.161062",
        "ticker_sentiment_score": "0.164397",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.064797",
        "ticker_sentiment_score": "0.163281",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.064797",
        "ticker_sentiment_score": "-0.003034",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.032425",
        "ticker_sentiment_score": "0.069403",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board",
    "url": "https://www.globenewswire.com/news-release/2024/08/05/2924217/0/en/4DMT-Advances-Leadership-in-Large-Market-Ophthalmology-with-Senior-Management-Hires-and-Formation-of-Ophthalmology-Advisory-Board.html",
    "time_published": "20240805T120000",
    "authors": [
      "4D Molecular Therapeutics",
      "Inc."
    ],
    "summary": "EMERYVILLE, Calif., Aug. 05, 2024 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT, 4DMT or the Company ) , a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today strengthened the ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/027d40cf-145a-47b2-a0b8-823759376823",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.241907,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALC",
        "relevance_score": "0.014367",
        "ticker_sentiment_score": "0.170162",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FDMT",
        "relevance_score": "0.071741",
        "ticker_sentiment_score": "0.05058",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.028729",
        "ticker_sentiment_score": "0.101195",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Emergent BioSolutions Reports Second Quarter 2024 Financial Results",
    "url": "https://www.globenewswire.com/news-release/2024/08/06/2925548/33240/en/Emergent-BioSolutions-Reports-Second-Quarter-2024-Financial-Results.html",
    "time_published": "20240806T210100",
    "authors": [
      "Inc.",
      "Emergent Biosolutions"
    ],
    "summary": "GAITHERSBURG, Md., Aug. 06, 2024 ( GLOBE NEWSWIRE ) -- Emergent BioSolutions Inc. ( NYSE: EBS ) today reported financial results for the second quarter ended June 30, 2024.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/56a9097d-af91-4bcf-8c42-5905e1614ef1",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.714479"
      }
    ],
    "overall_sentiment_score": 0.102174,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "EBS",
        "relevance_score": "0.0378",
        "ticker_sentiment_score": "0.0478",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.009453",
        "ticker_sentiment_score": "0.147821",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Healthy Returns: What drugmakers are saying about final negotiated prices with Medicare",
    "url": "https://www.cnbc.com/2024/08/06/healthy-returns-drugmakers-on-new-negotiated-prices-with-medicare.html",
    "time_published": "20240806T183827",
    "authors": [],
    "summary": "Drugmakers appear to be less concerned about the impact of negotiated prices on their businesses in the short term. Meanwhile, health care heads to Hollywood.",
    "banner_image": null,
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.13248,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.039033",
        "ticker_sentiment_score": "0.129101",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.039033",
        "ticker_sentiment_score": "-0.108452",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.039033",
        "ticker_sentiment_score": "-0.108452",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.039033",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBD",
        "relevance_score": "0.039033",
        "ticker_sentiment_score": "0.129101",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.039033",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.039033",
        "ticker_sentiment_score": "0.144887",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.116725",
        "ticker_sentiment_score": "-0.007979",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Is Kenvue Stock Trading Higher On Tuesday? - Kenvue  ( NYSE:KVUE ) ",
    "url": "https://www.benzinga.com/news/earnings/24/08/40192182/listerine-maker-kenvues-stock-soars-on-strong-q2-sales-from-its-essential-health-unit-reaffirms-ann",
    "time_published": "20240806T143049",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Consumer health company Kenvue Inc. KVUE stock is trading higher after the company reported better-than-expected second-quarter 2024 financial results. The Johnson & Johnson consumer spin-off reported sales of $4 billion, down 0.3% year-over-year ( up 1.5% organically ) , beating the consensus of ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/06/Bandung--Indonesia---July-8--2024-Lister.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.387875,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ICNB",
        "relevance_score": "0.206685",
        "ticker_sentiment_score": "0.387413",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.568148",
        "ticker_sentiment_score": "0.660952",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.104228",
        "ticker_sentiment_score": "-0.12382",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Intuitive Surgical  ( ISRG )  Rises 5% Post Earnings: What's Next?",
    "url": "https://www.zacks.com/stock/news/2316780/intuitive-surgical-isrg-rises-5-post-earnings-whats-next",
    "time_published": "20240806T115500",
    "authors": [
      "Indrajit Bandyopadhyay"
    ],
    "summary": "Intuitive Surgical (ISRG) is making strides in the robotic-assisted surgery market with its existing and new launches. However, macro challenges are likely to continue to hurt its performance.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/61/11728.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.337937,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MDT",
        "relevance_score": "0.078482",
        "ticker_sentiment_score": "0.280407",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.377712",
        "ticker_sentiment_score": "0.468537",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.078482",
        "ticker_sentiment_score": "0.280407",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is Trending Stock Johnson & Johnson a Buy Now? - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/news/earnings/24/08/40223098/is-trending-stock-johnson-johnson-a-buy-now",
    "time_published": "20240807T203017",
    "authors": [
      "Zacks"
    ],
    "summary": "Johnson & Johnson JNJ is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/07/kenny-eliason-8fdhgan5zg0-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.623304"
      }
    ],
    "overall_sentiment_score": 0.245067,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.433771",
        "ticker_sentiment_score": "0.113851",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Trending Stock Johnson & Johnson  ( JNJ )  a Buy Now?",
    "url": "https://www.zacks.com/stock/news/2317835/is-trending-stock-johnson-johnson-jnj-a-buy-now",
    "time_published": "20240807T130020",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default319.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.228526,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.473208",
        "ticker_sentiment_score": "0.13547",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vitreoretinal Surgery Device Market Size Projected to Reach a Valuation of USD 4.01 Billion by 2034, Says Fact.MR",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40216547/vitreoretinal-surgery-device-market-size-projected-to-reach-a-valuation-of-usd-4-01-billion-by-203",
    "time_published": "20240807T113000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Rockville, MD, Aug. 07, 2024 ( GLOBE NEWSWIRE ) -- As per a new research study released by Fact.MR, the global vitreoretinal surgery device market is estimated to be worth US$ 2.23 billion in 2024 and is analyzed to expand at 6.1% CAGR from 2024 to 2034.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/46c6da20-bbd4-4db0-9677-bc3ab41c94c9/vitreoretinal-surgery-device-market.jpg",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.370281,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALC",
        "relevance_score": "0.036756",
        "ticker_sentiment_score": "0.182389",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SAFLF",
        "relevance_score": "0.036756",
        "ticker_sentiment_score": "0.182389",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TOPCF",
        "relevance_score": "0.036756",
        "ticker_sentiment_score": "0.182389",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.036756",
        "ticker_sentiment_score": "0.182389",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Dividend Growth Stocks to Buy Hand Over Fist in August",
    "url": "https://www.fool.com/investing/2024/08/07/dividend-growth-stocks-buy-hand-over-fist-august/",
    "time_published": "20240807T091000",
    "authors": [
      "Justin Pope"
    ],
    "summary": "There are blue-chip bargains paying large and growing dividends in the healthcare space.",
    "banner_image": "https://g.foolcdn.com/editorial/images/785724/money-trees-long-term-investing.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999701"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.9545"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.280693,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.046633",
        "ticker_sentiment_score": "0.067943",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.093108",
        "ticker_sentiment_score": "0.081485",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.317722",
        "ticker_sentiment_score": "0.354872",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.317722",
        "ticker_sentiment_score": "0.154637",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Genmab Announces Financial Results for the First Half of 2024",
    "url": "https://www.globenewswire.com/news-release/2024/08/08/2927105/0/en/Genmab-Announces-Financial-Results-for-the-First-Half-of-2024.html",
    "time_published": "20240808T150300",
    "authors": [
      "Genmab A/S"
    ],
    "summary": "August 8, 2024 Copenhagen, Denmark. Interim Report for the First Six Months Ended June ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.159131,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVS",
        "relevance_score": "0.03157",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.094514",
        "ticker_sentiment_score": "0.083836",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GMAB",
        "relevance_score": "0.420483",
        "ticker_sentiment_score": "0.18174",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.125789",
        "ticker_sentiment_score": "0.110067",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.03157",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Genmab Updates 2024 Financial Guidance",
    "url": "https://www.globenewswire.com/news-release/2024/08/08/2927103/0/en/Genmab-Updates-2024-Financial-Guidance.html",
    "time_published": "20240808T150000",
    "authors": [
      "Genmab A/S"
    ],
    "summary": "Company Announcement ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.996023"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.09079,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVS",
        "relevance_score": "0.039679",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.039679",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GMAB",
        "relevance_score": "0.544495",
        "ticker_sentiment_score": "0.120768",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.079261",
        "ticker_sentiment_score": "0.016397",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.039679",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "J&J's  ( JNJ )  DePuy Synthes' TriLEAP System to Aid Ankle Surgery",
    "url": "https://www.zacks.com/stock/news/2320271/jjs-jnj-depuy-synthes-trileap-system-to-aid-ankle-surgery",
    "time_published": "20240809T170400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson's (JNJ) DePuy Synthes announces the launch of its TriLEAP System, which is likely to provide better orthopedic solutions to foot and ankle surgeons.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e0/1871.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.187252,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABM",
        "relevance_score": "0.265378",
        "ticker_sentiment_score": "0.11034",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.328236",
        "ticker_sentiment_score": "0.24113",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.200688",
        "ticker_sentiment_score": "0.120097",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bladder Cancer Therapeutics Market is Likely to Reach USD 456.3 million by 2034 at a CAGR of 4.8% | Report Analysis by Transparency Market Research Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40285956/bladder-cancer-therapeutics-market-is-likely-to-reach-usd-456-3-million-by-2034-at-a-cagr-of-4-8-r",
    "time_published": "20240809T141824",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research, Inc. , Aug. 09, 2024 ( GLOBE NEWSWIRE ) -- The global bladder cancer therapeutics market ( \ubc29\uad11\uc554 \uce58\ub8cc\uc81c \uc2dc\uc7a5 ) stood at US$ 271.4 million in 2023, and the global market is projected to reach US$ 456.3 million in 2034.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.083138,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.034282",
        "ticker_sentiment_score": "0.052793",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.034282",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.034282",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.034282",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.102595",
        "ticker_sentiment_score": "0.009846",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.034282",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.034282",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.034282",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "mHealth market to Reach USD 176.69 Billion by 2031, Growing at 13.8% CAGR | SkyQuest Technology",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40281810/mhealth-market-to-reach-usd-176-69-billion-by-2031-growing-at-13-8-cagr-skyquest-technology",
    "time_published": "20240809T120000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Westford, USA, Aug. 09, 2024 ( GLOBE NEWSWIRE ) -- SkyQuest projects that Global mHealth Market will attain a value of USD 176.69 Billion by 2031, with a CAGR of 13.8% over the forecast period ( 2024-2031 ) . There will be a significant increase in the global market over the next few years.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.320878,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "OMRNF",
        "relevance_score": "0.049322",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.049322",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.049322",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.049322",
        "ticker_sentiment_score": "0.051772",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PHG",
        "relevance_score": "0.049322",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.049322",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights",
    "url": "https://www.globenewswire.com/news-release/2024/08/09/2927688/0/en/Legend-Biotech-Reports-Second-Quarter-2024-Results-and-Recent-Highlights.html",
    "time_published": "20240809T110000",
    "authors": [
      "Legend Biotech USA Inc."
    ],
    "summary": "SOMERSET, N.J., Aug. 09, 2024 ( GLOBE NEWSWIRE ) -- Legend Biotech Corporation ( NASDAQ: LEGN ) ( Legend Biotech ) , a global leader in cell therapy, today reported its second quarter 2024 unaudited financial results and key corporate highlights.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/d3a680c2-cab6-4eb2-9ed0-7be055f9e180",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999998"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      }
    ],
    "overall_sentiment_score": 0.134435,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.025192",
        "ticker_sentiment_score": "0.053897",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LEGN",
        "relevance_score": "0.31858",
        "ticker_sentiment_score": "0.131011",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Healthcare Stocks to Buy Hand Over Fist in August",
    "url": "https://www.fool.com/investing/2024/08/09/2-healthcare-stocks-buy-hand-over-fist-in-august/",
    "time_published": "20240809T100200",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "These longtime winners still have a lot to offer.",
    "banner_image": "https://g.foolcdn.com/editorial/images/786004/doctor-holding-elderly-patients-hand.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.267759,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.053629",
        "ticker_sentiment_score": "0.19601",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.498827",
        "ticker_sentiment_score": "0.28759",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.362254",
        "ticker_sentiment_score": "0.316795",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 High-Yield Dividend Stocks to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/08/09/3-high-yield-dividend-stocks-to-buy-and-hold-forev/",
    "time_published": "20240809T092900",
    "authors": [
      "Daniel Miller"
    ],
    "summary": "Dividends remain one of the best long-term avenues to generating wealth. Here are three stocks you can buy and hold forever.",
    "banner_image": "https://media.ycharts.com/charts/4edf9d522e72623fb85c029c7462d3fd.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99793"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.235356,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "F",
        "relevance_score": "0.092036",
        "ticker_sentiment_score": "0.132106",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MO",
        "relevance_score": "0.314246",
        "ticker_sentiment_score": "0.179506",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "0.284525",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Nasdaq Sell-Off: 5 Unstoppable Stocks to Buy That Can Protect Your Principal and Grow Your Wealth in an Unpredictable Market",
    "url": "https://www.fool.com/investing/2024/08/09/nasdaq-sell-off-5-unstoppable-stocks-to-buy-wealth/",
    "time_published": "20240809T080600",
    "authors": [
      "Sean Williams"
    ],
    "summary": "Five exceptionally safe, time-tested stocks have the necessary tools to make their shareholders richer.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F786257%2Fstock-market-chart-crash-correction-buy-investment-planning-laptop-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.288416,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "WTM",
        "relevance_score": "0.085324",
        "ticker_sentiment_score": "0.119784",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "T",
        "relevance_score": "0.141726",
        "ticker_sentiment_score": "0.074562",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZO",
        "relevance_score": "0.197413",
        "ticker_sentiment_score": "0.26944",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.02849",
        "ticker_sentiment_score": "0.08967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.056943",
        "ticker_sentiment_score": "0.132012",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.056943",
        "ticker_sentiment_score": "0.143965",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NEE",
        "relevance_score": "0.085324",
        "ticker_sentiment_score": "0.135813",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development",
    "url": "https://www.globenewswire.com/news-release/2024/08/12/2928796/0/en/iBio-Expands-Executive-Leadership-Team-with-Appointment-of-Kristi-Sarno-as-Senior-Vice-President-of-Business-Development.html",
    "time_published": "20240812T203000",
    "authors": [
      "iBio",
      "Inc."
    ],
    "summary": "Life sciences industry veteran to lead strategic alliances for iBio's machine learning platform for antibody discovery and pipeline of cardiometabolic targets Life sciences industry veteran to lead strategic alliances for iBio's machine learning platform for antibody discovery and pipeline of ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/c472b1f4-0d21-4a83-b703-3214f1faebbc",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.24481,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LGND",
        "relevance_score": "0.049322",
        "ticker_sentiment_score": "0.078884",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNXYF",
        "relevance_score": "0.049322",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.049322",
        "ticker_sentiment_score": "0.078884",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QTTB",
        "relevance_score": "0.049322",
        "ticker_sentiment_score": "0.078884",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results",
    "url": "https://www.globenewswire.com/news-release/2024/08/12/2928280/0/en/MeiraGTx-Announces-50-Million-Offering-of-Ordinary-Shares-led-by-Sanofi-and-Reports-Second-Quarter-2024-Financial-and-Operational-Results.html",
    "time_published": "20240812T110500",
    "authors": [
      "MeiraGTx"
    ],
    "summary": "- Positive data from the Phase 1 AQUAx study in radiation-induced xerostomia ( RIX ) presented at the American Academy of Oral Medicine 2024 annual meeting ( AAOM ) showed meaningful improvements in patient-reported outcomes and saliva production with AAV2-hAQP1 treatment ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/6b45b8d0-975e-494b-8a46-b88360aa1791",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      }
    ],
    "overall_sentiment_score": 0.204291,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MGTX",
        "relevance_score": "0.195701",
        "ticker_sentiment_score": "0.178762",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.126561",
        "ticker_sentiment_score": "0.145146",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.028238",
        "ticker_sentiment_score": "0.10091",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Microdermabrasion Devices Market is Projected to Achieve US$ 549.0 Mn Milestone by 2031 with a CAGR of 7.5%, Investment Opportunities | Report by Transparency Market Research, Inc",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40354229/microdermabrasion-devices-market-is-projected-to-achieve-us-549-0-mn-milestone-by-2031-with-a-cagr",
    "time_published": "20240813T213000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research, Inc., Aug. 13, 2024 ( GLOBE NEWSWIRE ) -- As per the report published by Transparency Market Research, the global microdermabrasion devices market ( \u30de\u30a4\u30af\u30ed\u30c0\u30fc\u30de\u30d6\u30ec\u30fc\u30b7\u30e7\u30f3\u30c7\u30d0\u30a4\u30b9\u5e02\u5834 ) was worth US$ 290.3 Mn in 2022 and is expected to reach ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/0ad08915-27bd-4305-a12c-ed05c1ce895e/microdermabrasion-devices-market.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.350003,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.038906",
        "ticker_sentiment_score": "0.048973",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.038906",
        "ticker_sentiment_score": "0.059627",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.116348",
        "ticker_sentiment_score": "0.06846",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PHG",
        "relevance_score": "0.038906",
        "ticker_sentiment_score": "0.059627",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.038906",
        "ticker_sentiment_score": "0.059627",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results",
    "url": "https://www.globenewswire.com/news-release/2024/08/13/2929667/0/en/Cidara-Therapeutics-Provides-Corporate-Update-and-Reports-Second-Quarter-2024-Financial-Results.html",
    "time_published": "20240813T202900",
    "authors": [
      "Inc.",
      "Cidara Therapeutics"
    ],
    "summary": "SAN DIEGO, Aug. 13, 2024 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( Nasdaq: CDTX ) ( the Company ) , a biotechnology company using its proprietary Cloudbreak\u00ae platform to develop drug-Fc conjugate ( DFC ) immunotherapies designed to save lives and improve the standard of care for patients ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/97036182-e328-4e3f-a1ef-6d4a151e97cb",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.95493"
      }
    ],
    "overall_sentiment_score": 0.197424,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CAN",
        "relevance_score": "0.027134",
        "ticker_sentiment_score": "0.099569",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CDTX",
        "relevance_score": "0.081276",
        "ticker_sentiment_score": "0.149843",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.027134",
        "ticker_sentiment_score": "0.099569",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "J&J Moves Closer to Resolving Baby Powder Lawsuits, 75% of Plaintiffs Support $6.5B Settlement - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/news/24/08/40339516/j-j-moves-closer-to-resolving-baby-powder-lawsuits-75-of-plaintiffs-support-6-5b-settlement",
    "time_published": "20240813T135014",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Johnson & Johnson JNJ has reportedly taken a significant step forward in its efforts to resolve thousands of lawsuits related to claims that its baby powder caused cancer.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/13/Wooden-Gavel-With-Usa-Dollar-On-Desk--Cl.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": -0.01229,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.824067",
        "ticker_sentiment_score": "-0.074958",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Mersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results",
    "url": "https://www.globenewswire.com/news-release/2024/08/13/2929034/0/en/Mersana-Therapeutics-Provides-Business-Update-and-Announces-Second-Quarter-2024-Financial-Results.html",
    "time_published": "20240813T110000",
    "authors": [
      "Mersana Therapeutics",
      "Inc."
    ],
    "summary": "CAMBRIDGE, Mass., Aug. 13, 2024 ( GLOBE NEWSWIRE ) -- Mersana Therapeutics, Inc. ( NASDAQ: MRSN ) , a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates ( ADCs ) targeting cancers in areas of high unmet medical need, today ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/75b0bceb-3927-4f94-9ec8-22925b2a27a4",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.144768,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MRSN",
        "relevance_score": "0.119681",
        "ticker_sentiment_score": "0.126119",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GSK",
        "relevance_score": "0.030026",
        "ticker_sentiment_score": "0.043234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.119681",
        "ticker_sentiment_score": "0.0275",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma ETFs in Focus Post Solid Q2 Earnings - Bristol-Myers Squibb  ( NYSE:BMY ) , First Trust Nasdaq Pharmaceuticals ETF  ( NASDAQ:FTXH ) ",
    "url": "https://www.benzinga.com/news/earnings/24/08/40374036/pharma-etfs-in-focus-post-solid-q2-earnings",
    "time_published": "20240814T200034",
    "authors": [
      "Zacks"
    ],
    "summary": "The second-quarter results of the healthcare sector have been impressive, with earnings of 78.8% of the sector participants that have reported so far up 17.1% on 7.6% revenue growth. The earnings beat ratio of 85.7% and the revenue beat ratio of 75.5% are also assuring.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/14/ani-kolleshi-7jjnj-qa9fy-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999992"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.188212,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.162255",
        "ticker_sentiment_score": "0.196113",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.122062",
        "ticker_sentiment_score": "0.082696",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.122062",
        "ticker_sentiment_score": "0.074673",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.122062",
        "ticker_sentiment_score": "0.078615",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Looking Into Johnson & Johnson's Recent Short Interest - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/08/40372537/looking-into-johnson-johnsons-recent-short-interest",
    "time_published": "20240814T160020",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Johnson & Johnson's JNJ short percent of float has risen 4.0% since its last report. The company recently reported that it has 18.85 million shares sold short, which is 0.78% of all regular shares that are available for trading.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1723651217_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.287737,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.147012",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma ETFs in Focus Post Solid Q2 Earnings",
    "url": "https://www.zacks.com/stock/news/2322190/pharma-etfs-in-focus-post-solid-q2-earnings",
    "time_published": "20240814T154900",
    "authors": [
      "Sweta Killa"
    ],
    "summary": "Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default125.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999989"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.173992,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.121445",
        "ticker_sentiment_score": "0.166583",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.121445",
        "ticker_sentiment_score": "0.071772",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.081138",
        "ticker_sentiment_score": "0.066897",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.121445",
        "ticker_sentiment_score": "0.073403",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Elevai Labs Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update",
    "url": "https://www.globenewswire.com/news-release/2024/08/14/2930133/0/en/Elevai-Labs-Inc-Reports-Second-Quarter-2024-Financial-Results-and-Provides-Business-Update.html",
    "time_published": "20240814T130500",
    "authors": [
      "Elevai Labs Inc."
    ],
    "summary": "NEWPORT BEACH, Calif., Aug. 14, 2024 ( GLOBE NEWSWIRE ) -- Elevai Labs Inc. ( NASDAQ: ELAB ) ( \"Elevai\" or the \"Company\" ) , a pioneering force in medical aesthetics, today reported financial results for the second quarter ended June 30, 2024 and provided a business update.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/54cf5f33-04a3-4013-9a56-65d021e46a21",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.153943,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ELAB",
        "relevance_score": "0.107857",
        "ticker_sentiment_score": "0.029231",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.027042",
        "ticker_sentiment_score": "0.090675",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.027042",
        "ticker_sentiment_score": "0.090675",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.027042",
        "ticker_sentiment_score": "0.090675",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024",
    "url": "https://www.globenewswire.com/news-release/2024/08/15/2931252/0/en/Alvotech-Reports-Record-Revenues-and-Adjusted-EBITDA-for-the-Second-Quarter-and-First-Six-Months-of-2024.html",
    "time_published": "20240815T201500",
    "authors": [
      "Alvotech"
    ],
    "summary": "Alvotech ( NASDAQ: ALVO, or the \"Company\" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first six months of 2024 and provided a summary of recent corporate highlights.",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999941"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.141571,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.011148",
        "ticker_sentiment_score": "0.0851",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.011148",
        "ticker_sentiment_score": "0.0851",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.011148",
        "ticker_sentiment_score": "0.055246",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.011148",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.022295",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.461321",
        "ticker_sentiment_score": "0.217177",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.011148",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.011148",
        "ticker_sentiment_score": "0.055246",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.011148",
        "ticker_sentiment_score": "0.055246",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.011148",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.011148",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:ISK",
        "relevance_score": "0.022295",
        "ticker_sentiment_score": "0.078729",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:SEK",
        "relevance_score": "0.022295",
        "ticker_sentiment_score": "0.078729",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.022295",
        "ticker_sentiment_score": "0.114565",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024",
    "url": "https://www.globenewswire.com/news-release/2024/08/15/2931251/0/en/Alvotech-Reports-Record-Revenues-and-Adjusted-EBITDA-for-the-Second-Quarter-and-First-Six-Months-of-2024.html",
    "time_published": "20240815T201500",
    "authors": [
      "Alvotech"
    ],
    "summary": "REYKJAVIK, Iceland, Aug. 15, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO, or the \"Company\" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first six months of ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999941"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.141566,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.011123",
        "ticker_sentiment_score": "0.085082",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.011123",
        "ticker_sentiment_score": "0.085082",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.011123",
        "ticker_sentiment_score": "0.055234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.011123",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.022243",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.460377",
        "ticker_sentiment_score": "0.21687",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.011123",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.011123",
        "ticker_sentiment_score": "0.055234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.011123",
        "ticker_sentiment_score": "0.055234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.011123",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.011123",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:ISK",
        "relevance_score": "0.022243",
        "ticker_sentiment_score": "0.078708",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:SEK",
        "relevance_score": "0.022243",
        "ticker_sentiment_score": "0.078708",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.022243",
        "ticker_sentiment_score": "0.114538",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "ResMed Expands its Board of Directors and Appoints Healthcare Executive and Seasoned Finance Leader Christopher DelOrefice to its Board - ResMed  ( NYSE:RMD ) ",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40404876/resmed-expands-its-board-of-directors-and-appoints-healthcare-executive-and-seasoned-finance-leade",
    "time_published": "20240815T200500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "DelOrefice is the Chief Financial Officer at BD, one of the largest global MedTech companies in the world Board appointment brings over 30 years of strategic and operational finance expertise",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.245571,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RMD",
        "relevance_score": "0.458446",
        "ticker_sentiment_score": "0.44388",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AME",
        "relevance_score": "0.069495",
        "ticker_sentiment_score": "-0.031148",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "0.103325",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.069495",
        "ticker_sentiment_score": "-0.031148",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.069495",
        "ticker_sentiment_score": "-0.031148",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Nears $6.5B Long Standing Talc Settlement - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40398448/johnson-johnson-nears-approval-for-6-5b-long-standing-talc-settlement",
    "time_published": "20240815T150329",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Johnson & Johnson JNJ is expected to confirm a $6.48 billion settlement plan to resolve thousands of lawsuits alleging that its baby powder products cause cancer. What Happened: Reuters noted that the company will reveal Friday that over 75% of claimants have agreed to the settlement.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/15/Johnson-JohnsonJohnson.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.02723,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.739411",
        "ticker_sentiment_score": "-0.212366",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Comparative Study: Johnson & Johnson And Industry Competitors In Pharmaceuticals Industry - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/news/24/08/40398265/comparative-study-johnson-amp-johnson-and-industry-competitors-in-pharmaceuticals-industry",
    "time_published": "20240815T150045",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Amidst the fast-paced and highly competitive business environment of today, conducting comprehensive company analysis is essential for investors and industry enthusiasts.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1723734042_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.168486,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.065866",
        "ticker_sentiment_score": "0.041041",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.437082",
        "ticker_sentiment_score": "0.244978",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Biden administration to release prices for first 10 drugs subject to landmark Medicare negotiations",
    "url": "https://www.cnbc.com/2024/08/15/medicare-releases-prices-for-first-10-drugs-subject-to-negotiations.html",
    "time_published": "20240815T090001",
    "authors": [],
    "summary": "It is a milestone in a controversial process that aims to make costly medications more affordable for older Americans but is strongly opposed by drugmakers.",
    "banner_image": null,
    "source": "CNBC",
    "category_within_source": "Business",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.061655,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.02686",
        "ticker_sentiment_score": "0.150738",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.053689",
        "ticker_sentiment_score": "-0.025037",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.053689",
        "ticker_sentiment_score": "-0.067751",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.053689",
        "ticker_sentiment_score": "-0.072897",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.02686",
        "ticker_sentiment_score": "-0.054794",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Is Johnson & Johnson  ( JNJ )  Up 2.4% Since Last Earnings Report?",
    "url": "https://www.zacks.com/stock/news/2323209/why-is-johnson-johnson-jnj-up-24-since-last-earnings-report",
    "time_published": "20240816T153017",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default111.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999998"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.18987,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.086322",
        "ticker_sentiment_score": "0.079219",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Sysco Announces New Director to Board",
    "url": "https://www.globenewswire.com/news-release/2024/08/16/2931492/2867/en/Sysco-Announces-New-Director-to-Board.html",
    "time_published": "20240816T120000",
    "authors": [
      "Sysco Corporation"
    ],
    "summary": "HOUSTON, Aug. 16, 2024 ( GLOBE NEWSWIRE ) -- Sysco Corporation ( NYSE:SYY ) , the world's largest food distributor, announced today that Roberto Marques will join Sysco's Board of Directors effective August 15, 2024.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/68d96458-4295-4da9-b3e4-cd5526e10f87",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.187547,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AA",
        "relevance_score": "0.097457",
        "ticker_sentiment_score": "-0.031777",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDLZ",
        "relevance_score": "0.097457",
        "ticker_sentiment_score": "-0.031777",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.097457",
        "ticker_sentiment_score": "0.019966",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYY",
        "relevance_score": "0.537474",
        "ticker_sentiment_score": "0.363254",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.097457",
        "ticker_sentiment_score": "-0.031777",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Sysco Announces New Director to Board - Sysco  ( NYSE:SYY ) ",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40414844/sysco-announces-new-director-to-board",
    "time_published": "20240816T120000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "HOUSTON, Aug. 16, 2024 ( GLOBE NEWSWIRE ) -- Sysco Corporation SYY, the world's largest food distributor, announced today that Roberto Marques will join Sysco's Board of Directors effective August 15, 2024. Kevin Hourican, Sysco's chair of the board and CEO, said, \"We are very pleased to ...",
    "banner_image": "https://ml.globenewswire.com/media/68d96458-4295-4da9-b3e4-cd5526e10f87/small/sysco-logo-at-the-heart-color-v2-png.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.206049,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AA",
        "relevance_score": "0.089462",
        "ticker_sentiment_score": "-0.031145",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDLZ",
        "relevance_score": "0.089462",
        "ticker_sentiment_score": "-0.031145",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.089462",
        "ticker_sentiment_score": "0.019597",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYY",
        "relevance_score": "0.568435",
        "ticker_sentiment_score": "0.36807",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.089462",
        "ticker_sentiment_score": "-0.031145",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Top Dividend ETFs That Investors can Buy and Hold for Decades",
    "url": "https://www.fool.com/investing/2024/08/16/3-top-dividend-etfs-that-investors-can-buy-and-hol/",
    "time_published": "20240816T114500",
    "authors": [
      "David Jagielski"
    ],
    "summary": "You won't have to worry about tracking individual dividend stocks anymore with these funds.",
    "banner_image": "https://g.foolcdn.com/editorial/images/786772/a-person-smiling-and-reviewing-their-finances.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999691"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.188628,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.05257",
        "ticker_sentiment_score": "0.033787",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.05257",
        "ticker_sentiment_score": "0.033787",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MO",
        "relevance_score": "0.05257",
        "ticker_sentiment_score": "0.071007",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.05257",
        "ticker_sentiment_score": "0.033787",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.05257",
        "ticker_sentiment_score": "0.113597",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "T",
        "relevance_score": "0.05257",
        "ticker_sentiment_score": "0.071007",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.05257",
        "ticker_sentiment_score": "-0.127136",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.05257",
        "ticker_sentiment_score": "0.113597",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.05257",
        "ticker_sentiment_score": "-0.127136",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CL",
        "relevance_score": "0.05257",
        "ticker_sentiment_score": "0.113597",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PM",
        "relevance_score": "0.05257",
        "ticker_sentiment_score": "0.071007",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 High-Yield Dividend ETFs to Buy to Generate Passive Income",
    "url": "https://www.fool.com/investing/2024/08/18/3-high-yield-dividend-etfs-to-buy-to-generate-pass/",
    "time_published": "20240818T105000",
    "authors": [
      "CFA",
      "Lawrence Rothman"
    ],
    "summary": "ETFs offer a good way to own a diversified portfolio of income-producing equities.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F786809%2Fgettyimages-1413845348-1200x800-5b2df79.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.205532,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "UNIT",
        "relevance_score": "0.13347",
        "ticker_sentiment_score": "0.0462",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.095203",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EIX",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWK",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.095203",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.13347",
        "ticker_sentiment_score": "0.068768",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADP",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.095203",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Dow Jones Dividend Stocks With Above-Average Yields to Buy Now and Hold for at Least a Decade",
    "url": "https://www.fool.com/investing/2024/08/18/2-dow-jones-dividend-stocks-with-above-average-yie/",
    "time_published": "20240818T092500",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Investors seeking reliable dividend growth want to start with these two members of the Dow Jones Industrial Average.",
    "banner_image": "https://g.foolcdn.com/editorial/images/787460/wall-street-analyst-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.223194,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AWON",
        "relevance_score": "0.057767",
        "ticker_sentiment_score": "0.064039",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.057767",
        "ticker_sentiment_score": "0.064039",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.282886",
        "ticker_sentiment_score": "0.251201",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.282886",
        "ticker_sentiment_score": "0.250221",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Unusual Options Activity - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/options/24/08/40450237/johnson-johnson-unusual-options-activity",
    "time_published": "20240819T204526",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bullish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson JNJ we detected 9 trades. If we consider the specifics of each trade, it is accurate to state that 55% of the investors opened trades with bullish ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1724100323_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.148977,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.081276",
        "ticker_sentiment_score": "0.041691",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.524949",
        "ticker_sentiment_score": "0.245783",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "5 Dividend Growth Stocks to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/08/19/5-dividend-growth-stocks-to-buy-and-hold-forever/",
    "time_published": "20240819T133000",
    "authors": [
      "George Budwell"
    ],
    "summary": "Dividend growth stocks offer investors a powerful combination of income and capital appreciation potential, making them attractive for long-term portfolios.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F787696%2Fgetty-dividend-stocks-growing-money-income-cash.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.601843,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AAPL",
        "relevance_score": "0.088964",
        "ticker_sentiment_score": "0.369158",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.25762",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.193958",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.088964",
        "ticker_sentiment_score": "0.329279",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.3017",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Medical Education Market is Projected to Expand at 5.1% CAGR, Reaching US$ 57.95 Billion by 2034 | Fact.MR",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40436837/medical-education-market-is-projected-to-expand-at-5-1-cagr-reaching-us-57-95-billion-by-2034-fact",
    "time_published": "20240819T110000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Rockville, MD, Aug. 19, 2024 ( GLOBE NEWSWIRE ) -- Revenue from medical education is estimated to reach US$ 35.11 billion in 2024, as revealed in a study recently updated by Fact.MR, a market research and competitive intelligence provider.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/96fecbea-1805-4e9a-b6a1-89f981093e6f/medical-education-market.jpg",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.37,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ZBH",
        "relevance_score": "0.039811",
        "ticker_sentiment_score": "0.082112",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SEMHF",
        "relevance_score": "0.039811",
        "ticker_sentiment_score": "0.082112",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.039811",
        "ticker_sentiment_score": "0.082112",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OCPNF",
        "relevance_score": "0.039811",
        "ticker_sentiment_score": "0.082112",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAE",
        "relevance_score": "0.039811",
        "ticker_sentiment_score": "0.082112",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.039811",
        "ticker_sentiment_score": "0.082112",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Fidelity MSCI Health Care Index ETF  ( FHLC ) ?",
    "url": "https://www.zacks.com/stock/news/2323505/should-you-invest-in-the-fidelity-msci-health-care-index-etf-fhlc",
    "time_published": "20240819T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default99.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.303954,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "0.049883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "0.049883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "0.049883",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Trinity Biotech Appoints Diabetes Care Veteran as Biosensor Marketing Director",
    "url": "https://www.globenewswire.com/news-release/2024/08/20/2933178/8624/en/Trinity-Biotech-Appoints-Diabetes-Care-Veteran-as-Biosensor-Marketing-Director.html",
    "time_published": "20240820T210000",
    "authors": [
      "Trinity Biotech plc"
    ],
    "summary": "DUBLIN, Aug. 20, 2024 ( GLOBE NEWSWIRE ) -- Trinity Biotech plc ( Nasdaq: TRIB ) , a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the appointment of David Ouston as Biosensor Marketing ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/23a9d0e4-6c22-4509-971e-0c09c45ec985",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.332606,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TRIB",
        "relevance_score": "0.431554",
        "ticker_sentiment_score": "0.417604",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.045482",
        "ticker_sentiment_score": "0.056905",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Trinity Biotech Appoints Diabetes Care Veteran as Biosensor Marketing Director - Trinity Biotech  ( NASDAQ:TRIB ) ",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40474124/trinity-biotech-appoints-diabetes-care-veteran-as-biosensor-marketing-director",
    "time_published": "20240820T210000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "DUBLIN, Aug. 20, 2024 ( GLOBE NEWSWIRE ) -- Trinity Biotech plc TRIB, a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the appointment of David Ouston as Biosensor Marketing Director.",
    "banner_image": "https://ml.globenewswire.com/media/23a9d0e4-6c22-4509-971e-0c09c45ec985/small/trinity-biotech-plc-logo.jpg",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.334718,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TRIB",
        "relevance_score": "0.416614",
        "ticker_sentiment_score": "0.406395",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.043738",
        "ticker_sentiment_score": "0.056638",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bristol Myers'  ( BMY )  Breyanzi Label Expansion Application Validated",
    "url": "https://www.zacks.com/stock/news/2324618/bristol-myers-bmy-breyanzi-label-expansion-application-validated",
    "time_published": "20240820T170400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Bristol Myers' (BMY) application to expand Breyanzi's label for the treatment of adult patients with relapsed or refractory follicular lymphoma gets EMA validation.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/1981.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.257459,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KRYS",
        "relevance_score": "0.22335",
        "ticker_sentiment_score": "0.124624",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSVT",
        "relevance_score": "0.112797",
        "ticker_sentiment_score": "0.141668",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.05654",
        "ticker_sentiment_score": "0.191981",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.380426",
        "ticker_sentiment_score": "0.247258",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.05654",
        "ticker_sentiment_score": "0.191981",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Strikes $1.7B Deal To Acquire Heart-Tech Innovator V-Wave - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40464864/johnson-johnson-strikes-1-7b-deal-to-acquire-heart-tech-innovator-v-wave",
    "time_published": "20240820T143109",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Tuesday, Johnson & Johnson JNJ agreed to acquire V-Wave for an upfront payment of $600 million, with the potential for additional regulatory and commercial milestone payments up to approximately $1.1 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/20/JohnsonampJohnson-Shutterstock.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.166565,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.207571",
        "ticker_sentiment_score": "0.211162",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.642977",
        "ticker_sentiment_score": "0.243095",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here is What to Know Beyond Why Johnson & Johnson  ( JNJ )  is a Trending Stock",
    "url": "https://www.zacks.com/stock/news/2324217/here-is-what-to-know-beyond-why-johnson-johnson-jnj-is-a-trending-stock",
    "time_published": "20240820T130018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default209.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.223879,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.47672",
        "ticker_sentiment_score": "0.171475",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "LAVA Reports Second Quarter 2024 Financial Results and Business Update",
    "url": "https://www.globenewswire.com/news-release/2024/08/20/2932711/0/en/LAVA-Reports-Second-Quarter-2024-Financial-Results-and-Business-Update.html",
    "time_published": "20240820T113000",
    "authors": [
      "LAVA Therapeutics N.V."
    ],
    "summary": "UTRECHT, The Netherlands and PHILADELPHIA, Aug. 20, 2024 ( GLOBE NEWSWIRE ) -- LAVA Therapeutics N.V. ( NASDAQ: LVTX, \"LAVA,\" \"the Company\" ) , a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody\u00ae platform of bispecific gamma delta T cell engagers, today ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/4759b844-227f-4632-b22d-4fe63fad55b4",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.967645"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.102478,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LVTX",
        "relevance_score": "0.050201",
        "ticker_sentiment_score": "-0.018",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.100203",
        "ticker_sentiment_score": "0.060158",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.025113",
        "ticker_sentiment_score": "0.093688",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares U.S. Pharmaceuticals ETF  ( IHE ) ?",
    "url": "https://www.zacks.com/stock/news/2324114/should-you-invest-in-the-ishares-us-pharmaceuticals-etf-ihe",
    "time_published": "20240820T102008",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default235.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.172835,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.065506",
        "ticker_sentiment_score": "0.032025",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.130571",
        "ticker_sentiment_score": "0.069241",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.130571",
        "ticker_sentiment_score": "0.043051",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.130571",
        "ticker_sentiment_score": "0.069241",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.130571",
        "ticker_sentiment_score": "0.069241",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should iShares Core High Dividend ETF  ( HDV )  Be on Your Investing Radar?",
    "url": "https://www.zacks.com/stock/news/2324124/should-ishares-core-high-dividend-etf-hdv-be-on-your-investing-radar",
    "time_published": "20240820T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Style Box ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default217.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.244841,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.059488",
        "ticker_sentiment_score": "0.117",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.118647",
        "ticker_sentiment_score": "0.192288",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.118647",
        "ticker_sentiment_score": "0.067448",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.118647",
        "ticker_sentiment_score": "0.067448",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.118647",
        "ticker_sentiment_score": "0.067448",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Outperforms Broader Market: What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2325301/johnson-johnson-jnj-outperforms-broader-market-what-you-need-to-know",
    "time_published": "20240821T214506",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $161.43, denoting a +0.79% change from the preceding trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default32.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.222272,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.531019",
        "ticker_sentiment_score": "0.255266",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Alzheimer's Drugs Market on Track for USD 11.6 Billion Expansion with 10.0% Annual Growth by 2034- Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40490461/alzheimers-drugs-market-on-track-for-usd-11-6-billion-expansion-with-10-0-annual-growth-by-2034-tr",
    "time_published": "20240821T162923",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research, Inc., Aug. 21, 2024 ( GLOBE NEWSWIRE ) -- As per the report published by Transparency Market Research, the global Alzheimer's drugs market ( \u0633\u0648\u0642 \u0623\u062f\u0648\u064a\u0629 \u0627\u0644\u0632\u0647\u0627\u064a\u0645\u0631 ) was worth US$ 4.0 Bn in 2023 and is expected to reach US$ 11.6 Bn ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/9b22ed18-18b1-48a8-873b-9645f3b51691/alzheimer-s-drugs-market.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.157898,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.038101",
        "ticker_sentiment_score": "0.059448",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.038101",
        "ticker_sentiment_score": "0.002928",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SKXJF",
        "relevance_score": "0.038101",
        "ticker_sentiment_score": "0.002928",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.038101",
        "ticker_sentiment_score": "0.002928",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.038101",
        "ticker_sentiment_score": "0.002928",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.113956",
        "ticker_sentiment_score": "0.070153",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.038101",
        "ticker_sentiment_score": "0.002928",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OPHLF",
        "relevance_score": "0.038101",
        "ticker_sentiment_score": "0.002928",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "J&J  ( JNJ )  Gets FDA Nod for Chemotherapy-Free Lung Cancer Therapy",
    "url": "https://www.zacks.com/stock/news/2325154/jj-jnj-gets-fda-nod-for-chemotherapy-free-lung-cancer-therapy",
    "time_published": "20240821T143000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The approval is based on late-stage study data wherein treatment with J&J's (JNJ) Rybrevant plus Lazcluze cut the risk of disease progression or death by 30% in certain NSCLC patients.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.165142,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ARCT",
        "relevance_score": "0.270373",
        "ticker_sentiment_score": "0.145568",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.164282",
        "ticker_sentiment_score": "-0.016882",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FULC",
        "relevance_score": "0.270373",
        "ticker_sentiment_score": "0.188156",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.164282",
        "ticker_sentiment_score": "-0.030851",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "J&J  ( JNJ )  to Boost MedTech Business With V-Wave Acquisition",
    "url": "https://www.zacks.com/stock/news/2325077/jj-jnj-to-boost-medtech-business-with-v-wave-acquisition",
    "time_published": "20240821T142800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) inks a definitive agreement to acquire V-Wave Ltd. for an upfront payment of $600 million. The deal is likely to strengthen the company's MedTech business unit further.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999476"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.264727,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BVS",
        "relevance_score": "0.333557",
        "ticker_sentiment_score": "0.22373",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ILMN",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.157743",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FULC",
        "relevance_score": "0.269776",
        "ticker_sentiment_score": "0.096953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.61135",
        "ticker_sentiment_score": "0.425093",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "3 Vanguard Mutual Funds to Buy With Rate Cuts on the Horizon",
    "url": "https://www.zacks.com/stock/news/2324808/3-vanguard-mutual-funds-to-buy-with-rate-cuts-on-the-horizon",
    "time_published": "20240821T123900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Invest in Vanguard mutual funds like VGENX, VWNDX and VEIPX for high returns and risk reduction as the first rate cut appears on the horizon.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/79/7332.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.231285,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TTE",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.108222",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EIX",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.111215",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.178189",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.108222",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.111215",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSN",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.111215",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RYDAF",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.108222",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "A Big CEO Move, Big Buffett Buys, and More",
    "url": "https://www.fool.com/investing/2024/08/22/a-big-ceo-move-big-buffett-buys-and-more/",
    "time_published": "20240822T141100",
    "authors": [
      "Motley Fool Staff"
    ],
    "summary": "Motley Fool analysts talk over market news including earnings updates from Home Depot, Walmart, and Brinker.",
    "banner_image": "https://g.foolcdn.com/editorial/images/787851/mfm_16.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.99489"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.153938,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AAPL",
        "relevance_score": "0.029234",
        "ticker_sentiment_score": "0.116541",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRWD",
        "relevance_score": "0.005848",
        "ticker_sentiment_score": "0.018454",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ULTA",
        "relevance_score": "0.005848",
        "ticker_sentiment_score": "-0.038428",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.011696",
        "ticker_sentiment_score": "-0.036293",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.005848",
        "ticker_sentiment_score": "0.134626",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KLG",
        "relevance_score": "0.005848",
        "ticker_sentiment_score": "-0.021305",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "K",
        "relevance_score": "0.06426",
        "ticker_sentiment_score": "0.060294",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HEI",
        "relevance_score": "0.005848",
        "ticker_sentiment_score": "-0.038428",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ITW",
        "relevance_score": "0.005848",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBUX",
        "relevance_score": "0.128104",
        "ticker_sentiment_score": "0.057376",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BX",
        "relevance_score": "0.005848",
        "ticker_sentiment_score": "0.013177",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.023389",
        "ticker_sentiment_score": "0.099195",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EAT",
        "relevance_score": "0.011696",
        "ticker_sentiment_score": "-0.043447",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KD",
        "relevance_score": "0.011696",
        "ticker_sentiment_score": "-0.028132",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.005848",
        "ticker_sentiment_score": "0.027415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.156876",
        "ticker_sentiment_score": "0.084527",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.040919",
        "ticker_sentiment_score": "0.064237",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CB",
        "relevance_score": "0.011696",
        "ticker_sentiment_score": "0.0868",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.052595",
        "ticker_sentiment_score": "0.059002",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This Undervalued Stock Could Join the Race With Eli Lilly to the $1 Trillion Club",
    "url": "https://www.fool.com/investing/2024/08/22/this-undervalued-stock-could-join-the-race-with-el/",
    "time_published": "20240822T101700",
    "authors": [
      "Ryan Downie"
    ],
    "summary": "This leading pharmaceutical stock is flying under the radar right now.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F787705%2Fpills-dollar-sign-money-pharmaceuticals-1201x643-518128e.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999186"
      }
    ],
    "overall_sentiment_score": 0.178374,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.076358",
        "ticker_sentiment_score": "-0.050838",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.401915",
        "ticker_sentiment_score": "0.207704",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "1 Dividend Growth ETF That Can Turbocharge Your Portfolio",
    "url": "https://www.fool.com/investing/2024/08/24/1-dividend-growth-etf-that-can-turbocharge-your-po/",
    "time_published": "20240824T114500",
    "authors": [
      "George Budwell"
    ],
    "summary": "The iShares Core Dividend Growth ETF offers investors exposure to high-quality companies with a history of consistent dividend growth.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F788308%2Fgetty-dividend-stocks-growing-money-income-cash.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999975"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.519426,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MORN",
        "relevance_score": "0.058188",
        "ticker_sentiment_score": "0.232262",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.058188",
        "ticker_sentiment_score": "0.281063",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.058188",
        "ticker_sentiment_score": "0.281063",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.058188",
        "ticker_sentiment_score": "0.281063",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is Johnson & Johnson Stock a Buy?",
    "url": "https://www.fool.com/investing/2024/08/25/is-johnson-johnson-stock-a-buy/",
    "time_published": "20240825T101700",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The company hasn't performed well in recent years, ...",
    "banner_image": "https://media.ycharts.com/charts/71fe3f647f1b2fe425706bcc6788928c.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.028838,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.051886",
        "ticker_sentiment_score": "-0.079975",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.637738",
        "ticker_sentiment_score": "0.055075",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Aims New Policy For Hospital Payments Under 340B Drug Discount Program Related To Its Flagship Blood Thinner And Arthritis Drugs - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40560227/johnson-johnson-aims-new-policy-for-hospital-payments-under-340b-drug-discount-program-related-to",
    "time_published": "20240826T180918",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Friday, Johnson & Johnson JNJ announced that it would implement significant changes to offering 340B pricing for its popular drugs, Stelara and Xarelto. Stelara ( ustekinumab ) is indicated for moderate to severe psoriasis, active psoriatic arthritis, Crohn's disease, and ulcerative colitis.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/26/jnj-johnson-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.203013,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.593175",
        "ticker_sentiment_score": "0.122403",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Major Investor Says Galapagos Is 'Undervalued,' Plans To Push On Company's 'Performance' And 'Strategic Opportunities' - Galapagos  ( NASDAQ:GLPG ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40558289/major-investor-says-galapagos-is-undervalued-plans-to-push-on-companys-performance-and-strategic-",
    "time_published": "20240826T163802",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Galapagos NV GLPG stock is trading higher on Monday as Ecor1 Capital reported a 9.9% stake in the European biotech firm in a 13D filing. EcoR1 Capital is now planning to talk to the Belgian biotech about its performance, business, operations, strategic opportunities, and governance, including ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/26/pharma-lab-worker-ai.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.127002,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GLPG",
        "relevance_score": "0.749166",
        "ticker_sentiment_score": "-0.019847",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.114137",
        "ticker_sentiment_score": "0.138941",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Seeks Resolution With Plaintiffs, Pushes To Finalize $6.5B Talc Settlement - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40555615/johnson-johnson-seeks-resolution-with-plaintiffs-pushes-to-finalize-6-5b-talc-settlement",
    "time_published": "20240826T150647",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Johnson & Johnson JNJ is reportedly negotiating with plaintiffs' lawyers who have opposed its proposed $6.48 billion settlement over claims that its talc-based baby powder and other products cause cancer.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/26/JohnsonampJohnson-Shutterstock.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.113952,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.636698",
        "ticker_sentiment_score": "-0.373289",
        "ticker_sentiment_label": "Bearish"
      }
    ]
  },
  {
    "title": "J&J  ( JNJ )  Gets EU Approval for Bladder Cancer Drug Balversa",
    "url": "https://www.zacks.com/stock/news/2326921/jj-jnj-gets-eu-approval-for-bladder-cancer-drug-balversa",
    "time_published": "20240826T132900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The approval of J&J's (JNJ) Balversa (erdafitinib) for treating unresectable or metastatic urothelial carcinoma is based on data from the phase III THOR study.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.184924,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ARCT",
        "relevance_score": "0.480536",
        "ticker_sentiment_score": "0.293993",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.2872",
        "ticker_sentiment_score": "0.125863",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.2872",
        "ticker_sentiment_score": "0.05002",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Unstoppable Stocks That Are Screaming Buys in August",
    "url": "https://www.fool.com/investing/2024/08/26/2-unstoppable-stocks-that-are-screaming-buys-in-au/",
    "time_published": "20240826T104900",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "These stocks have quality businesses behind them.",
    "banner_image": "https://g.foolcdn.com/editorial/images/788078/young-professional-woman-and-man-speaking-laughing-in-office-1.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.15145,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.048133",
        "ticker_sentiment_score": "0.188824",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SBUX",
        "relevance_score": "0.282777",
        "ticker_sentiment_score": "0.141414",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.190793",
        "ticker_sentiment_score": "0.093021",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Franklin Templeton Mutual Funds for Sustainable Returns",
    "url": "https://www.zacks.com/stock/news/2326741/3-franklin-templeton-mutual-funds-for-sustainable-returns",
    "time_published": "20240826T101900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Franklin Templeton mutual funds like FQTEX, FNRAX and FKINX are wise picks for strategic, sustainable investing.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/49/817.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999767"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.253093,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LMT",
        "relevance_score": "0.066784",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COP",
        "relevance_score": "0.066784",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.066784",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.066784",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Aplastic Anemia Market Size & Share to Surpass USD 10.8 Billion by 2034, at a CAGR 4.3% - Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40547892/aplastic-anemia-market-size-share-to-surpass-usd-10-8-billion-by-2034-at-a-cagr-4-3-transparency-m",
    "time_published": "20240826T095700",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research Inc. -, Aug. 26, 2024 ( GLOBE NEWSWIRE ) -- The global aplastic anemia market ( \u518d\u751f\u4e0d\u826f\u6027\u8ca7\u8840\u5e02\u5834 ) was projected to attain US$ 6.7 billion in 2023. It is likely to garner a 4.3% CAGR from 2024 to 2034, and by 2034, the market is expected ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/a451981d-2bc5-493d-9565-2a9b9a72caed/aplastic-anemia-market-outlook.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.120697,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.04406",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.04406",
        "ticker_sentiment_score": "-0.116924",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.131643",
        "ticker_sentiment_score": "0.055761",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.04406",
        "ticker_sentiment_score": "-0.116924",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.04406",
        "ticker_sentiment_score": "-0.116924",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Donald Trump Owns These 21 Dividend Kings. Should You?",
    "url": "https://www.fool.com/investing/2024/08/26/donald-trump-owns-these-21-dividend-kings-should-y/",
    "time_published": "20240826T094600",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Some of Trump's Dividend Kings deserve a crown more than others.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F788310%2Ftrump-at-podium-image-source-official-white-house-photo-by-shealah-craighead.webp&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.996023"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.295291,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MO",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PH",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.11256",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FRT",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.199037",
        "ticker_sentiment_score": "0.336597",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DJT",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.109253",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.249154",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Stock Dips While Market Gains: Key Facts",
    "url": "https://www.zacks.com/stock/news/2327949/johnson-johnson-jnj-stock-dips-while-market-gains-key-facts",
    "time_published": "20240827T214508",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) closed the most recent trading day at $162.95, moving -1.01% from the previous trading session.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default341.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.928769"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.225098,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.582526",
        "ticker_sentiment_score": "0.241001",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Biologics Market Size to Surge to USD 855.8 Billion by 2031 with a 6.9% CAGR, Fueled by Advanced Targeting of Biological Pathways - Report by Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40589602/biologics-market-size-to-surge-to-usd-855-8-billion-by-2031-with-a-6-9-cagr-fueled-by-advanced-tar",
    "time_published": "20240827T213000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research, Inc. , Aug. 27, 2024 ( GLOBE NEWSWIRE ) -- As per the report published by Transparency Market Research, the global biologics market ( \uc0dd\ubb3c\ud559 \uc2dc\uc7a5 ) was worth US$ 515.6 Billion in 2022 and is expected to reach US$ 855.8 Billion by the ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/160ec401-8f80-4a37-bcad-8a849aaefcd1/biologics-market.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.151777,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.030563",
        "ticker_sentiment_score": "0.057473",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.030563",
        "ticker_sentiment_score": "0.052779",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.030563",
        "ticker_sentiment_score": "0.052779",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.030563",
        "ticker_sentiment_score": "0.052779",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.030563",
        "ticker_sentiment_score": "0.052779",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.030563",
        "ticker_sentiment_score": "0.052779",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.091509",
        "ticker_sentiment_score": "0.066724",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.061081",
        "ticker_sentiment_score": "0.111073",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.030563",
        "ticker_sentiment_score": "0.052779",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.030563",
        "ticker_sentiment_score": "0.121768",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Merck Stock Worth Watching on PAH Drug Winrevair's Approval in Europe?",
    "url": "https://www.zacks.com/stock/news/2327685/merck-stock-worth-watching-on-pah-drug-winrevairs-approval-in-europe",
    "time_published": "20240827T135700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "MRK's Winrevair becomes the first novel activin signaling inhibitor therapy approved in Europe to treat PAH.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.2493,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.180685",
        "ticker_sentiment_score": "0.123309",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.180685",
        "ticker_sentiment_score": "0.253473",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.121037",
        "ticker_sentiment_score": "0.201934",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Ways the Democratic Party's Platform Could Impact Biotech and Pharma Stocks if Implemented",
    "url": "https://www.fool.com/investing/2024/08/27/3-ways-the-democratic-partys-platform-could-impact/",
    "time_published": "20240827T134500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "There's no reason to succumb to gloom and doom here.",
    "banner_image": "https://g.foolcdn.com/editorial/images/788172/three-investors-meet-with-paperwork.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.11129,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.048036",
        "ticker_sentiment_score": "-0.021991",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.048036",
        "ticker_sentiment_score": "0.144686",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.095899",
        "ticker_sentiment_score": "-0.023858",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.048036",
        "ticker_sentiment_score": "-0.021991",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.095899",
        "ticker_sentiment_score": "-0.023858",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Is Addex Therapeutics Stock Trading Higher On Tuesday? - Indivior  ( NASDAQ:INDV ) , Addex Therapeutics  ( NASDAQ:ADXN ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40575482/johnson-johnson-partner-addex-therapeutics-selects-investigational-compound-for-substance-use-dis",
    "time_published": "20240827T124804",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Tuesday, Addex Therapeutics Ltd ADXN stock is trading higher with a session volume of 3.79 million versus the average volume of 4.16K as per data from Benzinga Pro. Addex Therapeutics and Indivior PLC INDV announced that they have selected clinical candidates from their GABAB-positive allosteric ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/27/ADXN.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.092151,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "INDV",
        "relevance_score": "0.473208",
        "ticker_sentiment_score": "-0.057774",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADXN",
        "relevance_score": "0.473208",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.387374",
        "ticker_sentiment_score": "0.016015",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Jim Cramer Believes In Dell CEO, Doesn't Like B&G Foods - e.l.f. Beauty  ( NYSE:ELF ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/08/40575289/jim-cramer-believes-in-dell-ceo-doesnt-like-b-g-foods",
    "time_published": "20240827T124014",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Mad Money Lightning Round,\" Jim Cramer called e.l.f. Beauty, Inc. ELF \"without a doubt, one of the most shorted stocks in the market.\" \"And every time anything bad happens in the cosmetic group, people come down on it, but then you have to buy,\" he said. Cramer said he doesn't like ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/27/Dell-Technologies.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.244793,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LCID",
        "relevance_score": "0.330286",
        "ticker_sentiment_score": "0.530071",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ACAD",
        "relevance_score": "0.330286",
        "ticker_sentiment_score": "0.190538",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DELL",
        "relevance_score": "0.223866",
        "ticker_sentiment_score": "0.373905",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SYM",
        "relevance_score": "0.330286",
        "ticker_sentiment_score": "0.019877",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BGS",
        "relevance_score": "0.330286",
        "ticker_sentiment_score": "0.302184",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.330286",
        "ticker_sentiment_score": "0.033397",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here Are 2 Great Vanguard Dividend ETFs: Which Is Right For You?",
    "url": "https://www.fool.com/investing/2024/08/27/here-are-2-great-vanguard-dividend-etfs-which-is-r/",
    "time_published": "20240827T104100",
    "authors": [
      "Matt Frankel"
    ],
    "summary": "Now could be a great time to buy excellent dividend stocks, but these two ETFs have different approaches.",
    "banner_image": "https://g.foolcdn.com/editorial/images/788392/holding-money-2022b.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.3231,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.135347",
        "ticker_sentiment_score": "0.125864",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.135347",
        "ticker_sentiment_score": "0.125864",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.201803",
        "ticker_sentiment_score": "0.138496",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.135347",
        "ticker_sentiment_score": "0.065707",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.135347",
        "ticker_sentiment_score": "0.065707",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should Invesco Large Cap Value ETF  ( PWV )  Be on Your Investing Radar?",
    "url": "https://www.zacks.com/stock/news/2327391/should-invesco-large-cap-value-etf-pwv-be-on-your-investing-radar",
    "time_published": "20240827T102008",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Style Box ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default7.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.270237,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.068619",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.184363",
        "ticker_sentiment_score": "0.196439",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.068619",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.068619",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Meet Wall Street's Safest Dividend Stock: A Small-Cap Company Few Investors Know Exists",
    "url": "https://www.fool.com/investing/2024/08/27/meet-wall-street-safest-dividend-stock-small-cap/",
    "time_published": "20240827T090600",
    "authors": [
      "Sean Williams"
    ],
    "summary": "This relative unknown hasn't missed a dividend payment to its shareholders in more than 200 years!",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F788528%2Fgetting-paid-dividends-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999822"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.243021,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SPGI",
        "relevance_score": "0.031282",
        "ticker_sentiment_score": "0.115722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "YORW",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.129471",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.216307",
        "ticker_sentiment_score": "0.147774",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWK",
        "relevance_score": "0.031282",
        "ticker_sentiment_score": "0.003792",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.10412",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Spotlight on Johnson & Johnson: Analyzing the Surge in Options Activity - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/options/24/08/40608345/spotlight-on-johnson-johnson-analyzing-the-surge-in-options-activity",
    "time_published": "20240828T173103",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bearish stance on Johnson & Johnson JNJ. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1724866260_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.111451,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.079392",
        "ticker_sentiment_score": "0.041571",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.630286",
        "ticker_sentiment_score": "0.181373",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "J&J's Rybrevant Receives EU Approval for Expanded Use in NSCLC",
    "url": "https://www.zacks.com/stock/news/2328493/jjs-rybrevant-receives-eu-approval-for-expanded-use-in-nsclc",
    "time_published": "20240828T170300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The European Commission approves JNJ's Rybrevant in combination with chemotherapy for treating EGFR-mutated NSCLC following failure of prior therapy.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.198142,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ILMN",
        "relevance_score": "0.187705",
        "ticker_sentiment_score": "0.164908",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FULC",
        "relevance_score": "0.24847",
        "ticker_sentiment_score": "0.100483",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.187705",
        "ticker_sentiment_score": "0.156147",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Mestag Therapeutics Awarded Significant Grant from Innovate UK's Prestigious Cancer Therapeutics Program to Accelerate the Path to the Clinic for MST-0300",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40598929/mestag-therapeutics-awarded-significant-grant-from-innovate-uks-prestigious-cancer-therapeutics-pr",
    "time_published": "20240828T122422",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "- Innovate UK, part of UK Research and Innovation, is investing \u00a310 million in innovation projects to advance next-generation immunotherapies for cancer, of which \u00a31.5 million has been awarded to Mestag",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.279768,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.04823",
        "ticker_sentiment_score": "-0.065001",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.096283",
        "ticker_sentiment_score": "0.033774",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bispecific Antibodies Market Size By Country Indication Approved Antibodies Sales Bispecific Antibodies Clinical Trials By Phase Companies Indication",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40593282/bispecific-antibodies-market-size-by-country-indication-approved-antibodies-sales-bispecific-antib",
    "time_published": "20240828T064523",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Delhi, Aug. 28, 2024 ( GLOBE NEWSWIRE ) -- Global Bispecific Antibody Market, Drugs Sales, Patent, Price and Clinical Trials Insight 2029 Report Highlights: Bispecific Antibodies Development Proprietary Platforms Insight: > 30 Platforms",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.291299,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NHPEF",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.254085",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.123898",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson's Golden Cross: A Bullish Prescription For Investors? - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40636339/johnson-johnsons-golden-cross-a-bullish-prescription-for-investors",
    "time_published": "20240829T191857",
    "authors": [
      "Surbhi Jain"
    ],
    "summary": "Johnson & Johnson JNJ has just made a significant technical move, achieving a Golden Cross. This technical pattern occurs when a stock's short-term moving average crosses above its long-term moving average, indicating a potential shift from a bearish to a bullish trend.",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/29140836/Screenshot-2024-08-29-at-6.36.57-PM-1.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.471825,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.655824",
        "ticker_sentiment_score": "0.701839",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40630058/johnson-johnson-seeks-fda-approval-for-muscle-weakness-drug-and-gears-up-showdown-with-argenx-and",
    "time_published": "20240829T162910",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Thursday, Johnson & Johnson JNJ announced the submission of a Biologics License Application ( BLA ) to the FDA seeking the first approval of nipocalimab globally for generalized myasthenia gravis ( gMG ) . gMG is an autoantibody-driven neuromuscular disease characterized by fluctuating ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/29/Johnson-Johnson-logo-in-front-of-one-of-.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.188242,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SSTK",
        "relevance_score": "0.118064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARGX",
        "relevance_score": "0.233556",
        "ticker_sentiment_score": "0.234595",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UCBJF",
        "relevance_score": "0.233556",
        "ticker_sentiment_score": "0.437059",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.447528",
        "ticker_sentiment_score": "0.132484",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Competitor Analysis: Evaluating Johnson & Johnson And Competitors In Pharmaceuticals Industry - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/news/24/08/40627915/competitor-analysis-evaluating-johnson-amp-johnson-and-competitors-in-pharmaceuticals-industry",
    "time_published": "20240829T150051",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In the fast-paced and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Johnson & Johnson JNJ in comparison to its major competitors within the ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1724943647_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.116967,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.068896",
        "ticker_sentiment_score": "0.041107",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.454945",
        "ticker_sentiment_score": "0.162626",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The International Myeloma Foundation  ( IMF )  Brings Back 'Do You #kNOwMyeloma?' for Blood Cancer Awareness Month 2024",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40624666/the-international-myeloma-foundation-imf-brings-back-do-you-knowmyeloma-for-blood-cancer-awareness",
    "time_published": "20240829T124500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LOS ANGELES, Aug. 29, 2024 ( GLOBE NEWSWIRE ) -- With Blood Cancer Awareness Month coming up this September, the International Myeloma Foundation ( IMF ) is reviving and amplifying its highly successful #kNOwMyeloma campaign, centering on the question: \"Do You Know Myeloma?\" The U.S.",
    "banner_image": "https://ml.globenewswire.com/media/57dccc34-3a03-41ff-9328-5263528b4fcd/small/imf-logo-rgb-png.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.219782,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KPTI",
        "relevance_score": "0.028188",
        "ticker_sentiment_score": "0.040933",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.112401",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.028188",
        "ticker_sentiment_score": "0.040933",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.028188",
        "ticker_sentiment_score": "0.040933",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.028188",
        "ticker_sentiment_score": "0.040933",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.028188",
        "ticker_sentiment_score": "0.040933",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Invesco Pharmaceuticals ETF  ( PJP )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2328667/is-invesco-pharmaceuticals-etf-pjp-a-strong-etf-right-now",
    "time_published": "20240829T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default80.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      }
    ],
    "overall_sentiment_score": 0.260316,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.114682",
        "ticker_sentiment_score": "0.060978",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.171282",
        "ticker_sentiment_score": "0.218383",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.114682",
        "ticker_sentiment_score": "0.060978",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.114682",
        "ticker_sentiment_score": "0.060978",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Johnson & Johnson, Kenvue and Eli Lilly",
    "url": "https://www.zacks.com/stock/news/2328646/the-zacks-analyst-blog-highlights-johnson-johnson-kenvue-and-eli-lilly",
    "time_published": "20240829T091500",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Johnson & Johnson, Kenvue and Eli Lilly are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999701"
      }
    ],
    "overall_sentiment_score": 0.181374,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.102741",
        "ticker_sentiment_score": "0.083444",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.102741",
        "ticker_sentiment_score": "0.121124",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.102741",
        "ticker_sentiment_score": "-0.015087",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Biocon arm inks pact to launch biosimilar Bmab 1200 in multiple countries",
    "url": "https://www.business-standard.com/markets/capital-market-news/biocon-arm-inks-pact-to-launch-biosimilar-bmab-1200-in-multiple-countries-124082900411_1.html",
    "time_published": "20240829T065100",
    "authors": [
      "Capital Market"
    ],
    "summary": "The biopharmaceutical company said that its subsidiary, Biocon Biologics has secured market entry for its proposed biosimilar, Bmab 1200, which is designed to compete with Stelara, in Europe, the UK, Canada, and Japan.",
    "banner_image": null,
    "source": "Business Standard",
    "category_within_source": "Markets",
    "source_domain": "www.business-standard.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.295556,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.09186",
        "ticker_sentiment_score": "0.102524",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Biocon Biologics secures deal with Janssen to launch biosimilar Bmab 1200",
    "url": "https://www.business-standard.com/companies/news/biocon-biologics-secures-deal-with-janssen-to-launch-biosimilar-bmab-1200-124082900365_1.html",
    "time_published": "20240829T062418",
    "authors": [
      "Aneeka Chatterjee"
    ],
    "summary": "Agreement clears way for Indian company to launch treatment in Europe, Canada and other markets ...",
    "banner_image": null,
    "source": "Business Standard",
    "category_within_source": "Companies",
    "source_domain": "www.business-standard.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.329547,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.136316",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Biocon inks pact with Janssen to commercialise biosimilar products in Japan",
    "url": "https://www.business-standard.com/companies/news/biocon-inks-pact-with-janssen-to-commercialise-biosimilar-products-in-japan-124082900202_1.html",
    "time_published": "20240829T051734",
    "authors": [
      "Press Trust of India"
    ],
    "summary": "Biocon Biologics on Thursday said it has inked a pact with Janssen for launching a biosimilar medication for the treatment of autoimmune diseases in Europe, the United Kingdom, Canada, and Japan. The company, a subsidiary of Biocon Ltd, has inked a settlement and licence agreement with Janssen ...",
    "banner_image": null,
    "source": "Business Standard",
    "category_within_source": "Companies",
    "source_domain": "www.business-standard.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.310518,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.126119",
        "ticker_sentiment_score": "0.149844",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Biocon Biologics signs settlement and license agreement with Janssen",
    "url": "https://www.business-standard.com/markets/capital-market-news/biocon-biologics-signs-settlement-and-license-agreement-with-janssen-124082900130_1.html",
    "time_published": "20240829T033300",
    "authors": [
      "Capital Market"
    ],
    "summary": "To commercialize its Bmab 1200, a proposed biosimilar to Stelara, in Europe, UK, Canada and Japan ...",
    "banner_image": null,
    "source": "Business Standard",
    "category_within_source": "Markets",
    "source_domain": "www.business-standard.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.257626,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.185306",
        "ticker_sentiment_score": "0.150755",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson-Spin Off Kenvue Wins Lawsuit Over Pain Killer Tylenol 'Rapid Release' Gelcaps - Kenvue  ( NYSE:KVUE ) ",
    "url": "https://www.benzinga.com/news/large-cap/24/08/40659011/johnson-johnson-spin-off-kenvue-wins-lawsuit-over-pain-killer-tylenol-rapid-release-gelcaps",
    "time_published": "20240830T174755",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Kenvue Inc. KVUE, the maker of Tylenol, has reportedly defended itself against a lawsuit in which consumers claimed being misled into overpaying for \"Rapid Release\" gelcaps, arguing that these gelcaps did not relieve pain any faster than less expensive Tylenol tablets.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/30/Bangkok--Thailand---1--January-2024---Ty.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": -0.05089,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.565345",
        "ticker_sentiment_score": "-0.058443",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RTA1:MU",
        "relevance_score": "0.124164",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ACI",
        "relevance_score": "0.245339",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.245339",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "JNJ Seeks First FDA Nod for Autoimmune Disease Drug Nipocalimab",
    "url": "https://www.zacks.com/stock/news/2329915/jnj-seeks-first-fda-nod-for-autoimmune-disease-drug-nipocalimab",
    "time_published": "20240830T160700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The Johnson & Johnson filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.198688,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ARGX",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.188099",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BVS",
        "relevance_score": "0.411176",
        "ticker_sentiment_score": "0.207099",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FULC",
        "relevance_score": "0.347614",
        "ticker_sentiment_score": "0.275209",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.281422",
        "ticker_sentiment_score": "0.14201",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "LAZCLUZE\u2122  ( lazertinib )  Now Available from Onco360 for the First-line Treatment, in Combination with Rybrevant\u00ae, of Adult Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Have EGFR Exon 19 Deletions or Exon 21 L858R Mutations",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40648954/lazcluze-lazertinib-now-available-from-onco360-for-the-first-line-treatment-in-combination-with-ry",
    "time_published": "20240830T113000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LOUISVILLE, Ky., Aug. 30, 2024 ( GLOBE NEWSWIRE ) -- Onco360\u00ae, the nation's leading independent specialty pharmacy, has been selected as a pharmacy partner by Johnson & Johnson for LAZCLUZE\u2122 ( lazertinib ) .",
    "banner_image": "https://ml.globenewswire.com/media/7af5aa20-16b6-4c17-af80-fa564e72633f/small/onco360-hor-png.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.026953,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.16171",
        "ticker_sentiment_score": "0.13666",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is iShares Core Dividend Growth ETF  ( DGRO )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2329325/is-ishares-core-dividend-growth-etf-dgro-a-strong-etf-right-now",
    "time_published": "20240830T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default301.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99999"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.292002,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.058615",
        "ticker_sentiment_score": "0.129998",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.116914",
        "ticker_sentiment_score": "0.061438",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.116914",
        "ticker_sentiment_score": "0.200207",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.116914",
        "ticker_sentiment_score": "0.061438",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.116914",
        "ticker_sentiment_score": "0.061438",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Johnson & Johnson the Best Dividend Stock for You?",
    "url": "https://www.fool.com/investing/2024/09/01/is-johnson-johnson-the-best-dividend-stock-for-you/",
    "time_published": "20240901T104500",
    "authors": [
      "Justin Pope"
    ],
    "summary": "You won't find a more dependable dividend payer on Wall Street. But whether it's the best stock for you depends on other factors.",
    "banner_image": "https://media.ycharts.com/charts/859abfc90bcfb23936f5d2f0e2f7b1c5.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.623304"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.308742,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.723597",
        "ticker_sentiment_score": "0.487024",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Worried About a Stock Market Sell-Off? Consider Coca-Cola, Pepsi, and These 3 Safe Dividend Kings for Decades of Passive Income.",
    "url": "https://www.fool.com/investing/2024/09/01/stock-market-sell-off-buy-safe-dividend-kings/",
    "time_published": "20240901T091200",
    "authors": [
      "Daniel Foelber"
    ],
    "summary": "Investing in equal parts of these five stocks produces an average dividend yield of 3%.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F788659%2Fgettyimages-1542729689-1200x800-5b2df79-1.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999995"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.222789,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TGT",
        "relevance_score": "0.300854",
        "ticker_sentiment_score": "-0.120465",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CELH",
        "relevance_score": "0.03853",
        "ticker_sentiment_score": "0.146648",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.076971",
        "ticker_sentiment_score": "-0.125608",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.076971",
        "ticker_sentiment_score": "0.107623",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.300854",
        "ticker_sentiment_score": "0.247993",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PEP",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "-0.040376",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ITW",
        "relevance_score": "0.300854",
        "ticker_sentiment_score": "0.2619",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.03853",
        "ticker_sentiment_score": "-0.095052",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Best Dividend Growth ETF to Invest $1,000 in Right Now",
    "url": "https://www.fool.com/investing/2024/09/01/the-best-dividend-growth-etf-to-invest-1000-in-rig/",
    "time_published": "20240901T090800",
    "authors": [
      "James Brumley"
    ],
    "summary": "Little things can turn into big things given enough time.",
    "banner_image": "https://media.ycharts.com/charts/c3d84a32487890a9195ce82005fb9612.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.353125,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.034282",
        "ticker_sentiment_score": "0.235561",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.034282",
        "ticker_sentiment_score": "0.235561",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SWK",
        "relevance_score": "0.034282",
        "ticker_sentiment_score": "0.039491",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.068502",
        "ticker_sentiment_score": "0.137524",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.034282",
        "ticker_sentiment_score": "0.039491",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.102595",
        "ticker_sentiment_score": "0.205493",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.034282",
        "ticker_sentiment_score": "0.295624",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CLX",
        "relevance_score": "0.034282",
        "ticker_sentiment_score": "0.039491",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Increases Despite Market Slip: Here's What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2331033/johnson-johnson-jnj-increases-despite-market-slip-heres-what-you-need-to-know",
    "time_published": "20240903T214519",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) concluded the recent trading session at $167.16, signifying a +0.78% move from its prior day's close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default195.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.171643,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.520477",
        "ticker_sentiment_score": "0.157213",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "CVRx Announces Appointment of Two New Board Members",
    "url": "https://www.globenewswire.com/news-release/2024/09/03/2939682/0/en/CVRx-Announces-Appointment-of-Two-New-Board-Members.html",
    "time_published": "20240903T123000",
    "authors": [
      "CVRx",
      "Inc."
    ],
    "summary": "Kevin Ballinger and Mitch Hill appointed as new independent Board members Kevin Ballinger and Mitch Hill appointed as new independent Board members ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/04c4feba-7841-4ac8-8ca5-6c03be383a0e",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.275124,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SILK",
        "relevance_score": "0.068502",
        "ticker_sentiment_score": "0.058309",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.068502",
        "ticker_sentiment_score": "0.058309",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVRX",
        "relevance_score": "0.452639",
        "ticker_sentiment_score": "0.392903",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NARI",
        "relevance_score": "0.068502",
        "ticker_sentiment_score": "0.107357",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DHR",
        "relevance_score": "0.068502",
        "ticker_sentiment_score": "0.058309",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.068502",
        "ticker_sentiment_score": "0.058309",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Court Orders Johnson & Johnson To Compensate Auris Health Shareholders $1B - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/09/40716074/court-orders-johnson-johnson-to-compensate-auris-health-shareholders-1b",
    "time_published": "20240904T181258",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Johnson & Johnson JNJ has reportedly been ordered to pay $1 billion in damages to Auris Health shareholders for breaching a 2019 acquisition agreement, according to a ruling by Delaware's Court of Chancery.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/04/jnj-johnson-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.061725,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.721785",
        "ticker_sentiment_score": "-0.257465",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "3 Dividend Stocks to Double Up on Right Now",
    "url": "https://www.fool.com/investing/2024/09/04/3-dividend-stocks-to-double-up-on-right-now/",
    "time_published": "20240904T122600",
    "authors": [
      "Matt DiLallo"
    ],
    "summary": "These companies have excellent records of growing their dividends.",
    "banner_image": "https://g.foolcdn.com/editorial/images/789488/a-person-sumitting-a-stock-order-on-a-mobile-device.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.938238"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.293248,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.052918",
        "ticker_sentiment_score": "0.145647",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NKE",
        "relevance_score": "0.357783",
        "ticker_sentiment_score": "0.396208",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.260004",
        "ticker_sentiment_score": "0.240397",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.309539",
        "ticker_sentiment_score": "0.431961",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Is Invesco S&P 500 Quality ETF  ( SPHQ )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2331113/is-invesco-sp-500-quality-etf-sphq-a-strong-etf-right-now",
    "time_published": "20240904T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default165.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999994"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.257689,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AAPL",
        "relevance_score": "0.114956",
        "ticker_sentiment_score": "0.05992",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.057628",
        "ticker_sentiment_score": "0.18609",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.171688",
        "ticker_sentiment_score": "0.085661",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.057628",
        "ticker_sentiment_score": "0.053957",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.114956",
        "ticker_sentiment_score": "0.05992",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Raises Talc Settlement Offer to $9B, Moves Closer to Settlement Victory - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/09/40738358/johnson-johnson-raises-talc-settlement-offer-to-9b-moves-closer-to-settlement-victory",
    "time_published": "20240905T183004",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Johnson & Johnson JNJ has reportedly increased its settlement offer by $1 billion, now totaling about $9 billion, to address claims that its talc baby powder caused gynecological cancer.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/05/johnsons-5671315-1920.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.039828,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DSSMY",
        "relevance_score": "0.371523",
        "ticker_sentiment_score": "0.218718",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.666827",
        "ticker_sentiment_score": "-0.173903",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration - ATAI Life Sciences  ( NASDAQ:ATAI ) , AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/markets/cannabis/24/09/40736485/psychedelic-drugs-market-set-to-grow-by-1-37b-by-2028-driven-by-mental-health-disorders-and-ai-i",
    "time_published": "20240905T165346",
    "authors": [
      "Juan Sp\u00ednelli"
    ],
    "summary": "The global psychedelic drugs market is poised for significant growth over the next five years, with an estimated increase of USD 1.37 billion from 2024 to 2028, according to a report by Technavio.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/05/3.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.176509,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CMPS",
        "relevance_score": "0.077094",
        "ticker_sentiment_score": "0.137835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.15347",
        "ticker_sentiment_score": "0.175227",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MNMD",
        "relevance_score": "0.15347",
        "ticker_sentiment_score": "0.175227",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.15347",
        "ticker_sentiment_score": "0.175227",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.15347",
        "ticker_sentiment_score": "0.175227",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Investors Heavily Search Johnson & Johnson  ( JNJ ) : Here is What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2331944/investors-heavily-search-johnson-johnson-jnj-here-is-what-you-need-to-know",
    "time_published": "20240905T130018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default218.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.236852,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.474082",
        "ticker_sentiment_score": "0.176361",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Dividend Stocks With Payouts That May Not Be as Safe as They Seem",
    "url": "https://www.fool.com/investing/2024/09/05/2-dividend-stocks-with-payouts-that-may-not-be-as/",
    "time_published": "20240905T115500",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Johnson & Johnson and Altria Group are two prominent dividend stocks, but I wouldn't rely on their payouts.",
    "banner_image": "https://g.foolcdn.com/editorial/images/789239/person-stressed-sitting-at-a-computer.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.989041"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.024423,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MO",
        "relevance_score": "0.263373",
        "ticker_sentiment_score": "0.059571",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.053629",
        "ticker_sentiment_score": "-0.107997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.362254",
        "ticker_sentiment_score": "0.162656",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.053629",
        "ticker_sentiment_score": "-0.107997",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pseudarthrosis Treatment Market is Projected to Reach $1.37 Billion at a CAGR 4.6% by 2034 | Fact.MR Report",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40725227/pseudarthrosis-treatment-market-is-projected-to-reach-1-37-billion-at-a-cagr-4-6-by-2034-fact-mr-r",
    "time_published": "20240905T100000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Rockville, MD, Sept. 05, 2024 ( GLOBE NEWSWIRE ) -- According to a new industry report released by Fact.MR, revenue from the global pseudarthrosis treatment market is estimated to reach US$ 879.4 million in 2024 and thereafter increase at a CAGR of 4.6% from 2024 to 2034.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/f8090b1b-bbdf-4755-97c9-4726ee946522/pseudarthrosis-treatment-market.jpg",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.302869,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ZBH",
        "relevance_score": "0.036812",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OFIX",
        "relevance_score": "0.036812",
        "ticker_sentiment_score": "0.068418",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FSNUF",
        "relevance_score": "0.036812",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.036812",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.036812",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALPMF",
        "relevance_score": "0.036812",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HKMPF",
        "relevance_score": "0.036812",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SKXJF",
        "relevance_score": "0.036812",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.036812",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.036812",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BVS",
        "relevance_score": "0.036812",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.036812",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Anthelmintic Drugs Market Projected Growth at 3.9% CAGR to Reach USD 3.7 billion by 2031 | Exclusive Research Report by Transparency Market Research Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40725223/anthelmintic-drugs-market-projected-growth-at-3-9-cagr-to-reach-usd-3-7-billion-by-2031-exclusive-",
    "time_published": "20240905T095900",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research Inc. -, Sept. 05, 2024 ( GLOBE NEWSWIRE ) -- As per the report published by Transparency Market Research, the anthelmintic drugs market ( \uad6c\ucda9\uc81c \uc2dc\uc7a5 ) was worth US$ 2.6 Bn in 2022 and is expected to reach US$ 3.7 Bn by the year 2031 ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/05daa975-7257-4177-99b3-a7ae96c4d2a9/anthelmintic-drugs-market.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.060655,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.037563",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.037563",
        "ticker_sentiment_score": "0.044869",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.037563",
        "ticker_sentiment_score": "0.044869",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZTS",
        "relevance_score": "0.037563",
        "ticker_sentiment_score": "0.044869",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.037563",
        "ticker_sentiment_score": "0.044869",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMRX",
        "relevance_score": "0.037563",
        "ticker_sentiment_score": "0.044869",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.112357",
        "ticker_sentiment_score": "0.070902",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Dell, CoStar, PayPal And A Major Health Care Stock On CNBC's 'Final Trades' - Dell Technologies  ( NYSE:DELL ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/09/40748757/dell-costar-paypal-and-a-major-health-care-stock-on-cnbcs-final-trades",
    "time_published": "20240906T124700",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Halftime Report Final Trades,\" Bill Baruch of Blue Line Capital named Dell Technologies Inc. DELL, which reported earnings last week. On Aug. 29, Dell reported second-quarter revenue of $25.03 billion, beating the consensus estimate of $24.14 billion, according to Benzinga Pro.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/06/untitled.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938238"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.229913,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PYPL",
        "relevance_score": "0.535653",
        "ticker_sentiment_score": "0.529549",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.230235",
        "ticker_sentiment_score": "0.381459",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CSGP",
        "relevance_score": "0.230235",
        "ticker_sentiment_score": "0.270669",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DELL",
        "relevance_score": "0.230235",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.441698",
        "ticker_sentiment_score": "-0.193036",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/news/24/09/40748268/wall-streets-most-accurate-analysts-weigh-in-on-3-health-care-stocks-with-over-3-dividend-yields",
    "time_published": "20240906T122122",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/06/JohnsonampJohnson-Shutterstock.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.115397,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CVS",
        "relevance_score": "0.194242",
        "ticker_sentiment_score": "-0.041248",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.097854",
        "ticker_sentiment_score": "-0.075969",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PDCO",
        "relevance_score": "0.194242",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.097854",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.194242",
        "ticker_sentiment_score": "0.107297",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Outpaces Stock Market Gains: What You Should Know",
    "url": "https://www.zacks.com/stock/news/2333674/johnson-johnson-jnj-outpaces-stock-market-gains-what-you-should-know",
    "time_published": "20240909T214517",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) closed the most recent trading day at $166.61, moving +1.36% from the previous trading session.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default292.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.990786"
      }
    ],
    "overall_sentiment_score": 0.213194,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.588876",
        "ticker_sentiment_score": "0.299065",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Enovis Appoints Tim Czartoski as President, U.S. Surgical and Global Product and Enabling Technologies",
    "url": "https://www.globenewswire.com/news-release/2024/09/09/2943164/0/en/Enovis-Appoints-Tim-Czartoski-as-President-U-S-Surgical-and-Global-Product-and-Enabling-Technologies.html",
    "time_published": "20240909T195000",
    "authors": [
      "Enovis Corporation"
    ],
    "summary": "WILMINGTON, DE, Sept. 09, 2024 ( GLOBE NEWSWIRE ) -- Enovis\u2122 ( NYSE: ENOV ) , an innovation-driven medical technology growth company, is pleased to announce the appointment of Tim Czartoski to the position of President, U.S. Surgical and Global Product and Enabling Technologies.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/b4532895-c0b7-4f6a-9a37-db4eefc89e3d",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.386813,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ENOV",
        "relevance_score": "0.666827",
        "ticker_sentiment_score": "0.712858",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "0.082643",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "0.047463",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "mRNA Vaccine Market Size to Achieve USD 9.6 Billion Revenue by 2034, Real-World Efficacy and Infrastructure Investments Boost Market Dynamics - Exclusive Report by Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40777820/mrna-vaccine-market-size-to-achieve-usd-9-6-billion-revenue-by-2034-real-world-efficacy-and-infras",
    "time_published": "20240909T163000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research, Inc., Sept. 09, 2024 ( GLOBE NEWSWIRE ) -- The global mRNA vaccine market ( mRNA \ubc31\uc2e0 \uc2dc\uc7a5 ) is estimated to decline at a CAGR of -4.3% from 2024 to 2034.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/564c2eb3-59f0-4d20-abb2-0ed6e0c92a9b/mrna-vaccine-market.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.352775,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.032558",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.032558",
        "ticker_sentiment_score": "0.212516",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.032558",
        "ticker_sentiment_score": "0.202383",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.032558",
        "ticker_sentiment_score": "0.267292",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVAX",
        "relevance_score": "0.032558",
        "ticker_sentiment_score": "0.202383",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.12969",
        "ticker_sentiment_score": "0.23683",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.097457",
        "ticker_sentiment_score": "0.034069",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.065061",
        "ticker_sentiment_score": "0.132765",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.065061",
        "ticker_sentiment_score": "0.132765",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.065061",
        "ticker_sentiment_score": "0.363654",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "There Are 4 Dividend Kings That Are Also in the Dow Jones Industrial Average. Here's Why 3 of Them Just Hit All-Time Highs.",
    "url": "https://www.fool.com/investing/2024/09/09/buy-dividend-kings-dow-dividend-stocks/",
    "time_published": "20240909T141500",
    "authors": [
      "Daniel Foelber"
    ],
    "summary": "These dividend stocks prove why yield isn't everything when it comes to generating reliable passive income.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F789433%2Fshopping-for-cleaning-supplies-1200x800-5b2df79-2.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99977"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.980509"
      }
    ],
    "overall_sentiment_score": 0.320942,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.040691",
        "ticker_sentiment_score": "0.122448",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DG",
        "relevance_score": "0.040691",
        "ticker_sentiment_score": "-0.053627",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.12165",
        "ticker_sentiment_score": "0.096729",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.040691",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.12165",
        "ticker_sentiment_score": "0.096729",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.524949",
        "ticker_sentiment_score": "0.359881",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Creyon Bio Appoints Venture Capitalists Serge Messerlian and Shaquille Vayda to Board of Directors",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40770995/creyon-bio-appoints-venture-capitalists-serge-messerlian-and-shaquille-vayda-to-board-of-directors",
    "time_published": "20240909T120059",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "SAN DIEGO and RESEARCH TRIANGLE PARK, N.C., Sept. 09, 2024 ( GLOBE NEWSWIRE ) -- Creyon Bio, Inc. ( \"Creyon\" ) , a clinical-stage leader in AI/machine learning-enabled engineering of oligonucleotide-based medicines ( OBMs ) , has appointed two prominent venture capitalists, Serge Messerlian, ...",
    "banner_image": "https://ml.globenewswire.com/media/d543d314-687c-4c1d-8ceb-0a04d5fb5e99/small/creyon-new-logo-2-2024-jan-26-1200x628-png.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.238717,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BAX",
        "relevance_score": "0.056808",
        "ticker_sentiment_score": "0.018964",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOC",
        "relevance_score": "0.056808",
        "ticker_sentiment_score": "0.020994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ILMN",
        "relevance_score": "0.056808",
        "ticker_sentiment_score": "0.020994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.056808",
        "ticker_sentiment_score": "0.018964",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer",
    "url": "https://www.globenewswire.com/news-release/2024/09/09/2942745/0/en/Cue-Biopharma-Appoints-Industry-Veteran-Lucinda-Warren-as-Chief-Business-Officer.html",
    "time_published": "20240909T120000",
    "authors": [
      "Inc.",
      "Cue Biopharma"
    ],
    "summary": "BOSTON, Sept. 09, 2024 ( GLOBE NEWSWIRE ) -- Cue Biopharma, Inc. ( Nasdaq: CUE ) , a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced the appointment of industry veteran Lucinda ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/e5a96ccc-fb0b-4cae-ad30-b777f8bc5bae",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.285311,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CUE",
        "relevance_score": "0.23228",
        "ticker_sentiment_score": "0.216344",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.067252",
        "ticker_sentiment_score": "0.128525",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer - Cue Biopharma  ( NASDAQ:CUE ) ",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40770840/cue-biopharma-appoints-industry-veteran-lucinda-warren-as-chief-business-officer",
    "time_published": "20240909T120000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "BOSTON, Sept. 09, 2024 ( GLOBE NEWSWIRE ) -- Cue Biopharma, Inc. CUE, a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced the appointment of industry veteran Lucinda Warren as ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.407481,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CUE",
        "relevance_score": "0.429671",
        "ticker_sentiment_score": "0.594909",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.128822",
        "ticker_sentiment_score": "0.147466",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "5 Stocks to Watch: Apple's Launch Week Showdown",
    "url": "https://moneymorning.com/2024/09/09/cool-stock-watchlist-title/",
    "time_published": "20240909T114708",
    "authors": [
      "Chris Johnson"
    ],
    "summary": "Technology Stock of the Week: IBM Last week I profiled Palantir ( PLTR ) as your \"Technology Stock of the Week\" based on its position in the AI Services Industry. This week's we're taking another stock from the group, IBM ( IBM ) .",
    "banner_image": "https://moneymorning.com/wp-content/blogs.dir/1/files/2024/09/IBM.png",
    "source": "Money Morning",
    "category_within_source": "RSS",
    "source_domain": "moneymorning.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999365"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.101983,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.090989",
        "ticker_sentiment_score": "0.340304",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.090989",
        "ticker_sentiment_score": "0.340304",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.180798",
        "ticker_sentiment_score": "-0.109324",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.180798",
        "ticker_sentiment_score": "-0.062646",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.180798",
        "ticker_sentiment_score": "0.049421",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "Z",
        "relevance_score": "0.090989",
        "ticker_sentiment_score": "0.168753",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RDFN",
        "relevance_score": "0.180798",
        "ticker_sentiment_score": "0.133094",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is iShares Core High Dividend ETF  ( HDV )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2333155/is-ishares-core-high-dividend-etf-hdv-a-strong-etf-right-now",
    "time_published": "20240909T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default123.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.222797,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.057352",
        "ticker_sentiment_score": "0.08195",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.114409",
        "ticker_sentiment_score": "0.169336",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.114409",
        "ticker_sentiment_score": "0.060923",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.114409",
        "ticker_sentiment_score": "0.060923",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.114409",
        "ticker_sentiment_score": "0.060923",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Opioid Overdose Treatment Market is Projected to Reach US$ 3.1 Billion by 2034 | Fact.MR Report",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40768658/opioid-overdose-treatment-market-is-projected-to-reach-us-3-1-billion-by-2034-fact-mr-report",
    "time_published": "20240909T100000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Rockville, MD, Sept. 09, 2024 ( GLOBE NEWSWIRE ) -- The global opioid overdose treatment market is expected to reach a value of US$ 1.54 billion in 2024, as revealed in a new industry analysis published by proficient researchers at Fact.MR, a market research and competitive intelligence provider.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/5318b412-14ef-49ab-8757-34f2d70bea76/opioid-overdose-treatment-market.jpg",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.302573,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "COLL",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "0.048524",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "0.048524",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "0.048524",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALPMF",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "0.048524",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HKMPF",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "0.048524",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMRX",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "0.048524",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "0.048524",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "0.048524",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines - Protagonist Therapeutics  ( NASDAQ:PTGX ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40800349/protagonist-therapeutics-two-investigational-candidates-target-over-10b-market-bull",
    "time_published": "20240910T171700",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Truist Securities initiated coverage on Protagonist Therapeutics Inc PTGX, citing its first-in-class lead asset with encouraging Phase 2 data in a rare form of blood cancer and a multi-billion dollar opportunity.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/10/PTGX.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.296701,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PTGX",
        "relevance_score": "0.474958",
        "ticker_sentiment_score": "0.468391",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.626443",
        "ticker_sentiment_score": "0.417206",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.200688",
        "ticker_sentiment_score": "0.446343",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Xencor Stock Gains 23% on Encouraging Pipeline Advancements",
    "url": "https://www.zacks.com/stock/news/2334182/xencor-stock-gains-23-on-encouraging-pipeline-advancements",
    "time_published": "20240910T162200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "XNCR moves four new XmAb drug development programs for autoimmune diseases. It also provided favorable updates for two of its oncology drug candidates.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.967321"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.144095,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "XNCR",
        "relevance_score": "0.377142",
        "ticker_sentiment_score": "0.160098",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BVS",
        "relevance_score": "0.377142",
        "ticker_sentiment_score": "0.187255",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FULC",
        "relevance_score": "0.377142",
        "ticker_sentiment_score": "0.277003",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.256989",
        "ticker_sentiment_score": "0.096636",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Kenvue Set To Pop Like A Tylenol Gelcap? Golden Cross Looms On Stock Chart - Kenvue  ( NYSE:KVUE ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/09/40792367/kenvue-set-to-pop-like-a-tylenol-gelcap-golden-cross-looms-on-stock-chart",
    "time_published": "20240910T124840",
    "authors": [
      "Surbhi Jain"
    ],
    "summary": "Kenvue Inc. KVUE - the parent company of well-known pharmacy items like Listerine, Mylanta, and Tylenol - is showing a bullish pattern on the charts Tuesday. The short-term moving average crossed above a long-term one, a signal that Kenvue's stock may be gearing up for another big move.",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/10075437/Screenshot-2024-09-10-at-5.16.01-PM.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.322313,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.634626",
        "ticker_sentiment_score": "0.554404",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.101974",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "SS Innovations Welcomes \"Father of Surgical Robotics\" Dr. Fredric Moll to Board",
    "url": "https://www.globenewswire.com/news-release/2024/09/10/2943651/0/en/SS-Innovations-Welcomes-Father-of-Surgical-Robotics-Dr-Fredric-Moll-to-Board.html",
    "time_published": "20240910T123000",
    "authors": [
      "SS Innovations"
    ],
    "summary": "FORT LAUDERDALE, Fla., Sept. 10, 2024 ( GLOBE NEWSWIRE ) -- SS Innovations International, Inc. ( the \"Company\" or \"SS Innovations\" ) ( OTC: SSII ) , a developer of innovative surgical robotic technologies dedicated to making world-class robotic surgery affordable and accessible to a global ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/9e7b27b4-d81b-4a50-af68-87e254ba3ec0",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.367549,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ISRG",
        "relevance_score": "0.044551",
        "ticker_sentiment_score": "0.109051",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.029538",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Summit Therapeutics a Buy Now?",
    "url": "https://www.fool.com/investing/2024/09/10/is-summit-therapeutics-a-buy-now/",
    "time_published": "20240910T082700",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "The clinical-stage drugmaker's cancer therapy candidate outperformed Keytruda, the world's top-selling cancer drug.",
    "banner_image": "https://g.foolcdn.com/editorial/images/790126/scientist-checking-samples-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      }
    ],
    "overall_sentiment_score": 0.073412,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AKESF",
        "relevance_score": "0.04823",
        "ticker_sentiment_score": "0.065938",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.096283",
        "ticker_sentiment_score": "0.017444",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.04823",
        "ticker_sentiment_score": "-0.112923",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMMT",
        "relevance_score": "0.283323",
        "ticker_sentiment_score": "-0.011028",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Metals in Tampons: FDA Initiates New Safety Measures and Testing - Johnson & Johnson  ( NYSE:JNJ ) , Edgewell Personal Care  ( NYSE:EPC ) ",
    "url": "https://www.benzinga.com/news/24/09/40820516/metals-in-tampons-fda-initiates-new-safety-measures-and-testing",
    "time_published": "20240911T183740",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "The FDA is addressing concerns about tampon safety following a 2024 study that discovered metals in tampons during laboratory testing. Some of the tampon makers include Procter & Gamble Co PG, Johnson & Johnson JNJ, Edgewell Personal Care EPC, and Kimberly-Clark Corporation KMB.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/11/Female-Hand-With-A-Tampon--Blue-Backgrou.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.193865,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EPC",
        "relevance_score": "0.213988",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMB",
        "relevance_score": "0.213988",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.107978",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.213988",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.213988",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Sony Music-Universal Music JV Hits Johnson & Johnson With Copyright Lawsuit Over Unlicensed Music Use Covering 80 Videos - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/09/40820416/sony-music-universal-music-jv-hits-johnson-johnson-with-copyright-lawsuit-over-unlicensed-music-u",
    "time_published": "20240911T183222",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Johnson & Johnson JNJ is reportedly facing a lawsuit for allegedly using copyrighted instrumental music without permission in numerous YouTube and Facebook videos.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/11/Dollar-Money-And-Judges-Gavel-On-Table--.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.077165,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SNEJF",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "-0.058108",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "0.004865",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "0.004865",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.741116",
        "ticker_sentiment_score": "-0.144088",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson's Mid-Stage Lung Cancer Trial Reveals Fewer Infusion-Related Reactions - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/09/40813730/johnson-johnsons-mid-stage-lung-cancer-trial-reveals-fewer-infusion-related-reactions",
    "time_published": "20240911T130823",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Tuesday, Johnson & Johnson JNJ announced results from the open-label Phase 2 SKIPPirr study, which evaluated additional prophylactic strategies to reduce the incidence of infusion-related reactions ( IRRs ) with intravenous ( IV ) Rybrevant ( amivantamab-vmjw ) in patients with advanced ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/11/biotech-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.13427,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.301315",
        "ticker_sentiment_score": "0.100614",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Hims & Hers Health the Next Teladoc?",
    "url": "https://www.fool.com/investing/2024/09/11/is-hims-hers-health-the-next-teladoc/",
    "time_published": "20240911T115000",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Telemedicine was one of the most in-demand services during the height of the COVID-19 pandemic.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F790093%2Fgettyimages-1438278348.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.187867,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TGT",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "0.101963",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TDOC",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "0.295043",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.158519",
        "ticker_sentiment_score": "0.172179",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "0.089934",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "0.08817",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "0.089934",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "0.089934",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Stocks That Are Passive Income Machines to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/09/11/2-stocks-that-are-passive-income-machines-to-buy-a/",
    "time_published": "20240911T105900",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "You can take these dividends straight to the bank.",
    "banner_image": "https://g.foolcdn.com/editorial/images/789836/doctor-holding-elderly-patients-hand.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      }
    ],
    "overall_sentiment_score": 0.213804,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.515636",
        "ticker_sentiment_score": "0.377301",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.37552",
        "ticker_sentiment_score": "0.323864",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the VanEck Pharmaceutical ETF  ( PPH ) ?",
    "url": "https://www.zacks.com/stock/news/2334367/should-you-invest-in-the-vaneck-pharmaceutical-etf-pph",
    "time_published": "20240911T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for PPH ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default319.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999998"
      }
    ],
    "overall_sentiment_score": 0.197602,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.061552",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.043079",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.061552",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.061552",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Unpacking the Latest Options Trading Trends in Johnson & Johnson - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/options/24/09/40843455/unpacking-the-latest-options-trading-trends-in-johnson-johnson",
    "time_published": "20240912T204922",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bullish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson JNJ we detected 10 trades. If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1726174159_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.19509,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.085324",
        "ticker_sentiment_score": "0.041984",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.608634",
        "ticker_sentiment_score": "0.277977",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "FDA Grants Label Expansion to J&J's Tremfya in Ulcerative Colitis",
    "url": "https://www.zacks.com/stock/news/2335423/fda-grants-label-expansion-to-jjs-tremfya-in-ulcerative-colitis",
    "time_published": "20240912T153900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "With this latest approval, JNJ's Tremfya is approved for a total of three immunology indications.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/1612.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.280659,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.253646",
        "ticker_sentiment_score": "0.277154",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.191675",
        "ticker_sentiment_score": "0.31084",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.253646",
        "ticker_sentiment_score": "0.384992",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Competitor Analysis: Evaluating Johnson & Johnson And Competitors In Pharmaceuticals Industry - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/news/24/09/40836156/competitor-analysis-evaluating-johnson-amp-johnson-and-competitors-in-pharmaceuticals-industry",
    "time_published": "20240912T150049",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In the fast-paced and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Johnson & Johnson JNJ in comparison to its major competitors within the ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1726153246_0_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.119399,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.069495",
        "ticker_sentiment_score": "0.041124",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.458446",
        "ticker_sentiment_score": "0.172995",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "How To Earn $500 A Month From Johnson & Johnson Stock - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/news/earnings/24/09/40831656/how-to-earn-500-a-month-from-johnson-johnson-stock",
    "time_published": "20240912T123340",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On Tuesday, Johnson & Johnson JNJ announced results from the open-label Phase 2 SKIPPirr study, which evaluated additional prophylactic strategies to reduce the incidence of infusion-related reactions ( IRRs ) with intravenous ( IV ) Rybrevant ( amivantamab-vmjw ) in patients with advanced ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/12/Dividendi-oltre-il-3--Le-azioni-scelte-d.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.723405"
      }
    ],
    "overall_sentiment_score": 0.151992,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.56415",
        "ticker_sentiment_score": "0.102357",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Medical Instruments Industry Stocks to Buy on genAI and M&A Boost",
    "url": "https://www.zacks.com/commentary/2335903/3-medical-instruments-industry-stocks-to-buy-on-genai-and-ma-boost",
    "time_published": "20240913T150300",
    "authors": [
      "Urmimala Biswas"
    ],
    "summary": "ISRG, MASI and VCYT from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and wage and supply issues mar the prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/1076.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.192468,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VCYT",
        "relevance_score": "0.146737",
        "ticker_sentiment_score": "0.151013",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MASI",
        "relevance_score": "0.088363",
        "ticker_sentiment_score": "0.123228",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EW",
        "relevance_score": "0.029508",
        "ticker_sentiment_score": "0.014038",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.11763",
        "ticker_sentiment_score": "0.134934",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.029508",
        "ticker_sentiment_score": "0.014038",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.029508",
        "ticker_sentiment_score": "0.014038",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "ONL Therapeutics Closes $65 Million in Oversubscribed Series D Financing",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40850977/onl-therapeutics-closes-65-million-in-oversubscribed-series-d-financing",
    "time_published": "20240913T110047",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "ANN ARBOR, Mich., Sept. 13, 2024 ( GLOBE NEWSWIRE ) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that it has secured $65M in Series D financing.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.229672,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.061473",
        "ticker_sentiment_score": "0.206139",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "These 3 Dividend ETFs Are a Retiree's Best Friend",
    "url": "https://www.fool.com/investing/2024/09/13/these-3-dividend-etfs-are-a-retirees-best-friend/",
    "time_published": "20240913T085000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Retirees can get diversification and solid income from these exchange-traded funds.",
    "banner_image": "https://g.foolcdn.com/editorial/images/790349/etf-board-and-person.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.199131,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.12013",
        "ticker_sentiment_score": "0.185629",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MO",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.114003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.073",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CFG",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.114003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IP",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.114003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.073",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "O",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.044998",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STT",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.067035",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EIX",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.044998",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IBM",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.044998",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.073",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.073",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.044998",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PM",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.114003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XEL",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.044998",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "J&J Announces Promising Phase 1b/2 Data For Amivantamab Combination In Metastatic Colorectal Cancer",
    "url": "https://markets.businessinsider.com/news/stocks/j-j-announces-promising-phase-1b-2-data-for-amivantamab-combination-in-metastatic-colorectal-cancer-1033771648",
    "time_published": "20240914T143916",
    "authors": [
      "markets.businessinsider.com"
    ],
    "summary": "( RTTNews ) - Janssen-Cilag International NV, a Johnson & Johnson ( JNJ ) company, announced new data from the Phase 1b/2 OrigAMI-1 study, which showed amivantamab combined with chemotherapy ( mFOLFOX6 [FOLFOX] or FOLFIRI ) demonstrated promising rapid and durable antitumour activity in patients ...",
    "banner_image": "https://markets.businessinsider.com/Images/FacebookIcon.jpg",
    "source": "Business Insider",
    "category_within_source": "RSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.031514,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.360752",
        "ticker_sentiment_score": "0.191299",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Where Will Merck Stock Be in 5 Years?",
    "url": "https://www.fool.com/investing/2024/09/14/where-will-merck-stock-be-in-5-years/",
    "time_published": "20240914T111500",
    "authors": [
      "Dan Victor"
    ],
    "summary": "This drugmaker faces a key test in the next several years.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F790399%2Fmerck-stock-bullish-outlook-2024.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.313952,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.057628",
        "ticker_sentiment_score": "0.114972",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.057628",
        "ticker_sentiment_score": "0.114972",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMMT",
        "relevance_score": "0.057628",
        "ticker_sentiment_score": "-0.07517",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.057628",
        "ticker_sentiment_score": "0.114972",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Exceeds Market Returns: Some Facts to Consider",
    "url": "https://www.zacks.com/stock/news/2336781/johnson-johnson-jnj-exceeds-market-returns-some-facts-to-consider",
    "time_published": "20240916T214523",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) closed the most recent trading day at $166.99, moving +0.89% from the previous trading session.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default74.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.211671,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.5341",
        "ticker_sentiment_score": "0.252925",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2336352/johnson-johnson-jnj-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20240916T130018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default35.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.250985,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.472338",
        "ticker_sentiment_score": "0.150278",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 American Century Mutual Funds to Buy for Exceptional Returns",
    "url": "https://www.zacks.com/stock/news/2336297/3-american-century-mutual-funds-to-buy-for-exceptional-returns",
    "time_published": "20240916T121600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Invest in American Century mutual funds like BGEIX, AGYWX and ALVDX for strong returns ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d9/554.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.260095,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.070725",
        "ticker_sentiment_score": "0.053221",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.070725",
        "ticker_sentiment_score": "0.053221",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZBH",
        "relevance_score": "0.070725",
        "ticker_sentiment_score": "0.051211",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZIJMY",
        "relevance_score": "0.070725",
        "ticker_sentiment_score": "0.047191",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.070725",
        "ticker_sentiment_score": "0.053221",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KGC",
        "relevance_score": "0.070725",
        "ticker_sentiment_score": "0.047191",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.070725",
        "ticker_sentiment_score": "0.051211",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AEM",
        "relevance_score": "0.070725",
        "ticker_sentiment_score": "0.047191",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.070725",
        "ticker_sentiment_score": "0.051211",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Zacks Industry Outlook Intuitive Surgical, Masimo and Veracyte",
    "url": "https://www.zacks.com/stock/news/2336211/zacks-industry-outlook-intuitive-surgical-masimo-and-veracyte",
    "time_published": "20240916T092500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Intuitive Surgical, Masimo and Veracyte have been highlighted in this Industry Outlook article ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/61/11728.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.19912,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VCYT",
        "relevance_score": "0.163909",
        "ticker_sentiment_score": "0.135863",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MASI",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.085569",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EW",
        "relevance_score": "0.027508",
        "ticker_sentiment_score": "0.063344",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.115027",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.027508",
        "ticker_sentiment_score": "0.063344",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.027508",
        "ticker_sentiment_score": "0.063344",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Mental Health Market to Surpass Market Valuation of USD 544.63 Billion by 2031 | SkyQuest Technology",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40897547/mental-health-market-to-surpass-market-valuation-of-usd-544-63-billion-by-2031-skyquest-technology",
    "time_published": "20240917T123000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Westford, USA, Sept. 17, 2024 ( GLOBE NEWSWIRE ) -- SkyQuest projects that the Global Mental Health Market will reach a value of USD 544.63 Billion by 2031, with a CAGR of 3.5% during the forecast period ( 2024-2031 ) .",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.102378,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WLDS",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "0.153396",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALKS",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JAZZ",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HKMPF",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "ISRG Stock Rallies 14% in 3 Months: Is It Still Worth Buying?",
    "url": "https://www.zacks.com/stock/news/2337049/isrg-stock-rallies-14-in-3-months-is-it-still-worth-buying",
    "time_published": "20240917T121200",
    "authors": [
      "Indrajit Bandyopadhyay"
    ],
    "summary": "Intuitive Surgical is making strides in the robotic-assisted surgery market with its existing and new launches. However, macro challenges are likely to continue to hurt its performance.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/61/11728.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.33291,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MDT",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.277151",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.37102",
        "ticker_sentiment_score": "0.445384",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.277151",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Global Oral Care Market is Expected to Develop at a High 6.4% CAGR through 2031 | SkyQuest Technology",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40896441/global-oral-care-market-is-expected-to-develop-at-a-high-6-4-cagr-through-2031-skyquest-technology",
    "time_published": "20240917T120000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Westford, USA, Sept. 17, 2024 ( GLOBE NEWSWIRE ) -- SkyQuest projects that the Oral Care Market will attain a value of USD 65.54 billion by 2031, with a CAGR of 6.4% over the forecast period ( 2024-2031 ) .",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Mergers",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.445837,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KAOCF",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "0.07593",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "0.07593",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "0.07593",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UL",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "0.07593",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HENKY",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "0.07593",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CL",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "0.07593",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LIOPF",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "0.07593",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MMM",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "0.07593",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ORKLF",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "0.07593",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PHG",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "0.07593",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HAIN",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "0.07593",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PRGO",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "0.07593",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease - AC Immune  ( NASDAQ:ACIU ) ",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40895144/ac-immune-receives-second-milestone-payment-following-progress-in-phase-2b-retain-trial-of-aci-35-",
    "time_published": "20240917T110000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Prescreening rate of Phase 2b ReTain trial triggers clinical development milestone payment in September Potentially registrational trial is targeting enrollment of approximately 500 participants with pre-symptomatic AD FDA Fast Track designation granted in July for ACI-35.030 ( now \"JNJ-2056\" ) ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.16347,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ACIU",
        "relevance_score": "0.293038",
        "ticker_sentiment_score": "0.096752",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.320784",
        "ticker_sentiment_score": "0.141189",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease",
    "url": "https://www.globenewswire.com/news-release/2024/09/17/2947287/0/en/AC-Immune-Receives-Second-Milestone-Payment-Following-Progress-in-Phase-2b-ReTain-Trial-of-ACI-35-030-in-Preclinical-Alzheimer-s-Disease.html",
    "time_published": "20240917T110000",
    "authors": [
      "AC Immune SA"
    ],
    "summary": "AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease \u2022 Potentially registrational trial is targeting enrollment of approximately 500 participants with pre-symptomatic AD \u2022 FDA Fast Track designation granted in ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/0065cdfd-b9fc-4994-8aca-731c1d031b51",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.168082,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ACIU",
        "relevance_score": "0.30021",
        "ticker_sentiment_score": "0.118133",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.30021",
        "ticker_sentiment_score": "0.127876",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results",
    "url": "https://www.globenewswire.com/news-release/2024/09/18/2948605/0/en/NANOBIOTIX-Provides-Business-Update-and-Reports-Half-Year-2024-Financial-Results.html",
    "time_published": "20240918T201500",
    "authors": [
      "Nanobiotix S.A."
    ],
    "summary": "PARIS and CAMBRIDGE, Mass., Sept. 18, 2024 ( GLOBE NEWSWIRE ) -- NANOBIOTIX ( Euronext: NANO - NASDAQ: NBTX - the \"Company\" ) , a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/36fb7b98-27d7-46cb-b989-fa31626657b8",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.928769"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.088609,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NBTX",
        "relevance_score": "0.236352",
        "ticker_sentiment_score": "0.037059",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.036897",
        "ticker_sentiment_score": "0.066952",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:NANO",
        "relevance_score": "0.018454",
        "ticker_sentiment_score": "0.009844",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Octane Medical Innovation Forum to be held on Oct 8-9 in Irvine, California",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40919837/octane-medical-innovation-forum-to-be-held-on-oct-8-9-in-irvine-california",
    "time_published": "20240918T133500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "IRVINE, Calif., Sept. 18, 2024 ( GLOBE NEWSWIRE ) -- via InvestorWire - Octane, an innovative organization building the SoCal of Tomorrow by connecting people, resources and capital to fuel technology growth in Southern California, is pleased to announce that the Octane Medical Innovation Forum ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.434322,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CAUD",
        "relevance_score": "0.025487",
        "ticker_sentiment_score": "0.259217",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.025487",
        "ticker_sentiment_score": "0.054007",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.025487",
        "ticker_sentiment_score": "0.054007",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Onychomycosis Market Forecast to Grow at 4.7% CAGR from 2024 to 2031 | SkyQuest Technology",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40917771/onychomycosis-market-forecast-to-grow-at-4-7-cagr-from-2024-to-2031-skyquest-technology",
    "time_published": "20240918T123000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Westford, USA, Sept. 18, 2024 ( GLOBE NEWSWIRE ) -- Onychomycosis Market size was valued at USD 3.5 billion in 2023 to USD 5.05 billion by 2031, at a CAGR of 4.7% during the forecast period ( 2024-2031 ) .",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Mergers",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.167802,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BAYZF",
        "relevance_score": "0.037741",
        "ticker_sentiment_score": "-0.040093",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.037741",
        "ticker_sentiment_score": "-0.040093",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.037741",
        "ticker_sentiment_score": "-0.040093",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.037741",
        "ticker_sentiment_score": "-0.040093",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHC",
        "relevance_score": "0.037741",
        "ticker_sentiment_score": "-0.040093",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.037741",
        "ticker_sentiment_score": "-0.040093",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.037741",
        "ticker_sentiment_score": "-0.040093",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Erythropoietin Drugs Market Estimated to Reach USD 14.3 billion, Advancing at a CAGR of 3.8% by 2034: Transparency Market Research Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40915965/erythropoietin-drugs-market-estimated-to-reach-usd-14-3-billion-advancing-at-a-cagr-of-3-8-by-2034",
    "time_published": "20240918T110500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research Inc. -, Sept. 18, 2024 ( GLOBE NEWSWIRE ) -- The global erythropoietin drugs market is estimated to surge at a CAGR of 3.8% from 2024 to 2034.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/fccc9f04-9cab-4849-803a-033e04f1e4d8/erythropoietin-drugs-market-outlook-2034.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.303245,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LEIC",
        "relevance_score": "0.037155",
        "ticker_sentiment_score": "0.035945",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.037155",
        "ticker_sentiment_score": "0.051523",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.037155",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.111144",
        "ticker_sentiment_score": "0.057315",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.165165",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.089317",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "FSLA Appoints New Leadership, Highlights Student Initiatives",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40944688/fsla-appoints-new-leadership-highlights-student-initiatives",
    "time_published": "20240919T172219",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "TAMPA, Sept. 19, 2024 ( GLOBE NEWSWIRE ) -- The Florida Surplus Lines Association ( FSLA ) , representing those providing solutions as a safety valve for Florida's insurance industry, installed its new leadership team for the 2024-2025 term during its Annual Convention held in Tampa, Fla.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.263845,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SLB",
        "relevance_score": "0.073546",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.146469",
        "ticker_sentiment_score": "0.150317",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Bavarian Nordic Receives EMA Approval of Mpox Vaccine for Adolescents",
    "url": "https://www.globenewswire.com/news-release/2024/09/19/2949111/0/en/Bavarian-Nordic-Receives-EMA-Approval-of-Mpox-Vaccine-for-Adolescents.html",
    "time_published": "20240919T134500",
    "authors": [
      "Bavarian Nordic A/S"
    ],
    "summary": "COPENHAGEN, Denmark, September 19, 2024 - Bavarian Nordic A/S ( OMX: BAVA ) announced today that the European Commission has adopted the Committee for Medicinal Products for Human Use ( CHMP ) recommendation for the approval of a type II variation for IMVANEX\u00ae ( MVA-BN ) smallpox and mpox ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/bbcf063e-cba2-4e1d-b8cd-9279c8088ae9",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.135359,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BVNKF",
        "relevance_score": "0.049221",
        "ticker_sentiment_score": "0.085209",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.049221",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eyconis, Inc. Announces Appointment of Dr. Mark J. Bachleda as Chief Executive Officer and Member of the Board of Directors",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40936543/eyconis-inc-announces-appointment-of-dr-mark-j-bachleda-as-chief-executive-officer-and-member-of-t",
    "time_published": "20240919T120049",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "REDWOOD CITY, Calif., Sept. 19, 2024 ( GLOBE NEWSWIRE ) -- Eyconis, Inc., a biopharmaceutical company focused on developing novel, best-in-class therapeutics for eye diseases, today announced that Mark J. Bachleda, Pharm.D., MBA, has been appointed as the Company's Chief Executive Officer and a ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.204347,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ASND",
        "relevance_score": "0.100099",
        "ticker_sentiment_score": "0.182163",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GRTX",
        "relevance_score": "0.050148",
        "ticker_sentiment_score": "-0.032658",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.050148",
        "ticker_sentiment_score": "-0.032658",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.050148",
        "ticker_sentiment_score": "-0.032658",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.050148",
        "ticker_sentiment_score": "-0.032658",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "J&J's Rybrevant Receives FDA Nod for Expanded Use in NSCLC",
    "url": "https://www.zacks.com/stock/news/2339452/jjs-rybrevant-receives-fda-nod-for-expanded-use-in-nsclc",
    "time_published": "20240920T173200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "With this approval, JNJ's Rybrevant is now approved for a total of four indications in the United States.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.144372,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ILMN",
        "relevance_score": "0.25168",
        "ticker_sentiment_score": "0.137156",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KRYS",
        "relevance_score": "0.25168",
        "ticker_sentiment_score": "0.071788",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.25168",
        "ticker_sentiment_score": "-0.033755",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson's Rybrevant Scores Third FDA-Approval Of 2024 For Certain Type Of Inoperable Lung Cancer In Pretreated Patients - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/09/40963255/johnson-johnsons-rybrevant-scores-third-fda-approval-of-2024-for-certain-type-of-inoperable-lung-",
    "time_published": "20240920T172915",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Thursday, the FDA approved Johnson & Johnson JNJ Rybrevant ( amivantamab-vmjw ) in combination with standard-of-care chemotherapy ( carboplatin and pemetrexed ) for locally advanced or metastatic non-small cell lung cancer ( NSCLC ) with epidermal growth factor receptor ( EGFR ) exon 19 ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/20/Cancer-Image-by-PDPics-from-Pixabay-.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.116257,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.42503",
        "ticker_sentiment_score": "0.105513",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Johnson & Johnson Stock a Buy?",
    "url": "https://www.fool.com/investing/2024/09/21/is-johnson-johnson-stock-a-buy/",
    "time_published": "20240921T151500",
    "authors": [
      "Dan Victor"
    ],
    "summary": "This healthcare blue chip is making all the right moves to reward shareholders.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F791090%2Fjohnson-johnson-bullish-stock-outlook-2024.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.995921"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.995077"
      }
    ],
    "overall_sentiment_score": 0.375035,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.056275",
        "ticker_sentiment_score": "0.173959",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.427726",
        "ticker_sentiment_score": "0.442931",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "J&J's Subsidiary Red River Talc Files For Chapter 11 Bankruptcy To Resolve Ovarian Cancer Claims",
    "url": "https://markets.businessinsider.com/news/stocks/j-j-s-subsidiary-red-river-talc-files-for-chapter-11-bankruptcy-to-resolve-ovarian-cancer-claims-1033787796",
    "time_published": "20240921T052132",
    "authors": [
      "markets.businessinsider.com"
    ],
    "summary": "( RTTNews ) - Johnson & Johnson ( JNJ ) announced that its subsidiary, Red River Talc LLC, has voluntarily filed for a prepackaged Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the Southern District of Texas.",
    "banner_image": "https://markets.businessinsider.com/Images/FacebookIcon.jpg",
    "source": "Business Insider",
    "category_within_source": "RSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.102773,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.592095",
        "ticker_sentiment_score": "-0.553799",
        "ticker_sentiment_label": "Bearish"
      }
    ]
  },
  {
    "title": "Adobe Dips 12.4% YTD: Can ADBE Stock Rebound on GenAI Strength? - IBM  ( NYSE:IBM ) , Adobe  ( NASDAQ:ADBE ) ",
    "url": "https://www.benzinga.com/news/earnings/24/09/40987828/adobe-dips-12-4-ytd-can-adbe-stock-rebound-on-genai-strength",
    "time_published": "20240923T201108",
    "authors": [
      "Zacks"
    ],
    "summary": "Adobe ADBE, a titan in the Portable Document Format ( PDF ) technology, has been facing macroeconomic and competitive challenges this year, with its stock price plummeting 12.4% in the year-to-date period against the Zacks Computer-Software industry, the broader technology sector and the S&P 500 ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/charts/c9/78842.jpg?v=1570621114",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.329542,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.0864",
        "ticker_sentiment_score": "0.195087",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.043264",
        "ticker_sentiment_score": "0.154431",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NWL",
        "relevance_score": "0.043264",
        "ticker_sentiment_score": "0.154431",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IBM",
        "relevance_score": "0.0864",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.043264",
        "ticker_sentiment_score": "0.154431",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ADBE",
        "relevance_score": "0.671179",
        "ticker_sentiment_score": "0.355236",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "DNTUF",
        "relevance_score": "0.043264",
        "ticker_sentiment_score": "0.154431",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SCHW",
        "relevance_score": "0.043264",
        "ticker_sentiment_score": "0.154431",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PEP",
        "relevance_score": "0.043264",
        "ticker_sentiment_score": "0.154431",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.043264",
        "ticker_sentiment_score": "0.154431",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Files for Bankruptcy Over Talc Lawsuits for the Third Time",
    "url": "https://www.zacks.com/stock/news/2340100/johnson-johnson-files-for-bankruptcy-over-talc-lawsuits-for-the-third-time",
    "time_published": "20240923T190000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The higher settlement offer and a high percentage of claimant support may improve JNJ's chances of success after the previous two failures.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.031987,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.211191",
        "ticker_sentiment_score": "0.098272",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.211191",
        "ticker_sentiment_score": "0.098272",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.538639",
        "ticker_sentiment_score": "-0.055105",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Adobe Dips 12.4% YTD: Can ADBE Stock Rebound on GenAI Strength?",
    "url": "https://www.zacks.com/stock/news/2340074/adobe-dips-124-ytd-can-adbe-stock-rebound-on-genai-strength",
    "time_published": "20240923T165300",
    "authors": [
      "Shilpa Mete"
    ],
    "summary": "ADBE's growing generative AI capabilities boost its prospects and drive customer momentum amid macro headwinds.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2b/4052.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.294273,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "0.26708",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.044304",
        "ticker_sentiment_score": "0.174715",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NWL",
        "relevance_score": "0.044304",
        "ticker_sentiment_score": "0.174715",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IBM",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.044304",
        "ticker_sentiment_score": "0.174715",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ADBE",
        "relevance_score": "0.625937",
        "ticker_sentiment_score": "0.388352",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "DNTUF",
        "relevance_score": "0.044304",
        "ticker_sentiment_score": "0.174715",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PEP",
        "relevance_score": "0.044304",
        "ticker_sentiment_score": "0.174715",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.044304",
        "ticker_sentiment_score": "0.174715",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "0.183435",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Stock Drops Despite Market Gains: Important Facts to Note",
    "url": "https://www.zacks.com/stock/news/2340840/johnson-johnson-jnj-stock-drops-despite-market-gains-important-facts-to-note",
    "time_published": "20240924T214519",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) closed at $162.78 in the latest trading session, marking a -0.27% move from the prior day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default114.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      }
    ],
    "overall_sentiment_score": 0.213693,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.571686",
        "ticker_sentiment_score": "0.299318",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "What's Going On With ACADIA Pharmaceuticals Stock? - ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) ",
    "url": "https://www.benzinga.com/news/24/09/41011838/whats-going-on-with-acadia-pharmaceuticals-stock",
    "time_published": "20240924T174428",
    "authors": [
      "Henry Khederian"
    ],
    "summary": "ACADIA Pharmaceuticals Inc ACAD shares are trading lower by 4.11% to $15.62 during Tuesday's session after the company appointed Catherine Owen Adams as CEO. What Happened: Acadia Pharmaceuticals announced that Catherine Owen Adams has succeeded Steve Davis as CEO and joined the board of ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/24/doctor-2568481.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.332435,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ACAD",
        "relevance_score": "0.530253",
        "ticker_sentiment_score": "0.375724",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NYMT",
        "relevance_score": "0.095899",
        "ticker_sentiment_score": "0.101963",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.095899",
        "ticker_sentiment_score": "0.164443",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.095899",
        "ticker_sentiment_score": "0.164443",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Files for Bankruptcy Over Talc Lawsuits for the Third Time - Bayer  ( OTC:BAYRY ) , Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/09/40991131/johnson-johnson-files-for-bankruptcy-over-talc-lawsuits-for-the-third-time",
    "time_published": "20240924T155553",
    "authors": [
      "Zacks"
    ],
    "summary": "Johnson & Johnson JNJ, via its subsidiary called Red River Talc, for the third time, filed for voluntary bankruptcy to resolve thousands of lawsuits related to its talc products.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/charts/52/78741.jpg?v=633076405",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.071284,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.201944",
        "ticker_sentiment_score": "0.141684",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.152178",
        "ticker_sentiment_score": "0.116441",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.518333",
        "ticker_sentiment_score": "-0.053958",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "J&J Seeks 3rd Talc-Related Bankruptcy: Time to Sell the Stock?",
    "url": "https://www.zacks.com/stock/news/2340436/jj-seeks-3rd-talc-related-bankruptcy-time-to-sell-the-stock",
    "time_published": "20240924T131100",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "We suggest a new investor should avoid buying JNJ's stock now due to uncertainty surrounding its legal battles.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.955357"
      }
    ],
    "overall_sentiment_score": 0.097438,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.097721",
        "ticker_sentiment_score": "0.109881",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.065238",
        "ticker_sentiment_score": "0.213554",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.097721",
        "ticker_sentiment_score": "-0.142317",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cancer Supportive Care Product Market is Set to Surge at 6.9% CAGR, to Reach US$ 68.93 Billion by 2034 | Fact.MR",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40997521/cancer-supportive-care-product-market-is-set-to-surge-at-6-9-cagr-to-reach-us-68-93-billion-by-203",
    "time_published": "20240924T100000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Rockville, MD, Sept. 24, 2024 ( GLOBE NEWSWIRE ) -- In its new study, Fact.MR states that the global cancer supportive care product market is estimated to reach a value of US$ 35.47 billion in 2024 and thereafter advance at a CAGR of 6.9% from 2024 to 2034.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/4051ce21-f8ad-45c0-a815-b601fdab078e/cancer-supportive-care-product-market.jpg",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.279437,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "-0.013415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "-0.013415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "-0.013415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAX",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "-0.013415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "-0.013415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "-0.013415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WLDS",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "0.551007",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "-0.013415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "-0.013415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HRTX",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "-0.013415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "-0.013415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "-0.013415",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Masimo Stock Crushed the Market Today",
    "url": "https://www.fool.com/investing/2024/09/25/why-masimo-stock-crushed-the-market-today/",
    "time_published": "20240925T224548",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "The company seems to be effecting a smooth transition in its leadership.",
    "banner_image": "https://g.foolcdn.com/editorial/images/791931/illuminated-exit-sign.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.271503,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MASI",
        "relevance_score": "0.730535",
        "ticker_sentiment_score": "0.315074",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "0.327495",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KFY",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "0.083529",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "RenovoRx Increases Production of FDA-Cleared RenovoCath\u00ae Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians - RenovoRx  ( NASDAQ:RNXT ) ",
    "url": "https://www.benzinga.com/pressreleases/24/09/g41023238/renovorx-increases-production-of-fda-cleared-renovocath-delivery-system-in-response-to-strong-dema",
    "time_published": "20240925T123000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LOS ALTOS, Calif., Sept. 25, 2024 ( GLOBE NEWSWIRE ) -- RenovoRx, Inc. ( \"RenovoRx\" or the \"Company\" ) RNXT, a life sciences company developing novel targeted oncology therapies based on a local drug-delivery platform, today announced that it is increasing the production of its FDA-cleared ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.16925,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.018327",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.018327",
        "ticker_sentiment_score": "0.043604",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RNXT",
        "relevance_score": "0.28678",
        "ticker_sentiment_score": "0.209923",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.018327",
        "ticker_sentiment_score": "0.043604",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff - Sanofi  ( NASDAQ:SNY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/09/41021471/private-equity-firms-circle-sanofis-consumer-health-business-amid-potential-spinoff",
    "time_published": "20240925T111854",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "In October 2023, Sanofi SA SNY announced its plans to spin off its consumer healthcare business as the French pharmaceutical company outlined its strategic update to increase investment in its drug-development pipeline and cut costs.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/25/Sanofi-OTC-Photo-via-Company.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.183248,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MS",
        "relevance_score": "0.192694",
        "ticker_sentiment_score": "0.009393",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.192694",
        "ticker_sentiment_score": "-0.116559",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.192694",
        "ticker_sentiment_score": "-0.116559",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HLN",
        "relevance_score": "0.192694",
        "ticker_sentiment_score": "-0.116559",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.192694",
        "ticker_sentiment_score": "0.009393",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GSK",
        "relevance_score": "0.192694",
        "ticker_sentiment_score": "-0.116559",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.606706",
        "ticker_sentiment_score": "0.181116",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off",
    "url": "https://www.fool.com/investing/2024/09/25/2-unstoppable-dividend-stocks-to-buy-if-a-selloff/",
    "time_published": "20240925T103500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "These dividend players could lift your portfolio no matter what the market is doing.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F791677%2Fgettyimages-an-investor-reads-something-on-his-phone.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99393"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928769"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.359918,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "0.372902",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Wound Cleanser Product Market to Surpass US$ 2.24 Billion, Expanding at a 1.4% CAGR by 2034: Fact.MR",
    "url": "https://www.benzinga.com/pressreleases/24/09/g41020148/wound-cleanser-product-market-to-surpass-us-2-24-billion-expanding-at-a-1-4-cagr-by-2034-fact-mr",
    "time_published": "20240925T100000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Rockville, MD, Sept. 25, 2024 ( GLOBE NEWSWIRE ) -- According to a new industry report released by Fact.MR, the global wound cleanser product market is estimated at US$ 1.96 billion in 2024 and is forecasted to reach US$ 2.24 billion by the end of 2034.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/a8bd69b4-2acf-40df-b810-366a1f1a2ed6/wound-cleanser-product-market.jpg",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.223552,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IART",
        "relevance_score": "0.038717",
        "ticker_sentiment_score": "-0.074152",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMTI",
        "relevance_score": "0.077343",
        "ticker_sentiment_score": "0.12272",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLPBY",
        "relevance_score": "0.077343",
        "ticker_sentiment_score": "-0.077932",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.038717",
        "ticker_sentiment_score": "-0.074152",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.038717",
        "ticker_sentiment_score": "-0.074152",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio\u00ae",
    "url": "https://www.globenewswire.com/news-release/2024/09/25/2952754/0/en/Alvotech-Initiates-Confirmatory-Patient-Study-for-AVT16-a-Proposed-Biosimilar-to-Entyvio.html",
    "time_published": "20240925T090100",
    "authors": [
      "Alvotech"
    ],
    "summary": "Alvotech ( NASDAQ: ALVO ) , a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of a confirmatory patient study for AVT16, a biosimilar candidate to Entyvio\u00ae ( vedolizumab ) .",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.130113,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALVO",
        "relevance_score": "0.460754",
        "ticker_sentiment_score": "0.214547",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.022264",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.022264",
        "ticker_sentiment_score": "0.064492",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.022264",
        "ticker_sentiment_score": "0.064492",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.022264",
        "ticker_sentiment_score": "0.064492",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.022264",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio\u00ae",
    "url": "https://www.globenewswire.com/news-release/2024/09/25/2952753/0/en/Alvotech-Initiates-Confirmatory-Patient-Study-for-AVT16-a-Proposed-Biosimilar-to-Entyvio.html",
    "time_published": "20240925T090000",
    "authors": [
      "Alvotech"
    ],
    "summary": "REYKJAVIK, Iceland, Sept. 25, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO ) , a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of a confirmatory patient study for AVT16, a biosimilar ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.127743,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.021978",
        "ticker_sentiment_score": "0.091919",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.021978",
        "ticker_sentiment_score": "0.091919",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.021978",
        "ticker_sentiment_score": "0.063462",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.021978",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.455525",
        "ticker_sentiment_score": "0.210099",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.021978",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.021978",
        "ticker_sentiment_score": "0.063462",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.021978",
        "ticker_sentiment_score": "0.063462",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Diabetic Neuropathy Market Size Set to Hit USD 8.5 Billion by 2034 with a 5.5% CAGR, Boosted by Biomarker-based Diagnostics and Stem Cell Therapy - Analysis by Transparency Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/09/g41051355/diabetic-neuropathy-market-size-set-to-hit-usd-8-5-billion-by-2034-with-a-5-5-cagr-boosted-by-biom",
    "time_published": "20240926T160636",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research, Inc., Sept. 26, 2024 ( GLOBE NEWSWIRE ) -- The diabetic neuropathy market ( \u0633\u0648\u0642 \u0627\u0644\u0627\u0639\u062a\u0644\u0627\u0644 \u0627\u0644\u0639\u0635\u0628\u064a \u0627\u0644\u0633\u0643\u0631\u064a ) was worth US$ 4.6 billion in 2023. A 5.5% CAGR is estimated from 2024 to 2034, leading to a market value of US$ 8.5 billion ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/7ba839aa-1ed6-4bbe-9600-8ce06518e1df/diabetic-neuropathy-market.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.254318,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NURO",
        "relevance_score": "0.033098",
        "ticker_sentiment_score": "0.06962",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALPMF",
        "relevance_score": "0.033098",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.033098",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.099066",
        "ticker_sentiment_score": "0.090806",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.033098",
        "ticker_sentiment_score": "0.196679",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.033098",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "In-Depth Analysis: Johnson & Johnson Versus Competitors In Pharmaceuticals Industry - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/news/24/09/41049607/in-depth-analysis-johnson-amp-johnson-versus-competitors-in-pharmaceuticals-industry",
    "time_published": "20240926T150049",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In today's rapidly evolving and fiercely competitive business landscape, it is crucial for investors and industry analysts to conduct comprehensive company evaluations. In this article, we will undertake an in-depth industry comparison, assessing Johnson & Johnson JNJ alongside its primary ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1727362846_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.190864,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.068698",
        "ticker_sentiment_score": "0.041102",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.453789",
        "ticker_sentiment_score": "0.261206",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "International Myeloma Foundation to Hold First Latin American Myeloma Network Summit in Brazil on September 28",
    "url": "https://www.benzinga.com/pressreleases/24/09/g41045878/international-myeloma-foundation-to-hold-first-latin-american-myeloma-network-summit-in-brazil-on-",
    "time_published": "20240926T124500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "RIO DE JANEIRO, Brazil, Sept. 26, 2024 ( GLOBE NEWSWIRE ) -- The International Myeloma Foundation ( IMF ) is proud to announce that the inaugural IMF Latin American Myeloma Network ( LAMN ) Summit will be held on Saturday, September 28, from 3pm - 7pm, after the International Myeloma Society ( ...",
    "banner_image": "https://ml.globenewswire.com/media/f70068f9-568b-4858-8283-3c96a2db91d6/small/imf-logo-png.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.983605"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.159738,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.036365",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.036365",
        "ticker_sentiment_score": "0.123094",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.036365",
        "ticker_sentiment_score": "0.123094",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.036365",
        "ticker_sentiment_score": "0.123094",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "SPAC King Chamath Palihapitiya Forecasts How AI Will Transform Healthcare Sector: 'It's Not All Roses, But Some Areas\u2026Are Just Bananas'",
    "url": "https://www.benzinga.com/news/24/09/41038801/spac-king-chamath-palihapitiya-forecasts-how-ai-will-transform-healthcare-sector-its-not-all-roses-b",
    "time_published": "20240926T042203",
    "authors": [
      "Ananya Gairola"
    ],
    "summary": "Chamath Palihapitiya, the billionaire investor and former Facebook executive, has shared his insights on the potential of artificial intelligence to revolutionize the healthcare industry.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/26/Chamath-Palihapitiya.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.048851,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.320525",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.110579",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.100302",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.110579",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CARVYKTI\u00ae is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line",
    "url": "https://www.globenewswire.com/news-release/2024/09/27/2954711/0/en/CARVYKTI-is-the-First-and-Only-Cell-Therapy-to-Significantly-Extend-Overall-Survival-Compared-to-Standard-of-Care-in-Patients-with-Multiple-Myeloma-as-Early-as-Second-Line.html",
    "time_published": "20240927T203500",
    "authors": [
      "Legend Biotech USA Inc."
    ],
    "summary": "SOMERSET, N.J., Sept. 27, 2024 ( GLOBE NEWSWIRE ) -- Legend Biotech Corporation ( NASDAQ: LEGN ) ( Legend Biotech ) , a global leader in cell therapy, today announced late-breaking three-year follow-up data from the Phase 3 CARTITUDE-4 study that shows a single infusion of CARVYKTI\u00ae ( ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/d3a680c2-cab6-4eb2-9ed0-7be055f9e180",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": -0.095282,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.016383",
        "ticker_sentiment_score": "0.055516",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LEGN",
        "relevance_score": "0.065461",
        "ticker_sentiment_score": "0.017123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRGNF",
        "relevance_score": "0.008192",
        "ticker_sentiment_score": "-0.006369",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Reports Updated Data From Two Early-Stage Multiple Myeloma Studies Of Talvey Combo Treatment - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/09/41070806/johnson-johnson-reports-updated-data-from-two-early-stage-multiple-myeloma-studies-of-talvey-comb",
    "time_published": "20240927T161449",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Friday, Johnson & Johnson JNJ released updated results from the investigational Phase 1b RedirecTT-1 study evaluating the combination of Talvey ( talquetamab ) and Tecvayli ( teclistamab ) in patients with relapsed or refractory multiple myeloma.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/27/jnj-johnson-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.154432,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.42503",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  is Attracting Investor Attention: Here is What You Should Know",
    "url": "https://www.zacks.com/stock/news/2342455/johnson-johnson-jnj-is-attracting-investor-attention-here-is-what-you-should-know",
    "time_published": "20240927T130018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default197.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.228434,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.472338",
        "ticker_sentiment_score": "0.140955",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eyewear Market to Surpass Market Valuation of USD 357.1 Billion by 2031 | SkyQuest Technology",
    "url": "https://www.benzinga.com/pressreleases/24/09/g41066388/eyewear-market-to-surpass-market-valuation-of-usd-357-1-billion-by-2031-skyquest-technology",
    "time_published": "20240927T130000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Westford, USA, Sept. 27, 2024 ( GLOBE NEWSWIRE ) -- SkyQuest projects that the Global Eyewear Market will reach a value of USD 357.1 Billion by 2031, with a CAGR of 8.4% during the forecast period ( 2024-2031 ) .",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.421423,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.03786",
        "ticker_sentiment_score": "0.113908",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Vanguard ETFs That Dividend Investors Can Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/09/27/2-vanguard-etfs-dividend-investors-can-buy-and-hol/",
    "time_published": "20240927T092600",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Dividend-focused funds can ensure you're collecting money on a recurring basis while keeping your risk low.",
    "banner_image": "https://g.foolcdn.com/editorial/images/791617/a-couple-meeting-with-an-advisor.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.254171,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "UNH",
        "relevance_score": "0.068698",
        "ticker_sentiment_score": "0.156672",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.068698",
        "ticker_sentiment_score": "0.156672",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.068698",
        "ticker_sentiment_score": "0.086271",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.068698",
        "ticker_sentiment_score": "0.086271",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.068698",
        "ticker_sentiment_score": "0.086271",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Excellent Dividend Stocks to Buy With Less Than $200",
    "url": "https://www.fool.com/investing/2024/09/28/2-excellent-dividend-stocks-to-buy-with-less-than/",
    "time_published": "20240928T090000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "Abbott Laboratories and Johnson & Johnson both have raised their dividends annually for more than 50 years.",
    "banner_image": "https://media.ycharts.com/charts/f09d2b0e2d98551346d9b46063a4402f.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.244485,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.25726",
        "ticker_sentiment_score": "0.311586",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.306325",
        "ticker_sentiment_score": "0.184425",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The Stock Market's as Strong as It's Ever Been, but There's a Catch",
    "url": "https://www.fool.com/investing/2024/09/29/the-stock-markets-as-strong-as-its-ever-been-but-t/",
    "time_published": "20240929T120500",
    "authors": [
      "James Brumley"
    ],
    "summary": "The market's also more prone to prolonged periods of underperformance than it's been in the past.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F791936%2F092524-sp500-rolling-average-annual-gains.png&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.995973"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.141034,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BBBYQ",
        "relevance_score": "0.035138",
        "ticker_sentiment_score": "0.034706",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CHTR",
        "relevance_score": "0.035138",
        "ticker_sentiment_score": "0.019147",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.035138",
        "ticker_sentiment_score": "0.148978",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.035138",
        "ticker_sentiment_score": "0.148978",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients - Legend Biotech  ( NASDAQ:LEGN ) , Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41093953/johnson-johnson-legend-biotech-partnered-blood-cancer-drug-extends-overall-survival",
    "time_published": "20240930T134737",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Friday, Legend Biotech Corporation LEGN and Johnson & Johnson JNJ announced late-breaking three-year follow-up data from the Phase 3 CARTITUDE-4 study.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/30/pharma-lab-worker-ai.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.076069,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.16117",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LEGN",
        "relevance_score": "0.239698",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is the Vanguard Value ETF a Millionaire Maker?",
    "url": "https://www.fool.com/investing/2024/09/30/is-the-vanguard-value-etf-a-millionaire-maker/",
    "time_published": "20240930T131400",
    "authors": [
      "James Brumley"
    ],
    "summary": "Value stocks never became wholly un-investable, but they're certainly more attractive now than they've been in some time.",
    "banner_image": "https://media.ycharts.com/charts/5e3cb12a2843fe54db434c46a1d2f7dc.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999346"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.337704,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BAC",
        "relevance_score": "0.042271",
        "ticker_sentiment_score": "0.257343",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.042271",
        "ticker_sentiment_score": "0.257343",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "15 Best Dividend Stocks for Lifelong Passive Income",
    "url": "https://www.fool.com/investing/2024/09/30/15-best-dividend-stocks-for-lifelong-passive-incom/",
    "time_published": "20240930T101500",
    "authors": [
      "George Budwell"
    ],
    "summary": "These 15 dividend stocks can deliver stable passive income for life.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F792319%2Fgrowth.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.865346"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.472024,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TGT",
        "relevance_score": "0.124164",
        "ticker_sentiment_score": "0.218295",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MO",
        "relevance_score": "0.124164",
        "ticker_sentiment_score": "0.247106",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.124164",
        "ticker_sentiment_score": "0.221423",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.082963",
        "ticker_sentiment_score": "0.253685",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.082963",
        "ticker_sentiment_score": "0.331384",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.124164",
        "ticker_sentiment_score": "0.274812",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "O",
        "relevance_score": "0.082963",
        "ticker_sentiment_score": "0.225766",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.124164",
        "ticker_sentiment_score": "0.090333",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "T",
        "relevance_score": "0.124164",
        "ticker_sentiment_score": "0.218615",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "V",
        "relevance_score": "0.124164",
        "ticker_sentiment_score": "0.207667",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.205458",
        "ticker_sentiment_score": "0.302178",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PEP",
        "relevance_score": "0.124164",
        "ticker_sentiment_score": "-0.049878",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PM",
        "relevance_score": "0.124164",
        "ticker_sentiment_score": "0.312981",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Veterinary Arthroscopy Device Market is Predicted to Reach US$ 721.9 Billion by 2034 | Fact.MR Report",
    "url": "https://www.benzinga.com/pressreleases/24/09/g41087297/veterinary-arthroscopy-device-market-is-predicted-to-reach-us-721-9-billion-by-2034-fact-mr-report",
    "time_published": "20240930T100000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Rockville, MD, Sept. 30, 2024 ( GLOBE NEWSWIRE ) -- According to a new research report by Fact.MR, the global veterinary arthroscopy device market is expected to reach US$ 401 million in 2024 and is further projected to expand at 6.1% CAGR from 2024 to 2034.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/a7b0d67d-b6c0-490c-b385-0470d327cb59/veterinary-arthroscopy-device-market.jpg",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.346025,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IART",
        "relevance_score": "0.036587",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.036587",
        "ticker_sentiment_score": "0.308225",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CNMD",
        "relevance_score": "0.036587",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.036587",
        "ticker_sentiment_score": "-0.061983",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Trocars Market is expected to generate a revenue of USD 1.19 Billion by 2031, Globally, at 6.1% CAGR: Verified Market Research\u00ae",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41120048/trocars-market-is-expected-to-generate-a-revenue-of-usd-1-19-billion-by-2031-globally-at-6-1-cagr-",
    "time_published": "20241001T141500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Lewes, Delaware, Oct. 01, 2024 ( GLOBE NEWSWIRE ) -- The Global Trocars Market Size is projected to grow at a CAGR of 6.1% from 2024 to 2031, according to a new report published by Verified Market Research\u00ae.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/f0603937-7e17-4165-961f-053ff56023b5/trocars-market-1024x576.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.254192,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "COO",
        "relevance_score": "0.025219",
        "ticker_sentiment_score": "0.055766",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.025219",
        "ticker_sentiment_score": "0.055766",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CNMD",
        "relevance_score": "0.025219",
        "ticker_sentiment_score": "0.055766",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.025219",
        "ticker_sentiment_score": "0.055766",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RSSS",
        "relevance_score": "0.025219",
        "ticker_sentiment_score": "0.166446",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TFX",
        "relevance_score": "0.025219",
        "ticker_sentiment_score": "0.055766",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions - AstraZeneca  ( NASDAQ:AZN ) , Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/partner/biotech/24/10/41114297/the-rush-for-non-addictive-painkillers-to-counter-the-opioid-crisis-puts-two-companies-closer-to-",
    "time_published": "20241001T113000",
    "authors": [
      "Mangeet Kaur Bouns"
    ],
    "summary": "This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/01/Screenshot-2024-09-30-at-9-13-36PM.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": -0.201281,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.048621",
        "ticker_sentiment_score": "-0.09299",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.048621",
        "ticker_sentiment_score": "-0.107931",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.048621",
        "ticker_sentiment_score": "-0.09299",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TNXP",
        "relevance_score": "0.121159",
        "ticker_sentiment_score": "-0.019561",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.097062",
        "ticker_sentiment_score": "-0.101306",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.048621",
        "ticker_sentiment_score": "-0.09299",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nxera Pharma Appoints Experienced Commercial R&D Executive Makoto Sugita as Chief Medical Officer and President of Nxera Pharma Japan",
    "url": "https://www.globenewswire.com/news-release/2024/10/01/2955788/0/en/Nxera-Pharma-Appoints-Experienced-Commercial-R-D-Executive-Makoto-Sugita-as-Chief-Medical-Officer-and-President-of-Nxera-Pharma-Japan.html",
    "time_published": "20241001T060400",
    "authors": [
      "Nxera Pharma"
    ],
    "summary": "Tokyo, Japan and Cambridge, UK, 1 October 2024 - Nxera Pharma Co., Ltd. ( \"Nxera\" or \"the Company\". TSE 4565 ) - formerly known as Sosei Group or Sosei Heptares - today announces the appointment of Dr. Makoto Sugita, M.D., Ph.D., MBA, as President of Nxera Pharma Japan, and Executive Officer, ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/5cc74d52-c86f-4e21-8684-3496281fee15",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.22407,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SOLTF",
        "relevance_score": "0.161349",
        "ticker_sentiment_score": "-0.001346",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.054114",
        "ticker_sentiment_score": "-0.014984",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.107978",
        "ticker_sentiment_score": "-0.02205",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.054114",
        "ticker_sentiment_score": "-0.014984",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson's Options: A Look at What the Big Money is Thinking - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/options/24/10/41147214/johnson-johnsons-options-a-look-at-what-the-big-money-is-thinking",
    "time_published": "20241002T171700",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bearish move on Johnson & Johnson. Our analysis of options history for Johnson & Johnson JNJ revealed 8 unusual trades. Delving into the details, we found 25% of traders were bullish, while 75% showed bearish tendencies.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1727889417_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.059893,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.074001",
        "ticker_sentiment_score": "0.041289",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.542539",
        "ticker_sentiment_score": "0.106453",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson's Erleada Shows Improved Overall Survival In Prostate Cancer Patients Compared To Pfizer's Drug - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41143856/johnson-johnsons-erleada-shows-improved-overall-survival-in-prostate-cancer-patients-compared-to-",
    "time_published": "20241002T150022",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Wednesday, Johnson & Johnson JNJ revealed results from a head-to-head study of Erleada ( apalutamide ) compared to Pfizer Inc's PFE Xtandi ( enzalutamide ) .",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/02/cancer.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.139946,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.24289",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.463792",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares U.S. Healthcare ETF  ( IYH ) ?",
    "url": "https://www.zacks.com/stock/news/2344495/should-you-invest-in-the-ishares-us-healthcare-etf-iyh",
    "time_published": "20241002T102008",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default59.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.217119,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.08818",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.13347",
        "ticker_sentiment_score": "0.070004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.13347",
        "ticker_sentiment_score": "0.070004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.13347",
        "ticker_sentiment_score": "0.070004",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Health Care Select Sector SPDR ETF  ( XLV ) ?",
    "url": "https://www.zacks.com/stock/news/2344496/should-you-invest-in-the-health-care-select-sector-spdr-etf-xlv",
    "time_published": "20241002T102008",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default259.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.276668,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.128822",
        "ticker_sentiment_score": "0.064107",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.064623",
        "ticker_sentiment_score": "0.127463",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STT",
        "relevance_score": "0.064623",
        "ticker_sentiment_score": "0.089081",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.128822",
        "ticker_sentiment_score": "0.064107",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.128822",
        "ticker_sentiment_score": "0.064107",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Johnson & Johnson  ( JNJ )  Dipped More Than Broader Market Today",
    "url": "https://www.zacks.com/stock/news/2345682/why-johnson-johnson-jnj-dipped-more-than-broader-market-today",
    "time_published": "20241003T214520",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) concluded the recent trading session at $160.50, signifying a -0.42% move from its prior day's close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default71.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.117605,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.514619",
        "ticker_sentiment_score": "0.109287",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Topical Drug Delivery Market is expected to generate a revenue of USD 177.97 Billion by 2031, Globally, at 6.3% CAGR: Verified Market Research\u00ae",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41165822/topical-drug-delivery-market-is-expected-to-generate-a-revenue-of-usd-177-97-billion-by-2031-globa",
    "time_published": "20241003T141500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Lewes, Delaware, Oct. 03, 2024 ( GLOBE NEWSWIRE ) -- The Global Topical Drug Delivery Market Size is projected to grow at a CAGR of 6.3% from 2024 to 2031, according to a new report published by Verified Market Research\u00ae.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/1509c540-c15c-4f3d-b040-0f8c2795e7a2/topical-drug-delivery-market-size-and-forecast-1024x576.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.256044,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BAYZF",
        "relevance_score": "0.024322",
        "ticker_sentiment_score": "-0.012949",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.024322",
        "ticker_sentiment_score": "-0.012949",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RSSS",
        "relevance_score": "0.024322",
        "ticker_sentiment_score": "0.165824",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.024322",
        "ticker_sentiment_score": "-0.012949",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHC",
        "relevance_score": "0.024322",
        "ticker_sentiment_score": "-0.012949",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MMM",
        "relevance_score": "0.024322",
        "ticker_sentiment_score": "-0.012949",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSOI",
        "relevance_score": "0.024322",
        "ticker_sentiment_score": "0.249164",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41189182/johnson-johnson-ends-phase-2-study-for-dengue-antiviral-amid-r-d-reprioritization",
    "time_published": "20241004T164613",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Friday, Johnson & Johnson JNJ announced discontinuing the Phase 2 field study evaluating the efficacy of investigational antiviral candidate mosnodenvir to prevent dengue virus in adults aged 18-65.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/04/jnj-johnson-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.103853,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.656549",
        "ticker_sentiment_score": "0.070176",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.472338",
        "ticker_sentiment_score": "-0.073191",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Smart Income Stocks to Buy Right Now",
    "url": "https://www.fool.com/investing/2024/10/04/2-smart-income-stocks-to-buy-right-now/",
    "time_published": "20241004T092000",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "These storied companies have a lot to offer different investors.",
    "banner_image": "https://g.foolcdn.com/editorial/images/792524/young-businesswoman-with-laptop-in-meeting-smiling.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.623304"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.268537,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KO",
        "relevance_score": "0.349945",
        "ticker_sentiment_score": "0.30097",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.266343",
        "ticker_sentiment_score": "0.134284",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Dividend Growth ETFs That You Can Count on for Recurring Income for Decades",
    "url": "https://www.fool.com/investing/2024/10/04/dividend-growth-etf-count-on-recurring-income/",
    "time_published": "20241004T091000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "These funds invest in stocks that have proven track records for dividend growth.",
    "banner_image": "https://media.ycharts.com/charts/afb38536c14f73ada428b1b6387fd2f2.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99737"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.34457,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.152018",
        "ticker_sentiment_score": "0.091278",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.076358",
        "ticker_sentiment_score": "0.051513",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.076358",
        "ticker_sentiment_score": "0.10163",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WT",
        "relevance_score": "0.434763",
        "ticker_sentiment_score": "0.300033",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.076358",
        "ticker_sentiment_score": "0.10163",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Optinose Appoints Terry Kohler as Chief Financial Officer",
    "url": "https://www.globenewswire.com/news-release/2024/10/07/2959340/0/en/Optinose-Appoints-Terry-Kohler-as-Chief-Financial-Officer.html",
    "time_published": "20241007T205900",
    "authors": [
      "OptiNose",
      "Inc."
    ],
    "summary": "YARDLEY, Pa., Oct. 07, 2024 ( GLOBE NEWSWIRE ) -- Optinose ( NASDAQ:OPTN ) , a pharmaceutical company focused on patients treated by ear, nose and throat ( ENT ) and allergy specialists, today announced the appointment of Terry Kohler as Chief Financial Officer.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/738ec635-d235-4c49-8d39-0a5636a4b767",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999995"
      }
    ],
    "overall_sentiment_score": 0.058264,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "OPTN",
        "relevance_score": "0.141726",
        "ticker_sentiment_score": "0.168725",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRCA",
        "relevance_score": "0.056943",
        "ticker_sentiment_score": "-0.001",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.02849",
        "ticker_sentiment_score": "-0.029958",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should JNJ Stock Be in Your Portfolio Ahead of Q3 Earnings?",
    "url": "https://www.zacks.com/stock/news/2347080/should-jnj-stock-be-in-your-portfolio-ahead-of-q3-earnings",
    "time_published": "20241007T190000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. It remains to be seen if MedTech sales improved.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.990678"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      }
    ],
    "overall_sentiment_score": 0.194534,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.073434",
        "ticker_sentiment_score": "0.158442",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.073434",
        "ticker_sentiment_score": "0.194941",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.217834",
        "ticker_sentiment_score": "0.16237",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Scraps Phase II Study on Antiviral for Dengue Virus",
    "url": "https://www.zacks.com/stock/news/2347027/johnson-johnson-scraps-phase-ii-study-on-antiviral-for-dengue-virus",
    "time_published": "20241007T165900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "As part of the strategic re-prioritization, JNJ terminates the phase II field study on mosnodenvir for the prevention of the dengue virus.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.9545"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.11554,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ANIP",
        "relevance_score": "0.291471",
        "ticker_sentiment_score": "0.319843",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BVS",
        "relevance_score": "0.359707",
        "ticker_sentiment_score": "0.291098",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.59972",
        "ticker_sentiment_score": "-0.076683",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth - Galapagos  ( NASDAQ:GLPG ) ",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41200334/galapagos-welcomes-oleg-nodelman-to-its-board-of-directors-to-support-strategic-growth",
    "time_published": "20241007T050000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Mr. Nodelman replaces Mr. Dan G. Baker who stepped down on October 6, 2024. The addition of Mr. Nodelman marks an important step in Galapagos' ongoing efforts to engage with shareholders and continue to execute on our Forward, Faster strategy to accelerate innovation and create near-and long-term ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.2842,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GLPG",
        "relevance_score": "0.481586",
        "ticker_sentiment_score": "0.57231",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.046816",
        "ticker_sentiment_score": "0.219522",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth",
    "url": "https://www.globenewswire.com/news-release/2024/10/07/2958632/0/en/Galapagos-welcomes-Oleg-Nodelman-to-its-Board-of-Directors-to-support-strategic-growth.html",
    "time_published": "20241007T050000",
    "authors": [
      "Galapagos NV"
    ],
    "summary": "Mechelen, Belgium. October 7, 2024, 07:00 CET - Galapagos NV ( Euronext & NASDAQ: GLPG ) , today announced the appointment by way of co-optation of Oleg Nodelman as Non-Executive Non-Independent Director to its Board of Directors, effective October 7, 2024.",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/13b034e2-76d4-408b-bffb-c80d85420b03",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.279455,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GLPG",
        "relevance_score": "0.516316",
        "ticker_sentiment_score": "0.593343",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.046543",
        "ticker_sentiment_score": "0.219442",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should Investors Consider High Yield Dividend Stocks?",
    "url": "https://www.zacks.com/stock/news/2347905/should-investors-consider-high-yield-dividend-stocks",
    "time_published": "20241008T234800",
    "authors": [
      "Derek Lewis"
    ],
    "summary": "When selecting dividend-paying stocks, one of the first things that investors look at is, of course, the annual yield. But is high yield always the way to go?",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/48/31067.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.12307,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KO",
        "relevance_score": "0.367865",
        "ticker_sentiment_score": "0.332428",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.367865",
        "ticker_sentiment_score": "0.332428",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.367865",
        "ticker_sentiment_score": "0.332428",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "What To Expect When Johnson & Johnson Reports Q3 Earnings Next Week? - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41236724/what-to-expect-when-johnson-johnson-reports-q3-earnings-next-week",
    "time_published": "20241008T180005",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Monday, Johnson & Johnson JNJ said it discontinued the Phase 3 SunRISe-2 trial of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy for muscle-invasive urothelial carcinoma ( MIBC ) patients who are not receiving radical cystectomy.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/08/Santa-Clara--Ca--Usa---Apr-29--2022-John.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.230806,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.195814",
        "ticker_sentiment_score": "0.188549",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.464633",
        "ticker_sentiment_score": "0.172444",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Analysts Estimate Johnson & Johnson  ( JNJ )  to Report a Decline in Earnings: What to Look Out for",
    "url": "https://www.zacks.com/stock/news/2347550/analysts-estimate-johnson-johnson-jnj-to-report-a-decline-in-earnings-what-to-look-out-for",
    "time_published": "20241008T140016",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default280.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.152651,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.295867",
        "ticker_sentiment_score": "-0.004418",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Anti-Infective Drugs Market Size Will Grow at a CAGR of 4.0% by 2031 | Surging Demand for Antivirals are Boost Market Development - Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41226987/anti-infective-drugs-market-size-will-grow-at-a-cagr-of-4-0-by-2031-surging-demand-for-antivirals-",
    "time_published": "20241008T123600",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research Inc. -, Oct. 08, 2024 ( GLOBE NEWSWIRE ) -- As per the report published by Transparency Market Research, the global anti-infective drugs market ( \u6297\u611f\u67d3\u75c7\u85ac\u5e02\u5834 ) was worth US$ 139.1 Bn in 2022 and is expected to reach US$ 177.9 Bn by ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/6aed864b-8b69-4f43-a4be-d1269957757a/anti-infective-drugs-market.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.080103,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.030331",
        "ticker_sentiment_score": "0.049906",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.030331",
        "ticker_sentiment_score": "0.002815",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.030331",
        "ticker_sentiment_score": "0.002815",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALPMF",
        "relevance_score": "0.030331",
        "ticker_sentiment_score": "0.002815",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.030331",
        "ticker_sentiment_score": "0.002815",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.030331",
        "ticker_sentiment_score": "0.002815",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.030331",
        "ticker_sentiment_score": "0.002815",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.090816",
        "ticker_sentiment_score": "0.063478",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.030331",
        "ticker_sentiment_score": "0.002815",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.030331",
        "ticker_sentiment_score": "0.002815",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.030331",
        "ticker_sentiment_score": "0.002815",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors",
    "url": "https://www.globenewswire.com/news-release/2024/10/08/2959579/0/en/MiNK-Therapeutics-and-Autonomous-Therapeutics-Announce-Collaboration-to-Develop-Novel-Therapies-Targeting-Metastatic-Tumors.html",
    "time_published": "20241008T113000",
    "authors": [
      "MiNK Therapeutics"
    ],
    "summary": "NEW YORK, Oct. 08, 2024 ( GLOBE NEWSWIRE ) -- MiNK Therapeutics ( MiNK, NASDAQ: INKT ) a clinical-stage company pioneering the development of allogeneic off-the-shelf, invariant natural killer T ( iNKT ) cell therapies and Autonomous Therapeutics, Inc. ( Autonomous ) , a leader developing ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/6aa8e960-515a-40d6-9894-39ca47f5c84e",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.142762,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "INKT",
        "relevance_score": "0.125953",
        "ticker_sentiment_score": "0.007415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.031612",
        "ticker_sentiment_score": "0.14451",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "ROME Therapeutics, Enara Bio, Nucleome Therapeutics and NYU Langone Health to Host 3rd Annual Dark Genome Symposium",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41222740/rome-therapeutics-enara-bio-nucleome-therapeutics-and-nyu-langone-health-to-host-3rd-annual-dark-g",
    "time_published": "20241008T090014",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "World-class lineup of speakers and panelists will discuss the latest research and progress in harnessing the dark genome to reveal novel druggable targets and advance new medicines",
    "banner_image": "https://ml.globenewswire.com/media/dd21ee1d-eded-45b1-ac0d-b7e6bf2f0c77/small/rome-logo-off-grey-png.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.152539,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PROF",
        "relevance_score": "0.028422",
        "ticker_sentiment_score": "0.099233",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.085122",
        "ticker_sentiment_score": "0.036837",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.085122",
        "ticker_sentiment_score": "0.066421",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Billionaire Ken Griffin Just Bought 7.9 Million Shares of This Beaten-Down Pharmaceutical Stock as It Eyes the Weight Loss Market",
    "url": "https://www.fool.com/investing/2024/10/09/billionaire-ken-griffin-just-bought-79-million/",
    "time_published": "20241009T134500",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Ken Griffin's Citadel continues to add to its position in Pfizer.",
    "banner_image": "https://media.ycharts.com/charts/13bf633e77ecda623ccd33b06a834168.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.026472,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.050679",
        "ticker_sentiment_score": "-0.021961",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.050679",
        "ticker_sentiment_score": "-0.081227",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.101154",
        "ticker_sentiment_score": "0.025043",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.659607",
        "ticker_sentiment_score": "0.003749",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.050679",
        "ticker_sentiment_score": "-0.081227",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here is What to Know Beyond Why Johnson & Johnson  ( JNJ )  is a Trending Stock",
    "url": "https://www.zacks.com/stock/news/2348084/here-is-what-to-know-beyond-why-johnson-johnson-jnj-is-a-trending-stock",
    "time_published": "20241009T130017",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default327.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.208565,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.477606",
        "ticker_sentiment_score": "0.124263",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Intuitive Surgical Stock Declines 0.7% in a Month: Is It Losing Steam?",
    "url": "https://www.zacks.com/stock/news/2348252/intuitive-surgical-stock-declines-07-in-a-month-is-it-losing-steam",
    "time_published": "20241009T124200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "ISRG stock has maintained an uptrend so far this year on the back of robust da Vinci portfolio performance. However, the stock has declined in the past month. Let's see if the trend might change.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/61/11728.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.267399,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MDT",
        "relevance_score": "0.068404",
        "ticker_sentiment_score": "0.276696",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.363147",
        "ticker_sentiment_score": "0.387017",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.068404",
        "ticker_sentiment_score": "0.276696",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 High-Yield Dividend ETFs to Buy to Generate Passive Income",
    "url": "https://www.fool.com/investing/2024/10/09/3-high-yield-dividend-etfs-to-buy-to-generate-pass/",
    "time_published": "20241009T121500",
    "authors": [
      "Lawrence Rothman",
      "CFA"
    ],
    "summary": "These ETFs pay handsome dividend yields.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F792958%2Fgettyimages-1413845348-1200x800-5b2df791.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": -0.043106,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "TTE",
        "relevance_score": "0.069697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BTI",
        "relevance_score": "0.069697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.069697",
        "ticker_sentiment_score": "0.067485",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.069697",
        "ticker_sentiment_score": "0.067485",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.069697",
        "ticker_sentiment_score": "-0.010113",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VOD",
        "relevance_score": "0.069697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.069697",
        "ticker_sentiment_score": "0.067485",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.138863",
        "ticker_sentiment_score": "-0.188017",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Is Invesco Large Cap Value ETF  ( PWV )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2347940/is-invesco-large-cap-value-etf-pwv-a-strong-etf-right-now",
    "time_published": "20241009T102008",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default1.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999996"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.31989,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.114956",
        "ticker_sentiment_score": "0.066606",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.171688",
        "ticker_sentiment_score": "0.292708",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IBM",
        "relevance_score": "0.114956",
        "ticker_sentiment_score": "0.066606",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.114956",
        "ticker_sentiment_score": "0.066606",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Stock Moves -0.09%: What You Should Know",
    "url": "https://www.zacks.com/stock/news/2349030/johnson-johnson-jnj-stock-moves--009-what-you-should-know",
    "time_published": "20241010T214519",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $160.51, denoting a -0.09% change from the preceding trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default225.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.111659,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.527969",
        "ticker_sentiment_score": "0.130679",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Adobe  ( ADBE )  Q3 2024 Earnings Call Transcript",
    "url": "https://www.fool.com/earnings/call-transcripts/2024/10/10/adobe-adbe-q3-2024-earnings-call-transcript/",
    "time_published": "20241010T174524",
    "authors": [
      "Motley Fool Transcribing"
    ],
    "summary": "ADBE earnings call for the period ending June 30, 2024.",
    "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.352925,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.018702",
        "ticker_sentiment_score": "0.178375",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HUM",
        "relevance_score": "0.004676",
        "ticker_sentiment_score": "0.120864",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NWL",
        "relevance_score": "0.009352",
        "ticker_sentiment_score": "0.161275",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.004676",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.004676",
        "ticker_sentiment_score": "0.120864",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.009352",
        "ticker_sentiment_score": "0.1478",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNEJF",
        "relevance_score": "0.004676",
        "ticker_sentiment_score": "0.19358",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.004676",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QCOM",
        "relevance_score": "0.004676",
        "ticker_sentiment_score": "0.19358",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "STGW",
        "relevance_score": "0.009352",
        "ticker_sentiment_score": "0.161275",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ADBE",
        "relevance_score": "0.176231",
        "ticker_sentiment_score": "0.281685",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "APG",
        "relevance_score": "0.009352",
        "ticker_sentiment_score": "0.058693",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DNTUF",
        "relevance_score": "0.009352",
        "ticker_sentiment_score": "0.161275",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SCHW",
        "relevance_score": "0.004676",
        "ticker_sentiment_score": "0.221307",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PEP",
        "relevance_score": "0.004676",
        "ticker_sentiment_score": "0.203054",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.009352",
        "ticker_sentiment_score": "0.177507",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Insights Into Johnson & Johnson's Performance Versus Peers In Pharmaceuticals Sector - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/news/24/10/41274543/insights-into-johnson-amp-johnsons-performance-versus-peers-in-pharmaceuticals-sector",
    "time_published": "20241010T150046",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Amidst the fast-paced and highly competitive business environment of today, conducting comprehensive company analysis is essential for investors and industry enthusiasts.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1728572443_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.149834,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.067158",
        "ticker_sentiment_score": "0.041065",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.444734",
        "ticker_sentiment_score": "0.244929",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates",
    "url": "https://www.zacks.com/stock/news/2348755/johnson-johnson-jnj-q3-earnings-preview-what-you-should-know-beyond-the-headline-estimates",
    "time_published": "20241010T131520",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default227.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.16444,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.343755",
        "ticker_sentiment_score": "0.137279",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Ailux Biologics, a Division of XtalPi, Enters into a License Agreement with Janssen Biotech on Biologics AI Platform",
    "url": "https://www.benzinga.com/pressreleases/24/10/n41270966/ailux-biologics-a-division-of-xtalpi-enters-into-a-license-agreement-with-janssen-biotech-on-biolo",
    "time_published": "20241010T125100",
    "authors": [
      "PRNewswire"
    ],
    "summary": "CAMBRIDGE, Mass., Oct. 10, 2024 /PRNewswire/ -- XtalPi, a global leader in AI drug discovery, announced today a license agreement between Ailux Biologics, a division of XtalPi Inc., and Janssen Biotech, Inc., ( Janssen ) a Johnson & Johnson company, on one of its proprietary biologics AI ...",
    "banner_image": "https://mma.prnewswire.com/media/2374018/XtalPi_EN_Logo.jpg",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.292043,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.151064",
        "ticker_sentiment_score": "0.204863",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Cramer's week ahead: Major banks, Taiwan Semi and Netflix report as earnings season gets into full swing",
    "url": "https://www.cnbc.com/2024/10/11/cramers-week-ahead-taiwan-semi-netflix-goldman-sachs-citi-earnings.html",
    "time_published": "20241011T224251",
    "authors": [],
    "summary": "Charles Schwab, Bank of America, Johnson & Johnson, Walgreens, UnitedHealth Group Morgan Stanley, Procter & Gamble and Abbott Laboratories all report earnings.",
    "banner_image": null,
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.967645"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      }
    ],
    "overall_sentiment_score": 0.097428,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.064276",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.064276",
        "ticker_sentiment_score": "-0.089474",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "0.231841",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "0.131823",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "0.131823",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.184864",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "-0.154208",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "SLB",
        "relevance_score": "0.064276",
        "ticker_sentiment_score": "0.010048",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "0.131823",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.064276",
        "ticker_sentiment_score": "-0.132152",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.184864",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.064276",
        "ticker_sentiment_score": "0.010048",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.064276",
        "ticker_sentiment_score": "0.010048",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SCHW",
        "relevance_score": "0.064276",
        "ticker_sentiment_score": "0.110539",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Q3 Earnings Season Kicks Off Positively",
    "url": "https://www.zacks.com/commentary/2349528/the-q3-earnings-season-kicks-off-positively",
    "time_published": "20241011T221300",
    "authors": [
      "Sheraz Mian"
    ],
    "summary": "The Q3 reporting cycle ramps up this week, with over 100 companies on deck to report results, including 40 S&P 500 members. Can the positivity continue?",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/charts/2a/81049.jpg?v=1821236077",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.215667,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.044551",
        "ticker_sentiment_score": "0.028509",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.044551",
        "ticker_sentiment_score": "0.028509",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.044551",
        "ticker_sentiment_score": "0.284002",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.304248",
        "ticker_sentiment_score": "0.254854",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.044551",
        "ticker_sentiment_score": "0.028509",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSX",
        "relevance_score": "0.044551",
        "ticker_sentiment_score": "0.028509",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.044551",
        "ticker_sentiment_score": "0.284002",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Market Whales and Their Recent Bets on JNJ Options - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/options/24/10/41294367/market-whales-and-their-recent-bets-on-jnj-options",
    "time_published": "20241011T154808",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bearish move on Johnson & Johnson. Our analysis of options history for Johnson & Johnson JNJ revealed 8 unusual trades. Delving into the details, we found 25% of traders were bullish, while 75% showed bearish tendencies.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1728661685_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.137572,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.072876",
        "ticker_sentiment_score": "0.041241",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.535653",
        "ticker_sentiment_score": "0.066502",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Jim Cramer's top 10 things to watch in the stock market Friday",
    "url": "https://www.cnbc.com/2024/10/11/jim-cramers-top-10-things-to-watch-in-the-stock-market-friday.html",
    "time_published": "20241011T132022",
    "authors": [],
    "summary": "Wholesale inflation came in below expectations. Meanwhile, skeptics are everywhere after Tesla's robotaxi event.",
    "banner_image": null,
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999499"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.980509"
      }
    ],
    "overall_sentiment_score": 0.203427,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.146321",
        "ticker_sentiment_score": "0.134991",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.146321",
        "ticker_sentiment_score": "0.210591",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.049019",
        "ticker_sentiment_score": "-0.063974",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.097854",
        "ticker_sentiment_score": "0.059613",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.097854",
        "ticker_sentiment_score": "0.049521",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.049019",
        "ticker_sentiment_score": "0.180624",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.049019",
        "ticker_sentiment_score": "0.167011",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.049019",
        "ticker_sentiment_score": "0.046448",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.049019",
        "ticker_sentiment_score": "0.008011",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOW",
        "relevance_score": "0.049019",
        "ticker_sentiment_score": "-0.063974",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.097854",
        "ticker_sentiment_score": "0.052758",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.049019",
        "ticker_sentiment_score": "0.167011",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice - Sanofi  ( NASDAQ:SNY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41290528/worlds-third-largest-otc-player-sanofis-consumer-health-unit-nears-16b-deal-with-clayton-dubilier",
    "time_published": "20241011T125733",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Friday, Sanofi SA SNY said it is negotiating with Clayton Dubilier & Rice ( CD&R ) to potentially sell a 50% controlling stake in Opella, its consumer healthcare business.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/11/Sanofi.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.218984,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BX",
        "relevance_score": "0.159569",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.159569",
        "ticker_sentiment_score": "0.008234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.159569",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.159569",
        "ticker_sentiment_score": "0.278214",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TPG",
        "relevance_score": "0.080188",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HLN",
        "relevance_score": "0.159569",
        "ticker_sentiment_score": "0.092152",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.159569",
        "ticker_sentiment_score": "0.008234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GSK",
        "relevance_score": "0.159569",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.635085",
        "ticker_sentiment_score": "0.249318",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Acquisition of The Sempre Group Holdings Ltd",
    "url": "https://www.globenewswire.com/news-release/2024/10/11/2961930/0/en/Acquisition-of-The-Sempre-Group-Holdings-Ltd.html",
    "time_published": "20241011T105900",
    "authors": [
      "Oxford Metrics"
    ],
    "summary": "11 October ...",
    "banner_image": "",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.460951,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RNSHF",
        "relevance_score": "0.037622",
        "ticker_sentiment_score": "0.182842",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.037622",
        "ticker_sentiment_score": "0.168967",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LDNXF",
        "relevance_score": "0.037622",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "There Are Only 28 S&P 500 Companies Warren Buffett Can't Buy Outright. Here's the Best of the Bunch for Income Investors.",
    "url": "https://www.fool.com/investing/2024/10/12/sp-500-warren-buffett-income-investors/",
    "time_published": "20241012T094000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "This Dividend King is beyond Buffett's reach to fully acquire and is a great pick for income investors.",
    "banner_image": "https://media.ycharts.com/charts/5729640a46f26b5fb18c6b12011941a8.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.30179,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.426824",
        "ticker_sentiment_score": "0.364633",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.056143",
        "ticker_sentiment_score": "0.143928",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.112008",
        "ticker_sentiment_score": "0.241559",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.112008",
        "ticker_sentiment_score": "0.241559",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.255637",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "All It Takes Is $1,000 Invested in Each of These 3 Dividend Kings to Help Generate Over $100 in Passive Income Per Year",
    "url": "https://www.fool.com/investing/2024/10/13/buy-dividend-king-stock-generate-passive-income/",
    "time_published": "20241013T092000",
    "authors": [
      "Daniel Foelber"
    ],
    "summary": "Target, PepsiCo, and Kenvue have high yields and inexpensive valuations.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F793694%2Fgettyimages-2153758481-1200x800-5b2df79-1.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.332737,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TGT",
        "relevance_score": "0.5752",
        "ticker_sentiment_score": "0.432981",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "KMB",
        "relevance_score": "0.037446",
        "ticker_sentiment_score": "0.030347",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.074809",
        "ticker_sentiment_score": "0.108582",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.037446",
        "ticker_sentiment_score": "0.037167",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.037446",
        "ticker_sentiment_score": "0.030347",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.426824",
        "ticker_sentiment_score": "0.26297",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PEP",
        "relevance_score": "0.148961",
        "ticker_sentiment_score": "0.082351",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.037446",
        "ticker_sentiment_score": "0.189302",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CLX",
        "relevance_score": "0.037446",
        "ticker_sentiment_score": "0.030347",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.257571",
        "ticker_sentiment_score": "0.180685",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/news/earnings/24/10/41318794/johnson-johnson-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnin",
    "time_published": "20241014T174817",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Johnson & Johnson JNJ will release earnings results for its third quarter before the opening bell on Tuesday, Oct. 15. Analysts expect the New Brunswick, New Jersey-based bank to report quarterly earnings at $2.21 per share, down from $2.66 per share in the year-ago period.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/14/JohnsonampJohnson-Shutterstock_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.133558,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MS",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.606385",
        "ticker_sentiment_score": "0.41769",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "This Is What Whales Are Betting On Johnson & Johnson - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/options/24/10/41318755/this-is-what-whales-are-betting-on-johnson-johnson",
    "time_published": "20241014T174546",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "High-rolling investors have positioned themselves bullish on Johnson & Johnson JNJ, and it's important for retail traders to take note. \\This activity came to our attention today through Benzinga's tracking of publicly available options data.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1728927943_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      }
    ],
    "overall_sentiment_score": 0.148812,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.068112",
        "ticker_sentiment_score": "0.041087",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.65287",
        "ticker_sentiment_score": "0.230736",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Q3 Earnings Results of U.S. Corporate Giants in Focus",
    "url": "https://www.zacks.com/stock/news/2350027/q3-earnings-results-of-us-corporate-giants-in-focus",
    "time_published": "20241014T150000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Today is a bank holiday: either Columbus Day ( depending how Italian-American your community ) or Indigenous Peoples' Day ( depending how \"woke\" ) . In any case, the stock market is open for business, but there are no major economic reports due out until tomorrow.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/83/93.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.124169,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.382925",
        "ticker_sentiment_score": "0.15731",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.197413",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.197413",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.197413",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.197413",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.197413",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.197413",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bank Holiday Ahead of Busy Stock Trading Week",
    "url": "https://www.zacks.com/stock/news/2350003/bank-holiday-ahead-of-busy-stock-trading-week",
    "time_published": "20241014T142400",
    "authors": [
      "Mark Vickery"
    ],
    "summary": "Despite today's day off from econ metrics, we see a pretty busy week ahead.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b6/81124.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.114788,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.368773",
        "ticker_sentiment_score": "0.142944",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.18967",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.18967",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.18967",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.18967",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.18967",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.18967",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Preps For Q3 Earnings As MedTech Expands, But Stock Sends Mixed Signals - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41313932/johnson-johnson-preps-for-q3-earnings-as-medtech-expands-but-stock-sends-mixed-signals",
    "time_published": "20241014T141440",
    "authors": [
      "Surbhi Jain"
    ],
    "summary": "Johnson & Johnson JNJ is set to announce its third quarter earnings on Oct. 15 before the market opens. Wall Street is expecting the pharmaceutical and healthcare giant to post earnings per share ( EPS ) of $2.21 and revenue of $22.16 billion.",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14084639/Screenshot-2024-10-14-at-4.15.57-PM.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.990786"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.0,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.427425",
        "ticker_sentiment_score": "-0.169565",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Veterinary Orthopedic Implant Market is Projected to Reach a Valuation of US$ 14.67 Billion at a CAGR of 17.7% by 2034 | Fact.MR Report",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41310389/veterinary-orthopedic-implant-market-is-projected-to-reach-a-valuation-of-us-14-67-billion-at-a-ca",
    "time_published": "20241014T113000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Rockville, MD, Oct. 14, 2024 ( GLOBE NEWSWIRE ) -- A new research report published by Fact.MR states that the global veterinary orthopedic implants market is set to reach a valuation of US$ 2.87 billion in 2024 and further expand at a CAGR of 17.7% from 2024 to 2034.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/b587d459-8fef-4612-8a2d-5ecdd9d6e167/veterinary-orthopedic-implant-market.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.334237,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IART",
        "relevance_score": "0.040145",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.040145",
        "ticker_sentiment_score": "-0.06866",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Columbus Day: Is Stock Market Open Today? - Abbott Laboratories  ( NYSE:ABT ) , Bank of America  ( NYSE:BAC ) ",
    "url": "https://www.benzinga.com/news/24/10/41309748/columbus-day-is-stock-market-open-today",
    "time_published": "20241014T104616",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "As Columbus Day approaches, investors and market participants are preparing for a unique trading environment. This U.S. holiday, observed on Monday, October 14, 2024, will see a mix of open and closed financial markets, impacting trading activities.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/14/Market-Update.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999696"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.173887,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.245339",
        "ticker_sentiment_score": "-0.10352",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.245339",
        "ticker_sentiment_score": "-0.10352",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.124164",
        "ticker_sentiment_score": "0.22275",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.245339",
        "ticker_sentiment_score": "-0.10352",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.245339",
        "ticker_sentiment_score": "-0.10352",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSM",
        "relevance_score": "0.245339",
        "ticker_sentiment_score": "-0.10352",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "JPMorgan and Wells Fargo are part of Zacks Earnings Preview",
    "url": "https://www.zacks.com/stock/news/2349622/jpmorgan-and-wells-fargo-are-part-of-zacks-earnings-preview",
    "time_published": "20241014T102200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "JPMorgan and Wells Fargo are highlights of Zacks Earnings Preview article.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/8f/410.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.216398,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.04912",
        "ticker_sentiment_score": "0.028778",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.04912",
        "ticker_sentiment_score": "0.028778",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.04912",
        "ticker_sentiment_score": "0.285306",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.333685",
        "ticker_sentiment_score": "0.239087",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.04912",
        "ticker_sentiment_score": "0.028778",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSX",
        "relevance_score": "0.04912",
        "ticker_sentiment_score": "0.028778",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.04912",
        "ticker_sentiment_score": "0.285306",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Cancer Drugs Propel J&J Beyond Wall Street Estimates - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/markets/24/10/41343215/cancer-drugs-propel-j-j-beyond-wall-street-estimates",
    "time_published": "20241015T192639",
    "authors": [
      "Upwallstreet"
    ],
    "summary": "On Tuesday, Johnson & Johnson JNJ posted better-than-expected third quarter sales and adjusted profit. Fueled by strong results, Johnson & Johnson raised its full year profit and sales guidance.",
    "banner_image": "https://cdn.benzinga.com/files/digital-tablet-pills-stethoscope-syringe-white-backdrop.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      }
    ],
    "overall_sentiment_score": 0.122242,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.422661",
        "ticker_sentiment_score": "0.078284",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.219477",
        "ticker_sentiment_score": "0.181233",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Q3 2024 Earnings Call Transcript",
    "url": "https://www.fool.com/earnings/call-transcripts/2024/10/15/johnson-johnson-jnj-q3-2024-earnings-call-transcri/",
    "time_published": "20241015T183016",
    "authors": [
      "Motley Fool Transcribing"
    ],
    "summary": "JNJ earnings call for the period ending September 30, 2024.",
    "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999965"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.955357"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.288314,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.009669",
        "ticker_sentiment_score": "0.087468",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.004835",
        "ticker_sentiment_score": "0.114342",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.004835",
        "ticker_sentiment_score": "0.101539",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.067605",
        "ticker_sentiment_score": "0.087668",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.004835",
        "ticker_sentiment_score": "0.051791",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nasdaq Down 150 Points; Johnson & Johnson Reports Better-Than-Expected Q3 Results - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/markets/equities/24/10/41341975/nasdaq-down-150-points-johnson-johnson-reports-better-than-expected-q3-results",
    "time_published": "20241015T181424",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling around 150 points on Tuesday. The Dow traded down 0.30% to 42,937.44 while the NASDAQ fell 0.84% to 18,347.17. The S&P 500 also fell, dropping, 0.43% to 5,834.67. Real estate shares jumped by 2% on Tuesday.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/15/Johnson-amp-Johnson-COVID-19-vaccine.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": -0.004886,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MGTX",
        "relevance_score": "0.193465",
        "ticker_sentiment_score": "0.397194",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PEGY",
        "relevance_score": "0.193465",
        "ticker_sentiment_score": "-0.290938",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "WOLF",
        "relevance_score": "0.193465",
        "ticker_sentiment_score": "0.087338",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CDNA",
        "relevance_score": "0.193465",
        "ticker_sentiment_score": "0.164316",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.193465",
        "ticker_sentiment_score": "0.404183",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SEEL",
        "relevance_score": "0.28664",
        "ticker_sentiment_score": "0.203128",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Google Goes Nuclear For AI Power, Israeli Restraint Impacts Stocks, Gold, And Oil - Apple  ( NASDAQ:AAPL ) ",
    "url": "https://www.benzinga.com/markets/24/10/41339316/google-goes-nuclear-for-ai-power-israeli-restraint-impacts-stocks-gold-and-oil",
    "time_published": "20241015T162142",
    "authors": [
      "The Arora Report"
    ],
    "summary": "To gain an edge, this is what you need to know today. Please click here for an enlarged chart of Nano Nuclear Energy Inc NNE. Selling in volatility index ( VIX ) futures As full disclosure, The Arora Report anticipated this scenario as the highest probability scenario and gave the following ...",
    "banner_image": "https://thearorareport.com/wp-content/uploads/2024/10/2024-10-15_08h50_10.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998311"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      }
    ],
    "overall_sentiment_score": 0.290806,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.110973",
        "ticker_sentiment_score": "0.168544",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.110973",
        "ticker_sentiment_score": "0.168544",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.110973",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.110973",
        "ticker_sentiment_score": "0.168544",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.110973",
        "ticker_sentiment_score": "0.168544",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.165788",
        "ticker_sentiment_score": "0.169089",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NNE",
        "relevance_score": "0.110973",
        "ticker_sentiment_score": "0.225193",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.110973",
        "ticker_sentiment_score": "-0.296314",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NEM",
        "relevance_score": "0.110973",
        "ticker_sentiment_score": "0.206299",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.110973",
        "ticker_sentiment_score": "0.137505",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.055621",
        "ticker_sentiment_score": "0.349021",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.110973",
        "ticker_sentiment_score": "-0.129755",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:NANO",
        "relevance_score": "0.055621",
        "ticker_sentiment_score": "0.203954",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRYPTO:NEM",
        "relevance_score": "0.055621",
        "ticker_sentiment_score": "0.186938",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "VNDA Rejects Second Takeover Bid by Cycle Group, Stock Rises",
    "url": "https://www.zacks.com/stock/news/2350851/vnda-rejects-second-takeover-bid-by-cycle-group-stock-rises",
    "time_published": "20241015T155100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vanda's board of directors unanimously rejects the second takeover proposal from Cycle Group Holdings. Shares rise on the news.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e6/2070.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.129096,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALNY",
        "relevance_score": "0.185781",
        "ticker_sentiment_score": "0.078547",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANIP",
        "relevance_score": "0.245959",
        "ticker_sentiment_score": "0.281176",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.062434",
        "ticker_sentiment_score": "-0.168342",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "VNDA",
        "relevance_score": "0.304679",
        "ticker_sentiment_score": "-0.013571",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.185781",
        "ticker_sentiment_score": "0.188996",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "J&J Beats on Q3 Earnings, Raises Sales View but Cuts EPS Guidance",
    "url": "https://www.zacks.com/stock/news/2350818/jj-beats-on-q3-earnings-raises-sales-view-but-cuts-eps-guidance",
    "time_published": "20241015T152600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "JNJ beats estimates for third-quarter earnings and sales. It lowers earnings expectations for 2024 but raises the sales guidance range.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999998"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.100143,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.058117",
        "ticker_sentiment_score": "0.06697",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.08708",
        "ticker_sentiment_score": "0.079239",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.08708",
        "ticker_sentiment_score": "0.042513",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.08708",
        "ticker_sentiment_score": "-0.020869",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Q3 Earnings Beats: C, GS, BAC, JNJ, WBA; Empire State Lower",
    "url": "https://www.zacks.com/stock/news/2350771/q3-earnings-beats-c-gs-bac-jnj-wba-empire-state-lower",
    "time_published": "20241015T142500",
    "authors": [
      "Mark Vickery"
    ],
    "summary": "While Goldman Sachs (GS) and Citi (C) both impressed on earnings this morning, Walgreens (WBA) looks to bounce back.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/91/69871.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.99915"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.195805,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "C",
        "relevance_score": "0.199037",
        "ticker_sentiment_score": "0.224456",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.13347",
        "ticker_sentiment_score": "0.095886",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.13347",
        "ticker_sentiment_score": "0.086704",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.13347",
        "ticker_sentiment_score": "0.095886",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.13347",
        "ticker_sentiment_score": "0.093006",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "White River Bancshares Co. Earns a Record $2.74 million, or $1.12 Per Diluted Share, in 3Q24; Highlighted by Net Interest Margin Expansion",
    "url": "https://www.globenewswire.com/news-release/2024/10/15/2963253/0/en/White-River-Bancshares-Co-Earns-a-Record-2-74-million-or-1-12-Per-Diluted-Share-in-3Q24-Highlighted-by-Net-Interest-Margin-Expansion.html",
    "time_published": "20241015T130000",
    "authors": [
      "White River Bancshares"
    ],
    "summary": "FAYETTEVILLE, Ark., Oct. 15, 2024 ( GLOBE NEWSWIRE ) -- White River Bancshares Company ( OTCQX: WRIV ) , ( the \"Company\" ) the holding company for Signature Bank of Arkansas ( the \"Bank\" ) , today reported net income increased substantially to $2.74 million, or $1.12 per diluted share, in the ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/59f98c26-e808-41b4-b248-610c5133e898",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928139"
      }
    ],
    "overall_sentiment_score": 0.235566,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KO",
        "relevance_score": "0.017145",
        "ticker_sentiment_score": "0.117127",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBNY",
        "relevance_score": "0.051404",
        "ticker_sentiment_score": "0.112604",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSN",
        "relevance_score": "0.017145",
        "ticker_sentiment_score": "0.117127",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.017145",
        "ticker_sentiment_score": "0.117127",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.017145",
        "ticker_sentiment_score": "0.117127",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.017145",
        "ticker_sentiment_score": "0.117127",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson's Q3 Earnings: Revenue And EPS Beat On Strong Cancer Drug Sales, Revises Annual Outlook To Reflect V-Wave Acquisition - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41329767/johnson-johnsons-q3-earnings-revenue-and-eps-beat-on-strong-cancer-drug-sales-revises-annual-outl",
    "time_published": "20241015T122021",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Tuesday, Johnson & Johnson JNJ reported a third-quarter adjusted EPS of $2.42, down 9.0% year-over-year, beating the consensus of $2.21. The pharmaceutical giant reported sales of $22.47 billion, up 5.2% year over year and beating the consensus of $22.16 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/15/Santa-Clara--Ca--Usa---Apr-29--2022-John.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.241835,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.504646",
        "ticker_sentiment_score": "0.083759",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Wellspring Accelerates Growth Trajectory with Key C-Suite Appointments Following Sopheon Acquisition",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41328747/wellspring-accelerates-growth-trajectory-with-key-c-suite-appointments-following-sopheon-acquisiti",
    "time_published": "20241015T120000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Arvada, CO, USA, Oct. 15, 2024 ( GLOBE NEWSWIRE ) -- Wellspring, the world's leading provider of Tech Transfer, Intellectual Property Management, and Innovation Management software solutions, today announced significant leadership appointments following its recent acquisition of Sopheon, a major ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Mergers",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.588641,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PHPYF",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.227001",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DOMO",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.300002",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BNXYF",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.189954",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.464259",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Tops Q3 Earnings and Revenue Estimates",
    "url": "https://www.zacks.com/stock/news/2350389/johnson-johnson-jnj-tops-q3-earnings-and-revenue-estimates",
    "time_published": "20241015T113503",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 9.01% and 1.27%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default267.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999997"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.175202,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.136499",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.393977",
        "ticker_sentiment_score": "0.172005",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Orthopedic Surgical Robot Market is Projected to Reach a Valuation of US$ 8.34 Billion at a CAGR of 13.5% by 2034 | Fact.MR Report",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41327222/orthopedic-surgical-robot-market-is-projected-to-reach-a-valuation-of-us-8-34-billion-at-a-cagr-of",
    "time_published": "20241015T110000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Rockville, MD , Oct. 15, 2024 ( GLOBE NEWSWIRE ) -- Fact.MR, a market research and intelligence provider, states in its latest industry report that the global orthopedic surgical robot market is estimated to reach a valuation of US$ 2.35 billion in 2024 and further expand at a CAGR of 13.5% from ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/348b5219-e529-4ca0-90be-bc4e9dbe030d/orthopedic-surgical-robot-market.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.314749,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ZBH",
        "relevance_score": "0.038284",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNN",
        "relevance_score": "0.038284",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GMED",
        "relevance_score": "0.038284",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.038284",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.038284",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NDSN",
        "relevance_score": "0.038284",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.038284",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.038284",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RNSHF",
        "relevance_score": "0.038284",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.038284",
        "ticker_sentiment_score": "0.204188",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Nasdaq, S&P 500 Could Start Tuesday's Session In The Red - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/10/41326823/wall-street-on-edge-as-nasdaq-nears-record-high-oil-prices-plummet-strategist-says-theres-opportuni",
    "time_published": "20241015T104350",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "Wall Street mood has become circumspect as traders gear up to receive a slew of earnings reports this week amid the market's record run. The Nasdaq Composite has been a laggard among the major averages and it remains to be seen if the early sentiment reverses and tech stocks could finish the ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/15/Nasdaq--New-York-City.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999864"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.131439,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.103628",
        "ticker_sentiment_score": "0.078269",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.069194",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.069194",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.069194",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PNC",
        "relevance_score": "0.069194",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.03463",
        "ticker_sentiment_score": "0.114532",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.069194",
        "ticker_sentiment_score": "0.00915",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.069194",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MU",
        "relevance_score": "0.069194",
        "ticker_sentiment_score": "0.00915",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.069194",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.03463",
        "ticker_sentiment_score": "0.139897",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.069194",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DJT",
        "relevance_score": "0.069194",
        "ticker_sentiment_score": "0.149687",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.069194",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.069194",
        "ticker_sentiment_score": "0.00915",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SCHW",
        "relevance_score": "0.069194",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WOLF",
        "relevance_score": "0.069194",
        "ticker_sentiment_score": "0.04814",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WT",
        "relevance_score": "0.03463",
        "ticker_sentiment_score": "0.086448",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.069194",
        "ticker_sentiment_score": "-0.077764",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.069194",
        "ticker_sentiment_score": "-0.101983",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Genmab Announces Net Sales of DARZALEX\u00ae  ( daratumumab )  for Third Quarter of 2024",
    "url": "https://www.globenewswire.com/news-release/2024/10/15/2963006/0/en/Genmab-Announces-Net-Sales-of-DARZALEX-daratumumab-for-Third-Quarter-of-2024.html",
    "time_published": "20241015T102500",
    "authors": [
      "Genmab A/S"
    ],
    "summary": "Company Announcement ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.009624,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GMAB",
        "relevance_score": "0.587597",
        "ticker_sentiment_score": "0.049193",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.011672",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Jim Cramer Says Earnings Season Will Fuel Market's Record Run, But Warns Of This 'Horrendous' Headwind That Could Apply Brakes To Rally - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41324660/jim-cramer-says-earnings-season-will-fuel-markets-record-run-but-warns-of-this-horr",
    "time_published": "20241015T080827",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "The S&P 500 and the Dow Jones Industrial Average are perched at record highs, while the Nasdaq Composite is on the cusp of joining its major counterparts in record territory. Unfazed by the stretched valuations, CNBC Mad Money host Jim Cramer on Monday raised the specter of further upside.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/15/Jim-Cramer-Names-7-Key-Stocks-To-Track-A.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999174"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928139"
      }
    ],
    "overall_sentiment_score": -0.012085,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "UAL",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PNC",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.153838",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SCHW",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur - Nurix Therapeutics  ( NASDAQ:NRIX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41368771/nurix-therapeutics-expands-its-board-of-directors-with-the-addition-of-drug-commercialization-expe",
    "time_published": "20241016T203541",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "SAN FRANCISCO, Oct. 16, 2024 ( GLOBE NEWSWIRE ) -- Nurix Therapeutics, Inc. NRIX, a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the appointment of Anil Kapur to its board of ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.142749,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GERN",
        "relevance_score": "0.100518",
        "ticker_sentiment_score": "0.017228",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GMAB",
        "relevance_score": "0.050359",
        "ticker_sentiment_score": "-0.014979",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VSTM",
        "relevance_score": "0.050359",
        "ticker_sentiment_score": "0.015949",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.050359",
        "ticker_sentiment_score": "0.015949",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.050359",
        "ticker_sentiment_score": "0.20333",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NRIX",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "0.013581",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur",
    "url": "https://www.globenewswire.com/news-release/2024/10/16/2964508/0/en/Nurix-Therapeutics-Expands-Its-Board-of-Directors-with-the-Addition-of-Drug-Commercialization-Expert-Anil-Kapur.html",
    "time_published": "20241016T203500",
    "authors": [
      "Nurix Therapeutics",
      "Inc."
    ],
    "summary": "SAN FRANCISCO, Oct. 16, 2024 ( GLOBE NEWSWIRE ) -- Nurix Therapeutics, Inc. ( Nasdaq: NRIX ) , a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the appointment of Anil Kapur ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/e95c30b7-0b40-4147-a34b-d48f933a63c7",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.041074,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GERN",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.016499",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GMAB",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "-0.014795",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VSTM",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "0.015705",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "0.015705",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "0.2008",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NRIX",
        "relevance_score": "0.12546",
        "ticker_sentiment_score": "0.009688",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Certara Appoints John Reynders as New Independent Board Member",
    "url": "https://www.globenewswire.com/news-release/2024/10/16/2964478/0/en/Certara-Appoints-John-Reynders-as-New-Independent-Board-Member.html",
    "time_published": "20241016T201500",
    "authors": [
      "Certara USA",
      "Inc."
    ],
    "summary": "Certara today announced the appointment of John Reynders, PhD to its Board of Directors, effective October 15, 2024.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/9eae2f39-7a9a-4b93-aeaa-2cf98d91156d",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.330797,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CERT",
        "relevance_score": "0.499789",
        "ticker_sentiment_score": "0.481733",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.108366",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.108366",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.108366",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Certara Appoints John Reynders as New Independent Board Member - Certara  ( NASDAQ:CERT ) ",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41368029/certara-appoints-john-reynders-as-new-independent-board-member",
    "time_published": "20241016T201500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "RADNOR, Pa., Oct. 16, 2024 ( GLOBE NEWSWIRE ) -- Certara, Inc. CERT, a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.338226,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CERT",
        "relevance_score": "0.453501",
        "ticker_sentiment_score": "0.452232",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.11983",
        "ticker_sentiment_score": "0.102934",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.11983",
        "ticker_sentiment_score": "0.102934",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.11983",
        "ticker_sentiment_score": "0.102934",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson's MedTech Challenges Loom Amid Chinese Market Pressures And Orthopedics Overhaul, Analysts Say - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41365780/johnson-johnsons-medtech-challenges-loom-amid-chinese-market-pressures-and-orthoped",
    "time_published": "20241016T183151",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Tuesday, Johnson & Johnson JNJ reported a third-quarter adjusted EPS of $2.42, down 9.0% year-over-year, beating the consensus of $2.21. The pharmaceutical giant reported sales of $22.47 billion, up 5.2% year over year and beating the consensus of $22.16 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/16/Santa-Clara--Ca--Usa---Apr-29--2022-John.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.08242,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.528475",
        "ticker_sentiment_score": "-0.040031",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Inner Circle acknowledges, Willette Murphy Klausner as a Top Pinnacle Professional",
    "url": "https://www.benzinga.com/pressreleases/24/10/n41364614/the-inner-circle-acknowledges-willette-murphy-klausner-as-a-top-pinnacle-professional",
    "time_published": "20241016T173400",
    "authors": [
      "PRNewswire"
    ],
    "summary": "LOS ANGELES, Oct. 16, 2024 /PRNewswire/ -- Willette Murphy Klausner shines brightly in The Inner Circle, celebrated as a Top Pinnacle Professional for her groundbreaking contributions as a Trailblazer in Theater and Film Production.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.401,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KO",
        "relevance_score": "0.046999",
        "ticker_sentiment_score": "0.054676",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GM",
        "relevance_score": "0.046999",
        "ticker_sentiment_score": "0.054676",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.046999",
        "ticker_sentiment_score": "0.054676",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.046999",
        "ticker_sentiment_score": "0.054676",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stock Market News for Oct 16, 2024",
    "url": "https://www.zacks.com/stock/news/2351324/stock-market-news-for-oct-16-2024",
    "time_published": "20241016T132800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Wall Street ended lower on Tuesday as investors digested Mary Daly's remarks during a meeting at New York University, regarding interest rates.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b1/2160.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": -0.043781,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BAC",
        "relevance_score": "0.251247",
        "ticker_sentiment_score": "0.149747",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.169081",
        "ticker_sentiment_score": "0.112284",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Breast Implants Market to Surpass USD 4.46 Billion By 2031 | SkyQuest Technology",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41354601/breast-implants-market-to-surpass-usd-4-46-billion-by-2031-skyquest-technology",
    "time_published": "20241016T120000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Westford, USA, Oct. 16, 2024 ( GLOBE NEWSWIRE ) -- SkyQuest projects that the Global Breast Implants Market will reach a value of USD 4.46 Billion by 2031, with a CAGR of 7.49% during the forecast period ( 2024-2031 ) .",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Mergers",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.271029,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ESTA",
        "relevance_score": "0.038468",
        "ticker_sentiment_score": "0.095531",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.038468",
        "ticker_sentiment_score": "0.095531",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Beats Wall Street Estimates. Is It Time to Buy, Sell, or Hold?",
    "url": "https://www.fool.com/investing/2024/10/16/johnson-johnson-beats-wall-street-estimates-again/",
    "time_published": "20241016T092700",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Third-quarter results exceeded estimates, but the company also lowered overall earnings expectations for 2024.",
    "banner_image": "https://g.foolcdn.com/editorial/images/794112/a-person-delivering-a-presentation-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.998645"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.156602,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BMY",
        "relevance_score": "0.098054",
        "ticker_sentiment_score": "0.114897",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.098054",
        "ticker_sentiment_score": "0.113168",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Wound Care Market to Witness 3.1% CAGR by 2031 | SkyQuest Technology",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41392335/wound-care-market-to-witness-3-1-cagr-by-2031-skyquest-technology",
    "time_published": "20241017T210000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Westford, USA, Oct. 17, 2024 ( GLOBE NEWSWIRE ) -- SkyQuest projects that Wound Care Market will attain the value of USD 16.32 Billion by 2031, with a CAGR of 3.1% during the forecast period ( 2024-2031 ) .",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.239225,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IART",
        "relevance_score": "0.043342",
        "ticker_sentiment_score": "0.021996",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAX",
        "relevance_score": "0.043342",
        "ticker_sentiment_score": "0.021996",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.043342",
        "ticker_sentiment_score": "0.021996",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Stock: Setting the Stage for 2025 Highs - Johnson & Johnson  ( NYSE:JNJ ) , Kenvue  ( NYSE:KVUE ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41378028/johnson-johnson-stock-setting-the-stage-for-2025-highs",
    "time_published": "20241017T175939",
    "authors": [
      "MarketBeat"
    ],
    "summary": "Johnson & Johnson's JNJ stock price advance has been reinvigorated. The stock price rally stalled a few years ago due to the COVID-19 bubble bursting and the divestiture of Kenvue KVUE, but those days are behind, and business growth is still ahead.",
    "banner_image": "https://www.marketbeat.com/logos/articles/med_20241015124542_chart-jnj-10152024.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.995973"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.989041"
      }
    ],
    "overall_sentiment_score": 0.306161,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.109705",
        "ticker_sentiment_score": "0.179352",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.370733",
        "ticker_sentiment_score": "0.259725",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "ETFs in Focus Post JNJ Q3 Earnings Beat, Target Price Hike",
    "url": "https://www.zacks.com/stock/news/2352605/etfs-in-focus-post-jnj-q3-earnings-beat-target-price-hike",
    "time_published": "20241017T161000",
    "authors": [
      "Sweta Killa"
    ],
    "summary": "Johnson & Johnson infused positive optimism after posting solid third-quarter 2024 earnings. A few analysts raised their target price on the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/1612.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999998"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.96136"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.24049,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.386211",
        "ticker_sentiment_score": "0.328252",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SF",
        "relevance_score": "0.044718",
        "ticker_sentiment_score": "0.138993",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This Magnificent Dividend Stock Is as Healthy as It Gets",
    "url": "https://www.fool.com/investing/2024/10/17/this-magnificent-dividend-stock-is-as-healthy-as-i/",
    "time_published": "20241017T081400",
    "authors": [
      "Matt DiLallo"
    ],
    "summary": "Johnson & Johnson's latest financial checkup shows it's still in excellent health.",
    "banner_image": "https://g.foolcdn.com/editorial/images/794177/stethoscope-on-money-cash-1200x801-d21b45d.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.94762"
      }
    ],
    "overall_sentiment_score": 0.262702,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.538939",
        "ticker_sentiment_score": "0.359795",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Why Eli Lilly Stock Is Soaring-And How It Plans To Stay On Top - Johnson & Johnson  ( NYSE:JNJ ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41399187/why-eli-lilly-stock-is-soaring-and-how-it-plans-to-stay-on-top",
    "time_published": "20241018T190300",
    "authors": [
      "MarketBeat"
    ],
    "summary": "In a year and a half, Eli Lilly LLY has roughly doubled in value. It is now the most valuable pharmaceutical company in the world. It took that mantle from the long-held dominance by Johnson and Johnson JNJ back in May of 2023 and hasn't looked back since.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/18/yiorgos-ntrahas-mcauhlgirvs-unsplash_3.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.990786"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.25492,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.339578",
        "ticker_sentiment_score": "0.160727",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.050044",
        "ticker_sentiment_score": "0.041577",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.09989",
        "ticker_sentiment_score": "0.130543",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.149346",
        "ticker_sentiment_score": "0.141852",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: JNJ's Q3 Earnings, FDA Nod to Some New Drugs",
    "url": "https://www.zacks.com/stock/news/2353423/pharma-stock-roundup-jnjs-q3-earnings-fda-nod-to-some-new-drugs",
    "time_published": "20241018T190000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "J&J tops third-quarter earnings and sales estimates. FDA approves new drugs of Pfizer, Roche and AbbVie.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/952.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.96136"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.139439,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.1871",
        "ticker_sentiment_score": "0.065313",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.140896",
        "ticker_sentiment_score": "0.01117",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.232661",
        "ticker_sentiment_score": "0.026981",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.364053",
        "ticker_sentiment_score": "0.037861",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Unusual Options Activity - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/options/24/10/41406477/johnson-johnson-unusual-options-activity",
    "time_published": "20241018T163043",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bearish stance on Johnson & Johnson JNJ. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1729269040_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.066676,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.067347",
        "ticker_sentiment_score": "0.041069",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.067347",
        "ticker_sentiment_score": "-0.086542",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.067347",
        "ticker_sentiment_score": "-0.086542",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.601928",
        "ticker_sentiment_score": "-0.042414",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 No-Brainer Pharmaceutical Stocks to Buy With $500 Right Now",
    "url": "https://www.fool.com/investing/2024/10/18/3-no-brainer-pharmaceutical-stocks-to-buy-with-500/",
    "time_published": "20241018T091000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "These stocks could deliver big over the long term.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F794412%2Fgettyimages-scientists-in-lab01.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.998311"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.372282,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.052455",
        "ticker_sentiment_score": "0.184634",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.104683",
        "ticker_sentiment_score": "0.078",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.207571",
        "ticker_sentiment_score": "0.110364",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.104683",
        "ticker_sentiment_score": "0.200124",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "All It Takes Is $2,500 Invested in Each of These 3 High-Yield Dow Dividend Stocks to Help Generate Over $300 in Passive Income Per Year",
    "url": "https://www.fool.com/investing/2024/10/19/all-it-takes-is-2500-invested-in-each-of-these-3-h/",
    "time_published": "20241019T214000",
    "authors": [
      "Daniel Foelber"
    ],
    "summary": "Investors looking for dividend stocks at reasonable valuations have come to the right place.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F793976%2Fgettyimages-869302164-1200x800-5b2df79-1.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999997"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928769"
      }
    ],
    "overall_sentiment_score": 0.144219,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.0362",
        "ticker_sentiment_score": "0.069867",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.350069",
        "ticker_sentiment_score": "0.192178",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.0362",
        "ticker_sentiment_score": "0.168036",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.0362",
        "ticker_sentiment_score": "0.168036",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.0362",
        "ticker_sentiment_score": "0.095357",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.108303",
        "ticker_sentiment_score": "0.087933",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.0362",
        "ticker_sentiment_score": "0.075621",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.0362",
        "ticker_sentiment_score": "0.168036",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever",
    "url": "https://www.fool.com/investing/2024/10/19/want-decades-of-passive-income-2-stocks-to-buy-now/",
    "time_published": "20241019T135700",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "These companies' longtime shareholders have generally been rewarded.",
    "banner_image": "https://g.foolcdn.com/editorial/images/794279/physicians-in-an-operating-room.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.300861,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.21258",
        "ticker_sentiment_score": "0.328311",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.263942",
        "ticker_sentiment_score": "0.256908",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Nvidia, Google, Microsoft and more head to Las Vegas to tout health-care AI tools",
    "url": "https://www.cnbc.com/2024/10/19/hlth-2024-tech-companies-head-to-las-vegas-to-tout-health-ai-tools-.html",
    "time_published": "20241019T130001",
    "authors": [],
    "summary": "Tech companies are in Las Vegas this week to talk health-care AI at the HLTH conference.",
    "banner_image": null,
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.168011,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.193852",
        "ticker_sentiment_score": "0.16456",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.193852",
        "ticker_sentiment_score": "0.208802",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.240965",
        "ticker_sentiment_score": "0.23861",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.048919",
        "ticker_sentiment_score": "0.042476",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What's Going On With Kenvue Stock Monday? - Kenvue  ( NYSE:KVUE ) ",
    "url": "https://www.benzinga.com/news/24/10/41435535/whats-going-on-with-kenvue-stock-monday",
    "time_published": "20241021T175436",
    "authors": [
      "Dylan Berman"
    ],
    "summary": "Kenvue Inc. KVUE shares are moving higher Monday following a report suggesting activist investor Starboard Value has acquired a stake in the company. The Details: According to the Wall Street Journal, Starboard has acquired a \"sizable\" stake in Kenvue and is pushing for changes to boost the ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/21/stock-exchange-3972315-1280.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.208777,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.823417",
        "ticker_sentiment_score": "0.348217",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HLN",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.220181",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ICNB",
        "relevance_score": "0.107495",
        "ticker_sentiment_score": "0.148052",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.107495",
        "ticker_sentiment_score": "-0.017461",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.115196",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Lithotripsy Market Size Worth $2.3 Billion, Globally, by 2031 - Exclusive Report by The Insight Partners",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41428910/lithotripsy-market-size-worth-2-3-billion-globally-by-2031-exclusive-report-by-the-insight-partner",
    "time_published": "20241021T135100",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "US & Canada, Oct. 21, 2024 ( GLOBE NEWSWIRE ) -- According to a new comprehensive report from The Insight Partners, the Lithotripsy Market is experiencing significant growth owing to the surging prevalence of kidney stones. The report runs an in-depth analysis of market trends, key players, and ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.236242,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SEMHF",
        "relevance_score": "0.040145",
        "ticker_sentiment_score": "0.041435",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OCPNF",
        "relevance_score": "0.040145",
        "ticker_sentiment_score": "0.041435",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.040145",
        "ticker_sentiment_score": "0.041435",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EDAP",
        "relevance_score": "0.040145",
        "ticker_sentiment_score": "0.041435",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.040145",
        "ticker_sentiment_score": "0.041435",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.040145",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares U.S. Pharmaceuticals ETF  ( IHE ) ?",
    "url": "https://www.zacks.com/stock/news/2353598/should-you-invest-in-the-ishares-us-pharmaceuticals-etf-ihe",
    "time_published": "20241021T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default79.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.156769,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.070203",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.043671",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.070203",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.070203",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Fidelity MSCI Health Care Index ETF  ( FHLC ) ?",
    "url": "https://www.zacks.com/stock/news/2353607/should-you-invest-in-the-fidelity-msci-health-care-index-etf-fhlc",
    "time_published": "20241021T102005",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default125.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.281477,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "0.049883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "0.049883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "0.049883",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Tylenol, Listerine Maker Kenvue Under Activist Spotlight With Starboard Value Stake - Overhaul Ahead For The Johnson & Johnson Spinoff? - Johnson & Johnson  ( NYSE:JNJ ) , Kenvue  ( NYSE:KVUE ) ",
    "url": "https://www.benzinga.com/markets/equities/24/10/41419988/tylenol-listerine-maker-kenvue-under-activist-spotlight-with-starboard-value-stake-overhaul-ahea",
    "time_published": "20241021T013300",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "Starboard Value, an activist investor, has reportedly acquired a substantial stake in Kenvue Inc KVUE, the company behind popular consumer products like Tylenol and Listerine.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/20/What-He-Said.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.256245,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ADSK",
        "relevance_score": "0.097457",
        "ticker_sentiment_score": "0.102376",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.097457",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.193465",
        "ticker_sentiment_score": "0.212362",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.097457",
        "ticker_sentiment_score": "0.045792",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UL",
        "relevance_score": "0.097457",
        "ticker_sentiment_score": "0.045792",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.672712",
        "ticker_sentiment_score": "0.415819",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "HLN",
        "relevance_score": "0.097457",
        "ticker_sentiment_score": "0.045792",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.28664",
        "ticker_sentiment_score": "0.207166",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Justice Department's Trustee Program Alleges Johnson & Johnson's Talc Litigation Bankruptcy Bid Is Bad-Faith Tactic To Avoid Liability - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41466839/justice-departments-trustee-program-alleges-johnson-johnsons-talc-litigation-bankruptcy-bid-is-ba",
    "time_published": "20241022T202737",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "The U.S. Trustee Program, a unit of the Department of Justice ( DOJ ) overseeing bankruptcy cases, has filed a motion in federal bankruptcy court in Houston to dismiss a Chapter 11 filing by a subsidiary of Johnson & Johnson JNJ.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/22/johnsons-5671315-1920.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.140622,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.533842",
        "ticker_sentiment_score": "0.030433",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Peering Into Johnson & Johnson's Recent Short Interest - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/10/41463653/peering-into-johnson-johnsons-recent-short-interest",
    "time_published": "20241022T181525",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Johnson & Johnson's JNJ short percent of float has fallen 14.58% since its last report. The company recently reported that it has 19.74 million shares sold short, which is 0.82% of all regular shares that are available for trading.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1729620922_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.26221,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.077712",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "5 Large Drug Stocks Likely to Outpace Q3 Earnings Estimates",
    "url": "https://www.zacks.com/stock/news/2354724/5-large-drug-stocks-likely-to-outpace-q3-earnings-estimates",
    "time_published": "20241022T123100",
    "authors": [
      "Ahan Chakraborty"
    ],
    "summary": "Let us look at some big drug/biotech stocks, NVO, NVS, PFE, REGN and BIIB, which are poised to beat on third-quarter earnings.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c2/1434.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.144846,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVS",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "-0.0014",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.214177",
        "ticker_sentiment_score": "-0.001651",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.296377",
        "ticker_sentiment_score": "0.032048",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.296377",
        "ticker_sentiment_score": "0.07412",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.296377",
        "ticker_sentiment_score": "0.034232",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.043342",
        "ticker_sentiment_score": "0.02777",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI\u2122  ( ustekinumab-aekn ) , Expanding its Label to Include Further Indications Approved for Reference Product, Stelara\u00ae  ( ustekinumab ) ",
    "url": "https://www.globenewswire.com/news-release/2024/10/22/2966767/0/en/Alvotech-and-Teva-Announce-U-S-FDA-Approval-of-Additional-Presentation-of-SELARSDI-ustekinumab-aekn-Expanding-its-Label-to-Include-Further-Indications-Approved-for-Reference-Produc.html",
    "time_published": "20241022T110000",
    "authors": [
      "Alvotech"
    ],
    "summary": "Alvotech ( NASDAQ: ALVO ) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. ( NYSE and TASE: TEVA ) , today announced that the U.S. Food and Drug Administration ( FDA ) has approved SELARSDI ( ustekinumab-aekn ) in a new presentation, 130 mg/26 mL ( 5 mg/mL ) ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.072236,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.011081",
        "ticker_sentiment_score": "0.083327",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.011081",
        "ticker_sentiment_score": "0.083327",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.011081",
        "ticker_sentiment_score": "0.05602",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.011081",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.29234",
        "ticker_sentiment_score": "0.167389",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.011081",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.055364",
        "ticker_sentiment_score": "0.093918",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.011081",
        "ticker_sentiment_score": "0.05602",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI\u2122  ( ustekinumab-aekn ) , Expanding its Label to Include Further Indications Approved for Reference Product, Stelara\u00ae  ( ustekinumab ) ",
    "url": "https://www.globenewswire.com/news-release/2024/10/22/2966769/0/en/Alvotech-and-Teva-Announce-U-S-FDA-Approval-of-Additional-Presentation-of-SELARSDI-ustekinumab-aekn-Expanding-its-Label-to-Include-Further-Indications-Approved-for-Reference-Produc.html",
    "time_published": "20241022T110000",
    "authors": [
      "Alvotech"
    ],
    "summary": "REYKJAVIK, Iceland & PARSIPPANY, N.J., Oct. 22, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO ) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. ( NYSE and TASE: TEVA ) , today announced that the U.S. Food and Drug Administration ( FDA ) has approved SELARSDI ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.07223,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.011046",
        "ticker_sentiment_score": "0.083302",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.011046",
        "ticker_sentiment_score": "0.083302",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.011046",
        "ticker_sentiment_score": "0.056003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.011046",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.291438",
        "ticker_sentiment_score": "0.166953",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.011046",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.055186",
        "ticker_sentiment_score": "0.091906",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.011046",
        "ticker_sentiment_score": "0.056003",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI\u2122  ( ustekinumab-aekn ) , Expanding its Label to Include Further Indications Approved for Reference Product, Stelara\u00ae  ( ustekinumab ) ",
    "url": "https://www.globenewswire.com/news-release/2024/10/22/2966770/0/en/Alvotech-and-Teva-Announce-U-S-FDA-Approval-of-Additional-Presentation-of-SELARSDI-ustekinumab-aekn-Expanding-its-Label-to-Include-Further-Indications-Approved-for-Reference-Produc.html",
    "time_published": "20241022T110000",
    "authors": [
      "Teva Pharmaceutical Industries Ltd"
    ],
    "summary": "REYKJAVIK, Iceland & PARSIPPANY, N.J., Oct. 22, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO ) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. ( NYSE and TASE: TEVA ) , today announced that the U.S. Food and Drug Administration ( FDA ) has approved SELARSDI ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/c2001734-949b-4cc2-8021-b4b64eda1f13",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.07223,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.011046",
        "ticker_sentiment_score": "0.083302",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.011046",
        "ticker_sentiment_score": "0.083302",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.011046",
        "ticker_sentiment_score": "0.056003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.011046",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.291438",
        "ticker_sentiment_score": "0.166953",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.011046",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.055186",
        "ticker_sentiment_score": "0.091906",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.011046",
        "ticker_sentiment_score": "0.056003",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI\u2122  ( ustekinumab-aekn ) , Expanding its Label to Include Further Indications Approved for Reference Product, Stelara\u00ae  ( ustekinumab )  - Alvotech  ( NASDAQ:ALVO ) , Teva Pharmaceutical Indus  ( NYSE:TEVA ) ",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41447702/alvotech-and-teva-announce-u-s-fda-approval-of-additional-presentation-of-selarsdi-ustekinumab-aek",
    "time_published": "20241022T110000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn's disease and ulcerative colitis The FDA previously approved SELARSDI 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled syringe for subcutaneous injection in ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.069704,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.010875",
        "ticker_sentiment_score": "0.083187",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.010875",
        "ticker_sentiment_score": "0.083187",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.010875",
        "ticker_sentiment_score": "0.047381",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.010875",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.317391",
        "ticker_sentiment_score": "0.164642",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.010875",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.054334",
        "ticker_sentiment_score": "0.080851",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.010875",
        "ticker_sentiment_score": "0.047381",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Tuesday's big stock stories: What's likely to move the market in the next trading session",
    "url": "https://www.cnbc.com/2024/10/21/tuesdays-big-stock-stories-whats-likely-to-move-the-market.html",
    "time_published": "20241022T001012",
    "authors": [],
    "summary": "The Dow Jones Industrial Average lost more than 340 points on Monday, snapping a three-day winning run. Here's what CNBC will be watching on Tuesday.",
    "banner_image": null,
    "source": "CNBC",
    "category_within_source": "Investing",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999612"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.091214,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.074572",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LMT",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESLT",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.037036",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.340915",
        "ticker_sentiment_score": "0.125282",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TXN",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STM",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.074572",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BWXT",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.037036",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HWM",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.037036",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRVL",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.074572",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Preferred Financing, Inc. Implements 2iG's PFC Insight",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41492481/johnson-johnson-preferred-financing-inc-implements-2igs-pfc-insight",
    "time_published": "20241023T151500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "PHILADELPHIA, Oct. 23, 2024 ( GLOBE NEWSWIRE ) -- 2iG Solutions, Inc. ( 2iG or 2iG Solutions ) , provider of leading-edge data analytics and artificial intelligence ( AI ) reporting software, is pleased to announce that South Carolina-based premium finance company Johnson & Johnson Preferred ...",
    "banner_image": "https://ml.globenewswire.com/media/9a8793ca-1804-4d7f-b27c-ee5cc08e011c/small/2ig-logo-full-color-png.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.401167,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.079392",
        "ticker_sentiment_score": "0.258216",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Craft Appoints Technology and Supply Chain Luminaries to Advisory Board",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41490363/craft-appoints-technology-and-supply-chain-luminaries-to-advisory-board",
    "time_published": "20241023T141330",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "SAN FRANCISCO, Oct. 23, 2024 ( GLOBE NEWSWIRE ) -- Craft, the supply chain resilience company, is proud to announce the launch of its Advisory Board with appointments of senior leaders and industry luminaries with deep technology, procurement, and supply chain experience across key global market ...",
    "banner_image": "https://ml.globenewswire.com/media/9ab22c6a-b0c6-4a39-bd83-cb5e0c218f67/small/craft-logo-positive-rgb-png.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.349096,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CL",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DELL",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "-0.149719",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "-0.149719",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KLG",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UL",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.014008",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Investors Heavily Search Johnson & Johnson  ( JNJ ) : Here is What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2355590/investors-heavily-search-johnson-johnson-jnj-here-is-what-you-need-to-know",
    "time_published": "20241023T130018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default109.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.217526,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.472338",
        "ticker_sentiment_score": "0.117509",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should iShares Core High Dividend ETF  ( HDV )  Be on Your Investing Radar?",
    "url": "https://www.zacks.com/stock/news/2355476/should-ishares-core-high-dividend-etf-hdv-be-on-your-investing-radar",
    "time_published": "20241023T102003",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Style Box ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default290.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.271139,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MORN",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.195615",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.068619",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.068619",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.068619",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron Pharmaceuticals and Biogen",
    "url": "https://www.zacks.com/stock/news/2355460/the-zacks-analyst-blog-highlights-novo-nordisk-novartis-pfizer-regeneron-pharmaceuticals-and-biogen",
    "time_published": "20241023T095600",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Novo Nordisk, Novartis, Pfizer, Regeneron Pharmaceuticals and Biogen are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.149301,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVS",
        "relevance_score": "0.157483",
        "ticker_sentiment_score": "-0.001315",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.234307",
        "ticker_sentiment_score": "-0.001763",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.308891",
        "ticker_sentiment_score": "0.024234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.308891",
        "ticker_sentiment_score": "0.054726",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.308891",
        "ticker_sentiment_score": "0.026452",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.039614",
        "ticker_sentiment_score": "0.027556",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock",
    "url": "https://www.fool.com/investing/2024/10/23/this-setback-for-johnson-johnson-is-1-more-green-l/",
    "time_published": "20241023T083000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Fewer contenders means fewer constraints on expanding market share.",
    "banner_image": "https://g.foolcdn.com/editorial/images/794812/three-investors-gather-around-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.980716"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.101339,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.515749",
        "ticker_sentiment_score": "0.16788",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.061949",
        "ticker_sentiment_score": "0.052065",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.035921",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Comparative Study: Johnson & Johnson And Industry Competitors In Pharmaceuticals Industry - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/news/24/10/41521297/comparative-study-johnson-amp-johnson-and-industry-competitors-in-pharmaceuticals-industry",
    "time_published": "20241024T150059",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In today's rapidly evolving and fiercely competitive business landscape, it is crucial for investors and industry analysts to conduct comprehensive company evaluations. In this article, we will undertake an in-depth industry comparison, assessing Johnson & Johnson JNJ alongside its primary ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1729782055_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.119381,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.041073",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.446966",
        "ticker_sentiment_score": "0.309413",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Medical Devices Market to Surpass $756.59 Billion by 2031 | SkyQuest Technology",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41513954/medical-devices-market-to-surpass-756-59-billion-by-2031-skyquest-technology",
    "time_published": "20241024T114500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Westford, USA, Oct. 24, 2024 ( GLOBE NEWSWIRE ) -- SkyQuest projects that the Medical Devices market will attain a value of $756.59 Billion by 2031, with a CAGR of 5.8% over the forecast period ( 2024-2031 ) . Medical devices are essential tools used in the healthcare sector to diagnose and ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.263153,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MFCSF",
        "relevance_score": "0.037622",
        "ticker_sentiment_score": "0.151177",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EW",
        "relevance_score": "0.037622",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FSNUF",
        "relevance_score": "0.037622",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.037622",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.037622",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.037622",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIO",
        "relevance_score": "0.037622",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.037622",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.037622",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.037622",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.037622",
        "ticker_sentiment_score": "0.151177",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Meet the Only 2 Game-Changing Businesses With a Higher Credit Rating Than the U.S. Government",
    "url": "https://www.fool.com/investing/2024/10/24/only-2-stocks-higher-credit-rating-us-government/",
    "time_published": "20241024T092100",
    "authors": [
      "Sean Williams"
    ],
    "summary": "In 1980, around five dozen publicly traded companies held the highest possible credit rating (AAA) from Standard & Poor's. Today, there are only two left.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F795017%2Fmagnifiying-glass-financial-newspaper-market-data-stocks-economy-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.234284,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.03916",
        "ticker_sentiment_score": "0.151444",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MCO",
        "relevance_score": "0.03916",
        "ticker_sentiment_score": "0.083676",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.305532",
        "ticker_sentiment_score": "0.195535",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.03916",
        "ticker_sentiment_score": "0.083676",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TWOH",
        "relevance_score": "0.03916",
        "ticker_sentiment_score": "0.138027",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.2317",
        "ticker_sentiment_score": "0.110715",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron and Biogen",
    "url": "https://www.zacks.com/stock/news/2356443/the-zacks-analyst-blog-highlights-novo-nordisk-novartis-pfizer-regeneron-and-biogen",
    "time_published": "20241024T085600",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Novo Nordisk, Novartis, Pfizer, Regeneron and Biogen are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/89/447.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.149302,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVS",
        "relevance_score": "0.157483",
        "ticker_sentiment_score": "-0.001315",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.234307",
        "ticker_sentiment_score": "-0.001763",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.308891",
        "ticker_sentiment_score": "0.024234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.308891",
        "ticker_sentiment_score": "0.054726",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.308891",
        "ticker_sentiment_score": "0.026455",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.039614",
        "ticker_sentiment_score": "0.027556",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson's Blockbuster Drug Tremfya Clears Plaque Psoriasis With Lesions Covering Body's Smaller Areas - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41552265/johnson-johnsons-blockbuster-drug-tremfya-clears-plaque-psoriasis-with-lesions-covering-bodys-sma",
    "time_published": "20241025T171924",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Friday, Johnson & Johnson JNJ announced that treatment with Tremfya ( guselkumab ) resulted in clear or almost clear skin in the majority of adults with low body surface area ( BSA ) moderate plaque psoriasis ( PsO ) with special site involvement who had failed topical treatment.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/25/Johnson-and-Johnson.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.143025,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.306963",
        "ticker_sentiment_score": "0.073061",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Kenvue Stock a Buy Now?",
    "url": "https://www.fool.com/investing/2024/10/25/is-kenvue-stock-a-buy-now/",
    "time_published": "20241025T093700",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "The growth rate of the consumer healthcare business could accelerate now that an activist investor is involved.",
    "banner_image": "https://media.ycharts.com/charts/132882ab969dd91b3a11240a018523c6.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.994953"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.245773,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.614315",
        "ticker_sentiment_score": "0.344384",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.114956",
        "ticker_sentiment_score": "-0.022155",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Billionaire Ken Griffin Just Increased His Position in This Dividend Stock by 5,848%. Here's Why Now May Be a Great Time to Buy.",
    "url": "https://www.fool.com/investing/2024/10/26/billionaire-ken-griffin-just-increased-his-positio/",
    "time_published": "20241026T224200",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Ken Griffin's Citadel just added 18 million shares of an under-the-radar consumer health stock.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F794813%2Fpharmacy-drug-store-shopping-sick.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.658903"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.204629,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.921592",
        "ticker_sentiment_score": "0.307639",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HUM",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.247523",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CLX",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.247523",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.247523",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.247523",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.11409",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Meet the 3.6%-Yielding Dividend King Stock That's Up 25% in 3 Months",
    "url": "https://www.fool.com/investing/2024/10/26/high-yield-dividend-king-stock-passive-income/",
    "time_published": "20241026T221200",
    "authors": [
      "Daniel Foelber"
    ],
    "summary": "An activist investor is taking a stake in Kenvue stock.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F795000%2Fgettyimages-1329442019-1200x800-5b2df79.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999976"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.27757,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.81619",
        "ticker_sentiment_score": "0.406175",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SBUX",
        "relevance_score": "0.199859",
        "ticker_sentiment_score": "0.144063",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.050465",
        "ticker_sentiment_score": "0.228405",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "How activist Starboard may help boost value in Kenvue's skin and beauty business",
    "url": "https://www.cnbc.com/2024/10/26/how-starboard-may-help-boost-value-in-kenvues-skin-beauty-business.html",
    "time_published": "20241026T122425",
    "authors": [],
    "summary": "Starboard Value and Kenvue seem to be aligned, and the conditions might be right for value creation.",
    "banner_image": null,
    "source": "CNBC",
    "category_within_source": "Investing",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.309768,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "OPNDF",
        "relevance_score": "0.031654",
        "ticker_sentiment_score": "0.138303",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.031654",
        "ticker_sentiment_score": "0.080548",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.279015",
        "ticker_sentiment_score": "0.27868",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CL",
        "relevance_score": "0.031654",
        "ticker_sentiment_score": "0.043883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HLN",
        "relevance_score": "0.031654",
        "ticker_sentiment_score": "0.043883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ICNB",
        "relevance_score": "0.031654",
        "ticker_sentiment_score": "0.138303",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LRLCF",
        "relevance_score": "0.031654",
        "ticker_sentiment_score": "0.190888",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Dividend Growth Stocks You Can Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/10/26/3-dividend-growth-stocks-you-can-buy-and-hold-fore/",
    "time_published": "20241026T113000",
    "authors": [
      "Keith Speights",
      "and Prosper Junior Bakiny",
      "David Jagielski"
    ],
    "summary": "These healthcare stocks have fantastic dividend track records.",
    "banner_image": "https://g.foolcdn.com/editorial/images/795225/couple-looking-at-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.320127,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.328455",
        "ticker_sentiment_score": "0.280552",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.167904",
        "ticker_sentiment_score": "0.151135",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.289381",
        "ticker_sentiment_score": "0.406408",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "3 Dividend Stocks to Double Up on Right Now",
    "url": "https://www.fool.com/investing/2024/10/27/3-dividend-stocks-to-double-up-on-right-now/",
    "time_published": "20241027T161600",
    "authors": [
      "David Butler"
    ],
    "summary": "While tech-based growth stocks might seem like the right play, you can't ignore dividends if you want to have a strong portfolio.",
    "banner_image": "https://media.ycharts.com/charts/daa56a5ccbd9b66eda0e33e34743f3d0.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.976671"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.238346,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.109206",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.054732",
        "ticker_sentiment_score": "0.146097",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.16317",
        "ticker_sentiment_score": "0.13087",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.268589",
        "ticker_sentiment_score": "0.183085",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Global Psychedelic Drugs Market Expected To Reach $10.2B By 2028 Amid Growing Mental Health Crises - Johnson & Johnson  ( NYSE:JNJ ) , Mydecine Innovations Gr  ( OTC:MYCOF ) ",
    "url": "https://www.benzinga.com/markets/cannabis/24/10/41589487/global-psychedelic-drugs-market-expected-to-reach-10-2b-by-2028-amid-growing-mental-health-crise",
    "time_published": "20241028T223919",
    "authors": [
      "Juan Sp\u00ednelli"
    ],
    "summary": "The global psychedelic drugs market is set for rapid expansion, with projections forecasting growth from $4.88 billion in 2023 to $10.2 billion by 2028, according to The Business Research Company.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/28/2-17.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.239032,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.219809",
        "ticker_sentiment_score": "0.298321",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.219809",
        "ticker_sentiment_score": "0.298321",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Adobe Down 6% in a Month: Should You Buy the Dip in ADBE Stock?",
    "url": "https://www.zacks.com/stock/news/2358945/adobe-down-6-in-a-month-should-you-buy-the-dip-in-adbe-stock",
    "time_published": "20241028T180200",
    "authors": [
      "Aniruddha Ganguly"
    ],
    "summary": "ADBE shares are benefiting from strong demand for its creative products and expanding clientele.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/931.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.364785,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.095517",
        "ticker_sentiment_score": "0.188686",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.047844",
        "ticker_sentiment_score": "0.132784",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.047844",
        "ticker_sentiment_score": "0.132784",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NWL",
        "relevance_score": "0.047844",
        "ticker_sentiment_score": "0.132784",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IBM",
        "relevance_score": "0.095517",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.047844",
        "ticker_sentiment_score": "0.132784",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADBE",
        "relevance_score": "0.866386",
        "ticker_sentiment_score": "0.479608",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "DNTUF",
        "relevance_score": "0.047844",
        "ticker_sentiment_score": "0.132784",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SCHW",
        "relevance_score": "0.047844",
        "ticker_sentiment_score": "0.132784",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PEP",
        "relevance_score": "0.047844",
        "ticker_sentiment_score": "0.132784",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.047844",
        "ticker_sentiment_score": "0.132784",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Will These 5 Big Drug Stocks Surpass Q3 Earnings Forecasts?",
    "url": "https://www.zacks.com/stock/news/2358849/will-these-5-big-drug-stocks-surpass-q3-earnings-forecasts",
    "time_published": "20241028T160600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Let's look at five pharma and drug companies, PFE, LLY, ABBV, MRK and BMY, that are scheduled to release their third-quarter 2024 results this week.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ab/2180.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.196752,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.221481",
        "ticker_sentiment_score": "0.036211",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.185306",
        "ticker_sentiment_score": "0.035956",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.185306",
        "ticker_sentiment_score": "0.034366",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.221481",
        "ticker_sentiment_score": "0.117668",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "-0.009697",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "-0.009697",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson's Tremfya Seeks Expanded Use Approval After It Shares Encouraging Late-Stage Study Data In Crohn's Disease - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41579342/johnson-johnsons-tremfya-seeks-expanded-use-approval-after-it-shares-encouraging-late-stage-study",
    "time_published": "20241028T153200",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Monday, Johnson & Johnson JNJ announced results from the Phase 3 GRAVITI study of Tremfya ( guselkumab ) for Crohn's disease. The findings demonstrated significant clinical remission and endoscopic response at 48 weeks in adults with moderately to severely active Crohn's disease.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/28/jnj-johnson-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.214929,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.434142",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Top Dividend ETFs That Could Build Generation-Spanning Wealth",
    "url": "https://www.fool.com/investing/2024/10/29/3-top-dividend-etfs-that-could-build-generation-sp/",
    "time_published": "20241029T110000",
    "authors": [
      "George Budwell"
    ],
    "summary": "These three dividend-focused ETFs offer a simple path to building lasting wealth through the power of compound growth.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F795518%2Fgenerational.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.392424,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.095084",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.095084",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.234055",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CSCO",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.114013",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.095084",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.114013",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.234055",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.234055",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.097259",
        "ticker_sentiment_score": "0.177821",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.286223",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TXN",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.114013",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.114013",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Idorsia announces financial results for the first nine months of 2024",
    "url": "https://www.globenewswire.com/news-release/2024/10/29/2970474/0/en/Idorsia-announces-financial-results-for-the-first-nine-months-of-2024.html",
    "time_published": "20241029T060000",
    "authors": [
      "Idorsia Pharmaceuticals Ltd"
    ],
    "summary": "Ad hoc announcement pursuant to Art. 53 LR ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/4001b830-054a-445d-8cff-99a44a82f438/image1.png",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.164265,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IDRSF",
        "relevance_score": "0.267093",
        "ticker_sentiment_score": "0.211062",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.012376",
        "ticker_sentiment_score": "0.078982",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NBIX",
        "relevance_score": "0.024749",
        "ticker_sentiment_score": "0.032027",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SGIOF",
        "relevance_score": "0.037117",
        "ticker_sentiment_score": "0.142075",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VTRS",
        "relevance_score": "0.123272",
        "ticker_sentiment_score": "0.061943",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Top Stock Reports for Amazon.com, Johnson & Johnson and Boston Scientific",
    "url": "https://www.zacks.com/research-daily/2360508/top-stock-reports-for-amazoncom-johnson-johnson-and-boston-scientific",
    "time_published": "20241030T202400",
    "authors": [
      "Mark Vickery"
    ],
    "summary": "Today's Research Daily features new research reports on 12 major stocks, including Amazon.com, Inc. (AMZN), Johnson & Johnson (JNJ) and Boston Scientific Corporation (BSX), as well as a micro-cap stock Armanino Foods of Distinction, Inc. (AMNF).",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/bf/2282.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.482795,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMZN",
        "relevance_score": "0.066047",
        "ticker_sentiment_score": "-0.113087",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.066047",
        "ticker_sentiment_score": "0.194559",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie Trumps Q3 Earnings & Sales Estimates, Raises '24 EPS View",
    "url": "https://www.zacks.com/stock/news/2360933/abbvie-trumps-q3-earnings-sales-estimates-raises-24-eps-view",
    "time_published": "20241030T160500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "ABBV's third-quarter 2024 earnings and sales beat estimates. The company increases the EPS guidance on encouraging product sales for immunology drugs.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/31/1512.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.083128,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.445959",
        "ticker_sentiment_score": "0.292145",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.094204",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This Big New Development Could Be Bullish for Kenvue Stock",
    "url": "https://www.fool.com/investing/2024/10/30/this-big-development-could-be-bullish-for-kenvue/",
    "time_published": "20241030T101500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Can tinkering around the edges actually make this stock more attractive?",
    "banner_image": "https://g.foolcdn.com/editorial/images/795336/two-investors-consider-a-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.918141"
      }
    ],
    "overall_sentiment_score": 0.153327,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.286193",
        "ticker_sentiment_score": "0.19245",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.116631",
        "ticker_sentiment_score": "0.007018",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.116631",
        "ticker_sentiment_score": "0.079987",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Amazon.com, Johnson & Johnson, Boston Scientific and Armanino Foods of Distinction",
    "url": "https://www.zacks.com/stock/news/2362066/the-zacks-analyst-blog-highlights-amazoncom-johnson-johnson-boston-scientific-and-armanino-foods-of-distinction",
    "time_published": "20241031T161000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "mazon.com, Johnson & Johnson, Boston Scientific and Armanino Foods of Distinction are part of the Zacks top Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/14/776.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.423635,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMZN",
        "relevance_score": "0.103331",
        "ticker_sentiment_score": "0.041249",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.154455",
        "ticker_sentiment_score": "0.083799",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.204936",
        "ticker_sentiment_score": "0.1653",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Legend Biotech Appoints Alan Bash as President of CARVYKTI\u00ae",
    "url": "https://www.globenewswire.com/news-release/2024/11/04/2973951/0/en/Legend-Biotech-Appoints-Alan-Bash-as-President-of-CARVYKTI.html",
    "time_published": "20241104T123000",
    "authors": [
      "Legend Biotech USA Inc."
    ],
    "summary": "Newly created position to lead efforts focused on continued growth and sales Newly created position to lead efforts focused on continued growth and sales ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/d3a680c2-cab6-4eb2-9ed0-7be055f9e180",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.087029,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LEGN",
        "relevance_score": "0.382925",
        "ticker_sentiment_score": "0.147992",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "-0.046866",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "-0.046866",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.349652",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is Invesco S&P 500 Quality ETF  ( SPHQ )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2362991/is-invesco-sp-500-quality-etf-sphq-a-strong-etf-right-now",
    "time_published": "20241104T112008",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default328.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999965"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.253733,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MORN",
        "relevance_score": "0.057215",
        "ticker_sentiment_score": "0.186069",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.114137",
        "ticker_sentiment_score": "0.066424",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.170475",
        "ticker_sentiment_score": "0.118395",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.057215",
        "ticker_sentiment_score": "0.059943",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.114137",
        "ticker_sentiment_score": "0.066424",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma - Legend Biotech  ( NASDAQ:LEGN ) ",
    "url": "https://www.benzinga.com/pressreleases/24/11/g41745698/legend-biotech-to-unveil-minimal-residual-disease-data-from-landmark-cartitude-4-trial-in-multiple",
    "time_published": "20241105T141000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New data will showcase significantly increased and sustained minimal residual disease ( MRD ) negativity rates, reinforcing the potential of CARVYKTI to transform outcomes in refractory multiple myeloma MRD data to be featured in oral presentation at the 66th Annual American Society of ...",
    "banner_image": "https://ml.globenewswire.com/media/d3a680c2-cab6-4eb2-9ed0-7be055f9e180/small/legend-logo-fullcolor-transparent-1-png.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": -0.099882,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.018278",
        "ticker_sentiment_score": "0.007117",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LEGN",
        "relevance_score": "0.063909",
        "ticker_sentiment_score": "0.012076",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRGNF",
        "relevance_score": "0.009139",
        "ticker_sentiment_score": "-0.006419",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2364194/johnson-johnson-jnj-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20241105T140018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default183.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.239821,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.474958",
        "ticker_sentiment_score": "0.129897",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Genmab Announces Financial Results for the First Nine Months of 2024",
    "url": "https://www.globenewswire.com/news-release/2024/11/06/2975872/0/en/Genmab-Announces-Financial-Results-for-the-First-Nine-Months-of-2024.html",
    "time_published": "20241106T160200",
    "authors": [
      "Genmab A/S"
    ],
    "summary": "November 6, 2024 Copenhagen, Denmark. Interim Report for the First Nine Months Ended September ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.129413,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVS",
        "relevance_score": "0.039353",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.117678",
        "ticker_sentiment_score": "0.071725",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GMAB",
        "relevance_score": "0.44622",
        "ticker_sentiment_score": "0.106738",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.039353",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/news/24/11/41773566/wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-with-over-3-dividend-yie",
    "time_published": "20241106T133908",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.",
    "banner_image": null,
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.172048,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RPRX",
        "relevance_score": "0.194242",
        "ticker_sentiment_score": "0.170844",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.287762",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.097854",
        "ticker_sentiment_score": "0.075969",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.097854",
        "ticker_sentiment_score": "-0.089749",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.194242",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNDX",
        "relevance_score": "0.097854",
        "ticker_sentiment_score": "0.177036",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.194242",
        "ticker_sentiment_score": "0.098207",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Rheumatoid Arthritis Drugs Market Size & Share to Surpass USD 29.3 billion by 2031 | Analysis by Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/11/g41771724/rheumatoid-arthritis-drugs-market-size-share-to-surpass-usd-29-3-billion-by-2031-analysis-by-trans",
    "time_published": "20241106T125000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research Inc. -, Nov. 06, 2024 ( GLOBE NEWSWIRE ) -- The rheumatoid arthritis drugs market ( \ub958\ub9c8\ud2f0\uc2a4 \uad00\uc808\uc5fc \uce58\ub8cc\uc81c \uc2dc\uc7a5 ) was valued at US$ 17.5 billion in 2022. The market is predicted to grow at a CAGR of 5.7% from 2023 to 2031, reaching US$ 29.3 ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/64fe8541-2552-46d0-a222-ff7eab058175/rheumatoid-arthritis-drugs-market.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.245804,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.03916",
        "ticker_sentiment_score": "0.053862",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.117104",
        "ticker_sentiment_score": "0.125172",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.03916",
        "ticker_sentiment_score": "0.204507",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.03916",
        "ticker_sentiment_score": "0.204507",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results",
    "url": "https://www.globenewswire.com/news-release/2024/11/07/2977235/0/en/Cidara-Therapeutics-Provides-Corporate-Update-and-Reports-Third-Quarter-2024-Financial-Results.html",
    "time_published": "20241107T211500",
    "authors": [
      "Inc.",
      "Cidara Therapeutics"
    ],
    "summary": "SAN DIEGO, Nov. 07, 2024 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( Nasdaq: CDTX ) ( the Company ) , a biotechnology company using its proprietary Cloudbreak\u00ae platform to develop drug-Fc conjugate ( DFC ) immunotherapies designed to save lives and improve the standard of care for patients ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/97036182-e328-4e3f-a1ef-6d4a151e97cb",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      }
    ],
    "overall_sentiment_score": 0.185421,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CDTX",
        "relevance_score": "0.063537",
        "ticker_sentiment_score": "0.064201",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.021199",
        "ticker_sentiment_score": "0.094371",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "FDA proposes ending use of decongestant found in many cold, allergy medicines",
    "url": "https://www.cnbc.com/2024/11/07/fda-decongestant-cold-medicines.html",
    "time_published": "20241107T155712",
    "authors": [],
    "summary": "The FDA said the proposed order is not final yet, which means companies can still market over-the-counter drugs containing oral phenylephrine for now.",
    "banner_image": null,
    "source": "CNBC",
    "category_within_source": "Business",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": -0.097366,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.062271",
        "ticker_sentiment_score": "-0.148079",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVS",
        "relevance_score": "0.124164",
        "ticker_sentiment_score": "0.042337",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.062271",
        "ticker_sentiment_score": "-0.148079",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.062271",
        "ticker_sentiment_score": "-0.148079",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Industry Comparison: Evaluating Johnson & Johnson Against Competitors In Pharmaceuticals Industry - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/news/24/11/41810565/industry-comparison-evaluating-johnson-amp-johnson-against-competitors-in-pharmaceuticals-industry",
    "time_published": "20241107T150053",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In the ever-changing and fiercely competitive business landscape, conducting thorough company analysis is crucial for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Johnson & Johnson JNJ and its primary competitors in the ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1730991650_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.131045,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.068112",
        "ticker_sentiment_score": "0.041087",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.450354",
        "ticker_sentiment_score": "0.252396",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Employers look to AI tools to plug skills gap and retain staff",
    "url": "https://www.ft.com/content/9cf58a76-5245-4cdf-9449-239e90077eb5",
    "time_published": "20241107T050046",
    "authors": [
      "Bethan Staton"
    ],
    "summary": "Technology can help boost corporate productivity and improve employees' career prospects ...",
    "banner_image": "https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fwww.ft.com%2F__origami%2Fservice%2Fimage%2Fv2%2Fimages%2Fraw%2Fhttps%253A%252F%252Fd1e00ek4ebabms.cloudfront.net%252Fproduction%252Fb2f0f29d-bc98-4f4b-a745-b2d290b2f458.jpg%3Fsource%3Dnext-article%26fit%3Dscale-down%26quality%3Dhighest%26width%3D700%26dpr%3D1?source=next&fit=scale-down&dpr=2&width=240",
    "source": "Financial Times",
    "category_within_source": "Companies",
    "source_domain": "www.ft.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.23207,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BAC",
        "relevance_score": "0.036146",
        "ticker_sentiment_score": "0.062049",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.036146",
        "ticker_sentiment_score": "0.124956",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever",
    "url": "https://www.fool.com/investing/2024/11/08/want-decades-of-passive-income-2-stocks-to-buy-now/",
    "time_published": "20241108T091500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "You'll also like these stocks for their track record of earnings growth.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F796743%2Fgettyimages-smiling-investor.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.980509"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.391827,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.116348",
        "ticker_sentiment_score": "0.187391",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.116348",
        "ticker_sentiment_score": "0.282322",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?",
    "url": "https://www.zacks.com/stock/news/2368271/will-these-5-biotech-stocks-surpass-q3-earnings-forecasts",
    "time_published": "20241111T154600",
    "authors": [
      "Ahan Chakraborty"
    ],
    "summary": "Let's look at five biotech and drug companies, AZN, NVAX, AXSM, TBPH and PRTA, slated to release their third-quarter 2024 results this week.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e5/1416.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.064366,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "TBPH",
        "relevance_score": "0.215894",
        "ticker_sentiment_score": "-0.026424",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.318897",
        "ticker_sentiment_score": "0.090423",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.03642",
        "ticker_sentiment_score": "0.063915",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.03642",
        "ticker_sentiment_score": "-0.021257",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VTRS",
        "relevance_score": "0.03642",
        "ticker_sentiment_score": "0.149714",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PRTA",
        "relevance_score": "0.318897",
        "ticker_sentiment_score": "-0.002275",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVAX",
        "relevance_score": "0.28511",
        "ticker_sentiment_score": "-0.092327",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "-0.013211",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "-0.013211",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXSM",
        "relevance_score": "0.215894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Biotechnology Market Value Set to Reach $2,667.36 Billion, Driven by 17.09% CAGR | Fact.MR Report",
    "url": "https://www.benzinga.com/pressreleases/24/11/g41875780/biotechnology-market-value-set-to-reach-2-667-36-billion-driven-by-17-09-cagr-fact-mr-report",
    "time_published": "20241111T123000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Rockville, MD, Nov. 11, 2024 ( GLOBE NEWSWIRE ) -- According to a new industry report by Fact.MR, a market research and competitive intelligence provider, the global biotechnology market is projected to reach a size of US$ 550.83 billion in 2024 and further touch US$ 2667.36 billion by the end ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/5570f77b-733f-4ab3-b5dd-e543a053beed/biotechnology-market.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.320652,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.039289",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.039289",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.039289",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.039289",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.039289",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.039289",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.039289",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the VanEck Pharmaceutical ETF  ( PPH ) ?",
    "url": "https://www.zacks.com/stock/news/2367863/should-you-invest-in-the-vaneck-pharmaceutical-etf-pph",
    "time_published": "20241111T112007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for PPH ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default80.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.191039,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.061552",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.043079",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.061552",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.061552",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is iShares Core High Dividend ETF  ( HDV )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2367866/is-ishares-core-high-dividend-etf-hdv-a-strong-etf-right-now",
    "time_published": "20241111T112007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default146.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.291745,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MORN",
        "relevance_score": "0.112532",
        "ticker_sentiment_score": "0.173863",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.112532",
        "ticker_sentiment_score": "0.066075",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.112532",
        "ticker_sentiment_score": "0.066075",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.112532",
        "ticker_sentiment_score": "0.066075",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Did the Vanguard Growth ETF and the Vanguard Value ETF Both Hit All-Time Highs on the Same Day?",
    "url": "https://www.fool.com/investing/2024/11/12/vanguard-growth-value-etf-buy-stock/",
    "time_published": "20241112T150700",
    "authors": [
      "Daniel Foelber"
    ],
    "summary": "Record highs across the S&P 500, Nasdaq Composite, and Dow Jones showcase just how widespread the 2024 stock market rally has been.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F797299%2Fhappy-woman-high-five-celebrate-win-1200x675-128554e-1.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      }
    ],
    "overall_sentiment_score": 0.385815,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.052685",
        "ticker_sentiment_score": "0.06598",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.052685",
        "ticker_sentiment_score": "0.299879",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.105141",
        "ticker_sentiment_score": "0.187219",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.052685",
        "ticker_sentiment_score": "0.137613",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.052685",
        "ticker_sentiment_score": "0.06598",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.052685",
        "ticker_sentiment_score": "0.137613",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.052685",
        "ticker_sentiment_score": "0.06598",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.052685",
        "ticker_sentiment_score": "0.137613",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Will ISRG Stock Continue Its Uptrend After Gaining 9.9% in a Month?",
    "url": "https://www.zacks.com/stock/news/2368614/will-isrg-stock-continue-its-uptrend-after-gaining-99-in-a-month",
    "time_published": "20241112T131000",
    "authors": [
      "Indrajit Bandyopadhyay"
    ],
    "summary": "Intuitive Surgical has maintained an uptrend so far this year on the back of robust da Vinci portfolio performance. The stock also gained during the past month. Let's see if the trend might change.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/61/11728.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.323918,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MDT",
        "relevance_score": "0.056876",
        "ticker_sentiment_score": "0.297023",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.407404",
        "ticker_sentiment_score": "0.429664",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.056876",
        "ticker_sentiment_score": "0.297023",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms",
    "url": "https://www.globenewswire.com/news-release/2024/11/12/2978712/0/en/NANOBIOTIX-Provides-Third-Quarter-2024-Update-and-Progress-on-Nanotherapeutics-Platforms.html",
    "time_published": "20241112T073000",
    "authors": [
      "Nanobiotix S.A."
    ],
    "summary": "PARIS and CAMBRIDGE, Mass., Nov. 12, 2024 ( GLOBE NEWSWIRE ) -- NANOBIOTIX ( Euronext: NANO - NASDAQ: NBTX - the \"Company\" ) , a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/36fb7b98-27d7-46cb-b989-fa31626657b8",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.10753,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NBTX",
        "relevance_score": "0.547823",
        "ticker_sentiment_score": "0.160699",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.028558",
        "ticker_sentiment_score": "0.013118",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:NANO",
        "relevance_score": "0.028558",
        "ticker_sentiment_score": "0.011402",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "After-sun Products Market Size on Track for USD 3.3 Billion by 2031, Rising at a CAGR of 3.7% - Report by Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/11/g41944241/after-sun-products-market-size-on-track-for-usd-3-3-billion-by-2031-rising-at-a-cagr-of-3-7-report",
    "time_published": "20241113T154105",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research, Inc. , Nov. 13, 2024 ( GLOBE NEWSWIRE ) -- After-sun products ( Produits apr\u00e8s-soleil ) accounted for a global market value of US$ 2.4 billion in 2022. From 2023 to 2031, it is expected to expand at a CAGR of 3.7%, reaching US$ ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/a6c83d85-7787-4f32-8520-554b09555ccb/after-sun-products-market-1-.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.39163,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.038468",
        "ticker_sentiment_score": "0.053723",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.115048",
        "ticker_sentiment_score": "0.153642",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.038468",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.038468",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Challenges Government Drug Pricing Dispute Over Two Drugs - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/11/41941391/johnson-johnson-challenges-government-drug-pricing-dispute-over-two-drugs",
    "time_published": "20241113T144105",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Johnson & Johnson JNJ has filed a lawsuit against a U.S. government agency over a contentious disagreement about payment methods. What Happened: The legal spat stems from the federal 340B Drug Pricing Program, which provides discounted medications to hospitals serving vulnerable patients.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/13/JohnsonampJohnson-Shutterstock.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.053773,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.475461",
        "ticker_sentiment_score": "-0.285227",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results",
    "url": "https://markets.businessinsider.com/news/stocks/mersana-therapeutics-provides-business-update-and-announces-third-quarter-2024-financial-results-1034007472",
    "time_published": "20241113T120050",
    "authors": [
      "markets.businessinsider.com"
    ],
    "summary": "\u2022 Plan to announce initial clinical data for XMT-1660 at a company event by the end of 2024",
    "banner_image": "https://ml.globenewswire.com/media/YzMyOTFhNTEtMjQ2NS00Y2U3LThhMWQtNDUzNjc1ODA5YWI4LTEwOTU2MDI=/tiny/Mersana-Therapeutics-Inc-.png",
    "source": "Business Insider",
    "category_within_source": "RSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.066168,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MRSN",
        "relevance_score": "0.150827",
        "ticker_sentiment_score": "0.085702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GSK",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "-0.057764",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.1879",
        "ticker_sentiment_score": "0.040563",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Trump Taps RFK Jr. For Health Secretary Role, Sends 5 Vaccine Stocks Lower - AstraZeneca  ( NASDAQ:AZN ) , Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower",
    "time_published": "20241114T220453",
    "authors": [
      "Michael Cohen"
    ],
    "summary": "President-elect Donald Trump picked Robert F. Kennedy Jr., known for his vaccine skepticism, as his nominee Thursday to lead the Department of Health and Human Services. This move, which comes after Kennedy ended his presidential campaign and endorsed Trump, positions the environmental activist ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/14/Trump-Has-Asked-Me-To-Do-3-Things--Says-.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.021735,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.179788",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.179788",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Is Johnson & Johnson  ( JNJ )  Down 6.7% Since Last Earnings Report?",
    "url": "https://www.zacks.com/stock/news/2370554/why-is-johnson-johnson-jnj-down-67-since-last-earnings-report",
    "time_published": "20241114T163015",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default138.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.918141"
      }
    ],
    "overall_sentiment_score": 0.136213,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.089378",
        "ticker_sentiment_score": "0.015892",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Dividend Stocks to Buy Hand Over Fist in November",
    "url": "https://www.fool.com/investing/2024/11/14/2-dividend-stocks-to-buy-hand-over-fist-november/",
    "time_published": "20241114T151500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "These companies have solid businesses and excellent dividend growth track records.",
    "banner_image": "https://g.foolcdn.com/editorial/images/797409/pharmacist-talking-to-patient.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.30695,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.528798",
        "ticker_sentiment_score": "0.274951",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.399734",
        "ticker_sentiment_score": "0.306577",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.052226",
        "ticker_sentiment_score": "0.023093",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Are These 3 Vanguard ETFs Underperforming the S&P 500 Since Election Day?",
    "url": "https://www.fool.com/investing/2024/11/14/low-cost-vanguard-etfs-lag-election-sell/",
    "time_published": "20241114T131200",
    "authors": [
      "Daniel Foelber"
    ],
    "summary": "Stocks in these \"safe\" sectors are selling off as investors gravitate toward growth.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F797222%2Fgettyimages-1207323692-1200x800-5b2df79.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.23936,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "COST",
        "relevance_score": "0.16171",
        "ticker_sentiment_score": "0.05106",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MO",
        "relevance_score": "0.040691",
        "ticker_sentiment_score": "0.175137",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.081276",
        "ticker_sentiment_score": "-0.015509",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.040691",
        "ticker_sentiment_score": "0.102116",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.081276",
        "ticker_sentiment_score": "-0.015509",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.12165",
        "ticker_sentiment_score": "-0.018684",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.040691",
        "ticker_sentiment_score": "-0.149518",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PM",
        "relevance_score": "0.040691",
        "ticker_sentiment_score": "0.175137",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.12165",
        "ticker_sentiment_score": "-0.018684",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.16171",
        "ticker_sentiment_score": "0.05106",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Artmarket.com: Q3 2024 revenue +13%. Study on AI search engines shows Artprice has the world's biggest, best and most useful art market database, thanks to its Intuitive Artmarket\u00ae AI - Apple  ( NASDAQ:AAPL ) , Amazon.com  ( NASDAQ:AMZN ) ",
    "url": "https://www.benzinga.com/pressreleases/24/11/n41963542/artmarket-com-q3-2024-revenue-13-study-on-ai-search-engines-shows-artprice-has-the-worlds-biggest-",
    "time_published": "20241114T073000",
    "authors": [
      "PRNewswire"
    ],
    "summary": "In October 2024, Artprice by Artmarket has reached a new milestone with its Intuitive Artmarket\u00ae AI and its positive impact on annual recurring revenue growth.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.9545"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.214606,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.032338",
        "ticker_sentiment_score": "0.071055",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.032338",
        "ticker_sentiment_score": "0.13734",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.008087",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.024256",
        "ticker_sentiment_score": "0.084827",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.016172",
        "ticker_sentiment_score": "0.057578",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.016172",
        "ticker_sentiment_score": "0.124588",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.008087",
        "ticker_sentiment_score": "0.117445",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.008087",
        "ticker_sentiment_score": "0.117445",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NYT",
        "relevance_score": "0.008087",
        "ticker_sentiment_score": "-0.025332",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IT",
        "relevance_score": "0.008087",
        "ticker_sentiment_score": "0.095752",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DOMO",
        "relevance_score": "0.008087",
        "ticker_sentiment_score": "0.069507",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.016172",
        "ticker_sentiment_score": "0.057578",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:GBP",
        "relevance_score": "0.008087",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:EUR",
        "relevance_score": "0.032338",
        "ticker_sentiment_score": "0.060154",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.008087",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.056559",
        "ticker_sentiment_score": "0.101923",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:ETH",
        "relevance_score": "0.040416",
        "ticker_sentiment_score": "0.106948",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Big investors call for break-up of Smith & Nephew",
    "url": "https://www.ft.com/content/4a98e172-4f94-41cd-bacb-2627c550a6a8",
    "time_published": "20241114T050041",
    "authors": [
      "Ian Johnston",
      "Harriet Agnew"
    ],
    "summary": "Three top 20 shareholders say medical devices company should consider spinning off orthopaedics unit ...",
    "banner_image": "https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fd1e00ek4ebabms.cloudfront.net%2Fproduction%2F593a4afc-d741-4c7c-b3e7-a771ee458937.jpg?source=next-article&fit=scale-down&quality=highest&width=700&dpr=1",
    "source": "Financial Times",
    "category_within_source": "Companies",
    "source_domain": "www.ft.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.036188,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ZBH",
        "relevance_score": "0.066784",
        "ticker_sentiment_score": "-0.035047",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNN",
        "relevance_score": "0.32478",
        "ticker_sentiment_score": "-0.202114",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.32478",
        "ticker_sentiment_score": "-0.202114",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.066784",
        "ticker_sentiment_score": "-0.035047",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This Is What Whales Are Betting On Johnson & Johnson - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/options/24/11/42014122/this-is-what-whales-are-betting-on-johnson-johnson",
    "time_published": "20241115T170117",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bullish approach towards Johnson & Johnson JNJ, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1731690074_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      }
    ],
    "overall_sentiment_score": 0.209332,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.073773",
        "ticker_sentiment_score": "0.041279",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.691568",
        "ticker_sentiment_score": "0.35793",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Tremfya's Promising Debut Boosts Momentum for IL-23 Class in Ulcerative Colitis Treatment, According to Spherix Global Insights",
    "url": "https://www.benzinga.com/pressreleases/24/11/g42009841/tremfyas-promising-debut-boosts-momentum-for-il-23-class-in-ulcerative-colitis-treatment-according",
    "time_published": "20241115T143834",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "EXTON, PA, Nov. 15, 2024 ( GLOBE NEWSWIRE ) -- In what has been a transformative year for ulcerative colitis ( UC ) treatment, the IL-23 class has solidified its role as a key therapeutic treatment option.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.285679,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.054236",
        "ticker_sentiment_score": "0.073905",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.054236",
        "ticker_sentiment_score": "0.073905",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This Johnson & Johnson Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/24/11/42005399/this-johnson-here-are-top-5-initiations-for-friday",
    "time_published": "20241115T122237",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Goldman Sachs analyst David Roman initiated coverage on HealthEquity, Inc.",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15072028/image-169-1024x569.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.273696,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HQY",
        "relevance_score": "0.379051",
        "ticker_sentiment_score": "0.158524",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EME",
        "relevance_score": "0.379051",
        "ticker_sentiment_score": "0.158524",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.130926",
        "ticker_sentiment_score": "0.072883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NSIT",
        "relevance_score": "0.379051",
        "ticker_sentiment_score": "0.15598",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.379051",
        "ticker_sentiment_score": "0.15598",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.490323",
        "ticker_sentiment_score": "0.442164",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Mounjaro-Maker Eli Lilly Files Lawsuit Against US Agency Over Drug Rebate Program - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/11/42002487/mounjaro-maker-eli-lilly-files-lawsuit-against-us-agency-over-drug-rebate-program",
    "time_published": "20241115T100258",
    "authors": [
      "Pooja Rajkumari"
    ],
    "summary": "Eli Lilly And Co. LLY has filed a lawsuit against the Health Resources and Services Administration ( HRSA ) . The pharmaceutical giant claims that HRSA obstructed its attempt to alter drug discount offerings to hospitals.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/15/Eli-Lilly.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.03881,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.548633",
        "ticker_sentiment_score": "-0.084695",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.09989",
        "ticker_sentiment_score": "-0.041519",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Numab Therapeutics and Kaken Pharmaceutical Enter Collaboration and Option Agreement for Multi-specific Antibody ND081 for Treatment of Inflammatory Bowel Disease",
    "url": "https://www.benzinga.com/pressreleases/24/11/g42002094/numab-therapeutics-and-kaken-pharmaceutical-enter-collaboration-and-option-agreement-for-multi-spe",
    "time_published": "20241115T093000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Numab to receive R&D funding for the preclinical development of ND081 Kaken Pharmaceutical receives an option to in-license ND081 in certain Asian territories in exchange for funding global development up to clinical POC",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.301911,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.116067",
        "ticker_sentiment_score": "0.159755",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KKPCF",
        "relevance_score": "0.284861",
        "ticker_sentiment_score": "0.286412",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Karolinska Development's portfolio company SVF Vaccines appoints Dr Gaston Picchio as acting CEO",
    "url": "https://www.globenewswire.com/news-release/2024/11/15/2981784/0/en/Karolinska-Development-s-portfolio-company-SVF-Vaccines-appoints-Dr-Gaston-Picchio-as-acting-CEO.html",
    "time_published": "20241115T073000",
    "authors": [
      "Karolinska Development AB (publ)"
    ],
    "summary": "STOCKHOLM, Sweden, 15 November 2024. Karolinska Development AB ( Nasdaq Stockholm: KDEV ) today announces that its portfolio company SVF Vaccines has appointed Dr Gaston Picchio as acting CEO. He will assume the position with effect from today, Friday November 15th, as Dr Richard Bethell has ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/3626524f-14a1-4bc4-9461-b2613ec9035e",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.258392,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABUS",
        "relevance_score": "0.220809",
        "ticker_sentiment_score": "0.062768",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.220809",
        "ticker_sentiment_score": "0.062768",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline - Aclaris Therapeutics  ( NASDAQ:ACRS ) ",
    "url": "https://www.benzinga.com/pressreleases/24/11/g42034751/aclaris-therapeutics-announces-exclusive-global-license-agreement-with-biosion-inc-adding-potentia",
    "time_published": "20241118T131004",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "- Enhances Aclaris' pipeline with complementary biologics portfolio - - Expands leadership team with addition of seasoned biotech executives - - Management to host conference call today at 8:30 AM ET - WAYNE, Pa., Nov. 18, 2024 ( GLOBE NEWSWIRE ) -- Aclaris Therapeutics, Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.187777,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ACRS",
        "relevance_score": "0.092807",
        "ticker_sentiment_score": "0.1715",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.030998",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline",
    "url": "https://www.globenewswire.com/news-release/2024/11/18/2982759/37216/en/Aclaris-Therapeutics-Announces-Exclusive-Global-License-Agreement-with-Biosion-Inc-adding-Potential-Best-in-Class-Biologics-Assets-to-Pipeline.html",
    "time_published": "20241118T131000",
    "authors": [
      "Aclaris Therapeutics",
      "Inc."
    ],
    "summary": "- Enhances Aclaris' pipeline with complementary biologics portfolio - - Expands leadership team with addition of seasoned biotech executives - - Management to host conference call today at 8:30 AM ET -",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/de2bcb21-de59-4226-bc8b-b1b747461f51",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.185492,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ACRS",
        "relevance_score": "0.096155",
        "ticker_sentiment_score": "0.180559",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.032121",
        "ticker_sentiment_score": "-0.033449",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CHMP Endorses J&J's Rybrevant-Lazcluze Combo for Use in NSCLC",
    "url": "https://www.zacks.com/stock/news/2371369/chmp-endorses-jjs-rybrevant-lazcluze-combo-for-use-in-nsclc",
    "time_published": "20241118T124200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The CHMP's opinion is based on late-stage study data, which show that treatment with JNJ's combo drug reduces the risk of disease progression or death by 30% in certain NSCLC patients.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/1612.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.133019,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SPRO",
        "relevance_score": "0.313218",
        "ticker_sentiment_score": "0.048632",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "-0.0012",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSTL",
        "relevance_score": "0.252987",
        "ticker_sentiment_score": "0.09797",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.313218",
        "ticker_sentiment_score": "-0.144218",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  is Attracting Investor Attention: Here is What You Should Know",
    "url": "https://www.zacks.com/stock/news/2372032/johnson-johnson-jnj-is-attracting-investor-attention-here-is-what-you-should-know",
    "time_published": "20241119T140017",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default221.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.206204,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.477606",
        "ticker_sentiment_score": "0.118345",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "1 Dividend King at a 52-Week Low and Another at a 52-Week High to Buy Now",
    "url": "https://www.fool.com/investing/2024/11/20/buy-walmart-pepsi-dividend-king-stock/",
    "time_published": "20241120T092300",
    "authors": [
      "Daniel Foelber"
    ],
    "summary": "Walmart and Pepsi are moving in opposite directions but could both be worth a closer look.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F798081%2Fgettyimages-1425139113-1200x800-5b2df79.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999365"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.165647,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DG",
        "relevance_score": "0.038345",
        "ticker_sentiment_score": "0.063271",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.038345",
        "ticker_sentiment_score": "0.12083",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DLTR",
        "relevance_score": "0.038345",
        "ticker_sentiment_score": "0.063271",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.038345",
        "ticker_sentiment_score": "0.12083",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.038345",
        "ticker_sentiment_score": "0.12083",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PEP",
        "relevance_score": "0.076602",
        "ticker_sentiment_score": "-0.036138",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.586247",
        "ticker_sentiment_score": "0.327355",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.076602",
        "ticker_sentiment_score": "-0.035046",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Spotlight on Johnson & Johnson: Analyzing the Surge in Options Activity - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/options/24/11/42118417/spotlight-on-johnson-johnson-analyzing-the-surge-in-options-activity",
    "time_published": "20241121T170359",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bullish approach towards Johnson & Johnson JNJ, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1732208636_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.22979,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.073773",
        "ticker_sentiment_score": "0.041279",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.645516",
        "ticker_sentiment_score": "0.335384",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Reasons Adobe Stock is a Buy Despite a 19% Decline in a Year",
    "url": "https://www.zacks.com/stock/news/2373527/3-reasons-adobe-stock-is-a-buy-despite-a-19-decline-in-a-year",
    "time_published": "20241121T163400",
    "authors": [
      "Aniruddha Ganguly"
    ],
    "summary": "ADBE shares are benefiting from strong demand for its creative products and expanding clientele.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/931.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.378447,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.089965",
        "ticker_sentiment_score": "0.200813",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.045054",
        "ticker_sentiment_score": "0.132096",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.045054",
        "ticker_sentiment_score": "0.132096",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NWL",
        "relevance_score": "0.045054",
        "ticker_sentiment_score": "0.132096",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IBM",
        "relevance_score": "0.089965",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.045054",
        "ticker_sentiment_score": "0.132096",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADBE",
        "relevance_score": "0.786109",
        "ticker_sentiment_score": "0.541739",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "DNTUF",
        "relevance_score": "0.045054",
        "ticker_sentiment_score": "0.132096",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SCHW",
        "relevance_score": "0.045054",
        "ticker_sentiment_score": "0.132096",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PEP",
        "relevance_score": "0.045054",
        "ticker_sentiment_score": "0.132096",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.045054",
        "ticker_sentiment_score": "0.132096",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Price Over Earnings Overview: Johnson & Johnson - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/news/24/11/42109778/price-over-earnings-overview-johnson-johnson",
    "time_published": "20241121T130014",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In the current market session, Johnson & Johnson Inc. JNJ share price is at $153.45, after a 0.22% increase. Moreover, over the past month, the stock decreased by 6.45%, but in the past year, went up by 0.40%.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1732194011_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.229707,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.324495",
        "ticker_sentiment_score": "0.107258",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Emergent's Vaccine Production Failure: Contamination Scandal, Investor Backlash, and $40M Settlement - Emergent BioSolutions  ( NYSE:EBS ) ",
    "url": "https://www.benzinga.com/markets/24/11/42146928/emergents-vaccine-production-failure-contamination-scandal-investor-backlash-and-40m-settlement",
    "time_published": "20241122T203100",
    "authors": [
      "Stan Vick"
    ],
    "summary": "On June 1, 2020, Emergent announced a $628 million contract with the U.S. government to produce COVID-19 vaccines. The company started producing vaccine materials for Johnson & Johnson and AstraZeneca at its Baltimore facility in late 2020.",
    "banner_image": "https://lh7-rt.googleusercontent.com/docsz/AD_4nXeIIZlLXwwooy_Zuo42Ez05mIVStfl0HOwUqkb9SlYYDcrmYOLAsAZF0seiSDHOA3ONme9YjpCgNgGOq0vGoQc-apf2vdPLSufxtKjA92BHR-VPz2Bk12OYqeUoyRBv-UZ97kKnZU0RrwHGwCBSKGT8671r?key=KYxIxnLygQzR6Mc3yd4O5SaK",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": -0.137304,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.31482",
        "ticker_sentiment_score": "-0.257519",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "EBS",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "-0.012214",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.247478",
        "ticker_sentiment_score": "-0.111883",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Adobe, Microsoft, International Business Machines and Alphabet",
    "url": "https://www.zacks.com/stock/news/2373717/the-zacks-analyst-blog-highlights-adobe-microsoft-international-business-machines-and-alphabet",
    "time_published": "20241122T100000",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Adobe, Microsoft, International Business Machines and Alphabet are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2b/4052.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.376072,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.124593",
        "ticker_sentiment_score": "0.093131",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "0.153867",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "0.153867",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NWL",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "0.153867",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IBM",
        "relevance_score": "0.124593",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "0.153867",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ADBE",
        "relevance_score": "0.790287",
        "ticker_sentiment_score": "0.477329",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "DNTUF",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "0.153867",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SCHW",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "0.153867",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PEP",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "0.153867",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "0.153867",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Dividend Stocks That Are Screaming Buys in November",
    "url": "https://www.fool.com/investing/2024/11/23/dividend-stocks-that-are-screaming-buys-november/",
    "time_published": "20241123T122000",
    "authors": [
      "Justin Pope"
    ],
    "summary": "Political uncertainty has created buying opportunities among blue-chip healthcare stocks with big-time dividends.",
    "banner_image": "https://g.foolcdn.com/editorial/images/798476/healthcare-consulting.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.972193"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.692272"
      }
    ],
    "overall_sentiment_score": 0.179363,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.329237",
        "ticker_sentiment_score": "0.034308",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.329237",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.28442",
        "ticker_sentiment_score": "0.319877",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Unstoppable Dividend Stocks to Buy Now With $500",
    "url": "https://www.fool.com/investing/2024/11/23/2-unstoppable-dividend-stocks-to-buy-now-with-500/",
    "time_published": "20241123T103600",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "Whether you prefer growth stocks, value stocks, dividend stocks, or a mixture of investments in your portfolio, price should only be one factor you consider when determining which businesses to add.Dividends can be a great way to increase your returns with time while giving you extra capital to ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/798435/getty-couple-reviewing-papers-budgeting.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.255767,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "UPS",
        "relevance_score": "0.364529",
        "ticker_sentiment_score": "0.243546",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.265089",
        "ticker_sentiment_score": "0.200445",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Dow Jones Dividend Stocks With Yields Above 3% You Can Buy Now and Hold at Least a Decade",
    "url": "https://www.fool.com/investing/2024/11/23/2-dow-jones-dividend-stocks-with-above-average-yie/",
    "time_published": "20241123T090200",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "If you have any faith in economic indicators, right now seems like a terrible time to buy stocks. A long bull market has pushed the major market indices up to record highs.From the end of 2022 through Nov. 19, the benchmark S&P 500 index rose a stunning 54.1%.",
    "banner_image": "https://media.ycharts.com/charts/f9641eef5c9ba242c349e790d9effe42.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.995077"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.938238"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.156716,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KO",
        "relevance_score": "0.269776",
        "ticker_sentiment_score": "0.121973",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CURN",
        "relevance_score": "0.04583",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.093897",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stem Cell Therapy Market is expected to generate a revenue of USD 31.41 Billion by 2030, Globally, at 13.95% CAGR: Verified Market Research\u00ae",
    "url": "https://www.benzinga.com/pressreleases/24/11/g42166497/stem-cell-therapy-market-is-expected-to-generate-a-revenue-of-usd-31-41-billion-by-2030-globally-a",
    "time_published": "20241125T151500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Lewes, Delaware, Nov. 25, 2024 ( GLOBE NEWSWIRE ) -- The Global Stem Cell Therapy Market Size is projected to grow at a CAGR of 13.95% from 2024 to 2030, according to a new report published by Verified Market Research\u00ae.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/1f006a22-4e5d-46c2-8bb0-b868de56c51f/health.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.257746,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MESO",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.018041",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.018041",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.018041",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.018041",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RSSS",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.165446",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "J&J Seeks FDA Nod for Subcutaneous Tremfya as Induction Regimen in UC",
    "url": "https://www.zacks.com/stock/news/2374611/jj-seeks-fda-nod-for-subcutaneous-tremfya-as-induction-regimen-in-uc",
    "time_published": "20241125T140800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "If approved, JNJ's Tremfya will be the first IL-23 inhibitor to offer a choice of subcutaneous or intravenous use as induction treatment in ulcerative colitis.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/1612.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.260148,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.210274",
        "ticker_sentiment_score": "0.243306",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.158519",
        "ticker_sentiment_score": "0.274495",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.210274",
        "ticker_sentiment_score": "0.200519",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Merck Stock Up as Winrevair Meets Goal in Advanced PAH Study",
    "url": "https://www.zacks.com/stock/news/2375640/merck-stock-up-as-winrevair-meets-goal-in-advanced-pah-study",
    "time_published": "20241126T200000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "MRK's study of PAH drug Winrevair in a more advanced form of the disease shows overwhelming efficacy.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.243221,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.152499",
        "ticker_sentiment_score": "0.114016",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.152499",
        "ticker_sentiment_score": "0.227276",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.102013",
        "ticker_sentiment_score": "0.18991",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "International Expansion Supports BSX Stock Amid Macroeconomic Woes",
    "url": "https://www.zacks.com/stock/news/2375415/international-expansion-supports-bsx-stock-amid-macroeconomic-woes",
    "time_published": "20241126T145000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "BSX's Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of gastrointestinal (GI) and pulmonary treatment options.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.95493"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.928769"
      }
    ],
    "overall_sentiment_score": 0.220036,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EW",
        "relevance_score": "0.045569",
        "ticker_sentiment_score": "0.060863",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNN",
        "relevance_score": "0.045569",
        "ticker_sentiment_score": "0.060863",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.045569",
        "ticker_sentiment_score": "0.060863",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.47037",
        "ticker_sentiment_score": "0.198467",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.045569",
        "ticker_sentiment_score": "0.060863",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PEN",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.052674",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RMD",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.052674",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.045569",
        "ticker_sentiment_score": "0.060863",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HAE",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.125312",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXNX",
        "relevance_score": "0.045569",
        "ticker_sentiment_score": "0.142193",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Very Healthy Dividend Stocks to Hold for Decades of Income",
    "url": "https://www.fool.com/investing/2024/11/26/2-very-healthy-dividend-stocks-to-hold-for-decades/",
    "time_published": "20241126T111800",
    "authors": [
      "Matt DiLallo"
    ],
    "summary": "Checking a company's vital signs before investing in its stock for dividend income is essential. If the underlying company isn't financially healthy, its dividend probably won't last very long.That won't be a problem with Johnson & Johnson ( NYSE: JNJ ) and Medtronic ( NYSE: MDT ) .",
    "banner_image": "https://g.foolcdn.com/editorial/images/798928/stethoscope-on-money-cash-1200x801-d21b45d.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.955357"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.316257,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MDT",
        "relevance_score": "0.47672",
        "ticker_sentiment_score": "0.511046",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.063594",
        "ticker_sentiment_score": "0.251518",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.423504",
        "ticker_sentiment_score": "0.330514",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Surgical Robotics Market Size to Reach USD 28.54 Billion by 2031 at 13.7% CAGR| The Insight Partners",
    "url": "https://www.benzinga.com/pressreleases/24/11/g42184464/surgical-robotics-market-size-to-reach-usd-28-54-billion-by-2031-at-13-7-cagr-the-insight-partners",
    "time_published": "20241126T111653",
    "authors": [],
    "summary": "US & Canada, Nov. 26, 2024 ( GLOBE NEWSWIRE ) -- According to a new comprehensive report from The Insight Partners, global surgical robotics market is observing significant growth owing to a surging number of surgical procedures and a growing prevalence of chronic diseases.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/b3dbb4a6-1685-4360-aaf3-1b8f109ec8dd/image1.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.276783,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SNN",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STE",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.111747",
        "ticker_sentiment_score": "0.123577",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.166935",
        "ticker_sentiment_score": "0.151874",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.111747",
        "ticker_sentiment_score": "0.151376",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RNSHF",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Women Intimate Care Products Market Expected to See Substantial Revenue Growth, Reaching US$ 46.8 Billion by 2034 | Transparency Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/11/g42216491/women-intimate-care-products-market-expected-to-see-substantial-revenue-growth-reaching-us-46-8-bi",
    "time_published": "20241127T152156",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research Inc., Nov. 27, 2024 ( GLOBE NEWSWIRE ) -- The global women intimate care products market ( march\u00e9 des produits de soins intimes pour femmes ) , valued at US$ 28.3 billion in 2023, is projected to grow at a CAGR of 4.7% from 2024 ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/3319c7aa-11e4-4a37-9646-e79c89b27732/women-intimate-care-products-market.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.402705,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.044469",
        "ticker_sentiment_score": "0.054786",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMB",
        "relevance_score": "0.044469",
        "ticker_sentiment_score": "0.137615",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.088799",
        "ticker_sentiment_score": "0.198192",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.044469",
        "ticker_sentiment_score": "0.325183",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EPC",
        "relevance_score": "0.088799",
        "ticker_sentiment_score": "0.085763",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.132855",
        "ticker_sentiment_score": "0.151857",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RBGPF",
        "relevance_score": "0.044469",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Excellent Healthcare Stocks to Hold Through the Next Decade",
    "url": "https://www.fool.com/investing/2024/11/28/2-excellent-healthcare-stocks-to-hold-through-the/",
    "time_published": "20241128T124500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "Although excellent medical care is always in high demand, the healthcare sector continuously evolves. Companies aren't automatically worth investing in just because they provide essential medical services. Only those that can keep up with the changing nature of the industry can hope to deliver ...",
    "banner_image": "https://media.ycharts.com/charts/158051f531e814223a82176fbb2fb53f.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      }
    ],
    "overall_sentiment_score": 0.312221,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MDT",
        "relevance_score": "0.118647",
        "ticker_sentiment_score": "0.028266",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.290952",
        "ticker_sentiment_score": "0.202139",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.345674",
        "ticker_sentiment_score": "0.118588",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.059488",
        "ticker_sentiment_score": "0.025",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bristol-Myers Squibb Files Lawsuit Against US Agency For Overreach In 340B Drug Pricing Program - Bristol-Myers Squibb  ( NYSE:BMY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/11/42248288/bristol-myers-squibb-files-lawsuit-against-us-agency-for-overreach-in-340b-drug-pricing-program",
    "time_published": "20241129T173743",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Bristol-Myers Squibb Co BMY filed a lawsuit on Tuesday against the U.S. Health Resources and Services Administration ( HRSA ) and the U.S. Department of Health and Human Services ( HHS ) , alleging that HRSA's rejection of its proposed rebate model for the 340B Drug Pricing Program violates ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.236406,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.172713",
        "ticker_sentiment_score": "-0.214064",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.337427",
        "ticker_sentiment_score": "-0.297406",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.172713",
        "ticker_sentiment_score": "-0.419214",
        "ticker_sentiment_label": "Bearish"
      }
    ]
  },
  {
    "title": "Reasons to Retain Medtronic Stock in Your Portfolio Now",
    "url": "https://www.zacks.com/stock/news/2376863/reasons-to-retain-medtronic-stock-in-your-portfolio-now",
    "time_published": "20241129T123800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Investors continue to be optimistic about MDT due to its impressive international expansion. Yet, the dull macroeconomic scenario poses a concern to the company's margins.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.287448,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GMED",
        "relevance_score": "0.152178",
        "ticker_sentiment_score": "0.152463",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.051003",
        "ticker_sentiment_score": "0.122382",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.051003",
        "ticker_sentiment_score": "0.122382",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.051003",
        "ticker_sentiment_score": "0.122382",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PEN",
        "relevance_score": "0.201944",
        "ticker_sentiment_score": "0.123432",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.345674",
        "ticker_sentiment_score": "0.266811",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HAE",
        "relevance_score": "0.201944",
        "ticker_sentiment_score": "0.143241",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later",
    "url": "https://www.fool.com/investing/2024/12/01/3-fantastic-dividend-stocks-to-buy-sooner-rather-t/",
    "time_published": "20241201T105200",
    "authors": [
      "Keith Speights",
      "and Prosper Junior Bakiny",
      "David Jagielski"
    ],
    "summary": "You don't have to be an income investor to like dividends. Many billionaires who definitely don't need income still have dividend stocks in their portfolios.Which dividend stocks are great picks right now? Here's why three Fool.com contributors chose AbbVie ( NYSE: ABBV ) , Johnson & Johnson ( ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/799375/dividends-blackboard-sketch-doodle.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.623304"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.857896"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.221663,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.260652",
        "ticker_sentiment_score": "0.131004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.382274",
        "ticker_sentiment_score": "0.451133",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.342685",
        "ticker_sentiment_score": "0.199546",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Costco Sales Topped $250 Billion in Fiscal 2024. But Less Than 2% of Those Sales Are Key to Understanding the Entire Business.",
    "url": "https://www.fool.com/investing/2024/12/01/costco-sales-250-billion-fiscal-2024-member-fee/",
    "time_published": "20241201T100700",
    "authors": [
      "Jon Quast"
    ],
    "summary": "Costco Wholesale ( NASDAQ: COST ) operates around 900 warehouse-style retail stores around the world. Its fiscal 2024 ended on Sept. 1. And during the fiscal year, it generated a whopping $254 billion in total revenue.This makes Costco one of the largest businesses on the entire planet.",
    "banner_image": "https://media.ycharts.com/charts/2eb8c8170ec6146336c9018d2531a606.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.990999"
      }
    ],
    "overall_sentiment_score": 0.18824,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.054732",
        "ticker_sentiment_score": "0.037871",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.727969",
        "ticker_sentiment_score": "0.312008",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.054732",
        "ticker_sentiment_score": "0.037871",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.054732",
        "ticker_sentiment_score": "0.037871",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.054732",
        "ticker_sentiment_score": "0.037871",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "These 3 Dividend-Focused Vanguard ETFs Are Up 14% to 31% in 2024. Here's the Best One to Buy Now.",
    "url": "https://www.fool.com/investing/2024/12/01/vanguard-dividend-etf-buy-passive-income/",
    "time_published": "20241201T095500",
    "authors": [
      "Daniel Foelber"
    ],
    "summary": "Investment management company Vanguard offers more than 60 equity-focused exchange-traded funds ( ETFs ) that focus on various investment styles and themes -- all while charging expense ratios as low as 0.03% to as high as 0.22%.While plenty of dividend-focused Vanguard funds are great for ...",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F799347%2Fgettyimages-491217964-1200x806-3c89936.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.32985,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AVGO",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.158675",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "COP",
        "relevance_score": "0.04583",
        "ticker_sentiment_score": "0.186192",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.04583",
        "ticker_sentiment_score": "0.090674",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.04583",
        "ticker_sentiment_score": "0.113688",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.179841",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EOG",
        "relevance_score": "0.04583",
        "ticker_sentiment_score": "0.186192",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.04583",
        "ticker_sentiment_score": "0.113688",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SO",
        "relevance_score": "0.04583",
        "ticker_sentiment_score": "0.050882",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NEE",
        "relevance_score": "0.04583",
        "ticker_sentiment_score": "0.050882",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.181819",
        "ticker_sentiment_score": "0.17014",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Investors Heavily Search Johnson & Johnson  ( JNJ ) : Here is What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2377778/investors-heavily-search-johnson-johnson-jnj-here-is-what-you-need-to-know",
    "time_published": "20241202T182905",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default356.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.21759,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.477606",
        "ticker_sentiment_score": "0.121357",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Digital Health Market is Expected to Expand at an Exceptional 18.6% CAGR through 2031 | SkyQuest Technology",
    "url": "https://www.benzinga.com/pressreleases/24/12/g42261424/digital-health-market-is-expected-to-expand-at-an-exceptional-18-6-cagr-through-2031-skyquest-tech",
    "time_published": "20241202T102433",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Westford, USA, Dec. 02, 2024 ( GLOBE NEWSWIRE ) -- SkyQuest projects that the digital health market size will attain a value of USD 881 billion by 2031, with a CAGR of 18.6% over the forecast period ( 2024-2031 ) .",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.190054,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.042496",
        "ticker_sentiment_score": "-0.084898",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AFGVY",
        "relevance_score": "0.042496",
        "ticker_sentiment_score": "-0.084898",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.084871",
        "ticker_sentiment_score": "-0.089179",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.042496",
        "ticker_sentiment_score": "-0.084898",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TDOC",
        "relevance_score": "0.042496",
        "ticker_sentiment_score": "-0.084898",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WIT",
        "relevance_score": "0.042496",
        "ticker_sentiment_score": "-0.084898",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MCK",
        "relevance_score": "0.084871",
        "ticker_sentiment_score": "0.012441",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IBM",
        "relevance_score": "0.084871",
        "ticker_sentiment_score": "-0.089179",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QCOM",
        "relevance_score": "0.042496",
        "ticker_sentiment_score": "-0.084898",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.042496",
        "ticker_sentiment_score": "-0.084898",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INFY",
        "relevance_score": "0.042496",
        "ticker_sentiment_score": "-0.084898",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "J&J Seeks FDA Approval for Tremfya for Psoriasis in Kids",
    "url": "https://www.zacks.com/stock/news/2378129/jj-seeks-fda-approval-for-tremfya-for-psoriasis-in-kids",
    "time_published": "20241203T135800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "J&J files for FDA approval of Tremfya for plaque psoriasis and psoriatic arthritis indications in pediatric patients ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.270878,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.219312",
        "ticker_sentiment_score": "0.221839",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.219312",
        "ticker_sentiment_score": "0.172527",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RXDX",
        "relevance_score": "0.055492",
        "ticker_sentiment_score": "0.036",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.055492",
        "ticker_sentiment_score": "0.109865",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.219312",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.110717",
        "ticker_sentiment_score": "0.088801",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Ray Dalio's Bridgewater Adds Broadcom, Apple, SMCI In Q3, While Offloading Stake In AI Giant Nvidia And Other Big Tech Companies - Apple  ( NASDAQ:AAPL ) , Advanced Micro Devices  ( NASDAQ:AMD ) ",
    "url": "https://www.benzinga.com/markets/equities/24/12/42287009/ray-dalios-bridgewater-adds-broadcom-apple-in-q3-while-diluting-stake-in-topmost-ai-play-nvidia-",
    "time_published": "20241203T123011",
    "authors": [
      "Rishabh Mishra"
    ],
    "summary": "Bridgewater Associates sold its positions in the topmost AI-linked stock. The hedge fund added stake in Apple and Broadcom. Benzinga shares with you top insiders news",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/03/Ray-Dalio.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.2591,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.337811",
        "ticker_sentiment_score": "0.142399",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.229149",
        "ticker_sentiment_score": "0.212572",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.337811",
        "ticker_sentiment_score": "0.286615",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.439786",
        "ticker_sentiment_score": "0.164937",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.439786",
        "ticker_sentiment_score": "0.237066",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.337811",
        "ticker_sentiment_score": "0.290285",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.229149",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.337811",
        "ticker_sentiment_score": "0.290285",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.229149",
        "ticker_sentiment_score": "0.104902",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.229149",
        "ticker_sentiment_score": "0.245977",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Stock Slides as Market Rises: Facts to Know Before You Trade",
    "url": "https://www.zacks.com/stock/news/2379190/johnson-johnson-jnj-stock-slides-as-market-rises-facts-to-know-before-you-trade",
    "time_published": "20241204T224504",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the most recent trading session, Johnson & Johnson (JNJ) closed at $150.47, indicating a -1.24% shift from the previous trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default183.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.165868,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.470894",
        "ticker_sentiment_score": "0.224818",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Like Passive Income? Then You'll Love These 3 Super Safe Dividend Stocks That Are Up Between 28% and 42% in 6 Months.",
    "url": "https://www.fool.com/investing/2024/12/04/like-passive-income-buy-safe-dividend-stocks/",
    "time_published": "20241204T145300",
    "authors": [
      "Daniel Foelber"
    ],
    "summary": "These three dividend-paying companies have all raised their payouts every year for at least 40 consecutive years.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F799476%2Fhome-apartment-rental-real-estate-cleaning-1200x800-5b2df79.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.147458,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.401331",
        "ticker_sentiment_score": "0.121661",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DG",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "-0.128395",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLX",
        "relevance_score": "0.570165",
        "ticker_sentiment_score": "0.229102",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DLTR",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "-0.128395",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "0.032935",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.682689",
        "ticker_sentiment_score": "0.169249",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the Health Care Select Sector SPDR ETF  ( XLV ) ?",
    "url": "https://www.zacks.com/stock/news/2378613/should-you-invest-in-the-health-care-select-sector-spdr-etf-xlv",
    "time_published": "20241204T112008",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default278.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.281421,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.126119",
        "ticker_sentiment_score": "0.063471",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.063258",
        "ticker_sentiment_score": "0.127337",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STT",
        "relevance_score": "0.063258",
        "ticker_sentiment_score": "0.08904",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.126119",
        "ticker_sentiment_score": "0.063471",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.126119",
        "ticker_sentiment_score": "0.063471",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares U.S. Healthcare ETF  ( IYH ) ?",
    "url": "https://www.zacks.com/stock/news/2378618/should-you-invest-in-the-ishares-us-healthcare-etf-iyh",
    "time_published": "20241204T112007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default118.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.235195,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.132368",
        "ticker_sentiment_score": "0.069712",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.132368",
        "ticker_sentiment_score": "0.069712",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.132368",
        "ticker_sentiment_score": "0.069712",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Top Analyst Reports for Home Depot, Johnson & Johnson & Salesforce",
    "url": "https://www.zacks.com/research-daily/2379401/top-analyst-reports-for-home-depot-johnson-johnson-salesforce",
    "time_published": "20241205T214000",
    "authors": [
      "Mark Vickery"
    ],
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), Johnson & Johnson (JNJ) and Salesforce, Inc. (CRM), as well as two micro-cap stocks, Preformed Line Products Company (PLPC) and Cooper-Standard Holdings Inc. (CPS).",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fe/76.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.186916,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PLPC",
        "relevance_score": "0.122581",
        "ticker_sentiment_score": "0.100495",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.182967",
        "ticker_sentiment_score": "0.269925",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CPS",
        "relevance_score": "0.122581",
        "ticker_sentiment_score": "0.100495",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.122581",
        "ticker_sentiment_score": "0.100495",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Horticultural Ingredient Market is Projected to Reach a Valuation of US$ 35.7 Billion, Growing at a CAGR of 5.3% by 2034",
    "url": "https://www.benzinga.com/pressreleases/24/12/g42334012/horticultural-ingredient-market-is-projected-to-reach-a-valuation-of-us-35-7-billion-growing-at-a-",
    "time_published": "20241205T103000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Rockville, MD, Dec. 05, 2024 ( GLOBE NEWSWIRE ) -- According to a newly published report by Fact.MR, a market research and competitive intelligence provider, the global Horticultural Ingredients Market is estimated to reach a worth of US$ 21.3 billion in 2024.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/b5ac153b-86a1-4dc7-afd9-586cfbb4464e/image.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.378762,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HLF",
        "relevance_score": "0.030998",
        "ticker_sentiment_score": "0.132116",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMS-P-B",
        "relevance_score": "0.030998",
        "ticker_sentiment_score": "0.132116",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.030998",
        "ticker_sentiment_score": "0.067981",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NSRGF",
        "relevance_score": "0.030998",
        "ticker_sentiment_score": "0.219319",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.030998",
        "ticker_sentiment_score": "0.241157",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "ISRG Stock Reaches All-Time High: Strength in Uptrend to Continue?",
    "url": "https://www.zacks.com/stock/news/2380078/isrg-stock-reaches-all-time-high-strength-in-uptrend-to-continue",
    "time_published": "20241206T135200",
    "authors": [
      "Indrajit Bandyopadhyay"
    ],
    "summary": "Intuitive Surgical has maintained an uptrend so far this year on the back of robust da Vinci portfolio performance. The has stock also gained during the past month. Let's see if the trend might change.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/61/11728.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.345928,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MDT",
        "relevance_score": "0.057767",
        "ticker_sentiment_score": "0.297062",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.423558",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.057767",
        "ticker_sentiment_score": "0.297062",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Home Depot, Johnson & Johnson, Salesforce, Preformed Line and Cooper-Standard",
    "url": "https://www.zacks.com/stock/news/2379952/the-zacks-analyst-blog-highlights-home-depot-johnson-johnson-salesforce-preformed-line-and-cooper-standard",
    "time_published": "20241206T100000",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Home Depot, Johnson & Johnson, Salesforce, Preformed Line and Cooper-Standard are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.176722,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PLPC",
        "relevance_score": "0.116914",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.174587",
        "ticker_sentiment_score": "0.17228",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CPS",
        "relevance_score": "0.116914",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.116914",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Coca-Cola cs. Procter & Gamble: Which Is the Better Dow Dividend King Stock to Buy Before the End of the Year?",
    "url": "https://www.fool.com/investing/2024/12/08/coca-cola-pg-buy-dow-dividend-king-stock/",
    "time_published": "20241208T100500",
    "authors": [
      "Daniel Foelber"
    ],
    "summary": "When investors look for reliable dividend-paying companies, they typically consider factors such as the track record for paying and raising the dividend over time, if the company is an industry leader, if it is a growing business that can support a higher dividend expense, and the dividend ...",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F799838%2Fgettyimages-1236903031-1200x800-5b2df79-1.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99977"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.938238"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.22263,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AAPL",
        "relevance_score": "0.040829",
        "ticker_sentiment_score": "0.085457",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.081552",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MNST",
        "relevance_score": "0.040829",
        "ticker_sentiment_score": "0.085457",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.040829",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.081552",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.122062",
        "ticker_sentiment_score": "0.009248",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Adobe Stock Ahead of Q4 Earnings Results: Smart Buy or Risky Move?",
    "url": "https://www.zacks.com/stock/news/2381018/adobe-stock-ahead-of-q4-earnings-results-smart-buy-or-risky-move",
    "time_published": "20241209T154400",
    "authors": [
      "Aniruddha Ganguly"
    ],
    "summary": "ADBE's fourth-quarter fiscal 2024 results are likely to reflect strong demand for Generative AI solutions amid growing competition and stretched valuation.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/931.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928769"
      }
    ],
    "overall_sentiment_score": 0.347852,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.232217",
        "ticker_sentiment_score": "0.182174",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.140621",
        "ticker_sentiment_score": "0.078092",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.047092",
        "ticker_sentiment_score": "0.110702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NWL",
        "relevance_score": "0.047092",
        "ticker_sentiment_score": "0.110702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IBM",
        "relevance_score": "0.09402",
        "ticker_sentiment_score": "0.117262",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.047092",
        "ticker_sentiment_score": "0.110702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADBE",
        "relevance_score": "0.762438",
        "ticker_sentiment_score": "0.564459",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "DNTUF",
        "relevance_score": "0.047092",
        "ticker_sentiment_score": "0.110702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SCHW",
        "relevance_score": "0.047092",
        "ticker_sentiment_score": "0.110702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PEP",
        "relevance_score": "0.047092",
        "ticker_sentiment_score": "0.110702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.047092",
        "ticker_sentiment_score": "0.110702",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Coca-Cola Stock a Buy, Sell, or Hold in 2025?",
    "url": "https://www.fool.com/investing/2024/12/09/is-coca-cola-stock-a-buy-sell-or-hold-in-2025/",
    "time_published": "20241209T124500",
    "authors": [
      "Demitri Kalogeropoulos"
    ],
    "summary": "Coca-Cola ( NYSE: KO ) will likely be selling many more beverages in a few years than it did in 2024. There's little to challenge the beverage giant's dominant global network, which accounts for billions of servings of drinks consumed each year, including both sparkling and nontraditional drinks ...",
    "banner_image": "https://media.ycharts.com/charts/b7dec62353119cfe41dad60608fe2d31.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.182238,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KO",
        "relevance_score": "0.257668",
        "ticker_sentiment_score": "0.209949",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.065506",
        "ticker_sentiment_score": "0.131228",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MNST",
        "relevance_score": "0.065506",
        "ticker_sentiment_score": "0.216609",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.065506",
        "ticker_sentiment_score": "0.131228",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Tissue Glue and Bio-Adhesive Sealant Market to Reach US$ 4.91 Billion by 2034, Growing at 8% CAGR | Fact.MR Report",
    "url": "https://www.benzinga.com/pressreleases/24/12/g42386928/tissue-glue-and-bio-adhesive-sealant-market-to-reach-us-4-91-billion-by-2034-growing-at-8-cagr-fac",
    "time_published": "20241209T123000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Rockville, MD, Dec. 09, 2024 ( GLOBE NEWSWIRE ) -- Tissue glue and bio-adhesive sealants effectively seal skin wounds and lacerations, which has been driving their increasing popularity worldwide.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/6eb21e79-8f32-468a-b2a8-003c2b2165d8/tissue-glue-and-bio-adhesive-sealant-market.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.309842,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BAX",
        "relevance_score": "0.041181",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XRAY",
        "relevance_score": "0.041181",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.041181",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.041181",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LUNA",
        "relevance_score": "0.041181",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cosmetic Manufacturing Market to Reach US$ 878.88 Billion by 2034, Growing at 6.4% CAGR | Fact.MR Report",
    "url": "https://www.benzinga.com/pressreleases/24/12/g42385538/cosmetic-manufacturing-market-to-reach-us-878-88-billion-by-2034-growing-at-6-4-cagr-fact-mr-repor",
    "time_published": "20241209T113000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Rockville, MD , Dec. 09, 2024 ( GLOBE NEWSWIRE ) -- According to a new industry report compiled by Fact.MR, a market research and competitive intelligence provider, worldwide revenue from the Cosmetic Manufacturing Market is projected to reach US$ 473.38 billion in 2024 and thereafter increase ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/8b9fec2b-523b-4901-a38b-60f497baee74/cosmetic-manufacturing-market.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.430754,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "0.14136",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDRFF",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "0.094965",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KAOCF",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "0.094965",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSDOF",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "0.094965",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REVRQ",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "0.094965",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "0.094965",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "0.094965",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UL",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "0.094965",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HENKY",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "0.094965",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CL",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "0.094965",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COTY",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "0.094965",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Stock Moves -0.25%: What You Should Know",
    "url": "https://www.zacks.com/stock/news/2381809/johnson-johnson-jnj-stock-moves--025-what-you-should-know",
    "time_published": "20241210T224510",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the latest trading session, Johnson & Johnson (JNJ) closed at $149.23, marking a -0.25% move from the previous day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default12.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.139082,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.600271",
        "ticker_sentiment_score": "0.174953",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027",
    "url": "https://www.globenewswire.com/news-release/2024/12/10/2994415/0/en/LAVA-Reports-Third-Quarter-2024-Financial-Results-and-Announces-Pipeline-Reprioritization-and-Cash-Runway-Extension-into-2027.html",
    "time_published": "20241210T123000",
    "authors": [
      "LAVA Therapeutics N.V."
    ],
    "summary": "UTRECHT, The Netherlands and PHILADELPHIA, Dec. 10, 2024 ( GLOBE NEWSWIRE ) -- LAVA Therapeutics N.V. ( NASDAQ: LVTX, \"LAVA,\" \"the Company\" ) , a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody\u00ae platform of bispecific gamma delta T cell engagers, reported ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/4759b844-227f-4632-b22d-4fe63fad55b4",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.114276,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LVTX",
        "relevance_score": "0.09638",
        "ticker_sentiment_score": "0.061595",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.072362",
        "ticker_sentiment_score": "0.074831",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.2379",
        "ticker_sentiment_score": "0.130403",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Invesco Pharmaceuticals ETF  ( PJP ) ?",
    "url": "https://www.zacks.com/stock/news/2381261/should-you-invest-in-the-invesco-pharmaceuticals-etf-pjp",
    "time_published": "20241210T112008",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default292.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.220947,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.132004",
        "ticker_sentiment_score": "0.070801",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.132004",
        "ticker_sentiment_score": "0.070801",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.196877",
        "ticker_sentiment_score": "0.141519",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.132004",
        "ticker_sentiment_score": "0.070801",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CARVYKTI\u00ae Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma",
    "url": "https://www.globenewswire.com/news-release/2024/12/10/2994149/0/en/CARVYKTI-Significantly-Improved-Minimal-Residual-Disease-Negativity-Compared-to-Standard-of-Care-for-Patients-with-Relapsed-or-Refractory-Multiple-Myeloma.html",
    "time_published": "20241210T003500",
    "authors": [
      "Legend Biotech USA Inc."
    ],
    "summary": "SOMERSET, N.J., Dec. 09, 2024 ( GLOBE NEWSWIRE ) -- Legend Biotech Corporation ( NASDAQ: LEGN ) ( Legend Biotech ) , a global leader in cell therapy, announced today new results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI\u00ae ( ciltacabtagene autoleucel.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/d3a680c2-cab6-4eb2-9ed0-7be055f9e180",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": -0.090572,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.017115",
        "ticker_sentiment_score": "0.055819",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LEGN",
        "relevance_score": "0.06838",
        "ticker_sentiment_score": "0.01619",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRGNF",
        "relevance_score": "0.008558",
        "ticker_sentiment_score": "-0.00639",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Elon Musk's Net Worth Surpasses Market Cap Of US Giants Like BofA, Johnson & Johnson, Salesforce, Chevron, Coca-Cola And More: Only 25 Companies Have Higher Market Cap - Tesla  ( NASDAQ:TSLA ) ",
    "url": "https://www.benzinga.com/markets/equities/24/12/42435201/elon-musks-net-worth-surpasses-market-cap-of-us-giants-like-bofa-johnson-johnson-salesforce-chev",
    "time_published": "20241211T130825",
    "authors": [
      "Rishabh Mishra"
    ],
    "summary": "Only 25 listed companies have a higher market capitalization than Elon Musk's net worth. Musk has added $155 billion to his wealth this year so far. Elon Musk's net worth is now more than the market capitalization of most of the listed companies in the U.S. and the world.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/11/Why-It-Matters_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.273488,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.123133",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.147818",
        "ticker_sentiment_score": "0.247127",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "-0.007105",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "-0.007105",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "-0.007105",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "-0.007105",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "-0.077354",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HESAF",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "-0.077354",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ASML",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "-0.077354",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSNLF",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "-0.077354",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.107953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.290607",
        "ticker_sentiment_score": "0.286785",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.107953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.107953",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Soft Tissue Anchor Market is Projected to Reach US$ 8.7 Billion with Growing at 5.3% CAGR by 2034 | Fact.MR Report",
    "url": "https://www.benzinga.com/pressreleases/24/12/g42434052/soft-tissue-anchor-market-is-projected-to-reach-us-8-7-billion-with-growing-at-5-3-cagr-by-2034-fa",
    "time_published": "20241211T123000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Rockville, MD, Dec. 11, 2024 ( GLOBE NEWSWIRE ) -- The global soft tissue anchors market is expanding significantly in tandem with rapid technological breakthroughs in the medical field.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/3454ef66-490b-4066-8b14-e4b019c0cbdc/soft-tissue-anchor-market.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.320565,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ZBH",
        "relevance_score": "0.040553",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNN",
        "relevance_score": "0.081001",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.040553",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.081001",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.040553",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.040553",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IART",
        "relevance_score": "0.040553",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.040553",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "These Are the 5 Worst-Performing Stocks in the Dow Jones Industrial Average With 2024 Almost Over",
    "url": "https://www.fool.com/investing/2024/12/12/these-are-the-5-worst-performing-stocks-in-the-dow/",
    "time_published": "20241212T192318",
    "authors": [
      "Jeremy Bowman"
    ],
    "summary": "It's been a banner year for the stock market. However, not every stock has been a winner as some sectors performed better than others. Tech and utilities soared, while others like real estate and healthcare underperformed.So what are the five worst performers on the Dow Jones Industrial Average ( ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/800728/economic-crisis-stock-chart-falling-down-business-global-money-bankruptcy.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.108209,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NKE",
        "relevance_score": "0.308246",
        "ticker_sentiment_score": "-0.106374",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.208464",
        "ticker_sentiment_score": "-0.175279",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "FL",
        "relevance_score": "0.105141",
        "ticker_sentiment_score": "-0.051732",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.402941",
        "ticker_sentiment_score": "-0.228311",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.208464",
        "ticker_sentiment_score": "0.086678",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Innovations and Buyouts Support BSX Stock Amid Macroeconomic Woes",
    "url": "https://www.zacks.com/stock/news/2382700/innovations-and-buyouts-support-bsx-stock-amid-macroeconomic-woes",
    "time_published": "20241212T142600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.990678"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.875462"
      }
    ],
    "overall_sentiment_score": 0.209215,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EW",
        "relevance_score": "0.04497",
        "ticker_sentiment_score": "0.06077",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNN",
        "relevance_score": "0.04497",
        "ticker_sentiment_score": "0.06077",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.04497",
        "ticker_sentiment_score": "0.06077",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.46494",
        "ticker_sentiment_score": "0.128537",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.04497",
        "ticker_sentiment_score": "0.06077",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PEN",
        "relevance_score": "0.134339",
        "ticker_sentiment_score": "0.090351",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PAHC",
        "relevance_score": "0.089797",
        "ticker_sentiment_score": "0.052721",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.04497",
        "ticker_sentiment_score": "0.06077",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HAE",
        "relevance_score": "0.134339",
        "ticker_sentiment_score": "0.108445",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXNX",
        "relevance_score": "0.04497",
        "ticker_sentiment_score": "0.146008",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Adobe Q4 Earnings Beat Estimates, Shares Fall on Weak Outlook",
    "url": "https://www.zacks.com/stock/news/2382693/adobe-q4-earnings-beat-estimates-shares-fall-on-weak-outlook",
    "time_published": "20241212T141900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "ADBE's fourth-quarter fiscal 2024 results reflect strong adoption of Digital Media and Digital Experience.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/931.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.99992"
      }
    ],
    "overall_sentiment_score": 0.154824,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.093897",
        "ticker_sentiment_score": "0.010626",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.031364",
        "ticker_sentiment_score": "0.168536",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.031364",
        "ticker_sentiment_score": "-0.016947",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.031364",
        "ticker_sentiment_score": "-0.015163",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.031364",
        "ticker_sentiment_score": "0.082312",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.031364",
        "ticker_sentiment_score": "-0.015163",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.031364",
        "ticker_sentiment_score": "0.082312",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.031364",
        "ticker_sentiment_score": "0.082312",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADBE",
        "relevance_score": "0.654648",
        "ticker_sentiment_score": "0.326761",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.031364",
        "ticker_sentiment_score": "0.082312",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HUBS",
        "relevance_score": "0.031364",
        "ticker_sentiment_score": "0.168536",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.093897",
        "ticker_sentiment_score": "-0.018977",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Mod Op Expands Live Event Offerings with Image Media Acquisition",
    "url": "https://www.benzinga.com/pressreleases/24/12/g42460879/mod-op-expands-live-event-offerings-with-image-media-acquisition",
    "time_published": "20241212T140000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, Dec. 12, 2024 ( GLOBE NEWSWIRE ) -- Mod Op, a full-service digital marketing agency known for driving client growth through creativity, data science, and innovation, today announced its acquisition of Image Media, a premier experiential and events agency renowned for its large-scale ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.527863,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TGHI",
        "relevance_score": "0.061473",
        "ticker_sentiment_score": "0.190275",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NSRGF",
        "relevance_score": "0.061473",
        "ticker_sentiment_score": "0.082125",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.061473",
        "ticker_sentiment_score": "0.385898",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.061473",
        "ticker_sentiment_score": "0.082125",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Jim Cramer: AMD CEO Lisa Su 'Built An Amazing Company' - Constellation Energy  ( NASDAQ:CEG ) , Advanced Micro Devices  ( NASDAQ:AMD ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/12/42460676/jim-cramer-amd-ceo-lisa-su-built-an-amazing-company",
    "time_published": "20241212T135538",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Mad Money Lightning Round,\" Jim Cramer recommended buying Netflix, Inc. NFLX. On Wednesday, JPMorgan analyst Doug Anmuth maintained Netflix with an Overweight and raised the price target from $850 to $1,010.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/12/Lisa-Su---Amd-Chairman-And-Ceo-Hold-A-Ch.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.221166,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.399734",
        "ticker_sentiment_score": "0.163416",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.206685",
        "ticker_sentiment_score": "0.321204",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.104228",
        "ticker_sentiment_score": "-0.07841",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CEG",
        "relevance_score": "0.487546",
        "ticker_sentiment_score": "-0.050753",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.104228",
        "ticker_sentiment_score": "-0.187883",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.399734",
        "ticker_sentiment_score": "-0.140333",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SRE",
        "relevance_score": "0.206685",
        "ticker_sentiment_score": "-0.076157",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.399734",
        "ticker_sentiment_score": "0.394553",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "RBRK",
        "relevance_score": "0.399734",
        "ticker_sentiment_score": "0.567687",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Jim Cramer Bullish On Netflix Nearing $1,000 And AMD's 'Cheap' Valuation Despite Nvidia Dominance - Advanced Micro Devices  ( NASDAQ:AMD ) , JD.com  ( NASDAQ:JD ) ",
    "url": "https://www.benzinga.com/markets/equities/24/12/42452602/jim-cramer-bullish-in-netflix-as-stock-nears-1000-amid-streaming-success",
    "time_published": "20241212T031014",
    "authors": [
      "Kaustubh Bagalkote"
    ],
    "summary": "CNBC's Jim Cramer expressed strong buying conviction for Netflix Inc. NFLX during Wednesday's Lightning Round on \"Mad Money,\" as the streaming giant's shares traded near $934 amid broader tech market strength.",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/11212832/Screenshot-2024-12-12-at-7.57.40%E2%80%AFAM-1024x378.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.237795,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMD",
        "relevance_score": "0.207571",
        "ticker_sentiment_score": "0.161941",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.489394",
        "ticker_sentiment_score": "0.371115",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.207571",
        "ticker_sentiment_score": "0.161941",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.104683",
        "ticker_sentiment_score": "0.053638",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CCORF",
        "relevance_score": "0.104683",
        "ticker_sentiment_score": "0.053638",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.207571",
        "ticker_sentiment_score": "0.161941",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Adobe  ( ADBE )  Q4 2024 Earnings Call Transcript",
    "url": "https://www.fool.com/earnings/call-transcripts/2024/12/11/adobe-adbe-q4-2024-earnings-call-transcript/",
    "time_published": "20241212T023016",
    "authors": [
      "Motley Fool Transcribing"
    ],
    "summary": "ADBE earnings call for the period ending September 30, 2024.",
    "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.972756"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.308555,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.004519",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PYPL",
        "relevance_score": "0.004519",
        "ticker_sentiment_score": "0.033786",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSCDF",
        "relevance_score": "0.004519",
        "ticker_sentiment_score": "0.033786",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.004519",
        "ticker_sentiment_score": "0.103242",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.009038",
        "ticker_sentiment_score": "0.03332",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.004519",
        "ticker_sentiment_score": "0.188754",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.004519",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.004519",
        "ticker_sentiment_score": "0.169675",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.004519",
        "ticker_sentiment_score": "0.188754",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.004519",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.009038",
        "ticker_sentiment_score": "0.140591",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSNLF",
        "relevance_score": "0.004519",
        "ticker_sentiment_score": "0.033786",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.004519",
        "ticker_sentiment_score": "0.169675",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.009038",
        "ticker_sentiment_score": "0.028916",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.004519",
        "ticker_sentiment_score": "0.188754",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ADBE",
        "relevance_score": "0.20117",
        "ticker_sentiment_score": "0.234009",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.009038",
        "ticker_sentiment_score": "0.118566",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CNC",
        "relevance_score": "0.004519",
        "ticker_sentiment_score": "0.033786",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HUBS",
        "relevance_score": "0.009038",
        "ticker_sentiment_score": "0.062295",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALIZF",
        "relevance_score": "0.004519",
        "ticker_sentiment_score": "0.033786",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NSRGF",
        "relevance_score": "0.004519",
        "ticker_sentiment_score": "0.188754",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Options Trading: A Deep Dive into Market Sentiment - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/insights/options/24/12/42489986/johnson-johnson-options-trading-a-deep-dive-into-market-sentiment",
    "time_published": "20241213T184658",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bearish move on Johnson & Johnson. Our analysis of options history for Johnson & Johnson JNJ revealed 10 unusual trades. Delving into the details, we found 20% of traders were bullish, while 80% showed bearish tendencies.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1734115615_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.132943,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.081001",
        "ticker_sentiment_score": "0.041673",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.081001",
        "ticker_sentiment_score": "0.023805",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.584103",
        "ticker_sentiment_score": "0.055875",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2383236/johnson-johnson-jnj-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20241213T140017",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default236.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.23763,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.474082",
        "ticker_sentiment_score": "0.117768",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Stock Declines While Market Improves: Some Information for Investors",
    "url": "https://www.zacks.com/stock/news/2384193/johnson-johnson-jnj-stock-declines-while-market-improves-some-information-for-investors",
    "time_published": "20241216T224517",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the most recent trading session, Johnson & Johnson (JNJ) closed at $143.85, indicating a -1.89% shift from the previous trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default61.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.177387,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.516073",
        "ticker_sentiment_score": "0.272893",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Medical Instruments Industry Stocks to Buy on the GenAI Wave",
    "url": "https://www.zacks.com/commentary/2384013/3-medical-instruments-industry-stocks-to-buy-on-the-genai-wave",
    "time_published": "20241216T161500",
    "authors": [
      "Urmimala Biswas"
    ],
    "summary": "MASI, PEN and VCYT from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and wage and supply issues mar their prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928769"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.211283,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PEN",
        "relevance_score": "0.118647",
        "ticker_sentiment_score": "0.076866",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VCYT",
        "relevance_score": "0.148",
        "ticker_sentiment_score": "0.134737",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MASI",
        "relevance_score": "0.118647",
        "ticker_sentiment_score": "0.072225",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EW",
        "relevance_score": "0.029765",
        "ticker_sentiment_score": "0.071027",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.029765",
        "ticker_sentiment_score": "0.071027",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.029765",
        "ticker_sentiment_score": "0.071027",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "EMA Panel Endorses Lilly's Omvoh for Expanded Use in Crohn's Disease",
    "url": "https://www.zacks.com/stock/news/2383727/ema-panel-endorses-lillys-omvoh-for-expanded-use-in-crohns-disease",
    "time_published": "20241216T122300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The CHMP's opinion is based on late-stage data, which show that LLY's Omvoh is effective in Crohn's disease patients with or without prior biologic failure.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.281043,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.331765",
        "ticker_sentiment_score": "0.295927",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.279015",
        "ticker_sentiment_score": "0.292425",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.056943",
        "ticker_sentiment_score": "0.157973",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "0.129758",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.056943",
        "ticker_sentiment_score": "0.157973",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Epidermal Growth Factors  ( EGFs )  Market to Reach US$ 3.7 Billion by 2034 | Expanding Applications in Regenerative Medicine and Cancer Therapy Drive Growth, Latest Report by TMR",
    "url": "https://www.benzinga.com/pressreleases/24/12/g42503394/epidermal-growth-factors-egfs-market-to-reach-us-3-7-billion-by-2034-expanding-applications-in-reg",
    "time_published": "20241216T103000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, Transparency Market Research Inc. , Dec. 16, 2024 ( GLOBE NEWSWIRE ) -- The global Epidermal Growth Factors ( EGFs ) market ( March\u00e9 des Facteurs de croissance \u00e9pidermiques ( EGF ) ) was valued at US$ 1.1 Bn in 2023 and is anticipated to expand at a CAGR of 11.3% from 2024 ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/27e1d943-6840-4b94-a03f-719fb05a4273/epidermal-growth-factors-egfs-market.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.180609,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.038717",
        "ticker_sentiment_score": "0.053774",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "0.049244",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.038717",
        "ticker_sentiment_score": "0.170484",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "0.175364",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.077343",
        "ticker_sentiment_score": "0.136257",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.038717",
        "ticker_sentiment_score": "-0.254204",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.038717",
        "ticker_sentiment_score": "0.170484",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.077343",
        "ticker_sentiment_score": "0.096741",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "0.058068",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GSK",
        "relevance_score": "0.038717",
        "ticker_sentiment_score": "0.170484",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSOI",
        "relevance_score": "0.038717",
        "ticker_sentiment_score": "0.09193",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:NANO",
        "relevance_score": "0.038717",
        "ticker_sentiment_score": "0.031583",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "FDA Rejects Johnson & Johnson's Injectable Version Of Approved Drug For Lung Cancer - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/12/42535810/fda-rejects-johnson-johnsons-injectable-version-of-approved-drug-for-lung-cancer",
    "time_published": "20241217T172144",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "The FDA issued a complete Response letter ( CRL ) for Johnson & Johnson's SC amivantamab due to manufacturing facility inspection issues. The CRL does not impact the approved IV formulation of Rybrevant and no additional clinical studies were requested. Get New Picks of the Market's Top Stocks",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/17/FDA-And-CDC-Involvement.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.192553,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.197413",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.382925",
        "ticker_sentiment_score": "0.139448",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "FDA Gives CRL to J&J's BLA for Subcutaneous Rybrevant in NSCLC",
    "url": "https://www.zacks.com/stock/news/2384424/fda-gives-crl-to-jjs-bla-for-subcutaneous-rybrevant-in-nsclc",
    "time_published": "20241217T132100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The FDA issues a complete response letter to JNJ's BLA seeking approval for the subcutaneous formulation of Rybrevant in EGFR-mutated non-small cell lung cancer.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.167535,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SPRO",
        "relevance_score": "0.222838",
        "ticker_sentiment_score": "0.047543",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSTL",
        "relevance_score": "0.222838",
        "ticker_sentiment_score": "0.048486",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.112532",
        "ticker_sentiment_score": "-0.052062",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Dow on a Record Losing Streak: Should You Buy its ETF?",
    "url": "https://www.zacks.com/stock/news/2385358/dow-on-a-record-losing-streak-should-you-buy-its-etf",
    "time_published": "20241218T152500",
    "authors": [
      "Sweta Killa"
    ],
    "summary": "The Dow Jones has been on its worst losing streak in nearly 50 years. Should you buy its ETF for 2025?",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/84/11877.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980716"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.060657,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.254973",
        "ticker_sentiment_score": "-0.173275",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.129168",
        "ticker_sentiment_score": "-0.108157",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.129168",
        "ticker_sentiment_score": "-0.108157",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.129168",
        "ticker_sentiment_score": "-0.108157",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Akari Therapeutics Announces Key Leadership Appointments - Akari Therapeutics  ( NASDAQ:AKTX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/12/g42553004/akari-therapeutics-announces-key-leadership-appointments",
    "time_published": "20241218T135129",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Samir R. Patel, M.D., appointed as Chief Executive Officer Abizer Gaslightwala appointed to Board of Directors BOSTON and LONDON, Dec. 18, 2024 ( GLOBE NEWSWIRE ) -- Akari Therapeutics, Plc AKTX today announced the appointment of Samir R. Patel, M.D., as Chief Executive Officer, effective ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/110aebf9-2683-41c9-ba9d-bf06f7e42054/image1.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.165645,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AKTX",
        "relevance_score": "0.094112",
        "ticker_sentiment_score": "0.05996",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CURN",
        "relevance_score": "0.023579",
        "ticker_sentiment_score": "0.034377",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JAZZ",
        "relevance_score": "0.047138",
        "ticker_sentiment_score": "0.07564",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.023579",
        "ticker_sentiment_score": "0.116935",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RZLT",
        "relevance_score": "0.023579",
        "ticker_sentiment_score": "0.030003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.094112",
        "ticker_sentiment_score": "0.094619",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Akari Therapeutics Announces Key Leadership Appointments",
    "url": "https://www.globenewswire.com/news-release/2024/12/18/2999072/0/en/Akari-Therapeutics-Announces-Key-Leadership-Appointments.html",
    "time_published": "20241218T135100",
    "authors": [
      "Akari Therapeutics Plc"
    ],
    "summary": "Samir R. Patel, M.D., appointed as Chief Executive Officer ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/110aebf9-2683-41c9-ba9d-bf06f7e42054/image1.png",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.16341,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AKTX",
        "relevance_score": "0.097754",
        "ticker_sentiment_score": "0.062871",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CURN",
        "relevance_score": "0.024496",
        "ticker_sentiment_score": "0.034558",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JAZZ",
        "relevance_score": "0.048969",
        "ticker_sentiment_score": "0.075796",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.024496",
        "ticker_sentiment_score": "0.119418",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RZLT",
        "relevance_score": "0.024496",
        "ticker_sentiment_score": "0.031086",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.097754",
        "ticker_sentiment_score": "0.097682",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Global Surgical Robots Market to Exceed US$ 20.8 Bn by 2031 Amid Soaring Demand for Precision-Driven Minimally Invasive Surgeries - TMR",
    "url": "https://www.benzinga.com/pressreleases/24/12/g42552434/global-surgical-robots-market-to-exceed-us-20-8-bn-by-2031-amid-soaring-demand-for-precision-drive",
    "time_published": "20241218T133418",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, Transparency Market Research Inc., Dec. 18, 2024 ( GLOBE NEWSWIRE ) -- Rising Demand for Surgical Robots: A Game-Changer for the Healthcare Industry",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/a23bc600-26b3-45fd-a35f-44e0dee378a1/surgical-robots-market.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.321728,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.04303",
        "ticker_sentiment_score": "0.054561",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZBH",
        "relevance_score": "0.04303",
        "ticker_sentiment_score": "0.330676",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ARAY",
        "relevance_score": "0.04303",
        "ticker_sentiment_score": "0.330676",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.04303",
        "ticker_sentiment_score": "0.229239",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.085936",
        "ticker_sentiment_score": "0.186666",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.085936",
        "ticker_sentiment_score": "0.231148",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RNSHF",
        "relevance_score": "0.04303",
        "ticker_sentiment_score": "0.330676",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.128592",
        "ticker_sentiment_score": "0.027156",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study",
    "url": "https://www.zacks.com/stock/news/2385100/sny-teva-stocks-jump-on-encouraging-data-from-ibd-drug-study",
    "time_published": "20241218T132100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Treatment with a Sanofi-Teva-partnered experimental drug meets the primary goals in a mid-stage study for Ulcerative colitis and Crohn's disease indications.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.211447,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.222022",
        "ticker_sentiment_score": "0.24879",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.178459",
        "ticker_sentiment_score": "0.050537",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.089797",
        "ticker_sentiment_score": "0.121313",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.536492",
        "ticker_sentiment_score": "0.249183",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Confocal Microscope Market is Projected to Reach $1.8 Billion with 3.3% CAGR by 2034 | Fact.MR Report",
    "url": "https://www.benzinga.com/pressreleases/24/12/g42549790/confocal-microscope-market-is-projected-to-reach-1-8-billion-with-3-3-cagr-by-2034-fact-mr-report",
    "time_published": "20241218T120000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Rockville, MD, Dec. 18, 2024 ( GLOBE NEWSWIRE ) -- The global confocal microscope market is estimated at US$ 1.3 billion in 2024, as per a newly published industry analysis by Fact.MR, a market research and competitive intelligence provider.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/1db89957-29d2-42ff-87ea-26cf8b676ad5/confocal-microscope-market.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.323644,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ZBH",
        "relevance_score": "0.040484",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OFIX",
        "relevance_score": "0.040484",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZIMV",
        "relevance_score": "0.040484",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GMED",
        "relevance_score": "0.040484",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.040484",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.040484",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Smartest Dividend Stocks to Buy With $500 Right Now",
    "url": "https://www.fool.com/investing/2024/12/18/the-smartest-dividend-stocks-to-buy-with-500/",
    "time_published": "20241218T101500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "As an investor, your goal is to select quality stocks that will advance over a period of years -- but this doesn't mean you have to wait a long time for all of the rewards. If you add a few dividend stocks to your portfolio, you'll start collecting returns on a regular basis -- without lifting a ...",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801154%2Fgettyimages-135538318.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.955357"
      }
    ],
    "overall_sentiment_score": 0.342913,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TRMNF",
        "relevance_score": "0.047654",
        "ticker_sentiment_score": "0.35124",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.095138",
        "ticker_sentiment_score": "0.108093",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.28008",
        "ticker_sentiment_score": "0.258465",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.095138",
        "ticker_sentiment_score": "0.140836",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Is Putting Dividend Growth Stocks to Shame With Yet Another Huge Increase to Its Payout",
    "url": "https://www.fool.com/investing/2024/12/18/eli-lilly-is-putting-dividend-growth-stocks-to-sha/",
    "time_published": "20241218T101100",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Dividend investors often prioritize stocks that have long track records for raising their payouts. But that can be a mistake. A long streak doesn't necessarily make a dividend stock a good long-term buy. After all, those increases may only be modest, for the sake of keeping the streak going.",
    "banner_image": "https://media.ycharts.com/charts/ce4c8f5241378e109533c345e91598be.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.995077"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.184714,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.656158",
        "ticker_sentiment_score": "0.463853",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.102247",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.102247",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "-0.102096",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Can Dow Jones ETF Reverse From the Worst Losing Streak in 50 Years?",
    "url": "https://www.zacks.com/stock/news/2385942/can-dow-jones-etf-reverse-from-the-worst-losing-streak-in-50-years",
    "time_published": "20241219T180000",
    "authors": [
      "Sanghamitra Saha"
    ],
    "summary": "The Dow Jones ETF has recorded the longest losing streak since 1978. Can it reverse the trend in 2025?",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f2/1072.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.012075,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.122581",
        "ticker_sentiment_score": "0.091318",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.410697",
        "ticker_sentiment_score": "0.03925",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.122581",
        "ticker_sentiment_score": "0.091318",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.242285",
        "ticker_sentiment_score": "0.076017",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.182967",
        "ticker_sentiment_score": "0.065664",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.122581",
        "ticker_sentiment_score": "-0.030924",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.122581",
        "ticker_sentiment_score": "-0.030924",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.122581",
        "ticker_sentiment_score": "0.091318",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.182967",
        "ticker_sentiment_score": "-0.004616",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRVL",
        "relevance_score": "0.122581",
        "ticker_sentiment_score": "0.047882",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Adobe Stock Slips 20% in a Week: Should You Brace for a Tough 2025?",
    "url": "https://www.zacks.com/stock/news/2385862/adobe-stock-slips-20-in-a-week-should-you-brace-for-a-tough-2025",
    "time_published": "20241219T162300",
    "authors": [
      "Aniruddha Ganguly"
    ],
    "summary": "ADBE shares are benefiting from strong demand for its creative products and expanding clientele amid increasing competition and stretched valuation.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/931.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      }
    ],
    "overall_sentiment_score": 0.284965,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.197816",
        "ticker_sentiment_score": "0.121928",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.194833",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.055468",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "-0.016966",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.081987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "-0.016966",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.081987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.081987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADBE",
        "relevance_score": "0.765945",
        "ticker_sentiment_score": "0.399433",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.081987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HUBS",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.194833",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.149038",
        "ticker_sentiment_score": "0.0706",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Applied Therapeutics Appoints John H. Johnson as Executive Chairman - Applied Therapeutics  ( NASDAQ:APLT ) , Reviva Pharmaceuticals  ( NASDAQ:RVPH ) ",
    "url": "https://www.benzinga.com/pressreleases/24/12/g42613049/applied-therapeutics-appoints-john-h-johnson-as-executive-chairman",
    "time_published": "20241220T120000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer NEW YORK, Dec. 20, 2024 ( GLOBE NEWSWIRE ) -- Applied Therapeutics, Inc. APLT, a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998333"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.211563,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AXGN",
        "relevance_score": "0.018173",
        "ticker_sentiment_score": "0.007558",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.036338",
        "ticker_sentiment_score": "0.025557",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XERS",
        "relevance_score": "0.054483",
        "ticker_sentiment_score": "0.026892",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APLT",
        "relevance_score": "0.215415",
        "ticker_sentiment_score": "0.228016",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RVPH",
        "relevance_score": "0.036338",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OPK",
        "relevance_score": "0.018173",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.018173",
        "ticker_sentiment_score": "0.06552",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VSTM",
        "relevance_score": "0.036338",
        "ticker_sentiment_score": "0.008492",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Vanguard ETFs to Buy With $1,500 and Hold Forever",
    "url": "https://www.fool.com/investing/2024/12/20/3-vanguard-etfs-to-buy-with-1500-and-hold-forever/",
    "time_published": "20241220T093900",
    "authors": [
      "Justin Pope"
    ],
    "summary": "These top-notch ETFs should be a go-to choice for almost every investor.",
    "banner_image": "https://media.ycharts.com/charts/737cb267e0dcd120926775370ed6c4f1.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.308384,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AVGO",
        "relevance_score": "0.058759",
        "ticker_sentiment_score": "0.072985",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.058759",
        "ticker_sentiment_score": "0.280096",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.058759",
        "ticker_sentiment_score": "0.280096",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.058759",
        "ticker_sentiment_score": "0.280096",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Ascends But Remains Behind Market: Some Facts to Note",
    "url": "https://www.zacks.com/stock/news/2387146/johnson-johnson-jnj-ascends-but-remains-behind-market-some-facts-to-note",
    "time_published": "20241223T224518",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the most recent trading session, Johnson & Johnson (JNJ) closed at $145.27, indicating a +0.55% shift from the previous trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default4.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.158537,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.510302",
        "ticker_sentiment_score": "0.192119",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
    "url": "https://www.zacks.com/stock/news/2386771/why-investors-need-to-take-advantage-of-these-2-medical-stocks-now",
    "time_published": "20241223T135006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default116.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999937"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.36529,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.269776",
        "ticker_sentiment_score": "0.279349",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.333557",
        "ticker_sentiment_score": "0.323652",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Worried About a Stock Market Sell-Off in 2025? Consider Buying This Ultra-Safe Vanguard ETF in December.",
    "url": "https://www.fool.com/investing/2024/12/23/stock-market-sell-off-2025-buy-safe-vanguard-etf/",
    "time_published": "20241223T130000",
    "authors": [
      "Daniel Foelber"
    ],
    "summary": "Volatility spiked in the broader indexes after the Federal Reserve indicated that it could keep interest rates higher for longer. The S&P 500 fell 3% on Dec. 18, and the Nasdaq Composite tumbled 3.6%. Investors who are worried about a further sell-off -- but want to keep putting new savings to ...",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801698%2Fhappy-older-couple-retirement-wealth-invest-1200x664-163dd79-1.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.238392,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GIS",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.102735",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.211631",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.12013",
        "ticker_sentiment_score": "0.306503",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CSCO",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.211631",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.211631",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.102735",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.102735",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TXN",
        "relevance_score": "0.179343",
        "ticker_sentiment_score": "0.125861",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares U.S. Pharmaceuticals ETF  ( IHE ) ?",
    "url": "https://www.zacks.com/stock/news/2386648/should-you-invest-in-the-ishares-us-pharmaceuticals-etf-ihe",
    "time_published": "20241223T112006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default117.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      }
    ],
    "overall_sentiment_score": 0.20659,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.070203",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.043671",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.070203",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.070203",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "A Bull Market Is Here: 2 Super Stocks Down 21% and 30% to Buy Right Now",
    "url": "https://www.fool.com/investing/2024/12/23/bull-market-here-super-stocks-down-buy-now/",
    "time_published": "20241223T102500",
    "authors": [
      "Keith Noonan and Lee Samaha"
    ],
    "summary": "Even with the recent bout of market volatility, 2024 has been a fantastic year for stocks. The S&P 500 index has delivered a dividend-adjusted total return of roughly 25% across this year's trading. Meanwhile, the more growth-heavy Nasdaq Composite index has delivered a total return of 30%.This ...",
    "banner_image": "https://media.ycharts.com/charts/9cca1501f0ddb3f5a43760272ba2e4ff.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999982"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.96136"
      }
    ],
    "overall_sentiment_score": 0.393656,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.163909",
        "ticker_sentiment_score": "0.184601",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.109705",
        "ticker_sentiment_score": "0.233427",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.370733",
        "ticker_sentiment_score": "0.554366",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.163909",
        "ticker_sentiment_score": "0.091066",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharmaceuticals & Medicine Manufacturing Market Set to Surge at 8.9% CAGR, to Reach US$ 2,516.46 Million by 2034 | Fact.MR Report",
    "url": "https://www.benzinga.com/pressreleases/24/12/g42667458/pharmaceuticals-medicine-manufacturing-market-set-to-surge-at-8-9-cagr-to-reach-us-2-516-46-millio",
    "time_published": "20241224T113000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Rockville, MD , Dec. 24, 2024 ( GLOBE NEWSWIRE ) -- According to the newly released report by Fact.MR, a market research and competitive intelligence provider, the global Pharmaceuticals & Medicine Manufacturing Market is evaluated to reach US$ 1,073.08 billion in 2024.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/6e48fdb3-4d93-4cfc-ae26-9bd07c9c98f0/pharmaceuticals-medicine-manufacturing-market.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.334998,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SSNLF",
        "relevance_score": "0.104835",
        "ticker_sentiment_score": "0.018952",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WUXAY",
        "relevance_score": "0.035035",
        "ticker_sentiment_score": "0.070483",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.035035",
        "ticker_sentiment_score": "0.070483",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.035035",
        "ticker_sentiment_score": "0.070483",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.035035",
        "ticker_sentiment_score": "0.070483",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FUJIF",
        "relevance_score": "0.035035",
        "ticker_sentiment_score": "0.070483",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.035035",
        "ticker_sentiment_score": "0.070483",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.035035",
        "ticker_sentiment_score": "0.070483",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.017274",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSOI",
        "relevance_score": "0.035035",
        "ticker_sentiment_score": "0.165496",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.035035",
        "ticker_sentiment_score": "0.070483",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Fidelity MSCI Health Care Index ETF  ( FHLC ) ?",
    "url": "https://www.zacks.com/stock/news/2387264/should-you-invest-in-the-fidelity-msci-health-care-index-etf-fhlc",
    "time_published": "20241224T112007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default211.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.270903,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.127119",
        "ticker_sentiment_score": "0.049759",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.127119",
        "ticker_sentiment_score": "0.049759",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.127119",
        "ticker_sentiment_score": "0.049759",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should iShares Core High Dividend ETF  ( HDV )  Be on Your Investing Radar?",
    "url": "https://www.zacks.com/stock/news/2387262/should-ishares-core-high-dividend-etf-hdv-be-on-your-investing-radar",
    "time_published": "20241224T112007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Style Box ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default175.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.262088,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MORN",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.194106",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.068087",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.068087",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.068087",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Give Yourself the Gift That Will Keep On Giving in 2025 and Buy These 3 Top Dividend Stocks",
    "url": "https://www.fool.com/investing/2024/12/24/give-yourself-the-gift-that-will-keep-on-giving-in/",
    "time_published": "20241224T103400",
    "authors": [
      "Matt DiLallo"
    ],
    "summary": "Dividend-paying stocks are the gift that keeps on giving. They pay you a recurring stream of passive income that you can use to make new investments or cover some of your expenses. The best dividend stocks will send you more money each year by increasing their payments.",
    "banner_image": "https://g.foolcdn.com/editorial/images/801927/holiday-bag-full-of-money-snowflakes.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.967321"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.361558,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KO",
        "relevance_score": "0.365166",
        "ticker_sentiment_score": "0.466263",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.365166",
        "ticker_sentiment_score": "0.45144",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NEE",
        "relevance_score": "0.307731",
        "ticker_sentiment_score": "0.458145",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Top 7 Blue-Chip Stocks With The Best Return Potential Going Into 2025 - Caterpillar  ( NYSE:CAT ) , Amazon.com  ( NASDAQ:AMZN ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42678014/top-7-blue-chip-stocks-with-the-best-return-potential-going-into-2025",
    "time_published": "20241225T140048",
    "authors": [
      "Rishabh Mishra"
    ],
    "summary": "Dow also saw one of its longest 10-day losing streak, the first ever since 1974. Following are the top seven blue-chip stocks with the highest return potential going into 2025. The year 2024 saw the U.S. stock market make new records, with major indices breaching key milestones.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/25/Wall-Street-Bulls.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990893"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.185442,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.026532",
        "ticker_sentiment_score": "0.068229",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.053035",
        "ticker_sentiment_score": "-0.08467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.053035",
        "ticker_sentiment_score": "-0.08467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.053035",
        "ticker_sentiment_score": "-0.041006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SHW",
        "relevance_score": "0.105836",
        "ticker_sentiment_score": "0.035524",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.184096",
        "ticker_sentiment_score": "0.152113",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.158173",
        "ticker_sentiment_score": "0.13707",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.184096",
        "ticker_sentiment_score": "0.042234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.053035",
        "ticker_sentiment_score": "-0.08467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.026532",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.158173",
        "ticker_sentiment_score": "0.103475",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HES",
        "relevance_score": "0.053035",
        "ticker_sentiment_score": "0.009",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.053035",
        "ticker_sentiment_score": "0.009",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.105836",
        "ticker_sentiment_score": "0.168035",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Better Buy: Eli Lilly vs. Novo Nordisk. The Answer Is Becoming Abundantly More Clear.",
    "url": "https://www.fool.com/investing/2024/12/26/better-buy-eli-lilly-vs-novo-nordisk-the-answer-is/",
    "time_published": "20241226T151500",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for investors.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801921%2Fgettyimages-2025836701-2.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.179568,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.598368",
        "ticker_sentiment_score": "0.456767",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.051441",
        "ticker_sentiment_score": "0.098935",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.394236",
        "ticker_sentiment_score": "0.39924",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.051441",
        "ticker_sentiment_score": "0.098935",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.051441",
        "ticker_sentiment_score": "0.098935",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  is Attracting Investor Attention: Here is What You Should Know",
    "url": "https://www.zacks.com/stock/news/2388173/johnson-johnson-jnj-is-attracting-investor-attention-here-is-what-you-should-know",
    "time_published": "20241226T140019",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default209.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.623304"
      }
    ],
    "overall_sentiment_score": 0.22003,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.473208",
        "ticker_sentiment_score": "0.129628",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Smartest Dividend Stocks to Buy With $1,000 Right Now",
    "url": "https://www.fool.com/investing/2024/12/26/the-smartest-dividend-stocks-to-buy-with-1000-now/",
    "time_published": "20241226T103500",
    "authors": [
      "Selena Maranjian"
    ],
    "summary": "If you're looking for attractive dividend-paying stocks, that's a smart move. If you're not, perhaps reconsider -- because:Here are three dividend stocks to consider for your long-term portfolio.Image source: Getty Images.Continue reading ...",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F802040%2Fgetty-pointing-to-cash-fanned-out-in-hand.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.343141,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.130571",
        "ticker_sentiment_score": "0.044521",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.257668",
        "ticker_sentiment_score": "0.118563",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "T",
        "relevance_score": "0.130571",
        "ticker_sentiment_score": "0.193745",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.194763",
        "ticker_sentiment_score": "0.372067",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Death Cross: Stock Stumbles Despite Pipeline Promise - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/12/42708390/johnson-johnson-death-cross-stock-stumbles-despite-pipeline-promise",
    "time_published": "20241227T183239",
    "authors": [
      "Surbhi Jain"
    ],
    "summary": "Johnson & Johnson JNJ, the iconic healthcare giant known for its stable dividends and defensive appeal, has entered a bearish technical pattern: the Death Cross. This occurs when the stock's 50-day moving average falls below its 200-day moving average, signaling potential downside.",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27121413/JNJ-Death-Cross.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.085737,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.666827",
        "ticker_sentiment_score": "-0.083643",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KKPCF",
        "relevance_score": "0.096283",
        "ticker_sentiment_score": "0.036102",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "JNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723",
    "url": "https://www.zacks.com/stock/news/2388625/jnj-inks-licensing-deal-with-kaken-for-eczema-candidate-kp-723",
    "time_published": "20241227T121700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson announces a global licensing deal with Kaken for the latter's eczema candidate, KP-723, to further strengthen its dermatology portfolio.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/1612.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.928139"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.068527,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CTMX",
        "relevance_score": "0.244109",
        "ticker_sentiment_score": "0.007533",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPRO",
        "relevance_score": "0.184363",
        "ticker_sentiment_score": "0.037926",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSTL",
        "relevance_score": "0.244109",
        "ticker_sentiment_score": "0.096047",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.607406",
        "ticker_sentiment_score": "0.407117",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "KKPCF",
        "relevance_score": "0.061949",
        "ticker_sentiment_score": "0.081167",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Dividend-Paying Value Stocks to Buy Even If There's a Stock Market Sell-Off in 2025",
    "url": "https://www.fool.com/investing/2024/12/29/3-dividend-paying-value-stocks-buy-2025/",
    "time_published": "20241229T140700",
    "authors": [
      "Daniel Foelber"
    ],
    "summary": "Investing by equal parts in these three dividend stocks produces an average yield of 3%.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F802255%2Fgettyimages-902863704-1201x801-d21b45d.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.3131,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.484881",
        "ticker_sentiment_score": "0.531455",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "LMT",
        "relevance_score": "0.1871",
        "ticker_sentiment_score": "0.105198",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWK",
        "relevance_score": "0.321273",
        "ticker_sentiment_score": "0.357026",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.047185",
        "ticker_sentiment_score": "0.07298",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is American Century U.S. Quality Value ETF  ( VALQ )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2389227/is-american-century-us-quality-value-etf-valq-a-strong-etf-right-now",
    "time_published": "20241230T112008",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default314.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.329304,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.113329",
        "ticker_sentiment_score": "0.042997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.113329",
        "ticker_sentiment_score": "0.042997",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "5 Unbeatable Stocks I'm Eager to Buy in 2025",
    "url": "https://www.fool.com/investing/2024/12/30/5-unbeatable-stocks-im-eager-to-buy-in-2025/",
    "time_published": "20241230T100600",
    "authors": [
      "Sean Williams"
    ],
    "summary": "These value, growth, and income stocks are incredibly cheap in a historically pricey stock market.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F802213%2Fstopwatch-second-hand-time-to-buy-invest-stock-market-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.983783"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.261448,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BABA",
        "relevance_score": "0.162364",
        "ticker_sentiment_score": "0.110009",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SIRI",
        "relevance_score": "0.287762",
        "ticker_sentiment_score": "0.068853",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.032691",
        "ticker_sentiment_score": "0.103026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PUBM",
        "relevance_score": "0.256989",
        "ticker_sentiment_score": "0.327937",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.162364",
        "ticker_sentiment_score": "0.217245",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.162364",
        "ticker_sentiment_score": "0.179911",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Ascends While Market Falls: Some Facts to Note",
    "url": "https://www.zacks.com/stock/news/2390217/johnson-johnson-jnj-ascends-while-market-falls-some-facts-to-note",
    "time_published": "20241231T224519",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The latest trading day saw Johnson & Johnson (JNJ) settling at $144.62, representing a +0.89% change from its previous close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default196.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.983783"
      }
    ],
    "overall_sentiment_score": 0.15148,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.511734",
        "ticker_sentiment_score": "0.183824",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Marjorie Taylor Greene Went Christmas Shopping For Stocks, Here's What She Bought Before Holiday - Applied Mat  ( NASDAQ:AMAT ) , Adobe  ( NASDAQ:ADBE ) ",
    "url": "https://www.benzinga.com/24/12/42747345/marjorie-taylor-green-went-christmas-shopping-for-stocks-heres-what-she-bought-before-holiday",
    "time_published": "20241231T184627",
    "authors": [
      "Chris Katje"
    ],
    "summary": "Rep. Marjorie Taylor Greene ( R-Ga. ) disclosed recent purchases of several stocks on Christmas Eve, according to Benzinga Government Trades. Here's a look at what the far-right politician bought. What Happened: Greene has been an active trader of stocks while in Congress, based on her ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/31/Congresswoman-Marjorie-Taylor-Greene-Spe.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998356"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.188505,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.169279",
        "ticker_sentiment_score": "0.061679",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMAT",
        "relevance_score": "0.113329",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDLZ",
        "relevance_score": "0.113329",
        "ticker_sentiment_score": "0.306371",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.113329",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.056808",
        "ticker_sentiment_score": "0.098933",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.056808",
        "ticker_sentiment_score": "0.098933",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.169279",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.224383",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.113329",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HSY",
        "relevance_score": "0.224383",
        "ticker_sentiment_score": "0.133528",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NSC",
        "relevance_score": "0.169279",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 American Century Investments Mutual Funds for Higher Returns",
    "url": "https://www.zacks.com/stock/news/2389783/3-american-century-investments-mutual-funds-for-higher-returns",
    "time_published": "20241231T101500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Consider investing in American Century Investments mutual funds like ALVDX, BGEIX and BULIX for long-term returns.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ad/591.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.260052,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ZIJMY",
        "relevance_score": "0.075397",
        "ticker_sentiment_score": "0.047412",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CEG",
        "relevance_score": "0.075397",
        "ticker_sentiment_score": "0.050442",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.075397",
        "ticker_sentiment_score": "0.051452",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NEM",
        "relevance_score": "0.075397",
        "ticker_sentiment_score": "0.047412",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AEM",
        "relevance_score": "0.075397",
        "ticker_sentiment_score": "0.047412",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DUK",
        "relevance_score": "0.075397",
        "ticker_sentiment_score": "0.051452",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.075397",
        "ticker_sentiment_score": "0.051452",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SO",
        "relevance_score": "0.075397",
        "ticker_sentiment_score": "0.050442",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NEE",
        "relevance_score": "0.075397",
        "ticker_sentiment_score": "0.050442",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  }
]